<SEC-DOCUMENT>0001193125-12-231316.txt : 20120514
<SEC-HEADER>0001193125-12-231316.hdr.sgml : 20120514
<ACCEPTANCE-DATETIME>20120514161057
ACCESSION NUMBER:		0001193125-12-231316
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		14
CONFORMED PERIOD OF REPORT:	20120331
FILED AS OF DATE:		20120514
DATE AS OF CHANGE:		20120514

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Galena Biopharma, Inc.
		CENTRAL INDEX KEY:			0001390478
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-33958
		FILM NUMBER:		12838808

	BUSINESS ADDRESS:	
		STREET 1:		310 N. STATE STREET
		STREET 2:		SUITE 208
		CITY:			LAKE OSWEGO
		STATE:			OR
		ZIP:			97034
		BUSINESS PHONE:		855 855 GALE

	MAIL ADDRESS:	
		STREET 1:		310 N. STATE STREET
		STREET 2:		SUITE 208
		CITY:			LAKE OSWEGO
		STATE:			OR
		ZIP:			97034

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	RXi Pharmaceuticals Corp
		DATE OF NAME CHANGE:	20110926

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	GALENA BIOPHARMA, INC.
		DATE OF NAME CHANGE:	20110922

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	RXI PHARMACEUTICALS CORP
		DATE OF NAME CHANGE:	20110921
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>d333623d10q.htm
<DESCRIPTION>FORM 10-Q
<TEXT>
<HTML><HEAD>
<TITLE>Form 10-Q</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="line-height:0px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P> <P STYLE="margin-top:4px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>UNITED STATES </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>SECURITIES AND EXCHANGE COMMISSION </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="3"><B>WASHINGTON, D.C. 20549 </B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>FORM 10-Q
</B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(Mark One) </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B></B><FONT STYLE="FONT-FAMILY:WINGDINGS">&#120;</FONT><B></B><B></B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 </B></FONT></TD></TR></TABLE>
 <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>For the quarterly period ended March&nbsp;31, 2012 </B></FONT></P>
 <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>OR </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B></B><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT><B></B><B></B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 </B></FONT></TD></TR></TABLE>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>For the transition period from &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; to
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Commission File Number: 001-33958
</B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="6"><B>Galena Biopharma, Inc. </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>(Exact name of registrant as specified in its charter) </B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="50%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Delaware</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>20-8099512</B></FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(State of incorporation)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(I.R.S. Employer</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>Identification No.)</B></FONT></P></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>310 N. State Street, Suite 208, Lake Oswego, OR 97034 </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Address of principal executive office) (Zip code) </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Registrant&#146;s telephone number: (855)&nbsp;855-4253 </B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Indicate by check mark whether
the Registrant (1)&nbsp;has filed all reports required to be filed by Section&nbsp;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12&nbsp;months (or for such shorter period that the Registrant was required to file such
reports), and (2)&nbsp;has been subject to such filing requirements for the past 90&nbsp;days. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">Yes&nbsp;&nbsp;<FONT
STYLE="FONT-FAMILY:WINGDINGS">&#120;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT> </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Indicate
by check mark whether the registrant has submitted electronically and posted on it corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule&nbsp;405 of Regulation&nbsp;S-T (&#167;232.405 of this
chapter) during the preceding 12&nbsp;months (or for such shorter time that the registrant was required to submit and post such files). </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Yes&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#120;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT> </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company.
See the definitions of &#147;large accelerated filer,&#148; &#147;accelerated filer&#148; and &#147;smaller reporting company&#148; in Rule&nbsp;12b-2 of the Exchange Act. (Check one): </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="16%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="60%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="20%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="1%"></TD></TR>


<TR>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Large&nbsp;accelerated&nbsp;filer</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Accelerated filer</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Non-accelerated&nbsp;filer</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT>&nbsp;&nbsp;(Do not check if a smaller reporting company)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Smaller&nbsp;reporting&nbsp;company</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#120;</FONT></FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Indicate by checkmark whether the Registrant is a shell company (as defined in Rule&nbsp;12b-2 of the Exchange Act).
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">Yes&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;<FONT
STYLE="FONT-FAMILY:WINGDINGS">&#120;</FONT> </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">As of May&nbsp;11, 2012, Galena Biopharma, Inc. had 65,643,905 shares of common stock, $0.0001
par value, outstanding, exclusive of treasury shares. </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="line-height:0px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc"></A>GALENA BIOPHARMA, INC. </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>FORM 10-Q &#151; QUARTER ENDED MARCH 31, 2012 </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><U>INDEX</U> </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="5%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="86%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:28pt"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Part&nbsp;No.</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Item&nbsp;No.</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Description</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Page<BR>No.</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">I</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">FINANCIAL INFORMATION</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#toc333623_1">Financial Statements</A></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#toc333623_2">Condensed Consolidated Balance Sheets as of March&nbsp;31, 2012 and December&nbsp;31, 2011 (unaudited)</A></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#toc333623_3">Condensed Consolidated Statements of Expenses for the three months ended March&nbsp;
31, 2012 and 2011 and for the period January&nbsp;1, 2003 (date of inception) to March&nbsp;31, 2012 (unaudited)</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#toc333623_4">Condensed Consolidated Statements of Cash Flows for the three months ended March&nbsp;
31, 2012 and 2011 and for the period January&nbsp;1, 2003 (date of inception) to March 31, 2012 (unaudited)</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#toc333623_5">Notes to Condensed Consolidated Financial Statements (unaudited)</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">2</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#toc333623_6">Management&#146;s Discussion and Analysis of Financial Condition and Results of
Operations</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">14</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">3</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#toc333623_6a">Quantitative and Qualitative Disclosures About Market Risk </A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">16</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">4</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#toc333623_7">Controls and Procedures</A></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">16</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">II</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#toc333623_8">OTHER INFORMATION</A></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#toc333623_9">Legal Proceedings</A></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">16</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">1A</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#toc333623_10">Risk Factors</A></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">16</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">2</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#toc333623_11">Unregistered Sales of Equity Securities and Use of Proceeds</A></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">16</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">3</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#toc333623_12">Defaults Upon Senior Securities</A></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">16</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">4</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#toc333623_13">Mine Safety Disclosures</A></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">16</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">5</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#toc333623_14">Other Information</A></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">17</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">6</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#toc333623_15">Exhibits</A></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">17</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="16" COLSPAN="5"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="5"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#toc333623_16">Index to Exhibits</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD HEIGHT="8" COLSPAN="5"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="5"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#toc333623_17">Signatures</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">18</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="5"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#toc333623_18">EX-31.1</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="5"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#toc333623_19">EX-31.2</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="5"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#toc333623_20">EX-32.1</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc333623_1"></A>PART I </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc333623_2"></A>ITEM&nbsp;1. FINANCIAL STATEMENTS </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>GALENA BIOPHARMA, INC. </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(A Development Stage Company) </B></FONT></P>
 <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>CONDENSED CONSOLIDATED BALANCE SHEETS </B></FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(Amounts in thousands, except share and per share data) </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(Unaudited) </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="84%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>March 31,<BR>2012</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>December&nbsp;31,<BR>2011</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>ASSETS</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Current assets:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Cash and cash equivalents</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">8,701</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">11,433</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Restricted cash</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">101</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">101</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Prepaid expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">290</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">276</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total current assets</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">9,092</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">11,810</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Equipment and furnishings, net</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">351</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">393</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">In-process research and development</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">12,864</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">12,864</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Goodwill</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5,898</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5,898</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Deposits</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total assets</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">28,208</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">30,968</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>LIABILITIES AND STOCKHOLDERS&#146; (DEFICIT) EQUITY</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Current liabilities:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Accounts payable</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,581</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,155</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Accrued expenses and other current liabilities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,532</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,984</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Current maturities of capital lease obligations</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">24</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">35</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Convertible notes payable, current</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">500</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Fair value of warrants potentially settleable in cash</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">20,357</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,746</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Current contingent purchase price consideration</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">898</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,782</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total current liabilities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">27,392</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">11,202</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Capital lease obligations, net of current maturities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">36</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">32</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Convertible notes payable, non-current</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Deferred tax liability, non-current</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5,053</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5,053</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Contingent purchase price consideration, net of current portion</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5,297</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4,569</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total liabilities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">38,778</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">20,856</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Stockholders&#146; (deficit) equity:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Preferred stock, $0.0001 par value; 5,000,000 shares authorized; no shares issued and outstanding</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Common stock, $0.0001 par value; 125,000,000 shares authorized; 50,082,148 shares issued and 49,407,148 shares outstanding and
47,811,453 shares issued and 47,136,453 outstanding at March&nbsp;31, 2012 and December&nbsp;31, 2011, respectively</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Additional paid-in capital</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">85,263</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">81,184</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Deficit accumulated during the developmental stage</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(91,989</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(67,228</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Less treasury shares at cost, 675,000 shares</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(3,849</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(3,849</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total stockholders&#146; (deficit) equity</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(10,570</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">10,112</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total liabilities and stockholders&#146; equity</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">28,208</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">30,968</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">The accompanying notes are an integral part of these consolidated financial statements. </FONT></P>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">1 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc333623_3"></A>GALENA BIOPHARMA, INC. </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(A Development Stage Company) </B></FONT></P>
 <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>CONDENSED CONSOLIDATED STATEMENTS OF EXPENSES </B></FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(Amounts in thousands, except share and per share data) </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(Unaudited) </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="67%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>For the Three<BR>Months&nbsp;Ended<BR>March&nbsp;31,<BR>2012</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>For the Three<BR>Months&nbsp;Ended<BR>March&nbsp;31,<BR>2011</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Period&nbsp;from<BR>January 1, 2003<BR>(Date&nbsp;of&nbsp;Inception)<BR>to
March&nbsp;31,<BR>2012</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Expenses:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Research and development expense</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,392</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,941</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">40,817</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Research and development employee stock-based compensation expense</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">72</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">246</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,345</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Research and development non-employee stock-based compensation expense (income)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">157</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(31</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6,150</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Fair value of common stock issued in exchange for research and development expense</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">50</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4,004</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total research and development expense</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,671</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,156</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">54,316</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">General and administrative expense</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,458</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,921</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">29,431</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">General and administrative employee stock-based compensation expense</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">198</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,099</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">9,788</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Fair value of common stock warrants issued for general and administrative expense</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">148</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">76</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,550</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Fair value of common stock issued in exchange for general and administrative expense</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">135</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">23</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">489</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total general and administrative expense</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,939</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,119</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">42,258</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Operating loss</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(5,610</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(5,275</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(96,574</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Interest (expense) income</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(37</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">621</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Other (expense) income</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(19,114</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,435</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(6,077</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:7.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net loss </FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(24,761</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(3,841</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(102,030</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net loss per common share:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Basic and diluted loss per share</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(0.52</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(0.19</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">N/A</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Weighted average common shares outstanding:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Basic and diluted</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">47,967,499</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">20,316,170</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">N/A</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">The accompanying notes are an integral part of these consolidated financial statements. </FONT></P>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">2 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc333623_4"></A>GALENA BIOPHARMA, INC. </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(A Development Stage Company) </B></FONT></P>
 <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS </B></FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(Amounts in thousands) </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>(Unaudited) </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="66%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>For&nbsp;the&nbsp;Three<BR>Months&nbsp;Ended<BR>March&nbsp;31,<BR>2012</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>For&nbsp;the&nbsp;Three<BR>Months&nbsp;Ended<BR>March&nbsp;31,<BR>2011</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Period&nbsp;from<BR>January 1, 2003<BR>(Date&nbsp;of&nbsp;Inception)<BR>through<BR>March&nbsp;31,
2012</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Cash flows from operating activities:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net loss</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(24,761</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(3,841</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(102,030</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Adjustments to reconcile net loss to net cash used in operating activities:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Depreciation and amortization expense</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">42</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">37</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">706</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Loss on disposal of equipment</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">19</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Non-cash rent expense</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">29</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Accretion and receipt of bond discount</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">35</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Non-cash share-based compensation</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">427</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,314</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">19,285</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Loss on exchange of equity instruments</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">900</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Fair value of shares mandatorily redeemable for cash upon exercise of warrants</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(785</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Fair value of common stock warrants issued in exchange for services</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">148</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">76</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,550</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Fair value of common stock issued in exchange for services</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">185</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">23</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">539</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Change in fair value of common stock warrants issued in connection with various equity financings</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">18,270</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1,435</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6,198</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Fair value of common stock issued in exchange for licensing rights</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,954</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Change in fair value of contingent purchase consideration</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">844</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">735</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Changes in assets and liabilities:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:7.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Prepaid expenses and other current assets</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(14</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(133</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(263</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:7.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Accounts payable</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">426</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,650</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:7.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Due to former parent</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(207</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:7.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Accrued expenses and other current liabilities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(452</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">930</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,022</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Net cash used in operating activities</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(4,885</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(3,027</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(63,663</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Cash flows from investing activities:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Change in restricted cash</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(101</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Cash received in acquisition</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">168</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Purchase of short-term investments</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(37,532</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Maturities of short-term investments</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">37,497</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Cash paid for purchase of equipment and furnishings</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(40</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(739</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Disposal of equipment and furnishings</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Cash refunded (paid)&nbsp;for lease deposit</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(45</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Net cash used in investing activities</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(40</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(753</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Cash flows from financing activities:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net proceeds from issuance of common stock</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">385</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7,314</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">65,367</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Cash paid for repurchase of common stock</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(3,849</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net proceeds from exercise of common stock options</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">610</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net proceeds from exercise of common stock warrants</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,236</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,386</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Common stock issued in connection with ESPP</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">39</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">54</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net proceeds from issuance of convertible notes payable</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">500</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Repayments of capital lease obligations</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(7</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(23</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(217</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Cash advances from former parent company, net</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">8,766</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Net cash provided by financing activities</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,153</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7,291</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">73,117</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net (decrease) increase in cash and cash equivalents</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2,732</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4,224</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">8,701</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Cash and cash equivalents at the beginning of period</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">11,433</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6,891</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Cash and cash equivalents at end of period</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">8,701</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">11,115</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">8,701</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Supplemental disclosure of cash flow information:</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Cash received during the period for interest</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">727</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Cash paid during the period for interest</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">12</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Supplemental disclosure of non-cash investing and financing activities:</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Settlement of corporate formation expenses in exchange for common stock</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">978</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Fair value of warrants issued in connection with common stock recorded as a cost of equity</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4,212</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">18,038</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Issuance of common stock in exchange for outstanding warrants</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,120</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Fair value of shares mandatorily redeemable for cash upon the exercise of warrants</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">785</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Reclassification of warrant liability upon exercise</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,659</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,659</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Allocation of management expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">551</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Equipment and furnishings exchanged for common stock</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">48</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Equipment and furnishings acquired through capital lease</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">44</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">277</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Value of restricted stock units and common stock issued in lieu of bonuses included in accrued expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">427</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">634</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Non-cash lease deposit</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">50</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">The accompanying notes are an integral part of these consolidated financial statements. </FONT></P>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">3 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc333623_5"></A>GALENA BIOPHARMA, INC. </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(A Development Stage Company) </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(Unaudited)
</B></FONT></P>
 <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>1. Description of Business and Basis of Presentation </B></FONT></P>
 <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Galena Biopharma, Inc. (&#147;we,&#148; &#147;us,&#148; &#147;our,&#148; &#147;Galena&#148; or the &#147;Company&#148;)
is a biopharmaceutical company focused on developing innovative, next-generation cancer immunotherapies which address major unmet medical needs to advance care. Galena is developing innovative, peptide antigen-based &#147;off the shelf&#148; cancer
immunotherapies for potential application to treatment of large populations of Cancer Survivors. Peptide vaccines have several potential clinical advantages over existing cancer treatments including excellent safety profiles, long-lasting protection
through immune system activation, as well as an acceptable mode of administration (intradermal injection). A key differentiator in Galena&#146;s approach is the focus on &#147;minimal residual disease&#148; that may remain in Cancer Survivors. The
strategy is to prevent recurrence in early stage patient groups who may harbor &#147;occult&#148; residual cancer cells that are not detectable by current imaging and biomarkers, and despite adjuvant therapy and radiation therapy will relapse in
significant numbers over time. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%;padding-bottom:0px;"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our lead product candidate, NeuVax<FONT
STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&#153;</SUP></FONT> (E75), targets the HER2 tumor associated antigen peptide and is being developed to prevent or delay breast cancer
recurrence in a Phase 3 clinical trial under an FDA approved SPA (Special Protocol Assessment) and in combination with
Herceptin<B><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT></B> (trastuzumab: Genentech/Roche) in a Phase 2 clinical trial. Our second product candidate,
Folate Binding Protein (FBP), a targeted vaccine which consists of the E39 peptide over-expressed (20-80 fold) in more than 90% of ovarian and endometrial cancers, is currently in a Phase 1 clinical trial. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company was incorporated as Argonaut Pharmaceuticals, Inc., in Delaware, on April&nbsp;3, 2006. The Company changed its name to RXi
Pharmaceuticals Corporation on November&nbsp;28, 2006. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We acquired Apthera Inc., or &#147;Apthera,&#148; and our NeuVax
product candidate in April 2011. Prior to that time, we were engaged primarily in conducting discovery research and preclinical development activities based on RNAi. Our acquisition of Apthera followed from the determination by our board of
directors to broaden our strategic direction by giving us access to a late-stage clinical candidate, NeuVax. In connection with our acquisition of Apthera, we reduced the scope of our RNAi activities. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">On September&nbsp;26, 2011, the Company changed its name from RXi Pharmaceuticals Corporation to Galena Biopharma, Inc. in connection
with the Company&#146;s separation into two companies: (i)&nbsp;Galena, which will operate as a late-stage oncology drug development company; and (ii)&nbsp;RXi Pharmaceuticals Corporation, or RXi, which will continue to develop novel RNAi-based
therapies utilizing our historical RNAi assets. RXi was initially incorporated as RNCS, Inc. and assumed the name RXi Pharmaceuticals Corporation in conjunction with the change in the Company&#146;s name to Galena. On April 27, 2012, the planned
spin-out of RXi was completed (See Note 4). </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company has not generated any revenue from inception through March&nbsp;31,
2012 and is considered a development-stage company for accounting purposes. The Company may not generate product revenue in the foreseeable future, if ever. The Company expects to incur significant operating losses as it advances its product
candidates through the drug development and regulatory process. The Company expects to continue to devote a substantial portion of its resources to research and development programs. As a result of the costs expected to be incurred in connection
with our recently commenced clinical trials of NeuVax and FBP, the Company expects that our research and development expense will increase significantly from historic levels for the foreseeable future. The Company will need to generate significant
revenue to achieve profitability and might never do so. In the absence of product revenue, our potential sources of operational funding are expected to be the proceeds from equity financings, funded research and development payments and payments
received under partnership and collaborative agreements. There is no guarantee that additional funding will be available to the Company on acceptable terms, or at all. If the Company fails to obtain additional funding when needed, it would be forced
to scale back or terminate operations or to seek to merge with or to be acquired by another company. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Use of Estimates </I></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The preparation of consolidated financial statements in accordance with accounting principles generally accepted in the United States of
America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses
during the reporting period. Actual results could differ from these estimates. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Derivative Financial Instruments </I></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;During the normal course of business, from time to time, the Company issues warrants and options to
vendors as consideration to perform services. It may also issue warrants as part of financing transactions. The Company does not enter into any derivative contracts for speculative purposes. The Company recognizes all derivatives, including
warrants, as assets or liabilities measured at fair value with changes in fair value of derivatives reflected as current period income or loss unless the derivatives qualify for hedge accounting and are accounted for as such. In accordance with
Financial Accounting Standards Board (&#147;FASB&#148;) Accounting Standards Codification (&#147;ASC&#148;) Topic 815-40, &#147;<I>Derivatives and Hedging &#151; Contracts in Entity&#146;s Own Stock</I>&#148;, the value of some of our warrants is
required to be recorded as a liability, as the holders have an option to put the warrants back to the Company in specified events (see Note 9). </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Principles of Consolidation </I></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The consolidated financial statements include the accounts of Galena and its consolidated subsidiaries. All material intercompany accounts have been eliminated in consolidation. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Comprehensive Loss </I></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The
Company&#146;s comprehensive loss is equal to its net loss for all periods presented. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">4 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>2. Recent Accounting Pronouncements </B></FONT></P>
 <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I></I>In May&nbsp;2011, the FASB issued Accounting Standards Updated (&#147;ASU&#148;) 2011-04<I>, Fair Value
Measurement</I> (Topic 820): <I>Amendments to Achieve Common Fair Value Measurement and Disclosure Requirements in U.S. GAAP and IFRSs</I>, a new accounting standard that clarifies the application of certain existing fair value measurement guidance
and expands the disclosures for fair value measurements that are estimated using significant unobservable (Level 3) inputs. This new standard is effective on a prospective basis for annual and interim reporting periods beginning on or after
December&nbsp;15, 2011. The Company&#146;s adoption of this new standard did not have a material impact on the Company&#146;s consolidated financial statements. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><I></I>In June&nbsp;2011, the FASB issued ASU 2011-05, <I>Comprehensive Income</I> (Topic 220): <I>Presentation of Comprehensive Income</I>, a new accounting standard that eliminates the option to present
the components of other comprehensive income as part of the statement of changes in stockholders&#146; equity, requires the consecutive presentation of the statement of net income and other comprehensive income and requires an entity to present
reclassification adjustments on the face of the financial statements from other comprehensive income to net income. The amendments in this new standard do not change the items that must be reported in other comprehensive income or when an item of
other comprehensive income must be reclassified to net income nor do the amendments affect how earnings per share is calculated or presented. This new standard is required to be applied retrospectively and is effective for fiscal years and interim
periods within those years beginning after December&nbsp;15, 2011. As this new standard only requires enhanced disclosure, the adoption of this standard did not impact the Company&#146;s consolidated financial statements. </FONT></P>
 <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>3.&nbsp;Apthera Acquisition </B></FONT></P>
 <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">On April&nbsp;13, 2011, the Company completed its acquisition of Apthera, Inc., a Delaware corporation
(&#147;Apthera&#148;), under an Agreement and Plan of Merger (&#147;Merger Agreement&#148;) entered into on March&nbsp;31, 2011. Subject to the terms and conditions of the Merger Agreement, the Company&#146;s wholly owned subsidiary formed for this
purpose was merged with and into Apthera, with Apthera surviving as a wholly-owned subsidiary of the Company. Under the Merger Agreement, the Company issued to Apthera&#146;s stockholders approximately 5.0&nbsp;million shares of common stock of the
Company (the &#147;Aggregate Stock Consideration&#148;) and agreed to make future contingent payments of up to $32&nbsp;million based on the achievement of certain development and commercial milestones relating to the Company&#146;s NeuVax&#153;
product candidate. The contingent consideration is payable, at the election of the Company, in either cash or additional shares of common stock, provided that the Company may not issue any shares in satisfaction of any contingent consideration
unless it has first obtained approval of its stockholders in accordance with Rule 5635(a) of the NASDAQ Marketplace Rules. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In
connection with the Merger Agreement, the Company deposited with a third-party escrow agent certificates representing 10% of the Aggregate Stock Consideration, which shares will be available to compensate the Company and related parties for certain
indemnifiable losses as described in the Merger Agreement. On October&nbsp;13, 2011, the escrow agent released from the escrow 5% of the Aggregate Stock Consideration, or 248,705 shares. The remaining Aggregate Stock Consideration held with the
escrow agent was released in April 2012 (see Note 11). </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company&#146;s acquisition of Apthera was in concert with the
decision by the Company&#146;s Board of Directors to diversify its development programs and to become a late stage clinical development company. The Company does not expect any of its goodwill to be deductible for tax purposes. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The purchase price consideration and allocation of purchase price of Apthera were as follows: </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="91%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(in 000&#146;s)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Calculation of allocable purchase price:</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Fair value of shares issued at closing including escrowed shares expected to be released</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;6,367</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">(i)</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Estimated value of earn-out</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6,460</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total allocable purchase price</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">12,827</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Allocation of purchase price:</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Cash</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">168</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Prepaid expenses and other current assets</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">14</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Equipment and furnishings</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">11</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Goodwill</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5,898</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">In-process research and development</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">12,864</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Accounts payable</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(931</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Accrued expenses and other current liabilities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(143</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Notes payable</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Deferred tax liability, non-current</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(5,053</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">12,827</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(i)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">The value of the Company&#146;s common stock was based upon a per share value of $1.28, the closing price of the Company&#146;s common stock as of the close of business
on April&nbsp;13, 2011. </FONT></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">5 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The estimated value of the earn-out consideration of $6.5 million originally recorded was
based on the expected probability of achievement in the future of certain development and commercial milestones relating to the Company&#146;s NeuVax product candidate and then applying a discount rate, based on a corporate debt interest rate index
publicly issued, to the expected future payments. The expected timing of the milestones, the probability of success for each milestone and the discount rates applied are updated quarterly using the most current information to measure the contingent
liability as of the reporting date. On January&nbsp;19, 2012, the first milestone of $1,000,000 of this contingent liability was triggered with the first patient enrolled in our Phase 3 PRESENT clinical trial of NeuVax for breast cancer. The Company
issued 1,315,789 restricted shares of common stock in payment of the first milestone. The certificates evidencing the milestone shares have been deposited with a third party escrow agent. The milestone shares will be released to the Apthera
shareholders from escrow if the issuance of the milestone shares is approved by the stockholders of the Company at our 2012 annual stockholders meeting. Since the release of the shares is subject to stockholder approval, the $1,000,000 has been
recorded in accrued expenses and other current liabilities at March&nbsp;31, 2012 in the accompanying condensed consolidated balance sheet. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">If stockholder approval is obtained, the number of milestone shares will be subject to increase to the extent that $0.76 (<I>i.e</I>., the closing price of the Company&#146;s common stock as reported on
The NASDAQ Capital Market on January&nbsp;18, 2012, the day prior to achievement of its first milestone, used for purposes of determining the number of milestone shares) is greater than the closing price of common stock as of the most recent trading
day prior to the receipt of stockholder approval. Whether or not stockholder approval is obtained, in addition to the release from escrow of the milestone shares or the payment in cash of the initial milestone, as the case may be, the Company will
pay concurrently to the former Apthera shareholders in cash an interest factor of ten percent (10%)&nbsp;per annum on the amount of the final milestone from February&nbsp;10, 2012 through the day immediately prior to the release of the milestone
shares from escrow or the cash payment, as the case may be, less certain legal fees of the stockholder representative to be paid or reimbursed by the Company. As of March&nbsp;31, 2012, $13,699 of interest had been accrued on this note and is
included in accrued expenses and other current liabilities in the accompanying condensed consolidated balance sheet. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The
increase in the fair value of the contingent liability during the three months ended March&nbsp;31, 2012 is $844,000, which was included in other income (expense) in the accompanying consolidated statements of expenses. The fair value of the
contingent liability at March&nbsp;31, 2012 was $6,195,000. Of this amount, $898,000 was recorded as a current contingent liability. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The following presents the pro forma net loss and pro forma net loss per common share for the three months ended March&nbsp;31, 2011: </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="87%"></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>For the Three<BR>Months&nbsp;Ended<BR>March&nbsp;31,&nbsp;2011</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net loss</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(4,397</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net loss per common share</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(0.17</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Weighted average shares outstanding</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">25,290,260</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>4.&nbsp;RXi Spin-Out </B></FONT></P>
 <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Contribution Agreement </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">On September&nbsp;24, 2011, the Company entered into a Contribution Agreement (&#147;Contribution Agreement&#148;) with RXi pursuant to which we assigned and contributed to RXi substantially all of the
Company&#146;s RNAi-related technologies and assets. The contributed assets consist primarily of our novel RNAi compounds and licenses relating to our RNAi technologies, as well as the lease of our Worcester, Massachusetts laboratory facility, fixed
assets and other equipment located at the facility and our employment arrangements with certain scientific, corporate and administrative personnel who have become employees of RXi. The Company also contributed $1.5&nbsp;million of cash to the
capital of RXi. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pursuant to the Contribution Agreement, RXi assumed certain accrued expenses of our RXI-109 development
program and all subsequent obligations under the contributed licenses, employment arrangements and other agreements. RXi has agreed to make future milestone payments to us of up to $45&nbsp;million, consisting of two one-time payments of
$15&nbsp;million and $30&nbsp;million, respectively, if RXi achieves annual net sales equal to or greater than $500 million and $1&nbsp;billion, respectively, of any covered products that may be developed with the contributed RNAi technologies.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In the Contribution Agreement, the Company made customary representations and warranties to RXi regarding the contributed
assets and other matters, and the parties have agreed to customary covenants regarding the conduct of RXi&#146;s business pending the spin-off of RXi. The parties also have agreed to indemnify each other against losses arising from a breach of their
respective representations, warranties and covenants set forth in the Contribution Agreement. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">6 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Securities Purchase Agreement </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">On September&nbsp;24, 2011, the Company also entered into a Securities Purchase Agreement (&#147;Securities Purchase Agreement&#148;) with
RXi and two institutional Investors (the &#147;Investors&#148;), pursuant to which the Investors agreed to purchase a total of $9,500,000 of Series&nbsp;A Preferred Stock of RXi (&#147;RXi Preferred Stock&#148;) at the closing of the spin-off of
RXi, and to lend up to $1,500,000 to RXi to fund its operations between signing and closing (the &#147;Bridge Loan&#148;). The outstanding principal and accrued interest from the Bridge Loan will, except under certain circumstances described below,
be converted into RXi Preferred Stock at the closing of the spin-off of RXi and will represent a portion of the $9,500,000 total investment, which is referred to herein as the &#147;RXi financing.&#148; The RXi&nbsp;financing and the spin-off of RXi
were subject to customary closing conditions, including the registration under the Securities Act of 1933, as amended (the &#147;Securities Act&#148;), of the distribution by us of the spin-off shares. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The RXi Preferred Stock will be convertible by a holder at any time into shares of RXi common stock, except to the extent that the holder
would own more than 9.999% of the shares of RXi common stock outstanding immediately after giving effect to such conversion. Without regard to this conversion limitation, the shares of the Preferred Stock to be held by the Investors upon completion
of the RXi financing and the spin-off of RXi will be convertible into shares of RXi common stock representing approximately 83% of the shares of RXi common stock that would be outstanding, assuming the conversion in full of the Preferred Stock,
which we refer to as the &#147;as-converted common stock.&#148; The Company will own approximately 12% of the as-converted common stock immediately prior to the spin-off of RXi, and Advirna, LLC, a licensor of RXi, will be issued the remaining 5% of
the as-converted common stock pursuant to the agreement with Advirna, LLC as described below. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Spin-Off </I></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company agreed in the Securities Purchase Agreement to undertake to distribute to our stockholders on a share-for-share basis
approximately 8% of the as-converted common stock of RXi, subject to the registration of the distribution of such shares under the Securities Act of 1933 and other conditions, which distribution was completed on April 27, 2012 (see Note 11). The
Company has retained 4% of the as-converted common stock, and has agreed, in the Securities Purchase Agreement, not to sell or dispose of the Company&#146;s shares of RXi common stock for a one-year period following completion of the spin-off of
RXi. Under the Securities Purchase Agreement, one share of RXi was distributed as a dividend on each share of Galena that is issued and outstanding as of the record date for the distribution of April 23, 2012. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Purchase Agreement Terms and Conditions </I></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">In the Securities Purchase Agreement, the parties have made customary representations and warranties to the other parties and have agreed to customary covenants regarding the parties&#146; actions in
connection with the spin-off of RXi and other matters, including the filing of a resale registration statement registering a portion of the common stock underlying the conversion of the Preferred Stock. The parties also have agreed to indemnify each
other against losses arising from a breach of their respective representations, warranties and covenants set forth in the Securities Purchase Agreement. Per the agreement, upon the closing of the transaction, on April 27, 2012, RXi reimbursed the
Company and the Investors in the amount of $300,000 and $100,000, respectively, for transaction costs relating to the Contribution Agreement, the Securities Purchase Agreement and the transactions called for by the agreements. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Bridge Loan </I></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Pursuant to the Securities Purchase Agreement, the Investors provided Bridge Loans by purchasing $1,000,000 of secured convertible promissory notes of RXi (&#147;RXi convertible notes&#148;). The RXi
convertible notes will, except as described below, be convertible into shares of RXi Preferred Stock at a conversion price of $1,000 per share. The RXi convertible notes accrued interest at a rate of 7%&nbsp;per annum (or 18%&nbsp;per annum in the
case of an event of default) and matured on April&nbsp;27, 2012, the closing date. As of March 31, 2012, RXi had $1,000,000 of RXi convertible notes outstanding. As the Company was relieved of this obligation upon the spin-out, the amount has been
recorded as a long-term liability as of March 31, 2012. Approximately $21,000 of interest has been recorded in accrued expenses and other current liabilities at March&nbsp;31, 2012 in the accompanying condensed consolidated balance sheet.
</FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Advirna Agreement </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">As part of the closing transaction as detailed in the Contribution Agreement and Securities Purchase Agreement, RXi entered into an agreement with Advirna, LLC, which the Company refers to as
&#147;Advirna,&#148; a company affiliated with Anastasia Khvorova, Ph.D., RXi&#146;s former Senior Vice President and Chief Scientific Officer. In the agreement, Advirna has agreed to amend its existing patent and technology assignment agreement
with RXi to eliminate all clinical milestone and royalty payments to Advirna under the amended agreement; obligations remain to make an annual $100,000 maintenance fee and a one-time milestone payment of $350,000 to Advirna upon the issuance of a
patent with valid claims covering the assigned technology. Additionally, RXi will be required to pay a 1% royalty to Advirna for any licensing revenue received by RXi on the license of the assigned Advirna technology. In exchange, RXi issued to
Advirna upon the closing transaction a number of shares of RXi common stock equal to 5% of the as-converted common stock of RXi. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The transactions contemplated by the Securities Purchase Agreement were completed in April 2012 (see Note 11). </FONT></P>
 <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>5. Fair Value Measurements </B></FONT></P>
 <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company follows the provisions of FASB ASC Topic 820, <I>&#147;Fair Value Measurements and Disclosures&#148;</I>
(&#147;ASC 820&#148;) for the Company&#146;s financial assets and liabilities that are re-measured and reported at fair value at each reporting period, and are re-measured and reported at fair value at least annually using a fair value hierarchy
that is broken down into three levels. Level inputs are as defined as follows: </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Level 1 &#151; quoted prices in active markets for identical
assets or liabilities. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">7 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Level 2 &#151; other significant observable inputs for the assets or liabilities through corroboration with
market data at the measurement date. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Level 3 &#151; significant unobservable inputs that reflect management&#146;s best estimate of what
market participants would use to price the assets or liabilities at the measurement date. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company categorized its cash
equivalents as a Level 1 hierarchy. The valuation for Level 1 was determined based on a &#147;market approach&#148; using quoted prices in active markets for identical assets. Valuations of these assets do not require a significant degree of
judgment. The Company categorized its warrants potentially settled in cash as a Level 2 hierarchy. The warrants are measured at fair market value on a recurring basis and are being marked to market each quarter-end until they are settled. The
contingent purchase price consideration is categorized as a Level 3 hierarchy and is measured at its estimated fair value on a recurring basis and is adjusted at each quarter-end until it is completely settled. The contingent price consideration is
valued based on the expected timing of milestones, the expected probability of success for each milestone and the updated discount rates based on a corporate debt interest rate index publicly issued. </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="66%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Description</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>March&nbsp;31,<BR>2012</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Quoted<BR>Prices&nbsp;in<BR>Active<BR>Markets<BR>(Level&nbsp;1)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Significant<BR>Other<BR>Observable<BR>Inputs<BR>(Level 2)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Unobservable<BR>Inputs<BR>(Level&nbsp;3)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Assets:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Cash equivalents</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7,453</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7,453</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total assets</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7,453</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7,453</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Liabilities:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Warrants potentially settleable in cash</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">20,357</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">20,357</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Contingent purchase price consideration</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6,195</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6,195</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total liabilities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">26,552</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">20,357</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6,195</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="66%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Description</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>December&nbsp;31,<BR>2011</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Quoted<BR>Prices in<BR>Active<BR>Markets<BR>(Level&nbsp;1)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Significant<BR>Other<BR>Observable<BR>Inputs<BR>(Level 2)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Unobservable<BR>Inputs<BR>(Level&nbsp;3)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Assets:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Cash equivalents</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">11,433</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">11,433</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total assets</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">11,433</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">11,433</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Liabilities:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Warrants potentially settleable in cash</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,746</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,746</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Contingent purchase price consideration</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6,351</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6,351</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total liabilities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">10,097</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,746</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6,351</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Fair Value of Financial Instruments </I></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The carrying amounts reported in the balance sheet for cash equivalents, accounts payable, capital leases and convertible notes payable approximate their fair values due to their short-term nature and
market rates of interest. </FONT></P>
 <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>6. Stock Based Compensation </B></FONT></P>
 <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company follows the provisions of the FASB ASC Topic 718, &#147;<I>Compensation &#151; Stock Compensation</I>&#148;
(&#147;ASC 718&#148;), which requires the measurement and recognition of compensation expense for all share-based payment awards made to employees, non-employee directors, and consultants, including employee stock options. Stock compensation expense
based on the grant date fair value estimated in accordance with the provisions of ASC 718 is recognized as an expense over the requisite service period. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">For stock options granted as consideration for services rendered by non-employees, the Company recognizes compensation expense in accordance with the requirements of FASB ASC Topic 505-50, &#147;<I>Equity
Based Payments to Non-Employees.&#148;</I> </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Non-employee option grants that do not vest immediately upon grant are recorded as
an expense over the vesting period of the underlying stock options. At the end of each financial reporting period prior to vesting, the value of these options, as calculated using the Black-Scholes option-pricing model, will be re-measured using the
fair value of the Company&#146;s common stock and the non-cash compensation recognized during the period will be adjusted accordingly. Since the fair market value of options granted to non-employees is subject to change in the future, the amount of
the future compensation expense will include fair value re-measurements until the stock options are fully vested. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">8 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company is currently using the Black-Scholes option-pricing model to determine the fair
value of all its option grants. For option grants issued in the three month period ended March&nbsp;31, 2012 and 2011, the following assumptions were used: </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="89%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>For The Three<BR>Months Ended<BR>March 31,</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2012</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2011</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Weighted average risk-free interest rate</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.06</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.33</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Weighted average expected volatility</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">75.69</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">112.95</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Weighted average expected lives (years)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6.10</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5.76</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Weighted average expected dividend yield</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.00</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.00</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The weighted average fair value of options granted during the three month period ended March&nbsp;31,
2012 and 2011 was $0.48 and $1.20 per share, respectively. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company&#146;s expected common stock price volatility
assumption is based upon the volatility of a basket of comparable companies. The expected life assumptions for employee grants were based upon the simplified method provided for under ASC 718-10. The expected life assumptions for non-employees were
based upon the contractual term of the option. The dividend yield assumption of zero is based upon the fact that the Company has never paid cash dividends and presently has no intention of paying cash dividends. The risk-free interest rate used for
each grant was also based upon prevailing short-term interest rates. The Company has estimated an annualized forfeiture rate of 15.0% for options granted to its employees, 8.0% for options granted to senior management and no forfeiture rate for the
directors. RXi will record additional expense if the actual forfeitures are lower than estimated and will record a recovery of prior expense if the actual forfeiture rates are higher than estimated. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following table summarizes stock option activity from January&nbsp;1, 2012 through March&nbsp;31, 2012: </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="77%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Total<BR>Number of<BR>Shares</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Weighted<BR>Average<BR>Exercise<BR>Price</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Aggregate<BR>Intrinsic<BR>Value</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Outstanding at January&nbsp;1, 2012</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6,163,137</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.03</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Granted</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,275,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.72</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,912,500</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Exercised</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Cancelled</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Outstanding at March&nbsp;31, 2012</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7,438,137</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.63</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5,308,950</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Options exercisable at March&nbsp;31, 2012</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4,985,548</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.31</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,365,593</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The aggregate intrinsic values of outstanding and exercisable options at March&nbsp;31, 2012 were
calculated based on the closing price of the Company&#146;s common stock on March&nbsp;31, 2012 of $2.22 per share less the exercise price of those shares. The aggregate intrinsic values of options exercised was calculated based on the difference
between the exercise price of the underlying awards and the quoted price of the Company&#146;s common stock on the date of exercise. </FONT></P>
 <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>7. Net Loss Per Share </B></FONT></P>
 <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company accounts for and discloses net loss per common share in accordance with FASB ASC Topic 260 &#147;
<I>Earnings per Share.&#148;</I> Basic net loss per common share is computed by dividing net loss attributable to common stockholders by the weighted average number of common shares outstanding. Diluted net loss per common share is computed by
dividing net loss attributable to common stockholders by the weighted average number of common shares that would have been outstanding during the period assuming the issuance of common shares for all potential dilutive common shares outstanding.
Potential common shares consist of shares issuable upon the exercise of stock options and warrants. Because the inclusion of potential common shares would be anti-dilutive for all periods presented diluted net loss per common share is the same as
basic net loss per common share. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following table sets forth the potential common shares excluded from the calculation of
net loss per common share because their inclusion would be anti-dilutive: </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="82%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>March&nbsp;31,</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2012</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2011</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Options to purchase common stock</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7,438,137</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6,065,264</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Warrants to purchase common stock</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">13,116,698</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">8,250,642</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">20,554,835</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">14,315,906</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>8. License Agreements </B></FONT></P>
 <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">9 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">As part of its business, the Company enters into licensing agreements, which often require
milestone and royalty payments based on the progress of the asset through development stages. Milestone payments may be required, for example, upon approval of the product for marketing by a regulatory agency. In certain agreements, the Company is
required to make royalty payments based upon a percentage of product sales. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">An individual milestone payment required under
the licensing arrangements may be material, and in the event that multiple milestones are reached in the same period, the aggregate payments associated with the milestones could adversely affect the results of operations or affect the comparability
of our period-to-period results. In addition, these licensing arrangements often give the Company the discretion to unilaterally terminate development of the product, which would allow the Company to avoid making the contingent payments; however,
the Company is unlikely to cease development if the compound successfully achieves clinical testing objectives. The Company&#146;s contractual obligations relating to minimum annual maintenance fees and milestone payments have not changed
significantly from December&nbsp;31, 2011. </FONT></P>
 <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>9. Stockholders&#146; Equity </B></FONT></P>
 <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Preferred Stock</I> &#151; The Company has authorized up to 5,000,000&nbsp;shares of preferred stock,
$0.0001&nbsp;par value per share, for issuance. The preferred stock will have such rights, preferences, privileges and restrictions, including voting rights, dividend rights, conversion rights, redemption privileges and liquidation preferences, as
shall be determined by the Company&#146;s board of directors upon its issuance. To date, the Company has not issued any preferred shares. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><I>Common Stock</I> &#151; The Company has authorized up to 125,000,000&nbsp;shares of common stock, $0.0001&nbsp;par value per share, for issuance. Shares of common stock are reserved as follows:
</FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="89%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>As of<BR>March&nbsp;31,<BR>2012</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Warrants outstanding</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">13,116,698</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Stock options outstanding</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7,438,137</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Options reserved for future issuance under the Company&#146;s 2007 Incentive Plan</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">24,717</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total reserved for future issuance</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">20,579,552</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Common Stock Warrants</I> &#151; On August&nbsp;7, 2008, the Company issued 190,000 warrants to an
investment bank as consideration for investment and business advisory services. The warrants have an exercise price of $7.036 per share and expire 5&nbsp;years from the date of issuance, on August&nbsp;7, 2013. The warrants vested as to
94,000&nbsp;shares upon issuance, and vested at a rate of 32,000&nbsp;shares&nbsp;per month starting on the 90&nbsp;day anniversary of issuance, and are exercisable for a period of five years. All shares were vested and compensation cost was fully
recorded at December&nbsp;31, 2009. The Company also agreed to give the holder of the warrants unlimited &#147;piggy back&#148; registration rights with respect to the shares of the Company&#146;s common stock underlying the warrants in any
registration statement the Company files in connection with an underwritten offering of its common stock. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">On January&nbsp;29,
2009, the Company issued 142,500 warrants to an investment bank as consideration for investment and business advisory services. The warrants have an exercise price of $4.273 per share and expire five years from the date of issuance on
January&nbsp;29, 2014. The warrants vested as to 71,250&nbsp;shares upon issuance, and vested at a rate of 23,750&nbsp;shares&nbsp;per month starting on the 90&nbsp;day anniversary of issuance, and are exercisable for a period of five years. All
shares were vested and compensation expense was fully recorded at December&nbsp;31, 2009. The Company has also agreed to give the holder of the warrants unlimited &#147;piggy back&#148; registration rights with respect to the shares of Common Stock
underlying the warrants in any registration statement the Company files in connection with an underwritten offering of the common stock. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">In connection with the 2009 Offering, the Company issued warrants to purchase 978,142&nbsp;shares of the Company&#146;s common stock. Details of the transaction can be found under the heading &#147;2009
Registered Direct Offering&#148; below. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In connection with the 2010 Offering, the Company issued warrants to purchase
540,000&nbsp;shares of the Company&#146;s common stock. Details of the transaction can be found under the heading &#147;2010 Registered Direct Offering&#148; below. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">In connection with the March 2011 Offering, the Company issued warrants to purchase 6,000,000&nbsp;shares of the Company&#146;s common stock. Details of the transaction can be found under the heading
&#147;March 2011 Registered Direct Offering&#148; below. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In connection with the April 2011 Offering, the Company issued
warrants to purchase 11,950,000&nbsp;shares of the Company&#146;s common stock. Details of the transaction can be found under the heading &#147;April 2011 Registered Direct Offering&#148; below. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">During 2011, the Company issued 150,000 warrants in exchange for business advisory services. The Company recognizes the total fair value
of these warrants as stock compensation expense, over the requisite service period. The Company used the Black-Scholes option pricing model to compute the estimated fair value of these warrant grants on the date of the award. Total expense related
to these warrants was $108,000 in 2011 and compensation expense was fully recorded as of December 31, 2011. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">During the
quarter ended March&nbsp;31, 2012, the Company issued 400,000 warrants in exchange for business advisory services. The Company recognizes the total fair value of these warrants as stock compensation expense, over the requisite service period. The
Company used the Black-Scholes option pricing model to compute the estimated fair value of these warrant grants which are marked to market over the vesting period of the related warrants. Total expense related to these warrants was $148,000 for the
quarter ended March&nbsp;31, 2012. </FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">10 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Private Investment in Public Equity</I> &#151; On June 24, 2008, the Company entered into
a Securities Purchase Agreement pursuant to which the Company issued and sold to certain investors an aggregate of 1,073,299&nbsp;shares of common stock in a private placement at a price of $8.12 per share. Net proceeds to the Company were
approximately $7.9&nbsp;million. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>2009 Registered Direct Offering</I> &#151; On March&nbsp;17, 2009, the Company entered
into a placement agency agreement, which was subsequently amended on May&nbsp;26, 2009 and July&nbsp;22, 2009, with Rodman&nbsp;&amp; Renshaw, LLC (&#147;Rodman&#148;) as the exclusive placement agent, relating to a proposed offering by the Company
of new securities to potential investors. On July&nbsp;30, 2009, the Company entered into definitive agreements for the sale and issuance by the Company to certain investors of 2,385,715&nbsp;units, with each unit consisting of one share of the
Company&#146;s common stock and a warrant to purchase 0.40 of a share of common stock, at a purchase price of $3.50 per unit (the &#147;2009 Offering&#148;). The 2009 Offering closed on August&nbsp;4, 2009. The warrants have an exercise price of
$4.50 per share and are exercisable for a period beginning on February&nbsp;3, 2010 until their expiration on August&nbsp;3, 2014. The Company raised gross proceeds of approximately $8,350,000 in the 2009 Offering and net cash proceeds, after
deducting the placement agents&#146; fees and other offering expenses payable by the Company, of approximately $7.7&nbsp;million. Total warrants issued in connection with the transaction were 954,285. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">As part of the placement agency agreement, the Company issued a warrant to purchase 23,857&nbsp;shares of the Company&#146;s common stock
to Rodman. The warrant has an exercise price of $4.38 per share. The warrant is immediately vested and is exercisable until its expiration on August&nbsp;3, 2014. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Certain warrants issued in connection with the stock offering on August&nbsp;4, 2009 were determined not to be indexed to the Company&#146;s common stock as they are potentially settleable in cash. The
fair value of the warrants at the dates of issuance totaling $2,863,000 was recorded as a liability and a cost of equity and was determined using the Black-Scholes option pricing model. Due to the fact that the Company has limited trading history,
the Company&#146;s expected stock volatility assumption is based on a combination of implied volatilities of similar entities whose share or option prices are publicly traded. The Company used a weighted average expected stock volatility of 122.69%.
The expected life assumption is based on the contract term of five years. The dividend yield of zero is based on the fact that the Company has no present intention to pay cash dividends in the future. The risk free rate of 1.72% used for the warrant
is equal to the zero coupon rate in effect at the time of the grant. The increase in the fair value of warrants from December&nbsp;31, 2011 to March&nbsp;31, 2012 of $384,000 has been included in other expense in the accompanying condensed
statements of expenses for the three months ended March&nbsp;31, 2012. The fair value of the warrants at March&nbsp;31, 2012 of $448,000 is included as a current liability in the accompanying condensed balance sheets and was determined using the
Black-Scholes option pricing model. Due to the fact that the Company has limited trading history, the Company&#146;s expected stock volatility assumption is based on a combination of implied volatilities of similar entities whose share or option
prices are publically traded. The Company used a weighted average expected stock volatility of 68.29%. The expected life assumption is based on the remaining contract term of 2.3 years. The dividend yield of zero is based on the fact that we have no
present intention to pay cash dividends. The risk free rate of 0.39% used for the warrants is equal to the zero coupon rate in effect on the date of the re-measurement. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><I>2010 Registered Direct Offering</I> &#151; On March&nbsp;22, 2010, the Company entered into a placement agency agreement relating to a proposed offering by the Company of new securities to potential
investors. On March&nbsp;23, 2010, the Company entered into definitive agreements for the sale and issuance by the Company to certain investors of 2,700,000&nbsp;units, with each unit consisting of one share of the Company&#146;s common stock and a
warrant to purchase 0.20 of a share of the Company&#146;s common stock, at a purchase price of $6.00 per unit (the &#147;2010 Offering&#148;). The 2010 Offering closed on March&nbsp;26, 2010. The Company issued warrants to purchase
540,000&nbsp;shares of the Company&#146;s common stock at an exercise price of $6.00 per share and that are exercisable beginning on September&nbsp;26, 2010 until their expiration on March&nbsp;26, 2016. The Company raised gross proceeds of
approximately $16.2&nbsp;million in the 2010 Offering and net cash proceeds, after deducting the placement agent fees and other offering expenses payable by the Company, of approximately $15.2&nbsp;million. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">As part of the 2010 Offering, the Company entered in a stock redemption agreement whereby the Company was required to use 25% of the net
proceeds from the 2010 Offering to repurchase from CytRx Corporation (&#147;CytRx&#148;) 675,000 shares of the Company&#146;s common stock held by CytRx (&#147;CytRx shares&#148;). The Company repurchased such shares on March&nbsp;29, 2010. The
values of the shares at the date of repurchase totaling $3,849,000 were recorded at cost and have been included in treasury stock in the accompanying condensed consolidated balance sheet at March 31, 2012 and 2011. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Certain warrants issued in connection with the 2010 Offering were determined not to be indexed to the
Company&#146;s common stock as they are potentially settleable in cash. The fair value of the warrants at the dates of issuance totaling $2,466,000 was recorded as a liability and a cost of equity and was determined using the Black-Scholes option
pricing model. Due to the fact that the Company has limited trading history, the Company&#146;s expected stock volatility assumption is based on a combination of implied volatilities of similar entities whose share or option prices are publically
traded. The Company used a weighted average expected stock volatility of 119.49%. The expected life assumption is based on the contract term of 6.5&nbsp;years. The dividend yield of zero is based on the fact that the Company has no present intention
to pay cash dividends. The risk free rate of 3.22% used for the warrant is equal to the zero coupon rate in effect at the time of the grant. During the three months ended March 31, 2012, 180,000 of the five-year warrants were exercised at $2.50 per
common share. These warrants were marked to market through March 31, 2012, resulting in additional expense of $215,000. Upon exercise, a liability in the amount of $254,000 was relieved as a credit to additional paid-in capital. The increase in the
fair value of warrants from December&nbsp;31, 2011 to March&nbsp;31, 2012 of $402,000 has been included in other expense in the accompanying condensed statements of expenses for the three months ended March&nbsp;31, 2012. The fair value of the
warrants at March&nbsp;31, 2012 of $479,000 is included as a current liability in the accompanying condensed balance sheets and was determined using the Black-Scholes option pricing model. Due to the fact that the Company has limited trading
history, the Company&#146;s expected stock volatility assumption is based on a combination of implied volatilities of similar entities whose share or option prices are publically traded. The Company used a weighted average expected stock volatility
of 81.86%. The expected life assumption is based on the remaining contract term of 4.5 years. The dividend yield of zero is based on the fact that we have no present intention to pay cash dividends. The risk free rate of 0.91% used for the warrants
is equal to the zero coupon rate in effect on the date of the re-measurement. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">11 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>March 2011 Registered Direct Offering</I> &#151; On March&nbsp;4, 2011, the Company
closed an underwritten public offering of 6,000,000 units at a price to the public of $1.35 per unit for gross proceeds of $8.1&nbsp;million (the &#147;March&nbsp;2011 Offering&#148;). The offering provided approximately $7.3&nbsp;million to the
Company after deducting the underwriting discounts and commissions and offering expenses. Each unit consists of (i)&nbsp;one share of common stock, (ii)&nbsp;a thirteen-month warrant to purchase 0.50 of a share of common stock at an exercise price
of $1.70 per share (subject to anti-dilution adjustment) and (iii)&nbsp;a five-year warrant to purchase 0.50 of a share of common stock at an exercise price of $1.87 per share (subject to anti-dilution adjustment). On April&nbsp;15, 2011, the
holders of outstanding warrants issued in the March&nbsp;2011 Offering to purchase an aggregate of 3,450,000 shares of common stock agreed to exchange such warrants for warrants exercisable for the same number of shares as those being exchanged, but
otherwise on the same terms of the warrants sold in the Company&#146;s April&nbsp;2011 financing. Prior to the exchange, the Company recorded a decrease in fair value of $1,000,000 related to the exchanged warrants. Upon the exchange, the Company
recorded a loss of $900,000, which represented the difference between the adjusted fair value of the March&nbsp;2011 warrants as compared to the fair value of the April&nbsp;2011 warrants received in the exchange. As a result of a subsequent
offering that was completed on April&nbsp;15, 2011, the exercise price of the remaining 2,550,000 outstanding warrants sold in the March&nbsp;2011 Offering was reduced to $1.00 per share as a result of the anti-dilution adjustment. As a result of
the subsequent offering on September&nbsp;26, 2011, the exercise price of all warrants sold in the March&nbsp;4, 2011 Offering were reduced to $0.65 per share as a result of the anti-dilution adjustment. At March&nbsp;31, 2012, of the 2,550,000
unexchanged warrants from the March&nbsp;2011 Offering, 1,373,944 warrants had been exercised with a remaining outstanding balance of 1,176,056. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The thirteen-month and five-year warrants issued in connection with the March 2011 Offering were determined not to be indexed to the Company&#146;s common stock as they are potentially settleable in cash.
The fair value of the 2,550,000 warrants at the date of issuance totaling $1,790,000 was recorded as a liability and a cost of equity and was determined using the Black-Scholes option pricing model. Due to the fact that the Company has limited
trading history, the Company expected stock volatility assumption is based on a combination of implied volatilities of similar entities whose shares or options are publicly traded. The Company used a weighted average expected stock volatility of
113.25%. The expected life assumption is based on the contract term of 1.08 years used for the thirteen-month warrants and 5 years used for the five-year warrants. The dividend yield of zero is based on the fact that we have no present intention to
pay cash dividends. The risk free rate of 0.26% used for the thirteen-month warrants and 2.17% used for the five-year warrants is equal to the zero coupon rate in effect at the time of the grant. In July 2011, 75,000 of the thirteen-month warrants
were exercised at $1.00 per common share, which resulted in a $34,000 reduction of the warrant liability. In July 2011, 75,000 of the five-year warrants were exercised at $1.00 per common share, which resulted in a $68,000 reduction of the warrant
liability. During the three months ended March 31, 2012, 862,500 of the thirteen-month warrants and 361,444 of the five-year warrants were exercised at $0.65 per common share. These warrants were marked to market through March 31, 2012, resulting in
additional expense of $1,256,000. Upon exercise, a liability in the amount of $1,405,000 was relieved as a credit to additional paid-in capital. The increase in the fair value of warrants from December&nbsp;31, 2011 to March&nbsp;31, 2012 of
$1,765,000 has been included in other expense in the accompanying condensed statements of expenses for the three months ended March&nbsp;31, 2012. The fair value of the warrants at March&nbsp;31, 2012 of $2,028,000 is included as a current liability
in the accompanying condensed balance sheets and was determined using the Black-Scholes option pricing model. Due to the fact that the Company has limited trading history, the Company&#146;s expected stock volatility assumption is based on a
combination of implied volatilities of similar entities whose share or option prices are publically traded. The Company used a weighted average expected stock volatility of 47.29% for the thirteen-month warrants and 81.99% for the five-year
warrants. The expected life assumption is based on the remaining contract term of 0.01 years used for the thirteen-month warrants and 3.93 years used for the five-year warrants. The dividend yield of zero is based on the fact that we have no present
intention to pay cash dividends. The risk free rate of 0.01% used for the thirteen-month warrants and 0.78% used for the five-year warrants is equal to the zero coupon rate in effect at the time of the re-measurement. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>April 2011 Registered Direct Offering</I> &#151; On April&nbsp;20, 2011, the Company completed an underwritten public offering of
11,950,000 units at a price to the public of $1.00 per unit for gross proceeds of approximately $12&nbsp;million (the &#147;April&nbsp;2011 Offering&#148;). Each unit consisted of one share of common stock and a warrant to purchase one share of
common stock at an exercise price of $1.00 per share (subject to anti-dilution adjustment). The shares of common stock and warrants were immediately separable and no separate units were issued. The warrants are exercisable beginning one year and one
day from the date of issuance, and expire on the sixth anniversary of the date of issuance. Net proceeds, after underwriting discounts and commissions and other offering expenses, were approximately $10.9&nbsp;million. As a result of the subsequent
offering that was completed on September&nbsp;26, 2011, the exercise price of the 11,950,000 outstanding warrants sold in the April&nbsp;2011 Offering was reduced to $0.65 per share as a result of the anti-dilution adjustment.&nbsp;On
December&nbsp;6, 2011, the Company effected a warrant exchange with a ratio of 1.42857 warrants in exchange for one share of common stock with several of the April 2011 warrant holders. In total, 5,930,000 warrants were exchanged for 4,151,000
shares of common stock in this transaction. At March 31, 2012, 6,020,000 warrants sold in the April&nbsp;20, 2011 Offering remained outstanding. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The warrants issued in connection with the April 2011 Offering, including the warrants issued in exchange for the 3,450,000&nbsp;March 2011 warrants, were
determined not to be indexed to the Company&#146;s common stock as they are potentially settleable in cash. The fair value of the warrants at the dates of issuance totaling $11,442,000 was recorded as a liability and a cost of equity and was
determined using the Black-Scholes option pricing model. Due to the fact that the Company has limited trading history, the Company&#146;s expected stock volatility assumption is based on a combination of implied volatilities of similar entities
whose shares or options are publicly traded. The Company used a weighted average expected stock volatility of 99.04%. The expected life assumption is based on the contract term of 6.0 years. The dividend yield of zero is based on the fact that we
have no present intention to pay cash dividends. The risk free rate of 2.81% used for the warrants is equal to the zero coupon rate in effect at the time of the grant. In December 2011, the Company exchanged 4,151,000 shares of common stock in
exchange for 5,930,000 of these April warrants at a ratio of 0.7 common shares for each warrant which resulted in a reduction to warrant liability of $3,120,000. The increase in the fair market value of the warrants, including the warrants exchanged
for the 3,450,000 March 2011 warrants, from December&nbsp;31, 2011 to March&nbsp;31, 2012 of $14,248,000 has been included in other expense in the accompanying condensed statements of expenses for the three months ended March&nbsp;31, 2012. The fair
value of the warrants at March&nbsp;31, 2012 of $17,402,000 is included as a current liability in the accompanying condensed balance sheets and was determined using the Black-Scholes option pricing model. Due to the fact that the Company has limited
trading history, the </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">12 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
Company&#146;s expected stock volatility assumption is based on a combination of implied volatilities of similar entities whose share or option prices are publically traded. The Company used a
weighted average expected stock volatility of 79.77%. The expected life assumption is based on the remaining contract term of 5.1 years. The dividend yield of zero is based on the fact that we have no present intention to pay cash dividends. The
risk free rate of 1.04% used for the warrants is equal to the zero coupon rate in effect on the date of the re-measurement. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>September 2011 Registered Direct Offering</I> &#151; On September&nbsp;26, 2011, the Company completed a direct offering of 700,000
shares of common stock for gross proceeds of $455,000. </FONT></P>
 <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>10. Litigation </B></FONT></P>
 <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company is in litigation with several of its April 2011 warrants holders (&#147;Plaintiffs&#148;) who have asserted
that the Company&#146;s spin-off of RXi and related actions give the Plaintiffs the right to require us to repurchase our outstanding warrants held by them. Originally, the Plaintiffs made aggregate repurchase demands to the Company to repurchase
6,850,000 warrants, which represented an approximate total demand of $5.2 million. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">On March&nbsp;21, 2012, we received
letters from each of the plaintiff-warrant holders withdrawing their repurchase demands with respect to their warrants covering an aggregate of 6,350,000 shares out of a total of 6,850,000 shares of common stock purchasable under their warrants (the
&#147;Withdrawal Notice<B>s</B>&#148;). After giving effect to the Withdrawal Notices, the plaintiff-warrant holders continued to demand that we repurchase their warrants covering the balance of 500,000 shares of common stock in the aggregate. Based
on the plaintiff-warrant holders&#146; claims in their Complaints, we believe that the repurchase price for these warrants is $0.71 per underlying share, or an aggregate of $355,000. On March 27, 2012, we tendered to the plaintiff-warrant holders an
aggregate of $355,000 as payment in full of the repurchase price for those warrants. We believe that the Withdrawal Notices and our tender of payment as described above render moot the majority of the claims of the plaintiff-warrant holders in their
Complaints, although the Withdrawal Notices purport to reserve all rights of the plaintiff-warrant holders under the Complaints. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">On May&nbsp;7, 2012, the Company entered into a confidential settlement agreement with one of the Plaintiffs, <U></U>in which the Plaintiff withdrew all claims in the aforementioned matter. </FONT></P>
 <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>11. Subsequent Events </B></FONT></P>
 <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company evaluated all events or transactions that occurred after March&nbsp;31, 2012 up through the date these
financial statements were issued. Other than what is disclosed below, the Company did not have any material recognizable or unrecognizable subsequent events. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Since March 31, 2012, the Company has issued 6,363,191 shares of the Company&#146;s common stock pursuant to the exercise of outstanding warrants from various warrant holders. The Company received
$4,136,074 in total payments at an exercise price of $0.65 per share. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">On April&nbsp;5, 2012, the Company issued 120,065
shares of common stock in connection with a cashless exercise of 182,500 thirteen-month warrants from the March 2011 Offering which had expired, in the money, on April&nbsp;4, 2012. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">On April&nbsp;11, 2012, the Company issued 8,500,000 shares of its common stock in an underwritten public offering at $1.50 per share.
The Company also granted to the underwriters a 30-day option to purchase up to an additional 1,275,000 shares to cover overallotments in connection with the offering. On April&nbsp;13, 2012, the underwriters exercised their option to purchase an
additional 1,251,000 shares of common stock. After the underwriting discount and estimated offering expenses payable by the Company, the Company received net proceeds of approximately $13.3 million. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">On April&nbsp;26, 2012, the Company completed the spin-off of RXi, its wholly-owned subsidiary prior to the spin-off, pursuant to the
Securities Purchase Agreement described in Note 4, and on April&nbsp;27, 2012, the Company closed the transactions under the Securities Purchase Agreement. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">On May&nbsp;7, 2012, as more fully described in Note 10, the Company entered into a confidential settlement agreement with one of the Plaintiffs in the actions described in Note 10. </FONT></P>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">13 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc333623_6"></A>ITEM&nbsp;2. MANAGEMENT&#146;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION
AND RESULTS OF OPERATIONS </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>In this document, &#147;we,&#148; &#147;our,&#148; &#147;ours&#148; and &#147;us&#148; refer
to Galena Biopharma, Inc. and its consolidated subsidiaries. </I></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>This management&#146;s discussion and analysis of
financial condition as of March&nbsp;31, 2012 and results of operations for the three months ended March&nbsp;31, 2012 and 2011, respectively, should be read in conjunction with management&#146;s discussion and analysis of financial condition and
results of operations included in our Annual Report on Form 10-K for the year ended December&nbsp;31, 2011 which was filed with the SEC on March 28, 2012. </I></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><I>The discussion and analysis below includes certain forward-looking statements related to future operating losses and our potential for profitability, the sufficiency of our cash resources, our ability
to obtain additional equity or debt financing, possible partnering or other strategic opportunities for the development of our products, as well as other statements related to the progress and timing of product development, present or future
licensing, collaborative or financing arrangements or that otherwise relate to future periods, which are all forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. These statements represent, among other
things, the expectations, beliefs, plans and objectives of management and/or assumptions underlying or judgments concerning the future financial performance and other matters discussed in this document. The words &#147;may,&#148; &#147;will,&#148;
&#147;should,&#148; &#147;plan,&#148; &#147;believe,&#148; &#147;estimate,&#148; &#147;intend,&#148; &#147;anticipate,&#148; &#147;project,&#148; and &#147;expect&#148; and similar expressions are intended to identify forward-looking statements. All
forward-looking statements involve certain risks, uncertainties and other factors described elsewhere in our Annual Report on Form 10-K for the year ended December&nbsp;31, 2011, that could cause our actual results of operations, performance,
financial position and business prospects and opportunities for this quarter and the periods that follow to differ materially from those expressed in, or implied by, those forward-looking statements. We caution investors not to place significant
reliance on the forward-looking statements contained in this report. These statements, like all statements in this report, speak only as of the date of this report (unless another date is indicated) and we undertake no obligation to update or revise
forward-looking statements. </I></FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Overview </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Galena Biopharma, Inc. (&#147;we,&#148; &#147;us,&#148; &#147;our,&#148; &#147;Galena&#148; or the &#147;Company&#148;) is a biopharmaceutical company focused on developing innovative, next-generation
cancer immunotherapies which address major unmet medical needs to advance care. Galena is developing innovative, peptide antigen-based &#147;off the shelf&#148; cancer immunotherapies for potential application to treatment of large populations of
Cancer Survivors. Peptide vaccines have several potential clinical advantages over existing cancer treatments including excellent safety profiles, long-lasting protection through immune system activation, as well as an acceptable mode of
administration (intradermal injection). A key differentiator in Galena&#146;s approach is the focus on &#147;minimal residual disease&#148; that may remain in Cancer Survivors. The strategy is to prevent recurrence in early stage patient groups who
may harbor &#147;occult&#148; residual cancer cells that are not detectable by current imaging and biomarkers, and despite adjuvant therapy and radiation therapy will relapse in significant numbers over time. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%;padding-bottom:0px;"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our lead product candidate, NeuVax<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&#153;</SUP></FONT> (E75), targets the HER2 tumor associated antigen peptide and is being developed to prevent or delay breast cancer recurrence in a Phase 3 clinical trial under a US
FDA approved SPA (Special Protocol Assessment) and in combination with Herceptin<B><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT></B> (trastuzumab:
Genentech/Roche) in a Phase 2 clinical trial. Our second product candidate, Folate Binding Protein (FBP), a targeted vaccine which consists of the E39 peptide over-expressed (20-80 fold) in more than 90% of ovarian and endometrial cancers, is
currently in a Phase 1 clinical trial. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company was incorporated as Argonaut Pharmaceuticals, Inc., in Delaware, on
April&nbsp;3, 2006. The Company changed its name to RXi Pharmaceuticals Corporation on November&nbsp;28, 2006. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We acquired
Apthera Inc., or &#147;Apthera,&#148; and our NeuVax product candidate in April 2011. Prior to that time, we were engaged primarily in conducting discovery research and preclinical development activities based on RNAi. Our acquisition of Apthera
followed from the determination by our board of directors to broaden our strategic direction by giving us access to a late-stage clinical candidate, NeuVax. In connection with our acquisition of Apthera, we reduced the scope of our RNAi activities.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">On September&nbsp;26, 2011, the Company changed its name from RXi Pharmaceuticals Corporation to Galena Biopharma, Inc. in
connection with the Company&#146;s separation into two companies: (i)&nbsp;Galena, which will operate as a late-stage oncology drug development company; and (ii)&nbsp;RXi Pharmaceuticals Corporation, or RXi, which will continue to develop novel
RNAi-based therapies utilizing our historical RNAi assets. RXi was initially incorporated as RNCS, Inc. and assumed the name RXi Pharmaceuticals Corporation in conjunction with the change in the Company&#146;s name to Galena. On April 27, 2012, the
planned spin-out up RXi was completed (See Note 4). </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our new RXi subsidiary was formed by us
in agreement with two institutional investors. On September&nbsp;24, 2011, we contributed to RXi substantially all of our RNAi-related technologies and assets and entered into a number of agreements relating to RXi&#146;s ongoing business and
operations. RXi will focus on developing and commercializing therapeutic products based on RNAi technologies for the treatment of human diseases, including its lead anti-scarring and anti-fibrosis product candidate, RXI-109, with initial financing
to be provided by us and the institutional investors. In these agreements, we have committed, among other things, to undertake to distribute to our stockholders a portion of the RXi common stock held by Galena in order to accomplish the spin-off of
RXi. On April&nbsp;27, 2012, the Company completed the spin-off of RXi. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company has not generated any revenues since
inception nor are any revenues expected for the foreseeable future. The Company expects to incur significant operating losses for the foreseeable future while the Company advances its future product candidates from discovery through pre-clinical
studies and clinical trials and seek regulatory approval and potential commercialization, even if the Company is collaborating with pharmaceutical and larger biotechnology companies. In addition to these increasing research and development expenses,
the Company expects general and administrative costs to increase as the Company recruits additional management and administrative personnel. The Company will need to generate significant revenues to achieve profitability and may never do so.
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">14 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Results of Operations </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>For the Three Months Ended March&nbsp;31, 2012 and March&nbsp;31, 2011 </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">For the three months ended March&nbsp;31, 2012, our net loss was approximately $24,761,000 compared with a net loss of $3,841,000 for the three months ended March&nbsp;31, 2011. The loss increased by
$20,920,000 or approximately 545%. Reasons for the variations in the losses between the quarters are discussed below. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Research and
Development Expense </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Research and development expense consists primarily of compensation-related costs for our
employees dedicated to research and development activities and for our Scientific Advisory Board (&#147;SAB&#148;) members as well as clinical trial expenses, licensing fees and patent prosecution costs. We expect research and development expenses
to increase as we expand our clinical development activities. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total research and development expenses were approximately
$3,671,000 for the three months ended March&nbsp;31, 2012, compared with $2,156,000 for the three months ended March&nbsp;31, 2011. The increase of $1,515,000, or 70% was due to an increase of $1,451,000 related to the ramp up of our Phase 3 PRESENT
clinical trial and an increase of $238,000 related to higher expenses for non-employee stock based compensation, offset by a decrease in employee stock based compensation of $174,000, primarily related to timing of grants and changes in our
Black-Scholes assumptions. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>General and Administrative Expense </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">General and administrative expense includes compensation-related costs for our employees dedicated to general and administrative
activities, legal fees, audit and tax fees, consultants and professional services, and general corporate expenses. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">General
and administrative expense was $1,939,000 for the three months ended March&nbsp;31, 2012, compared with $3,119,000 for the three months ended March&nbsp;31, 2011. The decrease of $1,180,000, or 38%, was due to a $901,000 decrease in non-cash
employee share based compensation expense and a $463,000 decrease in personnel related costs, professional and outside services, which was partially offset by a $112,000 increase in non-cash compensation expense recorded for exchange of services and
$72,000 related to a warrant issued for business advisory services. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Interest Income/Expense </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Interest income (expense) was negligible for each of the three months ended March&nbsp;31, 2012 and 2011. The key objectives of our
investment policy are to preserve principal and ensure sufficient liquidity, so our invested cash may not earn as high a level of income as longer-term or higher risk securities, which generally have less liquidity and more volatility. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Other Income/Expense </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Other expense was $19,114,000 for the three months ended March 31, 2012, compared with other income of $1,435,000 for the three months ended March 31, 2011. The increase in other expense of $20,549,000
was due to an increase in the fair value of warrants accounted for as a liability as well as warrants settled during the three months ended March 31, 2012 of $19,705,000 and an increase in non-cash expense related to the change in fair value of a
contingent purchase price consideration liability of $844,000. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Liquidity and Capital Resources </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We had cash and cash equivalents of approximately $8.7&nbsp;million as of March&nbsp;31, 2012, compared with $11.4&nbsp;million as of
December 31, 2011 and $24.9&nbsp;million as of April&nbsp;30, 2012. The increase in our cash and cash equivalents from March&nbsp;31, 2012 to April&nbsp;30, 2012 is attributable to the net proceeds of approximately $13.3&nbsp;million from the
offering that closed on April&nbsp;15, 2012 and the proceeds of approximately of $4.1 million from the exercise of warrants. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We have not generated revenue to date and may not generate product revenue in the foreseeable future, if ever. We expect to incur
significant operating losses as we advance our product candidates through the drug development and regulatory process. In addition to increasing research and development expenses, we expect general and administrative costs to increase as we add
personnel and other administrative expenses. We will need to generate significant revenues to achieve profitability and might never do so. In the absence of product revenues, our potential sources of operational funding are expected to be the
proceeds from the sale of equity, funded research and development payments and payments received under partnership and collaborative agreements. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We believe that our existing cash and cash equivalents should be sufficient to fund our operations through at least the second quarter of 2013. In the future, we will be dependent on obtaining funding
from third parties, such as proceeds from the sale of equity, funded research and development payments and payments under partnership and collaborative agreements, in order to maintain our operations and meet our obligations to licensors. There is
no guarantee that debt, additional equity or other funding will be available to us on acceptable terms, or at all. If we fail to obtain additional funding when needed, we would be forced to scale back, or terminate, our operations or to seek to
merge with or to be acquired by another company. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Net Cash Flow from Operating Activities </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net cash used in operating activities was approximately $4,885,000 for the three months ended March&nbsp;31, 2012, compared with
$3,027,000 for the three months ended March&nbsp;31, 2011. The increase of approximately $1,858,000 resulted primarily from a net loss of $24,761,000, of which $18,270,000 reflects the fair value of warrants issued with the registered direct
financings completed by the Company in 2009, 2010 and 2011, $844,000 related to changes in fair value of contingent purchase price consideration, $427,000 related to stock-based compensation, $148,000 related to stock warrant expense in exchange for
services, $185,000 related to common stock issued in exchange for services, $42,000 related to depreciation and $40,000 related to changes in assets and liabilities. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>Net Cash Flow from Investing Activities </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net cash used in investing
activities was zero for the three months ended March&nbsp;31, 2012, compared with $40,000 for the three months ended March&nbsp;31, 2011. The decrease was primarily due to purchases of equipment and furnishings in 2011. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Net Cash Flow from Financing Activities </I></B></FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">15 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net cash provided by financing activities was $2,153,000 for the three months ended
March&nbsp;31, 2012, compared with $7,291,000 for the three months ended March&nbsp;31, 2011. The decrease was primarily due to $1,236,000 from the exercise of warrants, $500,000 from issuance of convertible notes, net proceeds from the issuance of
common stock to a strategic partner in the amount of $385,000 and $39,000 for common stock issued in connection with the ESPP offset by $7,000 in repayments of capital lease obligations in the first quarter of 2012, compared with net proceeds from
the issuance of common stock in the amount of $7,314,000 to institutional investors offset by $23,000 in repayments of capital lease obligations in the first quarter of 2011. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Off-Balance Sheet Arrangements </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We have not entered into off-balance sheet
financing, other than operating leases. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Critical Accounting Policies and Estimates </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In our Annual Report on Form 10-K for the year ended December&nbsp;31, 2011, we disclosed our critical accounting policies and estimates
upon which our financial statements are derived. There have been no changes to these policies since December&nbsp;31, 2011. Readers are encouraged to review these disclosures in conjunction with the review of this quarterly report on Form 10-Q.
</FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc333623_6a"></A>ITEM&nbsp;3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK. </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Not applicable </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc333623_7"></A>ITEM&nbsp;4. CONTROLS AND PROCEDURES </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Disclosure Controls and Procedures </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">As of the end of the period covered by
this quarterly report on Form 10-Q, our Chief Executive Officer and Principal Financial Officer (the &#147;Certifying Officers&#148;), evaluated the effectiveness of our disclosure controls and procedures. Disclosure controls and procedures are
controls and procedures designed to reasonably assure that information required to be disclosed in our reports filed under the Securities Exchange Act of 1934 (the &#147;Exchange Act&#148;), such as this Form 10-Q, is recorded, processed, summarized
and reported within the time periods specified in the SEC rules and forms. Disclosure controls and procedures are also designed to reasonably assure that such information is accumulated and communicated to our management, including the Certifying
Officers, as appropriate to allow timely decisions regarding required disclosure. Based on these evaluations, the Certifying Officers have concluded, that, as of the end of the period covered by this quarterly report on Form 10-Q: </FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">our disclosure controls and procedures were effective to provide reasonable assurance that information required to be disclosed by us in the reports we file or submit
under the Exchange Act was recorded, processed, summarized and reported within the time periods specified in the SEC&#146;s rules and forms; and </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">our disclosure controls and procedures were effective to provide reasonable assurance that material information required to be disclosed by us in the reports we file or
submit under the Exchange Act was accumulated and communicated to our management, including the Certifying Officers, as appropriate to allow timely decisions regarding required disclosure. </FONT></TD></TR></TABLE>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Changes in Internal Control over Financial Reporting </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">There has not been any change in our internal control over financial reporting that occurred during the quarterly period ended March&nbsp;31, 2012 that has materially affected, or is reasonably likely to
materially affect, our internal control over financial reporting. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc333623_8"></A>PART II &#151; OTHER INFORMATION
</B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc333623_9"></A>ITEM&nbsp;1. LEGAL PROCEEDINGS </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The Company is in litigation with several of its April 2011 warrants holders (&#147;Plaintiffs&#148;) who have asserted that the Company&#146;s spin-off of RXi and related actions give the Plaintiffs the
right to require us to repurchase our outstanding warrants held by them. Originally, the Plaintiffs made aggregate repurchase demands to the Company to repurchase 6,850,000 warrants, which represented an approximate total demand of $5.2 million.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">On March&nbsp;21, 2012, we received letters from each of the plaintiff-warrant holders withdrawing their repurchase demands
with respect to their warrants covering an aggregate of 6,350,000 shares out of a total of 6,850,000 shares of common stock purchasable under their warrants (the &#147;Withdrawal Notice<B>s</B>&#148;). After giving effect to the Withdrawal Notices,
the plaintiff-warrant holders continued to demand that we repurchase their warrants covering the balance of 500,000 shares of common stock in the aggregate. Based on the plaintiff-warrant holders&#146; claims in their Complaints, we believe that the
repurchase price for these warrants is $0.71 per underlying share, or an aggregate of $355,000. On March 27, 2012, we tendered to the plaintiff-warrant holders an aggregate of $355,000 as payment in full of the repurchase price for those warrants.
We believe that the Withdrawal Notices and our tender of payment as described above render moot the majority of the claims of the plaintiff-warrant holders in their Complaints, although the Withdrawal Notices purport to reserve all rights of the
plaintiff-warrant holders under the Complaints. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px;page-break-before:always"></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">On
May&nbsp;7, 2012, the Company entered into a confidential settlement agreement with one of the Plaintiffs, <U></U>in which the Plaintiff withdrew all claims in the aforementioned matter. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc333623_10"></A>ITEM&nbsp;1.A RISK FACTORS </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>You should consider the
&#147;Risk Factors&#148; included under Item&nbsp;1A. of our Annual Report on Form&nbsp;10-K for the year ended December&nbsp;31, 2011, filed on March&nbsp;28, 2012 with the SEC. </I></FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc333623_11"></A>ITEM&nbsp;2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">In February 2012, the Company issued 400,000 warrants to purchase its common stock in exchange for business advisory services. The warrants were issued by us in a private transaction exempt from
registration under the Securities Act of 1933 pursuant to Section&nbsp;4(2) of the Securities Act of 1933 and Regulation&nbsp;D under the Act. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc333623_12"></A>ITEM&nbsp;3. DEFAULTS UPON SENIOR SECURITIES </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">None </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc333623_13"></A>ITEM&nbsp;4. MINE SAFETY DISCLOSURES </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Not applicable </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">16 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc333623_14"></A>ITEM&nbsp;5. OTHER INFORMATION </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">None </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc333623_15"></A>ITEM&nbsp;6. EXHIBITS </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc333623_16"></A>EXHIBIT INDEX </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:28pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Exhibit<BR>Number</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Description</B></FONT></P></TD></TR>


<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;1.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Underwriting Agreement dated as of April&nbsp;5, 2012 by and between Galena Biopharma, Inc. and Roth Capital Partners, LLC, as representative of the several underwriters named
therein. (1)</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;4.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Warrant No. 2012-1 in favor of Legend Securities, Inc. issued in February 2012. (2).</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">10.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Amendment No. 1 to License Agreement, dated as of January 13, 2012, by and among Apthera, Inc., Kwangdong Pharmaceutical Co., Ltd., and Galena Biopharma, Inc. (2)</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">10.2</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">First Amendment to Contingent Value Rights Agreement among Galena Biopharma, Inc. (formerly RXi Pharmaceuticals Corporation), Computershare Trust Company, N.A., Computershare Inc.,
and Robert E Kennedy, dated February 15, 2012. (2)</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">10.3</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Controlled Equity Offering</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">SM</SUP></FONT><FONT
STYLE="font-family:Times New Roman" SIZE="2"> Sales Agreement, dated as of February&nbsp;17, 2012, between Galena Biopharma, Inc. and Cantor Fitzgerald &amp; Co. (3)</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">10.4</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Omnibus Amendment to Securities Purchase Agreement, dated as of February 6, 2012, among RXi Pharmaceuticals Corporation (formerly RNCS, Inc.), Galena Biopharma, Inc. (formerly RXi
Pharmaceuticals Corporation), Tang Capital Partners, LP and RTW Investments, LLC. (4)</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">10.5</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Second Omnibus Amendment to Securities Purchase Agreement, dated as of March 5, 2012, among RXi Pharmaceuticals Corporation (formerly RNCS, Inc.), Galena Biopharma, Inc. (formerly
RXi Pharmaceuticals Corporation), Tang Capital Partners, LP and RTW Investments, LLC. (2)</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">10.6</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Third Omnibus Amendment to Securities Purchase Agreement, dated as of March 30, 2012, among RXi Pharmaceuticals Corporation (formerly RNCS, Inc.), Galena Biopharma, Inc. (formerly
RXi Pharmaceuticals Corporation), Tang Capital Partners, LP and RTW Investments, LLC. **</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">10.7</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Fourth Omnibus Amendment to Securities Purchase Agreement, dated as of April 3, 2012, among RXi Pharmaceuticals Corporation (formerly RNCS, Inc.), Galena Biopharma, Inc. (formerly
RXi Pharmaceuticals Corporation), Tang Capital Partners, LP and RTW Investments, LLC. **</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">10.8</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Fifth Omnibus Amendment to Securities Purchase Agreement, dated as of April 11, 2012, among RXi Pharmaceuticals Corporation (formerly RNCS, Inc.), Galena Biopharma, Inc. (formerly
RXi Pharmaceuticals Corporation), Tang Capital Partners, LP and RTW Investments, LLC. **</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">10.9</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Sixth Omnibus Amendment to Securities Purchase Agreement, dated as of April 18, 2012, among RXi Pharmaceuticals Corporation (formerly RNCS, Inc.), Galena Biopharma, Inc. (formerly
RXi Pharmaceuticals Corporation), Tang Capital Partners, LP and RTW Investments, LLC. **</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">10.10</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Seventh Amendment Agreement to Securities Purchase Agreement, dated as of April 25, 2012, among RXi Pharmaceuticals Corporation (formerly RNCS, Inc.), Galena Biopharma, Inc.
(formerly RXi Pharmaceuticals Corporation), Tang Capital Partners, LP and RTW Investments, LLC. **</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">31.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Sarbanes-Oxley Act Section&nbsp;302 Certification of Chief Executive Officer.**</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">31.2</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Sarbanes-Oxley Act Section&nbsp;302 Certification of Principal Financial Officer.**</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">32.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Sarbanes-Oxley Act Section&nbsp;906 Certification of Chief Executive Officer and Principal Financial Officer.**</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">101</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following financial information from the Quarterly Report on Form 10-Q of Galena Biopharma, Inc. for the quarter ended March 31, 2012, formatted in XBRL (eXtensible Business
Reporting Language): (1)&nbsp;Condensed Consolidated Balance Sheets as of March 31, 2012 and December&nbsp;31, 2011; (2)&nbsp;Condensed Consolidated Statements of Expenses for the three months ended March 31, 2012 and 2011 and for the period from
January&nbsp;1, 2003 (inception)&nbsp;to March 31, 2012; (3)&nbsp;Condensed Consolidated Statements of Cash Flows for the three months ended March 31, 2012 and 2011 and for the cumulative period from January&nbsp;1, 2003 (inception)&nbsp;to March
31, 2012; and (4)&nbsp;Notes to Condensed Consolidated Financial Statements. (5)</FONT></TD></TR>
</TABLE> <P STYLE="line-height:8px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Previously filed as an Exhibit to the Company&#146;s Form 8-K filed on April 5, 2012 (File No.&nbsp;001-33958) and incorporated by reference herein.
</FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Previously filed as an Exhibit to the Company&#146;s Form 10-K filed on March&nbsp;28, 2012 (File No.&nbsp;001-33958) and incorporated by reference herein.
</FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(3)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Previously filed as an Exhibit to the Company&#146;s Form 8-K filed on February&nbsp;17, 2012 (File No.&nbsp;001-33958) and incorporated by reference herein.
</FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(4)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Previously filed as an Exhibit to Amendment No.&nbsp;4 to RXi Pharmaceuticals Corporation&#146;s Registration Statement on Form S-1 filed on February&nbsp;7, 2012 (File
No.&nbsp;333-177498) and incorporated by reference herein. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(5)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">In accordance with Rule&nbsp;406T of Regulation&nbsp;S-T, the XBRL-related information in Exhibit 101 to this Quarterly Report on Form 10-Q is deemed not filed or part
of a registration statement or prospectus for purposes of Sections 11 and 12 of the Securities Act, is deemed not filed for purposes of Section&nbsp;18 of the Exchange Act, and otherwise is not subject to liability under these sections, is not part
of any registration statement or prospectus to which it relates and is not incorporated by reference into any registration statement, prospectus or other document. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">**</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Filed herewith. </FONT></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">17 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U><A NAME="toc333623_17"></A>Table of Contents</U> </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">SIGNATURES </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its
behalf by the undersigned thereunto duly authorized. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="7%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="90%"></TD></TR>


<TR>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2">GALENA BIOPHARMA, INC.</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(Registrant)</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">By:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ <I>Mark Ahn</I></FONT></P></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Mark J. Ahn</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">President and Chief Executive Officer</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Date: May&nbsp;14, 2012</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">By:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ <I>Kwang S. Lee</I></FONT></P></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Kwang S. Lee</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Vice President, Finance (Principal</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Financial and Accounting Officer)</FONT></P></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Date: May&nbsp;14, 2012</FONT></TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">18 </FONT></P>


</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.6
<SEQUENCE>2
<FILENAME>d333623dex106.htm
<DESCRIPTION>THIRD OMNIBUS AMENDMENT TO SECURITIES PURCHASE AGREEMENT
<TEXT>
<HTML><HEAD>
<TITLE>Third Omnibus Amendment to Securities Purchase Agreement</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Exhibit 10.6 </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>THIRD OMNIBUS AMENDMENT </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">This THIRD OMNIBUS AMENDMENT (this &#147;<U>Third
Amendment</U>&#148;) is made and entered into as of March&nbsp;30, 2012, by and among Tang Capital Partners, LP, RTW Investments, LLC, Galena Biopharma, Inc. (formerly RXi Pharmaceuticals Corporation) and RXi Pharmaceuticals Corporation (formerly
RNCS, Inc.). </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">WHEREAS, the parties entered into a Securities Purchase Agreement dated as of September&nbsp;24, 2011 (the
&#147;<U>Securities Purchase Agreement</U>&#148;) and the Ancillary Agreements related thereto, including the Bridge Notes; </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">WHEREAS, the parties entered into an Omnibus Amendment dated as of February&nbsp;6, 2012 (the &#147;<U>First Amendment</U>&#148;) and a
Second Omnibus Amendment dated as of March&nbsp;5, 2012 (the &#147;<U>Second Amendment</U>&#148; and, together with the First Amendment, the &#147;<U>Previous Amendments</U>&#148;), amending certain provisions of the Securities Purchase Agreement
and the Bridge Notes; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">WHEREAS, the Securities Purchase Agreement, as amended by the Previous Amendments, in
Section&nbsp;8.01(c) thereof provides that the Agreement may be terminated by either the Company or the Investors if the Closing has not occurred on or before 5:00 p.m., Eastern Standard Time, on March&nbsp;31, 2012, which date may be extended from
time to time by mutual written consent of the Company and the Investors; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">WHEREAS, the Bridge Notes dated September&nbsp;24,
2011 held by the Investors, as amended by the First Amendment, in Section&nbsp;1.1 thereof each provide for a Maturity Date (as defined in the Bridge Notes) of the earlier of (i)&nbsp;March&nbsp;31, 2012 or (ii)&nbsp;an Event of Default (as defined
in the Bridge Notes); </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">WHEREAS, the parties desire to amend such provisions of the Securities Purchase Agreement and the
Bridge Notes to extend the March&nbsp;31, 2012 date; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">NOW, THEREFORE, in consideration of the premises and mutual covenants
herein, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties agree as follows: </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">1. <U>Securities Purchase Agreement Amendment</U>. Section&nbsp;8.01(c) of the Securities Purchase Agreement, as amended by the Previous Amendments, is hereby further amended to replace &#147;March 31,
2012&#148; with &#147;April 4, 2012&#148;. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">2. <U>Bridge Notes Amendment</U>. The Bridge Notes, as amended by the Previous
Amendments, are hereby further amended to replace references to &#147;March 31, 2012&#148; with &#147;April 4, 2012&#148;. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.
<U>Miscellaneous</U>. Capitalized terms used herein and not defined shall have the meanings set forth in the Securities Purchase Agreement or in the Bridge Notes, in each case, as amended, as applicable. The terms and conditions set forth in Article
X of the Securities </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Purchase Agreement are incorporated herein by reference. Nothing herein shall constitute a
waiver of any provision of the Securities Purchase Agreement or any of the Ancillary Documents pursuant to Section&nbsp;10.03 of the Securities Purchase Agreement. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><I>[Signature Page Follows] </I></FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">2 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">IN WITNESS WHEREOF, the parties hereto have executed this Third Amendment as of the date
first above written. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="12%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="80%"></TD></TR>


<TR>
<TD VALIGN="top" COLSPAN="5"><FONT STYLE="font-family:Times New Roman" SIZE="2">GALENA BIOPHARMA, INC.</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">By:</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="3" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ Mark J. Ahn &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Name:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Mark J. Ahn</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Title:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">President and Chief Executive</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Officer</FONT></P></TD></TR>
<TR>
<TD HEIGHT="16" COLSPAN="5"></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="5"><FONT STYLE="font-family:Times New Roman" SIZE="2">RXi&nbsp;PHARMACEUTICALS&nbsp;CORPORATION</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">By:</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="3" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ Mark J. Ahn &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Name:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Mark J. Ahn</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Title:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">President</FONT></TD></TR>
<TR>
<TD HEIGHT="16" COLSPAN="5"></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="5"><FONT STYLE="font-family:Times New Roman" SIZE="2">TANG CAPITAL PARTNERS, LP</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">By:</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="3" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ Kevin C. Tang &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Name:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Kevin C. Tang</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Title:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Managing Director</FONT></TD></TR>
<TR>
<TD HEIGHT="16" COLSPAN="5"></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="5"><FONT STYLE="font-family:Times New Roman" SIZE="2">RTW INVESTMENTS, LLC</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">By:</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="3" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ Roderick Wong &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Name:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Roderick Wong</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Title:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Managing Member</FONT></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:18px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>[Signature Page to Third Omnibus Agreement] </I></FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">3 </FONT></P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.7
<SEQUENCE>3
<FILENAME>d333623dex107.htm
<DESCRIPTION>FOURTH OMNIBUS AMENDMENT TO SECURITIES PURCHASE AGREEMENT
<TEXT>
<HTML><HEAD>
<TITLE>Fourth Omnibus Amendment to Securities Purchase Agreement</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Exhibit 10.7 </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>FOURTH OMNIBUS AMENDMENT </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">This FOURTH OMNIBUS AMENDMENT (this
&#147;<U>Fourth Amendment</U>&#148;) is made and entered into as of April&nbsp;3, 2012, by and among Tang Capital Partners, LP, RTW Investments, LLC, Galena Biopharma, Inc. (formerly RXi Pharmaceuticals Corporation) and RXi Pharmaceuticals
Corporation (formerly RNCS, Inc.). </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">WHEREAS, the parties entered into a Securities Purchase Agreement dated as of
September&nbsp;24, 2011 (the &#147;<U>Securities Purchase Agreement</U>&#148;) and the Ancillary Agreements related thereto, including the Bridge Notes; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">WHEREAS, the parties entered into an Omnibus Amendment dated as of February&nbsp;6, 2012 (the &#147;<U>First Amendment</U>&#148;), a Second Omnibus Amendment dated as of March&nbsp;5, 2012 (the
&#147;<U>Second Amendment</U>&#148;) and a Third Omnibus Amendment dated as of March&nbsp;30, 2012 (the &#147;<U>Third Amendment</U>&#148; and, together with the First Amendment and the Second Amendment, the &#147;<U>Previous Amendments</U>&#148;),
amending certain provisions of the Securities Purchase Agreement and the Bridge Notes; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">WHEREAS, the Securities Purchase
Agreement, as amended by the Previous Amendments, in Section&nbsp;8.01(c) thereof provides that the Agreement may be terminated by either the Company or the Investors if the Closing has not occurred on or before 5:00 p.m., Eastern Standard Time, on
March&nbsp;31, 2012, which date may be extended from time to time by mutual written consent of the Company and the Investors; </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">WHEREAS, the Bridge Notes dated September&nbsp;24, 2011 held by the Investors, as amended by the First Amendment, in Section&nbsp;1.1
thereof each provide for a Maturity Date (as defined in the Bridge Notes) of the earlier of (i)&nbsp;April&nbsp;4, 2012 or (ii)&nbsp;an Event of Default (as defined in the Bridge Notes); </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">WHEREAS, the parties desire to amend such provisions of the Securities Purchase Agreement and the Bridge Notes to extend the
April&nbsp;4, 2012 date; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">NOW, THEREFORE, in consideration of the premises and mutual covenants herein, and for other good and
valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties agree as follows: </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.
<U>Securities Purchase Agreement Amendment</U>. Section&nbsp;8.01(c) of the Securities Purchase Agreement, as amended by the Previous Amendments, is hereby further amended to replace &#147;April 4, 2012&#148; with &#147;April 11, 2012&#148;.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">2. <U>Bridge Notes Amendment</U>. The Bridge Notes, as amended by the Previous Amendments, are hereby further amended to
replace references to &#147;April 4, 2012&#148; with &#147;April 11, 2012&#148;. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">3. <U>Miscellaneous</U>. Capitalized terms
used herein and not defined shall have the meanings set forth in the Securities Purchase Agreement or in the Bridge Notes, in each case, as amended, as applicable. The terms and conditions set forth in Article X of the Securities Purchase Agreement
are incorporated herein by reference. Nothing herein shall constitute a waiver of any provision of the Securities Purchase Agreement or any of the Ancillary Documents pursuant to Section&nbsp;10.03 of the Securities Purchase Agreement. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>[Signature Page Follows] </I></FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">IN WITNESS WHEREOF, the parties hereto have executed this Fourth Amendment as of the date
first above written. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2">GALENA BIOPHARMA, INC.</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">By:</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ Mark J. Ahn</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Name: Mark J. Ahn</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Title:&nbsp;&nbsp; President and Chief Executive</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Officer</FONT></P></TD></TR>
</TABLE></DIV> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2">RXi PHARMACEUTICALS CORPORATION</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">By:</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ Mark J. Ahn</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Name: Mark J. Ahn</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Title:
&nbsp;&nbsp;President</FONT></P></TD></TR>
</TABLE></DIV> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2">TANG CAPITAL PARTNERS, LP</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">By:</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ Kevin C. Tang</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Name: Kevin C. Tang</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Title:&nbsp;&nbsp; Managing Director</FONT></P></TD></TR>
</TABLE></DIV> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2">RTW INVESTMENTS, LLC</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">By:</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ Roderick Wong</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Name: Roderick Wong</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Title:&nbsp;&nbsp; Managing Member</FONT></P></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>[Signature Page to Fourth Omnibus Agreement] </I></FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">2 </FONT></P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.8
<SEQUENCE>4
<FILENAME>d333623dex108.htm
<DESCRIPTION>FIFTH OMNIBUS AMENDMENT TO SECURITIES PURCHASE AGREEMENT
<TEXT>
<HTML><HEAD>
<TITLE>Fifth Omnibus Amendment to Securities Purchase Agreement</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Exhibit 10.8 </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>FIFTH OMNIBUS AMENDMENT </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">This FIFTH OMNIBUS AMENDMENT (this &#147;<U>Fifth
Amendment</U>&#148;) is made and entered into as of April&nbsp;11, 2012, by and among Tang Capital Partners, LP, RTW Investments, LLC, Galena Biopharma, Inc. (formerly RXi Pharmaceuticals Corporation) and RXi Pharmaceuticals Corporation (formerly
RNCS, Inc.). </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">WHEREAS, the parties entered into a Securities Purchase Agreement dated as of September&nbsp;24, 2011 (the
&#147;<U>Securities Purchase Agreement</U>&#148;) and the Ancillary Agreements related thereto, including the Bridge Notes; </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">WHEREAS, the parties entered into an Omnibus Amendment dated as of February&nbsp;6, 2012 (the &#147;<U>First Amendment</U>&#148;), a
Second Omnibus Amendment dated as of March&nbsp;5, 2012 (the &#147;<U>Second Amendment</U>&#148;), a Third Omnibus Amendment dated as of March&nbsp;30, 2012 (the &#147;<U>Third Amendment</U>&#148;) and a Fourth Omnibus Amendment dated as of
April&nbsp;3, 2012 (the &#147;<U>Fourth Amendment</U>&#148; and, together with the First Amendment, the Second Amendment and Third Amendment, the &#147;<U>Previous Amendments</U>&#148;), amending certain provisions of the Securities Purchase
Agreement and the Bridge Notes; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">WHEREAS, the Securities Purchase Agreement, as amended by the Previous Amendments, in
Section&nbsp;8.01(c) thereof provides that the Agreement may be terminated by either the Company or the Investors if the Closing has not occurred on or before 5:00 p.m., Eastern Standard Time, on April&nbsp;11, 2012, which date may be extended from
time to time by mutual written consent of the Company and the Investors; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">WHEREAS, the Bridge Notes dated September&nbsp;24,
2011 held by the Investors, as amended by the First Amendment, in Section&nbsp;1.1 thereof each provide for a Maturity Date (as defined in the Bridge Notes) of the earlier of (i)&nbsp;April&nbsp;11, 2012 or (ii)&nbsp;an Event of Default (as defined
in the Bridge Notes); </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">WHEREAS, the parties desire to amend such provisions of the Securities Purchase Agreement and the
Bridge Notes to extend the April&nbsp;11, 2012 date; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">NOW, THEREFORE, in consideration of the premises and mutual covenants
herein, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties agree as follows: </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">1. <U>Securities Purchase Agreement Amendment</U>. Section&nbsp;8.01(c) of the Securities Purchase Agreement, as amended by the Previous Amendments, is hereby further amended to replace &#147;April 11,
2012&#148; with &#147;April 18, 2012&#148;. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">2. <U>Bridge Notes Amendment</U>. The Bridge Notes, as amended by the Previous
Amendments, are hereby further amended to replace references to &#147;April 11, 2012&#148; with &#147;April 18, 2012&#148;. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">3. <U>Miscellaneous</U>. Capitalized terms used herein and not defined shall have the meanings set forth in the Securities Purchase
Agreement or in the Bridge Notes, in each case, as amended, as applicable. The terms and conditions set forth in Article X of the Securities Purchase Agreement are incorporated herein by reference. Nothing herein shall constitute a waiver of any
provision of the Securities Purchase Agreement or any of the Ancillary Documents pursuant to Section&nbsp;10.03 of the Securities Purchase Agreement. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><I>[Signature Page Follows] </I></FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">IN WITNESS WHEREOF, the parties hereto have executed this Fifth Amendment as of the date
first above written. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2">GALENA BIOPHARMA, INC.</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">By:</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ Mark J. Ahn</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Name: Mark J. Ahn</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Title: President and Chief Executive Officer</FONT></TD></TR>
</TABLE></DIV> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2">RXi PHARMACEUTICALS CORPORATION</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">By:</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ Mark J. Ahn</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Name: Mark J. Ahn</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Title: President</FONT></TD></TR>
</TABLE></DIV> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2">TANG CAPITAL PARTNERS, LP</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">By:</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ Kevin C. Tang</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Name: Kevin C. Tang</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Title: Managing Director</FONT></TD></TR>
</TABLE></DIV> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2">RTW INVESTMENTS, LLC</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">By:</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ Roderick Wong</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Name: Roderick Wong</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Title: Managing Member</FONT></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>[Signature Page to Fifth Omnibus Amendment] </I></FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">2 </FONT></P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.9
<SEQUENCE>5
<FILENAME>d333623dex109.htm
<DESCRIPTION>SIXTH OMNIBUS AMENDMENT TO SECURITIES PURCHASE AGREEMENT
<TEXT>
<HTML><HEAD>
<TITLE>Sixth Omnibus Amendment to Securities Purchase Agreement</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Exhibit 10.9 </B></FONT></P> <P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>SIXTH OMNIBUS AMENDMENT </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">This SIXTH OMNIBUS AMENDMENT (this &#147;<U>Sixth
Amendment</U>&#148;) is made and entered into as of April&nbsp;18, 2012, by and among Tang Capital Partners, LP, RTW Investments, LLC, Galena Biopharma, Inc. (formerly RXi Pharmaceuticals Corporation) and RXi Pharmaceuticals Corporation (formerly
RNCS, Inc.). </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">WHEREAS, the parties entered into a Securities Purchase Agreement dated as of September&nbsp;24, 2011 (the
&#147;<U>Securities Purchase Agreement</U>&#148;) and the Ancillary Agreements related thereto, including the Bridge Notes; </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">WHEREAS, the parties entered into an Omnibus Amendment dated as of February&nbsp;6, 2012 (the &#147;<U>First Amendment</U>&#148;), a
Second Omnibus Amendment dated as of March&nbsp;5, 2012 (the &#147;<U>Second Amendment</U>&#148;), a Third Omnibus Amendment dated as of March&nbsp;30, 2012 (the &#147;<U>Third Amendment</U>&#148;), a Fourth Omnibus Amendment dated as of
April&nbsp;3, 2012 (the &#147;<U>Fourth Amendment</U>&#148;), a Fifth Omnibus Amendment dated as of April&nbsp;11, 2012 (the &#147;<U>Fifth Amendment</U>&#148; and, together with the First Amendment, the Second Amendment, the Third Amendment, the
Fourth Amendment and the Fifth Amendment, the &#147;<U>Previous Amendments</U>&#148;), amending certain provisions of the Securities Purchase Agreement and the Bridge Notes; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">WHEREAS, the Securities Purchase Agreement, as amended by the Previous Amendments, in Section&nbsp;8.01(c) thereof provides that the Agreement may be terminated by either the Company or the Investors if
the Closing has not occurred on or before 5:00 p.m., Eastern Standard Time, on April&nbsp;18, 2012, which date may be extended from time to time by mutual written consent of the Company and the Investors; </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">WHEREAS, the Bridge Notes dated September&nbsp;24, 2011 held by the Investors, as amended by the First Amendment, in Section&nbsp;1.1
thereof each provide for a Maturity Date (as defined in the Bridge Notes) of the earlier of (i)&nbsp;April&nbsp;18, 2012 or (ii)&nbsp;an Event of Default (as defined in the Bridge Notes); </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">WHEREAS, the parties desire to amend such provisions of the Securities Purchase Agreement and the Bridge Notes to extend the
April&nbsp;18, 2012 date; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">NOW, THEREFORE, in consideration of the premises and mutual covenants herein, and for other good
and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties agree as follows: </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.
<U>Securities Purchase Agreement Amendment</U>. Section&nbsp;8.01(c) of the Securities Purchase Agreement, as amended by the Previous Amendments, is hereby further amended to replace &#147;April 18, 2012&#148; with &#147;April 30, 2012&#148;.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">2. <U>Bridge Notes Amendment</U>. The Bridge Notes, as amended by the Previous Amendments, are hereby further amended to
replace references to &#147;April 18, 2012&#148; with &#147;April 30, 2012&#148;. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">3. <U>Miscellaneous</U>. Capitalized terms
used herein and not defined shall have the meanings set forth in the Securities Purchase Agreement or in the Bridge Notes, in each case, as amended, as applicable. The terms and conditions set forth in Article X of the Securities Purchase Agreement
are incorporated herein by reference. Nothing herein shall constitute a waiver of any provision of the Securities Purchase Agreement or any of the Ancillary Documents pursuant to Section&nbsp;10.03 of the Securities Purchase Agreement. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>[Signature Page Follows] </I></FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">IN WITNESS WHEREOF, the parties hereto have executed this Sixth Amendment as of the date
first above written. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2">GALENA BIOPHARMA, INC.</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">By:</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ Mark J. Ahn</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Name: Mark J. Ahn</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Title: President and Chief Executive Officer</FONT></TD></TR>
<TR>
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2">RXi PHARMACEUTICALS CORPORATION</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">By:</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ Mark J. Ahn</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Name: Mark J. Ahn</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Title: President</FONT></TD></TR>
<TR>
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2">TANG CAPITAL PARTNERS, LP</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">By:</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ Kevin C. Tang</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Name: Kevin C. Tang</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Title: Managing Director</FONT></TD></TR>
<TR>
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2">RTW INVESTMENTS, LLC</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">By:</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ Roderick Wong</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Name: Roderick Wong</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Title: Managing Member</FONT></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>[Signature Page to Sixth Omnibus Amendment] </I></FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">1 </FONT></P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.10
<SEQUENCE>6
<FILENAME>d333623dex1010.htm
<DESCRIPTION>SEVENTH AMENDMENT TO SECURITIES PURCHASE AGREEMENT
<TEXT>
<HTML><HEAD>
<TITLE>Seventh Amendment to Securities Purchase Agreement</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Exhibit 10.10 </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>SEVENTH AMENDMENT AGREEMENT </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">This SEVENTH AMENDMENT AGREEMENT (this
&#147;<U>Seventh Amendment</U>&#148;) is made and entered into as of April&nbsp;25, 2012, by and among Tang Capital Partners, LP, RTW Investments, LLC, Galena Biopharma, Inc. (formerly RXi Pharmaceuticals Corporation, &#147;<U>Galena</U>&#148;) and
RXi Pharmaceuticals Corporation (formerly RNCS, Inc., &#147;<U>RXi</U>&#148;). </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">WHEREAS, the parties entered into a Securities
Purchase Agreement dated as of September&nbsp;24, 2011 (the &#147;<U>Securities Purchase Agreement</U>&#148;) and the Ancillary Agreements related thereto, including the Bridge Notes; </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">WHEREAS, the parties entered into several Omnibus Amendments dated as of February&nbsp;6, 2012,&nbsp;March&nbsp;5,
2012,&nbsp;March&nbsp;30, 2012,&nbsp;April&nbsp;3, 2012,&nbsp;April&nbsp;11, 2012 and April&nbsp;18, 2012 (the &#147;<U>Previous Amendments</U>&#148;), amending certain provisions of the Securities Purchase Agreement and the Bridge Notes;
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">WHEREAS, in light of certain developments with respect to litigation to which Galena is a party, RXi and the Investors wish
to be indemnified and held harmless against any losses arising out of such litigation, and Galena wishes to so indemnify RXi and the Investors; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">WHEREAS, Galena wishes to be assured, prior to effecting the Spin-Off, that certain facts of which the Investors are presently aware would not constitute a failure of a condition to the obligations of the
Investors at the Closing; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">WHEREAS, the parties desire to amend or waive certain other provisions of the Securities Purchase
Agreement; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">NOW, THEREFORE, in consideration of the premises and mutual covenants herein, and for other good and valuable
consideration, the receipt and sufficiency of which are hereby acknowledged, the parties agree as follows: </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1. <U>Certain
Definitions</U>. References herein to the &#147;Securities Purchase Agreement&#148; mean the Securities Purchase Agreement as amended by the Previous Amendments and by this Amendment, as the context requires. Capitalized terms used but not defined
herein have the meanings ascribed in the Securities Purchase Agreement. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">2. <U>Indemnification of RXi and the Investors</U>.
Galena hereby agrees that, subject to the Closing, Galena&#146;s indemnification obligations under Section&nbsp;9.01 of the Securities Purchase Agreement shall apply to all losses, liabilities, deficiencies, costs, damages and expenses (including,
without limitation, reasonable attorneys&#146; fees, charges and disbursements) incurred after the Closing as a result of as a result of claims brought by any of Galena&#146;s warrant holders solely arising out of or relating to the transactions
contemplated by the Securities Purchase Agreement. Galena further agrees to indemnify RXi to the same extent it agrees to indemnify the Investors pursuant to the foregoing sentence. Galena&#146;s obligations under this Section&nbsp;2 are subject to
all of the provisions of Article IX of the Securities Purchase Agreement. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">3. <U>Certain Assurances</U>. Each of the Investors
hereby agrees and represents that, based on the information available to it, the execution and delivery of the Separation and </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
Settlement Agreement, dated as of the Closing Date, among RXi, Galena, the Investors, Anastasia Khvorova, Ph.D. and Advirna, LLC resolves and satisfies any and all conditions to the Closing
contained in Article V of the Agreement as they relate to the employment of Dr.&nbsp;Khvorova by RXi or Galena or RXi&#146;s or Galena&#146;s prior dealings with Advirna, LLC. Each of the Investors and the other parties further agrees and represents
that the provisions of Section&nbsp;4.12(a) and Section&nbsp;4.13(b) solely with respect to the time limits contained therein are hereby waived by all the parties. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">4. <U>Miscellaneous</U>. Capitalized terms used herein and not defined shall have the meanings set forth in the Securities Purchase Agreement as amended. The terms and conditions set forth in Article X of
the Securities Purchase Agreement are incorporated herein by reference. Except as specifically set forth in Section&nbsp;3 hereof, nothing herein shall constitute a waiver of any provision of the Securities Purchase Agreement or any of the Ancillary
Documents pursuant to Section&nbsp;10.03 of the Securities Purchase Agreement. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>[Signature Page Follows] </I></FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">2 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">IN WITNESS WHEREOF, the parties hereto have executed this Seventh Amendment as of the date
first above written. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2">GALENA BIOPHARMA, INC.</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">By:</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ Mark J. Ahn</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Name: Mark J. Ahn</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Title:&nbsp;&nbsp; President and Chief Executive</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Officer</FONT></P></TD></TR>
</TABLE></DIV> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2">RXi PHARMACEUTICALS CORPORATION</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">By:</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ Mark J. Ahn</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Name: Mark J. Ahn</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Title:&nbsp;&nbsp; President</FONT></P></TD></TR>
</TABLE></DIV> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2">TANG CAPITAL PARTNERS, LP</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">By:</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ Kevin C. Tang</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Name: Kevin C. Tang</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Title:&nbsp;&nbsp; Managing Director</FONT></P></TD></TR>
</TABLE></DIV> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2">RTW INVESTMENTS, LLC</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">By:</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ Roderick Wong</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Name: Roderick Wong</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Title:&nbsp;&nbsp;Managing Member</FONT></P></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>[Signature Page to Seventh Omnibus Agreement] </I></FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">3 </FONT></P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>7
<FILENAME>d333623dex311.htm
<DESCRIPTION>SARBANES-OXLEY ACT SECTION 302 CERTIFICATION OF CHIEF EXECUTIVE OFFICER
<TEXT>
<HTML><HEAD>
<TITLE>Sarbanes-Oxley Act Section 302 Certification of Chief Executive Officer</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Exhibit&nbsp;31.1 </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>CERTIFICATION OF CHIEF EXECUTIVE OFFICER </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">I, Mark J. Ahn, certify that:
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">1. I have reviewed this Quarterly Report on Form 10-Q of Galena Biopharma, Inc.; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under
which such statements were made, not misleading with respect to the period covered by this report; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">3. Based on my knowledge, the financial
statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">4. The registrant&#146;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures
(as defined in Exchange Act Rules&nbsp;13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure
that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our
supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">c) Evaluated the effectiveness of the registrant&#146;s disclosure controls and procedures and presented in this report our conclusions about the
effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">d)
Disclosed in this report any change in the registrant&#146;s internal control over financial reporting that occurred during the registrant&#146;s most recent fiscal quarter (the registrant&#146;s fourth fiscal quarter in the case of an annual
report) that has materially affected, or is reasonably likely to materially affect, the registrant&#146;s internal control over financial reporting; and </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">5. The registrant&#146;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#146;s auditors and the audit
committee of the registrant&#146;s board of directors (or persons performing the equivalent functions): </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">a) All significant deficiencies and
material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#146;s ability to record, process, summarize and report financial information; and </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#146;s internal control
over financial reporting. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Dated: May&nbsp;14, 2012 </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="100%"></TD></TR>


<TR>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ <I>Mark Ahn</I></FONT></P></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Mark J. Ahn</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">President and Chief Executive Officer</FONT></TD></TR>
</TABLE></DIV>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>8
<FILENAME>d333623dex312.htm
<DESCRIPTION>SARBANES-OXLEY ACT SECTION 302 CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER
<TEXT>
<HTML><HEAD>
<TITLE>Sarbanes-Oxley Act Section 302 Certification of Principal Financial Officer</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Exhibit&nbsp;31.2 </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">I, Kwang S. Lee, certify that:
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">1. I have reviewed this Quarterly Report on Form 10-Q of Galena Biopharma, Inc.; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under
which such statements were made, not misleading with respect to the period covered by this report; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">3. Based on my knowledge, the financial
statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">4. The registrant&#146;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures
(as defined in Exchange Act Rules&nbsp;13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure
that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our
supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">c) Evaluated the effectiveness of the registrant&#146;s disclosure controls and procedures and presented in this report our conclusions about the
effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">d)
Disclosed in this report any change in the registrant&#146;s internal control over financial reporting that occurred during the registrant&#146;s most recent fiscal quarter (the registrant&#146;s fourth fiscal quarter in the case of an annual
report) that has materially affected, or is reasonably likely to materially affect, the registrant&#146;s internal control over financial reporting; and </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">5. The registrant&#146;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#146;s auditors and the audit
committee of the registrant&#146;s board of directors (or persons performing the equivalent functions): </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">a) All significant deficiencies and
material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#146;s ability to record, process, summarize and report financial information; and </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#146;s internal control
over financial reporting. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Dated: May&nbsp;14, 2012 </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="100%"></TD></TR>


<TR>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ <I>Kwang S. Lee</I></FONT></P></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Kwang S. Lee</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Vice President, Finance (Principal Financial and Accounting Officer)</FONT></TD></TR>
</TABLE></DIV>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>9
<FILENAME>d333623dex321.htm
<DESCRIPTION>SARBANES-OXLEY ACT SECTION 906 CERTIFICATION OF CEO AND PFO
<TEXT>
<HTML><HEAD>
<TITLE>Sarbanes-Oxley Act Section 906 Certification of CEO and PFO</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Exhibit&nbsp;32.1 </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>CERTIFICATION PURSUANT TO </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>18 U.S.C. SECTION 1350 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>AS ADOPTED PURSUANT TO </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">In connection with the Quarterly Report of Galena Biopharma, Inc., (the &#147;Company&#148;) on Form 10-Q for the period ended March&nbsp;31, 2012 as filed with the Securities and Exchange Commission on
the date hereof (the &#147;Report&#148;), the undersigned officers of the Company certify, pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to &#167; 906 of the Sarbanes-Oxley Act of 2002, that to their knowledge: </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">1. The Report fully complies with the requirements of Section&nbsp;13(a) or 15(d) of the Securities Exchange Act of 1934; and </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">2. The information contained in the Report fairly presents, in all material respects, the Company&#146;s financial condition and result of operations.
</FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="49%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="3%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="46%"></TD></TR>


<TR>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ <I>Mark Ahn</I></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ <I>Kwang S. Lee</I></FONT></P></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Mark J. Ahn</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Kwang S. Lee</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">President and Chief Executive Officer</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Vice President, Finance (Principal Financial and Accounting Officer</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">May&nbsp;14, 2012</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">May&nbsp;14, 2012</FONT></TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>10
<FILENAME>rxii-20120331.xml
<DESCRIPTION>XBRL INSTANCE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- XBRL Generated with XBRLMark Copyright (C) by RR Donnelley -->
<!-- Based on XBRL 2.1 -->
<xbrl xmlns="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:rxii="http://rxipharma.com/20120331" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:us-gaap="http://fasb.org/us-gaap/2011-01-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2011-01-31" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:schemaRef xlink:type="simple" xlink:href="rxii-20120331.xsd" />
<!-- Context Section -->
<context id="BalanceAsOf_11May2012">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
</entity>
<period>
<instant>2012-05-11</instant>
</period>
</context>
<context id="BalanceAsOf_31Mar2012">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
</entity>
<period>
<instant>2012-03-31</instant>
</period>
</context>
<context id="BalanceAsOf_31Dec2011">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
</entity>
<period>
<instant>2011-12-31</instant>
</period>
</context>
<context id="ThreeMonthsEnded_31Mar2012">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
</entity>
<period>
<startDate>2012-01-01</startDate>
<endDate>2012-03-31</endDate>
</period>
</context>
<context id="ThreeMonthsEnded_31Mar2011">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
</entity>
<period>
<startDate>2011-01-01</startDate>
<endDate>2011-03-31</endDate>
</period>
</context>
<context id="ForThePeriod_1Jan2003Through31Mar2012">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
</entity>
<period>
<startDate>2003-01-01</startDate>
<endDate>2012-03-31</endDate>
</period>
</context>
<context id="BalanceAsOf_31Dec2010">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
</entity>
<period>
<instant>2010-12-31</instant>
</period>
</context>
<context id="BalanceAsOf_31Mar2011">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
</entity>
<period>
<instant>2011-03-31</instant>
</period>
</context>
<!--Unit Section-->
 <unit id="USDEPS">
   <divide>
     <unitNumerator>
       <measure>iso4217:USD</measure>
     </unitNumerator>
     <unitDenominator>
       <measure>xbrli:shares</measure>
     </unitDenominator>
   </divide>
 </unit>
 <unit id="Shares">
   <measure>xbrli:shares</measure>
  </unit>
  <unit id="USD">
    <measure>iso4217:USD</measure>
  </unit>

<!-- Element Section -->
<!--Document Information-->
<dei:EntityRegistrantName contextRef="ThreeMonthsEnded_31Mar2012">Galena Biopharma, Inc.</dei:EntityRegistrantName>
<dei:EntityCentralIndexKey contextRef="ThreeMonthsEnded_31Mar2012">0001390478</dei:EntityCentralIndexKey>
<dei:CurrentFiscalYearEndDate contextRef="ThreeMonthsEnded_31Mar2012">--12-31</dei:CurrentFiscalYearEndDate>
<dei:EntityFilerCategory contextRef="ThreeMonthsEnded_31Mar2012">Smaller Reporting Company</dei:EntityFilerCategory>
<dei:DocumentType contextRef="ThreeMonthsEnded_31Mar2012">10-Q</dei:DocumentType>
<dei:AmendmentFlag contextRef="ThreeMonthsEnded_31Mar2012">false</dei:AmendmentFlag>
<dei:DocumentPeriodEndDate contextRef="ThreeMonthsEnded_31Mar2012">2012-03-31</dei:DocumentPeriodEndDate>
<dei:DocumentFiscalPeriodFocus contextRef="ThreeMonthsEnded_31Mar2012">Q1</dei:DocumentFiscalPeriodFocus>
<dei:DocumentFiscalYearFocus contextRef="ThreeMonthsEnded_31Mar2012">2012</dei:DocumentFiscalYearFocus>
<dei:EntityCommonStockSharesOutstanding contextRef="BalanceAsOf_11May2012" decimals="INF" unitRef="Shares">65643905</dei:EntityCommonStockSharesOutstanding>
<!-- Instance Elements for BALANCE_SHEETS -->
<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="BalanceAsOf_31Mar2012" unitRef="USD" decimals="-3">8701000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="BalanceAsOf_31Dec2011" unitRef="USD" decimals="-3">11433000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
<us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue contextRef="BalanceAsOf_31Mar2012" unitRef="USD" decimals="-3">101000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
<us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue contextRef="BalanceAsOf_31Dec2011" unitRef="USD" decimals="-3">101000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
<us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="BalanceAsOf_31Mar2012" unitRef="USD" decimals="-3">290000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
<us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="BalanceAsOf_31Dec2011" unitRef="USD" decimals="-3">276000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
<us-gaap:AssetsCurrent contextRef="BalanceAsOf_31Mar2012" unitRef="USD" decimals="-3">9092000</us-gaap:AssetsCurrent>
<us-gaap:AssetsCurrent contextRef="BalanceAsOf_31Dec2011" unitRef="USD" decimals="-3">11810000</us-gaap:AssetsCurrent>
<us-gaap:PropertyPlantAndEquipmentNet contextRef="BalanceAsOf_31Mar2012" unitRef="USD" decimals="-3">351000</us-gaap:PropertyPlantAndEquipmentNet>
<us-gaap:PropertyPlantAndEquipmentNet contextRef="BalanceAsOf_31Dec2011" unitRef="USD" decimals="-3">393000</us-gaap:PropertyPlantAndEquipmentNet>
<rxii:InProcessResearchDevelopment contextRef="BalanceAsOf_31Mar2012" unitRef="USD" decimals="-3">12864000</rxii:InProcessResearchDevelopment>
<rxii:InProcessResearchDevelopment contextRef="BalanceAsOf_31Dec2011" unitRef="USD" decimals="-3">12864000</rxii:InProcessResearchDevelopment>
<us-gaap:Goodwill contextRef="BalanceAsOf_31Mar2012" unitRef="USD" decimals="-3">5898000</us-gaap:Goodwill>
<us-gaap:Goodwill contextRef="BalanceAsOf_31Dec2011" unitRef="USD" decimals="-3">5898000</us-gaap:Goodwill>
<us-gaap:DepositsAssetsNoncurrent contextRef="BalanceAsOf_31Mar2012" unitRef="USD" decimals="-3">3000</us-gaap:DepositsAssetsNoncurrent>
<us-gaap:DepositsAssetsNoncurrent contextRef="BalanceAsOf_31Dec2011" unitRef="USD" decimals="-3">3000</us-gaap:DepositsAssetsNoncurrent>
<us-gaap:Assets contextRef="BalanceAsOf_31Mar2012" unitRef="USD" decimals="-3">28208000</us-gaap:Assets>
<us-gaap:Assets contextRef="BalanceAsOf_31Dec2011" unitRef="USD" decimals="-3">30968000</us-gaap:Assets>
<us-gaap:AccountsPayableCurrent contextRef="BalanceAsOf_31Mar2012" unitRef="USD" decimals="-3">2581000</us-gaap:AccountsPayableCurrent>
<us-gaap:AccountsPayableCurrent contextRef="BalanceAsOf_31Dec2011" unitRef="USD" decimals="-3">2155000</us-gaap:AccountsPayableCurrent>
<us-gaap:AccruedLiabilitiesCurrent contextRef="BalanceAsOf_31Mar2012" unitRef="USD" decimals="-3">3532000</us-gaap:AccruedLiabilitiesCurrent>
<us-gaap:AccruedLiabilitiesCurrent contextRef="BalanceAsOf_31Dec2011" unitRef="USD" decimals="-3">2984000</us-gaap:AccruedLiabilitiesCurrent>
<us-gaap:CapitalLeaseObligationsCurrent contextRef="BalanceAsOf_31Mar2012" unitRef="USD" decimals="-3">24000</us-gaap:CapitalLeaseObligationsCurrent>
<us-gaap:CapitalLeaseObligationsCurrent contextRef="BalanceAsOf_31Dec2011" unitRef="USD" decimals="-3">35000</us-gaap:CapitalLeaseObligationsCurrent>
<us-gaap:ConvertibleNotesPayableCurrent contextRef="BalanceAsOf_31Mar2012" unitRef="USD" decimals="-3">0</us-gaap:ConvertibleNotesPayableCurrent>
<us-gaap:ConvertibleNotesPayableCurrent contextRef="BalanceAsOf_31Dec2011" unitRef="USD" decimals="-3">500000</us-gaap:ConvertibleNotesPayableCurrent>
<rxii:FairValueOfWarrantsPotentiallySettleableInCash contextRef="BalanceAsOf_31Mar2012" unitRef="USD" decimals="-3">20357000</rxii:FairValueOfWarrantsPotentiallySettleableInCash>
<rxii:FairValueOfWarrantsPotentiallySettleableInCash contextRef="BalanceAsOf_31Dec2011" unitRef="USD" decimals="-3">3746000</rxii:FairValueOfWarrantsPotentiallySettleableInCash>
<rxii:CurrentContingentPurchasePriceConsideration contextRef="BalanceAsOf_31Mar2012" unitRef="USD" decimals="-3">898000</rxii:CurrentContingentPurchasePriceConsideration>
<rxii:CurrentContingentPurchasePriceConsideration contextRef="BalanceAsOf_31Dec2011" unitRef="USD" decimals="-3">1782000</rxii:CurrentContingentPurchasePriceConsideration>
<us-gaap:LiabilitiesCurrent contextRef="BalanceAsOf_31Mar2012" unitRef="USD" decimals="-3">27392000</us-gaap:LiabilitiesCurrent>
<us-gaap:LiabilitiesCurrent contextRef="BalanceAsOf_31Dec2011" unitRef="USD" decimals="-3">11202000</us-gaap:LiabilitiesCurrent>
<us-gaap:CapitalLeaseObligationsNoncurrent contextRef="BalanceAsOf_31Mar2012" unitRef="USD" decimals="-3">36000</us-gaap:CapitalLeaseObligationsNoncurrent>
<us-gaap:CapitalLeaseObligationsNoncurrent contextRef="BalanceAsOf_31Dec2011" unitRef="USD" decimals="-3">32000</us-gaap:CapitalLeaseObligationsNoncurrent>
<us-gaap:ConvertibleLongTermNotesPayable contextRef="BalanceAsOf_31Mar2012" unitRef="USD" decimals="-3">1000000</us-gaap:ConvertibleLongTermNotesPayable>
<us-gaap:ConvertibleLongTermNotesPayable contextRef="BalanceAsOf_31Dec2011" unitRef="USD" decimals="-3">0</us-gaap:ConvertibleLongTermNotesPayable>
<us-gaap:DeferredTaxAssetsLiabilitiesNetNoncurrent contextRef="BalanceAsOf_31Mar2012" unitRef="USD" decimals="-3">-5053000</us-gaap:DeferredTaxAssetsLiabilitiesNetNoncurrent>
<us-gaap:DeferredTaxAssetsLiabilitiesNetNoncurrent contextRef="BalanceAsOf_31Dec2011" unitRef="USD" decimals="-3">-5053000</us-gaap:DeferredTaxAssetsLiabilitiesNetNoncurrent>
<rxii:ContingentPurchasePriceConsiderationNetOfCurrentPortion contextRef="BalanceAsOf_31Mar2012" unitRef="USD" decimals="-3">5297000</rxii:ContingentPurchasePriceConsiderationNetOfCurrentPortion>
<rxii:ContingentPurchasePriceConsiderationNetOfCurrentPortion contextRef="BalanceAsOf_31Dec2011" unitRef="USD" decimals="-3">4569000</rxii:ContingentPurchasePriceConsiderationNetOfCurrentPortion>
<us-gaap:Liabilities contextRef="BalanceAsOf_31Mar2012" unitRef="USD" decimals="-3">38778000</us-gaap:Liabilities>
<us-gaap:Liabilities contextRef="BalanceAsOf_31Dec2011" unitRef="USD" decimals="-3">20856000</us-gaap:Liabilities>
<us-gaap:PreferredStockValue contextRef="BalanceAsOf_31Mar2012" unitRef="USD" xsi:nil="true" />
<us-gaap:PreferredStockValue contextRef="BalanceAsOf_31Dec2011" unitRef="USD" xsi:nil="true" />
<us-gaap:PreferredStockParOrStatedValuePerShare contextRef="BalanceAsOf_31Mar2012" unitRef="USDEPS" decimals="INF">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
<us-gaap:PreferredStockParOrStatedValuePerShare contextRef="BalanceAsOf_31Dec2011" unitRef="USDEPS" decimals="INF">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
<us-gaap:PreferredStockSharesAuthorized contextRef="BalanceAsOf_31Mar2012" unitRef="Shares" decimals="INF">5000000</us-gaap:PreferredStockSharesAuthorized>
<us-gaap:PreferredStockSharesAuthorized contextRef="BalanceAsOf_31Dec2011" unitRef="Shares" decimals="INF">5000000</us-gaap:PreferredStockSharesAuthorized>
<us-gaap:PreferredStockSharesIssued contextRef="BalanceAsOf_31Mar2012" unitRef="Shares" xsi:nil="true" />
<us-gaap:PreferredStockSharesIssued contextRef="BalanceAsOf_31Dec2011" unitRef="Shares" xsi:nil="true" />
<us-gaap:PreferredStockSharesOutstanding contextRef="BalanceAsOf_31Mar2012" unitRef="Shares" xsi:nil="true" />
<us-gaap:PreferredStockSharesOutstanding contextRef="BalanceAsOf_31Dec2011" unitRef="Shares" xsi:nil="true" />
<us-gaap:CommonStockValue contextRef="BalanceAsOf_31Mar2012" unitRef="USD" decimals="-3">5000</us-gaap:CommonStockValue>
<us-gaap:CommonStockValue contextRef="BalanceAsOf_31Dec2011" unitRef="USD" decimals="-3">5000</us-gaap:CommonStockValue>
<us-gaap:CommonStockParOrStatedValuePerShare contextRef="BalanceAsOf_31Mar2012" unitRef="USDEPS" decimals="INF">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
<us-gaap:CommonStockParOrStatedValuePerShare contextRef="BalanceAsOf_31Dec2011" unitRef="USDEPS" decimals="INF">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
<us-gaap:CommonStockSharesAuthorized contextRef="BalanceAsOf_31Mar2012" unitRef="Shares" decimals="INF">125000000</us-gaap:CommonStockSharesAuthorized>
<us-gaap:CommonStockSharesAuthorized contextRef="BalanceAsOf_31Dec2011" unitRef="Shares" decimals="INF">125000000</us-gaap:CommonStockSharesAuthorized>
<us-gaap:CommonStockSharesIssued contextRef="BalanceAsOf_31Mar2012" unitRef="Shares" decimals="INF">50082148</us-gaap:CommonStockSharesIssued>
<us-gaap:CommonStockSharesIssued contextRef="BalanceAsOf_31Dec2011" unitRef="Shares" decimals="INF">47811453</us-gaap:CommonStockSharesIssued>
<us-gaap:CommonStockSharesOutstanding contextRef="BalanceAsOf_31Mar2012" unitRef="Shares" decimals="INF">49407148</us-gaap:CommonStockSharesOutstanding>
<us-gaap:CommonStockSharesOutstanding contextRef="BalanceAsOf_31Dec2011" unitRef="Shares" decimals="INF">47136453</us-gaap:CommonStockSharesOutstanding>
<us-gaap:AdditionalPaidInCapitalCommonStock contextRef="BalanceAsOf_31Mar2012" unitRef="USD" decimals="-3">85263000</us-gaap:AdditionalPaidInCapitalCommonStock>
<us-gaap:AdditionalPaidInCapitalCommonStock contextRef="BalanceAsOf_31Dec2011" unitRef="USD" decimals="-3">81184000</us-gaap:AdditionalPaidInCapitalCommonStock>
<rxii:DeficitAccumulatedDuringDevelopmentalStage contextRef="BalanceAsOf_31Mar2012" unitRef="USD" decimals="-3">-91989000</rxii:DeficitAccumulatedDuringDevelopmentalStage>
<rxii:DeficitAccumulatedDuringDevelopmentalStage contextRef="BalanceAsOf_31Dec2011" unitRef="USD" decimals="-3">-67228000</rxii:DeficitAccumulatedDuringDevelopmentalStage>
<us-gaap:TreasuryStockValue contextRef="BalanceAsOf_31Mar2012" unitRef="USD" decimals="-3">3849000</us-gaap:TreasuryStockValue>
<us-gaap:TreasuryStockValue contextRef="BalanceAsOf_31Dec2011" unitRef="USD" decimals="-3">3849000</us-gaap:TreasuryStockValue>
<us-gaap:TreasuryStockShares contextRef="BalanceAsOf_31Mar2012" unitRef="Shares" decimals="INF">675000</us-gaap:TreasuryStockShares>
<us-gaap:TreasuryStockShares contextRef="BalanceAsOf_31Dec2011" unitRef="Shares" decimals="INF">675000</us-gaap:TreasuryStockShares>
<us-gaap:StockholdersEquity contextRef="BalanceAsOf_31Mar2012" unitRef="USD" decimals="-3">-10570000</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="BalanceAsOf_31Dec2011" unitRef="USD" decimals="-3">10112000</us-gaap:StockholdersEquity>
<us-gaap:LiabilitiesAndStockholdersEquity contextRef="BalanceAsOf_31Mar2012" unitRef="USD" decimals="-3">28208000</us-gaap:LiabilitiesAndStockholdersEquity>
<us-gaap:LiabilitiesAndStockholdersEquity contextRef="BalanceAsOf_31Dec2011" unitRef="USD" decimals="-3">30968000</us-gaap:LiabilitiesAndStockholdersEquity>
<!-- Instance Elements for STMNT_INCOME -->
<us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="ThreeMonthsEnded_31Mar2012" unitRef="USD" decimals="-3">3392000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
<us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="ThreeMonthsEnded_31Mar2011" unitRef="USD" decimals="-3">1941000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
<us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="ForThePeriod_1Jan2003Through31Mar2012" unitRef="USD" decimals="-3">40817000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
<rxii:ResearchAndDevelopmentEmployeeStockBasedCompensationExpense contextRef="ThreeMonthsEnded_31Mar2012" unitRef="USD" decimals="-3">72000</rxii:ResearchAndDevelopmentEmployeeStockBasedCompensationExpense>
<rxii:ResearchAndDevelopmentEmployeeStockBasedCompensationExpense contextRef="ThreeMonthsEnded_31Mar2011" unitRef="USD" decimals="-3">246000</rxii:ResearchAndDevelopmentEmployeeStockBasedCompensationExpense>
<rxii:ResearchAndDevelopmentEmployeeStockBasedCompensationExpense contextRef="ForThePeriod_1Jan2003Through31Mar2012" unitRef="USD" decimals="-3">3345000</rxii:ResearchAndDevelopmentEmployeeStockBasedCompensationExpense>
<rxii:ResearchAndDevelopmentNonEmployeeStockBasedCompensationExpense contextRef="ThreeMonthsEnded_31Mar2012" unitRef="USD" decimals="-3">157000</rxii:ResearchAndDevelopmentNonEmployeeStockBasedCompensationExpense>
<rxii:ResearchAndDevelopmentNonEmployeeStockBasedCompensationExpense contextRef="ThreeMonthsEnded_31Mar2011" unitRef="USD" decimals="-3">-31000</rxii:ResearchAndDevelopmentNonEmployeeStockBasedCompensationExpense>
<rxii:ResearchAndDevelopmentNonEmployeeStockBasedCompensationExpense contextRef="ForThePeriod_1Jan2003Through31Mar2012" unitRef="USD" decimals="-3">6150000</rxii:ResearchAndDevelopmentNonEmployeeStockBasedCompensationExpense>
<rxii:FairValueOfCommonStockInExchangeForResearchAndDevelopmentExpenses contextRef="ThreeMonthsEnded_31Mar2012" unitRef="USD" decimals="-3">50000</rxii:FairValueOfCommonStockInExchangeForResearchAndDevelopmentExpenses>
<rxii:FairValueOfCommonStockInExchangeForResearchAndDevelopmentExpenses contextRef="ForThePeriod_1Jan2003Through31Mar2012" unitRef="USD" decimals="-3">4004000</rxii:FairValueOfCommonStockInExchangeForResearchAndDevelopmentExpenses>
<us-gaap:ResearchAndDevelopmentExpense contextRef="ThreeMonthsEnded_31Mar2012" unitRef="USD" decimals="-3">3671000</us-gaap:ResearchAndDevelopmentExpense>
<us-gaap:ResearchAndDevelopmentExpense contextRef="ThreeMonthsEnded_31Mar2011" unitRef="USD" decimals="-3">2156000</us-gaap:ResearchAndDevelopmentExpense>
<us-gaap:ResearchAndDevelopmentExpense contextRef="ForThePeriod_1Jan2003Through31Mar2012" unitRef="USD" decimals="-3">54316000</us-gaap:ResearchAndDevelopmentExpense>
<rxii:GeneralAndAdministrativeExpenses contextRef="ThreeMonthsEnded_31Mar2012" unitRef="USD" decimals="-3">1458000</rxii:GeneralAndAdministrativeExpenses>
<rxii:GeneralAndAdministrativeExpenses contextRef="ThreeMonthsEnded_31Mar2011" unitRef="USD" decimals="-3">1921000</rxii:GeneralAndAdministrativeExpenses>
<rxii:GeneralAndAdministrativeExpenses contextRef="ForThePeriod_1Jan2003Through31Mar2012" unitRef="USD" decimals="-3">29431000</rxii:GeneralAndAdministrativeExpenses>
<rxii:GeneralAndAdministrativeEmployeeStockBasedCompensation contextRef="ThreeMonthsEnded_31Mar2012" unitRef="USD" decimals="-3">198000</rxii:GeneralAndAdministrativeEmployeeStockBasedCompensation>
<rxii:GeneralAndAdministrativeEmployeeStockBasedCompensation contextRef="ThreeMonthsEnded_31Mar2011" unitRef="USD" decimals="-3">1099000</rxii:GeneralAndAdministrativeEmployeeStockBasedCompensation>
<rxii:GeneralAndAdministrativeEmployeeStockBasedCompensation contextRef="ForThePeriod_1Jan2003Through31Mar2012" unitRef="USD" decimals="-3">9788000</rxii:GeneralAndAdministrativeEmployeeStockBasedCompensation>
<rxii:FairValueOfCommonStockWarrantsIssuedForGeneralAndAdministrativeExpenses contextRef="ThreeMonthsEnded_31Mar2012" unitRef="USD" decimals="-3">148000</rxii:FairValueOfCommonStockWarrantsIssuedForGeneralAndAdministrativeExpenses>
<rxii:FairValueOfCommonStockWarrantsIssuedForGeneralAndAdministrativeExpenses contextRef="ThreeMonthsEnded_31Mar2011" unitRef="USD" decimals="-3">76000</rxii:FairValueOfCommonStockWarrantsIssuedForGeneralAndAdministrativeExpenses>
<rxii:FairValueOfCommonStockWarrantsIssuedForGeneralAndAdministrativeExpenses contextRef="ForThePeriod_1Jan2003Through31Mar2012" unitRef="USD" decimals="-3">2550000</rxii:FairValueOfCommonStockWarrantsIssuedForGeneralAndAdministrativeExpenses>
<rxii:FairValueOfCommonStockIssuedInExchangeForGeneralAndAdministrativeExpenses contextRef="ThreeMonthsEnded_31Mar2012" unitRef="USD" decimals="-3">135000</rxii:FairValueOfCommonStockIssuedInExchangeForGeneralAndAdministrativeExpenses>
<rxii:FairValueOfCommonStockIssuedInExchangeForGeneralAndAdministrativeExpenses contextRef="ThreeMonthsEnded_31Mar2011" unitRef="USD" decimals="-3">23000</rxii:FairValueOfCommonStockIssuedInExchangeForGeneralAndAdministrativeExpenses>
<rxii:FairValueOfCommonStockIssuedInExchangeForGeneralAndAdministrativeExpenses contextRef="ForThePeriod_1Jan2003Through31Mar2012" unitRef="USD" decimals="-3">489000</rxii:FairValueOfCommonStockIssuedInExchangeForGeneralAndAdministrativeExpenses>
<us-gaap:GeneralAndAdministrativeExpense contextRef="ThreeMonthsEnded_31Mar2012" unitRef="USD" decimals="-3">1939000</us-gaap:GeneralAndAdministrativeExpense>
<us-gaap:GeneralAndAdministrativeExpense contextRef="ThreeMonthsEnded_31Mar2011" unitRef="USD" decimals="-3">3119000</us-gaap:GeneralAndAdministrativeExpense>
<us-gaap:GeneralAndAdministrativeExpense contextRef="ForThePeriod_1Jan2003Through31Mar2012" unitRef="USD" decimals="-3">42258000</us-gaap:GeneralAndAdministrativeExpense>
<us-gaap:OperatingExpenses contextRef="ThreeMonthsEnded_31Mar2012" unitRef="USD" decimals="-3">5610000</us-gaap:OperatingExpenses>
<us-gaap:OperatingExpenses contextRef="ThreeMonthsEnded_31Mar2011" unitRef="USD" decimals="-3">5275000</us-gaap:OperatingExpenses>
<us-gaap:OperatingExpenses contextRef="ForThePeriod_1Jan2003Through31Mar2012" unitRef="USD" decimals="-3">96574000</us-gaap:OperatingExpenses>
<rxii:InterestIncome contextRef="ThreeMonthsEnded_31Mar2012" unitRef="USD" decimals="-3">-37000</rxii:InterestIncome>
<rxii:InterestIncome contextRef="ThreeMonthsEnded_31Mar2011" unitRef="USD" decimals="-3">-1000</rxii:InterestIncome>
<rxii:InterestIncome contextRef="ForThePeriod_1Jan2003Through31Mar2012" unitRef="USD" decimals="-3">621000</rxii:InterestIncome>
<us-gaap:OtherNonoperatingIncomeExpense contextRef="ThreeMonthsEnded_31Mar2012" unitRef="USD" decimals="-3">-19114000</us-gaap:OtherNonoperatingIncomeExpense>
<us-gaap:OtherNonoperatingIncomeExpense contextRef="ThreeMonthsEnded_31Mar2011" unitRef="USD" decimals="-3">1435000</us-gaap:OtherNonoperatingIncomeExpense>
<us-gaap:OtherNonoperatingIncomeExpense contextRef="ForThePeriod_1Jan2003Through31Mar2012" unitRef="USD" decimals="-3">-6077000</us-gaap:OtherNonoperatingIncomeExpense>
<us-gaap:NetIncomeLoss contextRef="ThreeMonthsEnded_31Mar2012" unitRef="USD" decimals="-3">-24761000</us-gaap:NetIncomeLoss>
<us-gaap:NetIncomeLoss contextRef="ThreeMonthsEnded_31Mar2011" unitRef="USD" decimals="-3">-3841000</us-gaap:NetIncomeLoss>
<us-gaap:NetIncomeLoss contextRef="ForThePeriod_1Jan2003Through31Mar2012" unitRef="USD" decimals="-3">-102030000</us-gaap:NetIncomeLoss>
<us-gaap:EarningsPerShareBasicAndDiluted contextRef="ThreeMonthsEnded_31Mar2012" unitRef="USDEPS" decimals="2">-0.52</us-gaap:EarningsPerShareBasicAndDiluted>
<us-gaap:EarningsPerShareBasicAndDiluted contextRef="ThreeMonthsEnded_31Mar2011" unitRef="USDEPS" decimals="2">-0.19</us-gaap:EarningsPerShareBasicAndDiluted>
<rxii:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="ThreeMonthsEnded_31Mar2012" unitRef="Shares" decimals="0">47967499</rxii:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
<rxii:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="ThreeMonthsEnded_31Mar2011" unitRef="Shares" decimals="0">20316170</rxii:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
<!-- Instance Elements for STMNT_CASH_FLOWS -->
<rxii:NetIncomeLossIncludingOther contextRef="ThreeMonthsEnded_31Mar2012" unitRef="USD" decimals="-3">-24761000</rxii:NetIncomeLossIncludingOther>
<rxii:NetIncomeLossIncludingOther contextRef="ThreeMonthsEnded_31Mar2011" unitRef="USD" decimals="-3">-3841000</rxii:NetIncomeLossIncludingOther>
<rxii:NetIncomeLossIncludingOther contextRef="ForThePeriod_1Jan2003Through31Mar2012" unitRef="USD" decimals="-3">-102030000</rxii:NetIncomeLossIncludingOther>
<us-gaap:DepreciationDepletionAndAmortization contextRef="ThreeMonthsEnded_31Mar2012" unitRef="USD" decimals="-3">42000</us-gaap:DepreciationDepletionAndAmortization>
<us-gaap:DepreciationDepletionAndAmortization contextRef="ThreeMonthsEnded_31Mar2011" unitRef="USD" decimals="-3">37000</us-gaap:DepreciationDepletionAndAmortization>
<us-gaap:DepreciationDepletionAndAmortization contextRef="ForThePeriod_1Jan2003Through31Mar2012" unitRef="USD" decimals="-3">706000</us-gaap:DepreciationDepletionAndAmortization>
<us-gaap:GainLossOnDispositionOfAssets contextRef="ForThePeriod_1Jan2003Through31Mar2012" unitRef="USD" decimals="-3">-19000</us-gaap:GainLossOnDispositionOfAssets>
<rxii:NonCashRentExpense contextRef="ForThePeriod_1Jan2003Through31Mar2012" unitRef="USD" decimals="-3">29000</rxii:NonCashRentExpense>
<us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments contextRef="ForThePeriod_1Jan2003Through31Mar2012" unitRef="USD" decimals="-3">-35000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
<us-gaap:ShareBasedCompensation contextRef="ThreeMonthsEnded_31Mar2012" unitRef="USD" decimals="-3">427000</us-gaap:ShareBasedCompensation>
<us-gaap:ShareBasedCompensation contextRef="ThreeMonthsEnded_31Mar2011" unitRef="USD" decimals="-3">1314000</us-gaap:ShareBasedCompensation>
<us-gaap:ShareBasedCompensation contextRef="ForThePeriod_1Jan2003Through31Mar2012" unitRef="USD" decimals="-3">19285000</us-gaap:ShareBasedCompensation>
<rxii:LossOnExchangeOfEquityInstruments contextRef="ForThePeriod_1Jan2003Through31Mar2012" unitRef="USD" decimals="-3">900000</rxii:LossOnExchangeOfEquityInstruments>
<rxii:FairValueOfSharesMandatorilyRedeemableForCashUponExerciseOfWarrants contextRef="ForThePeriod_1Jan2003Through31Mar2012" unitRef="USD" decimals="-3">785000</rxii:FairValueOfSharesMandatorilyRedeemableForCashUponExerciseOfWarrants>
<rxii:FairValueOfParentCompanyCommonStockIssuedInExchangeForServices contextRef="ThreeMonthsEnded_31Mar2012" unitRef="USD" decimals="-3">148000</rxii:FairValueOfParentCompanyCommonStockIssuedInExchangeForServices>
<rxii:FairValueOfParentCompanyCommonStockIssuedInExchangeForServices contextRef="ThreeMonthsEnded_31Mar2011" unitRef="USD" decimals="-3">76000</rxii:FairValueOfParentCompanyCommonStockIssuedInExchangeForServices>
<rxii:FairValueOfParentCompanyCommonStockIssuedInExchangeForServices contextRef="ForThePeriod_1Jan2003Through31Mar2012" unitRef="USD" decimals="-3">2550000</rxii:FairValueOfParentCompanyCommonStockIssuedInExchangeForServices>
<us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims contextRef="ThreeMonthsEnded_31Mar2012" unitRef="USD" decimals="-3">185000</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
<us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims contextRef="ThreeMonthsEnded_31Mar2011" unitRef="USD" decimals="-3">23000</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
<us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims contextRef="ForThePeriod_1Jan2003Through31Mar2012" unitRef="USD" decimals="-3">539000</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
<rxii:ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings contextRef="ThreeMonthsEnded_31Mar2012" unitRef="USD" decimals="-3">-18270000</rxii:ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings>
<rxii:ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings contextRef="ThreeMonthsEnded_31Mar2011" unitRef="USD" decimals="-3">1435000</rxii:ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings>
<rxii:ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings contextRef="ForThePeriod_1Jan2003Through31Mar2012" unitRef="USD" decimals="-3">-6198000</rxii:ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings>
<rxii:FairValueOfCommonStockIssuedInExchangeForLicensingRights contextRef="ForThePeriod_1Jan2003Through31Mar2012" unitRef="USD" decimals="-3">3954000</rxii:FairValueOfCommonStockIssuedInExchangeForLicensingRights>
<rxii:ChangeInFairValueOfContingentPurchaseConsideration contextRef="ThreeMonthsEnded_31Mar2012" unitRef="USD" decimals="-3">-844000</rxii:ChangeInFairValueOfContingentPurchaseConsideration>
<rxii:ChangeInFairValueOfContingentPurchaseConsideration contextRef="ForThePeriod_1Jan2003Through31Mar2012" unitRef="USD" decimals="-3">-735000</rxii:ChangeInFairValueOfContingentPurchaseConsideration>
<us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="ThreeMonthsEnded_31Mar2012" unitRef="USD" decimals="-3">14000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
<us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="ThreeMonthsEnded_31Mar2011" unitRef="USD" decimals="-3">133000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
<us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="ForThePeriod_1Jan2003Through31Mar2012" unitRef="USD" decimals="-3">263000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
<us-gaap:IncreaseDecreaseInAccountsPayable contextRef="ThreeMonthsEnded_31Mar2012" unitRef="USD" decimals="-3">426000</us-gaap:IncreaseDecreaseInAccountsPayable>
<us-gaap:IncreaseDecreaseInAccountsPayable contextRef="ThreeMonthsEnded_31Mar2011" unitRef="USD" decimals="-3">2000</us-gaap:IncreaseDecreaseInAccountsPayable>
<us-gaap:IncreaseDecreaseInAccountsPayable contextRef="ForThePeriod_1Jan2003Through31Mar2012" unitRef="USD" decimals="-3">1650000</us-gaap:IncreaseDecreaseInAccountsPayable>
<us-gaap:IncreaseDecreaseInDueToOtherRelatedPartiesCurrent contextRef="ForThePeriod_1Jan2003Through31Mar2012" unitRef="USD" decimals="-3">-207000</us-gaap:IncreaseDecreaseInDueToOtherRelatedPartiesCurrent>
<us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="ThreeMonthsEnded_31Mar2012" unitRef="USD" decimals="-3">-452000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
<us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="ThreeMonthsEnded_31Mar2011" unitRef="USD" decimals="-3">930000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
<us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="ForThePeriod_1Jan2003Through31Mar2012" unitRef="USD" decimals="-3">3022000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
<us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="ThreeMonthsEnded_31Mar2012" unitRef="USD" decimals="-3">-4885000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
<us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="ThreeMonthsEnded_31Mar2011" unitRef="USD" decimals="-3">-3027000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
<us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="ForThePeriod_1Jan2003Through31Mar2012" unitRef="USD" decimals="-3">-63663000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
<us-gaap:IncreaseDecreaseInRestrictedCash contextRef="ForThePeriod_1Jan2003Through31Mar2012" unitRef="USD" decimals="-3">101000</us-gaap:IncreaseDecreaseInRestrictedCash>
<rxii:CashReceivedInAcquisition contextRef="ForThePeriod_1Jan2003Through31Mar2012" unitRef="USD" decimals="-3">-168000</rxii:CashReceivedInAcquisition>
<us-gaap:PaymentsToAcquireShortTermInvestments contextRef="ForThePeriod_1Jan2003Through31Mar2012" unitRef="USD" decimals="-3">37532000</us-gaap:PaymentsToAcquireShortTermInvestments>
<us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments contextRef="ForThePeriod_1Jan2003Through31Mar2012" unitRef="USD" decimals="-3">37497000</us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments>
<us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="ThreeMonthsEnded_31Mar2011" unitRef="USD" decimals="-3">40000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
<us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="ForThePeriod_1Jan2003Through31Mar2012" unitRef="USD" decimals="-3">739000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
<us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment contextRef="ForThePeriod_1Jan2003Through31Mar2012" unitRef="USD" decimals="-3">-1000</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
<rxii:CashRefundedPaidForLeaseDeposit contextRef="ForThePeriod_1Jan2003Through31Mar2012" unitRef="USD" decimals="-3">-45000</rxii:CashRefundedPaidForLeaseDeposit>
<us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="ThreeMonthsEnded_31Mar2011" unitRef="USD" decimals="-3">-40000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
<us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="ForThePeriod_1Jan2003Through31Mar2012" unitRef="USD" decimals="-3">-753000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
<us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="ThreeMonthsEnded_31Mar2012" unitRef="USD" decimals="-3">385000</us-gaap:ProceedsFromIssuanceOfCommonStock>
<us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="ThreeMonthsEnded_31Mar2011" unitRef="USD" decimals="-3">7314000</us-gaap:ProceedsFromIssuanceOfCommonStock>
<us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="ForThePeriod_1Jan2003Through31Mar2012" unitRef="USD" decimals="-3">65367000</us-gaap:ProceedsFromIssuanceOfCommonStock>
<us-gaap:PaymentsForRepurchaseOfCommonStock contextRef="ForThePeriod_1Jan2003Through31Mar2012" unitRef="USD" decimals="-3">3849000</us-gaap:PaymentsForRepurchaseOfCommonStock>
<us-gaap:ProceedsFromStockOptionsExercised contextRef="ForThePeriod_1Jan2003Through31Mar2012" unitRef="USD" decimals="-3">610000</us-gaap:ProceedsFromStockOptionsExercised>
<rxii:NetProceedsFromExerciseOfCommonStockWarrants contextRef="ThreeMonthsEnded_31Mar2012" unitRef="USD" decimals="-3">1236000</rxii:NetProceedsFromExerciseOfCommonStockWarrants>
<rxii:NetProceedsFromExerciseOfCommonStockWarrants contextRef="ForThePeriod_1Jan2003Through31Mar2012" unitRef="USD" decimals="-3">1386000</rxii:NetProceedsFromExerciseOfCommonStockWarrants>
<rxii:CommonStockIssuedInConnectionWithEspp contextRef="ThreeMonthsEnded_31Mar2012" unitRef="USD" decimals="-3">-39000</rxii:CommonStockIssuedInConnectionWithEspp>
<rxii:CommonStockIssuedInConnectionWithEspp contextRef="ForThePeriod_1Jan2003Through31Mar2012" unitRef="USD" decimals="-3">-54000</rxii:CommonStockIssuedInConnectionWithEspp>
<rxii:NetProceedsFromIssuanceOfConvertibleNotesPayable contextRef="ThreeMonthsEnded_31Mar2012" unitRef="USD" decimals="-3">-500000</rxii:NetProceedsFromIssuanceOfConvertibleNotesPayable>
<rxii:NetProceedsFromIssuanceOfConvertibleNotesPayable contextRef="ForThePeriod_1Jan2003Through31Mar2012" unitRef="USD" decimals="-3">-1000000</rxii:NetProceedsFromIssuanceOfConvertibleNotesPayable>
<us-gaap:RepaymentsOfLongTermCapitalLeaseObligations contextRef="ThreeMonthsEnded_31Mar2012" unitRef="USD" decimals="-3">7000</us-gaap:RepaymentsOfLongTermCapitalLeaseObligations>
<us-gaap:RepaymentsOfLongTermCapitalLeaseObligations contextRef="ThreeMonthsEnded_31Mar2011" unitRef="USD" decimals="-3">23000</us-gaap:RepaymentsOfLongTermCapitalLeaseObligations>
<us-gaap:RepaymentsOfLongTermCapitalLeaseObligations contextRef="ForThePeriod_1Jan2003Through31Mar2012" unitRef="USD" decimals="-3">217000</us-gaap:RepaymentsOfLongTermCapitalLeaseObligations>
<us-gaap:ProceedsFromRelatedPartyDebt contextRef="ForThePeriod_1Jan2003Through31Mar2012" unitRef="USD" decimals="-3">8766000</us-gaap:ProceedsFromRelatedPartyDebt>
<us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="ThreeMonthsEnded_31Mar2012" unitRef="USD" decimals="-3">2153000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
<us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="ThreeMonthsEnded_31Mar2011" unitRef="USD" decimals="-3">7291000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
<us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="ForThePeriod_1Jan2003Through31Mar2012" unitRef="USD" decimals="-3">73117000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
<us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="ThreeMonthsEnded_31Mar2012" unitRef="USD" decimals="-3">-2732000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
<us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="ThreeMonthsEnded_31Mar2011" unitRef="USD" decimals="-3">4224000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
<us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="ForThePeriod_1Jan2003Through31Mar2012" unitRef="USD" decimals="-3">8701000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="BalanceAsOf_31Dec2010" unitRef="USD" decimals="-3">6891000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="BalanceAsOf_31Mar2011" unitRef="USD" decimals="-3">11115000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
<us-gaap:ProceedsFromInterestReceived contextRef="ThreeMonthsEnded_31Mar2012" unitRef="USD" decimals="-3">1000</us-gaap:ProceedsFromInterestReceived>
<us-gaap:ProceedsFromInterestReceived contextRef="ForThePeriod_1Jan2003Through31Mar2012" unitRef="USD" decimals="-3">727000</us-gaap:ProceedsFromInterestReceived>
<us-gaap:InterestPaid contextRef="ThreeMonthsEnded_31Mar2012" unitRef="USD" decimals="-3">1000</us-gaap:InterestPaid>
<us-gaap:InterestPaid contextRef="ThreeMonthsEnded_31Mar2011" unitRef="USD" decimals="-3">1000</us-gaap:InterestPaid>
<us-gaap:InterestPaid contextRef="ForThePeriod_1Jan2003Through31Mar2012" unitRef="USD" decimals="-3">12000</us-gaap:InterestPaid>
<us-gaap:StockIssued1 contextRef="ForThePeriod_1Jan2003Through31Mar2012" unitRef="USD" decimals="-3">978000</us-gaap:StockIssued1>
<rxii:FairValueOfWarrantsIssuedInConnectionWithCommonStockRecordedAsCostOfEquity contextRef="ThreeMonthsEnded_31Mar2011" unitRef="USD" decimals="-3">4212000</rxii:FairValueOfWarrantsIssuedInConnectionWithCommonStockRecordedAsCostOfEquity>
<rxii:FairValueOfWarrantsIssuedInConnectionWithCommonStockRecordedAsCostOfEquity contextRef="ForThePeriod_1Jan2003Through31Mar2012" unitRef="USD" decimals="-3">18038000</rxii:FairValueOfWarrantsIssuedInConnectionWithCommonStockRecordedAsCostOfEquity>
<rxii:IssuanceOfCommonStockInExchangeOfOutstandingWarrants contextRef="ForThePeriod_1Jan2003Through31Mar2012" unitRef="USD" decimals="-3">3120000</rxii:IssuanceOfCommonStockInExchangeOfOutstandingWarrants>
<rxii:FairValueOfSharesMandatorilyRedeemableForCashUponExerciseOfWarrant contextRef="ForThePeriod_1Jan2003Through31Mar2012" unitRef="USD" decimals="-3">785000</rxii:FairValueOfSharesMandatorilyRedeemableForCashUponExerciseOfWarrant>
<rxii:ReclassificationOfWarrantLiabilityUponExercise contextRef="ThreeMonthsEnded_31Mar2012" unitRef="USD" decimals="-3">1659000</rxii:ReclassificationOfWarrantLiabilityUponExercise>
<rxii:ReclassificationOfWarrantLiabilityUponExercise contextRef="ForThePeriod_1Jan2003Through31Mar2012" unitRef="USD" decimals="-3">1659000</rxii:ReclassificationOfWarrantLiabilityUponExercise>
<rxii:AllocationOfManagementExpenses contextRef="ForThePeriod_1Jan2003Through31Mar2012" unitRef="USD" decimals="-3">551000</rxii:AllocationOfManagementExpenses>
<rxii:EquipmentAndFurnishingsExchangedForCommonStock contextRef="ForThePeriod_1Jan2003Through31Mar2012" unitRef="USD" decimals="-3">48000</rxii:EquipmentAndFurnishingsExchangedForCommonStock>
<us-gaap:FairValueOfAssetsAcquired contextRef="ThreeMonthsEnded_31Mar2011" unitRef="USD" decimals="-3">44000</us-gaap:FairValueOfAssetsAcquired>
<us-gaap:FairValueOfAssetsAcquired contextRef="ForThePeriod_1Jan2003Through31Mar2012" unitRef="USD" decimals="-3">277000</us-gaap:FairValueOfAssetsAcquired>
<rxii:ValueOfRestrictedStockUnitsAndCommonStockIssuedInLieuOfCashBonuses contextRef="ThreeMonthsEnded_31Mar2011" unitRef="USD" decimals="-3">427000</rxii:ValueOfRestrictedStockUnitsAndCommonStockIssuedInLieuOfCashBonuses>
<rxii:ValueOfRestrictedStockUnitsAndCommonStockIssuedInLieuOfCashBonuses contextRef="ForThePeriod_1Jan2003Through31Mar2012" unitRef="USD" decimals="-3">634000</rxii:ValueOfRestrictedStockUnitsAndCommonStockIssuedInLieuOfCashBonuses>
<us-gaap:CapitalLeaseObligationsIncurred contextRef="ForThePeriod_1Jan2003Through31Mar2012" unitRef="USD" decimals="-3">50000</us-gaap:CapitalLeaseObligationsIncurred>
<!-- Begin Block Tagged Note -->
<us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock contextRef="ThreeMonthsEnded_31Mar2012">&lt;!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --&gt;
   &lt;!-- Begin Block Tagged Note 1 - us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock--&gt;
   &lt;!-- xbrl,ns --&gt;
   &lt;!-- xbrl,nx --&gt;
   &lt;font style="font-family:times new roman" size="2"&gt;&lt;b&gt;&lt;/b&gt;&lt;/font&gt;
   &lt;font style="font-family:times new roman" size="2"&gt;&lt;b&gt;&lt;/b&gt;&lt;/font&gt;
   &lt;font style="font-family:times new roman" size="2"&gt;
   &lt;b&gt;&lt;/b&gt;&lt;/font&gt;
   &lt;font style="font-family:times new roman" size="2"&gt;&lt;b&gt;
   &lt;/b&gt;&lt;/font&gt;
   &lt;p style="margin-top:12px;margin-bottom:0px"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&lt;b&gt;1. Description of Business and Basis of Presentation &lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:6px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Galena Biopharma, Inc. (&amp;#8220;we,&amp;#8221; &amp;#8220;us,&amp;#8221; &amp;#8220;our,&amp;#8221; &amp;#8220;Galena&amp;#8221; or the &amp;#8220;Company&amp;#8221;)
   is a biopharmaceutical company focused on developing innovative, next-generation cancer immunotherapies which address major unmet medical needs to advance care. Galena is developing innovative, peptide antigen-based &amp;#8220;off the shelf&amp;#8221; cancer
   immunotherapies for potential application to treatment of large populations of Cancer Survivors. Peptide vaccines have several potential clinical advantages over existing cancer treatments including excellent safety profiles, long-lasting protection
   through immune system activation, as well as an acceptable mode of administration (intradermal injection). A key differentiator in Galena&amp;#8217;s approach is the focus on &amp;#8220;minimal residual disease&amp;#8221; that may remain in Cancer Survivors. The
   strategy is to prevent recurrence in early stage patient groups who may harbor &amp;#8220;occult&amp;#8221; residual cancer cells that are not detectable by current imaging and biomarkers, and despite adjuvant therapy and radiation therapy will relapse in
   significant numbers over time. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:12px;margin-bottom:0px; text-indent:4%;padding-bottom:0px;"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Our lead product candidate, NeuVax&lt;font style="font-family:times new roman" size="1"&gt;
   &lt;sup&gt;&amp;#8482;&lt;/sup&gt;&lt;/font&gt; (E75), targets the HER2 tumor associated antigen peptide and is being developed to prevent or delay breast cancer
   recurrence in a Phase 3 clinical trial under an FDA approved SPA (Special Protocol Assessment) and in combination with
   Herceptin&lt;b&gt;&lt;font style="font-family:times new roman" size="1"&gt;&lt;sup&gt;&amp;reg;&lt;/sup&gt;&lt;/font&gt;&lt;/b&gt; (trastuzumab: Genentech/Roche) in a Phase 2 clinical trial. Our second product candidate,
   Folate Binding Protein (FBP), a targeted vaccine which consists of the E39 peptide over-expressed (20-80 fold) in more than 90% of ovarian and endometrial cancers, is currently in a Phase 1 clinical trial. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:12px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;The Company was incorporated as Argonaut Pharmaceuticals, Inc., in Delaware, on April&amp;#160;3, 2006. The Company changed its name to RXi
   Pharmaceuticals Corporation on November&amp;#160;28, 2006. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:12px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;We acquired Apthera Inc., or &amp;#8220;Apthera,&amp;#8221; and our NeuVax
   product candidate in April 2011. Prior to that time, we were engaged primarily in conducting discovery research and preclinical development activities based on RNAi. Our acquisition of Apthera followed from the determination by our board of
   directors to broaden our strategic direction by giving us access to a late-stage clinical candidate, NeuVax. In connection with our acquisition of Apthera, we reduced the scope of our RNAi activities. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:12px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;On September&amp;#160;26, 2011, the Company changed its name from RXi Pharmaceuticals Corporation to Galena Biopharma, Inc. in connection
   with the Company&amp;#8217;s separation into two companies: (i)&amp;#160;Galena, which will operate as a late-stage oncology drug development company; and (ii)&amp;#160;RXi Pharmaceuticals Corporation, or RXi, which will continue to develop novel RNAi-based
   therapies utilizing our historical RNAi assets. RXi was initially incorporated as RNCS, Inc. and assumed the name RXi Pharmaceuticals Corporation in conjunction with the change in the Company&amp;#8217;s name to Galena. On April 27, 2012, the planned
   spin-out of RXi was completed (See Note 4). &lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:12px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;The Company has not generated any revenue from inception through March&amp;#160;31,
   2012 and is considered a development-stage company for accounting purposes. The Company may not generate product revenue in the foreseeable future, if ever. The Company expects to incur significant operating losses as it advances its product
   candidates through the drug development and regulatory process. The Company expects to continue to devote a substantial portion of its resources to research and development programs. As a result of the costs expected to be incurred in connection
   with our recently commenced clinical trials of NeuVax and FBP, the Company expects that our research and development expense will increase significantly from historic levels for the foreseeable future. The Company will need to generate significant
   revenue to achieve profitability and might never do so. In the absence of product revenue, our potential sources of operational funding are expected to be the proceeds from equity financings, funded research and development payments and payments
   received under partnership and collaborative agreements. There is no guarantee that additional funding will be available to the Company on acceptable terms, or at all. If the Company fails to obtain additional funding when needed, it would be forced
   to scale back or terminate operations or to seek to merge with or to be acquired by another company. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:18px;margin-bottom:0px"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&lt;i&gt;Use of Estimates &lt;/i&gt;&lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:6px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;The preparation of consolidated financial statements in accordance with accounting principles generally accepted in the United States of
   America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses
   during the reporting period. Actual results could differ from these estimates. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:18px;margin-bottom:0px"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&lt;i&gt;Derivative Financial Instruments &lt;/i&gt;&lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:6px;margin-bottom:0px"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;During the normal course of business, from time to time, the Company issues warrants and options to
   vendors as consideration to perform services. It may also issue warrants as part of financing transactions. The Company does not enter into any derivative contracts for speculative purposes. The Company recognizes all derivatives, including
   warrants, as assets or liabilities measured at fair value with changes in fair value of derivatives reflected as current period income or loss unless the derivatives qualify for hedge accounting and are accounted for as such. In accordance with
   Financial Accounting Standards Board (&amp;#8220;FASB&amp;#8221;) Accounting Standards Codification (&amp;#8220;ASC&amp;#8221;) Topic 815-40, &amp;#8220;&lt;i&gt;Derivatives and Hedging &amp;#8212; Contracts in Entity&amp;#8217;s Own Stock&lt;/i&gt;&amp;#8221;, the value of some of our warrants is
   required to be recorded as a liability, as the holders have an option to put the warrants back to the Company in specified events (see Note 9). &lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:18px;margin-bottom:0px"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&lt;i&gt;Principles of Consolidation &lt;/i&gt;&lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:6px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;
   The consolidated financial statements include the accounts of Galena and its consolidated subsidiaries. All material intercompany accounts have been eliminated in consolidation. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:18px;margin-bottom:0px"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&lt;i&gt;Comprehensive Loss &lt;/i&gt;&lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:6px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;The
   Company&amp;#8217;s comprehensive loss is equal to its net loss for all periods presented. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="font-size:1px;margin-top:18px;margin-bottom:0px"&gt;&amp;#160;&lt;/p&gt;
</us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock>
<!-- End Block Tagged Note -->
<!-- Begin Block Tagged Note -->
<us-gaap:AccountingChangesAndErrorCorrectionsTextBlock contextRef="ThreeMonthsEnded_31Mar2012">&lt;!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --&gt;
   &lt;!-- Begin Block Tagged Note 2 - us-gaap:AccountingChangesAndErrorCorrectionsTextBlock--&gt;
   &lt;p style="margin-top:0px;margin-bottom:0px"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&lt;b&gt;2. Recent Accounting Pronouncements &lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:6px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&lt;i&gt;&lt;/i&gt;In May&amp;#160;2011, the FASB issued Accounting Standards Updated (&amp;#8220;ASU&amp;#8221;) 2011-04&lt;i&gt;, Fair Value
   Measurement&lt;/i&gt; (Topic 820): &lt;i&gt;Amendments to Achieve Common Fair Value Measurement and Disclosure Requirements in U.S. GAAP and IFRSs&lt;/i&gt;, a new accounting standard that clarifies the application of certain existing fair value measurement guidance
   and expands the disclosures for fair value measurements that are estimated using significant unobservable (Level 3) inputs. This new standard is effective on a prospective basis for annual and interim reporting periods beginning on or after
   December&amp;#160;15, 2011. The Company&amp;#8217;s adoption of this new standard did not have a material impact on the Company&amp;#8217;s consolidated financial statements. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:12px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;
   &lt;i&gt;&lt;/i&gt;In June&amp;#160;2011, the FASB issued ASU 2011-05, &lt;i&gt;Comprehensive Income&lt;/i&gt; (Topic 220): &lt;i&gt;Presentation of Comprehensive Income&lt;/i&gt;, a new accounting standard that eliminates the option to present
   the components of other comprehensive income as part of the statement of changes in stockholders&amp;#8217; equity, requires the consecutive presentation of the statement of net income and other comprehensive income and requires an entity to present
   reclassification adjustments on the face of the financial statements from other comprehensive income to net income. The amendments in this new standard do not change the items that must be reported in other comprehensive income or when an item of
   other comprehensive income must be reclassified to net income nor do the amendments affect how earnings per share is calculated or presented. This new standard is required to be applied retrospectively and is effective for fiscal years and interim
   periods within those years beginning after December&amp;#160;15, 2011. As this new standard only requires enhanced disclosure, the adoption of this standard did not impact the Company&amp;#8217;s consolidated financial statements. &lt;/font&gt;&lt;/p&gt;
</us-gaap:AccountingChangesAndErrorCorrectionsTextBlock>
<!-- End Block Tagged Note -->
<!-- Begin Block Tagged Note -->
<us-gaap:BusinessCombinationDisclosureTextBlock contextRef="ThreeMonthsEnded_31Mar2012">&lt;!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --&gt;
   &lt;!-- Begin Block Tagged Note 3 - us-gaap:BusinessCombinationDisclosureTextBlock--&gt;
   &lt;p style="margin-top:18px;margin-bottom:0px"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&lt;b&gt;3.&amp;#160;Apthera Acquisition &lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:6px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;On April&amp;#160;13, 2011, the Company completed its acquisition of Apthera, Inc., a Delaware corporation
   (&amp;#8220;Apthera&amp;#8221;), under an Agreement and Plan of Merger (&amp;#8220;Merger Agreement&amp;#8221;) entered into on March&amp;#160;31, 2011. Subject to the terms and conditions of the Merger Agreement, the Company&amp;#8217;s wholly owned subsidiary formed for this
   purpose was merged with and into Apthera, with Apthera surviving as a wholly-owned subsidiary of the Company. Under the Merger Agreement, the Company issued to Apthera&amp;#8217;s stockholders approximately 5.0&amp;#160;million shares of common stock of the
   Company (the &amp;#8220;Aggregate Stock Consideration&amp;#8221;) and agreed to make future contingent payments of up to $32&amp;#160;million based on the achievement of certain development and commercial milestones relating to the Company&amp;#8217;s NeuVax&amp;#8482;
   product candidate. The contingent consideration is payable, at the election of the Company, in either cash or additional shares of common stock, provided that the Company may not issue any shares in satisfaction of any contingent consideration
   unless it has first obtained approval of its stockholders in accordance with Rule 5635(a) of the NASDAQ Marketplace Rules. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:12px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;In
   connection with the Merger Agreement, the Company deposited with a third-party escrow agent certificates representing 10% of the Aggregate Stock Consideration, which shares will be available to compensate the Company and related parties for certain
   indemnifiable losses as described in the Merger Agreement. On October&amp;#160;13, 2011, the escrow agent released from the escrow 5% of the Aggregate Stock Consideration, or 248,705 shares. The remaining Aggregate Stock Consideration held with the
   escrow agent was released in April 2012 (see Note 11). &lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:12px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;The Company&amp;#8217;s acquisition of Apthera was in concert with the
   decision by the Company&amp;#8217;s Board of Directors to diversify its development programs and to become a late stage clinical development company. The Company does not expect any of its goodwill to be deductible for tax purposes. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:12px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;The purchase price consideration and allocation of purchase price of Apthera were as follows: &lt;/font&gt;&lt;/p&gt;
   &lt;p style="font-size:12px;margin-top:0px;margin-bottom:0px"&gt;&amp;#160;&lt;/p&gt;
   &lt;table cellspacing="0" cellpadding="0" width="92%" border="0" style="border-collapse:collapse; text-align: left" align="center"&gt;
   &lt;!-- Begin Table Head --&gt;
   &lt;tr&gt;
   &lt;td width="91%"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom" width="5%"&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"&gt;&lt;font style="font-family:times new roman" size="1"&gt;&lt;b&gt;(in 000&amp;#8217;s)&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;!-- End Table Head --&gt;
   &lt;!-- Begin Table Body --&gt;
   &lt;tr bgcolor="#cceeff"&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&lt;b&gt;Calculation of allocable purchase price:&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Fair value of shares issued at closing including escrowed shares expected to be released&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;6,367&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;(i)&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr bgcolor="#cceeff"&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Estimated value of earn-out&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;6,460&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size:1px"&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Total allocable purchase price&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;12,827&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size:1px"&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr bgcolor="#cceeff"&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&lt;b&gt;Allocation of purchase price:&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Cash&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;168&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr bgcolor="#cceeff"&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Prepaid expenses and other current assets&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;14&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Equipment and furnishings&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;11&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr bgcolor="#cceeff"&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Goodwill&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;5,898&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;In-process research and development&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;12,864&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr bgcolor="#cceeff"&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Accounts payable&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;(931&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;)&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Accrued expenses and other current liabilities&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;(143&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;)&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr bgcolor="#cceeff"&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Notes payable&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;(1&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;)&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Deferred tax liability, non-current&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;(5,053&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;)&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size:1px"&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr bgcolor="#cceeff"&gt;
   &lt;td valign="top"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;12,827&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size:1px"&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;!-- End Table Body --&gt;
   &lt;/table&gt;
   &lt;p style="line-height:8px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:10%"&gt;&amp;#160;&lt;/p&gt;
   &lt;table style="border-collapse:collapse; text-align: left" border="0" cellpadding="0" cellspacing="0" width="100%"&gt;
   &lt;tr&gt;
   &lt;td width="4%" valign="top" align="left"&gt;&lt;font style="font-family:times new roman" size="2"&gt;(i)&lt;/font&gt;&lt;/td&gt;
   &lt;td align="left" valign="top"&gt;&lt;font style="font-family:times new roman" size="2"&gt;The value of the Company&amp;#8217;s common stock was based upon a per share value of $1.28, the closing price of the Company&amp;#8217;s common stock as of the close of business
   on April&amp;#160;13, 2011. &lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;/table&gt;
   &lt;p style="font-size:1px;margin-top:12px;margin-bottom:0px"&gt;&amp;#160;&lt;/p&gt;
   &lt;p style="margin-top:0px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;The estimated value of
   the earn-out consideration of $6.5 million originally recorded was based on the expected probability of achievement in the future of certain development and commercial milestones relating to the Company&amp;#8217;s NeuVax product candidate and then
   applying a discount rate, based on a corporate debt interest rate index publicly issued, to the expected future payments. The expected timing of the milestones, the probability of success for each milestone and the discount rates applied are updated
   quarterly using the most current information to measure the contingent liability as of the reporting date. On January&amp;#160;19, 2012, the first milestone of $1,000,000 of this contingent liability was triggered with the first patient enrolled in our
   Phase 3 PRESENT clinical trial of NeuVax for breast cancer. The Company issued 1,315,789 restricted shares of common stock in payment of the first milestone. The certificates evidencing the milestone shares have been deposited with a third party
   escrow agent. The milestone shares will be released to the Apthera shareholders from escrow if the issuance of the milestone shares is approved by the stockholders of the Company at our 2012 annual stockholders meeting. Since the release of the
   shares is subject to stockholder approval, the $1,000,000 has been recorded in accrued expenses and other current liabilities at March&amp;#160;31, 2012 in the accompanying condensed consolidated balance sheet. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:12px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;If stockholder approval is obtained, the number of milestone shares will be subject to increase to the extent that $0.76 (&lt;i&gt;i.e&lt;/i&gt;.,
   the closing price of the Company&amp;#8217;s common stock as reported on The NASDAQ Capital Market on January&amp;#160;18, 2012, the day prior to achievement of its first milestone, used for purposes of determining the number of milestone shares) is greater
   than the closing price of common stock as of the most recent trading day prior to the receipt of stockholder approval. Whether or not stockholder approval is obtained, in addition to the release from escrow of the milestone shares or the payment in
   cash of the initial milestone, as the case may be, the Company will pay concurrently to the former Apthera shareholders in cash an interest factor of ten percent (10%)&amp;#160;per annum on the amount of the final milestone from February&amp;#160;10, 2012
   through the day immediately prior to the release of the milestone shares from escrow or the cash payment, as the case may be, less certain legal fees of the stockholder representative to be paid or reimbursed by the Company. As of March&amp;#160;31,
   2012, $13,699 of interest had been accrued on this note and is included in accrued expenses and other current liabilities in the accompanying condensed consolidated balance sheet. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:12px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;The increase in the fair value of the contingent liability during the three months ended March&amp;#160;31, 2012 is $844,000, which was
   included in other income (expense) in the accompanying consolidated statements of expenses. The fair value of the contingent liability at March&amp;#160;31, 2012 was $6,195,000. Of this amount, $898,000 was recorded as a current contingent liability.
   &lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:12px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;The following presents the pro forma net loss and pro forma net loss per common share for the three months ended
   March&amp;#160;31, 2011: &lt;/font&gt;&lt;/p&gt;
   &lt;p style="font-size:12px;margin-top:0px;margin-bottom:0px"&gt;&amp;#160;&lt;/p&gt;
   &lt;table cellspacing="0" cellpadding="0" width="92%" border="0" style="border-collapse:collapse; text-align: left" align="center"&gt;
   &lt;!-- Begin Table Head --&gt;
   &lt;tr&gt;
   &lt;td width="87%"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom" width="8%"&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"&gt;&lt;font style="font-family:times new roman" size="1"&gt;&lt;b&gt;For the Three&lt;br /&gt;Months&amp;#160;Ended&lt;br /&gt;March&amp;#160;31,&amp;#160;2011&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;!-- End Table Head --&gt;
   &lt;!-- Begin Table Body --&gt;
   &lt;tr bgcolor="#cceeff"&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Net loss&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;(4,397&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;)&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size:1px"&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Net loss per common share&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;(0.17&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;)&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size:1px"&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr bgcolor="#cceeff"&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Weighted average shares outstanding&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;25,290,260&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size:1px"&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;!-- End Table Body --&gt;
   &lt;/table&gt;
</us-gaap:BusinessCombinationDisclosureTextBlock>
<!-- End Block Tagged Note -->
<!-- Begin Block Tagged Note -->
<rxii:PartnerCompanyTextBlock contextRef="ThreeMonthsEnded_31Mar2012">&lt;!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --&gt;
   &lt;!-- Begin Block Tagged Note 4 - rxii:PartnerCompanyTextBlock--&gt;
   &lt;p style="margin-top:18px;margin-bottom:0px"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&lt;b&gt;4.&amp;#160;RXi Spin-Out &lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:6px;margin-bottom:0px; margin-left:2%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&lt;b&gt;&lt;i&gt;Contribution Agreement &lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:6px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;
   On September&amp;#160;24, 2011, the Company entered into a Contribution Agreement (&amp;#8220;Contribution Agreement&amp;#8221;) with RXi pursuant to which we assigned and contributed to RXi substantially all of the
   Company&amp;#8217;s RNAi-related technologies and assets. The contributed assets consist primarily of our novel RNAi compounds and licenses relating to our RNAi technologies, as well as the lease of our Worcester, Massachusetts laboratory facility, fixed
   assets and other equipment located at the facility and our employment arrangements with certain scientific, corporate and administrative personnel who have become employees of RXi. The Company also contributed $1.5&amp;#160;million of cash to the
   capital of RXi. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:12px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Pursuant to the Contribution Agreement, RXi assumed certain accrued expenses of our RXI-109 development
   program and all subsequent obligations under the contributed licenses, employment arrangements and other agreements. RXi has agreed to make future milestone payments to us of up to $45&amp;#160;million, consisting of two one-time payments of
   $15&amp;#160;million and $30&amp;#160;million, respectively, if RXi achieves annual net sales equal to or greater than $500 million and $1&amp;#160;billion, respectively, of any covered products that may be developed with the contributed RNAi technologies.
   &lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:12px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;In the Contribution Agreement, the Company made customary representations and warranties to RXi regarding the contributed
   assets and other matters, and the parties have agreed to customary covenants regarding the conduct of RXi&amp;#8217;s business pending the spin-off of RXi. The parties also have agreed to indemnify each other against losses arising from a breach of their
   respective representations, warranties and covenants set forth in the Contribution Agreement. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="font-size:1px;margin-top:18px;margin-bottom:0px"&gt;&amp;#160;&lt;/p&gt;
   &lt;p style="margin-top:0px;margin-bottom:0px; margin-left:2%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&lt;b&gt;&lt;i&gt;Securities
   Purchase Agreement &lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:6px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;On September&amp;#160;24, 2011, the Company also entered into a Securities Purchase Agreement
   (&amp;#8220;Securities Purchase Agreement&amp;#8221;) with RXi and two institutional Investors (the &amp;#8220;Investors&amp;#8221;), pursuant to which the Investors agreed to purchase a total of $9,500,000 of Series&amp;#160;A Preferred Stock of RXi (&amp;#8220;RXi Preferred
   Stock&amp;#8221;) at the closing of the spin-off of RXi, and to lend up to $1,500,000 to RXi to fund its operations between signing and closing (the &amp;#8220;Bridge Loan&amp;#8221;). The outstanding principal and accrued interest from the Bridge Loan will,
   except under certain circumstances described below, be converted into RXi Preferred Stock at the closing of the spin-off of RXi and will represent a portion of the $9,500,000 total investment, which is referred to herein as the &amp;#8220;RXi
   financing.&amp;#8221; The RXi&amp;#160;financing and the spin-off of RXi were subject to customary closing conditions, including the registration under the Securities Act of 1933, as amended (the &amp;#8220;Securities Act&amp;#8221;), of the distribution by us of the
   spin-off shares. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:12px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;The RXi Preferred Stock will be convertible by a holder at any time into shares of RXi common stock, except
   to the extent that the holder would own more than 9.999% of the shares of RXi common stock outstanding immediately after giving effect to such conversion. Without regard to this conversion limitation, the shares of the Preferred Stock to be held by
   the Investors upon completion of the RXi financing and the spin-off of RXi will be convertible into shares of RXi common stock representing approximately 83% of the shares of RXi common stock that would be outstanding, assuming the conversion in
   full of the Preferred Stock, which we refer to as the &amp;#8220;as-converted common stock.&amp;#8221; The Company will own approximately 12% of the as-converted common stock immediately prior to the spin-off of RXi, and Advirna, LLC, a licensor of RXi, will
   be issued the remaining 5% of the as-converted common stock pursuant to the agreement with Advirna, LLC as described below. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:18px;margin-bottom:0px; margin-left:2%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&lt;i&gt;Spin-Off &lt;/i&gt;&lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:6px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;The Company agreed in the Securities Purchase Agreement to undertake to distribute to our stockholders on a share-for-share basis
   approximately 8% of the as-converted common stock of RXi, subject to the registration of the distribution of such shares under the Securities Act of 1933 and other conditions, which distribution was completed on April 27, 2012 (see Note 11). The
   Company has retained 4% of the as-converted common stock, and has agreed, in the Securities Purchase Agreement, not to sell or dispose of the Company&amp;#8217;s shares of RXi common stock for a one-year period following completion of the spin-off of
   RXi. Under the Securities Purchase Agreement, one share of RXi was distributed as a dividend on each share of Galena that is issued and outstanding as of the record date for the distribution of April 23, 2012. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:18px;margin-bottom:0px; margin-left:2%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&lt;i&gt;Purchase Agreement Terms and Conditions &lt;/i&gt;&lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:6px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;
   In the Securities Purchase Agreement, the parties have made customary representations and warranties to the other parties and have agreed to customary covenants regarding the parties&amp;#8217; actions in
   connection with the spin-off of RXi and other matters, including the filing of a resale registration statement registering a portion of the common stock underlying the conversion of the Preferred Stock. The parties also have agreed to indemnify each
   other against losses arising from a breach of their respective representations, warranties and covenants set forth in the Securities Purchase Agreement. Per the agreement, upon the closing of the transaction, on April 27, 2012, RXi reimbursed the
   Company and the Investors in the amount of $300,000 and $100,000, respectively, for transaction costs relating to the Contribution Agreement, the Securities Purchase Agreement and the transactions called for by the agreements. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:18px;margin-bottom:0px; margin-left:2%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&lt;i&gt;Bridge Loan &lt;/i&gt;&lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:6px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;
   Pursuant to the Securities Purchase Agreement, the Investors provided Bridge Loans by purchasing $1,000,000 of secured convertible promissory notes of RXi (&amp;#8220;RXi convertible notes&amp;#8221;). The RXi
   convertible notes will, except as described below, be convertible into shares of RXi Preferred Stock at a conversion price of $1,000 per share. The RXi convertible notes accrued interest at a rate of 7%&amp;#160;per annum (or 18%&amp;#160;per annum in the
   case of an event of default) and matured on April&amp;#160;27, 2012, the closing date. As of March 31, 2012, RXi had $1,000,000 of RXi convertible notes outstanding. As the Company was relieved of this obligation upon the spin-out, the amount has been
   recorded as a long-term liability as of March 31, 2012. Approximately $21,000 of interest has been recorded in accrued expenses and other current liabilities at March&amp;#160;31, 2012 in the accompanying condensed consolidated balance sheet.
   &lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:18px;margin-bottom:0px; margin-left:2%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&lt;b&gt;&lt;i&gt;Advirna Agreement &lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:6px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;
   As part of the closing transaction as detailed in the Contribution Agreement and Securities Purchase Agreement, RXi entered into an agreement with Advirna, LLC, which the Company refers to as
   &amp;#8220;Advirna,&amp;#8221; a company affiliated with Anastasia Khvorova, Ph.D., RXi&amp;#8217;s former Senior Vice President and Chief Scientific Officer. In the agreement, Advirna has agreed to amend its existing patent and technology assignment agreement
   with RXi to eliminate all clinical milestone and royalty payments to Advirna under the amended agreement; obligations remain to make an annual $100,000 maintenance fee and a one-time milestone payment of $350,000 to Advirna upon the issuance of a
   patent with valid claims covering the assigned technology. Additionally, RXi will be required to pay a 1% royalty to Advirna for any licensing revenue received by RXi on the license of the assigned Advirna technology. In exchange, RXi issued to
   Advirna upon the closing transaction a number of shares of RXi common stock equal to 5% of the as-converted common stock of RXi. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:12px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;
   The transactions contemplated by the Securities Purchase Agreement were completed in April 2012 (see Note 11). &lt;/font&gt;&lt;/p&gt;
</rxii:PartnerCompanyTextBlock>
<!-- End Block Tagged Note -->
<!-- Begin Block Tagged Note -->
<us-gaap:FinancialInstrumentsDisclosureTextBlock contextRef="ThreeMonthsEnded_31Mar2012">&lt;!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --&gt;
   &lt;!-- Begin Block Tagged Note 5 - us-gaap:FinancialInstrumentsDisclosureTextBlock--&gt;
   &lt;p style="margin-top:18px;margin-bottom:0px"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&lt;b&gt;5. Fair Value Measurements &lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:6px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;The Company follows the provisions of FASB ASC Topic 820, &lt;i&gt;&amp;#8220;Fair Value Measurements and Disclosures&amp;#8221;&lt;/i&gt;
   (&amp;#8220;ASC 820&amp;#8221;) for the Company&amp;#8217;s financial assets and liabilities that are re-measured and reported at fair value at each reporting period, and are re-measured and reported at fair value at least annually using a fair value hierarchy
   that is broken down into three levels. Level inputs are as defined as follows: &lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:12px;margin-bottom:0px"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Level 1 &amp;#8212; quoted prices in active markets for identical
   assets or liabilities. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:0px;margin-bottom:0px"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Level 2 &amp;#8212; other significant observable inputs for the assets or liabilities through corroboration with
   market data at the measurement date. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:12px;margin-bottom:0px"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Level 3 &amp;#8212; significant unobservable inputs that reflect management&amp;#8217;s best estimate of what
   market participants would use to price the assets or liabilities at the measurement date. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:12px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;The Company categorized its cash
   equivalents as a Level 1 hierarchy. The valuation for Level 1 was determined based on a &amp;#8220;market approach&amp;#8221; using quoted prices in active markets for identical assets. Valuations of these assets do not require a significant degree of
   judgment. The Company categorized its warrants potentially settled in cash as a Level 2 hierarchy. The warrants are measured at fair market value on a recurring basis and are being marked to market each quarter-end until they are settled. The
   contingent purchase price consideration is categorized as a Level 3 hierarchy and is measured at its estimated fair value on a recurring basis and is adjusted at each quarter-end until it is completely settled. The contingent price consideration is
   valued based on the expected timing of milestones, the expected probability of success for each milestone and the updated discount rates based on a corporate debt interest rate index publicly issued. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="font-size:12px;margin-top:0px;margin-bottom:0px"&gt;&amp;#160;&lt;/p&gt;
   &lt;table cellspacing="0" cellpadding="0" width="100%" border="0" style="border-collapse:collapse; text-align: left" align="center"&gt;
   &lt;!-- Begin Table Head --&gt;
   &lt;tr&gt;
   &lt;td width="66%"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom" width="4%"&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom" width="4%"&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom" width="4%"&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom" width="4%"&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="font-family:times new roman" size="1"&gt;&lt;b&gt;Description&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"&gt;&lt;font style="font-family:times new roman" size="1"&gt;&lt;b&gt;March&amp;#160;31,&lt;br /&gt;2012&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"&gt;&lt;font style="font-family:times new roman" size="1"&gt;&lt;b&gt;Quoted&lt;br /&gt;Prices&amp;#160;in&lt;br /&gt;Active&lt;br /&gt;Markets&lt;br /&gt;(Level&amp;#160;1)&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"&gt;&lt;font style="font-family:times new roman" size="1"&gt;&lt;b&gt;Significant&lt;br /&gt;Other&lt;br /&gt;Observable&lt;br /&gt;Inputs&lt;br /&gt;(Level 2)&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"&gt;&lt;font style="font-family:times new roman" size="1"&gt;&lt;b&gt;Unobservable&lt;br /&gt;Inputs&lt;br /&gt;(Level&amp;#160;3)&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;!-- End Table Head --&gt;
   &lt;!-- Begin Table Body --&gt;
   &lt;tr bgcolor="#cceeff"&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Assets:&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Cash equivalents&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;7,453&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;7,453&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size:1px"&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr bgcolor="#cceeff"&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:3.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Total assets&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;7,453&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;7,453&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size:1px"&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Liabilities:&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr bgcolor="#cceeff"&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Warrants potentially settleable in cash&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;20,357&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;20,357&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Contingent purchase price consideration&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;6,195&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;6,195&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size:1px"&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr bgcolor="#cceeff"&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:3.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Total liabilities&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;26,552&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;20,357&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;6,195&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size:1px"&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;!-- End Table Body --&gt;
   &lt;/table&gt;
   &lt;p style="font-size:12px;margin-top:0px;margin-bottom:0px"&gt;&amp;#160;&lt;/p&gt;
   &lt;table cellspacing="0" cellpadding="0" width="100%" border="0" style="border-collapse:collapse; text-align: left" align="center"&gt;
   &lt;!-- Begin Table Head --&gt;
   &lt;tr&gt;
   &lt;td width="66%"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom" width="4%"&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom" width="4%"&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom" width="4%"&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom" width="4%"&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="font-family:times new roman" size="1"&gt;&lt;b&gt;Description&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"&gt;&lt;font style="font-family:times new roman" size="1"&gt;&lt;b&gt;December&amp;#160;31,&lt;br /&gt;2011&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"&gt;&lt;font style="font-family:times new roman" size="1"&gt;&lt;b&gt;Quoted&lt;br /&gt;Prices in&lt;br /&gt;Active&lt;br /&gt;Markets&lt;br /&gt;(Level&amp;#160;1)&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"&gt;&lt;font style="font-family:times new roman" size="1"&gt;&lt;b&gt;Significant&lt;br /&gt;Other&lt;br /&gt;Observable&lt;br /&gt;Inputs&lt;br /&gt;(Level 2)&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"&gt;&lt;font style="font-family:times new roman" size="1"&gt;&lt;b&gt;Unobservable&lt;br /&gt;Inputs&lt;br /&gt;(Level&amp;#160;3)&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;!-- End Table Head --&gt;
   &lt;!-- Begin Table Body --&gt;
   &lt;tr bgcolor="#cceeff"&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Assets:&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Cash equivalents&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;11,433&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;11,433&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size:1px"&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr bgcolor="#cceeff"&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:3.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Total assets&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;11,433&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;11,433&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size:1px"&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Liabilities:&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr bgcolor="#cceeff"&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Warrants potentially settleable in cash&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;3,746&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;3,746&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Contingent purchase price consideration&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;6,351&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;6,351&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size:1px"&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr bgcolor="#cceeff"&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:3.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Total liabilities&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;10,097&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;3,746&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;6,351&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size:1px"&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;!-- End Table Body --&gt;
   &lt;/table&gt;
   &lt;p style="margin-top:18px;margin-bottom:0px"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&lt;i&gt;Fair Value of Financial Instruments &lt;/i&gt;&lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:6px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;
   The carrying amounts reported in the balance sheet for cash equivalents, accounts payable, capital leases and convertible notes payable approximate their fair values due to their short-term nature and
   market rates of interest. &lt;/font&gt;&lt;/p&gt;
</us-gaap:FinancialInstrumentsDisclosureTextBlock>
<!-- End Block Tagged Note -->
<!-- Begin Block Tagged Note -->
<us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="ThreeMonthsEnded_31Mar2012">&lt;!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --&gt;
   &lt;!-- Begin Block Tagged Note 6 - us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock--&gt;
   &lt;p style="margin-top:18px;margin-bottom:0px"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&lt;b&gt;6. Stock Based Compensation &lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:6px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;The Company follows the provisions of the FASB ASC Topic 718, &amp;#8220;&lt;i&gt;Compensation &amp;#8212; Stock Compensation&lt;/i&gt;&amp;#8221;
   (&amp;#8220;ASC 718&amp;#8221;), which requires the measurement and recognition of compensation expense for all share-based payment awards made to employees, non-employee directors, and consultants, including employee stock options. Stock compensation expense
   based on the grant date fair value estimated in accordance with the provisions of ASC 718 is recognized as an expense over the requisite service period. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:12px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;
   For stock options granted as consideration for services rendered by non-employees, the Company recognizes compensation expense in accordance with the requirements of FASB ASC Topic 505-50, &amp;#8220;&lt;i&gt;Equity
   Based Payments to Non-Employees.&amp;#8221;&lt;/i&gt; &lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:12px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Non-employee option grants that do not vest immediately upon grant are recorded as
   an expense over the vesting period of the underlying stock options. At the end of each financial reporting period prior to vesting, the value of these options, as calculated using the Black-Scholes option-pricing model, will be re-measured using the
   fair value of the Company&amp;#8217;s common stock and the non-cash compensation recognized during the period will be adjusted accordingly. Since the fair market value of options granted to non-employees is subject to change in the future, the amount of
   the future compensation expense will include fair value re-measurements until the stock options are fully vested. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="font-size:1px;margin-top:12px;margin-bottom:0px"&gt;&amp;#160;&lt;/p&gt;
   &lt;p style="margin-top:0px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;The Company is
   currently using the Black-Scholes option-pricing model to determine the fair value of all its option grants. For option grants issued in the three month period ended March&amp;#160;31, 2012 and 2011, the following assumptions were used: &lt;/font&gt;&lt;/p&gt;
   &lt;p style="font-size:12px;margin-top:0px;margin-bottom:0px"&gt;&amp;#160;&lt;/p&gt;
   &lt;table cellspacing="0" cellpadding="0" width="100%" border="0" style="border-collapse:collapse; text-align: left" align="center"&gt;
   &lt;!-- Begin Table Head --&gt;
   &lt;tr&gt;
   &lt;td width="89%"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom" width="2%"&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom" width="2%"&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" colspan="6" align="center" style="border-bottom:1px solid #000000"&gt;&lt;font style="font-family:times new roman" size="1"&gt;&lt;b&gt;For The Three&lt;br /&gt;Months Ended&lt;br /&gt;March 31,&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"&gt;&lt;font style="font-family:times new roman" size="1"&gt;&lt;b&gt;2012&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"&gt;&lt;font style="font-family:times new roman" size="1"&gt;&lt;b&gt;2011&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;!-- End Table Head --&gt;
   &lt;!-- Begin Table Body --&gt;
   &lt;tr bgcolor="#cceeff"&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Weighted average risk-free interest rate&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;1.06&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;%&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;2.33&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;%&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Weighted average expected volatility&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;75.69&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;%&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;112.95&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;%&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr bgcolor="#cceeff"&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Weighted average expected lives (years)&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;6.10&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;5.76&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Weighted average expected dividend yield&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;0.00&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;%&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;0.00&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;%&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;!-- End Table Body --&gt;
   &lt;/table&gt;
   &lt;p style="margin-top:12px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;The weighted average fair value of options granted during the three month period ended March&amp;#160;31,
   2012 and 2011 was $0.48 and $1.20 per share, respectively. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:12px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;The Company&amp;#8217;s expected common stock price volatility
   assumption is based upon the volatility of a basket of comparable companies. The expected life assumptions for employee grants were based upon the simplified method provided for under ASC 718-10. The expected life assumptions for non-employees were
   based upon the contractual term of the option. The dividend yield assumption of zero is based upon the fact that the Company has never paid cash dividends and presently has no intention of paying cash dividends. The risk-free interest rate used for
   each grant was also based upon prevailing short-term interest rates. The Company has estimated an annualized forfeiture rate of 15.0% for options granted to its employees, 8.0% for options granted to senior management and no forfeiture rate for the
   directors. RXi will record additional expense if the actual forfeitures are lower than estimated and will record a recovery of prior expense if the actual forfeiture rates are higher than estimated. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:12px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;The following table summarizes stock option activity from January&amp;#160;1, 2012 through March&amp;#160;31, 2012: &lt;/font&gt;&lt;/p&gt;
   &lt;p style="font-size:12px;margin-top:0px;margin-bottom:0px"&gt;&amp;#160;&lt;/p&gt;
   &lt;table cellspacing="0" cellpadding="0" width="100%" border="0" style="border-collapse:collapse; text-align: left" align="center"&gt;
   &lt;!-- Begin Table Head --&gt;
   &lt;tr&gt;
   &lt;td width="77%"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom" width="2%"&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom" width="2%"&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom" width="2%"&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"&gt;&lt;font style="font-family:times new roman" size="1"&gt;&lt;b&gt;Total&lt;br /&gt;Number of&lt;br /&gt;Shares&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"&gt;&lt;font style="font-family:times new roman" size="1"&gt;&lt;b&gt;Weighted&lt;br /&gt;Average&lt;br /&gt;Exercise&lt;br /&gt;Price&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"&gt;&lt;font style="font-family:times new roman" size="1"&gt;&lt;b&gt;Aggregate&lt;br /&gt;Intrinsic&lt;br /&gt;Value&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;!-- End Table Head --&gt;
   &lt;!-- Begin Table Body --&gt;
   &lt;tr bgcolor="#cceeff"&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Outstanding at January&amp;#160;1, 2012&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;6,163,137&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;3.03&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:3.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Granted&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;1,275,000&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;0.72&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;1,912,500&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr bgcolor="#cceeff"&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:3.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Exercised&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:3.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Cancelled&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size:1px"&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr bgcolor="#cceeff"&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Outstanding at March&amp;#160;31, 2012&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;7,438,137&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;2.63&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;5,308,950&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size:1px"&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Options exercisable at March&amp;#160;31, 2012&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;4,985,548&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;3.31&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;2,365,593&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size:1px"&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;!-- End Table Body --&gt;
   &lt;/table&gt;
   &lt;p style="margin-top:12px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;The aggregate intrinsic values of outstanding and exercisable options at March&amp;#160;31, 2012 were
   calculated based on the closing price of the Company&amp;#8217;s common stock on March&amp;#160;31, 2012 of $2.22 per share less the exercise price of those shares. The aggregate intrinsic values of options exercised was calculated based on the difference
   between the exercise price of the underlying awards and the quoted price of the Company&amp;#8217;s common stock on the date of exercise. &lt;/font&gt;&lt;/p&gt;
</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
<!-- End Block Tagged Note -->
<!-- Begin Block Tagged Note -->
<us-gaap:EarningsPerShareTextBlock contextRef="ThreeMonthsEnded_31Mar2012">&lt;!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --&gt;
   &lt;!-- Begin Block Tagged Note 7 - us-gaap:EarningsPerShareTextBlock--&gt;
   &lt;p style="margin-top:18px;margin-bottom:0px"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&lt;b&gt;7. Net Loss Per Share &lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:6px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;The Company accounts for and discloses net loss per common share in accordance with FASB ASC Topic 260 &amp;#8220;
   &lt;i&gt;Earnings per Share.&amp;#8221;&lt;/i&gt; Basic net loss per common share is computed by dividing net loss attributable to common stockholders by the weighted average number of common shares outstanding. Diluted net loss per common share is computed by
   dividing net loss attributable to common stockholders by the weighted average number of common shares that would have been outstanding during the period assuming the issuance of common shares for all potential dilutive common shares outstanding.
   Potential common shares consist of shares issuable upon the exercise of stock options and warrants. Because the inclusion of potential common shares would be anti-dilutive for all periods presented diluted net loss per common share is the same as
   basic net loss per common share. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:12px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;The following table sets forth the potential common shares excluded from the calculation of
   net loss per common share because their inclusion would be anti-dilutive: &lt;/font&gt;&lt;/p&gt;
   &lt;p style="font-size:12px;margin-top:0px;margin-bottom:0px"&gt;&amp;#160;&lt;/p&gt;
   &lt;table cellspacing="0" cellpadding="0" width="100%" border="0" style="border-collapse:collapse; text-align: left" align="center"&gt;
   &lt;!-- Begin Table Head --&gt;
   &lt;tr&gt;
   &lt;td width="82%"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom" width="1%"&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom" width="1%"&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" colspan="6" align="center" style="border-bottom:1px solid #000000"&gt;&lt;font style="font-family:times new roman" size="1"&gt;&lt;b&gt;March&amp;#160;31,&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"&gt;&lt;font style="font-family:times new roman" size="1"&gt;&lt;b&gt;2012&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"&gt;&lt;font style="font-family:times new roman" size="1"&gt;&lt;b&gt;2011&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;!-- End Table Head --&gt;
   &lt;!-- Begin Table Body --&gt;
   &lt;tr bgcolor="#cceeff"&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Options to purchase common stock&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;7,438,137&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;6,065,264&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Warrants to purchase common stock&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;13,116,698&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;8,250,642&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size:1px"&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr bgcolor="#cceeff"&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Total&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;20,554,835&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;14,315,906&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size:1px"&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;!-- End Table Body --&gt;
   &lt;/table&gt;
</us-gaap:EarningsPerShareTextBlock>
<!-- End Block Tagged Note -->
<!-- Begin Block Tagged Note -->
<us-gaap:IntangibleAssetsDisclosureTextBlock contextRef="ThreeMonthsEnded_31Mar2012">&lt;!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --&gt;
   &lt;!-- Begin Block Tagged Note 8 - us-gaap:IntangibleAssetsDisclosureTextBlock--&gt;
   &lt;p style="margin-top:18px;margin-bottom:0px"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&lt;b&gt;8. License Agreements &lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
   &lt;p style="font-size:6px;margin-top:0px;margin-bottom:0px"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
   &lt;p style="font-size:1px;margin-top:12px;margin-bottom:0px"&gt;&amp;#160;&lt;/p&gt;
   &lt;p style="margin-top:0px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;As part of its
   business, the Company enters into licensing agreements, which often require milestone and royalty payments based on the progress of the asset through development stages. Milestone payments may be required, for example, upon approval of the product
   for marketing by a regulatory agency. In certain agreements, the Company is required to make royalty payments based upon a percentage of product sales. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:12px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;
   An individual milestone payment required under the licensing arrangements may be material, and in the event that multiple milestones are reached in the same period, the aggregate payments associated with
   the milestones could adversely affect the results of operations or affect the comparability of our period-to-period results. In addition, these licensing arrangements often give the Company the discretion to unilaterally terminate development of the
   product, which would allow the Company to avoid making the contingent payments; however, the Company is unlikely to cease development if the compound successfully achieves clinical testing objectives. The Company&amp;#8217;s contractual obligations
   relating to minimum annual maintenance fees and milestone payments have not changed significantly from December&amp;#160;31, 2011. &lt;/font&gt;&lt;/p&gt;
</us-gaap:IntangibleAssetsDisclosureTextBlock>
<!-- End Block Tagged Note -->
<!-- Begin Block Tagged Note -->
<us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="ThreeMonthsEnded_31Mar2012">&lt;!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --&gt;
   &lt;!-- Begin Block Tagged Note 9 - us-gaap:StockholdersEquityNoteDisclosureTextBlock--&gt;
   &lt;p style="margin-top:18px;margin-bottom:0px"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&lt;b&gt;9. Stockholders&amp;#8217; Equity &lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:6px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&lt;i&gt;Preferred Stock&lt;/i&gt; &amp;#8212; The Company has authorized up to 5,000,000&amp;#160;shares of preferred stock,
   $0.0001&amp;#160;par value per share, for issuance. The preferred stock will have such rights, preferences, privileges and restrictions, including voting rights, dividend rights, conversion rights, redemption privileges and liquidation preferences, as
   shall be determined by the Company&amp;#8217;s board of directors upon its issuance. To date, the Company has not issued any preferred shares. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:12px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;
   &lt;i&gt;Common Stock&lt;/i&gt; &amp;#8212; The Company has authorized up to 125,000,000&amp;#160;shares of common stock, $0.0001&amp;#160;par value per share, for issuance. Shares of common stock are reserved as follows:
   &lt;/font&gt;&lt;/p&gt;
   &lt;p style="font-size:12px;margin-top:0px;margin-bottom:0px"&gt;&amp;#160;&lt;/p&gt;
   &lt;table cellspacing="0" cellpadding="0" width="92%" border="0" style="border-collapse:collapse; text-align: left" align="center"&gt;
   &lt;!-- Begin Table Head --&gt;
   &lt;tr&gt;
   &lt;td width="89%"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom" width="2%"&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"&gt;&lt;font style="font-family:times new roman" size="1"&gt;&lt;b&gt;As of&lt;br /&gt;March&amp;#160;31,&lt;br /&gt;2012&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;!-- End Table Head --&gt;
   &lt;!-- Begin Table Body --&gt;
   &lt;tr bgcolor="#cceeff"&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Warrants outstanding&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;13,116,698&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Stock options outstanding&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;7,438,137&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr bgcolor="#cceeff"&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Options reserved for future issuance under the Company&amp;#8217;s 2007 Incentive Plan&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;24,717&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size:1px"&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Total reserved for future issuance&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;20,579,552&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size:1px"&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;!-- End Table Body --&gt;
   &lt;/table&gt;
   &lt;p style="margin-top:12px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&lt;i&gt;Common Stock Warrants&lt;/i&gt; &amp;#8212; On August&amp;#160;7, 2008, the Company issued 190,000 warrants to an
   investment bank as consideration for investment and business advisory services. The warrants have an exercise price of $7.036 per share and expire 5&amp;#160;years from the date of issuance, on August&amp;#160;7, 2013. The warrants vested as to
   94,000&amp;#160;shares upon issuance, and vested at a rate of 32,000&amp;#160;shares&amp;#160;per month starting on the 90&amp;#160;day anniversary of issuance, and are exercisable for a period of five years. All shares were vested and compensation cost was fully
   recorded at December&amp;#160;31, 2009. The Company also agreed to give the holder of the warrants unlimited &amp;#8220;piggy back&amp;#8221; registration rights with respect to the shares of the Company&amp;#8217;s common stock underlying the warrants in any
   registration statement the Company files in connection with an underwritten offering of its common stock. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:12px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;On January&amp;#160;29,
   2009, the Company issued 142,500 warrants to an investment bank as consideration for investment and business advisory services. The warrants have an exercise price of $4.273 per share and expire five years from the date of issuance on
   January&amp;#160;29, 2014. The warrants vested as to 71,250&amp;#160;shares upon issuance, and vested at a rate of 23,750&amp;#160;shares&amp;#160;per month starting on the 90&amp;#160;day anniversary of issuance, and are exercisable for a period of five years. All
   shares were vested and compensation expense was fully recorded at December&amp;#160;31, 2009. The Company has also agreed to give the holder of the warrants unlimited &amp;#8220;piggy back&amp;#8221; registration rights with respect to the shares of Common Stock
   underlying the warrants in any registration statement the Company files in connection with an underwritten offering of the common stock. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:12px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;
   In connection with the 2009 Offering, the Company issued warrants to purchase 978,142&amp;#160;shares of the Company&amp;#8217;s common stock. Details of the transaction can be found under the heading &amp;#8220;2009
   Registered Direct Offering&amp;#8221; below. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:12px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;In connection with the 2010 Offering, the Company issued warrants to purchase
   540,000&amp;#160;shares of the Company&amp;#8217;s common stock. Details of the transaction can be found under the heading &amp;#8220;2010 Registered Direct Offering&amp;#8221; below. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:12px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;
   In connection with the March 2011 Offering, the Company issued warrants to purchase 6,000,000&amp;#160;shares of the Company&amp;#8217;s common stock. Details of the transaction can be found under the heading
   &amp;#8220;March 2011 Registered Direct Offering&amp;#8221; below. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:12px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;In connection with the April 2011 Offering, the Company issued
   warrants to purchase 11,950,000&amp;#160;shares of the Company&amp;#8217;s common stock. Details of the transaction can be found under the heading &amp;#8220;April 2011 Registered Direct Offering&amp;#8221; below. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:12px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;During 2011, the Company issued 150,000 warrants in exchange for business advisory services. The Company recognizes the total fair value
   of these warrants as stock compensation expense, over the requisite service period. The Company used the Black-Scholes option pricing model to compute the estimated fair value of these warrant grants on the date of the award. Total expense related
   to these warrants was $108,000 in 2011 and compensation expense was fully recorded as of December 31, 2011. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:12px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;During the
   quarter ended March&amp;#160;31, 2012, the Company issued 400,000 warrants in exchange for business advisory services. The Company recognizes the total fair value of these warrants as stock compensation expense, over the requisite service period. The
   Company used the Black-Scholes option pricing model to compute the estimated fair value of these warrant grants which are marked to market over the vesting period of the related warrants. Total expense related to these warrants was $148,000 for the
   quarter ended March&amp;#160;31, 2012. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="font-size:18px;margin-top:0px;margin-bottom:0px"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
   &lt;p style="font-size:1px;margin-top:12px;margin-bottom:0px"&gt;&amp;#160;&lt;/p&gt;
   &lt;p style="margin-top:0px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&lt;i&gt;Private Investment
   in Public Equity&lt;/i&gt; &amp;#8212; On June 24, 2008, the Company entered into a Securities Purchase Agreement pursuant to which the Company issued and sold to certain investors an aggregate of 1,073,299&amp;#160;shares of common stock in a private placement at
   a price of $8.12 per share. Net proceeds to the Company were approximately $7.9&amp;#160;million. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:12px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&lt;i&gt;2009 Registered Direct
   Offering&lt;/i&gt; &amp;#8212; On March&amp;#160;17, 2009, the Company entered into a placement agency agreement, which was subsequently amended on May&amp;#160;26, 2009 and July&amp;#160;22, 2009, with Rodman&amp;#160;&amp;#038; Renshaw, LLC (&amp;#8220;Rodman&amp;#8221;) as the exclusive
   placement agent, relating to a proposed offering by the Company of new securities to potential investors. On July&amp;#160;30, 2009, the Company entered into definitive agreements for the sale and issuance by the Company to certain investors of
   2,385,715&amp;#160;units, with each unit consisting of one share of the Company&amp;#8217;s common stock and a warrant to purchase 0.40 of a share of common stock, at a purchase price of $3.50 per unit (the &amp;#8220;2009 Offering&amp;#8221;). The 2009 Offering
   closed on August&amp;#160;4, 2009. The warrants have an exercise price of $4.50 per share and are exercisable for a period beginning on February&amp;#160;3, 2010 until their expiration on August&amp;#160;3, 2014. The Company raised gross proceeds of
   approximately $8,350,000 in the 2009 Offering and net cash proceeds, after deducting the placement agents&amp;#8217; fees and other offering expenses payable by the Company, of approximately $7.7&amp;#160;million. Total warrants issued in connection with the
   transaction were 954,285. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:12px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;As part of the placement agency agreement, the Company issued a warrant to purchase
   23,857&amp;#160;shares of the Company&amp;#8217;s common stock to Rodman. The warrant has an exercise price of $4.38 per share. The warrant is immediately vested and is exercisable until its expiration on August&amp;#160;3, 2014. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:12px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Certain warrants issued in connection with the stock offering on August&amp;#160;4, 2009 were determined not to be indexed to the
   Company&amp;#8217;s common stock as they are potentially settleable in cash. The fair value of the warrants at the dates of issuance totaling $2,863,000 was recorded as a liability and a cost of equity and was determined using the Black-Scholes option
   pricing model. Due to the fact that the Company has limited trading history, the Company&amp;#8217;s expected stock volatility assumption is based on a combination of implied volatilities of similar entities whose share or option prices are publicly
   traded. The Company used a weighted average expected stock volatility of 122.69%. The expected life assumption is based on the contract term of five years. The dividend yield of zero is based on the fact that the Company has no present intention to
   pay cash dividends in the future. The risk free rate of 1.72% used for the warrant is equal to the zero coupon rate in effect at the time of the grant. The increase in the fair value of warrants from December&amp;#160;31, 2011 to March&amp;#160;31, 2012 of
   $384,000 has been included in other expense in the accompanying condensed statements of expenses for the three months ended March&amp;#160;31, 2012. The fair value of the warrants at March&amp;#160;31, 2012 of $448,000 is included as a current liability in
   the accompanying condensed balance sheets and was determined using the Black-Scholes option pricing model. Due to the fact that the Company has limited trading history, the Company&amp;#8217;s expected stock volatility assumption is based on a
   combination of implied volatilities of similar entities whose share or option prices are publically traded. The Company used a weighted average expected stock volatility of 68.29%. The expected life assumption is based on the remaining contract term
   of 2.3 years. The dividend yield of zero is based on the fact that we have no present intention to pay cash dividends. The risk free rate of 0.39% used for the warrants is equal to the zero coupon rate in effect on the date of the re-measurement.
   &lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:12px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&lt;i&gt;2010 Registered Direct Offering&lt;/i&gt; &amp;#8212; On March&amp;#160;22, 2010, the Company entered into a placement agency agreement
   relating to a proposed offering by the Company of new securities to potential investors. On March&amp;#160;23, 2010, the Company entered into definitive agreements for the sale and issuance by the Company to certain investors of 2,700,000&amp;#160;units,
   with each unit consisting of one share of the Company&amp;#8217;s common stock and a warrant to purchase 0.20 of a share of the Company&amp;#8217;s common stock, at a purchase price of $6.00 per unit (the &amp;#8220;2010 Offering&amp;#8221;). The 2010 Offering closed
   on March&amp;#160;26, 2010. The Company issued warrants to purchase 540,000&amp;#160;shares of the Company&amp;#8217;s common stock at an exercise price of $6.00 per share and that are exercisable beginning on September&amp;#160;26, 2010 until their expiration on
   March&amp;#160;26, 2016. The Company raised gross proceeds of approximately $16.2&amp;#160;million in the 2010 Offering and net cash proceeds, after deducting the placement agent fees and other offering expenses payable by the Company, of approximately
   $15.2&amp;#160;million. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:12px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;As part of the 2010 Offering, the Company entered in a stock redemption agreement whereby the Company was
   required to use 25% of the net proceeds from the 2010 Offering to repurchase from CytRx Corporation (&amp;#8220;CytRx&amp;#8221;) 675,000 shares of the Company&amp;#8217;s common stock held by CytRx (&amp;#8220;CytRx shares&amp;#8221;). The Company repurchased such shares
   on March&amp;#160;29, 2010. The values of the shares at the date of repurchase totaling $3,849,000 were recorded at cost and have been included in treasury stock in the accompanying condensed consolidated balance sheet at March 31, 2012 and 2011.
   &lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:12px;margin-bottom:0px"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Certain warrants issued in connection with the 2010 Offering were determined not to be
   indexed to the Company&amp;#8217;s common stock as they are potentially settleable in cash. The fair value of the warrants at the dates of issuance totaling $2,466,000 was recorded as a liability and a cost of equity and was determined using the
   Black-Scholes option pricing model. Due to the fact that the Company has limited trading history, the Company&amp;#8217;s expected stock volatility assumption is based on a combination of implied volatilities of similar entities whose share or option
   prices are publically traded. The Company used a weighted average expected stock volatility of 119.49%. The expected life assumption is based on the contract term of 6.5&amp;#160;years. The dividend yield of zero is based on the fact that the Company
   has no present intention to pay cash dividends. The risk free rate of 3.22% used for the warrant is equal to the zero coupon rate in effect at the time of the grant. During the three months ended March 31, 2012, 180,000 of the five-year warrants
   were exercised at $2.50 per common share. These warrants were marked to market through March 31, 2012, resulting in additional expense of $215,000. Upon exercise, a liability in the amount of $254,000 was relieved as a credit to additional paid-in
   capital. The increase in the fair value of warrants from December&amp;#160;31, 2011 to March&amp;#160;31, 2012 of $402,000 has been included in other expense in the accompanying condensed statements of expenses for the three months ended March&amp;#160;31,
   2012. The fair value of the warrants at March&amp;#160;31, 2012 of $479,000 is included as a current liability in the accompanying condensed balance sheets and was determined using the Black-Scholes option pricing model. Due to the fact that the Company
   has limited trading history, the Company&amp;#8217;s expected stock volatility assumption is based on a combination of implied volatilities of similar entities whose share or option prices are publically traded. The Company used a weighted average
   expected stock volatility of 81.86%. The expected life assumption is based on the remaining contract term of 4.5 years. The dividend yield of zero is based on the fact that we have no present intention to pay cash dividends. The risk free rate of
   0.91% used for the warrants is equal to the zero coupon rate in effect on the date of the re-measurement. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="font-size:1px;margin-top:12px;margin-bottom:0px"&gt;&amp;#160;&lt;/p&gt;
   &lt;p style="margin-top:0px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&lt;i&gt;March 2011
   Registered Direct Offering&lt;/i&gt; &amp;#8212; On March&amp;#160;4, 2011, the Company closed an underwritten public offering of 6,000,000 units at a price to the public of $1.35 per unit for gross proceeds of $8.1&amp;#160;million (the &amp;#8220;March&amp;#160;2011
   Offering&amp;#8221;). The offering provided approximately $7.3&amp;#160;million to the Company after deducting the underwriting discounts and commissions and offering expenses. Each unit consists of (i)&amp;#160;one share of common stock, (ii)&amp;#160;a
   thirteen-month warrant to purchase 0.50 of a share of common stock at an exercise price of $1.70 per share (subject to anti-dilution adjustment) and (iii)&amp;#160;a five-year warrant to purchase 0.50 of a share of common stock at an exercise price of
   $1.87 per share (subject to anti-dilution adjustment). On April&amp;#160;15, 2011, the holders of outstanding warrants issued in the March&amp;#160;2011 Offering to purchase an aggregate of 3,450,000 shares of common stock agreed to exchange such warrants
   for warrants exercisable for the same number of shares as those being exchanged, but otherwise on the same terms of the warrants sold in the Company&amp;#8217;s April&amp;#160;2011 financing. Prior to the exchange, the Company recorded a decrease in fair
   value of $1,000,000 related to the exchanged warrants. Upon the exchange, the Company recorded a loss of $900,000, which represented the difference between the adjusted fair value of the March&amp;#160;2011 warrants as compared to the fair value of the
   April&amp;#160;2011 warrants received in the exchange. As a result of a subsequent offering that was completed on April&amp;#160;15, 2011, the exercise price of the remaining 2,550,000 outstanding warrants sold in the March&amp;#160;2011 Offering was reduced to
   $1.00 per share as a result of the anti-dilution adjustment. As a result of the subsequent offering on September&amp;#160;26, 2011, the exercise price of all warrants sold in the March&amp;#160;4, 2011 Offering were reduced to $0.65 per share as a result of
   the anti-dilution adjustment. At March&amp;#160;31, 2012, of the 2,550,000 unexchanged warrants from the March&amp;#160;2011 Offering, 1,373,944 warrants had been exercised with a remaining outstanding balance of 1,176,056. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:12px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;The thirteen-month and five-year warrants issued in connection with the March 2011 Offering were determined not to be indexed to the
   Company&amp;#8217;s common stock as they are potentially settleable in cash. The fair value of the 2,550,000 warrants at the date of issuance totaling $1,790,000 was recorded as a liability and a cost of equity and was determined using the Black-Scholes
   option pricing model. Due to the fact that the Company has limited trading history, the Company expected stock volatility assumption is based on a combination of implied volatilities of similar entities whose shares or options are publicly traded.
   The Company used a weighted average expected stock volatility of 113.25%. The expected life assumption is based on the contract term of 1.08 years used for the thirteen-month warrants and 5 years used for the five-year warrants. The dividend yield
   of zero is based on the fact that we have no present intention to pay cash dividends. The risk free rate of 0.26% used for the thirteen-month warrants and 2.17% used for the five-year warrants is equal to the zero coupon rate in effect at the time
   of the grant. In July 2011, 75,000 of the thirteen-month warrants were exercised at $1.00 per common share, which resulted in a $34,000 reduction of the warrant liability. In July 2011, 75,000 of the five-year warrants were exercised at $1.00 per
   common share, which resulted in a $68,000 reduction of the warrant liability. During the three months ended March 31, 2012, 862,500 of the thirteen-month warrants and 361,444 of the five-year warrants were exercised at $0.65 per common share. These
   warrants were marked to market through March 31, 2012, resulting in additional expense of $1,256,000. Upon exercise, a liability in the amount of $1,405,000 was relieved as a credit to additional paid-in capital. The increase in the fair value of
   warrants from December&amp;#160;31, 2011 to March&amp;#160;31, 2012 of $1,765,000 has been included in other expense in the accompanying condensed statements of expenses for the three months ended March&amp;#160;31, 2012. The fair value of the warrants at
   March&amp;#160;31, 2012 of $2,028,000 is included as a current liability in the accompanying condensed balance sheets and was determined using the Black-Scholes option pricing model. Due to the fact that the Company has limited trading history, the
   Company&amp;#8217;s expected stock volatility assumption is based on a combination of implied volatilities of similar entities whose share or option prices are publically traded. The Company used a weighted average expected stock volatility of 47.29% for
   the thirteen-month warrants and 81.99% for the five-year warrants. The expected life assumption is based on the remaining contract term of 0.01 years used for the thirteen-month warrants and 3.93 years used for the five-year warrants. The dividend
   yield of zero is based on the fact that we have no present intention to pay cash dividends. The risk free rate of 0.01% used for the thirteen-month warrants and 0.78% used for the five-year warrants is equal to the zero coupon rate in effect at the
   time of the re-measurement. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:12px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&lt;i&gt;April 2011 Registered Direct Offering&lt;/i&gt; &amp;#8212; On April&amp;#160;20, 2011, the Company completed
   an underwritten public offering of 11,950,000 units at a price to the public of $1.00 per unit for gross proceeds of approximately $12&amp;#160;million (the &amp;#8220;April&amp;#160;2011 Offering&amp;#8221;). Each unit consisted of one share of common stock and a
   warrant to purchase one share of common stock at an exercise price of $1.00 per share (subject to anti-dilution adjustment). The shares of common stock and warrants were immediately separable and no separate units were issued. The warrants are
   exercisable beginning one year and one day from the date of issuance, and expire on the sixth anniversary of the date of issuance. Net proceeds, after underwriting discounts and commissions and other offering expenses, were approximately
   $10.9&amp;#160;million. As a result of the subsequent offering that was completed on September&amp;#160;26, 2011, the exercise price of the 11,950,000 outstanding warrants sold in the April&amp;#160;2011 Offering was reduced to $0.65 per share as a result of
   the anti-dilution adjustment.&amp;#160;On December&amp;#160;6, 2011, the Company effected a warrant exchange with a ratio of 1.42857 warrants in exchange for one share of common stock with several of the April 2011 warrant holders. In total, 5,930,000
   warrants were exchanged for 4,151,000 shares of common stock in this transaction. At March 31, 2012, 6,020,000 warrants sold in the April&amp;#160;20, 2011 Offering remained outstanding. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:12px;margin-bottom:0px"&gt;&lt;font style="font-family:times new roman" size="2"&gt;
   &amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;The warrants issued in connection with the April 2011 Offering, including the warrants issued in exchange for the 3,450,000&amp;#160;March 2011 warrants, were
   determined not to be indexed to the Company&amp;#8217;s common stock as they are potentially settleable in cash. The fair value of the warrants at the dates of issuance totaling $11,442,000 was recorded as a liability and a cost of equity and was
   determined using the Black-Scholes option pricing model. Due to the fact that the Company has limited trading history, the Company&amp;#8217;s expected stock volatility assumption is based on a combination of implied volatilities of similar entities
   whose shares or options are publicly traded. The Company used a weighted average expected stock volatility of 99.04%. The expected life assumption is based on the contract term of 6.0 years. The dividend yield of zero is based on the fact that we
   have no present intention to pay cash dividends. The risk free rate of 2.81% used for the warrants is equal to the zero coupon rate in effect at the time of the grant. In December 2011, the Company exchanged 4,151,000 shares of common stock in
   exchange for 5,930,000 of these April warrants at a ratio of 0.7 common shares for each warrant which resulted in a reduction to warrant liability of $3,120,000. The increase in the fair market value of the warrants, including the warrants exchanged
   for the 3,450,000 March 2011 warrants, from December&amp;#160;31, 2011 to March&amp;#160;31, 2012 of $14,248,000 has been included in other expense in the accompanying condensed statements of expenses for the three months ended March&amp;#160;31, 2012. The fair
   value of the warrants at March&amp;#160;31, 2012 of $17,402,000 is included as a current liability in the accompanying condensed balance sheets and was determined using the Black-Scholes option pricing model. Due to the fact that the Company has limited
   trading history, the Company&amp;#8217;s expected stock volatility assumption is based on a combination of implied volatilities of similar entities whose share or option prices are publically traded. The Company used a
   weighted average expected stock volatility of 79.77%. The expected life assumption is based on the remaining contract term of 5.1 years. The dividend yield of zero is based on the fact that we have no present intention to pay cash dividends. The
   risk free rate of 1.04% used for the warrants is equal to the zero coupon rate in effect on the date of the re-measurement. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:12px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&lt;i&gt;September 2011 Registered Direct Offering&lt;/i&gt; &amp;#8212; On September&amp;#160;26, 2011, the Company completed a direct offering of 700,000
   shares of common stock for gross proceeds of $455,000. &lt;/font&gt;&lt;/p&gt;
</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
<!-- End Block Tagged Note -->
<!-- Begin Block Tagged Note -->
<us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="ThreeMonthsEnded_31Mar2012">&lt;!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --&gt;
   &lt;!-- Begin Block Tagged Note 10 - us-gaap:CommitmentsAndContingenciesDisclosureTextBlock--&gt;
   &lt;p style="margin-top:18px;margin-bottom:0px"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&lt;b&gt;10. Litigation &lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:6px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;The Company is in litigation with several of its April 2011 warrants holders (&amp;#8220;Plaintiffs&amp;#8221;) who have asserted
   that the Company&amp;#8217;s spin-off of RXi and related actions give the Plaintiffs the right to require us to repurchase our outstanding warrants held by them. Originally, the Plaintiffs made aggregate repurchase demands to the Company to repurchase
   6,850,000 warrants, which represented an approximate total demand of $5.2 million. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:12px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;On March&amp;#160;21, 2012, we received
   letters from each of the plaintiff-warrant holders withdrawing their repurchase demands with respect to their warrants covering an aggregate of 6,350,000 shares out of a total of 6,850,000 shares of common stock purchasable under their warrants (the
   &amp;#8220;Withdrawal Notice&lt;b&gt;s&lt;/b&gt;&amp;#8221;). After giving effect to the Withdrawal Notices, the plaintiff-warrant holders continued to demand that we repurchase their warrants covering the balance of 500,000 shares of common stock in the aggregate. Based
   on the plaintiff-warrant holders&amp;#8217; claims in their Complaints, we believe that the repurchase price for these warrants is $0.71 per underlying share, or an aggregate of $355,000. On March 27, 2012, we tendered to the plaintiff-warrant holders an
   aggregate of $355,000 as payment in full of the repurchase price for those warrants. We believe that the Withdrawal Notices and our tender of payment as described above render moot the majority of the claims of the plaintiff-warrant holders in their
   Complaints, although the Withdrawal Notices purport to reserve all rights of the plaintiff-warrant holders under the Complaints. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:12px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;
   On May&amp;#160;7, 2012, the Company entered into a confidential settlement agreement with one of the Plaintiffs, &lt;u&gt;&lt;/u&gt;in which the Plaintiff withdrew all claims in the aforementioned matter. &lt;/font&gt;&lt;/p&gt;
</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
<!-- End Block Tagged Note -->
<!-- Begin Block Tagged Note -->
<us-gaap:SubsequentEventsTextBlock contextRef="ThreeMonthsEnded_31Mar2012">&lt;!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --&gt;
   &lt;!-- Begin Block Tagged Note 11 - us-gaap:SubsequentEventsTextBlock--&gt;
   &lt;p style="margin-top:18px;margin-bottom:0px"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&lt;b&gt;11. Subsequent Events &lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:6px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;The Company evaluated all events or transactions that occurred after March&amp;#160;31, 2012 up through the date these
   financial statements were issued. Other than what is disclosed below, the Company did not have any material recognizable or unrecognizable subsequent events. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:12px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;
   Since March 31, 2012, the Company has issued 6,363,191 shares of the Company&amp;#8217;s common stock pursuant to the exercise of outstanding warrants from various warrant holders. The Company received
   $4,136,074 in total payments at an exercise price of $0.65 per share. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:12px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;On April&amp;#160;5, 2012, the Company issued 120,065
   shares of common stock in connection with a cashless exercise of 182,500 thirteen-month warrants from the March 2011 Offering which had expired, in the money, on April&amp;#160;4, 2012. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:12px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;On April&amp;#160;11, 2012, the Company issued 8,500,000 shares of its common stock in an underwritten public offering at $1.50 per share.
   The Company also granted to the underwriters a 30-day option to purchase up to an additional 1,275,000 shares to cover overallotments in connection with the offering. On April&amp;#160;13, 2012, the underwriters exercised their option to purchase an
   additional 1,251,000 shares of common stock. After the underwriting discount and estimated offering expenses payable by the Company, the Company received net proceeds of approximately $13.3 million. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:12px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;On April&amp;#160;26, 2012, the Company completed the spin-off of RXi, its wholly-owned subsidiary prior to the spin-off, pursuant to the
   Securities Purchase Agreement described in Note 4, and on April&amp;#160;27, 2012, the Company closed the transactions under the Securities Purchase Agreement. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:12px;margin-bottom:0px; text-indent:4%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;
   On May&amp;#160;7, 2012, as more fully described in Note 10, the Company entered into a confidential settlement agreement with one of the Plaintiffs in the actions described in Note 10. &lt;/font&gt;&lt;/p&gt;
</us-gaap:SubsequentEventsTextBlock>
<!-- End Block Tagged Note -->
<!--Footnote Section-->

</xbrl>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>11
<FILENAME>rxii-20120331.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- XBRL Generated with XBRLMark Copyright (C) by RR Donnelley -->
<!-- Based on XBRL 2.1 -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" targetNamespace="http://rxipharma.com/20120331" xmlns:rxii="http://rxipharma.com/20120331" elementFormDefault="qualified" attributeFormDefault="unqualified" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:us-types="http://xbrl.sec.gov/us-types/2011-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric">
  <annotation>
    <appinfo>
      <link:roleType roleURI="http://rxipharma.com/role/DocumentAndEntityInformation" id="DocumentAndEntityInformation">
        <link:definition>00 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://rxipharma.com/role/BalanceSheets" id="BalanceSheets">
        <link:definition>01 - Statement - Condensed Consolidated Balance Sheets (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://rxipharma.com/role/BalanceSheetsParenthetical" id="BalanceSheetsParenthetical">
        <link:definition>011 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://rxipharma.com/role/StatementsOfIncome" id="StatementsOfIncome">
        <link:definition>02 - Statement - Condensed Consolidated Statements of Expenses (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://rxipharma.com/role/StatementsOfCashFlows" id="StatementsOfCashFlows">
        <link:definition>03 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://rxipharma.com/role/DescriptionOfBusinessAndBasisOfPresentation" id="DescriptionOfBusinessAndBasisOfPresentation">
        <link:definition>06001 - Disclosure - Description of Business and Basis of Presentation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://rxipharma.com/role/RecentAccountingPronouncements" id="RecentAccountingPronouncements">
        <link:definition>06002 - Disclosure - Recent Accounting Pronouncements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://rxipharma.com/role/AptheraAcquisition" id="AptheraAcquisition">
        <link:definition>06003 - Disclosure - Apthera Acquisition</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://rxipharma.com/role/RxiSpinOut" id="RxiSpinOut">
        <link:definition>06004 - Disclosure - RXi Spin-Out</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://rxipharma.com/role/FairValueMeasurements" id="FairValueMeasurements">
        <link:definition>06005 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://rxipharma.com/role/StockBasedCompensation" id="StockBasedCompensation">
        <link:definition>06006 - Disclosure - Stock Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://rxipharma.com/role/NetLossPerShare" id="NetLossPerShare">
        <link:definition>06007 - Disclosure - Net Loss Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://rxipharma.com/role/LicenseAgreements" id="LicenseAgreements">
        <link:definition>06008 - Disclosure - License Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://rxipharma.com/role/StockholdersEquity" id="StockholdersEquity">
        <link:definition>06009 - Disclosure - Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://rxipharma.com/role/Litigation" id="Litigation">
        <link:definition>06010 - Disclosure - Litigation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://rxipharma.com/role/SubsequentEvents" id="SubsequentEvents">
        <link:definition>06011 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:type="simple" xlink:href="rxii-20120331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Calculation Links, all" />
      <link:linkbaseRef xlink:type="simple" xlink:href="rxii-20120331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links, all" />
      <link:linkbaseRef xlink:type="simple" xlink:href="rxii-20120331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links, all" />
    </appinfo>
  </annotation>
  <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
  <import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />
  <import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
  <import namespace="http://fasb.org/us-types/2011-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2011/elts/us-types-2011-01-31.xsd" />
  <import namespace="http://fasb.org/us-gaap/2011-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd" />
  <import namespace="http://xbrl.sec.gov/dei/2011-01-31" schemaLocation="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd" />
  <!-- elements -->
  <element name="DocumentAndEntityInformationAbstract" id="rxii_DocumentAndEntityInformationAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" abstract="true" nillable="true" />
  <element name="InProcessResearchDevelopment" id="rxii_InProcessResearchDevelopment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" />
  <element name="FairValueOfWarrantsPotentiallySettleableInCash" id="rxii_FairValueOfWarrantsPotentiallySettleableInCash" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" />
  <element name="CurrentContingentPurchasePriceConsideration" id="rxii_CurrentContingentPurchasePriceConsideration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" />
  <element name="ContingentPurchasePriceConsiderationNetOfCurrentPortion" id="rxii_ContingentPurchasePriceConsiderationNetOfCurrentPortion" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" />
  <element name="DeficitAccumulatedDuringDevelopmentalStage" id="rxii_DeficitAccumulatedDuringDevelopmentalStage" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" />
  <element name="ResearchAndDevelopmentEmployeeStockBasedCompensationExpense" id="rxii_ResearchAndDevelopmentEmployeeStockBasedCompensationExpense" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" />
  <element name="ResearchAndDevelopmentNonEmployeeStockBasedCompensationExpense" id="rxii_ResearchAndDevelopmentNonEmployeeStockBasedCompensationExpense" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" />
  <element name="FairValueOfCommonStockInExchangeForResearchAndDevelopmentExpenses" id="rxii_FairValueOfCommonStockInExchangeForResearchAndDevelopmentExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" />
  <element name="GeneralAndAdministrativeExpenses" id="rxii_GeneralAndAdministrativeExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" />
  <element name="GeneralAndAdministrativeEmployeeStockBasedCompensation" id="rxii_GeneralAndAdministrativeEmployeeStockBasedCompensation" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" />
  <element name="FairValueOfCommonStockWarrantsIssuedForGeneralAndAdministrativeExpenses" id="rxii_FairValueOfCommonStockWarrantsIssuedForGeneralAndAdministrativeExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" />
  <element name="FairValueOfCommonStockIssuedInExchangeForGeneralAndAdministrativeExpenses" id="rxii_FairValueOfCommonStockIssuedInExchangeForGeneralAndAdministrativeExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" />
  <element name="InterestIncome" id="rxii_InterestIncome" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" />
  <element name="WeightedAverageNumberOfShareOutstandingBasicAndDiluted" id="rxii_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <element name="NetIncomeLossIncludingOther" id="rxii_NetIncomeLossIncludingOther" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" />
  <element name="NonCashRentExpense" id="rxii_NonCashRentExpense" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" />
  <element name="LossOnExchangeOfEquityInstruments" id="rxii_LossOnExchangeOfEquityInstruments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" />
  <element name="FairValueOfSharesMandatorilyRedeemableForCashUponExerciseOfWarrants" id="rxii_FairValueOfSharesMandatorilyRedeemableForCashUponExerciseOfWarrants" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" />
  <element name="FairValueOfParentCompanyCommonStockIssuedInExchangeForServices" id="rxii_FairValueOfParentCompanyCommonStockIssuedInExchangeForServices" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" />
  <element name="ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings" id="rxii_ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" />
  <element name="FairValueOfCommonStockIssuedInExchangeForLicensingRights" id="rxii_FairValueOfCommonStockIssuedInExchangeForLicensingRights" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" />
  <element name="ChangeInFairValueOfContingentPurchaseConsideration" id="rxii_ChangeInFairValueOfContingentPurchaseConsideration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" />
  <element name="CashReceivedInAcquisition" id="rxii_CashReceivedInAcquisition" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" />
  <element name="CashRefundedPaidForLeaseDeposit" id="rxii_CashRefundedPaidForLeaseDeposit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" />
  <element name="NetProceedsFromExerciseOfCommonStockWarrants" id="rxii_NetProceedsFromExerciseOfCommonStockWarrants" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" />
  <element name="CommonStockIssuedInConnectionWithEspp" id="rxii_CommonStockIssuedInConnectionWithEspp" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" />
  <element name="NetProceedsFromIssuanceOfConvertibleNotesPayable" id="rxii_NetProceedsFromIssuanceOfConvertibleNotesPayable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" />
  <element name="FairValueOfWarrantsIssuedInConnectionWithCommonStockRecordedAsCostOfEquity" id="rxii_FairValueOfWarrantsIssuedInConnectionWithCommonStockRecordedAsCostOfEquity" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" />
  <element name="IssuanceOfCommonStockInExchangeOfOutstandingWarrants" id="rxii_IssuanceOfCommonStockInExchangeOfOutstandingWarrants" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" />
  <element name="FairValueOfSharesMandatorilyRedeemableForCashUponExerciseOfWarrant" id="rxii_FairValueOfSharesMandatorilyRedeemableForCashUponExerciseOfWarrant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" />
  <element name="ReclassificationOfWarrantLiabilityUponExercise" id="rxii_ReclassificationOfWarrantLiabilityUponExercise" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" />
  <element name="AllocationOfManagementExpenses" id="rxii_AllocationOfManagementExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" />
  <element name="EquipmentAndFurnishingsExchangedForCommonStock" id="rxii_EquipmentAndFurnishingsExchangedForCommonStock" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" />
  <element name="ValueOfRestrictedStockUnitsAndCommonStockIssuedInLieuOfCashBonuses" id="rxii_ValueOfRestrictedStockUnitsAndCommonStockIssuedInLieuOfCashBonuses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" />
  <element name="PartnerCompanyTextBlock" id="rxii_PartnerCompanyTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>12
<FILENAME>rxii-20120331_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- XBRL Generated with XBRLMark Copyright (C) by RR Donnelley -->
<!-- Based on XBRL 2.1 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<roleRef xlink:type="simple" xlink:href="rxii-20120331.xsd#DocumentAndEntityInformation" roleURI="http://rxipharma.com/role/DocumentAndEntityInformation" />
<calculationLink xlink:type="extended" xlink:role="http://rxipharma.com/role/DocumentAndEntityInformation" xlink:title="00 - Document - Document and Entity Information" />
<roleRef roleURI="http://rxipharma.com/role/BalanceSheets" xlink:href="rxii-20120331.xsd#BalanceSheets" xlink:type="simple" />
<roleRef roleURI="http://rxipharma.com/role/BalanceSheetsParenthetical" xlink:href="rxii-20120331.xsd#BalanceSheetsParenthetical" xlink:type="simple" />

<roleRef roleURI="http://rxipharma.com/role/StatementsOfIncome" xlink:href="rxii-20120331.xsd#StatementsOfIncome" xlink:type="simple" />
<roleRef roleURI="http://rxipharma.com/role/StatementsOfCashFlows" xlink:href="rxii-20120331.xsd#StatementsOfCashFlows" xlink:type="simple" />
<calculationLink xlink:role="http://rxipharma.com/role/BalanceSheets" xlink:title="01 - Statement - Condensed Consolidated Balance Sheets (Unaudited)" xlink:type="extended">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_AssetsCurrent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_CashAndCashEquivalentsAtCarryingValue" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_AssetsCurrent" xlink:to="loc_CashAndCashEquivalentsAtCarryingValue" order="1" use="optional" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="loc_RestrictedCashAndCashEquivalentsAtCarryingValue" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_AssetsCurrent" xlink:to="loc_RestrictedCashAndCashEquivalentsAtCarryingValue" order="2" use="optional" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_PrepaidExpenseAndOtherAssetsCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_AssetsCurrent" xlink:to="loc_PrepaidExpenseAndOtherAssetsCurrent" order="3" use="optional" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Assets" xlink:label="loc_Assets" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_Assets" xlink:to="loc_AssetsCurrent" order="4" use="optional" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_PropertyPlantAndEquipmentNet" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_Assets" xlink:to="loc_PropertyPlantAndEquipmentNet" order="5" use="optional" weight="1" />
<loc xlink:type="locator" xlink:href="rxii-20120331.xsd#rxii_InProcessResearchDevelopment" xlink:label="rxii_InProcessResearchDevelopment" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_Assets" xlink:to="rxii_InProcessResearchDevelopment" order="6" use="optional" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_Goodwill" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_Assets" xlink:to="loc_Goodwill" order="7" use="optional" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DepositsAssetsNoncurrent" xlink:label="loc_DepositsAssetsNoncurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_Assets" xlink:to="loc_DepositsAssetsNoncurrent" order="8" use="optional" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_LiabilitiesCurrent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_AccountsPayableCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_LiabilitiesCurrent" xlink:to="loc_AccountsPayableCurrent" order="9" use="optional" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_AccruedLiabilitiesCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_LiabilitiesCurrent" xlink:to="loc_AccruedLiabilitiesCurrent" order="10" use="optional" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CapitalLeaseObligationsCurrent" xlink:label="loc_CapitalLeaseObligationsCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_LiabilitiesCurrent" xlink:to="loc_CapitalLeaseObligationsCurrent" order="11" use="optional" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ConvertibleNotesPayableCurrent" xlink:label="loc_ConvertibleNotesPayableCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_LiabilitiesCurrent" xlink:to="loc_ConvertibleNotesPayableCurrent" order="12" use="optional" weight="1" />
<loc xlink:type="locator" xlink:href="rxii-20120331.xsd#rxii_FairValueOfWarrantsPotentiallySettleableInCash" xlink:label="rxii_FairValueOfWarrantsPotentiallySettleableInCash" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_LiabilitiesCurrent" xlink:to="rxii_FairValueOfWarrantsPotentiallySettleableInCash" order="13" use="optional" weight="1" />
<loc xlink:type="locator" xlink:href="rxii-20120331.xsd#rxii_CurrentContingentPurchasePriceConsideration" xlink:label="rxii_CurrentContingentPurchasePriceConsideration" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_LiabilitiesCurrent" xlink:to="rxii_CurrentContingentPurchasePriceConsideration" order="14" use="optional" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_Liabilities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_Liabilities" xlink:to="loc_LiabilitiesCurrent" order="15" use="optional" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CapitalLeaseObligationsNoncurrent" xlink:label="loc_CapitalLeaseObligationsNoncurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_Liabilities" xlink:to="loc_CapitalLeaseObligationsNoncurrent" order="16" use="optional" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ConvertibleLongTermNotesPayable" xlink:label="loc_ConvertibleLongTermNotesPayable" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_Liabilities" xlink:to="loc_ConvertibleLongTermNotesPayable" order="17" use="optional" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent" xlink:label="loc_DeferredTaxAssetsLiabilitiesNetNoncurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_Liabilities" xlink:to="loc_DeferredTaxAssetsLiabilitiesNetNoncurrent" order="18" use="optional" weight="-1" />
<loc xlink:type="locator" xlink:href="rxii-20120331.xsd#rxii_ContingentPurchasePriceConsiderationNetOfCurrentPortion" xlink:label="rxii_ContingentPurchasePriceConsiderationNetOfCurrentPortion" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_Liabilities" xlink:to="rxii_ContingentPurchasePriceConsiderationNetOfCurrentPortion" order="19" use="optional" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_LiabilitiesAndStockholdersEquity" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_LiabilitiesAndStockholdersEquity" xlink:to="loc_Liabilities" order="20" use="optional" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_StockholdersEquity" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_PreferredStockValue" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_StockholdersEquity" xlink:to="loc_PreferredStockValue" order="21" use="optional" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_CommonStockValue" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_StockholdersEquity" xlink:to="loc_CommonStockValue" order="22" use="optional" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_AdditionalPaidInCapitalCommonStock" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_StockholdersEquity" xlink:to="loc_AdditionalPaidInCapitalCommonStock" order="23" use="optional" weight="1" />
<loc xlink:type="locator" xlink:href="rxii-20120331.xsd#rxii_DeficitAccumulatedDuringDevelopmentalStage" xlink:label="rxii_DeficitAccumulatedDuringDevelopmentalStage" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_StockholdersEquity" xlink:to="rxii_DeficitAccumulatedDuringDevelopmentalStage" order="24" use="optional" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_TreasuryStockValue" xlink:label="loc_TreasuryStockValue" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_StockholdersEquity" xlink:to="loc_TreasuryStockValue" order="25" use="optional" weight="-1" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_LiabilitiesAndStockholdersEquity" xlink:to="loc_StockholdersEquity" order="26" use="optional" weight="1" />
</calculationLink>
<calculationLink xlink:role="http://rxipharma.com/role/StatementsOfIncome" xlink:title="02 - Statement - Condensed Consolidated Statements of Expenses (Unaudited)" xlink:type="extended">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_ResearchAndDevelopmentExpense" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="loc_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ResearchAndDevelopmentExpense" xlink:to="loc_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" order="27" use="optional" weight="1" />
<loc xlink:type="locator" xlink:href="rxii-20120331.xsd#rxii_ResearchAndDevelopmentEmployeeStockBasedCompensationExpense" xlink:label="rxii_ResearchAndDevelopmentEmployeeStockBasedCompensationExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ResearchAndDevelopmentExpense" xlink:to="rxii_ResearchAndDevelopmentEmployeeStockBasedCompensationExpense" order="28" use="optional" weight="1" />
<loc xlink:type="locator" xlink:href="rxii-20120331.xsd#rxii_ResearchAndDevelopmentNonEmployeeStockBasedCompensationExpense" xlink:label="rxii_ResearchAndDevelopmentNonEmployeeStockBasedCompensationExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ResearchAndDevelopmentExpense" xlink:to="rxii_ResearchAndDevelopmentNonEmployeeStockBasedCompensationExpense" order="29" use="optional" weight="1" />
<loc xlink:type="locator" xlink:href="rxii-20120331.xsd#rxii_FairValueOfCommonStockInExchangeForResearchAndDevelopmentExpenses" xlink:label="rxii_FairValueOfCommonStockInExchangeForResearchAndDevelopmentExpenses" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ResearchAndDevelopmentExpense" xlink:to="rxii_FairValueOfCommonStockInExchangeForResearchAndDevelopmentExpenses" order="30" use="optional" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_OperatingExpenses" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_OperatingExpenses" xlink:to="loc_ResearchAndDevelopmentExpense" order="31" use="optional" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_GeneralAndAdministrativeExpense" />
<loc xlink:type="locator" xlink:href="rxii-20120331.xsd#rxii_GeneralAndAdministrativeExpenses" xlink:label="rxii_GeneralAndAdministrativeExpenses" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_GeneralAndAdministrativeExpense" xlink:to="rxii_GeneralAndAdministrativeExpenses" order="32" use="optional" weight="1" />
<loc xlink:type="locator" xlink:href="rxii-20120331.xsd#rxii_GeneralAndAdministrativeEmployeeStockBasedCompensation" xlink:label="rxii_GeneralAndAdministrativeEmployeeStockBasedCompensation" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_GeneralAndAdministrativeExpense" xlink:to="rxii_GeneralAndAdministrativeEmployeeStockBasedCompensation" order="33" use="optional" weight="1" />
<loc xlink:type="locator" xlink:href="rxii-20120331.xsd#rxii_FairValueOfCommonStockWarrantsIssuedForGeneralAndAdministrativeExpenses" xlink:label="rxii_FairValueOfCommonStockWarrantsIssuedForGeneralAndAdministrativeExpenses" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_GeneralAndAdministrativeExpense" xlink:to="rxii_FairValueOfCommonStockWarrantsIssuedForGeneralAndAdministrativeExpenses" order="34" use="optional" weight="1" />
<loc xlink:type="locator" xlink:href="rxii-20120331.xsd#rxii_FairValueOfCommonStockIssuedInExchangeForGeneralAndAdministrativeExpenses" xlink:label="rxii_FairValueOfCommonStockIssuedInExchangeForGeneralAndAdministrativeExpenses" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_GeneralAndAdministrativeExpense" xlink:to="rxii_FairValueOfCommonStockIssuedInExchangeForGeneralAndAdministrativeExpenses" order="35" use="optional" weight="1" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_OperatingExpenses" xlink:to="loc_GeneralAndAdministrativeExpense" order="36" use="optional" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_NetIncomeLoss" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_NetIncomeLoss" xlink:to="loc_OperatingExpenses" order="37" use="optional" weight="-1" />
<loc xlink:type="locator" xlink:href="rxii-20120331.xsd#rxii_InterestIncome" xlink:label="rxii_InterestIncome" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_NetIncomeLoss" xlink:to="rxii_InterestIncome" order="38" use="optional" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_OtherNonoperatingIncomeExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_NetIncomeLoss" xlink:to="loc_OtherNonoperatingIncomeExpense" order="39" use="optional" weight="1" />
</calculationLink>
<calculationLink xlink:role="http://rxipharma.com/role/StatementsOfCashFlows" xlink:title="03 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)" xlink:type="extended">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_NetCashProvidedByUsedInOperatingActivities" />
<loc xlink:type="locator" xlink:href="rxii-20120331.xsd#rxii_NetIncomeLossIncludingOther" xlink:label="rxii_NetIncomeLossIncludingOther" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_NetCashProvidedByUsedInOperatingActivities" xlink:to="rxii_NetIncomeLossIncludingOther" order="40" use="optional" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_DepreciationDepletionAndAmortization" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_DepreciationDepletionAndAmortization" order="41" use="optional" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets" xlink:label="loc_GainLossOnDispositionOfAssets" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_GainLossOnDispositionOfAssets" order="42" use="optional" weight="-1" />
<loc xlink:type="locator" xlink:href="rxii-20120331.xsd#rxii_NonCashRentExpense" xlink:label="rxii_NonCashRentExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_NetCashProvidedByUsedInOperatingActivities" xlink:to="rxii_NonCashRentExpense" order="43" use="optional" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="loc_AccretionAmortizationOfDiscountsAndPremiumsInvestments" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_AccretionAmortizationOfDiscountsAndPremiumsInvestments" order="44" use="optional" weight="-1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_ShareBasedCompensation" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_ShareBasedCompensation" order="45" use="optional" weight="1" />
<loc xlink:type="locator" xlink:href="rxii-20120331.xsd#rxii_LossOnExchangeOfEquityInstruments" xlink:label="rxii_LossOnExchangeOfEquityInstruments" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_NetCashProvidedByUsedInOperatingActivities" xlink:to="rxii_LossOnExchangeOfEquityInstruments" order="46" use="optional" weight="1" />
<loc xlink:type="locator" xlink:href="rxii-20120331.xsd#rxii_FairValueOfSharesMandatorilyRedeemableForCashUponExerciseOfWarrants" xlink:label="rxii_FairValueOfSharesMandatorilyRedeemableForCashUponExerciseOfWarrants" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_NetCashProvidedByUsedInOperatingActivities" xlink:to="rxii_FairValueOfSharesMandatorilyRedeemableForCashUponExerciseOfWarrants" order="47" use="optional" weight="-1" />
<loc xlink:type="locator" xlink:href="rxii-20120331.xsd#rxii_FairValueOfParentCompanyCommonStockIssuedInExchangeForServices" xlink:label="rxii_FairValueOfParentCompanyCommonStockIssuedInExchangeForServices" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_NetCashProvidedByUsedInOperatingActivities" xlink:to="rxii_FairValueOfParentCompanyCommonStockIssuedInExchangeForServices" order="48" use="optional" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="loc_IssuanceOfStockAndWarrantsForServicesOrClaims" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_IssuanceOfStockAndWarrantsForServicesOrClaims" order="49" use="optional" weight="1" />
<loc xlink:type="locator" xlink:href="rxii-20120331.xsd#rxii_ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings" xlink:label="rxii_ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_NetCashProvidedByUsedInOperatingActivities" xlink:to="rxii_ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings" order="50" use="optional" weight="-1" />
<loc xlink:type="locator" xlink:href="rxii-20120331.xsd#rxii_FairValueOfCommonStockIssuedInExchangeForLicensingRights" xlink:label="rxii_FairValueOfCommonStockIssuedInExchangeForLicensingRights" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_NetCashProvidedByUsedInOperatingActivities" xlink:to="rxii_FairValueOfCommonStockIssuedInExchangeForLicensingRights" order="51" use="optional" weight="1" />
<loc xlink:type="locator" xlink:href="rxii-20120331.xsd#rxii_ChangeInFairValueOfContingentPurchaseConsideration" xlink:label="rxii_ChangeInFairValueOfContingentPurchaseConsideration" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_NetCashProvidedByUsedInOperatingActivities" xlink:to="rxii_ChangeInFairValueOfContingentPurchaseConsideration" order="52" use="optional" weight="-1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="53" use="optional" weight="-1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_IncreaseDecreaseInAccountsPayable" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_IncreaseDecreaseInAccountsPayable" order="54" use="optional" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInDueToOtherRelatedPartiesCurrent" xlink:label="loc_IncreaseDecreaseInDueToOtherRelatedPartiesCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_IncreaseDecreaseInDueToOtherRelatedPartiesCurrent" order="55" use="optional" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_IncreaseDecreaseInAccruedLiabilities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_IncreaseDecreaseInAccruedLiabilities" order="56" use="optional" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_CashAndCashEquivalentsPeriodIncreaseDecrease" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="loc_NetCashProvidedByUsedInOperatingActivities" order="57" use="optional" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_NetCashProvidedByUsedInInvestingActivities" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInRestrictedCash" xlink:label="loc_IncreaseDecreaseInRestrictedCash" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_NetCashProvidedByUsedInInvestingActivities" xlink:to="loc_IncreaseDecreaseInRestrictedCash" order="58" use="optional" weight="-1" />
<loc xlink:type="locator" xlink:href="rxii-20120331.xsd#rxii_CashReceivedInAcquisition" xlink:label="rxii_CashReceivedInAcquisition" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_NetCashProvidedByUsedInInvestingActivities" xlink:to="rxii_CashReceivedInAcquisition" order="59" use="optional" weight="-1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PaymentsToAcquireShortTermInvestments" xlink:label="loc_PaymentsToAcquireShortTermInvestments" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_NetCashProvidedByUsedInInvestingActivities" xlink:to="loc_PaymentsToAcquireShortTermInvestments" order="60" use="optional" weight="-1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:label="loc_ProceedsFromSaleMaturityAndCollectionsOfInvestments" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_NetCashProvidedByUsedInInvestingActivities" xlink:to="loc_ProceedsFromSaleMaturityAndCollectionsOfInvestments" order="61" use="optional" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_PaymentsToAcquirePropertyPlantAndEquipment" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_NetCashProvidedByUsedInInvestingActivities" xlink:to="loc_PaymentsToAcquirePropertyPlantAndEquipment" order="62" use="optional" weight="-1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="loc_ProceedsFromSaleOfPropertyPlantAndEquipment" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_NetCashProvidedByUsedInInvestingActivities" xlink:to="loc_ProceedsFromSaleOfPropertyPlantAndEquipment" order="63" use="optional" weight="1" />
<loc xlink:type="locator" xlink:href="rxii-20120331.xsd#rxii_CashRefundedPaidForLeaseDeposit" xlink:label="rxii_CashRefundedPaidForLeaseDeposit" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_NetCashProvidedByUsedInInvestingActivities" xlink:to="rxii_CashRefundedPaidForLeaseDeposit" order="64" use="optional" weight="1" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="loc_NetCashProvidedByUsedInInvestingActivities" order="65" use="optional" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_NetCashProvidedByUsedInFinancingActivities" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_ProceedsFromIssuanceOfCommonStock" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_ProceedsFromIssuanceOfCommonStock" order="66" use="optional" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="loc_PaymentsForRepurchaseOfCommonStock" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_PaymentsForRepurchaseOfCommonStock" order="67" use="optional" weight="-1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_ProceedsFromStockOptionsExercised" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_ProceedsFromStockOptionsExercised" order="68" use="optional" weight="1" />
<loc xlink:type="locator" xlink:href="rxii-20120331.xsd#rxii_NetProceedsFromExerciseOfCommonStockWarrants" xlink:label="rxii_NetProceedsFromExerciseOfCommonStockWarrants" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_NetCashProvidedByUsedInFinancingActivities" xlink:to="rxii_NetProceedsFromExerciseOfCommonStockWarrants" order="69" use="optional" weight="1" />
<loc xlink:type="locator" xlink:href="rxii-20120331.xsd#rxii_CommonStockIssuedInConnectionWithEspp" xlink:label="rxii_CommonStockIssuedInConnectionWithEspp" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_NetCashProvidedByUsedInFinancingActivities" xlink:to="rxii_CommonStockIssuedInConnectionWithEspp" order="70" use="optional" weight="-1" />
<loc xlink:type="locator" xlink:href="rxii-20120331.xsd#rxii_NetProceedsFromIssuanceOfConvertibleNotesPayable" xlink:label="rxii_NetProceedsFromIssuanceOfConvertibleNotesPayable" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_NetCashProvidedByUsedInFinancingActivities" xlink:to="rxii_NetProceedsFromIssuanceOfConvertibleNotesPayable" order="71" use="optional" weight="-1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RepaymentsOfLongTermCapitalLeaseObligations" xlink:label="loc_RepaymentsOfLongTermCapitalLeaseObligations" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_RepaymentsOfLongTermCapitalLeaseObligations" order="72" use="optional" weight="-1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromRelatedPartyDebt" xlink:label="loc_ProceedsFromRelatedPartyDebt" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_ProceedsFromRelatedPartyDebt" order="73" use="optional" weight="1" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="loc_NetCashProvidedByUsedInFinancingActivities" order="74" use="optional" weight="1" />
</calculationLink>

<roleRef xlink:type="simple" xlink:href="rxii-20120331.xsd#DescriptionOfBusinessAndBasisOfPresentation" roleURI="http://rxipharma.com/role/DescriptionOfBusinessAndBasisOfPresentation" />
<calculationLink xlink:type="extended" xlink:role="http://rxipharma.com/role/DescriptionOfBusinessAndBasisOfPresentation" xlink:title="06001 - Disclosure - Description of Business and Basis of Presentation" />
<roleRef xlink:type="simple" xlink:href="rxii-20120331.xsd#RecentAccountingPronouncements" roleURI="http://rxipharma.com/role/RecentAccountingPronouncements" />
<calculationLink xlink:type="extended" xlink:role="http://rxipharma.com/role/RecentAccountingPronouncements" xlink:title="06002 - Disclosure - Recent Accounting Pronouncements" />
<roleRef xlink:type="simple" xlink:href="rxii-20120331.xsd#AptheraAcquisition" roleURI="http://rxipharma.com/role/AptheraAcquisition" />
<calculationLink xlink:type="extended" xlink:role="http://rxipharma.com/role/AptheraAcquisition" xlink:title="06003 - Disclosure - Apthera Acquisition" />
<roleRef xlink:type="simple" xlink:href="rxii-20120331.xsd#RxiSpinOut" roleURI="http://rxipharma.com/role/RxiSpinOut" />
<calculationLink xlink:type="extended" xlink:role="http://rxipharma.com/role/RxiSpinOut" xlink:title="06004 - Disclosure - RXi Spin-Out" />
<roleRef xlink:type="simple" xlink:href="rxii-20120331.xsd#FairValueMeasurements" roleURI="http://rxipharma.com/role/FairValueMeasurements" />
<calculationLink xlink:type="extended" xlink:role="http://rxipharma.com/role/FairValueMeasurements" xlink:title="06005 - Disclosure - Fair Value Measurements" />
<roleRef xlink:type="simple" xlink:href="rxii-20120331.xsd#StockBasedCompensation" roleURI="http://rxipharma.com/role/StockBasedCompensation" />
<calculationLink xlink:type="extended" xlink:role="http://rxipharma.com/role/StockBasedCompensation" xlink:title="06006 - Disclosure - Stock Based Compensation" />
<roleRef xlink:type="simple" xlink:href="rxii-20120331.xsd#NetLossPerShare" roleURI="http://rxipharma.com/role/NetLossPerShare" />
<calculationLink xlink:type="extended" xlink:role="http://rxipharma.com/role/NetLossPerShare" xlink:title="06007 - Disclosure - Net Loss Per Share" />
<roleRef xlink:type="simple" xlink:href="rxii-20120331.xsd#LicenseAgreements" roleURI="http://rxipharma.com/role/LicenseAgreements" />
<calculationLink xlink:type="extended" xlink:role="http://rxipharma.com/role/LicenseAgreements" xlink:title="06008 - Disclosure - License Agreements" />
<roleRef xlink:type="simple" xlink:href="rxii-20120331.xsd#StockholdersEquity" roleURI="http://rxipharma.com/role/StockholdersEquity" />
<calculationLink xlink:type="extended" xlink:role="http://rxipharma.com/role/StockholdersEquity" xlink:title="06009 - Disclosure - Stockholders' Equity" />
<roleRef xlink:type="simple" xlink:href="rxii-20120331.xsd#Litigation" roleURI="http://rxipharma.com/role/Litigation" />
<calculationLink xlink:type="extended" xlink:role="http://rxipharma.com/role/Litigation" xlink:title="06010 - Disclosure - Litigation" />
<roleRef xlink:type="simple" xlink:href="rxii-20120331.xsd#SubsequentEvents" roleURI="http://rxipharma.com/role/SubsequentEvents" />
<calculationLink xlink:type="extended" xlink:role="http://rxipharma.com/role/SubsequentEvents" xlink:title="06011 - Disclosure - Subsequent Events" />
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>13
<FILENAME>rxii-20120331_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- XBRL Generated with XBRLMark Copyright (C) by RR Donnelley -->
<!-- Based on XBRL 2.1 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
  <labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:label="rxii_DocumentAndEntityInformationAbstract" xlink:href="rxii-20120331.xsd#rxii_DocumentAndEntityInformationAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rxii_DocumentAndEntityInformationAbstract" xlink:to="rxii_DocumentAndEntityInformationAbstract_lbl" />
    <label xlink:type="resource" xlink:label="rxii_DocumentAndEntityInformationAbstract_lbl" xml:lang="en-US" xlink:role="http://www.xbrl.org/2003/role/label">Document and Entity Information [Abstract]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">ASSETS</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">Assets [Abstract]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Current assets:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Assets, Current [Abstract]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Restricted cash</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Restricted Cash and Cash Equivalents, Current</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US">Prepaid expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US">Prepaid Expense and Other Assets, Current</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Total current assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Assets, Current, Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Total current assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Equipment and furnishings, net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Property, Plant and Equipment, Net</label>
    <loc xlink:type="locator" xlink:href="rxii-20120331.xsd#rxii_InProcessResearchDevelopment" xlink:label="rxii_InProcessResearchDevelopment" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rxii_InProcessResearchDevelopment" xlink:to="rxii_InProcessResearchDevelopment_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rxii_InProcessResearchDevelopment_lbl" xml:lang="en-US">In Process Research Development</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="rxii_InProcessResearchDevelopment_lbl" xml:lang="en-US">In-process research and development</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rxii_InProcessResearchDevelopment_lbl" xml:lang="en-US">In-process research and development</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Goodwill" xlink:to="us-gaap_Goodwill_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_Goodwill_lbl" xml:lang="en-US">Goodwill</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Goodwill_lbl" xml:lang="en-US">Goodwill</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DepositsAssetsNoncurrent" xlink:label="us-gaap_DepositsAssetsNoncurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepositsAssetsNoncurrent" xlink:to="us-gaap_DepositsAssetsNoncurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DepositsAssetsNoncurrent_lbl" xml:lang="en-US">Deposits</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepositsAssetsNoncurrent_lbl" xml:lang="en-US">Deposits Assets, Noncurrent</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Total assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Assets, Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Total assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS' (DEFICIT) EQUITY</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">Liabilities and Equity [Abstract]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Current liabilities:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Liabilities, Current [Abstract]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US">Accounts payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US">Accounts Payable, Current</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accrued expenses and other current liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accrued Liabilities, Current</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CapitalLeaseObligationsCurrent" xlink:label="us-gaap_CapitalLeaseObligationsCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalLeaseObligationsCurrent" xlink:to="us-gaap_CapitalLeaseObligationsCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CapitalLeaseObligationsCurrent_lbl" xml:lang="en-US">Current maturities of capital lease obligations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CapitalLeaseObligationsCurrent_lbl" xml:lang="en-US">Capital Lease Obligations, Current</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ConvertibleNotesPayableCurrent" xlink:label="us-gaap_ConvertibleNotesPayableCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleNotesPayableCurrent" xlink:to="us-gaap_ConvertibleNotesPayableCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ConvertibleNotesPayableCurrent_lbl" xml:lang="en-US">Convertible notes payable, current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleNotesPayableCurrent_lbl" xml:lang="en-US">Convertible Notes Payable, Current</label>
    <loc xlink:type="locator" xlink:href="rxii-20120331.xsd#rxii_FairValueOfWarrantsPotentiallySettleableInCash" xlink:label="rxii_FairValueOfWarrantsPotentiallySettleableInCash" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rxii_FairValueOfWarrantsPotentiallySettleableInCash" xlink:to="rxii_FairValueOfWarrantsPotentiallySettleableInCash_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rxii_FairValueOfWarrantsPotentiallySettleableInCash_lbl" xml:lang="en-US">Fair Value of Warrants Potentially Settleable in Cash</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="rxii_FairValueOfWarrantsPotentiallySettleableInCash_lbl" xml:lang="en-US">Fair value of warrants potentially settleable in cash</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rxii_FairValueOfWarrantsPotentiallySettleableInCash_lbl" xml:lang="en-US">Fair value of warrants potentially settleable in cash</label>
    <loc xlink:type="locator" xlink:href="rxii-20120331.xsd#rxii_CurrentContingentPurchasePriceConsideration" xlink:label="rxii_CurrentContingentPurchasePriceConsideration" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rxii_CurrentContingentPurchasePriceConsideration" xlink:to="rxii_CurrentContingentPurchasePriceConsideration_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rxii_CurrentContingentPurchasePriceConsideration_lbl" xml:lang="en-US">Current Contingent Purchase Price Consideration</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="rxii_CurrentContingentPurchasePriceConsideration_lbl" xml:lang="en-US">Current contingent purchase price consideration</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rxii_CurrentContingentPurchasePriceConsideration_lbl" xml:lang="en-US">Current contingent purchase price consideration</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Total current liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Liabilities, Current, Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Total current liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CapitalLeaseObligationsNoncurrent" xlink:label="us-gaap_CapitalLeaseObligationsNoncurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalLeaseObligationsNoncurrent" xlink:to="us-gaap_CapitalLeaseObligationsNoncurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CapitalLeaseObligationsNoncurrent_lbl" xml:lang="en-US">Capital lease obligations, net of current maturities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CapitalLeaseObligationsNoncurrent_lbl" xml:lang="en-US">Capital Lease Obligations, Noncurrent</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ConvertibleLongTermNotesPayable" xlink:label="us-gaap_ConvertibleLongTermNotesPayable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleLongTermNotesPayable" xlink:to="us-gaap_ConvertibleLongTermNotesPayable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ConvertibleLongTermNotesPayable_lbl" xml:lang="en-US">Convertible notes payable, non-current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleLongTermNotesPayable_lbl" xml:lang="en-US">Convertible Notes Payable, Noncurrent</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent_lbl" xml:lang="en-US">Deferred tax liability, non-current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent_lbl" xml:lang="en-US">Deferred Tax Assets (Liabilities), Net, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent_lbl" xml:lang="en-US">Deferred tax liability, non-current</label>
    <loc xlink:type="locator" xlink:href="rxii-20120331.xsd#rxii_ContingentPurchasePriceConsiderationNetOfCurrentPortion" xlink:label="rxii_ContingentPurchasePriceConsiderationNetOfCurrentPortion" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rxii_ContingentPurchasePriceConsiderationNetOfCurrentPortion" xlink:to="rxii_ContingentPurchasePriceConsiderationNetOfCurrentPortion_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rxii_ContingentPurchasePriceConsiderationNetOfCurrentPortion_lbl" xml:lang="en-US">Contingent Purchase Price Consideration Net of Current Portion</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="rxii_ContingentPurchasePriceConsiderationNetOfCurrentPortion_lbl" xml:lang="en-US">Contingent purchase price consideration, net of current portion</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rxii_ContingentPurchasePriceConsiderationNetOfCurrentPortion_lbl" xml:lang="en-US">Contingent purchase price consideration, net of current portion</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">Total liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">Liabilities, Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">Total liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">Stockholders' (deficit) equity:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US">Preferred stock, $0.0001 par value; 5,000,000 shares authorized; no shares issued and outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US">Preferred Stock, Value, Issued</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Preferred stock, par value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US">Preferred stock, shares authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US">Preferred Stock, Shares Authorized</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US">Preferred stock, shares issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US">Preferred Stock, Shares Issued</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US">Preferred stock, shares outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US">Preferred Stock, Shares Outstanding</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common stock, $0.0001 par value; 125,000,000 shares authorized; 50,082,148 shares issued and 49,407,148 shares outstanding and 47,811,453 shares issued and 47,136,453 outstanding at March 31, 2012 and December 31, 2011, respectively</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common Stock, Value, Issued</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common stock, par value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common stock, shares authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common Stock, Shares Authorized</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common stock, shares issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common Stock, Shares, Issued</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common stock, shares outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common Stock, Shares, Outstanding</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xml:lang="en-US">Additional paid-in capital</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xml:lang="en-US">Additional Paid in Capital, Common Stock</label>
    <loc xlink:type="locator" xlink:href="rxii-20120331.xsd#rxii_DeficitAccumulatedDuringDevelopmentalStage" xlink:label="rxii_DeficitAccumulatedDuringDevelopmentalStage" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rxii_DeficitAccumulatedDuringDevelopmentalStage" xlink:to="rxii_DeficitAccumulatedDuringDevelopmentalStage_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rxii_DeficitAccumulatedDuringDevelopmentalStage_lbl" xml:lang="en-US">Deficit Accumulated During Developmental Stage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="rxii_DeficitAccumulatedDuringDevelopmentalStage_lbl" xml:lang="en-US">Deficit accumulated during the developmental stage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rxii_DeficitAccumulatedDuringDevelopmentalStage_lbl" xml:lang="en-US">Deficit accumulated during the developmental stage</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_TreasuryStockValue" xlink:label="us-gaap_TreasuryStockValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockValue" xlink:to="us-gaap_TreasuryStockValue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_TreasuryStockValue_lbl" xml:lang="en-US">Less treasury shares at cost, 675,000 shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TreasuryStockValue_lbl" xml:lang="en-US">Treasury Stock, Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_TreasuryStockValue_lbl" xml:lang="en-US">Less treasury shares at cost, 675,000 shares</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_TreasuryStockShares" xlink:label="us-gaap_TreasuryStockShares" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockShares" xlink:to="us-gaap_TreasuryStockShares_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_TreasuryStockShares_lbl" xml:lang="en-US">Treasury stock, shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TreasuryStockShares_lbl" xml:lang="en-US">Treasury Stock, Shares</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Total stockholders' (deficit) equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Stockholders' Equity Attributable to Parent, Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Total stockholders' (deficit) equity</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Total liabilities and stockholders' equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Liabilities and Equity, Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Total liabilities and stockholders' equity</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US">Expenses:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US">Operating Expenses [Abstract]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:to="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_lbl" xml:lang="en-US">Research and development expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_lbl" xml:lang="en-US">Research and Development Expense (Excluding Acquired in Process Cost)</label>
    <loc xlink:type="locator" xlink:href="rxii-20120331.xsd#rxii_ResearchAndDevelopmentEmployeeStockBasedCompensationExpense" xlink:label="rxii_ResearchAndDevelopmentEmployeeStockBasedCompensationExpense" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rxii_ResearchAndDevelopmentEmployeeStockBasedCompensationExpense" xlink:to="rxii_ResearchAndDevelopmentEmployeeStockBasedCompensationExpense_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rxii_ResearchAndDevelopmentEmployeeStockBasedCompensationExpense_lbl" xml:lang="en-US">Research and Development Employee Stock Based Compensation Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="rxii_ResearchAndDevelopmentEmployeeStockBasedCompensationExpense_lbl" xml:lang="en-US">Research and development employee stock-based compensation expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rxii_ResearchAndDevelopmentEmployeeStockBasedCompensationExpense_lbl" xml:lang="en-US">Research and development employee stock-based compensation expense</label>
    <loc xlink:type="locator" xlink:href="rxii-20120331.xsd#rxii_ResearchAndDevelopmentNonEmployeeStockBasedCompensationExpense" xlink:label="rxii_ResearchAndDevelopmentNonEmployeeStockBasedCompensationExpense" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rxii_ResearchAndDevelopmentNonEmployeeStockBasedCompensationExpense" xlink:to="rxii_ResearchAndDevelopmentNonEmployeeStockBasedCompensationExpense_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rxii_ResearchAndDevelopmentNonEmployeeStockBasedCompensationExpense_lbl" xml:lang="en-US">Research and Development Non Employee Stock Based Compensation Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="rxii_ResearchAndDevelopmentNonEmployeeStockBasedCompensationExpense_lbl" xml:lang="en-US">Research and development non-employee stock-based compensation expense (income)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rxii_ResearchAndDevelopmentNonEmployeeStockBasedCompensationExpense_lbl" xml:lang="en-US">Research and development non-employee stock-based compensation expense (income)</label>
    <loc xlink:type="locator" xlink:href="rxii-20120331.xsd#rxii_FairValueOfCommonStockInExchangeForResearchAndDevelopmentExpenses" xlink:label="rxii_FairValueOfCommonStockInExchangeForResearchAndDevelopmentExpenses" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rxii_FairValueOfCommonStockInExchangeForResearchAndDevelopmentExpenses" xlink:to="rxii_FairValueOfCommonStockInExchangeForResearchAndDevelopmentExpenses_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rxii_FairValueOfCommonStockInExchangeForResearchAndDevelopmentExpenses_lbl" xml:lang="en-US">Fair Value of Common Stock in Exchange for Research and Development Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="rxii_FairValueOfCommonStockInExchangeForResearchAndDevelopmentExpenses_lbl" xml:lang="en-US">Fair value of common stock issued in exchange for research and development expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rxii_FairValueOfCommonStockInExchangeForResearchAndDevelopmentExpenses_lbl" xml:lang="en-US">Fair value of common stock issued in exchange for research and development expense</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Total research and development expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and Development Expense, Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Total research and development expense</label>
    <loc xlink:type="locator" xlink:href="rxii-20120331.xsd#rxii_GeneralAndAdministrativeExpenses" xlink:label="rxii_GeneralAndAdministrativeExpenses" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rxii_GeneralAndAdministrativeExpenses" xlink:to="rxii_GeneralAndAdministrativeExpenses_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rxii_GeneralAndAdministrativeExpenses_lbl" xml:lang="en-US">General and Administrative Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="rxii_GeneralAndAdministrativeExpenses_lbl" xml:lang="en-US">General and administrative expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rxii_GeneralAndAdministrativeExpenses_lbl" xml:lang="en-US">General and administrative expense</label>
    <loc xlink:type="locator" xlink:href="rxii-20120331.xsd#rxii_GeneralAndAdministrativeEmployeeStockBasedCompensation" xlink:label="rxii_GeneralAndAdministrativeEmployeeStockBasedCompensation" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rxii_GeneralAndAdministrativeEmployeeStockBasedCompensation" xlink:to="rxii_GeneralAndAdministrativeEmployeeStockBasedCompensation_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rxii_GeneralAndAdministrativeEmployeeStockBasedCompensation_lbl" xml:lang="en-US">General and Administrative Employee Stock Based Compensation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="rxii_GeneralAndAdministrativeEmployeeStockBasedCompensation_lbl" xml:lang="en-US">General and administrative employee stock-based compensation expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rxii_GeneralAndAdministrativeEmployeeStockBasedCompensation_lbl" xml:lang="en-US">General and administrative employee stock-based compensation expense</label>
    <loc xlink:type="locator" xlink:href="rxii-20120331.xsd#rxii_FairValueOfCommonStockWarrantsIssuedForGeneralAndAdministrativeExpenses" xlink:label="rxii_FairValueOfCommonStockWarrantsIssuedForGeneralAndAdministrativeExpenses" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rxii_FairValueOfCommonStockWarrantsIssuedForGeneralAndAdministrativeExpenses" xlink:to="rxii_FairValueOfCommonStockWarrantsIssuedForGeneralAndAdministrativeExpenses_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rxii_FairValueOfCommonStockWarrantsIssuedForGeneralAndAdministrativeExpenses_lbl" xml:lang="en-US">Fair Value of Common Stock Warrants Issued for General and Administrative Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="rxii_FairValueOfCommonStockWarrantsIssuedForGeneralAndAdministrativeExpenses_lbl" xml:lang="en-US">Fair value of common stock warrants issued for general and administrative expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rxii_FairValueOfCommonStockWarrantsIssuedForGeneralAndAdministrativeExpenses_lbl" xml:lang="en-US">Fair value of common stock warrants issued for general and administrative expense</label>
    <loc xlink:type="locator" xlink:href="rxii-20120331.xsd#rxii_FairValueOfCommonStockIssuedInExchangeForGeneralAndAdministrativeExpenses" xlink:label="rxii_FairValueOfCommonStockIssuedInExchangeForGeneralAndAdministrativeExpenses" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rxii_FairValueOfCommonStockIssuedInExchangeForGeneralAndAdministrativeExpenses" xlink:to="rxii_FairValueOfCommonStockIssuedInExchangeForGeneralAndAdministrativeExpenses_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rxii_FairValueOfCommonStockIssuedInExchangeForGeneralAndAdministrativeExpenses_lbl" xml:lang="en-US">Fair Value of Common Stock Issued in Exchange for General and Administrative Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="rxii_FairValueOfCommonStockIssuedInExchangeForGeneralAndAdministrativeExpenses_lbl" xml:lang="en-US">Fair value of common stock issued in exchange for general and administrative expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rxii_FairValueOfCommonStockIssuedInExchangeForGeneralAndAdministrativeExpenses_lbl" xml:lang="en-US">Fair value of common stock issued in exchange for general and administrative expense</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">Total general and administrative expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General and Administrative Expense, Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">Total general and administrative expense</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US">Operating loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US">Operating Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US">Operating loss</label>
    <loc xlink:type="locator" xlink:href="rxii-20120331.xsd#rxii_InterestIncome" xlink:label="rxii_InterestIncome" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rxii_InterestIncome" xlink:to="rxii_InterestIncome_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rxii_InterestIncome_lbl" xml:lang="en-US">Interest Income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="rxii_InterestIncome_lbl" xml:lang="en-US">Interest (expense) income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rxii_InterestIncome_lbl" xml:lang="en-US">Interest (expense) income</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xml:lang="en-US">Other (expense) income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xml:lang="en-US">Other Nonoperating Income (Expense)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net Income (Loss) Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net loss</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xml:lang="en-US">Net Loss Per Share [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xml:lang="en-US">Net loss per common share:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xml:lang="en-US">Basic and diluted loss per share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xml:lang="en-US">Earnings Per Share, Basic and Diluted</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" xml:lang="en-US">Weighted average common shares outstanding:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted [Abstract]</label>
    <loc xlink:type="locator" xlink:href="rxii-20120331.xsd#rxii_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="rxii_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rxii_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="rxii_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rxii_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xml:lang="en-US">Weighted Average Number of Share Outstanding Basic and Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="rxii_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xml:lang="en-US">Basic and diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rxii_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xml:lang="en-US">Basic and diluted</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from operating activities:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <loc xlink:type="locator" xlink:href="rxii-20120331.xsd#rxii_NetIncomeLossIncludingOther" xlink:label="rxii_NetIncomeLossIncludingOther" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rxii_NetIncomeLossIncludingOther" xlink:to="rxii_NetIncomeLossIncludingOther_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rxii_NetIncomeLossIncludingOther_lbl" xml:lang="en-US">Net Income Loss Including Other</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="rxii_NetIncomeLossIncludingOther_lbl" xml:lang="en-US">Net loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rxii_NetIncomeLossIncludingOther_lbl" xml:lang="en-US">Net loss</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xml:lang="en-US">Depreciation and amortization expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xml:lang="en-US">Depreciation, Depletion and Amortization</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets" xlink:label="us-gaap_GainLossOnDispositionOfAssets" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnDispositionOfAssets" xlink:to="us-gaap_GainLossOnDispositionOfAssets_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_GainLossOnDispositionOfAssets_lbl" xml:lang="en-US">Loss on disposal of equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainLossOnDispositionOfAssets_lbl" xml:lang="en-US">Gain (Loss) on Disposition of Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_GainLossOnDispositionOfAssets_lbl" xml:lang="en-US">Loss on disposal of equipment</label>
    <loc xlink:type="locator" xlink:href="rxii-20120331.xsd#rxii_NonCashRentExpense" xlink:label="rxii_NonCashRentExpense" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rxii_NonCashRentExpense" xlink:to="rxii_NonCashRentExpense_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rxii_NonCashRentExpense_lbl" xml:lang="en-US">Non Cash Rent Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="rxii_NonCashRentExpense_lbl" xml:lang="en-US">Non-cash rent expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rxii_NonCashRentExpense_lbl" xml:lang="en-US">Non-cash rent expense</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl" xml:lang="en-US">Accretion and receipt of bond discount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl" xml:lang="en-US">Accretion (Amortization) of Discounts and Premiums, Investments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl" xml:lang="en-US">Accretion and receipt of bond discount</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Non-cash share-based compensation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Share-based Compensation</label>
    <loc xlink:type="locator" xlink:href="rxii-20120331.xsd#rxii_LossOnExchangeOfEquityInstruments" xlink:label="rxii_LossOnExchangeOfEquityInstruments" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rxii_LossOnExchangeOfEquityInstruments" xlink:to="rxii_LossOnExchangeOfEquityInstruments_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rxii_LossOnExchangeOfEquityInstruments_lbl" xml:lang="en-US">Loss on Exchange of Equity Instruments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="rxii_LossOnExchangeOfEquityInstruments_lbl" xml:lang="en-US">Loss on exchange of equity instruments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rxii_LossOnExchangeOfEquityInstruments_lbl" xml:lang="en-US">Loss on exchange of equity instruments</label>
    <loc xlink:type="locator" xlink:href="rxii-20120331.xsd#rxii_FairValueOfSharesMandatorilyRedeemableForCashUponExerciseOfWarrants" xlink:label="rxii_FairValueOfSharesMandatorilyRedeemableForCashUponExerciseOfWarrants" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rxii_FairValueOfSharesMandatorilyRedeemableForCashUponExerciseOfWarrants" xlink:to="rxii_FairValueOfSharesMandatorilyRedeemableForCashUponExerciseOfWarrants_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rxii_FairValueOfSharesMandatorilyRedeemableForCashUponExerciseOfWarrants_lbl" xml:lang="en-US">Fair Value of Shares Mandatorily Redeemable for Cash Upon Exercise of Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="rxii_FairValueOfSharesMandatorilyRedeemableForCashUponExerciseOfWarrants_lbl" xml:lang="en-US">Fair value of shares mandatorily redeemable for cash upon exercise of warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rxii_FairValueOfSharesMandatorilyRedeemableForCashUponExerciseOfWarrants_lbl" xml:lang="en-US">Fair value of shares mandatorily redeemable for cash upon exercise of warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="rxii_FairValueOfSharesMandatorilyRedeemableForCashUponExerciseOfWarrants_lbl" xml:lang="en-US">Fair value of shares mandatorily redeemable for cash upon exercise of warrants</label>
    <loc xlink:type="locator" xlink:href="rxii-20120331.xsd#rxii_FairValueOfParentCompanyCommonStockIssuedInExchangeForServices" xlink:label="rxii_FairValueOfParentCompanyCommonStockIssuedInExchangeForServices" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rxii_FairValueOfParentCompanyCommonStockIssuedInExchangeForServices" xlink:to="rxii_FairValueOfParentCompanyCommonStockIssuedInExchangeForServices_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rxii_FairValueOfParentCompanyCommonStockIssuedInExchangeForServices_lbl" xml:lang="en-US">Fair Value of Parent Company Common Stock Issued in Exchange for Services</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="rxii_FairValueOfParentCompanyCommonStockIssuedInExchangeForServices_lbl" xml:lang="en-US">Fair value of common stock warrants issued in exchange for services</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rxii_FairValueOfParentCompanyCommonStockIssuedInExchangeForServices_lbl" xml:lang="en-US">Fair value of common stock warrants issued in exchange for services</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:to="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_lbl" xml:lang="en-US">Fair value of common stock issued in exchange for services</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_lbl" xml:lang="en-US">Issuance of Stock and Warrants for Services or Claims</label>
    <loc xlink:type="locator" xlink:href="rxii-20120331.xsd#rxii_ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings" xlink:label="rxii_ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rxii_ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings" xlink:to="rxii_ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rxii_ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings_lbl" xml:lang="en-US">Change in Fair Value of Common Stock Warrants Issued in Connection with Various Equity Financings</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="rxii_ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings_lbl" xml:lang="en-US">Change in fair value of common stock warrants issued in connection with various equity financings</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rxii_ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings_lbl" xml:lang="en-US">Change in fair value of common stock warrants issued in connection with various equity financings</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="rxii_ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings_lbl" xml:lang="en-US">Change in fair value of common stock warrants issued in connection with various equity financings</label>
    <loc xlink:type="locator" xlink:href="rxii-20120331.xsd#rxii_FairValueOfCommonStockIssuedInExchangeForLicensingRights" xlink:label="rxii_FairValueOfCommonStockIssuedInExchangeForLicensingRights" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rxii_FairValueOfCommonStockIssuedInExchangeForLicensingRights" xlink:to="rxii_FairValueOfCommonStockIssuedInExchangeForLicensingRights_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rxii_FairValueOfCommonStockIssuedInExchangeForLicensingRights_lbl" xml:lang="en-US">Fair Value of Common Stock Issued in Exchange for Licensing Rights</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="rxii_FairValueOfCommonStockIssuedInExchangeForLicensingRights_lbl" xml:lang="en-US">Fair value of common stock issued in exchange for licensing rights</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rxii_FairValueOfCommonStockIssuedInExchangeForLicensingRights_lbl" xml:lang="en-US">Fair value of common stock issued in exchange for licensing rights</label>
    <loc xlink:type="locator" xlink:href="rxii-20120331.xsd#rxii_ChangeInFairValueOfContingentPurchaseConsideration" xlink:label="rxii_ChangeInFairValueOfContingentPurchaseConsideration" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rxii_ChangeInFairValueOfContingentPurchaseConsideration" xlink:to="rxii_ChangeInFairValueOfContingentPurchaseConsideration_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rxii_ChangeInFairValueOfContingentPurchaseConsideration_lbl" xml:lang="en-US">Change in Fair Value of Contingent Purchase Consideration</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="rxii_ChangeInFairValueOfContingentPurchaseConsideration_lbl" xml:lang="en-US">Change in fair value of contingent purchase consideration</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rxii_ChangeInFairValueOfContingentPurchaseConsideration_lbl" xml:lang="en-US">Change in fair value of contingent purchase consideration</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="rxii_ChangeInFairValueOfContingentPurchaseConsideration_lbl" xml:lang="en-US">Change in fair value of contingent purchase consideration</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Changes in assets and liabilities:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US">Prepaid expenses and other current assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US">Prepaid expenses and other current assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xml:lang="en-US">Accounts payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xml:lang="en-US">Increase (Decrease) in Accounts Payable</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInDueToOtherRelatedPartiesCurrent" xlink:label="us-gaap_IncreaseDecreaseInDueToOtherRelatedPartiesCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDueToOtherRelatedPartiesCurrent" xlink:to="us-gaap_IncreaseDecreaseInDueToOtherRelatedPartiesCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInDueToOtherRelatedPartiesCurrent_lbl" xml:lang="en-US">Due to former parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInDueToOtherRelatedPartiesCurrent_lbl" xml:lang="en-US">Increase (Decrease) in Due to Other Related Parties, Current</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xml:lang="en-US">Accrued expenses and other current liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net cash used in operating activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net cash used in operating activities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from investing activities:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInRestrictedCash" xlink:label="us-gaap_IncreaseDecreaseInRestrictedCash" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInRestrictedCash" xlink:to="us-gaap_IncreaseDecreaseInRestrictedCash_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInRestrictedCash_lbl" xml:lang="en-US">Change in restricted cash</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInRestrictedCash_lbl" xml:lang="en-US">Increase (Decrease) in Restricted Cash</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInRestrictedCash_lbl" xml:lang="en-US">Change in restricted cash</label>
    <loc xlink:type="locator" xlink:href="rxii-20120331.xsd#rxii_CashReceivedInAcquisition" xlink:label="rxii_CashReceivedInAcquisition" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rxii_CashReceivedInAcquisition" xlink:to="rxii_CashReceivedInAcquisition_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rxii_CashReceivedInAcquisition_lbl" xml:lang="en-US">Cash Received in Acquisition</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="rxii_CashReceivedInAcquisition_lbl" xml:lang="en-US">Cash received in acquisition</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rxii_CashReceivedInAcquisition_lbl" xml:lang="en-US">Cash received in acquisition</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="rxii_CashReceivedInAcquisition_lbl" xml:lang="en-US">Cash received in acquisition</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PaymentsToAcquireShortTermInvestments" xlink:label="us-gaap_PaymentsToAcquireShortTermInvestments" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireShortTermInvestments" xlink:to="us-gaap_PaymentsToAcquireShortTermInvestments_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PaymentsToAcquireShortTermInvestments_lbl" xml:lang="en-US">Purchase of short-term investments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireShortTermInvestments_lbl" xml:lang="en-US">Payments to Acquire Short-term Investments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquireShortTermInvestments_lbl" xml:lang="en-US">Purchase of short-term investments</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:label="us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:to="us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_lbl" xml:lang="en-US">Maturities of short-term investments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_lbl" xml:lang="en-US">Proceeds from Sale, Maturity and Collection of Investments</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Cash paid for purchase of equipment and furnishings</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Cash paid for purchase of equipment and furnishings</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:to="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_lbl" xml:lang="en-US">Disposal of equipment and furnishings</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_lbl" xml:lang="en-US">Proceeds from Sale of Property, Plant, and Equipment</label>
    <loc xlink:type="locator" xlink:href="rxii-20120331.xsd#rxii_CashRefundedPaidForLeaseDeposit" xlink:label="rxii_CashRefundedPaidForLeaseDeposit" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rxii_CashRefundedPaidForLeaseDeposit" xlink:to="rxii_CashRefundedPaidForLeaseDeposit_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rxii_CashRefundedPaidForLeaseDeposit_lbl" xml:lang="en-US">Cash Refunded Paid for Lease Deposit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="rxii_CashRefundedPaidForLeaseDeposit_lbl" xml:lang="en-US">Cash refunded (paid) for lease deposit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rxii_CashRefundedPaidForLeaseDeposit_lbl" xml:lang="en-US">Cash refunded (paid) for lease deposit</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net cash used in investing activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net cash used in investing activities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from financing activities:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Net proceeds from issuance of common stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Proceeds from Issuance of Common Stock</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="us-gaap_PaymentsForRepurchaseOfCommonStock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:to="us-gaap_PaymentsForRepurchaseOfCommonStock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PaymentsForRepurchaseOfCommonStock_lbl" xml:lang="en-US">Cash paid for repurchase of common stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForRepurchaseOfCommonStock_lbl" xml:lang="en-US">Payments for Repurchase of Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsForRepurchaseOfCommonStock_lbl" xml:lang="en-US">Cash paid for repurchase of common stock</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xml:lang="en-US">Net proceeds from exercise of common stock options</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xml:lang="en-US">Proceeds from Stock Options Exercised</label>
    <loc xlink:type="locator" xlink:href="rxii-20120331.xsd#rxii_NetProceedsFromExerciseOfCommonStockWarrants" xlink:label="rxii_NetProceedsFromExerciseOfCommonStockWarrants" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rxii_NetProceedsFromExerciseOfCommonStockWarrants" xlink:to="rxii_NetProceedsFromExerciseOfCommonStockWarrants_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rxii_NetProceedsFromExerciseOfCommonStockWarrants_lbl" xml:lang="en-US">Net Proceeds from Exercise of Common Stock Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="rxii_NetProceedsFromExerciseOfCommonStockWarrants_lbl" xml:lang="en-US">Net proceeds from exercise of common stock warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rxii_NetProceedsFromExerciseOfCommonStockWarrants_lbl" xml:lang="en-US">Net proceeds from exercise of common stock warrants</label>
    <loc xlink:type="locator" xlink:href="rxii-20120331.xsd#rxii_CommonStockIssuedInConnectionWithEspp" xlink:label="rxii_CommonStockIssuedInConnectionWithEspp" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rxii_CommonStockIssuedInConnectionWithEspp" xlink:to="rxii_CommonStockIssuedInConnectionWithEspp_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rxii_CommonStockIssuedInConnectionWithEspp_lbl" xml:lang="en-US">Common Stock Issued in Connection with Espp</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="rxii_CommonStockIssuedInConnectionWithEspp_lbl" xml:lang="en-US">Common stock issued in connection with ESPP</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rxii_CommonStockIssuedInConnectionWithEspp_lbl" xml:lang="en-US">Common stock issued in connection with ESPP</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="rxii_CommonStockIssuedInConnectionWithEspp_lbl" xml:lang="en-US">Common stock issued in connection with ESPP</label>
    <loc xlink:type="locator" xlink:href="rxii-20120331.xsd#rxii_NetProceedsFromIssuanceOfConvertibleNotesPayable" xlink:label="rxii_NetProceedsFromIssuanceOfConvertibleNotesPayable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rxii_NetProceedsFromIssuanceOfConvertibleNotesPayable" xlink:to="rxii_NetProceedsFromIssuanceOfConvertibleNotesPayable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rxii_NetProceedsFromIssuanceOfConvertibleNotesPayable_lbl" xml:lang="en-US">Net Proceeds from Issuance of Convertible Notes Payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="rxii_NetProceedsFromIssuanceOfConvertibleNotesPayable_lbl" xml:lang="en-US">Net proceeds from issuance of convertible notes payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rxii_NetProceedsFromIssuanceOfConvertibleNotesPayable_lbl" xml:lang="en-US">Net proceeds from issuance of convertible notes payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="rxii_NetProceedsFromIssuanceOfConvertibleNotesPayable_lbl" xml:lang="en-US">Net proceeds from issuance of convertible notes payable</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RepaymentsOfLongTermCapitalLeaseObligations" xlink:label="us-gaap_RepaymentsOfLongTermCapitalLeaseObligations" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfLongTermCapitalLeaseObligations" xlink:to="us-gaap_RepaymentsOfLongTermCapitalLeaseObligations_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RepaymentsOfLongTermCapitalLeaseObligations_lbl" xml:lang="en-US">Repayments of capital lease obligations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfLongTermCapitalLeaseObligations_lbl" xml:lang="en-US">Repayments of Long-term Capital Lease Obligations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RepaymentsOfLongTermCapitalLeaseObligations_lbl" xml:lang="en-US">Repayments of capital lease obligations</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromRelatedPartyDebt" xlink:label="us-gaap_ProceedsFromRelatedPartyDebt" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromRelatedPartyDebt" xlink:to="us-gaap_ProceedsFromRelatedPartyDebt_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromRelatedPartyDebt_lbl" xml:lang="en-US">Cash advances from former parent company, net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromRelatedPartyDebt_lbl" xml:lang="en-US">Proceeds from Related Party Debt</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net cash provided by financing activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net cash provided by financing activities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl" xml:lang="en-US">Net (decrease) increase in cash and cash equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl" xml:lang="en-US">Cash and Cash Equivalents, Period Increase (Decrease)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl" xml:lang="en-US">Net (decrease) increase in cash and cash equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalents at the beginning of period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalents at end of period</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US">Supplemental disclosure of cash flow information:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromInterestReceived" xlink:label="us-gaap_ProceedsFromInterestReceived" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromInterestReceived" xlink:to="us-gaap_ProceedsFromInterestReceived_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromInterestReceived_lbl" xml:lang="en-US">Cash received during the period for interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromInterestReceived_lbl" xml:lang="en-US">Proceeds from Interest Received</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_InterestPaid" xlink:label="us-gaap_InterestPaid" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaid" xlink:to="us-gaap_InterestPaid_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_InterestPaid_lbl" xml:lang="en-US">Cash paid during the period for interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPaid_lbl" xml:lang="en-US">Interest Paid</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xml:lang="en-US">Supplemental disclosure of non-cash investing and financing activities:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xml:lang="en-US">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssued1" xlink:label="us-gaap_StockIssued1" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssued1" xlink:to="us-gaap_StockIssued1_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssued1_lbl" xml:lang="en-US">Settlement of corporate formation expenses in exchange for common stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssued1_lbl" xml:lang="en-US">Stock Issued</label>
    <loc xlink:type="locator" xlink:href="rxii-20120331.xsd#rxii_FairValueOfWarrantsIssuedInConnectionWithCommonStockRecordedAsCostOfEquity" xlink:label="rxii_FairValueOfWarrantsIssuedInConnectionWithCommonStockRecordedAsCostOfEquity" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rxii_FairValueOfWarrantsIssuedInConnectionWithCommonStockRecordedAsCostOfEquity" xlink:to="rxii_FairValueOfWarrantsIssuedInConnectionWithCommonStockRecordedAsCostOfEquity_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rxii_FairValueOfWarrantsIssuedInConnectionWithCommonStockRecordedAsCostOfEquity_lbl" xml:lang="en-US">Fair Value of Warrants Issued in Connection with Common Stock Recorded As Cost of Equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="rxii_FairValueOfWarrantsIssuedInConnectionWithCommonStockRecordedAsCostOfEquity_lbl" xml:lang="en-US">Fair value of warrants issued in connection with common stock recorded as a cost of equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rxii_FairValueOfWarrantsIssuedInConnectionWithCommonStockRecordedAsCostOfEquity_lbl" xml:lang="en-US">Fair value of warrants issued in connection with common stock recorded as a cost of equity</label>
    <loc xlink:type="locator" xlink:href="rxii-20120331.xsd#rxii_IssuanceOfCommonStockInExchangeOfOutstandingWarrants" xlink:label="rxii_IssuanceOfCommonStockInExchangeOfOutstandingWarrants" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rxii_IssuanceOfCommonStockInExchangeOfOutstandingWarrants" xlink:to="rxii_IssuanceOfCommonStockInExchangeOfOutstandingWarrants_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rxii_IssuanceOfCommonStockInExchangeOfOutstandingWarrants_lbl" xml:lang="en-US">Issuance of Common Stock in Exchange of Outstanding Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="rxii_IssuanceOfCommonStockInExchangeOfOutstandingWarrants_lbl" xml:lang="en-US">Issuance of common stock in exchange for outstanding warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rxii_IssuanceOfCommonStockInExchangeOfOutstandingWarrants_lbl" xml:lang="en-US">Issuance of common stock in exchange for outstanding warrants</label>
    <loc xlink:type="locator" xlink:href="rxii-20120331.xsd#rxii_FairValueOfSharesMandatorilyRedeemableForCashUponExerciseOfWarrant" xlink:label="rxii_FairValueOfSharesMandatorilyRedeemableForCashUponExerciseOfWarrant" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rxii_FairValueOfSharesMandatorilyRedeemableForCashUponExerciseOfWarrant" xlink:to="rxii_FairValueOfSharesMandatorilyRedeemableForCashUponExerciseOfWarrant_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rxii_FairValueOfSharesMandatorilyRedeemableForCashUponExerciseOfWarrant_lbl" xml:lang="en-US">Fair Value of Shares Mandatorily Redeemable for Cash Upon Exercise of Warrant</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="rxii_FairValueOfSharesMandatorilyRedeemableForCashUponExerciseOfWarrant_lbl" xml:lang="en-US">Fair value of shares mandatorily redeemable for cash upon the exercise of warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rxii_FairValueOfSharesMandatorilyRedeemableForCashUponExerciseOfWarrant_lbl" xml:lang="en-US">Fair value of shares mandatorily redeemable for cash upon the exercise of warrants</label>
    <loc xlink:type="locator" xlink:href="rxii-20120331.xsd#rxii_ReclassificationOfWarrantLiabilityUponExercise" xlink:label="rxii_ReclassificationOfWarrantLiabilityUponExercise" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rxii_ReclassificationOfWarrantLiabilityUponExercise" xlink:to="rxii_ReclassificationOfWarrantLiabilityUponExercise_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rxii_ReclassificationOfWarrantLiabilityUponExercise_lbl" xml:lang="en-US">Reclassification of Warrant Liability Upon Exercise</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="rxii_ReclassificationOfWarrantLiabilityUponExercise_lbl" xml:lang="en-US">Reclassification of warrant liability upon exercise</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rxii_ReclassificationOfWarrantLiabilityUponExercise_lbl" xml:lang="en-US">Reclassification of warrant liability upon exercise</label>
    <loc xlink:type="locator" xlink:href="rxii-20120331.xsd#rxii_AllocationOfManagementExpenses" xlink:label="rxii_AllocationOfManagementExpenses" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rxii_AllocationOfManagementExpenses" xlink:to="rxii_AllocationOfManagementExpenses_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rxii_AllocationOfManagementExpenses_lbl" xml:lang="en-US">Allocation of Management Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="rxii_AllocationOfManagementExpenses_lbl" xml:lang="en-US">Allocation of management expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rxii_AllocationOfManagementExpenses_lbl" xml:lang="en-US">Allocation of management expenses</label>
    <loc xlink:type="locator" xlink:href="rxii-20120331.xsd#rxii_EquipmentAndFurnishingsExchangedForCommonStock" xlink:label="rxii_EquipmentAndFurnishingsExchangedForCommonStock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rxii_EquipmentAndFurnishingsExchangedForCommonStock" xlink:to="rxii_EquipmentAndFurnishingsExchangedForCommonStock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rxii_EquipmentAndFurnishingsExchangedForCommonStock_lbl" xml:lang="en-US">Equipment and Furnishings Exchanged for Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="rxii_EquipmentAndFurnishingsExchangedForCommonStock_lbl" xml:lang="en-US">Equipment and furnishings exchanged for common stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rxii_EquipmentAndFurnishingsExchangedForCommonStock_lbl" xml:lang="en-US">Equipment and furnishings exchanged for common stock</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_FairValueOfAssetsAcquired" xlink:label="us-gaap_FairValueOfAssetsAcquired" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOfAssetsAcquired" xlink:to="us-gaap_FairValueOfAssetsAcquired_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FairValueOfAssetsAcquired_lbl" xml:lang="en-US">Equipment and furnishings acquired through capital lease</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueOfAssetsAcquired_lbl" xml:lang="en-US">Fair Value of Assets Acquired</label>
    <loc xlink:type="locator" xlink:href="rxii-20120331.xsd#rxii_ValueOfRestrictedStockUnitsAndCommonStockIssuedInLieuOfCashBonuses" xlink:label="rxii_ValueOfRestrictedStockUnitsAndCommonStockIssuedInLieuOfCashBonuses" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rxii_ValueOfRestrictedStockUnitsAndCommonStockIssuedInLieuOfCashBonuses" xlink:to="rxii_ValueOfRestrictedStockUnitsAndCommonStockIssuedInLieuOfCashBonuses_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rxii_ValueOfRestrictedStockUnitsAndCommonStockIssuedInLieuOfCashBonuses_lbl" xml:lang="en-US">Value of Restricted Stock Units and Common Stock Issued in Lieu of Cash Bonuses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="rxii_ValueOfRestrictedStockUnitsAndCommonStockIssuedInLieuOfCashBonuses_lbl" xml:lang="en-US">Value of restricted stock units and common stock issued in lieu of bonuses included in accrued expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rxii_ValueOfRestrictedStockUnitsAndCommonStockIssuedInLieuOfCashBonuses_lbl" xml:lang="en-US">Value of restricted stock units and common stock issued in lieu of bonuses included in accrued expenses</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CapitalLeaseObligationsIncurred" xlink:label="us-gaap_CapitalLeaseObligationsIncurred" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalLeaseObligationsIncurred" xlink:to="us-gaap_CapitalLeaseObligationsIncurred_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CapitalLeaseObligationsIncurred_lbl" xml:lang="en-US">Non-cash lease deposit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CapitalLeaseObligationsIncurred_lbl" xml:lang="en-US">Capital Lease Obligations Incurred</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:label="us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:to="us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_lbl" xml:lang="en-US">Description of Business and Basis of Presentation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_lbl" xml:lang="en-US">Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">Description of Business and Basis of Presentation [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">Description of Business and Basis of Presentation [Abstract]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccountingChangesAndErrorCorrectionsTextBlock" xlink:label="us-gaap_AccountingChangesAndErrorCorrectionsTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingChangesAndErrorCorrectionsTextBlock" xlink:to="us-gaap_AccountingChangesAndErrorCorrectionsTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AccountingChangesAndErrorCorrectionsTextBlock_lbl" xml:lang="en-US">Recent Accounting Pronouncements</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingChangesAndErrorCorrectionsTextBlock_lbl" xml:lang="en-US">Accounting Changes and Error Corrections [Text Block]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccountingChangesAndErrorCorrectionsAbstract" xlink:label="us-gaap_AccountingChangesAndErrorCorrectionsAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingChangesAndErrorCorrectionsAbstract" xlink:to="us-gaap_AccountingChangesAndErrorCorrectionsAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AccountingChangesAndErrorCorrectionsAbstract_lbl" xml:lang="en-US">Recent Accounting Pronouncements [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingChangesAndErrorCorrectionsAbstract_lbl" xml:lang="en-US">Recent Accounting Pronouncements [Abstract]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock" xlink:label="us-gaap_BusinessCombinationDisclosureTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationDisclosureTextBlock" xlink:to="us-gaap_BusinessCombinationDisclosureTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_BusinessCombinationDisclosureTextBlock_lbl" xml:lang="en-US">Apthera Acquisition</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationDisclosureTextBlock_lbl" xml:lang="en-US">Business Combination Disclosure [Text Block]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="us-gaap_BusinessCombinationsAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationsAbstract" xlink:to="us-gaap_BusinessCombinationsAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_BusinessCombinationsAbstract_lbl" xml:lang="en-US">Apthera Acquisition [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationsAbstract_lbl" xml:lang="en-US">Apthera Acquisition [Abstract]</label>
    <loc xlink:type="locator" xlink:href="rxii-20120331.xsd#rxii_PartnerCompanyTextBlock" xlink:label="rxii_PartnerCompanyTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rxii_PartnerCompanyTextBlock" xlink:to="rxii_PartnerCompanyTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rxii_PartnerCompanyTextBlock_lbl" xml:lang="en-US">Partner Company [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="rxii_PartnerCompanyTextBlock_lbl" xml:lang="en-US">RXi Spin-Out</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rxii_PartnerCompanyTextBlock_lbl" xml:lang="en-US">RXi Spin-Out</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xml:lang="en-US">RXi Spin-Out [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xml:lang="en-US">RXi Spin-Out [Abstract]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:label="us-gaap_FinancialInstrumentsDisclosureTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:to="us-gaap_FinancialInstrumentsDisclosureTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FinancialInstrumentsDisclosureTextBlock_lbl" xml:lang="en-US">Fair Value Measurements</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinancialInstrumentsDisclosureTextBlock_lbl" xml:lang="en-US">Financial Instruments Disclosure [Text Block]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:label="us-gaap_InvestmentsAllOtherInvestmentsAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:to="us-gaap_InvestmentsAllOtherInvestmentsAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_InvestmentsAllOtherInvestmentsAbstract_lbl" xml:lang="en-US">Fair Value Measurements [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentsAllOtherInvestmentsAbstract_lbl" xml:lang="en-US">Fair Value Measurements [Abstract]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US">Stock Based Compensation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US">Disclosure of Compensation Related Costs, Share-based Payments [Text Block]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xml:lang="en-US">Stock Based Compensation [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xml:lang="en-US">Stock Based Compensation [Abstract]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xml:lang="en-US">Net Loss Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xml:lang="en-US">Earnings Per Share [Text Block]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:to="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl" xml:lang="en-US">License Agreements</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl" xml:lang="en-US">Intangible Assets Disclosure [Text Block]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl" xml:lang="en-US">License Agreements [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl" xml:lang="en-US">License Agreements [Abstract]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">Stockholders' Equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EquityAbstract_lbl" xml:lang="en-US">Stockholders' Equity [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityAbstract_lbl" xml:lang="en-US">Stockholders' Equity [Abstract]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US">Litigation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US">Litigation [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US">Litigation [Abstract]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US">Subsequent Events</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US">Subsequent Events [Text Block]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US">Subsequent Events [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US">Subsequent Events [Abstract]</label>
    <loc xlink:type="locator" xlink:label="dei_AmendmentFlag" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_AmendmentFlag" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <label xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</label>
    <loc xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_CurrentFiscalYearEndDate" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" />
    <label xlink:type="resource" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US" xlink:role="http://www.xbrl.org/2003/role/label">Current Fiscal Year End Date</label>
    <loc xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentPeriodEndDate" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <label xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</label>
    <loc xlink:type="locator" xlink:label="dei_DocumentType" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentType" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <label xlink:type="resource" xlink:label="dei_DocumentType_lbl" xml:lang="en-US" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</label>
    <loc xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityCentralIndexKey" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <label xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</label>
    <loc xlink:type="locator" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityCommonStockSharesOutstanding" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" />
    <label xlink:type="resource" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US" xlink:role="http://www.xbrl.org/2003/role/label">Entity Common Stock, Shares Outstanding</label>
    <loc xlink:type="locator" xlink:label="dei_EntityFilerCategory" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityFilerCategory" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" />
    <label xlink:type="resource" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US" xlink:role="http://www.xbrl.org/2003/role/label">Entity Filer Category</label>
    <loc xlink:type="locator" xlink:label="dei_EntityRegistrantName" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityRegistrantName" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <label xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</label>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentFiscalPeriodFocus" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" />
    <label xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Period Focus</label>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalYearFocus" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentFiscalYearFocus" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" />
    <label xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Year Focus</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">Condensed Consolidated Balance Sheets [Abstract]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US">Condensed Consolidated Statements of Expenses [Abstract]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Condensed Consolidated Statements of Cash Flows [Abstract]</label>
  </labelLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>14
<FILENAME>rxii-20120331_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- XBRL Generated with XBRLMark Copyright (C) by RR Donnelley -->
<!-- Based on XBRL 2.1 -->
<linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink">
<roleRef roleURI="http://rxipharma.com/role/DocumentAndEntityInformation" xlink:type="simple" xlink:href="rxii-20120331.xsd#DocumentAndEntityInformation" />
<roleRef xlink:type="simple" xlink:href="rxii-20120331.xsd#DescriptionOfBusinessAndBasisOfPresentation" roleURI="http://rxipharma.com/role/DescriptionOfBusinessAndBasisOfPresentation" />
<roleRef xlink:type="simple" xlink:href="rxii-20120331.xsd#RecentAccountingPronouncements" roleURI="http://rxipharma.com/role/RecentAccountingPronouncements" />
<roleRef xlink:type="simple" xlink:href="rxii-20120331.xsd#AptheraAcquisition" roleURI="http://rxipharma.com/role/AptheraAcquisition" />
<roleRef xlink:type="simple" xlink:href="rxii-20120331.xsd#RxiSpinOut" roleURI="http://rxipharma.com/role/RxiSpinOut" />
<roleRef xlink:type="simple" xlink:href="rxii-20120331.xsd#FairValueMeasurements" roleURI="http://rxipharma.com/role/FairValueMeasurements" />
<roleRef xlink:type="simple" xlink:href="rxii-20120331.xsd#StockBasedCompensation" roleURI="http://rxipharma.com/role/StockBasedCompensation" />
<roleRef xlink:type="simple" xlink:href="rxii-20120331.xsd#NetLossPerShare" roleURI="http://rxipharma.com/role/NetLossPerShare" />
<roleRef xlink:type="simple" xlink:href="rxii-20120331.xsd#LicenseAgreements" roleURI="http://rxipharma.com/role/LicenseAgreements" />
<roleRef xlink:type="simple" xlink:href="rxii-20120331.xsd#StockholdersEquity" roleURI="http://rxipharma.com/role/StockholdersEquity" />
<roleRef xlink:type="simple" xlink:href="rxii-20120331.xsd#Litigation" roleURI="http://rxipharma.com/role/Litigation" />
<roleRef xlink:type="simple" xlink:href="rxii-20120331.xsd#SubsequentEvents" roleURI="http://rxipharma.com/role/SubsequentEvents" />
<presentationLink xlink:role="http://rxipharma.com/role/DocumentAndEntityInformation" xlink:title="00 - Document - Document and Entity Information" xlink:type="extended">
<loc xlink:type="locator" xlink:href="rxii-20120331.xsd#rxii_DocumentAndEntityInformationAbstract" xlink:label="rxii_DocumentAndEntityInformationAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rxii_DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentType" order="5.03" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rxii_DocumentAndEntityInformationAbstract" xlink:to="dei_AmendmentFlag" order="5.05" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rxii_DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentPeriodEndDate" order="5.04" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rxii_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityRegistrantName" order="5.01" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rxii_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityCentralIndexKey" order="5.02" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rxii_DocumentAndEntityInformationAbstract" xlink:to="dei_CurrentFiscalYearEndDate" order="5.08" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rxii_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityFilerCategory" order="5.12" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rxii_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding" order="5.14" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rxii_DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentFiscalPeriodFocus" order="5.07" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rxii_DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentFiscalYearFocus" order="5.06" use="optional" />
</presentationLink>
<roleRef xlink:type="simple" xlink:href="rxii-20120331.xsd#BalanceSheets" roleURI="http://rxipharma.com/role/BalanceSheets" />
<roleRef xlink:type="simple" xlink:href="rxii-20120331.xsd#BalanceSheetsParenthetical" roleURI="http://rxipharma.com/role/BalanceSheetsParenthetical" />
<roleRef xlink:type="simple" xlink:href="rxii-20120331.xsd#StatementsOfIncome" roleURI="http://rxipharma.com/role/StatementsOfIncome" />
<roleRef xlink:type="simple" xlink:href="rxii-20120331.xsd#StatementsOfCashFlows" roleURI="http://rxipharma.com/role/StatementsOfCashFlows" />
<presentationLink xlink:type="extended" xlink:role="http://rxipharma.com/role/BalanceSheets" xlink:title="01 - Statement - Condensed Consolidated Balance Sheets (Unaudited)">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_StatementOfFinancialPositionAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_AssetsAbstract" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_StatementOfFinancialPositionAbstract" xlink:to="loc_AssetsAbstract" order="1." use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_AssetsCurrentAbstract" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_AssetsAbstract" xlink:to="loc_AssetsCurrentAbstract" order="2.1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_CashAndCashEquivalentsAtCarryingValue" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_AssetsCurrentAbstract" xlink:to="loc_CashAndCashEquivalentsAtCarryingValue" order="3.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="loc_RestrictedCashAndCashEquivalentsAtCarryingValue" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_AssetsCurrentAbstract" xlink:to="loc_RestrictedCashAndCashEquivalentsAtCarryingValue" order="4.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_PrepaidExpenseAndOtherAssetsCurrent" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_AssetsCurrentAbstract" xlink:to="loc_PrepaidExpenseAndOtherAssetsCurrent" order="5.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_AssetsCurrent" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_AssetsCurrentAbstract" xlink:to="loc_AssetsCurrent" order="6.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_PropertyPlantAndEquipmentNet" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_AssetsAbstract" xlink:to="loc_PropertyPlantAndEquipmentNet" order="7.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="rxii-20120331.xsd#rxii_InProcessResearchDevelopment" xlink:label="rxii_InProcessResearchDevelopment" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_AssetsAbstract" xlink:to="rxii_InProcessResearchDevelopment" order="8.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_Goodwill" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_AssetsAbstract" xlink:to="loc_Goodwill" order="9.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DepositsAssetsNoncurrent" xlink:label="loc_DepositsAssetsNoncurrent" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_AssetsAbstract" xlink:to="loc_DepositsAssetsNoncurrent" order="10.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Assets" xlink:label="loc_Assets" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_AssetsAbstract" xlink:to="loc_Assets" order="11.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_LiabilitiesAndStockholdersEquityAbstract" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_StatementOfFinancialPositionAbstract" xlink:to="loc_LiabilitiesAndStockholdersEquityAbstract" order="12.1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_LiabilitiesCurrentAbstract" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_LiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_LiabilitiesCurrentAbstract" order="13.2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_AccountsPayableCurrent" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_LiabilitiesCurrentAbstract" xlink:to="loc_AccountsPayableCurrent" order="14.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_AccruedLiabilitiesCurrent" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_LiabilitiesCurrentAbstract" xlink:to="loc_AccruedLiabilitiesCurrent" order="15.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CapitalLeaseObligationsCurrent" xlink:label="loc_CapitalLeaseObligationsCurrent" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_LiabilitiesCurrentAbstract" xlink:to="loc_CapitalLeaseObligationsCurrent" order="16.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ConvertibleNotesPayableCurrent" xlink:label="loc_ConvertibleNotesPayableCurrent" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_LiabilitiesCurrentAbstract" xlink:to="loc_ConvertibleNotesPayableCurrent" order="17.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="rxii-20120331.xsd#rxii_FairValueOfWarrantsPotentiallySettleableInCash" xlink:label="rxii_FairValueOfWarrantsPotentiallySettleableInCash" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_LiabilitiesCurrentAbstract" xlink:to="rxii_FairValueOfWarrantsPotentiallySettleableInCash" order="18.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="rxii-20120331.xsd#rxii_CurrentContingentPurchasePriceConsideration" xlink:label="rxii_CurrentContingentPurchasePriceConsideration" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_LiabilitiesCurrentAbstract" xlink:to="rxii_CurrentContingentPurchasePriceConsideration" order="19.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_LiabilitiesCurrent" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_LiabilitiesCurrentAbstract" xlink:to="loc_LiabilitiesCurrent" order="20.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CapitalLeaseObligationsNoncurrent" xlink:label="loc_CapitalLeaseObligationsNoncurrent" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_LiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_CapitalLeaseObligationsNoncurrent" order="21.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ConvertibleLongTermNotesPayable" xlink:label="loc_ConvertibleLongTermNotesPayable" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_LiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_ConvertibleLongTermNotesPayable" order="22.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent" xlink:label="loc_DeferredTaxAssetsLiabilitiesNetNoncurrent" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_LiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_DeferredTaxAssetsLiabilitiesNetNoncurrent" order="23.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="rxii-20120331.xsd#rxii_ContingentPurchasePriceConsiderationNetOfCurrentPortion" xlink:label="rxii_ContingentPurchasePriceConsiderationNetOfCurrentPortion" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_LiabilitiesAndStockholdersEquityAbstract" xlink:to="rxii_ContingentPurchasePriceConsiderationNetOfCurrentPortion" order="24.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_Liabilities" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_LiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_Liabilities" order="25.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_StockholdersEquityAbstract" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_LiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_StockholdersEquityAbstract" order="26.1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_PreferredStockValue" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_StockholdersEquityAbstract" xlink:to="loc_PreferredStockValue" order="27.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_CommonStockValue" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_StockholdersEquityAbstract" xlink:to="loc_CommonStockValue" order="28.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_AdditionalPaidInCapitalCommonStock" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_StockholdersEquityAbstract" xlink:to="loc_AdditionalPaidInCapitalCommonStock" order="29.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="rxii-20120331.xsd#rxii_DeficitAccumulatedDuringDevelopmentalStage" xlink:label="rxii_DeficitAccumulatedDuringDevelopmentalStage" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_StockholdersEquityAbstract" xlink:to="rxii_DeficitAccumulatedDuringDevelopmentalStage" order="30.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_TreasuryStockValue" xlink:label="loc_TreasuryStockValue" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_StockholdersEquityAbstract" xlink:to="loc_TreasuryStockValue" order="31.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_StockholdersEquity" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_StockholdersEquityAbstract" xlink:to="loc_StockholdersEquity" order="32.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_LiabilitiesAndStockholdersEquity" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_LiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_LiabilitiesAndStockholdersEquity" order="33.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://rxipharma.com/role/BalanceSheetsParenthetical" xlink:title="011 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)" >
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_StatementOfFinancialPositionAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_PreferredStockParOrStatedValuePerShare" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_StatementOfFinancialPositionAbstract" xlink:to="loc_PreferredStockParOrStatedValuePerShare" order="27.1" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_PreferredStockSharesAuthorized" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_StatementOfFinancialPositionAbstract" xlink:to="loc_PreferredStockSharesAuthorized" order="27.2" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_PreferredStockSharesIssued" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_StatementOfFinancialPositionAbstract" xlink:to="loc_PreferredStockSharesIssued" order="27.3" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_PreferredStockSharesOutstanding" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_StatementOfFinancialPositionAbstract" xlink:to="loc_PreferredStockSharesOutstanding" order="27.4" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_CommonStockParOrStatedValuePerShare" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_StatementOfFinancialPositionAbstract" xlink:to="loc_CommonStockParOrStatedValuePerShare" order="28.1" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_CommonStockSharesAuthorized" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_StatementOfFinancialPositionAbstract" xlink:to="loc_CommonStockSharesAuthorized" order="28.2" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_CommonStockSharesIssued" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_StatementOfFinancialPositionAbstract" xlink:to="loc_CommonStockSharesIssued" order="28.3" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_CommonStockSharesOutstanding" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_StatementOfFinancialPositionAbstract" xlink:to="loc_CommonStockSharesOutstanding" order="28.4" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_TreasuryStockShares" xlink:label="loc_TreasuryStockShares" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_StatementOfFinancialPositionAbstract" xlink:to="loc_TreasuryStockShares" order="31.1" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://rxipharma.com/role/StatementsOfIncome" xlink:title="02 - Statement - Condensed Consolidated Statements of Expenses (Unaudited)">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_IncomeStatementAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_OperatingExpensesAbstract" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_IncomeStatementAbstract" xlink:to="loc_OperatingExpensesAbstract" order="1.1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="loc_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OperatingExpensesAbstract" xlink:to="loc_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" order="2.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="rxii-20120331.xsd#rxii_ResearchAndDevelopmentEmployeeStockBasedCompensationExpense" xlink:label="rxii_ResearchAndDevelopmentEmployeeStockBasedCompensationExpense" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OperatingExpensesAbstract" xlink:to="rxii_ResearchAndDevelopmentEmployeeStockBasedCompensationExpense" order="3.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="rxii-20120331.xsd#rxii_ResearchAndDevelopmentNonEmployeeStockBasedCompensationExpense" xlink:label="rxii_ResearchAndDevelopmentNonEmployeeStockBasedCompensationExpense" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OperatingExpensesAbstract" xlink:to="rxii_ResearchAndDevelopmentNonEmployeeStockBasedCompensationExpense" order="4.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="rxii-20120331.xsd#rxii_FairValueOfCommonStockInExchangeForResearchAndDevelopmentExpenses" xlink:label="rxii_FairValueOfCommonStockInExchangeForResearchAndDevelopmentExpenses" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OperatingExpensesAbstract" xlink:to="rxii_FairValueOfCommonStockInExchangeForResearchAndDevelopmentExpenses" order="5.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_ResearchAndDevelopmentExpense" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OperatingExpensesAbstract" xlink:to="loc_ResearchAndDevelopmentExpense" order="6.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="rxii-20120331.xsd#rxii_GeneralAndAdministrativeExpenses" xlink:label="rxii_GeneralAndAdministrativeExpenses" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OperatingExpensesAbstract" xlink:to="rxii_GeneralAndAdministrativeExpenses" order="7.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="rxii-20120331.xsd#rxii_GeneralAndAdministrativeEmployeeStockBasedCompensation" xlink:label="rxii_GeneralAndAdministrativeEmployeeStockBasedCompensation" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OperatingExpensesAbstract" xlink:to="rxii_GeneralAndAdministrativeEmployeeStockBasedCompensation" order="8.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="rxii-20120331.xsd#rxii_FairValueOfCommonStockWarrantsIssuedForGeneralAndAdministrativeExpenses" xlink:label="rxii_FairValueOfCommonStockWarrantsIssuedForGeneralAndAdministrativeExpenses" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OperatingExpensesAbstract" xlink:to="rxii_FairValueOfCommonStockWarrantsIssuedForGeneralAndAdministrativeExpenses" order="9.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="rxii-20120331.xsd#rxii_FairValueOfCommonStockIssuedInExchangeForGeneralAndAdministrativeExpenses" xlink:label="rxii_FairValueOfCommonStockIssuedInExchangeForGeneralAndAdministrativeExpenses" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OperatingExpensesAbstract" xlink:to="rxii_FairValueOfCommonStockIssuedInExchangeForGeneralAndAdministrativeExpenses" order="10.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_GeneralAndAdministrativeExpense" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OperatingExpensesAbstract" xlink:to="loc_GeneralAndAdministrativeExpense" order="11.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_OperatingExpenses" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_IncomeStatementAbstract" xlink:to="loc_OperatingExpenses" order="12.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" />
<loc xlink:type="locator" xlink:href="rxii-20120331.xsd#rxii_InterestIncome" xlink:label="rxii_InterestIncome" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_IncomeStatementAbstract" xlink:to="rxii_InterestIncome" order="13.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_OtherNonoperatingIncomeExpense" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_IncomeStatementAbstract" xlink:to="loc_OtherNonoperatingIncomeExpense" order="14.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_NetIncomeLoss" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_IncomeStatementAbstract" xlink:to="loc_NetIncomeLoss" order="15.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_EarningsPerShareAbstract" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_IncomeStatementAbstract" xlink:to="loc_EarningsPerShareAbstract" order="16.1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_EarningsPerShareBasicAndDiluted" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_EarningsPerShareAbstract" xlink:to="loc_EarningsPerShareBasicAndDiluted" order="17.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="loc_WeightedAverageNumberOfSharesOutstandingAbstract" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_IncomeStatementAbstract" xlink:to="loc_WeightedAverageNumberOfSharesOutstandingAbstract" order="18.1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
<loc xlink:type="locator" xlink:href="rxii-20120331.xsd#rxii_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="rxii_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="rxii_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" order="19.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://rxipharma.com/role/StatementsOfCashFlows" xlink:title="03 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_StatementOfCashFlowsAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_StatementOfCashFlowsAbstract" xlink:to="loc_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="1.1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
<loc xlink:type="locator" xlink:href="rxii-20120331.xsd#rxii_NetIncomeLossIncludingOther" xlink:label="rxii_NetIncomeLossIncludingOther" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="rxii_NetIncomeLossIncludingOther" order="2.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="3.1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_DepreciationDepletionAndAmortization" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_DepreciationDepletionAndAmortization" order="4.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets" xlink:label="loc_GainLossOnDispositionOfAssets" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_GainLossOnDispositionOfAssets" order="5.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="rxii-20120331.xsd#rxii_NonCashRentExpense" xlink:label="rxii_NonCashRentExpense" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="rxii_NonCashRentExpense" order="6.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="loc_AccretionAmortizationOfDiscountsAndPremiumsInvestments" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_AccretionAmortizationOfDiscountsAndPremiumsInvestments" order="7.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_ShareBasedCompensation" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_ShareBasedCompensation" order="8.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="rxii-20120331.xsd#rxii_LossOnExchangeOfEquityInstruments" xlink:label="rxii_LossOnExchangeOfEquityInstruments" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="rxii_LossOnExchangeOfEquityInstruments" order="9.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="rxii-20120331.xsd#rxii_FairValueOfSharesMandatorilyRedeemableForCashUponExerciseOfWarrants" xlink:label="rxii_FairValueOfSharesMandatorilyRedeemableForCashUponExerciseOfWarrants" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="rxii_FairValueOfSharesMandatorilyRedeemableForCashUponExerciseOfWarrants" order="10.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="rxii-20120331.xsd#rxii_FairValueOfParentCompanyCommonStockIssuedInExchangeForServices" xlink:label="rxii_FairValueOfParentCompanyCommonStockIssuedInExchangeForServices" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="rxii_FairValueOfParentCompanyCommonStockIssuedInExchangeForServices" order="11.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="loc_IssuanceOfStockAndWarrantsForServicesOrClaims" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_IssuanceOfStockAndWarrantsForServicesOrClaims" order="12.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="rxii-20120331.xsd#rxii_ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings" xlink:label="rxii_ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="rxii_ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings" order="13.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="rxii-20120331.xsd#rxii_FairValueOfCommonStockIssuedInExchangeForLicensingRights" xlink:label="rxii_FairValueOfCommonStockIssuedInExchangeForLicensingRights" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="rxii_FairValueOfCommonStockIssuedInExchangeForLicensingRights" order="14.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="rxii-20120331.xsd#rxii_ChangeInFairValueOfContingentPurchaseConsideration" xlink:label="rxii_ChangeInFairValueOfContingentPurchaseConsideration" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="rxii_ChangeInFairValueOfContingentPurchaseConsideration" order="15.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_IncreaseDecreaseInOperatingCapitalAbstract" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_IncreaseDecreaseInOperatingCapitalAbstract" order="16.1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="17.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_IncreaseDecreaseInAccountsPayable" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_IncreaseDecreaseInAccountsPayable" order="18.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInDueToOtherRelatedPartiesCurrent" xlink:label="loc_IncreaseDecreaseInDueToOtherRelatedPartiesCurrent" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_IncreaseDecreaseInDueToOtherRelatedPartiesCurrent" order="19.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_IncreaseDecreaseInAccruedLiabilities" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_IncreaseDecreaseInAccruedLiabilities" order="20.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_NetCashProvidedByUsedInOperatingActivities" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_NetCashProvidedByUsedInOperatingActivities" order="21.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_StatementOfCashFlowsAbstract" xlink:to="loc_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="22.1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInRestrictedCash" xlink:label="loc_IncreaseDecreaseInRestrictedCash" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_IncreaseDecreaseInRestrictedCash" order="23.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="rxii-20120331.xsd#rxii_CashReceivedInAcquisition" xlink:label="rxii_CashReceivedInAcquisition" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="rxii_CashReceivedInAcquisition" order="24.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PaymentsToAcquireShortTermInvestments" xlink:label="loc_PaymentsToAcquireShortTermInvestments" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_PaymentsToAcquireShortTermInvestments" order="25.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:label="loc_ProceedsFromSaleMaturityAndCollectionsOfInvestments" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_ProceedsFromSaleMaturityAndCollectionsOfInvestments" order="26.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_PaymentsToAcquirePropertyPlantAndEquipment" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_PaymentsToAcquirePropertyPlantAndEquipment" order="27.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="loc_ProceedsFromSaleOfPropertyPlantAndEquipment" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_ProceedsFromSaleOfPropertyPlantAndEquipment" order="28.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="rxii-20120331.xsd#rxii_CashRefundedPaidForLeaseDeposit" xlink:label="rxii_CashRefundedPaidForLeaseDeposit" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="rxii_CashRefundedPaidForLeaseDeposit" order="29.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_NetCashProvidedByUsedInInvestingActivities" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_NetCashProvidedByUsedInInvestingActivities" order="30.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_StatementOfCashFlowsAbstract" xlink:to="loc_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="31.1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_ProceedsFromIssuanceOfCommonStock" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_ProceedsFromIssuanceOfCommonStock" order="32.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="loc_PaymentsForRepurchaseOfCommonStock" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_PaymentsForRepurchaseOfCommonStock" order="33.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_ProceedsFromStockOptionsExercised" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_ProceedsFromStockOptionsExercised" order="34.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="rxii-20120331.xsd#rxii_NetProceedsFromExerciseOfCommonStockWarrants" xlink:label="rxii_NetProceedsFromExerciseOfCommonStockWarrants" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="rxii_NetProceedsFromExerciseOfCommonStockWarrants" order="35.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="rxii-20120331.xsd#rxii_CommonStockIssuedInConnectionWithEspp" xlink:label="rxii_CommonStockIssuedInConnectionWithEspp" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="rxii_CommonStockIssuedInConnectionWithEspp" order="36.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="rxii-20120331.xsd#rxii_NetProceedsFromIssuanceOfConvertibleNotesPayable" xlink:label="rxii_NetProceedsFromIssuanceOfConvertibleNotesPayable" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="rxii_NetProceedsFromIssuanceOfConvertibleNotesPayable" order="37.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RepaymentsOfLongTermCapitalLeaseObligations" xlink:label="loc_RepaymentsOfLongTermCapitalLeaseObligations" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_RepaymentsOfLongTermCapitalLeaseObligations" order="38.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromRelatedPartyDebt" xlink:label="loc_ProceedsFromRelatedPartyDebt" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_ProceedsFromRelatedPartyDebt" order="39.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_NetCashProvidedByUsedInFinancingActivities" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_NetCashProvidedByUsedInFinancingActivities" order="40.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_CashAndCashEquivalentsPeriodIncreaseDecrease" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_StatementOfCashFlowsAbstract" xlink:to="loc_CashAndCashEquivalentsPeriodIncreaseDecrease" order="41.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_CashAndCashEquivalentsAtCarryingValue" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_StatementOfCashFlowsAbstract" xlink:to="loc_CashAndCashEquivalentsAtCarryingValue" order="42.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_CashAndCashEquivalentsAtCarryingValue_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_StatementOfCashFlowsAbstract" xlink:to="loc_CashAndCashEquivalentsAtCarryingValue_1" order="43.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_SupplementalCashFlowInformationAbstract" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_StatementOfCashFlowsAbstract" xlink:to="loc_SupplementalCashFlowInformationAbstract" order="44.1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromInterestReceived" xlink:label="loc_ProceedsFromInterestReceived" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SupplementalCashFlowInformationAbstract" xlink:to="loc_ProceedsFromInterestReceived" order="45.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_InterestPaid" xlink:label="loc_InterestPaid" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SupplementalCashFlowInformationAbstract" xlink:to="loc_InterestPaid" order="46.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="loc_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_StatementOfCashFlowsAbstract" xlink:to="loc_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" order="47.1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssued1" xlink:label="loc_StockIssued1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="loc_StockIssued1" order="48.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="rxii-20120331.xsd#rxii_FairValueOfWarrantsIssuedInConnectionWithCommonStockRecordedAsCostOfEquity" xlink:label="rxii_FairValueOfWarrantsIssuedInConnectionWithCommonStockRecordedAsCostOfEquity" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="rxii_FairValueOfWarrantsIssuedInConnectionWithCommonStockRecordedAsCostOfEquity" order="49.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="rxii-20120331.xsd#rxii_IssuanceOfCommonStockInExchangeOfOutstandingWarrants" xlink:label="rxii_IssuanceOfCommonStockInExchangeOfOutstandingWarrants" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="rxii_IssuanceOfCommonStockInExchangeOfOutstandingWarrants" order="50.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="rxii-20120331.xsd#rxii_FairValueOfSharesMandatorilyRedeemableForCashUponExerciseOfWarrant" xlink:label="rxii_FairValueOfSharesMandatorilyRedeemableForCashUponExerciseOfWarrant" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="rxii_FairValueOfSharesMandatorilyRedeemableForCashUponExerciseOfWarrant" order="51.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="rxii-20120331.xsd#rxii_ReclassificationOfWarrantLiabilityUponExercise" xlink:label="rxii_ReclassificationOfWarrantLiabilityUponExercise" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="rxii_ReclassificationOfWarrantLiabilityUponExercise" order="52.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="rxii-20120331.xsd#rxii_AllocationOfManagementExpenses" xlink:label="rxii_AllocationOfManagementExpenses" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="rxii_AllocationOfManagementExpenses" order="53.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="rxii-20120331.xsd#rxii_EquipmentAndFurnishingsExchangedForCommonStock" xlink:label="rxii_EquipmentAndFurnishingsExchangedForCommonStock" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="rxii_EquipmentAndFurnishingsExchangedForCommonStock" order="54.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_FairValueOfAssetsAcquired" xlink:label="loc_FairValueOfAssetsAcquired" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="loc_FairValueOfAssetsAcquired" order="55.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="rxii-20120331.xsd#rxii_ValueOfRestrictedStockUnitsAndCommonStockIssuedInLieuOfCashBonuses" xlink:label="rxii_ValueOfRestrictedStockUnitsAndCommonStockIssuedInLieuOfCashBonuses" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="rxii_ValueOfRestrictedStockUnitsAndCommonStockIssuedInLieuOfCashBonuses" order="56.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CapitalLeaseObligationsIncurred" xlink:label="loc_CapitalLeaseObligationsIncurred" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="loc_CapitalLeaseObligationsIncurred" order="57.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://rxipharma.com/role/DescriptionOfBusinessAndBasisOfPresentation" xlink:title="06001 - Disclosure - Description of Business and Basis of Presentation">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_AccountingPoliciesAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:label="loc_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_AccountingPoliciesAbstract" xlink:to="loc_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" order="1.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://rxipharma.com/role/RecentAccountingPronouncements" xlink:title="06002 - Disclosure - Recent Accounting Pronouncements">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccountingChangesAndErrorCorrectionsAbstract" xlink:label="loc_AccountingChangesAndErrorCorrectionsAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccountingChangesAndErrorCorrectionsTextBlock" xlink:label="loc_AccountingChangesAndErrorCorrectionsTextBlock" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_AccountingChangesAndErrorCorrectionsAbstract" xlink:to="loc_AccountingChangesAndErrorCorrectionsTextBlock" order="1.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://rxipharma.com/role/AptheraAcquisition" xlink:title="06003 - Disclosure - Apthera Acquisition">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="loc_BusinessCombinationsAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock" xlink:label="loc_BusinessCombinationDisclosureTextBlock" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BusinessCombinationsAbstract" xlink:to="loc_BusinessCombinationDisclosureTextBlock" order="1.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://rxipharma.com/role/RxiSpinOut" xlink:title="06004 - Disclosure - RXi Spin-Out">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_RelatedPartyTransactionsAbstract" />
<loc xlink:type="locator" xlink:href="rxii-20120331.xsd#rxii_PartnerCompanyTextBlock" xlink:label="rxii_PartnerCompanyTextBlock" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_RelatedPartyTransactionsAbstract" xlink:to="rxii_PartnerCompanyTextBlock" order="1.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://rxipharma.com/role/FairValueMeasurements" xlink:title="06005 - Disclosure - Fair Value Measurements">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:label="loc_InvestmentsAllOtherInvestmentsAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:label="loc_FinancialInstrumentsDisclosureTextBlock" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_InvestmentsAllOtherInvestmentsAbstract" xlink:to="loc_FinancialInstrumentsDisclosureTextBlock" order="1.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://rxipharma.com/role/StockBasedCompensation" xlink:title="06006 - Disclosure - Stock Based Compensation">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" order="1.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://rxipharma.com/role/NetLossPerShare" xlink:title="06007 - Disclosure - Net Loss Per Share">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_EarningsPerShareAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_EarningsPerShareTextBlock" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_EarningsPerShareAbstract" xlink:to="loc_EarningsPerShareTextBlock" order="1.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://rxipharma.com/role/LicenseAgreements" xlink:title="06008 - Disclosure - License Agreements">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_GoodwillAndIntangibleAssetsDisclosureAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:label="loc_IntangibleAssetsDisclosureTextBlock" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_IntangibleAssetsDisclosureTextBlock" order="1.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://rxipharma.com/role/StockholdersEquity" xlink:title="06009 - Disclosure - Stockholders' Equity">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_EquityAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_StockholdersEquityNoteDisclosureTextBlock" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_EquityAbstract" xlink:to="loc_StockholdersEquityNoteDisclosureTextBlock" order="1.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://rxipharma.com/role/Litigation" xlink:title="06010 - Disclosure - Litigation">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_CommitmentsAndContingenciesDisclosureAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_CommitmentsAndContingenciesDisclosureTextBlock" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_CommitmentsAndContingenciesDisclosureTextBlock" order="1.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://rxipharma.com/role/SubsequentEvents" xlink:title="06011 - Disclosure - Subsequent Events">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_SubsequentEventsAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_SubsequentEventsTextBlock" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SubsequentEventsAbstract" xlink:to="loc_SubsequentEventsTextBlock" order="1.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
</linkbase>

</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	word-wrap: break-word;
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>RXi Spin-Out<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>RXi Spin-Out [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rxii_PartnerCompanyTextBlock', window );">RXi Spin-Out</a></td>
        <td class="text"><!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
   <!-- Begin Block Tagged Note 4 - rxii:PartnerCompanyTextBlock-->
   <p style="margin-top:18px;margin-bottom:0px"><font style="font-family:times new roman" size="2"><b>4.&#160;RXi Spin-Out </b></font></p>
   <p style="margin-top:6px;margin-bottom:0px; margin-left:2%"><font style="font-family:times new roman" size="2"><b><i>Contribution Agreement </i></b></font></p>
   <p style="margin-top:6px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">
   On September&#160;24, 2011, the Company entered into a Contribution Agreement (&#8220;Contribution Agreement&#8221;) with RXi pursuant to which we assigned and contributed to RXi substantially all of the
   Company&#8217;s RNAi-related technologies and assets. The contributed assets consist primarily of our novel RNAi compounds and licenses relating to our RNAi technologies, as well as the lease of our Worcester, Massachusetts laboratory facility, fixed
   assets and other equipment located at the facility and our employment arrangements with certain scientific, corporate and administrative personnel who have become employees of RXi. The Company also contributed $1.5&#160;million of cash to the
   capital of RXi. </font></p>
   <p style="margin-top:12px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">Pursuant to the Contribution Agreement, RXi assumed certain accrued expenses of our RXI-109 development
   program and all subsequent obligations under the contributed licenses, employment arrangements and other agreements. RXi has agreed to make future milestone payments to us of up to $45&#160;million, consisting of two one-time payments of
   $15&#160;million and $30&#160;million, respectively, if RXi achieves annual net sales equal to or greater than $500 million and $1&#160;billion, respectively, of any covered products that may be developed with the contributed RNAi technologies.
   </font></p>
   <p style="margin-top:12px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">In the Contribution Agreement, the Company made customary representations and warranties to RXi regarding the contributed
   assets and other matters, and the parties have agreed to customary covenants regarding the conduct of RXi&#8217;s business pending the spin-off of RXi. The parties also have agreed to indemnify each other against losses arising from a breach of their
   respective representations, warranties and covenants set forth in the Contribution Agreement. </font></p>
   <p style="font-size:1px;margin-top:18px;margin-bottom:0px">&#160;</p>
   <p style="margin-top:0px;margin-bottom:0px; margin-left:2%"><font style="font-family:times new roman" size="2"><b><i>Securities
   Purchase Agreement </i></b></font></p>
   <p style="margin-top:6px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">On September&#160;24, 2011, the Company also entered into a Securities Purchase Agreement
   (&#8220;Securities Purchase Agreement&#8221;) with RXi and two institutional Investors (the &#8220;Investors&#8221;), pursuant to which the Investors agreed to purchase a total of $9,500,000 of Series&#160;A Preferred Stock of RXi (&#8220;RXi Preferred
   Stock&#8221;) at the closing of the spin-off of RXi, and to lend up to $1,500,000 to RXi to fund its operations between signing and closing (the &#8220;Bridge Loan&#8221;). The outstanding principal and accrued interest from the Bridge Loan will,
   except under certain circumstances described below, be converted into RXi Preferred Stock at the closing of the spin-off of RXi and will represent a portion of the $9,500,000 total investment, which is referred to herein as the &#8220;RXi
   financing.&#8221; The RXi&#160;financing and the spin-off of RXi were subject to customary closing conditions, including the registration under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), of the distribution by us of the
   spin-off shares. </font></p>
   <p style="margin-top:12px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">The RXi Preferred Stock will be convertible by a holder at any time into shares of RXi common stock, except
   to the extent that the holder would own more than 9.999% of the shares of RXi common stock outstanding immediately after giving effect to such conversion. Without regard to this conversion limitation, the shares of the Preferred Stock to be held by
   the Investors upon completion of the RXi financing and the spin-off of RXi will be convertible into shares of RXi common stock representing approximately 83% of the shares of RXi common stock that would be outstanding, assuming the conversion in
   full of the Preferred Stock, which we refer to as the &#8220;as-converted common stock.&#8221; The Company will own approximately 12% of the as-converted common stock immediately prior to the spin-off of RXi, and Advirna, LLC, a licensor of RXi, will
   be issued the remaining 5% of the as-converted common stock pursuant to the agreement with Advirna, LLC as described below. </font></p>
   <p style="margin-top:18px;margin-bottom:0px; margin-left:2%"><font style="font-family:times new roman" size="2"><i>Spin-Off </i></font></p>
   <p style="margin-top:6px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">The Company agreed in the Securities Purchase Agreement to undertake to distribute to our stockholders on a share-for-share basis
   approximately 8% of the as-converted common stock of RXi, subject to the registration of the distribution of such shares under the Securities Act of 1933 and other conditions, which distribution was completed on April 27, 2012 (see Note 11). The
   Company has retained 4% of the as-converted common stock, and has agreed, in the Securities Purchase Agreement, not to sell or dispose of the Company&#8217;s shares of RXi common stock for a one-year period following completion of the spin-off of
   RXi. Under the Securities Purchase Agreement, one share of RXi was distributed as a dividend on each share of Galena that is issued and outstanding as of the record date for the distribution of April 23, 2012. </font></p>
   <p style="margin-top:18px;margin-bottom:0px; margin-left:2%"><font style="font-family:times new roman" size="2"><i>Purchase Agreement Terms and Conditions </i></font></p>
   <p style="margin-top:6px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">
   In the Securities Purchase Agreement, the parties have made customary representations and warranties to the other parties and have agreed to customary covenants regarding the parties&#8217; actions in
   connection with the spin-off of RXi and other matters, including the filing of a resale registration statement registering a portion of the common stock underlying the conversion of the Preferred Stock. The parties also have agreed to indemnify each
   other against losses arising from a breach of their respective representations, warranties and covenants set forth in the Securities Purchase Agreement. Per the agreement, upon the closing of the transaction, on April 27, 2012, RXi reimbursed the
   Company and the Investors in the amount of $300,000 and $100,000, respectively, for transaction costs relating to the Contribution Agreement, the Securities Purchase Agreement and the transactions called for by the agreements. </font></p>
   <p style="margin-top:18px;margin-bottom:0px; margin-left:2%"><font style="font-family:times new roman" size="2"><i>Bridge Loan </i></font></p>
   <p style="margin-top:6px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">
   Pursuant to the Securities Purchase Agreement, the Investors provided Bridge Loans by purchasing $1,000,000 of secured convertible promissory notes of RXi (&#8220;RXi convertible notes&#8221;). The RXi
   convertible notes will, except as described below, be convertible into shares of RXi Preferred Stock at a conversion price of $1,000 per share. The RXi convertible notes accrued interest at a rate of 7%&#160;per annum (or 18%&#160;per annum in the
   case of an event of default) and matured on April&#160;27, 2012, the closing date. As of March 31, 2012, RXi had $1,000,000 of RXi convertible notes outstanding. As the Company was relieved of this obligation upon the spin-out, the amount has been
   recorded as a long-term liability as of March 31, 2012. Approximately $21,000 of interest has been recorded in accrued expenses and other current liabilities at March&#160;31, 2012 in the accompanying condensed consolidated balance sheet.
   </font></p>
   <p style="margin-top:18px;margin-bottom:0px; margin-left:2%"><font style="font-family:times new roman" size="2"><b><i>Advirna Agreement </i></b></font></p>
   <p style="margin-top:6px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">
   As part of the closing transaction as detailed in the Contribution Agreement and Securities Purchase Agreement, RXi entered into an agreement with Advirna, LLC, which the Company refers to as
   &#8220;Advirna,&#8221; a company affiliated with Anastasia Khvorova, Ph.D., RXi&#8217;s former Senior Vice President and Chief Scientific Officer. In the agreement, Advirna has agreed to amend its existing patent and technology assignment agreement
   with RXi to eliminate all clinical milestone and royalty payments to Advirna under the amended agreement; obligations remain to make an annual $100,000 maintenance fee and a one-time milestone payment of $350,000 to Advirna upon the issuance of a
   patent with valid claims covering the assigned technology. Additionally, RXi will be required to pay a 1% royalty to Advirna for any licensing revenue received by RXi on the license of the assigned Advirna technology. In exchange, RXi issued to
   Advirna upon the closing transaction a number of shares of RXi common stock equal to 5% of the as-converted common stock of RXi. </font></p>
   <p style="margin-top:12px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">
   The transactions contemplated by the Securities Purchase Agreement were completed in April 2012 (see Note 11). </font></p>
<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rxii_PartnerCompanyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>RXi Spin-Out</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>rxii_PartnerCompanyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>rxii_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RelatedPartyTransactionsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>17
<FILENAME>Financial_Report.xls
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xls
M[[N_34E-12U697)S:6]N.B`Q+C`-"E@M1&]C=6UE;G0M5'EP93H@5V]R:V)O
M;VL-"D-O;G1E;G0M5'EP93H@;75L=&EP87)T+W)E;&%T960[(&)O=6YD87)Y
M/2(M+2TM/5].97AT4&%R=%]B969E.6,Q,5]C,F8S7S0X96-?83)A8E]F9C(X
M.38P-V5D8S`B#0H-"E1H:7,@9&]C=6UE;G0@:7,@82!3:6YG;&4@1FEL92!7
M96(@4&%G92P@86QS;R!K;F]W;B!A<R!A(%=E8B!!<F-H:79E(&9I;&4N("!)
M9B!Y;W4@87)E('-E96EN9R!T:&ES(&UE<W-A9V4L('EO=7(@8G)O=W-E<B!O
M<B!E9&ET;W(@9&]E<VXG="!S=7!P;W)T(%=E8B!!<F-H:79E(&9I;&5S+B`@
M4&QE87-E(&1O=VYL;V%D(&$@8G)O=W-E<B!T:&%T('-U<'!O<G1S(%=E8B!!
M<F-H:79E+"!S=6-H(&%S($UI8W)O<V]F="!);G1E<FYE="!%>'!L;W)E<BX-
M"@T*+2TM+2TM/5].97AT4&%R=%]B969E.6,Q,5]C,F8S7S0X96-?83)A8E]F
M9C(X.38P-V5D8S`-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO8F5F
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M;V9T+6-O;3IO9F9I8V4Z97AC96PB('AM;&YS/3-$(FAT='`Z+R]W=W<N=S,N
M;W)G+U12+U)%0RUH=&UL-#`B/@T*/&AE860^#0H\;65T82!N86UE/3-$(D5X
M8V5L(%=O<FMB;V]K($9R86UE<V5T(CX-"@T*/&UE=&$@;F%M93TS1%!R;V=)
M9"!C;VYT96YT/3-$17AC96PN4VAE970^#0H\;&EN:R!R96P],T1&:6QE+4QI
M<W0@:')E9CTS1")7;W)K<VAE971S+V9I;&5L:7-T+GAM;"(^#0H-"CPA+2U;
M:68@9W1E(&US;R`Y73X\>&UL/@T*(#QX.D5X8V5L5V]R:V)O;VL^#0H@(#QX
M.D5X8V5L5V]R:W-H965T<SX-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@
M(#QX.DYA;64^1&]C=6UE;G1?86YD7T5N=&ET>5]);F9O<FUA=&EO/"]X.DYA
M;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T
M<R]3:&5E=#`Q+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@
M(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^0V]N9&5N<V5D7T-O
M;G-O;&ED871E9%]"86QA;F-E/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T
M4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#`R+FAT;6PB+SX-"B`@
M(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*
M("`@(#QX.DYA;64^0V]N9&5N<V5D7T-O;G-O;&ED871E9%]"86QA;F-E,3PO
M>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS
M:&5E=',O4VAE970P,RYH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^
M#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/D-O;F1E;G-E
M9%]#;VYS;VQI9&%T961?4W1A=&5M93PO>#I.86UE/@T*("`@(#QX.E=O<FMS
M:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970P-"YH=&UL(B\^
M#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E
M=#X-"B`@("`\>#I.86UE/D-O;F1E;G-E9%]#;VYS;VQI9&%T961?4W1A=&5M
M93$\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7
M;W)K<VAE971S+U-H965T,#4N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H
M965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y$97-C
M<FEP=&EO;E]O9E]"=7-I;F5S<U]A;F1?0F$\+W@Z3F%M93X-"B`@("`\>#I7
M;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T,#8N:'1M
M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K
M<VAE970^#0H@("`@/'@Z3F%M93Y296-E;G1?06-C;W5N=&EN9U]0<F]N;W5N
M8V5M96X\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS
M1")7;W)K<VAE971S+U-H965T,#<N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R
M:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y!
M<'1H97)A7T%C<75I<VET:6]N/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T
M4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#`X+FAT;6PB+SX-"B`@
M(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*
M("`@(#QX.DYA;64^4EAI7U-P:6Y/=70\+W@Z3F%M93X-"B`@("`\>#I7;W)K
M<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T,#DN:'1M;"(O
M/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE
M970^#0H@("`@/'@Z3F%M93Y&86ER7U9A;'5E7TUE87-U<F5M96YT<SPO>#I.
M86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E
M=',O4VAE970Q,"YH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@
M("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/E-T;V-K7T)A<V5D
M7T-O;7!E;G-A=&EO;CPO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C
M92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970Q,2YH=&UL(B\^#0H@("`\+W@Z
M17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\
M>#I.86UE/DYE=%],;W-S7U!E<E]3:&%R93PO>#I.86UE/@T*("`@(#QX.E=O
M<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970Q,BYH=&UL
M(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS
M:&5E=#X-"B`@("`\>#I.86UE/DQI8V5N<V5?06=R965M96YT<SPO>#I.86UE
M/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O
M4VAE970Q,RYH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\
M>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/E-T;V-K:&]L9&5R<U]%
M<75I='D\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS
M1")7;W)K<VAE971S+U-H965T,30N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R
M:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y,
M:71I9V%T:6]N/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2
M968],T0B5V]R:W-H965T<R]3:&5E=#$U+FAT;6PB+SX-"B`@(#PO>#I%>&-E
M;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA
M;64^4W5B<V5Q=65N=%]%=F5N=',\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE
M9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T,38N:'1M;"(O/@T*
M("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`\+W@Z17AC96Q7;W)K<VAE971S
M/@T*("`\>#I3='EL97-H965T($A2968],T0B5V]R:W-H965T<R]R97!O<G0N
M8W-S(B\^#0H@(#QX.D%C=&EV95-H965T/C`\+W@Z06-T:79E4VAE970^#0H@
M(#QX.E!R;W1E8W13=')U8W1U<F4^1F%L<V4\+W@Z4')O=&5C=%-T<G5C='5R
M93X-"B`@/'@Z4')O=&5C=%=I;F1O=W,^1F%L<V4\+W@Z4')O=&5C=%=I;F1O
M=W,^#0H@/"]X.D5X8V5L5V]R:V)O;VL^#0H\+WAM;#X\(5ME;F1I9ETM+3X-
M"CPO:&5A9#X-"B`@/&)O9'D^#0H@("`\<#Y4:&ES('!A9V4@<VAO=6QD(&)E
M(&]P96YE9"!W:71H($UI8W)O<V]F="!%>&-E;"!84"!O<B!N97=E<BX\+W`^
M#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]B969E
M.6,Q,5]C,F8S7S0X96-?83)A8E]F9C(X.38P-V5D8S`-"D-O;G1E;G0M3&]C
M871I;VXZ(&9I;&4Z+R\O0SHO8F5F93EC,3%?8S)F,U\T.&5C7V$R86)?9F8R
M.#DV,#=E9&,P+U=O<FMS:&5E=',O4VAE970P,2YH=&UL#0I#;VYT96YT+51R
M86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT96YT+51Y
M<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*
M("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E
M(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T
M('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.
M;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@
M/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P15%!
M044^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P
M86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^1&]C=6UE;G0@86YD($5N=&ET
M>2!);F9O<FUA=&EO;CQB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XS($UO;G1H<R!%;F1E9#PO=&@^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/CPO=&@^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y-
M87(N(#,Q+"`R,#$R/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H
M/DUA>2`Q,2P@,C`Q,CQB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^/'-T<F]N9SY$;V-U;65N="!A;F0@16YT:71Y($EN9F]R;6%T:6]N
M(%M!8G-T<F%C=%T\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^16YT:71Y(%)E9VES=')A;G0@3F%M93PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^1V%L96YA($)I;W!H87)M82P@26YC+CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^16YT
M:71Y($-E;G1R86P@26YD97@@2V5Y/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XP,#`Q,SDP-#<X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y$;V-U;65N="!4>7!E/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XQ,"U1/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y$;V-U;65N="!097)I;V0@16YD
M($1A=&4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/DUA<B`S,2P-
M"@D),C`Q,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^06UE;F1M96YT($9L86<\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/F9A;'-E/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y$;V-U;65N="!&:7-C86P@665A<B!&;V-U<SPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^,C`Q,CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1&]C=6UE;G0@
M1FES8V%L(%!E<FEO9"!&;V-U<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^43$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/D-U<G)E;G0@1FES8V%L(%EE87(@16YD($1A=&4\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/BTM,3(M,S$\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5N=&ET>2!&:6QE
M<B!#871E9V]R>3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^4VUA
M;&QE<B!297!O<G1I;F<@0V]M<&%N>3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^16YT:71Y($-O;6UO;B!3=&]C:RP@
M4VAA<F5S($]U='-T86YD:6YG/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XV-2PV-#,L.3`U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM
M/5].97AT4&%R=%]B969E.6,Q,5]C,F8S7S0X96-?83)A8E]F9C(X.38P-V5D
M8S`-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO8F5F93EC,3%?8S)F
M,U\T.&5C7V$R86)?9F8R.#DV,#=E9&,P+U=O<FMS:&5E=',O4VAE970P,BYH
M=&UL#0I#;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I;G1A
M8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C
M:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV
M/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T
M/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$
M4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R
M:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P
M;W)T(&ED/3-$240P15%+04<^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0Q/CQS=')O;F<^0V]N
M9&5N<V5D($-O;G-O;&ED871E9"!"86QA;F-E(%-H965T<R`H56YA=61I=&5D
M*2`H55-$("0I/&)R/DEN(%1H;W5S86YD<RP@=6YL97-S(&]T:&5R=VES92!S
M<&5C:69I960\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M:#Y-87(N(#,Q+"`R,#$R/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1H/D1E8RX@,S$L(#(P,3$\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/CQS=')O;F<^0W5R<F5N="!A<W-E=',Z/"]S=')O;F<^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-A<V@@86YD(&-A<V@@
M97%U:79A;&5N=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@
M."PW,#$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XD(#$Q+#0S,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^4F5S=')I8W1E9"!C87-H/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XQ,#$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XQ,#$\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!R97!A:60@97AP96YS97,\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(Y,#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(W-CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E=3X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E1O=&%L(&-U
M<G)E;G0@87-S971S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XY
M+#`Y,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C$Q+#@Q,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^17%U:7!M96YT(&%N9"!F=7)N:7-H:6YG<RP@;F5T/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS-3$\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS.3,\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DEN+7!R;V-E
M<W,@<F5S96%R8V@@86YD(&1E=F5L;W!M96YT/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XQ,BPX-C0\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XQ,BPX-C0\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D=O;V1W:6QL/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XU+#@Y.#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4L.#DX/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y$97!O<VET<SPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;W4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y4;W1A;"!A<W-E
M=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(X+#(P.#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,P+#DV
M.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^/'-T<F]N9SY#=7)R96YT(&QI86)I;&ET:65S.CPO<W1R;VYG/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!8V-O=6YT<R!P87EA8FQE
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR+#4X,3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(L,34U/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!
M8V-R=65D(&5X<&5N<V5S(&%N9"!O=&AE<B!C=7)R96YT(&QI86)I;&ET:65S
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS+#4S,CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(L.3@T/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#
M=7)R96YT(&UA='5R:71I97,@;V8@8V%P:71A;"!L96%S92!O8FQI9V%T:6]N
M<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C0\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS-3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V]N=F5R
M=&EB;&4@;F]T97,@<&%Y86)L92P@8W5R<F5N=#PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C4P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^1F%I<B!V86QU92!O9B!W87)R86YT<R!P
M;W1E;G1I86QL>2!S971T;&5A8FQE(&EN(&-A<V@\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C(P+#,U-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C,L-S0V/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#=7)R96YT(&-O;G1I;F=E
M;G0@<'5R8VAA<V4@<')I8V4@8V]N<VED97)A=&EO;CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^.#DX/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,2PW.#(\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;W4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y4;W1A;"!C=7)R96YT(&QI
M86)I;&ET:65S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR-RPS
M.3(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XQ,2PR,#(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/D-A<&ET86P@;&5A<V4@;V)L:6=A=&EO;G,L(&YE="!O9B!C
M=7)R96YT(&UA='5R:71I97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C,V/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,S(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/D-O;G9E<G1I8FQE(&YO=&5S('!A>6%B;&4L(&YO;BUC=7)R
M96YT/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#`P,#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D1E
M9F5R<F5D('1A>"!L:6%B:6QI='DL(&YO;BUC=7)R96YT/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XU+#`U,SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4L,#4S/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#;VYT:6YG96YT('!U
M<F-H87-E('!R:6-E(&-O;G-I9&5R871I;VXL(&YE="!O9B!C=7)R96YT('!O
M<G1I;VX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4L,CDW/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-"PU
M-CD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R974^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y4;W1A;"!L:6%B:6QI=&EE<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,S@L-S<X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,C`L.#4V/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/E-T;V-K:&]L9&5R<R<@
M*&1E9FEC:70I(&5Q=6ET>3H\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^4')E9F5R<F5D('-T;V-K+"`D,"XP,#`Q('!A<B!V
M86QU93L@-2PP,#`L,#`P('-H87)E<R!A=71H;W)I>F5D.R!N;R!S:&%R97,@
M:7-S=65D(&%N9"!O=71S=&%N9&EN9SPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)FYB<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)FYB<W`[)FYB<W`[/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#;VUM;VX@<W1O
M8VLL("0P+C`P,#$@<&%R('9A;'5E.R`Q,C4L,#`P+#`P,"!S:&%R97,@875T
M:&]R:7IE9#L@-3`L,#@R+#$T."!S:&%R97,@:7-S=65D(&%N9"`T.2PT,#<L
M,30X('-H87)E<R!O=71S=&%N9&EN9R!A;F0@-#<L.#$Q+#0U,R!S:&%R97,@
M:7-S=65D(&%N9"`T-RPQ,S8L-#4S(&]U='-T86YD:6YG(&%T($UA<F-H(#,Q
M+"`R,#$R(&%N9"!$96-E;6)E<B`S,2P@,C`Q,2P@<F5S<&5C=&EV96QY/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^061D:71I;VYA;"!P
M86ED+6EN(&-A<&ET86P\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C@U+#(V,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C@Q+#$X-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^1&5F:6-I="!A8V-U;75L871E9"!D=7)I;F<@=&AE
M(&1E=F5L;W!M96YT86P@<W1A9V4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6T^*#DQ+#DX.2D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M/B@V-RPR,C@I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y,97-S('1R96%S=7)Y('-H87)E<R!A
M="!C;W-T+"`V-S4L,#`P('-H87)E<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;3XH,RPX-#DI/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;3XH,RPX-#DI/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F]U/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5&]T86P@<W1O8VMH;VQD97)S)R`H
M9&5F:6-I="D@97%U:71Y/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M/B@Q,"PU-S`I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,3`L,3$R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F5U/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^5&]T86P@;&EA8FEL:71I97,@86YD('-T;V-K
M:&]L9&5R<R<@97%U:71Y/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XD(#(X+#(P.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/B0@,S`L.38X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM
M+2TM/5].97AT4&%R=%]B969E.6,Q,5]C,F8S7S0X96-?83)A8E]F9C(X.38P
M-V5D8S`-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO8F5F93EC,3%?
M8S)F,U\T.&5C7V$R86)?9F8R.#DV,#=E9&,P+U=O<FMS:&5E=',O4VAE970P
M,RYH=&UL#0I#;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I
M;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M
M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q
M=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R
M<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C
M/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO
M<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$
M<F5P;W)T(&ED/3-$240P14%!044^#0H@("`@("`\='(^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0Q/CQS=')O;F<^
M0V]N9&5N<V5D($-O;G-O;&ED871E9"!"86QA;F-E(%-H965T<R`H56YA=61I
M=&5D*2`H4&%R96YT:&5T:6-A;"D@*%531"`D*3QB<CX\+W-T<F]N9SX\+W1H
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y-87(N(#,Q+"`R,#$R/&)R/CPO
M=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3$\8G(^
M/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^0V]N
M9&5N<V5D($-O;G-O;&ED871E9"!"86QA;F-E(%-H965T<R!;06)S=')A8W1=
M/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!R
M969E<G)E9"!S=&]C:RP@<&%R('9A;'5E/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XD(#`N,#`P,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/B0@,"XP,#`Q/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0<F5F97)R960@<W1O8VLL
M('-H87)E<R!A=71H;W)I>F5D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XU+#`P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XU+#`P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!R969E<G)E9"!S=&]C:RP@<VAA
M<F5S(&ES<W5E9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)FYB
M<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)FYB<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0<F5F97)R960@<W1O8VLL('-H87)E
M<R!O=71S=&%N9&EN9SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)FYB<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)FYB<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#;VUM;VX@<W1O8VLL('!A<B!V
M86QU93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`P+C`P,#$\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD
M(#`N,#`P,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^0V]M;6]N('-T;V-K+"!S:&%R97,@875T:&]R:7IE9#PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3(U+#`P,"PP,#`\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,C4L,#`P
M+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^0V]M;6]N('-T;V-K+"!S:&%R97,@:7-S=65D/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XU,"PP.#(L,30X/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-#<L.#$Q+#0U,SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V]M
M;6]N('-T;V-K+"!S:&%R97,@;W5T<W1A;F1I;F<\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C0Y+#0P-RPQ-#@\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT-RPQ,S8L-#4S/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y4<F5A<W5R
M>2!S=&]C:RP@<VAA<F5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XV-S4L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^-C<U+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM
M+3U?3F5X=%!A<G1?8F5F93EC,3%?8S)F,U\T.&5C7V$R86)?9F8R.#DV,#=E
M9&,P#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+V)E9F4Y8S$Q7V,R
M9C-?-#AE8U]A,F%B7V9F,C@Y-C`W961C,"]7;W)K<VAE971S+U-H965T,#0N
M:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT
M86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S
M8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I
M=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E
M=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS
M1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C
M<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E
M<&]R="!I9#TS1$E$,$5+-4%%/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/D-O
M;F1E;G-E9"!#;VYS;VQI9&%T960@4W1A=&5M96YT<R!O9B!%>'!E;G-E<R`H
M56YA=61I=&5D*2`H55-$("0I/&)R/DEN(%1H;W5S86YD<RP@97AC97!T(%-H
M87)E(&1A=&$L('5N;&5S<R!O=&AE<G=I<V4@<W!E8VEF:65D/"]S=')O;F<^
M/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#(^,R!-
M;VYT:',@16YD960\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS
M<&%N/3-$,3XQ,3$@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DUA<BX@,S$L(#(P
M,3(\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^36%R+B`S,2P@
M,C`Q,3QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y-87(N(#,Q
M+"`R,#$R/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\
M<W1R;VYG/D5X<&5N<V5S.CPO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y297-E87)C:"!A;F0@9&5V96QO<&UE;G0@97AP96YS
M93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`S+#,Y,CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,2PY
M-#$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XD(#0P+#@Q-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^4F5S96%R8V@@86YD(&1E=F5L;W!M96YT(&5M<&QO>65E
M('-T;V-K+6)A<V5D(&-O;7!E;G-A=&EO;B!E>'!E;G-E/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XW,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C(T-CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,L,S0U/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y297-E87)C:"!A;F0@
M9&5V96QO<&UE;G0@;F]N+65M<&QO>65E('-T;V-K+6)A<V5D(&-O;7!E;G-A
M=&EO;B!E>'!E;G-E("AI;F-O;64I/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XQ-3<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M/B@S,2D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XV+#$U,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^1F%I<B!V86QU92!O9B!C;VUM;VX@<W1O
M8VL@:7-S=65D(&EN(&5X8VAA;F=E(&9O<B!R97-E87)C:"!A;F0@9&5V96QO
M<&UE;G0@97AP96YS93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M-3`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XT+#`P-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O=3X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/E1O=&%L(')E<V5A<F-H(&%N9"!D979E;&]P;65N="!E>'!E
M;G-E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS+#8W,3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(L,34V
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M-30L,S$V/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y'96YE<F%L(&%N9"!A9&UI;FES=')A=&EV92!E>'!E;G-E/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#0U.#QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L.3(Q/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,CDL-#,Q
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y'96YE<F%L(&%N9"!A9&UI;FES=')A=&EV92!E;7!L;WEE92!S=&]C:RUB
M87-E9"!C;VUP96YS871I;VX@97AP96YS93PO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,3DX/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,2PP.3D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XY+#<X.#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1F%I<B!V86QU92!O9B!C;VUM
M;VX@<W1O8VL@=V%R<F%N=',@:7-S=65D(&9O<B!G96YE<F%L(&%N9"!A9&UI
M;FES=')A=&EV92!E>'!E;G-E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XQ-#@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XW-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C(L-34P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y&86ER('9A;'5E(&]F(&-O;6UO;B!S=&]C:R!I
M<W-U960@:6X@97AC:&%N9V4@9F]R(&=E;F5R86P@86YD(&%D;6EN:7-T<F%T
M:79E(&5X<&5N<V4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$S
M-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C(S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^-#@Y/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F5U/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^5&]T86P@9V5N97)A;"!A;F0@861M:6YI<W1R871I=F4@97AP
M96YS93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PY,SD\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS+#$Q
M.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C0R+#(U.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O=3X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/D]P97)A=&EN9R!L;W-S/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M/B@U+#8Q,"D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M/B@U+#(W-2D\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M/B@Y-BPU-S0I/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y);G1E<F5S="`H97AP
M96YS92D@:6YC;VUE/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@S
M-RD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M/B@Q*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C8R,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^3W1H97(@*&5X<&5N<V4I(&EN8V]M93PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;3XH,3DL,3$T*3QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L-#,U/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH-BPP-S<I/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F5U
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3F5T(&QO
M<W,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^)"`H,C0L-S8Q*3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^)"`H
M,RPX-#$I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;3XD("@Q,#(L,#,P*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY.970@;&]S<R!P97(@8V]M;6]N
M('-H87)E.CPO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y"87-I8R!A;F0@9&EL=71E9"!L;W-S('!E<B!S:&%R93PO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;3XD("@P+C4R*3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^)"`H,"XQ.2D\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O
M;F<^5V5I9VAT960@879E<F%G92!C;VUM;VX@<VAA<F5S(&]U='-T86YD:6YG
M.CPO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y"
M87-I8R!A;F0@9&EL=71E9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^-#<L.38W+#0Y.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C(P+#,Q-BPQ-S`\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*
M#0HM+2TM+2T]7TYE>'1087)T7V)E9F4Y8S$Q7V,R9C-?-#AE8U]A,F%B7V9F
M,C@Y-C`W961C,`T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B]B969E
M.6,Q,5]C,F8S7S0X96-?83)A8E]F9C(X.38P-V5D8S`O5V]R:W-H965T<R]3
M:&5E=#`U+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E
M9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T
M/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT
M='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[
M(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP
M="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT
M("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA
M<W,],T1R97!O<G0@:60],T1)1#!%5S-!23X-"B`@("`@(#QT<CX-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T
M<F]N9SY#;VYD96YS960@0V]N<V]L:61A=&5D(%-T871E;65N=',@;V8@0V%S
M:"!&;&]W<R`H56YA=61I=&5D*2`H55-$("0I/&)R/DEN(%1H;W5S86YD<RP@
M=6YL97-S(&]T:&5R=VES92!S<&5C:69I960\+W-T<F]N9SX\+W1H/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,CXS($UO;G1H<R!%;F1E
M9#PO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C$Q
M,2!-;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&@^36%R+B`S,2P@,C`Q,CQB<CX\+W1H
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y-87(N(#,Q+"`R,#$Q/&)R/CPO
M=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DUA<BX@,S$L(#(P,3(\8G(^
M/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^0V%S
M:"!F;&]W<R!F<F]M(&]P97)A=&EN9R!A8W1I=FET:65S.CPO<W1R;VYG/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.970@;&]S<SPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XD("@R-"PW-C$I/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XD("@S+#@T,2D\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B0@
M*#$P,BPP,S`I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#X\<W1R;VYG/D%D:G5S=&UE;G1S('1O(')E8V]N8VEL92!N
M970@;&]S<R!T;R!N970@8V%S:"!U<V5D(&EN(&]P97)A=&EN9R!A8W1I=FET
M:65S.CPO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y$97!R96-I871I;VX@86YD(&%M;W)T:7IA=&EO;B!E>'!E;G-E/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT,CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,W/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-S`V/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y,;W-S(&]N(&1I
M<W!O<V%L(&]F(&5Q=6EP;65N=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,3D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/DYO;BUC87-H(')E;G0@97AP96YS93PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,CD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%C8W)E=&EO;B!A;F0@<F5C96EP="!O
M9B!B;VYD(&1I<V-O=6YT/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XS-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^3F]N+6-A<V@@<VAA<F4M8F%S960@8V]M<&5N<V%T:6]N/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT,C<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#,Q-#QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$Y+#(X-3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3&]S
M<R!O;B!E>&-H86YG92!O9B!E<75I='D@:6YS=')U;65N=',\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/CDP,#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1F%I<B!V86QU92!O9B!S:&%R
M97,@;6%N9&%T;W)I;'D@<F5D965M86)L92!F;W(@8V%S:"!U<&]N(&5X97)C
M:7-E(&]F('=A<G)A;G1S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M/B@W.#4I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y&86ER('9A;'5E(&]F(&-O;6UO;B!S=&]C:R!W87)R86YT<R!I
M<W-U960@:6X@97AC:&%N9V4@9F]R('-E<G9I8V5S/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XQ-#@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XW-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C(L-34P/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y&86ER('9A;'5E(&]F(&-O
M;6UO;B!S=&]C:R!I<W-U960@:6X@97AC:&%N9V4@9F]R('-E<G9I8V5S/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ.#4\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR,SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4S.3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0VAA;F=E
M(&EN(&9A:7(@=F%L=64@;V8@8V]M;6]N('-T;V-K('=A<G)A;G1S(&ES<W5E
M9"!I;B!C;VYN96-T:6]N('=I=&@@=F%R:6]U<R!E<75I='D@9FEN86YC:6YG
M<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3@L,C<P/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,2PT,S4I
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M-BPQ.3@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/D9A:7(@=F%L=64@;V8@8V]M;6]N('-T;V-K(&ES<W5E9"!I;B!E
M>&-H86YG92!F;W(@;&EC96YS:6YG(')I9VAT<SPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,RPY-30\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-H86YG92!I;B!F86ER('9A;'5E(&]F
M(&-O;G1I;F=E;G0@<'5R8VAA<V4@8V]N<VED97)A=&EO;CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^.#0T/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-S,U/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D-H86YG97,@
M:6X@87-S971S(&%N9"!L:6%B:6QI=&EE<SH\+W-T<F]N9SX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4')E<&%I9"!E>'!E;G-E<R!A;F0@
M;W1H97(@8W5R<F5N="!A<W-E=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6T^*#$T*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6T^*#$S,RD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M/B@R-C,I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y!8V-O=6YT<R!P87EA8FQE/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XT,C8\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PV-3`\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D1U92!T;R!F;W)M
M97(@<&%R96YT/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@R,#<I
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y!8V-R=65D(&5X<&5N<V5S(&%N9"!O=&AE<B!C=7)R96YT(&QI86)I;&ET
M:65S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@T-3(I/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^.3,P/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,RPP
M,C(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R974^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y.970@8V%S:"!U<V5D(&EN(&]P97)A=&EN9R!A8W1I=FET:65S/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@T+#@X-2D\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@S+#`R-RD\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@V,RPV
M-C,I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#X\<W1R;VYG/D-A<V@@9FQO=W,@9G)O;2!I;G9E<W1I;F<@86-T:79I
M=&EE<SH\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^0VAA;F=E(&EN(')E<W1R:6-T960@8V%S:#PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;3XH,3`Q*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^0V%S:"!R96-E:79E9"!I;B!A8W%U:7-I
M=&EO;CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,38X/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0=7)C
M:&%S92!O9B!S:&]R="UT97)M(&EN=F5S=&UE;G1S/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M/B@S-RPU,S(I/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y-871U<FET:65S(&]F('-H;W)T
M+71E<FT@:6YV97-T;65N=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C,W+#0Y-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^0V%S:"!P86ED(&9O<B!P=7)C:&%S92!O9B!E<75I<&UE
M;G0@86YD(&9U<FYI<VAI;F=S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M/B@T,"D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M/B@W,SDI/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y$:7-P;W-A;"!O9B!E<75I<&UE;G0@86YD(&9U<FYI
M<VAI;F=S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@Q*3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V%S
M:"!R969U;F1E9"`H<&%I9"D@9F]R(&QE87-E(&1E<&]S:70\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6T^*#0U*3QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O=3X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYE="!C87-H('5S960@:6X@
M:6YV97-T:6YG(&%C=&EV:71I97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6T^*#0P*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6T^*#<U,RD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^0V%S:"!F;&]W<R!F<F]M(&9I;F%N
M8VEN9R!A8W1I=FET:65S.CPO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y.970@<')O8V5E9',@9G)O;2!I<W-U86YC92!O9B!C
M;VUM;VX@<W1O8VL\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,X
M-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C<L,S$T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^-C4L,S8W/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y#87-H('!A:60@9F]R(')E<'5R8VAA<V4@;V8@8V]M
M;6]N('-T;V-K/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@S+#@T
M.2D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/DYE="!P<F]C965D<R!F<F]M(&5X97)C:7-E(&]F(&-O;6UO;B!S=&]C
M:R!O<'1I;VYS/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XV,3`\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/DYE="!P<F]C965D<R!F<F]M(&5X97)C:7-E(&]F(&-O;6UO;B!S=&]C:R!W
M87)R86YT<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PR,S8\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ
M+#,X-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^0V]M;6]N('-T;V-K(&ES<W5E9"!I;B!C;VYN96-T:6]N('=I=&@@
M15-04#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,SD\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU-#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3F5T
M('!R;V-E961S(&9R;VT@:7-S=6%N8V4@;V8@8V]N=F5R=&EB;&4@;F]T97,@
M<&%Y86)L93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-3`P/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PP
M,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/E)E<&%Y;65N=',@;V8@8V%P:71A;"!L96%S92!O8FQI9V%T:6]N<SPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH-RD\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@R,RD\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@R,3<I/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#87-H
M(&%D=F%N8V5S(&9R;VT@9F]R;65R('!A<F5N="!C;VUP86YY+"!N970\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C@L-S8V/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F]U/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3F5T(&-A<V@@
M<')O=FED960@8GD@9FEN86YC:6YG(&%C=&EV:71I97,\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C(L,34S/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-RPR.3$\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XW,RPQ,3<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R974^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.970@*&1E
M8W)E87-E*2!I;F-R96%S92!I;B!C87-H(&%N9"!C87-H(&5Q=6EV86QE;G1S
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@R+#<S,BD\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT+#(R-#QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C@L
M-S`Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y#87-H(&%N9"!C87-H(&5Q=6EV86QE;G1S(&%T('1H92!B96=I;FYI
M;F<@;V8@<&5R:6]D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ
M,2PT,S,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XV+#@Y,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^0V%S:"!A;F0@8V%S:"!E<75I=F%L96YT<R!A="!E;F0@
M;V8@<&5R:6]D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XX+#<P
M,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C$Q+#$Q-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C@L-S`Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#X\<W1R;VYG/E-U<'!L96UE;G1A;"!D:7-C;&]S=7)E
M(&]F(&-A<V@@9FQO=R!I;F9O<FUA=&EO;CH\+W-T<F]N9SX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V%S:"!R96-E:79E9"!D=7)I;F<@
M=&AE('!E<FEO9"!F;W(@:6YT97)E<W0\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XW,C<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/D-A<V@@<&%I9"!D=7)I;F<@=&AE('!E<FEO9"!F
M;W(@:6YT97)E<W0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,3(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/CQS=')O;F<^4W5P<&QE;65N=&%L(&1I<V-L;W-U<F4@;V8@;F]N+6-A
M<V@@:6YV97-T:6YG(&%N9"!F:6YA;F-I;F<@86-T:79I=&EE<SH\+W-T<F]N
M9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4V5T=&QE;65N
M="!O9B!C;W)P;W)A=&4@9F]R;6%T:6]N(&5X<&5N<V5S(&EN(&5X8VAA;F=E
M(&9O<B!C;VUM;VX@<W1O8VL\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/CDW.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^1F%I<B!V86QU92!O9B!W87)R86YT<R!I<W-U960@:6X@8V]N
M;F5C=&EO;B!W:71H(&-O;6UO;B!S=&]C:R!R96-O<F1E9"!A<R!A(&-O<W0@
M;V8@97%U:71Y/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT+#(Q
M,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C$X+#`S.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^27-S=6%N8V4@;V8@8V]M;6]N('-T;V-K(&EN(&5X8VAA;F=E
M(&9O<B!O=71S=&%N9&EN9R!W87)R86YT<SPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,RPQ,C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/D9A:7(@=F%L=64@;V8@<VAA<F5S(&UA;F1A
M=&]R:6QY(')E9&5E;6%B;&4@9F]R(&-A<V@@=7!O;B!T:&4@97AE<F-I<V4@
M;V8@=V%R<F%N=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C<X
M-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^4F5C;&%S<VEF:6-A=&EO;B!O9B!W87)R86YT(&QI86)I;&ET>2!U<&]N
M(&5X97)C:7-E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#8U
M.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C$L-C4Y/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y!;&QO8V%T:6]N(&]F(&UA;F%G96UE;G0@97AP96YS97,\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4U,3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^17%U:7!M96YT(&%N
M9"!F=7)N:7-H:6YG<R!E>&-H86YG960@9F]R(&-O;6UO;B!S=&]C:SPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-#@\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5Q=6EP;65N="!A;F0@
M9G5R;FES:&EN9W,@86-Q=6ER960@=&AR;W5G:"!C87!I=&%L(&QE87-E/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT-#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(W-SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5F%L=64@;V8@
M<F5S=')I8W1E9"!S=&]C:R!U;FET<R!A;F0@8V]M;6]N('-T;V-K(&ES<W5E
M9"!I;B!L:65U(&]F(&)O;G5S97,@:6YC;'5D960@:6X@86-C<G5E9"!E>'!E
M;G-E<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-#(W/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-C,T/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.
M;VXM8V%S:"!L96%S92!D97!O<VET/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XD(#4P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].
M97AT4&%R=%]B969E.6,Q,5]C,F8S7S0X96-?83)A8E]F9C(X.38P-V5D8S`-
M"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO8F5F93EC,3%?8S)F,U\T
M.&5C7V$R86)?9F8R.#DV,#=E9&,P+U=O<FMS:&5E=',O4VAE970P-BYH=&UL
M#0I#;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE
M#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB
M#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$
M0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T
M9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO
M=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T
M/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T
M(&ED/3-$240P14U%/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/D1E<V-R:7!T
M:6]N(&]F($)U<VEN97-S(&%N9"!"87-I<R!O9B!0<F5S96YT871I;VX\8G(^
M/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A
M;CTS1#$^,R!-;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^36%R+B`S,2P@,C`Q,CQB
M<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY$
M97-C<FEP=&EO;B!O9B!"=7-I;F5S<R!A;F0@0F%S:7,@;V8@4')E<V5N=&%T
M:6]N(%M!8G-T<F%C=%T\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^1&5S8W)I<'1I;VX@;V8@0G5S:6YE<W,@86YD($)A<VES
M(&]F(%!R97-E;G1A=&EO;CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/"$M+41/0U194$4@:'1M;"!054),24,@(BTO+U<S0R\O1%1$(%A(5$U,
M(#$N,"!4<F%N<VET:6]N86PO+T5.(B`B:'1T<#HO+W=W=RYW,RYO<F<O5%(O
M>&AT;6PQ+T141"]X:'1M;#$M=')A;G-I=&EO;F%L+F1T9"(@+2T^#0H@("`\
M(2TM($)E9VEN($)L;V-K(%1A9V=E9"!.;W1E(#$@+2!U<RUG86%P.D]R9V%N
M:7IA=&EO;D-O;G-O;&ED871I;VY"87-I<T]F4')E<V5N=&%T:6]N0G5S:6YE
M<W-$97-C<FEP=&EO;D%N9$%C8V]U;G1I;F=0;VQI8VEE<U1E>'1";&]C:RTM
M/@T*("`@/"$M+2!X8G)L+&YS("TM/@T*("`@/"$M+2!X8G)L+&YX("TM/@T*
M("`@/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N
M)R!S:7IE/3-$,CX\8CX\+V(^/"]F;VYT/@T*("`@/&9O;G0@<W1Y;&4],T0G
M9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CX\8CX\+V(^
M/"]F;VYT/@T*("`@/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@
M;F5W(')O;6%N)R!S:7IE/3-$,CX-"B`@(#QB/CPO8CX\+V9O;G0^#0H@("`\
M9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I
M>F4],T0R/CQB/@T*("`@/"]B/CPO9F]N=#X-"B`@(#QP('-T>6QE/3-$;6%R
M9VEN+71O<#HQ,G!X.VUA<F=I;BUB;W1T;VTZ,'!X/CQF;VYT('-T>6QE/3-$
M)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^/&(^,2X@
M1&5S8W)I<'1I;VX@;V8@0G5S:6YE<W,@86YD($)A<VES(&]F(%!R97-E;G1A
M=&EO;B`\+V(^/"]F;VYT/CPO<#X-"B`@(#QP('-T>6QE/3-$)VUA<F=I;BUT
M;W`Z-G!X.VUA<F=I;BUB;W1T;VTZ,'!X.R!T97AT+6EN9&5N=#HT)2<^/&9O
M;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE
M/3-$,CY'86QE;F$@0FEO<&AA<FUA+"!);F,N("@F(S@R,C`[=V4L)B,X,C(Q
M.R`F(S@R,C`[=7,L)B,X,C(Q.R`F(S@R,C`[;W5R+"8C.#(R,3L@)B,X,C(P
M.T=A;&5N828C.#(R,3L@;W(@=&AE("8C.#(R,#M#;VUP86YY)B,X,C(Q.RD-
M"B`@(&ES(&$@8FEO<&AA<FUA8V5U=&EC86P@8V]M<&%N>2!F;V-U<V5D(&]N
M(&1E=F5L;W!I;F<@:6YN;W9A=&EV92P@;F5X="UG96YE<F%T:6]N(&-A;F-E
M<B!I;6UU;F]T:&5R87!I97,@=VAI8V@@861D<F5S<R!M86IO<B!U;FUE="!M
M961I8V%L(&YE961S('1O(&%D=F%N8V4@8V%R92X@1V%L96YA(&ES(&1E=F5L
M;W!I;F<@:6YN;W9A=&EV92P@<&5P=&ED92!A;G1I9V5N+6)A<V5D("8C.#(R
M,#MO9F8@=&AE('-H96QF)B,X,C(Q.R!C86YC97(-"B`@(&EM;75N;W1H97)A
M<&EE<R!F;W(@<&]T96YT:6%L(&%P<&QI8V%T:6]N('1O('1R96%T;65N="!O
M9B!L87)G92!P;W!U;&%T:6]N<R!O9B!#86YC97(@4W5R=FEV;W)S+B!097!T
M:61E('9A8V-I;F5S(&AA=F4@<V5V97)A;"!P;W1E;G1I86P@8VQI;FEC86P@
M861V86YT86=E<R!O=F5R(&5X:7-T:6YG(&-A;F-E<B!T<F5A=&UE;G1S(&EN
M8VQU9&EN9R!E>&-E;&QE;G0@<V%F971Y('!R;V9I;&5S+"!L;VYG+6QA<W1I
M;F<@<')O=&5C=&EO;@T*("`@=&AR;W5G:"!I;6UU;F4@<WES=&5M(&%C=&EV
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M("`@<W1R871E9WD@:7,@=&\@<')E=F5N="!R96-U<G)E;F-E(&EN(&5A<FQY
M('-T86=E('!A=&EE;G0@9W)O=7!S('=H;R!M87D@:&%R8F]R("8C.#(R,#MO
M8V-U;'0F(S@R,C$[(')E<VED=6%L(&-A;F-E<B!C96QL<R!T:&%T(&%R92!N
M;W0@9&5T96-T86)L92!B>2!C=7)R96YT(&EM86=I;F<@86YD(&)I;VUA<FME
M<G,L(&%N9"!D97-P:71E(&%D:G5V86YT('1H97)A<'D@86YD(')A9&EA=&EO
M;B!T:&5R87!Y('=I;&P@<F5L87!S92!I;@T*("`@<VEG;FEF:6-A;G0@;G5M
M8F5R<R!O=F5R('1I;64N(#PO9F]N=#X\+W`^#0H@("`\<"!S='EL93TS1"=M
M87)G:6XM=&]P.C$R<'@[;6%R9VEN+6)O='1O;3HP<'@[('1E>'0M:6YD96YT
M.C0E.W!A9&1I;F<M8F]T=&]M.C!P>#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M
M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^3W5R(&QE860@<')O
M9'5C="!C86YD:61A=&4L($YE=59A>#QF;VYT('-T>6QE/3-$)V9O;G0M9F%M
M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#$^#0H@("`\<W5P/B8C.#0X
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M>F4],T0Q/CQS=7`^)G)E9SL\+W-U<#X\+V9O;G0^/"]B/B`H=')A<W1U>G5M
M86(Z($=E;F5N=&5C:"]2;V-H92D@:6X@82!0:&%S92`R(&-L:6YI8V%L('1R
M:6%L+B!/=7(@<V5C;VYD('!R;V1U8W0@8V%N9&ED871E+`T*("`@1F]L871E
M($)I;F1I;F<@4')O=&5I;B`H1D)0*2P@82!T87)G971E9"!V86-C:6YE('=H
M:6-H(&-O;G-I<W1S(&]F('1H92!%,SD@<&5P=&ED92!O=F5R+65X<')E<W-E
M9"`H,C`M.#`@9F]L9"D@:6X@;6]R92!T:&%N(#DP)2!O9B!O=F%R:6%N(&%N
M9"!E;F1O;65T<FEA;"!C86YC97)S+"!I<R!C=7)R96YT;'D@:6X@82!0:&%S
M92`Q(&-L:6YI8V%L('1R:6%L+B`\+V9O;G0^/"]P/@T*("`@/'`@<W1Y;&4]
M,T0G;6%R9VEN+71O<#HQ,G!X.VUA<F=I;BUB;W1T;VTZ,'!X.R!T97AT+6EN
M9&5N=#HT)2<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W
M(')O;6%N)R!S:7IE/3-$,CY4:&4@0V]M<&%N>2!W87,@:6YC;W)P;W)A=&5D
M(&%S($%R9V]N875T(%!H87)M86-E=71I8V%L<RP@26YC+BP@:6X@1&5L87=A
M<F4L(&]N($%P<FEL)B,Q-C`[,RP@,C`P-BX@5&AE($-O;7!A;GD@8VAA;F=E
M9"!I=',@;F%M92!T;R!26&D-"B`@(%!H87)M86-E=71I8V%L<R!#;W)P;W)A
M=&EO;B!O;B!.;W9E;6)E<B8C,38P.S(X+"`R,#`V+B`\+V9O;G0^/"]P/@T*
M("`@/'`@<W1Y;&4],T0G;6%R9VEN+71O<#HQ,G!X.VUA<F=I;BUB;W1T;VTZ
M,'!X.R!T97AT+6EN9&5N=#HT)2<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI
M;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CY792!A8W%U:7)E9"!!<'1H
M97)A($EN8RXL(&]R("8C.#(R,#M!<'1H97)A+"8C.#(R,3L@86YD(&]U<B!.
M975687@-"B`@('!R;V1U8W0@8V%N9&ED871E(&EN($%P<FEL(#(P,3$N(%!R
M:6]R('1O('1H870@=&EM92P@=V4@=V5R92!E;F=A9V5D('!R:6UA<FEL>2!I
M;B!C;VYD=6-T:6YG(&1I<V-O=F5R>2!R97-E87)C:"!A;F0@<')E8VQI;FEC
M86P@9&5V96QO<&UE;G0@86-T:79I=&EE<R!B87-E9"!O;B!23D%I+B!/=7(@
M86-Q=6ES:71I;VX@;V8@07!T:&5R82!F;VQL;W=E9"!F<F]M('1H92!D971E
M<FUI;F%T:6]N(&)Y(&]U<B!B;V%R9"!O9@T*("`@9&ER96-T;W)S('1O(&)R
M;V%D96X@;W5R('-T<F%T96=I8R!D:7)E8W1I;VX@8GD@9VEV:6YG('5S(&%C
M8V5S<R!T;R!A(&QA=&4M<W1A9V4@8VQI;FEC86P@8V%N9&ED871E+"!.9756
M87@N($EN(&-O;FYE8W1I;VX@=VET:"!O=7(@86-Q=6ES:71I;VX@;V8@07!T
M:&5R82P@=V4@<F5D=6-E9"!T:&4@<V-O<&4@;V8@;W5R(%).06D@86-T:79I
M=&EE<RX@/"]F;VYT/CPO<#X-"B`@(#QP('-T>6QE/3-$)VUA<F=I;BUT;W`Z
M,3)P>#MM87)G:6XM8F]T=&]M.C!P>#L@=&5X="UI;F1E;G0Z-"4G/CQF;VYT
M('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS
M1#(^3VX@4V5P=&5M8F5R)B,Q-C`[,C8L(#(P,3$L('1H92!#;VUP86YY(&-H
M86YG960@:71S(&YA;64@9G)O;2!26&D@4&AA<FUA8V5U=&EC86QS($-O<G!O
M<F%T:6]N('1O($=A;&5N82!":6]P:&%R;6$L($EN8RX@:6X@8V]N;F5C=&EO
M;@T*("`@=VET:"!T:&4@0V]M<&%N>28C.#(Q-SMS('-E<&%R871I;VX@:6YT
M;R!T=V\@8V]M<&%N:65S.B`H:2DF(S$V,#M'86QE;F$L('=H:6-H('=I;&P@
M;W!E<F%T92!A<R!A(&QA=&4M<W1A9V4@;VYC;VQO9WD@9')U9R!D979E;&]P
M;65N="!C;VUP86YY.R!A;F0@*&EI*28C,38P.U)8:2!0:&%R;6%C975T:6-A
M;',@0V]R<&]R871I;VXL(&]R(%)8:2P@=VAI8V@@=VEL;"!C;VYT:6YU92!T
M;R!D979E;&]P(&YO=F5L(%).06DM8F%S960-"B`@('1H97)A<&EE<R!U=&EL
M:7II;F<@;W5R(&AI<W1O<FEC86P@4DY!:2!A<W-E=',N(%)8:2!W87,@:6YI
M=&EA;&QY(&EN8V]R<&]R871E9"!A<R!23D-3+"!);F,N(&%N9"!A<W-U;65D
M('1H92!N86UE(%)8:2!0:&%R;6%C975T:6-A;',@0V]R<&]R871I;VX@:6X@
M8V]N:G5N8W1I;VX@=VET:"!T:&4@8VAA;F=E(&EN('1H92!#;VUP86YY)B,X
M,C$W.W,@;F%M92!T;R!'86QE;F$N($]N($%P<FEL(#(W+"`R,#$R+"!T:&4@
M<&QA;FYE9`T*("`@<W!I;BUO=70@;V8@4EAI('=A<R!C;VUP;&5T960@*%-E
M92!.;W1E(#0I+B`\+V9O;G0^/"]P/@T*("`@/'`@<W1Y;&4],T0G;6%R9VEN
M+71O<#HQ,G!X.VUA<F=I;BUB;W1T;VTZ,'!X.R!T97AT+6EN9&5N=#HT)2<^
M/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S
M:7IE/3-$,CY4:&4@0V]M<&%N>2!H87,@;F]T(&=E;F5R871E9"!A;GD@<F5V
M96YU92!F<F]M(&EN8V5P=&EO;B!T:')O=6=H($UA<F-H)B,Q-C`[,S$L#0H@
M("`R,#$R(&%N9"!I<R!C;VYS:61E<F5D(&$@9&5V96QO<&UE;G0M<W1A9V4@
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M("`@=VET:"!O=7(@<F5C96YT;'D@8V]M;65N8V5D(&-L:6YI8V%L('1R:6%L
M<R!O9B!.975687@@86YD($9"4"P@=&AE($-O;7!A;GD@97AP96-T<R!T:&%T
M(&]U<B!R97-E87)C:"!A;F0@9&5V96QO<&UE;G0@97AP96YS92!W:6QL(&EN
M8W)E87-E('-I9VYI9FEC86YT;'D@9G)O;2!H:7-T;W)I8R!L979E;',@9F]R
M('1H92!F;W)E<V5E86)L92!F=71U<F4N(%1H92!#;VUP86YY('=I;&P@;F5E
M9"!T;R!G96YE<F%T92!S:6=N:69I8V%N=`T*("`@<F5V96YU92!T;R!A8VAI
M979E('!R;V9I=&%B:6QI='D@86YD(&UI9VAT(&YE=F5R(&1O('-O+B!);B!T
M:&4@86)S96YC92!O9B!P<F]D=6-T(')E=F5N=64L(&]U<B!P;W1E;G1I86P@
M<V]U<F-E<R!O9B!O<&5R871I;VYA;"!F=6YD:6YG(&%R92!E>'!E8W1E9"!T
M;R!B92!T:&4@<')O8V5E9',@9G)O;2!E<75I='D@9FEN86YC:6YG<RP@9G5N
M9&5D(')E<V5A<F-H(&%N9"!D979E;&]P;65N="!P87EM96YT<R!A;F0@<&%Y
M;65N=',-"B`@(')E8V5I=F5D('5N9&5R('!A<G1N97)S:&EP(&%N9"!C;VQL
M86)O<F%T:79E(&%G<F5E;65N=',N(%1H97)E(&ES(&YO(&=U87)A;G1E92!T
M:&%T(&%D9&ET:6]N86P@9G5N9&EN9R!W:6QL(&)E(&%V86EL86)L92!T;R!T
M:&4@0V]M<&%N>2!O;B!A8V-E<'1A8FQE('1E<FUS+"!O<B!A="!A;&PN($EF
M('1H92!#;VUP86YY(&9A:6QS('1O(&]B=&%I;B!A9&1I=&EO;F%L(&9U;F1I
M;F<@=VAE;B!N965D960L(&ET('=O=6QD(&)E(&9O<F-E9`T*("`@=&\@<V-A
M;&4@8F%C:R!O<B!T97)M:6YA=&4@;W!E<F%T:6]N<R!O<B!T;R!S965K('1O
M(&UE<F=E('=I=&@@;W(@=&\@8F4@86-Q=6ER960@8GD@86YO=&AE<B!C;VUP
M86YY+B`\+V9O;G0^/"]P/@T*("`@/'`@<W1Y;&4],T1M87)G:6XM=&]P.C$X
M<'@[;6%R9VEN+6)O='1O;3HP<'@^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI
M;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CX\:3Y5<V4@;V8@17-T:6UA
M=&5S(#PO:3X\+V9O;G0^/"]P/@T*("`@/'`@<W1Y;&4],T0G;6%R9VEN+71O
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M97,@;V8-"B`@($%M97)I8V$@<F5Q=6ER97,@;6%N86=E;65N="!T;R!M86ME
M(&5S=&EM871E<R!A;F0@87-S=6UP=&EO;G,@=&AA="!A9F9E8W0@=&AE(')E
M<&]R=&5D(&%M;W5N=',@;V8@87-S971S(&%N9"!L:6%B:6QI=&EE<R!A;F0@
M9&ES8VQO<W5R92!O9B!C;VYT:6YG96YT(&%S<V5T<R!A;F0@;&EA8FEL:71I
M97,@870@=&AE(&1A=&4@;V8@=&AE(&9I;F%N8VEA;"!S=&%T96UE;G1S(&%N
M9"!T:&4@<F5P;W)T960@86UO=6YT<R!O9B!E>'!E;G-E<PT*("`@9'5R:6YG
M('1H92!R97!O<G1I;F<@<&5R:6]D+B!!8W1U86P@<F5S=6QT<R!C;W5L9"!D
M:69F97(@9G)O;2!T:&5S92!E<W1I;6%T97,N(#PO9F]N=#X\+W`^#0H@("`\
M<"!S='EL93TS1&UA<F=I;BUT;W`Z,3AP>#MM87)G:6XM8F]T=&]M.C!P>#X\
M9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I
M>F4],T0R/CQI/D1E<FEV871I=F4@1FEN86YC:6%L($EN<W1R=6UE;G1S(#PO
M:3X\+V9O;G0^/"]P/@T*("`@/'`@<W1Y;&4],T1M87)G:6XM=&]P.C9P>#MM
M87)G:6XM8F]T=&]M.C!P>#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT
M:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B8C,38P.R8C,38P.R8C,38P.R8C
M,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.T1U<FEN9R!T:&4@;F]R;6%L
M(&-O=7)S92!O9B!B=7-I;F5S<RP@9G)O;2!T:6UE('1O('1I;64L('1H92!#
M;VUP86YY(&ES<W5E<R!W87)R86YT<R!A;F0@;W!T:6]N<R!T;PT*("`@=F5N
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M(S@R,C`[05-#)B,X,C(Q.RD@5&]P:6,@.#$U+30P+"`F(S@R,C`[/&D^1&5R
M:79A=&EV97,@86YD($AE9&=I;F<@)B,X,C$R.R!#;VYT<F%C=',@:6X@16YT
M:71Y)B,X,C$W.W,@3W=N(%-T;V-K/"]I/B8C.#(R,3LL('1H92!V86QU92!O
M9B!S;VUE(&]F(&]U<B!W87)R86YT<R!I<PT*("`@<F5Q=6ER960@=&\@8F4@
M<F5C;W)D960@87,@82!L:6%B:6QI='DL(&%S('1H92!H;VQD97)S(&AA=F4@
M86X@;W!T:6]N('1O('!U="!T:&4@=V%R<F%N=',@8F%C:R!T;R!T:&4@0V]M
M<&%N>2!I;B!S<&5C:69I960@979E;G1S("AS964@3F]T92`Y*2X@/"]F;VYT
M/CPO<#X-"B`@(#QP('-T>6QE/3-$;6%R9VEN+71O<#HQ.'!X.VUA<F=I;BUB
M;W1T;VTZ,'!X/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE
M=R!R;VUA;B<@<VEZ93TS1#(^/&D^4')I;F-I<&QE<R!O9B!#;VYS;VQI9&%T
M:6]N(#PO:3X\+V9O;G0^/"]P/@T*("`@/'`@<W1Y;&4],T0G;6%R9VEN+71O
M<#HV<'@[;6%R9VEN+6)O='1O;3HP<'@[('1E>'0M:6YD96YT.C0E)SX\9F]N
M="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4]
M,T0R/@T*("`@5&AE(&-O;G-O;&ED871E9"!F:6YA;F-I86P@<W1A=&5M96YT
M<R!I;F-L=61E('1H92!A8V-O=6YT<R!O9B!'86QE;F$@86YD(&ET<R!C;VYS
M;VQI9&%T960@<W5B<VED:6%R:65S+B!!;&P@;6%T97)I86P@:6YT97)C;VUP
M86YY(&%C8V]U;G1S(&AA=F4@8F5E;B!E;&EM:6YA=&5D(&EN(&-O;G-O;&ED
M871I;VXN(#PO9F]N=#X\+W`^#0H@("`\<"!S='EL93TS1&UA<F=I;BUT;W`Z
M,3AP>#MM87)G:6XM8F]T=&]M.C!P>#X\9F]N="!S='EL93TS1"=F;VYT+69A
M;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/CQI/D-O;7!R96AE;G-I
M=F4@3&]S<R`\+VD^/"]F;VYT/CPO<#X-"B`@(#QP('-T>6QE/3-$)VUA<F=I
M;BUT;W`Z-G!X.VUA<F=I;BUB;W1T;VTZ,'!X.R!T97AT+6EN9&5N=#HT)2<^
M/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S
M:7IE/3-$,CY4:&4-"B`@($-O;7!A;GDF(S@R,3<[<R!C;VUP<F5H96YS:79E
M(&QO<W,@:7,@97%U86P@=&\@:71S(&YE="!L;W-S(&9O<B!A;&P@<&5R:6]D
M<R!P<F5S96YT960N(#PO9F]N=#X\+W`^#0H@("`\<"!S='EL93TS1&9O;G0M
M<VEZ93HQ<'@[;6%R9VEN+71O<#HQ.'!X.VUA<F=I;BUB;W1T;VTZ,'!X/B8C
M,38P.SPO<#X-"CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X
M=%!A<G1?8F5F93EC,3%?8S)F,U\T.&5C7V$R86)?9F8R.#DV,#=E9&,P#0I#
M;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+V)E9F4Y8S$Q7V,R9C-?-#AE
M8U]A,F%B7V9F,C@Y-C`W961C,"]7;W)K<VAE971S+U-H965T,#<N:'1M;`T*
M0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*
M0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*
M#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O
M;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M
M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N
M:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\
M+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I
M9#TS1$E$,$5-13X-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY296-E;G0@06-C
M;W5N=&EN9R!0<F]N;W5N8V5M96YT<SQB<CX\+W-T<F]N9SX\+W1H/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XS($UO;G1H<R!%;F1E
M9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T:#Y-87(N(#,Q+"`R,#$R/&)R/CPO=&@^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/E)E8V5N="!!8V-O=6YT:6YG(%!R
M;VYO=6YC96UE;G1S(%M!8G-T<F%C=%T\+W-T<F]N9SX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^4F5C96YT($%C8V]U;G1I;F<@4')O;F]U
M;F-E;65N=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CPA+2U$
M3T-465!%(&AT;6P@4%5"3$E#("(M+R]7,T,O+T141"!82%1-3"`Q+C`@5')A
M;G-I=&EO;F%L+R]%3B(@(FAT='`Z+R]W=W<N=S,N;W)G+U12+WAH=&UL,2]$
M5$0O>&AT;6PQ+71R86YS:71I;VYA;"YD=&0B("TM/@T*("`@/"$M+2!"96=I
M;B!";&]C:R!486=G960@3F]T92`R("T@=7,M9V%A<#I!8V-O=6YT:6YG0VAA
M;F=E<T%N9$5R<F]R0V]R<F5C=&EO;G-497AT0FQO8VLM+3X-"B`@(#QP('-T
M>6QE/3-$;6%R9VEN+71O<#HP<'@[;6%R9VEN+6)O='1O;3HP<'@^/&9O;G0@
M<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$
M,CX\8CXR+B!296-E;G0@06-C;W5N=&EN9R!0<F]N;W5N8V5M96YT<R`\+V(^
M/"]F;VYT/CPO<#X-"B`@(#QP('-T>6QE/3-$)VUA<F=I;BUT;W`Z-G!X.VUA
M<F=I;BUB;W1T;VTZ,'!X.R!T97AT+6EN9&5N=#HT)2<^/&9O;G0@<W1Y;&4]
M,T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CX\:3X\
M+VD^26X@36%Y)B,Q-C`[,C`Q,2P@=&AE($9!4T(@:7-S=65D($%C8V]U;G1I
M;F<@4W1A;F1A<F1S(%5P9&%T960@*"8C.#(R,#M!4U4F(S@R,C$[*2`R,#$Q
M+3`T/&D^+"!&86ER(%9A;'5E#0H@("!-96%S=7)E;65N=#PO:3X@*%1O<&EC
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M90T*("`@86YD(&5X<&%N9',@=&AE(&1I<V-L;W-U<F5S(&9O<B!F86ER('9A
M;'5E(&UE87-U<F5M96YT<R!T:&%T(&%R92!E<W1I;6%T960@=7-I;F<@<VEG
M;FEF:6-A;G0@=6YO8G-E<G9A8FQE("A,979E;"`S*2!I;G!U=',N(%1H:7,@
M;F5W('-T86YD87)D(&ES(&5F9F5C=&EV92!O;B!A('!R;W-P96-T:79E(&)A
M<VES(&9O<B!A;FYU86P@86YD(&EN=&5R:6T@<F5P;W)T:6YG('!E<FEO9',@
M8F5G:6YN:6YG(&]N(&]R(&%F=&5R#0H@("!$96-E;6)E<B8C,38P.S$U+"`R
M,#$Q+B!4:&4@0V]M<&%N>28C.#(Q-SMS(&%D;W!T:6]N(&]F('1H:7,@;F5W
M('-T86YD87)D(&1I9"!N;W0@:&%V92!A(&UA=&5R:6%L(&EM<&%C="!O;B!T
M:&4@0V]M<&%N>28C.#(Q-SMS(&-O;G-O;&ED871E9"!F:6YA;F-I86P@<W1A
M=&5M96YT<RX@/"]F;VYT/CPO<#X-"B`@(#QP('-T>6QE/3-$)VUA<F=I;BUT
M;W`Z,3)P>#MM87)G:6XM8F]T=&]M.C!P>#L@=&5X="UI;F1E;G0Z-"4G/CQF
M;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ
M93TS1#(^#0H@("`\:3X\+VD^26X@2G5N928C,38P.S(P,3$L('1H92!&05-"
M(&ES<W5E9"!!4U4@,C`Q,2TP-2P@/&D^0V]M<')E:&5N<VEV92!);F-O;64\
M+VD^("A4;W!I8R`R,C`I.B`\:3Y0<F5S96YT871I;VX@;V8@0V]M<')E:&5N
M<VEV92!);F-O;64\+VD^+"!A(&YE=R!A8V-O=6YT:6YG('-T86YD87)D('1H
M870@96QI;6EN871E<R!T:&4@;W!T:6]N('1O('!R97-E;G0-"B`@('1H92!C
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M<B!C;VUP<F5H96YS:79E(&EN8V]M92!O<B!W:&5N(&%N(&ET96T@;V8-"B`@
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M:7-C86P@>65A<G,@86YD(&EN=&5R:6T-"B`@('!E<FEO9',@=VET:&EN('1H
M;W-E('EE87)S(&)E9VEN;FEN9R!A9G1E<B!$96-E;6)E<B8C,38P.S$U+"`R
M,#$Q+B!!<R!T:&ES(&YE=R!S=&%N9&%R9"!O;FQY(')E<75I<F5S(&5N:&%N
M8V5D(&1I<V-L;W-U<F4L('1H92!A9&]P=&EO;B!O9B!T:&ES('-T86YD87)D
M(&1I9"!N;W0@:6UP86-T('1H92!#;VUP86YY)B,X,C$W.W,@8V]N<V]L:61A
M=&5D(&9I;F%N8VEA;"!S=&%T96UE;G1S+B`\+V9O;G0^/"]P/@T*/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO
M8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]B969E.6,Q,5]C
M,F8S7S0X96-?83)A8E]F9C(X.38P-V5D8S`-"D-O;G1E;G0M3&]C871I;VXZ
M(&9I;&4Z+R\O0SHO8F5F93EC,3%?8S)F,U\T.&5C7V$R86)?9F8R.#DV,#=E
M9&,P+U=O<FMS:&5E=',O4VAE970P."YH=&UL#0I#;VYT96YT+51R86YS9F5R
M+45N8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E
M>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A
M9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E
M;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4]
M,T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M
M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^
M#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P14U%/@T*("`@
M("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R
M;W=S<&%N/3-$,CX\<W1R;VYG/D%P=&AE<F$@06-Q=6ES:71I;VX\8G(^/"]S
M=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS
M1#$^,R!-;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^36%R+B`S,2P@,C`Q,CQB<CX\
M+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY!<'1H
M97)A($%C<75I<VET:6]N(%M!8G-T<F%C=%T\+W-T<F]N9SX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^07!T:&5R82!!8W%U:7-I=&EO;CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/"$M+41/0U194$4@:'1M
M;"!054),24,@(BTO+U<S0R\O1%1$(%A(5$U,(#$N,"!4<F%N<VET:6]N86PO
M+T5.(B`B:'1T<#HO+W=W=RYW,RYO<F<O5%(O>&AT;6PQ+T141"]X:'1M;#$M
M=')A;G-I=&EO;F%L+F1T9"(@+2T^#0H@("`\(2TM($)E9VEN($)L;V-K(%1A
M9V=E9"!.;W1E(#,@+2!U<RUG86%P.D)U<VEN97-S0V]M8FEN871I;VY$:7-C
M;&]S=7)E5&5X=$)L;V-K+2T^#0H@("`\<"!S='EL93TS1&UA<F=I;BUT;W`Z
M,3AP>#MM87)G:6XM8F]T=&]M.C!P>#X\9F]N="!S='EL93TS1"=F;VYT+69A
M;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/CQB/C,N)B,Q-C`[07!T
M:&5R82!!8W%U:7-I=&EO;B`\+V(^/"]F;VYT/CPO<#X-"B`@(#QP('-T>6QE
M/3-$)VUA<F=I;BUT;W`Z-G!X.VUA<F=I;BUB;W1T;VTZ,'!X.R!T97AT+6EN
M9&5N=#HT)2<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W
M(')O;6%N)R!S:7IE/3-$,CY/;B!!<')I;"8C,38P.S$S+"`R,#$Q+"!T:&4@
M0V]M<&%N>2!C;VUP;&5T960@:71S(&%C<75I<VET:6]N(&]F($%P=&AE<F$L
M($EN8RXL(&$@1&5L87=A<F4@8V]R<&]R871I;VX-"B`@("@F(S@R,C`[07!T
M:&5R828C.#(R,3LI+"!U;F1E<B!A;B!!9W)E96UE;G0@86YD(%!L86X@;V8@
M365R9V5R("@F(S@R,C`[365R9V5R($%G<F5E;65N="8C.#(R,3LI(&5N=&5R
M960@:6YT;R!O;B!-87)C:"8C,38P.S,Q+"`R,#$Q+B!3=6)J96-T('1O('1H
M92!T97)M<R!A;F0@8V]N9&ET:6]N<R!O9B!T:&4@365R9V5R($%G<F5E;65N
M="P@=&AE($-O;7!A;GDF(S@R,3<[<R!W:&]L;'D@;W=N960@<W5B<VED:6%R
M>2!F;W)M960@9F]R('1H:7,-"B`@('!U<G!O<V4@=V%S(&UE<F=E9"!W:71H
M(&%N9"!I;G1O($%P=&AE<F$L('=I=&@@07!T:&5R82!S=7)V:79I;F<@87,@
M82!W:&]L;'DM;W=N960@<W5B<VED:6%R>2!O9B!T:&4@0V]M<&%N>2X@56YD
M97(@=&AE($UE<F=E<B!!9W)E96UE;G0L('1H92!#;VUP86YY(&ES<W5E9"!T
M;R!!<'1H97)A)B,X,C$W.W,@<W1O8VMH;VQD97)S(&%P<')O>&EM871E;'D@
M-2XP)B,Q-C`[;6EL;&EO;B!S:&%R97,@;V8@8V]M;6]N('-T;V-K(&]F('1H
M90T*("`@0V]M<&%N>2`H=&AE("8C.#(R,#M!9V=R96=A=&4@4W1O8VL@0V]N
M<VED97)A=&EO;B8C.#(R,3LI(&%N9"!A9W)E960@=&\@;6%K92!F=71U<F4@
M8V]N=&EN9V5N="!P87EM96YT<R!O9B!U<"!T;R`D,S(F(S$V,#MM:6QL:6]N
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M9&5R871I;VX-"B`@('5N;&5S<R!I="!H87,@9FER<W0@;V)T86EN960@87!P
M<F]V86P@;V8@:71S('-T;V-K:&]L9&5R<R!I;B!A8V-O<F1A;F-E('=I=&@@
M4G5L92`U-C,U*&$I(&]F('1H92!.05-$05$@36%R:V5T<&QA8V4@4G5L97,N
M(#PO9F]N=#X\+W`^#0H@("`\<"!S='EL93TS1"=M87)G:6XM=&]P.C$R<'@[
M;6%R9VEN+6)O='1O;3HP<'@[('1E>'0M:6YD96YT.C0E)SX\9F]N="!S='EL
M93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/DEN
M#0H@("!C;VYN96-T:6]N('=I=&@@=&AE($UE<F=E<B!!9W)E96UE;G0L('1H
M92!#;VUP86YY(&1E<&]S:71E9"!W:71H(&$@=&AI<F0M<&%R='D@97-C<F]W
M(&%G96YT(&-E<G1I9FEC871E<R!R97!R97-E;G1I;F<@,3`E(&]F('1H92!!
M9V=R96=A=&4@4W1O8VL@0V]N<VED97)A=&EO;BP@=VAI8V@@<VAA<F5S('=I
M;&P@8F4@879A:6QA8FQE('1O(&-O;7!E;G-A=&4@=&AE($-O;7!A;GD@86YD
M(')E;&%T960@<&%R=&EE<R!F;W(@8V5R=&%I;@T*("`@:6YD96UN:69I86)L
M92!L;W-S97,@87,@9&5S8W)I8F5D(&EN('1H92!-97)G97(@06=R965M96YT
M+B!/;B!/8W1O8F5R)B,Q-C`[,3,L(#(P,3$L('1H92!E<V-R;W<@86=E;G0@
M<F5L96%S960@9G)O;2!T:&4@97-C<F]W(#4E(&]F('1H92!!9V=R96=A=&4@
M4W1O8VL@0V]N<VED97)A=&EO;BP@;W(@,C0X+#<P-2!S:&%R97,N(%1H92!R
M96UA:6YI;F<@06=G<F5G871E(%-T;V-K($-O;G-I9&5R871I;VX@:&5L9"!W
M:71H('1H90T*("`@97-C<F]W(&%G96YT('=A<R!R96QE87-E9"!I;B!!<')I
M;"`R,#$R("AS964@3F]T92`Q,2DN(#PO9F]N=#X\+W`^#0H@("`\<"!S='EL
M93TS1"=M87)G:6XM=&]P.C$R<'@[;6%R9VEN+6)O='1O;3HP<'@[('1E>'0M
M:6YD96YT.C0E)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N
M97<@<F]M86XG('-I>F4],T0R/E1H92!#;VUP86YY)B,X,C$W.W,@86-Q=6ES
M:71I;VX@;V8@07!T:&5R82!W87,@:6X@8V]N8V5R="!W:71H('1H90T*("`@
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M97,N(#PO9F]N=#X\+W`^#0H@("`\<"!S='EL93TS1"=M87)G:6XM=&]P.C$R
M<'@[;6%R9VEN+6)O='1O;3HP<'@[('1E>'0M:6YD96YT.C0E)SX\9F]N="!S
M='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R
M/E1H92!P=7)C:&%S92!P<FEC92!C;VYS:61E<F%T:6]N(&%N9"!A;&QO8V%T
M:6]N(&]F('!U<F-H87-E('!R:6-E(&]F($%P=&AE<F$@=V5R92!A<R!F;VQL
M;W=S.B`\+V9O;G0^/"]P/@T*("`@/'`@<W1Y;&4],T1F;VYT+7-I>F4Z,3)P
M>#MM87)G:6XM=&]P.C!P>#MM87)G:6XM8F]T=&]M.C!P>#XF(S$V,#L\+W`^
M#0H@("`\=&%B;&4@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!W
M:61T:#TS1#DR)2!B;W)D97(],T0P('-T>6QE/3-$)V)O<F1E<BUC;VQL87!S
M93IC;VQL87!S93L@=&5X="UA;&EG;CH@;&5F="<@86QI9VX],T1C96YT97(^
M#0H@("`\(2TM($)E9VEN(%1A8FQE($AE860@+2T^#0H@("`\='(^(`T*("`@
M/'1D('=I9'1H/3-$.3$E/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS
M1&)O='1O;2!W:61T:#TS1#4E/B8C,38P.SPO=&0^(`T*("`@/'1D/B8C,38P
M.SPO=&0^(`T*("`@/'1D/B8C,38P.SPO=&0^(`T*("`@/'1D/B8C,38P.SPO
M=&0^#0H@("`\+W1R/B`-"B`@(#QT<CX@#0H@("`\=&0@=F%L:6=N/3-$8F]T
M=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT
M9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT
M/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,B!A
M;&EG;CTS1&-E;G1E<B!S='EL93TS1"=B;W)D97(M8F]T=&]M.C%P>"!S;VQI
M9"`C,#`P,#`P)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N
M97<@<F]M86XG('-I>F4],T0Q/CQB/BAI;B`P,#`F(S@R,3<[<RD\+V(^/"]F
M;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE
M/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X-"B`@(#PO='(^#0H@("`\(2TM($5N
M9"!486)L92!(96%D("TM/@T*("`@/"$M+2!"96=I;B!486)L92!";V1Y("TM
M/@T*("`@/'1R(&)G8V]L;W(],T0C8V-E969F/B`-"B`@(#QT9"!V86QI9VX]
M,T1T;W`^#0H@("`\<"!S='EL93TS1"=M87)G:6XM;&5F=#HQ+C`P96T[('1E
M>'0M:6YD96YT.BTQ+C`P96TG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY
M.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^/&(^0V%L8W5L871I;VX@;V8@
M86QL;V-A8FQE('!U<F-H87-E('!R:6-E.CPO8CX\+V9O;G0^/"]P/@T*("`@
M/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q
M/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^
M)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO
M=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3XF(S$V,#L\+W1D/@T*("`@
M/"]T<CX@#0H@("`\='(^(`T*("`@/'1D('9A;&EG;CTS1'1O<#X-"B`@(#QP
M('-T>6QE/3-$)VUA<F=I;BUL969T.C$N,#!E;3L@=&5X="UI;F1E;G0Z+3$N
M,#!E;2<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O
M;6%N)R!S:7IE/3-$,CY&86ER('9A;'5E(&]F('-H87)E<R!I<W-U960@870@
M8VQO<VEN9R!I;F-L=61I;F<@97-C<F]W960@<VAA<F5S(&5X<&5C=&5D('1O
M(&)E(')E;&5A<V5D/"]F;VYT/CPO<#X-"B`@(#PO=&0^(`T*("`@/'1D('9A
M;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T
M9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O
M;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)#PO9F]N=#X\
M+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\
M9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I
M>F4],T0R/B8C,38P.S8L,S8W/"]F;VYT/CPO=&0^(`T*("`@/'1D(&YO=W)A
M<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N
M="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXH:2D\+V9O;G0^
M/"]T9#X-"B`@(#PO='(^(`T*("`@/'1R(&)G8V]L;W(],T0C8V-E969F/B`-
M"B`@(#QT9"!V86QI9VX],T1T;W`^#0H@("`\<"!S='EL93TS1"=M87)G:6XM
M;&5F=#HQ+C`P96T[('1E>'0M:6YD96YT.BTQ+C`P96TG/CQF;VYT('-T>6QE
M/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^17-T
M:6UA=&5D('9A;'5E(&]F(&5A<FXM;W5T/"]F;VYT/CPO<#X-"B`@(#PO=&0^
M(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V
M,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT
M('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS
M1#(^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O
M;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I
M;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^-BPT-C`\+V9O;G0^/"]T9#X@#0H@
M("`\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;3X\9F]N="!S
M='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R
M/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@/"]T<CX@#0H@("`\='(@<W1Y;&4]
M,T1F;VYT+7-I>F4Z,7!X/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^)B,Q
M-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^
M(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`@(#QP('-T>6QE/3-$)V)O
M<F1E<BUT;W`Z,7!X('-O;&ED(",P,#`P,#`G/B8C,38P.SPO<#X-"B`@(#PO
M=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`@(#QP('-T>6QE/3-$
M)V)O<F1E<BUT;W`Z,7!X('-O;&ED(",P,#`P,#`G/B8C,38P.SPO<#X-"B`@
M(#PO=&0^(`T*("`@/'1D/B8C,38P.SPO=&0^#0H@("`\+W1R/B`-"B`@(#QT
M<CX@#0H@("`\=&0@=F%L:6=N/3-$=&]P/@T*("`@/'`@<W1Y;&4],T0G;6%R
M9VEN+6QE9G0Z,2XP,&5M.R!T97AT+6EN9&5N=#HM,2XP,&5M)SX\9F]N="!S
M='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R
M/E1O=&%L(&%L;&]C86)L92!P=7)C:&%S92!P<FEC93PO9F]N=#X\+W`^#0H@
M("`\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS
M1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O
M;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG
M('-I>F4],T0R/B0\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T
M=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ
M=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXQ,BPX,C<\+V9O;G0^/"]T9#X@
M#0H@("`\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;3X\9F]N
M="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4]
M,T0R/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@/"]T<CX@#0H@("`\='(@<W1Y
M;&4],T1F;VYT+7-I>F4Z,7!X/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^
M)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO
M=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`@(#QP('-T>6QE/3-$
M)V)O<F1E<BUT;W`Z,W!X(&1O=6)L92`C,#`P,#`P)SXF(S$V,#L\+W`^#0H@
M("`\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@("`\<"!S='EL
M93TS1"=B;W)D97(M=&]P.C-P>"!D;W5B;&4@(S`P,#`P,"<^)B,Q-C`[/"]P
M/@T*("`@/"]T9#X@#0H@("`\=&0^)B,Q-C`[/"]T9#X-"B`@(#PO='(^(`T*
M("`@/'1R(&)G8V]L;W(],T0C8V-E969F/B`-"B`@(#QT9"!V86QI9VX],T1T
M;W`^#0H@("`\<"!S='EL93TS1"=M87)G:6XM;&5F=#HQ+C`P96T[('1E>'0M
M:6YD96YT.BTQ+C`P96TG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I
M;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^/&(^06QL;V-A=&EO;B!O9B!P=7)C
M:&%S92!P<FEC93H\+V(^/"]F;VYT/CPO<#X-"B`@(#PO=&0^(`T*("`@/'1D
M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^
M/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^(`T*
M("`@/'1D('9A;&EG;CTS1&)O='1O;3XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V
M86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X-"B`@(#PO='(^(`T*("`@/'1R
M/B`-"B`@(#QT9"!V86QI9VX],T1T;W`^#0H@("`\<"!S='EL93TS1"=M87)G
M:6XM;&5F=#HQ+C`P96T[('1E>'0M:6YD96YT.BTQ+C`P96TG/CQF;VYT('-T
M>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^
M0V%S:#PO9F]N=#X\+W`^#0H@("`\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B
M;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@
M/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL
M>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B0\+V9O;G0^/"]T9#X@#0H@
M("`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y
M;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXQ
M-C@\+V9O;G0^/"]T9#X@#0H@("`\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG
M;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N
M97<@<F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@/"]T
M<CX@#0H@("`\='(@8F=C;VQO<CTS1"-C8V5E9F8^(`T*("`@/'1D('9A;&EG
M;CTS1'1O<#X-"B`@(#QP('-T>6QE/3-$)VUA<F=I;BUL969T.C$N,#!E;3L@
M=&5X="UI;F1E;G0Z+3$N,#!E;2<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI
M;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CY0<F5P86ED(&5X<&5N<V5S
M(&%N9"!O=&AE<B!C=7)R96YT(&%S<V5T<SPO9F]N=#X\+W`^#0H@("`\+W1D
M/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q
M-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N
M="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4]
M,T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T
M;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT
M:6UE<R!N97<@<F]M86XG('-I>F4],T0R/C$T/"]F;VYT/CPO=&0^(`T*("`@
M/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y
M;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXF
M(S$V,#L\+V9O;G0^/"]T9#X-"B`@(#PO='(^(`T*("`@/'1R/B`-"B`@(#QT
M9"!V86QI9VX],T1T;W`^#0H@("`\<"!S='EL93TS1"=M87)G:6XM;&5F=#HQ
M+C`P96T[('1E>'0M:6YD96YT.BTQ+C`P96TG/CQF;VYT('-T>6QE/3-$)V9O
M;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^17%U:7!M96YT
M(&%N9"!F=7)N:7-H:6YG<SPO9F]N=#X\+W`^#0H@("`\+W1D/B`-"B`@(#QT
M9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT
M/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS
M1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B8C,38P
M.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX]
M,T1R:6=H=#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@
M<F]M86XG('-I>F4],T0R/C$Q/"]F;VYT/CPO=&0^(`T*("`@/'1D(&YO=W)A
M<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N
M="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O
M;G0^/"]T9#X-"B`@(#PO='(^(`T*("`@/'1R(&)G8V]L;W(],T0C8V-E969F
M/B`-"B`@(#QT9"!V86QI9VX],T1T;W`^#0H@("`\<"!S='EL93TS1"=M87)G
M:6XM;&5F=#HQ+C`P96T[('1E>'0M:6YD96YT.BTQ+C`P96TG/CQF;VYT('-T
M>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^
M1V]O9'=I;&P\+V9O;G0^/"]P/@T*("`@/"]T9#X@#0H@("`\=&0@=F%L:6=N
M/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-
M"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF
M86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^
M/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^
M/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S
M:7IE/3-$,CXU+#@Y.#PO9F]N=#X\+W1D/B`-"B`@(#QT9"!N;W=R87`],T1N
M;W=R87`@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M
M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO
M=&0^#0H@("`\+W1R/B`-"B`@(#QT<CX@#0H@("`\=&0@=F%L:6=N/3-$=&]P
M/@T*("`@/'`@<W1Y;&4],T0G;6%R9VEN+6QE9G0Z,2XP,&5M.R!T97AT+6EN
M9&5N=#HM,2XP,&5M)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE
M<R!N97<@<F]M86XG('-I>F4],T0R/DEN+7!R;V-E<W,@<F5S96%R8V@@86YD
M(&1E=F5L;W!M96YT/"]F;VYT/CPO<#X-"B`@(#PO=&0^(`T*("`@/'1D('9A
M;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T
M9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O
M;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F
M;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I
M9VAT/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA
M;B<@<VEZ93TS1#(^,3(L.#8T/"]F;VYT/CPO=&0^(`T*("`@/'1D(&YO=W)A
M<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N
M="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O
M;G0^/"]T9#X-"B`@(#PO='(^(`T*("`@/'1R(&)G8V]L;W(],T0C8V-E969F
M/B`-"B`@(#QT9"!V86QI9VX],T1T;W`^#0H@("`\<"!S='EL93TS1"=M87)G
M:6XM;&5F=#HQ+C`P96T[('1E>'0M:6YD96YT.BTQ+C`P96TG/CQF;VYT('-T
M>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^
M06-C;W5N=',@<&%Y86)L93PO9F]N=#X\+W`^#0H@("`\+W1D/B`-"B`@(#QT
M9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT
M/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS
M1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B8C,38P
M.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX]
M,T1R:6=H=#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@
M<F]M86XG('-I>F4],T0R/B@Y,S$\+V9O;G0^/"]T9#X@#0H@("`\=&0@;F]W
M<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F
M;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/BD\+V9O;G0^
M/"]T9#X-"B`@(#PO='(^(`T*("`@/'1R/B`-"B`@(#QT9"!V86QI9VX],T1T
M;W`^#0H@("`\<"!S='EL93TS1"=M87)G:6XM;&5F=#HQ+C`P96T[('1E>'0M
M:6YD96YT.BTQ+C`P96TG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I
M;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^06-C<G5E9"!E>'!E;G-E<R!A;F0@
M;W1H97(@8W5R<F5N="!L:6%B:6QI=&EE<SPO9F]N=#X\+W`^#0H@("`\+W1D
M/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q
M-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N
M="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4]
M,T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T
M;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT
M:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B@Q-#,\+V9O;G0^/"]T9#X@#0H@
M("`\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;3X\9F]N="!S
M='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R
M/BD\+V9O;G0^/"]T9#X-"B`@(#PO='(^(`T*("`@/'1R(&)G8V]L;W(],T0C
M8V-E969F/B`-"B`@(#QT9"!V86QI9VX],T1T;W`^#0H@("`\<"!S='EL93TS
M1"=M87)G:6XM;&5F=#HQ+C`P96T[('1E>'0M:6YD96YT.BTQ+C`P96TG/CQF
M;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ
M93TS1#(^3F]T97,@<&%Y86)L93PO9F]N=#X\+W`^#0H@("`\+W1D/B`-"B`@
M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F
M;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL
M93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B8C
M,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@86QI
M9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N
M97<@<F]M86XG('-I>F4],T0R/B@Q/"]F;VYT/CPO=&0^(`T*("`@/'1D(&YO
M=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G
M9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXI/"]F;VYT
M/CPO=&0^#0H@("`\+W1R/B`-"B`@(#QT<CX@#0H@("`\=&0@=F%L:6=N/3-$
M=&]P/@T*("`@/'`@<W1Y;&4],T0G;6%R9VEN+6QE9G0Z,2XP,&5M.R!T97AT
M+6EN9&5N=#HM,2XP,&5M)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT
M:6UE<R!N97<@<F]M86XG('-I>F4],T0R/D1E9F5R<F5D('1A>"!L:6%B:6QI
M='DL(&YO;BUC=7)R96YT/"]F;VYT/CPO<#X-"B`@(#PO=&0^(`T*("`@/'1D
M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^
M/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$
M)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)B,Q-C`[
M/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS
M1')I9VAT/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R
M;VUA;B<@<VEZ93TS1#(^*#4L,#4S/"]F;VYT/CPO=&0^(`T*("`@/'1D(&YO
M=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G
M9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXI/"]F;VYT
M/CPO=&0^#0H@("`\+W1R/B`-"B`@(#QT<B!S='EL93TS1&9O;G0M<VEZ93HQ
M<'@^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3XF(S$V,#L\+W1D/B`-"B`@
M(#QT9"!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L
M:6=N/3-$8F]T=&]M/@T*("`@/'`@<W1Y;&4],T0G8F]R9&5R+71O<#HQ<'@@
M<V]L:60@(S`P,#`P,"<^)B,Q-C`[/"]P/@T*("`@/"]T9#X@#0H@("`\=&0@
M=F%L:6=N/3-$8F]T=&]M/@T*("`@/'`@<W1Y;&4],T0G8F]R9&5R+71O<#HQ
M<'@@<V]L:60@(S`P,#`P,"<^)B,Q-C`[/"]P/@T*("`@/"]T9#X@#0H@("`\
M=&0^)B,Q-C`[/"]T9#X-"B`@(#PO='(^(`T*("`@/'1R(&)G8V]L;W(],T0C
M8V-E969F/B`-"B`@(#QT9"!V86QI9VX],T1T;W`^)B,Q-C`[/"]T9#X@#0H@
M("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO
M9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y
M;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXD
M/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS
M1')I9VAT/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R
M;VUA;B<@<VEZ93TS1#(^,3(L.#(W/"]F;VYT/CPO=&0^(`T*("`@/'1D(&YO
M=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G
M9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXF(S$V,#L\
M+V9O;G0^/"]T9#X-"B`@(#PO='(^(`T*("`@/'1R('-T>6QE/3-$9F]N="US
M:7IE.C%P>#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^
M(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3XF(S$V,#L\+W1D/B`-"B`@(#QT
M9"!V86QI9VX],T1B;W1T;VT^#0H@("`\<"!S='EL93TS1"=B;W)D97(M=&]P
M.C-P>"!D;W5B;&4@(S`P,#`P,"<^)B,Q-C`[/"]P/@T*("`@/"]T9#X@#0H@
M("`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*("`@/'`@<W1Y;&4],T0G8F]R9&5R
M+71O<#HS<'@@9&]U8FQE(",P,#`P,#`G/B8C,38P.SPO<#X-"B`@(#PO=&0^
M(`T*("`@/'1D/B8C,38P.SPO=&0^#0H@("`\+W1R/@T*("`@/"$M+2!%;F0@
M5&%B;&4@0F]D>2`M+3X-"B`@(#PO=&%B;&4^#0H@("`\<"!S='EL93TS1"=L
M:6YE+6AE:6=H=#HX<'@[;6%R9VEN+71O<#HP<'@[;6%R9VEN+6)O='1O;3HR
M<'@[8F]R9&5R+6)O='1O;3HP+C5P="!S;VQI9"`C,#`P,#`P.W=I9'1H.C$P
M)2<^)B,Q-C`[/"]P/@T*("`@/'1A8FQE('-T>6QE/3-$)V)O<F1E<BUC;VQL
M87!S93IC;VQL87!S93L@=&5X="UA;&EG;CH@;&5F="<@8F]R9&5R/3-$,"!C
M96QL<&%D9&EN9STS1#`@8V5L;'-P86-I;F<],T0P('=I9'1H/3-$,3`P)3X@
M#0H@("`\='(^(`T*("`@/'1D('=I9'1H/3-$-"4@=F%L:6=N/3-$=&]P(&%L
M:6=N/3-$;&5F=#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N
M97<@<F]M86XG('-I>F4],T0R/BAI*3PO9F]N=#X\+W1D/B`-"B`@(#QT9"!A
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M9B!T:&4@8VQO<V4@;V8@8G5S:6YE<W,-"B`@(&]N($%P<FEL)B,Q-C`[,3,L
M(#(P,3$N(#PO9F]N=#X\+W1D/@T*("`@/"]T<CX-"B`@(#PO=&%B;&4^(`T*
M("`@/'`@<W1Y;&4],T1F;VYT+7-I>F4Z,7!X.VUA<F=I;BUT;W`Z,3)P>#MM
M87)G:6XM8F]T=&]M.C!P>#XF(S$V,#L\+W`^#0H@("`\<"!S='EL93TS1"=M
M87)G:6XM=&]P.C!P>#MM87)G:6XM8F]T=&]M.C!P>#L@=&5X="UI;F1E;G0Z
M-"4G/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA
M;B<@<VEZ93TS1#(^5&AE(&5S=&EM871E9"!V86QU92!O9@T*("`@=&AE(&5A
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M9&%T92!A;F0@=&AE;@T*("`@87!P;'EI;F<@82!D:7-C;W5N="!R871E+"!B
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M:&4@<F5P;W)T:6YG(&1A=&4N($]N($IA;G5A<GDF(S$V,#LQ.2P@,C`Q,BP@
M=&AE(&9I<G-T(&UI;&5S=&]N92!O9B`D,2PP,#`L,#`P(&]F('1H:7,@8V]N
M=&EN9V5N="!L:6%B:6QI='D@=V%S('1R:6=G97)E9"!W:71H('1H92!F:7)S
M="!P871I96YT(&5N<F]L;&5D(&EN(&]U<@T*("`@4&AA<V4@,R!04D5314Y4
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M<&%R='D-"B`@(&5S8W)O=R!A9V5N="X@5&AE(&UI;&5S=&]N92!S:&%R97,@
M=VEL;"!B92!R96QE87-E9"!T;R!T:&4@07!T:&5R82!S:&%R96AO;&1E<G,@
M9G)O;2!E<V-R;W<@:68@=&AE(&ES<W5A;F-E(&]F('1H92!M:6QE<W1O;F4@
M<VAA<F5S(&ES(&%P<')O=F5D(&)Y('1H92!S=&]C:VAO;&1E<G,@;V8@=&AE
M($-O;7!A;GD@870@;W5R(#(P,3(@86YN=6%L('-T;V-K:&]L9&5R<R!M965T
M:6YG+B!3:6YC92!T:&4@<F5L96%S92!O9B!T:&4-"B`@('-H87)E<R!I<R!S
M=6)J96-T('1O('-T;V-K:&]L9&5R(&%P<')O=F%L+"!T:&4@)#$L,#`P+#`P
M,"!H87,@8F5E;B!R96-O<F1E9"!I;B!A8V-R=65D(&5X<&5N<V5S(&%N9"!O
M=&AE<B!C=7)R96YT(&QI86)I;&ET:65S(&%T($UA<F-H)B,Q-C`[,S$L(#(P
M,3(@:6X@=&AE(&%C8V]M<&%N>6EN9R!C;VYD96YS960@8V]N<V]L:61A=&5D
M(&)A;&%N8V4@<VAE970N(#PO9F]N=#X\+W`^#0H@("`\<"!S='EL93TS1"=M
M87)G:6XM=&]P.C$R<'@[;6%R9VEN+6)O='1O;3HP<'@[('1E>'0M:6YD96YT
M.C0E)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M
M86XG('-I>F4],T0R/DEF('-T;V-K:&]L9&5R(&%P<')O=F%L(&ES(&]B=&%I
M;F5D+"!T:&4@;G5M8F5R(&]F(&UI;&5S=&]N92!S:&%R97,@=VEL;"!B92!S
M=6)J96-T('1O(&EN8W)E87-E('1O('1H92!E>'1E;G0@=&AA="`D,"XW-B`H
M/&D^:2YE/"]I/BXL#0H@("!T:&4@8VQO<VEN9R!P<FEC92!O9B!T:&4@0V]M
M<&%N>28C.#(Q-SMS(&-O;6UO;B!S=&]C:R!A<R!R97!O<G1E9"!O;B!4:&4@
M3D%31$%1($-A<&ET86P@36%R:V5T(&]N($IA;G5A<GDF(S$V,#LQ."P@,C`Q
M,BP@=&AE(&1A>2!P<FEO<B!T;R!A8VAI979E;65N="!O9B!I=',@9FER<W0@
M;6EL97-T;VYE+"!U<V5D(&9O<B!P=7)P;W-E<R!O9B!D971E<FUI;FEN9R!T
M:&4@;G5M8F5R(&]F(&UI;&5S=&]N92!S:&%R97,I(&ES(&=R96%T97(-"B`@
M('1H86X@=&AE(&-L;W-I;F<@<')I8V4@;V8@8V]M;6]N('-T;V-K(&%S(&]F
M('1H92!M;W-T(')E8V5N="!T<F%D:6YG(&1A>2!P<FEO<B!T;R!T:&4@<F5C
M96EP="!O9B!S=&]C:VAO;&1E<B!A<'!R;W9A;"X@5VAE=&AE<B!O<B!N;W0@
M<W1O8VMH;VQD97(@87!P<F]V86P@:7,@;V)T86EN960L(&EN(&%D9&ET:6]N
M('1O('1H92!R96QE87-E(&9R;VT@97-C<F]W(&]F('1H92!M:6QE<W1O;F4@
M<VAA<F5S(&]R('1H92!P87EM96YT(&EN#0H@("!C87-H(&]F('1H92!I;FET
M:6%L(&UI;&5S=&]N92P@87,@=&AE(&-A<V4@;6%Y(&)E+"!T:&4@0V]M<&%N
M>2!W:6QL('!A>2!C;VYC=7)R96YT;'D@=&\@=&AE(&9O<FUE<B!!<'1H97)A
M('-H87)E:&]L9&5R<R!I;B!C87-H(&%N(&EN=&5R97-T(&9A8W1O<B!O9B!T
M96X@<&5R8V5N="`H,3`E*28C,38P.W!E<B!A;FYU;2!O;B!T:&4@86UO=6YT
M(&]F('1H92!F:6YA;"!M:6QE<W1O;F4@9G)O;2!&96)R=6%R>28C,38P.S$P
M+"`R,#$R#0H@("!T:')O=6=H('1H92!D87D@:6UM961I871E;'D@<')I;W(@
M=&\@=&AE(')E;&5A<V4@;V8@=&AE(&UI;&5S=&]N92!S:&%R97,@9G)O;2!E
M<V-R;W<@;W(@=&AE(&-A<V@@<&%Y;65N="P@87,@=&AE(&-A<V4@;6%Y(&)E
M+"!L97-S(&-E<G1A:6X@;&5G86P@9F5E<R!O9B!T:&4@<W1O8VMH;VQD97(@
M<F5P<F5S96YT871I=F4@=&\@8F4@<&%I9"!O<B!R96EM8G5R<V5D(&)Y('1H
M92!#;VUP86YY+B!!<R!O9B!-87)C:"8C,38P.S,Q+`T*("`@,C`Q,BP@)#$S
M+#8Y.2!O9B!I;G1E<F5S="!H860@8F5E;B!A8V-R=65D(&]N('1H:7,@;F]T
M92!A;F0@:7,@:6YC;'5D960@:6X@86-C<G5E9"!E>'!E;G-E<R!A;F0@;W1H
M97(@8W5R<F5N="!L:6%B:6QI=&EE<R!I;B!T:&4@86-C;VUP86YY:6YG(&-O
M;F1E;G-E9"!C;VYS;VQI9&%T960@8F%L86YC92!S:&5E="X@/"]F;VYT/CPO
M<#X-"B`@(#QP('-T>6QE/3-$)VUA<F=I;BUT;W`Z,3)P>#MM87)G:6XM8F]T
M=&]M.C!P>#L@=&5X="UI;F1E;G0Z-"4G/CQF;VYT('-T>6QE/3-$)V9O;G0M
M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^5&AE(&EN8W)E87-E
M(&EN('1H92!F86ER('9A;'5E(&]F('1H92!C;VYT:6YG96YT(&QI86)I;&ET
M>2!D=7)I;F<@=&AE('1H<F5E(&UO;G1H<R!E;F1E9"!-87)C:"8C,38P.S,Q
M+"`R,#$R(&ES("0X-#0L,#`P+"!W:&EC:"!W87,-"B`@(&EN8VQU9&5D(&EN
M(&]T:&5R(&EN8V]M92`H97AP96YS92D@:6X@=&AE(&%C8V]M<&%N>6EN9R!C
M;VYS;VQI9&%T960@<W1A=&5M96YT<R!O9B!E>'!E;G-E<RX@5&AE(&9A:7(@
M=F%L=64@;V8@=&AE(&-O;G1I;F=E;G0@;&EA8FEL:71Y(&%T($UA<F-H)B,Q
M-C`[,S$L(#(P,3(@=V%S("0V+#$Y-2PP,#`N($]F('1H:7,@86UO=6YT+"`D
M.#DX+#`P,"!W87,@<F5C;W)D960@87,@82!C=7)R96YT(&-O;G1I;F=E;G0@
M;&EA8FEL:71Y+@T*("`@/"]F;VYT/CPO<#X-"B`@(#QP('-T>6QE/3-$)VUA
M<F=I;BUT;W`Z,3)P>#MM87)G:6XM8F]T=&]M.C!P>#L@=&5X="UI;F1E;G0Z
M-"4G/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA
M;B<@<VEZ93TS1#(^5&AE(&9O;&QO=VEN9R!P<F5S96YT<R!T:&4@<')O(&9O
M<FUA(&YE="!L;W-S(&%N9"!P<F\@9F]R;6$@;F5T(&QO<W,@<&5R(&-O;6UO
M;B!S:&%R92!F;W(@=&AE('1H<F5E(&UO;G1H<R!E;F1E9`T*("`@36%R8V@F
M(S$V,#LS,2P@,C`Q,3H@/"]F;VYT/CPO<#X-"B`@(#QP('-T>6QE/3-$9F]N
M="US:7IE.C$R<'@[;6%R9VEN+71O<#HP<'@[;6%R9VEN+6)O='1O;3HP<'@^
M)B,Q-C`[/"]P/@T*("`@/'1A8FQE(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D
M9&EN9STS1#`@=VED=&@],T0Y,B4@8F]R9&5R/3-$,"!S='EL93TS1"=B;W)D
M97(M8V]L;&%P<V4Z8V]L;&%P<V4[('1E>'0M86QI9VXZ(&QE9G0G(&%L:6=N
M/3-$8V5N=&5R/@T*("`@/"$M+2!"96=I;B!486)L92!(96%D("TM/@T*("`@
M/'1R/B`-"B`@(#QT9"!W:61T:#TS1#@W)3XF(S$V,#L\+W1D/B`-"B`@(#QT
M9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0X)3XF(S$V,#L\+W1D/B`-"B`@
M(#QT9#XF(S$V,#L\+W1D/B`-"B`@(#QT9#XF(S$V,#L\+W1D/B`-"B`@(#QT
M9#XF(S$V,#L\+W1D/@T*("`@/"]T<CX@#0H@("`\='(^(`T*("`@/'1D('9A
M;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T
M9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C
M,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@8V]L
M<W!A;CTS1#(@86QI9VX],T1C96YT97(@<W1Y;&4],T0G8F]R9&5R+6)O='1O
M;3HQ<'@@<V]L:60@(S`P,#`P,"<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI
M;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,3X\8CY&;W(@=&AE(%1H<F5E
M/&)R("\^36]N=&AS)B,Q-C`[16YD960\8G(@+SY-87)C:"8C,38P.S,Q+"8C
M,38P.S(P,3$\+V(^/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O
M='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X-"B`@(#PO
M='(^#0H@("`\(2TM($5N9"!486)L92!(96%D("TM/@T*("`@/"$M+2!"96=I
M;B!486)L92!";V1Y("TM/@T*("`@/'1R(&)G8V]L;W(],T0C8V-E969F/B`-
M"B`@(#QT9"!V86QI9VX],T1T;W`^#0H@("`\<"!S='EL93TS1"=M87)G:6XM
M;&5F=#HQ+C`P96T[('1E>'0M:6YD96YT.BTQ+C`P96TG/CQF;VYT('-T>6QE
M/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^3F5T
M(&QO<W,\+V9O;G0^/"]P/@T*("`@/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$
M8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@
M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI
M;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXD/"]F;VYT/CPO=&0^(`T*
M("`@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T
M>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^
M*#0L,SDW/"]F;VYT/CPO=&0^(`T*("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!V
M86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM
M97,@;F5W(')O;6%N)R!S:7IE/3-$,CXI)B,Q-C`[/"]F;VYT/CPO=&0^#0H@
M("`\+W1R/B`-"B`@(#QT<B!S='EL93TS1&9O;G0M<VEZ93HQ<'@^(`T*("`@
M/'1D('9A;&EG;CTS1&)O='1O;3XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI
M9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T
M=&]M/@T*("`@/'`@<W1Y;&4],T0G8F]R9&5R+71O<#HS<'@@9&]U8FQE(",P
M,#`P,#`G/B8C,38P.SPO<#X-"B`@(#PO=&0^(`T*("`@/'1D('9A;&EG;CTS
M1&)O='1O;3X-"B`@(#QP('-T>6QE/3-$)V)O<F1E<BUT;W`Z,W!X(&1O=6)L
M92`C,#`P,#`P)SXF(S$V,#L\+W`^#0H@("`\+W1D/B`-"B`@(#QT9#XF(S$V
M,#L\+W1D/@T*("`@/"]T<CX@#0H@("`\='(^(`T*("`@/'1D('9A;&EG;CTS
M1'1O<#X-"B`@(#QP('-T>6QE/3-$)VUA<F=I;BUL969T.C$N,#!E;3L@=&5X
M="UI;F1E;G0Z+3$N,#!E;2<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ
M=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CY.970@;&]S<R!P97(@8V]M;6]N
M('-H87)E/"]F;VYT/CPO<#X-"B`@(#PO=&0^(`T*("`@/'1D('9A;&EG;CTS
M1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@
M("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M
M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)#PO9F]N=#X\+W1D/B`-
M"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S
M='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R
M/B@P+C$W/"]F;VYT/CPO=&0^(`T*("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!V
M86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM
M97,@;F5W(')O;6%N)R!S:7IE/3-$,CXI)B,Q-C`[/"]F;VYT/CPO=&0^#0H@
M("`\+W1R/B`-"B`@(#QT<B!S='EL93TS1&9O;G0M<VEZ93HQ<'@^(`T*("`@
M/'1D('9A;&EG;CTS1&)O='1O;3XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI
M9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T
M=&]M/@T*("`@/'`@<W1Y;&4],T0G8F]R9&5R+71O<#HS<'@@9&]U8FQE(",P
M,#`P,#`G/B8C,38P.SPO<#X-"B`@(#PO=&0^(`T*("`@/'1D('9A;&EG;CTS
M1&)O='1O;3X-"B`@(#QP('-T>6QE/3-$)V)O<F1E<BUT;W`Z,W!X(&1O=6)L
M92`C,#`P,#`P)SXF(S$V,#L\+W`^#0H@("`\+W1D/B`-"B`@(#QT9#XF(S$V
M,#L\+W1D/@T*("`@/"]T<CX@#0H@("`\='(@8F=C;VQO<CTS1"-C8V5E9F8^
M(`T*("`@/'1D('9A;&EG;CTS1'1O<#X-"B`@(#QP('-T>6QE/3-$)VUA<F=I
M;BUL969T.C$N,#!E;3L@=&5X="UI;F1E;G0Z+3$N,#!E;2<^/&9O;G0@<W1Y
M;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CY7
M96EG:'1E9"!A=F5R86=E('-H87)E<R!O=71S=&%N9&EN9SPO9F]N=#X\+W`^
M#0H@("`\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ
M93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O
M='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M
M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI
M9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=F;VYT
M+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/C(U+#(Y,"PR-C`\
M+V9O;G0^/"]T9#X@#0H@("`\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS
M1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@
M<F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@/"]T<CX@
M#0H@("`\='(@<W1Y;&4],T1F;VYT+7-I>F4Z,7!X/B`-"B`@(#QT9"!V86QI
M9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T
M=&]M/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`@
M(#QP('-T>6QE/3-$)V)O<F1E<BUT;W`Z,W!X(&1O=6)L92`C,#`P,#`P)SXF
M(S$V,#L\+W`^#0H@("`\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^
M#0H@("`\<"!S='EL93TS1"=B;W)D97(M=&]P.C-P>"!D;W5B;&4@(S`P,#`P
M,"<^)B,Q-C`[/"]P/@T*("`@/"]T9#X@#0H@("`\=&0^)B,Q-C`[/"]T9#X-
M"B`@(#PO='(^#0H@("`\(2TM($5N9"!486)L92!";V1Y("TM/@T*("`@/"]T
M86)L93X@#0H\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'10
M87)T7V)E9F4Y8S$Q7V,R9C-?-#AE8U]A,F%B7V9F,C@Y-C`W961C,`T*0V]N
M=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B]B969E.6,Q,5]C,F8S7S0X96-?
M83)A8E]F9C(X.38P-V5D8S`O5V]R:W-H965T<R]3:&5E=#`Y+FAT;6P-"D-O
M;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O
M;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*
M/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT
M96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G
M/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS
M/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H
M96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60]
M,T1)1#!%344^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L
M(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^4EAI(%-P:6XM3W5T
M/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O
M;'-P86X],T0Q/C,@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DUA<BX@,S$L(#(P
M,3(\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O
M;F<^4EAI(%-P:6XM3W5T(%M!8G-T<F%C=%T\+W-T<F]N9SX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4EAI(%-P:6XM3W5T/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\(2TM1$]#5%E012!H=&UL(%!50DQ)
M0R`B+2\O5S-#+R]$5$0@6$A434P@,2XP(%1R86YS:71I;VYA;"\O14XB(")H
M='1P.B\O=W=W+G<S+F]R9R]44B]X:'1M;#$O1%1$+WAH=&UL,2UT<F%N<VET
M:6]N86PN9'1D(B`M+3X-"B`@(#PA+2T@0F5G:6X@0FQO8VL@5&%G9V5D($YO
M=&4@-"`M(')X:6DZ4&%R=&YE<D-O;7!A;GE497AT0FQO8VLM+3X-"B`@(#QP
M('-T>6QE/3-$;6%R9VEN+71O<#HQ.'!X.VUA<F=I;BUB;W1T;VTZ,'!X/CQF
M;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ
M93TS1#(^/&(^-"XF(S$V,#M26&D@4W!I;BU/=70@/"]B/CPO9F]N=#X\+W`^
M#0H@("`\<"!S='EL93TS1"=M87)G:6XM=&]P.C9P>#MM87)G:6XM8F]T=&]M
M.C!P>#L@;6%R9VEN+6QE9G0Z,B4G/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M
M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^/&(^/&D^0V]N=')I8G5T
M:6]N($%G<F5E;65N="`\+VD^/"]B/CPO9F]N=#X\+W`^#0H@("`\<"!S='EL
M93TS1"=M87)G:6XM=&]P.C9P>#MM87)G:6XM8F]T=&]M.C!P>#L@=&5X="UI
M;F1E;G0Z-"4G/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE
M=R!R;VUA;B<@<VEZ93TS1#(^#0H@("!/;B!397!T96UB97(F(S$V,#LR-"P@
M,C`Q,2P@=&AE($-O;7!A;GD@96YT97)E9"!I;G1O(&$@0V]N=')I8G5T:6]N
M($%G<F5E;65N="`H)B,X,C(P.T-O;G1R:6)U=&EO;B!!9W)E96UE;G0F(S@R
M,C$[*2!W:71H(%)8:2!P=7)S=6%N="!T;R!W:&EC:"!W92!A<W-I9VYE9"!A
M;F0@8V]N=')I8G5T960@=&\@4EAI('-U8G-T86YT:6%L;'D@86QL(&]F('1H
M90T*("`@0V]M<&%N>28C.#(Q-SMS(%).06DM<F5L871E9"!T96-H;F]L;V=I
M97,@86YD(&%S<V5T<RX@5&AE(&-O;G1R:6)U=&5D(&%S<V5T<R!C;VYS:7-T
M('!R:6UA<FEL>2!O9B!O=7(@;F]V96P@4DY!:2!C;VUP;W5N9',@86YD(&QI
M8V5N<V5S(')E;&%T:6YG('1O(&]U<B!23D%I('1E8VAN;VQO9VEE<RP@87,@
M=V5L;"!A<R!T:&4@;&5A<V4@;V8@;W5R(%=O<F-E<W1E<BP@36%S<V%C:'5S
M971T<R!L86)O<F%T;W)Y(&9A8VEL:71Y+"!F:7AE9`T*("`@87-S971S(&%N
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M:"!T;R!T:&4-"B`@(&-A<&ET86P@;V8@4EAI+B`\+V9O;G0^/"]P/@T*("`@
M/'`@<W1Y;&4],T0G;6%R9VEN+71O<#HQ,G!X.VUA<F=I;BUB;W1T;VTZ,'!X
M.R!T97AT+6EN9&5N=#HT)2<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ
M=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CY0=7)S=6%N="!T;R!T:&4@0V]N
M=')I8G5T:6]N($%G<F5E;65N="P@4EAI(&%S<W5M960@8V5R=&%I;B!A8V-R
M=65D(&5X<&5N<V5S(&]F(&]U<B!26$DM,3`Y(&1E=F5L;W!M96YT#0H@("!P
M<F]G<F%M(&%N9"!A;&P@<W5B<V5Q=65N="!O8FQI9V%T:6]N<R!U;F1E<B!T
M:&4@8V]N=')I8G5T960@;&EC96YS97,L(&5M<&QO>6UE;G0@87)R86YG96UE
M;G1S(&%N9"!O=&AE<B!A9W)E96UE;G1S+B!26&D@:&%S(&%G<F5E9"!T;R!M
M86ME(&9U='5R92!M:6QE<W1O;F4@<&%Y;65N=',@=&\@=7,@;V8@=7`@=&\@
M)#0U)B,Q-C`[;6EL;&EO;BP@8V]N<VES=&EN9R!O9B!T=V\@;VYE+71I;64@
M<&%Y;65N=',@;V8-"B`@("0Q-28C,38P.VUI;&QI;VX@86YD("0S,"8C,38P
M.VUI;&QI;VXL(')E<W!E8W1I=F5L>2P@:68@4EAI(&%C:&EE=F5S(&%N;G5A
M;"!N970@<V%L97,@97%U86P@=&\@;W(@9W)E871E<B!T:&%N("0U,#`@;6EL
M;&EO;B!A;F0@)#$F(S$V,#MB:6QL:6]N+"!R97-P96-T:79E;'DL(&]F(&%N
M>2!C;W9E<F5D('!R;V1U8W1S('1H870@;6%Y(&)E(&1E=F5L;W!E9"!W:71H
M('1H92!C;VYT<FEB=71E9"!23D%I('1E8VAN;VQO9VEE<RX-"B`@(#PO9F]N
M=#X\+W`^#0H@("`\<"!S='EL93TS1"=M87)G:6XM=&]P.C$R<'@[;6%R9VEN
M+6)O='1O;3HP<'@[('1E>'0M:6YD96YT.C0E)SX\9F]N="!S='EL93TS1"=F
M;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/DEN('1H92!#
M;VYT<FEB=71I;VX@06=R965M96YT+"!T:&4@0V]M<&%N>2!M861E(&-U<W1O
M;6%R>2!R97!R97-E;G1A=&EO;G,@86YD('=A<G)A;G1I97,@=&\@4EAI(')E
M9V%R9&EN9R!T:&4@8V]N=')I8G5T960-"B`@(&%S<V5T<R!A;F0@;W1H97(@
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M;V8@=&AE:7(-"B`@(')E<W!E8W1I=F4@<F5P<F5S96YT871I;VYS+"!W87)R
M86YT:65S(&%N9"!C;W9E;F%N=',@<V5T(&9O<G1H(&EN('1H92!#;VYT<FEB
M=71I;VX@06=R965M96YT+B`\+V9O;G0^/"]P/@T*("`@/'`@<W1Y;&4],T1F
M;VYT+7-I>F4Z,7!X.VUA<F=I;BUT;W`Z,3AP>#MM87)G:6XM8F]T=&]M.C!P
M>#XF(S$V,#L\+W`^#0H@("`\<"!S='EL93TS1"=M87)G:6XM=&]P.C!P>#MM
M87)G:6XM8F]T=&]M.C!P>#L@;6%R9VEN+6QE9G0Z,B4G/CQF;VYT('-T>6QE
M/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^/&(^
M/&D^4V5C=7)I=&EE<PT*("`@4'5R8VAA<V4@06=R965M96YT(#PO:3X\+V(^
M/"]F;VYT/CPO<#X-"B`@(#QP('-T>6QE/3-$)VUA<F=I;BUT;W`Z-G!X.VUA
M<F=I;BUB;W1T;VTZ,'!X.R!T97AT+6EN9&5N=#HT)2<^/&9O;G0@<W1Y;&4]
M,T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CY/;B!3
M97!T96UB97(F(S$V,#LR-"P@,C`Q,2P@=&AE($-O;7!A;GD@86QS;R!E;G1E
M<F5D(&EN=&\@82!396-U<FET:65S(%!U<F-H87-E($%G<F5E;65N=`T*("`@
M*"8C.#(R,#M396-U<FET:65S(%!U<F-H87-E($%G<F5E;65N="8C.#(R,3LI
M('=I=&@@4EAI(&%N9"!T=V\@:6YS=&ET=71I;VYA;"!);G9E<W1O<G,@*'1H
M92`F(S@R,C`[26YV97-T;W)S)B,X,C(Q.RDL('!U<G-U86YT('1O('=H:6-H
M('1H92!);G9E<W1O<G,@86=R965D('1O('!U<F-H87-E(&$@=&]T86P@;V8@
M)#DL-3`P+#`P,"!O9B!397)I97,F(S$V,#M!(%!R969E<G)E9"!3=&]C:R!O
M9B!26&D@*"8C.#(R,#M26&D@4')E9F5R<F5D#0H@("!3=&]C:R8C.#(R,3LI
M(&%T('1H92!C;&]S:6YG(&]F('1H92!S<&EN+6]F9B!O9B!26&DL(&%N9"!T
M;R!L96YD('5P('1O("0Q+#4P,"PP,#`@=&\@4EAI('1O(&9U;F0@:71S(&]P
M97)A=&EO;G,@8F5T=V5E;B!S:6=N:6YG(&%N9"!C;&]S:6YG("AT:&4@)B,X
M,C(P.T)R:61G92!,;V%N)B,X,C(Q.RDN(%1H92!O=71S=&%N9&EN9R!P<FEN
M8VEP86P@86YD(&%C8W)U960@:6YT97)E<W0@9G)O;2!T:&4@0G)I9&=E($QO
M86X@=VEL;"P-"B`@(&5X8V5P="!U;F1E<B!C97)T86EN(&-I<F-U;7-T86YC
M97,@9&5S8W)I8F5D(&)E;&]W+"!B92!C;VYV97)T960@:6YT;R!26&D@4')E
M9F5R<F5D(%-T;V-K(&%T('1H92!C;&]S:6YG(&]F('1H92!S<&EN+6]F9B!O
M9B!26&D@86YD('=I;&P@<F5P<F5S96YT(&$@<&]R=&EO;B!O9B!T:&4@)#DL
M-3`P+#`P,"!T;W1A;"!I;G9E<W1M96YT+"!W:&EC:"!I<R!R969E<G)E9"!T
M;R!H97)E:6X@87,@=&AE("8C.#(R,#M26&D-"B`@(&9I;F%N8VEN9RXF(S@R
M,C$[(%1H92!26&DF(S$V,#MF:6YA;F-I;F<@86YD('1H92!S<&EN+6]F9B!O
M9B!26&D@=V5R92!S=6)J96-T('1O(&-U<W1O;6%R>2!C;&]S:6YG(&-O;F1I
M=&EO;G,L(&EN8VQU9&EN9R!T:&4@<F5G:7-T<F%T:6]N('5N9&5R('1H92!3
M96-U<FET:65S($%C="!O9B`Q.3,S+"!A<R!A;65N9&5D("AT:&4@)B,X,C(P
M.U-E8W5R:71I97,@06-T)B,X,C(Q.RDL(&]F('1H92!D:7-T<FEB=71I;VX@
M8GD@=7,@;V8@=&AE#0H@("!S<&EN+6]F9B!S:&%R97,N(#PO9F]N=#X\+W`^
M#0H@("`\<"!S='EL93TS1"=M87)G:6XM=&]P.C$R<'@[;6%R9VEN+6)O='1O
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M92!0<F5F97)R960@4W1O8VL@=&\@8F4@:&5L9"!B>0T*("`@=&AE($EN=F5S
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M;G9E<G-I;VX@:6X-"B`@(&9U;&P@;V8@=&AE(%!R969E<G)E9"!3=&]C:RP@
M=VAI8V@@=V4@<F5F97(@=&\@87,@=&AE("8C.#(R,#MA<RUC;VYV97)T960@
M8V]M;6]N('-T;V-K+B8C.#(R,3L@5&AE($-O;7!A;GD@=VEL;"!O=VX@87!P
M<F]X:6UA=&5L>2`Q,B4@;V8@=&AE(&%S+6-O;G9E<G1E9"!C;VUM;VX@<W1O
M8VL@:6UM961I871E;'D@<')I;W(@=&\@=&AE('-P:6XM;V9F(&]F(%)8:2P@
M86YD($%D=FER;F$L($Q,0RP@82!L:6-E;G-O<B!O9B!26&DL('=I;&P-"B`@
M(&)E(&ES<W5E9"!T:&4@<F5M86EN:6YG(#4E(&]F('1H92!A<RUC;VYV97)T
M960@8V]M;6]N('-T;V-K('!U<G-U86YT('1O('1H92!A9W)E96UE;G0@=VET
M:"!!9'9I<FYA+"!,3$,@87,@9&5S8W)I8F5D(&)E;&]W+B`\+V9O;G0^/"]P
M/@T*("`@/'`@<W1Y;&4],T0G;6%R9VEN+71O<#HQ.'!X.VUA<F=I;BUB;W1T
M;VTZ,'!X.R!M87)G:6XM;&5F=#HR)2<^/&9O;G0@<W1Y;&4],T0G9F]N="UF
M86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CX\:3Y3<&EN+4]F9B`\
M+VD^/"]F;VYT/CPO<#X-"B`@(#QP('-T>6QE/3-$)VUA<F=I;BUT;W`Z-G!X
M.VUA<F=I;BUB;W1T;VTZ,'!X.R!T97AT+6EN9&5N=#HT)2<^/&9O;G0@<W1Y
M;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CY4
M:&4@0V]M<&%N>2!A9W)E960@:6X@=&AE(%-E8W5R:71I97,@4'5R8VAA<V4@
M06=R965M96YT('1O('5N9&5R=&%K92!T;R!D:7-T<FEB=71E('1O(&]U<B!S
M=&]C:VAO;&1E<G,@;VX@82!S:&%R92UF;W(M<VAA<F4@8F%S:7,-"B`@(&%P
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M*'-E92!.;W1E(#$Q*2X@5&AE#0H@("!#;VUP86YY(&AA<R!R971A:6YE9"`T
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M"B`@(%)8:2X@56YD97(@=&AE(%-E8W5R:71I97,@4'5R8VAA<V4@06=R965M
M96YT+"!O;F4@<VAA<F4@;V8@4EAI('=A<R!D:7-T<FEB=71E9"!A<R!A(&1I
M=FED96YD(&]N(&5A8V@@<VAA<F4@;V8@1V%L96YA('1H870@:7,@:7-S=65D
M(&%N9"!O=71S=&%N9&EN9R!A<R!O9B!T:&4@<F5C;W)D(&1A=&4@9F]R('1H
M92!D:7-T<FEB=71I;VX@;V8@07!R:6P@,C,L(#(P,3(N(#PO9F]N=#X\+W`^
M#0H@("`\<"!S='EL93TS1"=M87)G:6XM=&]P.C$X<'@[;6%R9VEN+6)O='1O
M;3HP<'@[(&UA<F=I;BUL969T.C(E)SX\9F]N="!S='EL93TS1"=F;VYT+69A
M;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/CQI/E!U<F-H87-E($%G
M<F5E;65N="!497)M<R!A;F0@0V]N9&ET:6]N<R`\+VD^/"]F;VYT/CPO<#X-
M"B`@(#QP('-T>6QE/3-$)VUA<F=I;BUT;W`Z-G!X.VUA<F=I;BUB;W1T;VTZ
M,'!X.R!T97AT+6EN9&5N=#HT)2<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI
M;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CX-"B`@($EN('1H92!396-U
M<FET:65S(%!U<F-H87-E($%G<F5E;65N="P@=&AE('!A<G1I97,@:&%V92!M
M861E(&-U<W1O;6%R>2!R97!R97-E;G1A=&EO;G,@86YD('=A<G)A;G1I97,@
M=&\@=&AE(&]T:&5R('!A<G1I97,@86YD(&AA=F4@86=R965D('1O(&-U<W1O
M;6%R>2!C;W9E;F%N=',@<F5G87)D:6YG('1H92!P87)T:65S)B,X,C$W.R!A
M8W1I;VYS(&EN#0H@("!C;VYN96-T:6]N('=I=&@@=&AE('-P:6XM;V9F(&]F
M(%)8:2!A;F0@;W1H97(@;6%T=&5R<RP@:6YC;'5D:6YG('1H92!F:6QI;F<@
M;V8@82!R97-A;&4@<F5G:7-T<F%T:6]N('-T871E;65N="!R96=I<W1E<FEN
M9R!A('!O<G1I;VX@;V8@=&AE(&-O;6UO;B!S=&]C:R!U;F1E<FQY:6YG('1H
M92!C;VYV97)S:6]N(&]F('1H92!0<F5F97)R960@4W1O8VLN(%1H92!P87)T
M:65S(&%L<V\@:&%V92!A9W)E960@=&\@:6YD96UN:69Y(&5A8V@-"B`@(&]T
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M(%)8:2!R96EM8G5R<V5D('1H90T*("`@0V]M<&%N>2!A;F0@=&AE($EN=F5S
M=&]R<R!I;B!T:&4@86UO=6YT(&]F("0S,#`L,#`P(&%N9"`D,3`P+#`P,"P@
M<F5S<&5C=&EV96QY+"!F;W(@=')A;G-A8W1I;VX@8V]S=',@<F5L871I;F<@
M=&\@=&AE($-O;G1R:6)U=&EO;B!!9W)E96UE;G0L('1H92!396-U<FET:65S
M(%!U<F-H87-E($%G<F5E;65N="!A;F0@=&AE('1R86YS86-T:6]N<R!C86QL
M960@9F]R(&)Y('1H92!A9W)E96UE;G1S+B`\+V9O;G0^/"]P/@T*("`@/'`@
M<W1Y;&4],T0G;6%R9VEN+71O<#HQ.'!X.VUA<F=I;BUB;W1T;VTZ,'!X.R!M
M87)G:6XM;&5F=#HR)2<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM
M97,@;F5W(')O;6%N)R!S:7IE/3-$,CX\:3Y"<FED9V4@3&]A;B`\+VD^/"]F
M;VYT/CPO<#X-"B`@(#QP('-T>6QE/3-$)VUA<F=I;BUT;W`Z-G!X.VUA<F=I
M;BUB;W1T;VTZ,'!X.R!T97AT+6EN9&5N=#HT)2<^/&9O;G0@<W1Y;&4],T0G
M9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CX-"B`@(%!U
M<G-U86YT('1O('1H92!396-U<FET:65S(%!U<F-H87-E($%G<F5E;65N="P@
M=&AE($EN=F5S=&]R<R!P<F]V:61E9"!"<FED9V4@3&]A;G,@8GD@<'5R8VAA
M<VEN9R`D,2PP,#`L,#`P(&]F('-E8W5R960@8V]N=F5R=&EB;&4@<')O;6ES
M<V]R>2!N;W1E<R!O9B!26&D@*"8C.#(R,#M26&D@8V]N=F5R=&EB;&4@;F]T
M97,F(S@R,C$[*2X@5&AE(%)8:0T*("`@8V]N=F5R=&EB;&4@;F]T97,@=VEL
M;"P@97AC97!T(&%S(&1E<V-R:6)E9"!B96QO=RP@8F4@8V]N=F5R=&EB;&4@
M:6YT;R!S:&%R97,@;V8@4EAI(%!R969E<G)E9"!3=&]C:R!A="!A(&-O;G9E
M<G-I;VX@<')I8V4@;V8@)#$L,#`P('!E<B!S:&%R92X@5&AE(%)8:2!C;VYV
M97)T:6)L92!N;W1E<R!A8V-R=65D(&EN=&5R97-T(&%T(&$@<F%T92!O9B`W
M)28C,38P.W!E<B!A;FYU;2`H;W(@,3@E)B,Q-C`[<&5R(&%N;G5M(&EN('1H
M90T*("`@8V%S92!O9B!A;B!E=F5N="!O9B!D969A=6QT*2!A;F0@;6%T=7)E
M9"!O;B!!<')I;"8C,38P.S(W+"`R,#$R+"!T:&4@8VQO<VEN9R!D871E+B!!
M<R!O9B!-87)C:"`S,2P@,C`Q,BP@4EAI(&AA9"`D,2PP,#`L,#`P(&]F(%)8
M:2!C;VYV97)T:6)L92!N;W1E<R!O=71S=&%N9&EN9RX@07,@=&AE($-O;7!A
M;GD@=V%S(')E;&EE=F5D(&]F('1H:7,@;V)L:6=A=&EO;B!U<&]N('1H92!S
M<&EN+6]U="P@=&AE(&%M;W5N="!H87,@8F5E;@T*("`@<F5C;W)D960@87,@
M82!L;VYG+71E<FT@;&EA8FEL:71Y(&%S(&]F($UA<F-H(#,Q+"`R,#$R+B!!
M<'!R;WAI;6%T96QY("0R,2PP,#`@;V8@:6YT97)E<W0@:&%S(&)E96X@<F5C
M;W)D960@:6X@86-C<G5E9"!E>'!E;G-E<R!A;F0@;W1H97(@8W5R<F5N="!L
M:6%B:6QI=&EE<R!A="!-87)C:"8C,38P.S,Q+"`R,#$R(&EN('1H92!A8V-O
M;7!A;GEI;F<@8V]N9&5N<V5D(&-O;G-O;&ED871E9"!B86QA;F-E('-H965T
M+@T*("`@/"]F;VYT/CPO<#X-"B`@(#QP('-T>6QE/3-$)VUA<F=I;BUT;W`Z
M,3AP>#MM87)G:6XM8F]T=&]M.C!P>#L@;6%R9VEN+6QE9G0Z,B4G/CQF;VYT
M('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS
M1#(^/&(^/&D^061V:7)N82!!9W)E96UE;G0@/"]I/CPO8CX\+V9O;G0^/"]P
M/@T*("`@/'`@<W1Y;&4],T0G;6%R9VEN+71O<#HV<'@[;6%R9VEN+6)O='1O
M;3HP<'@[('1E>'0M:6YD96YT.C0E)SX\9F]N="!S='EL93TS1"=F;VYT+69A
M;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/@T*("`@07,@<&%R="!O
M9B!T:&4@8VQO<VEN9R!T<F%N<V%C=&EO;B!A<R!D971A:6QE9"!I;B!T:&4@
M0V]N=')I8G5T:6]N($%G<F5E;65N="!A;F0@4V5C=7)I=&EE<R!0=7)C:&%S
M92!!9W)E96UE;G0L(%)8:2!E;G1E<F5D(&EN=&\@86X@86=R965M96YT('=I
M=&@@061V:7)N82P@3$Q#+"!W:&EC:"!T:&4@0V]M<&%N>2!R969E<G,@=&\@
M87,-"B`@("8C.#(R,#M!9'9I<FYA+"8C.#(R,3L@82!C;VUP86YY(&%F9FEL
M:6%T960@=VET:"!!;F%S=&%S:6$@2VAV;W)O=F$L(%!H+D0N+"!26&DF(S@R
M,3<[<R!F;W)M97(@4V5N:6]R(%9I8V4@4')E<VED96YT(&%N9"!#:&EE9B!3
M8VEE;G1I9FEC($]F9FEC97(N($EN('1H92!A9W)E96UE;G0L($%D=FER;F$@
M:&%S(&%G<F5E9"!T;R!A;65N9"!I=',@97AI<W1I;F<@<&%T96YT(&%N9"!T
M96-H;F]L;V=Y(&%S<VEG;FUE;G0@86=R965M96YT#0H@("!W:71H(%)8:2!T
M;R!E;&EM:6YA=&4@86QL(&-L:6YI8V%L(&UI;&5S=&]N92!A;F0@<F]Y86QT
M>2!P87EM96YT<R!T;R!!9'9I<FYA('5N9&5R('1H92!A;65N9&5D(&%G<F5E
M;65N=#L@;V)L:6=A=&EO;G,@<F5M86EN('1O(&UA:V4@86X@86YN=6%L("0Q
M,#`L,#`P(&UA:6YT96YA;F-E(&9E92!A;F0@82!O;F4M=&EM92!M:6QE<W1O
M;F4@<&%Y;65N="!O9B`D,S4P+#`P,"!T;R!!9'9I<FYA('5P;VX@=&AE(&ES
M<W5A;F-E(&]F(&$-"B`@('!A=&5N="!W:71H('9A;&ED(&-L86EM<R!C;W9E
M<FEN9R!T:&4@87-S:6=N960@=&5C:&YO;&]G>2X@061D:71I;VYA;&QY+"!2
M6&D@=VEL;"!B92!R97%U:7)E9"!T;R!P87D@82`Q)2!R;WEA;'1Y('1O($%D
M=FER;F$@9F]R(&%N>2!L:6-E;G-I;F<@<F5V96YU92!R96-E:79E9"!B>2!2
M6&D@;VX@=&AE(&QI8V5N<V4@;V8@=&AE(&%S<VEG;F5D($%D=FER;F$@=&5C
M:&YO;&]G>2X@26X@97AC:&%N9V4L(%)8:2!I<W-U960@=&\-"B`@($%D=FER
M;F$@=7!O;B!T:&4@8VQO<VEN9R!T<F%N<V%C=&EO;B!A(&YU;6)E<B!O9B!S
M:&%R97,@;V8@4EAI(&-O;6UO;B!S=&]C:R!E<75A;"!T;R`U)2!O9B!T:&4@
M87,M8V]N=F5R=&5D(&-O;6UO;B!S=&]C:R!O9B!26&DN(#PO9F]N=#X\+W`^
M#0H@("`\<"!S='EL93TS1"=M87)G:6XM=&]P.C$R<'@[;6%R9VEN+6)O='1O
M;3HP<'@[('1E>'0M:6YD96YT.C0E)SX\9F]N="!S='EL93TS1"=F;VYT+69A
M;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/@T*("`@5&AE('1R86YS
M86-T:6]N<R!C;VYT96UP;&%T960@8GD@=&AE(%-E8W5R:71I97,@4'5R8VAA
M<V4@06=R965M96YT('=E<F4@8V]M<&QE=&5D(&EN($%P<FEL(#(P,3(@*'-E
M92!.;W1E(#$Q*2X@/"]F;VYT/CPO<#X-"CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^
M#0H-"BTM+2TM+3U?3F5X=%!A<G1?8F5F93EC,3%?8S)F,U\T.&5C7V$R86)?
M9F8R.#DV,#=E9&,P#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+V)E
M9F4Y8S$Q7V,R9C-?-#AE8U]A,F%B7V9F,C@Y-C`W961C,"]7;W)K<VAE971S
M+U-H965T,3`N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O
M=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S
M970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@
M:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M
M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R
M:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE
M;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C
M;&%S<STS1')E<&]R="!I9#TS1$E$,$5-13X-"B`@("`@(#QT<CX-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T
M<F]N9SY&86ER(%9A;'5E($UE87-U<F5M96YT<SQB<CX\+W-T<F]N9SX\+W1H
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XS($UO;G1H
M<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T:#Y-87(N(#,Q+"`R,#$R/&)R/CPO=&@^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D9A:7(@5F%L=64@365A
M<W5R96UE;G1S(%M!8G-T<F%C=%T\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^1F%I<B!686QU92!-96%S=7)E;65N=',\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CPA+2U$3T-465!%(&AT;6P@
M4%5"3$E#("(M+R]7,T,O+T141"!82%1-3"`Q+C`@5')A;G-I=&EO;F%L+R]%
M3B(@(FAT='`Z+R]W=W<N=S,N;W)G+U12+WAH=&UL,2]$5$0O>&AT;6PQ+71R
M86YS:71I;VYA;"YD=&0B("TM/@T*("`@/"$M+2!"96=I;B!";&]C:R!486=G
M960@3F]T92`U("T@=7,M9V%A<#I&:6YA;F-I86Q);G-T<G5M96YT<T1I<V-L
M;W-U<F5497AT0FQO8VLM+3X-"B`@(#QP('-T>6QE/3-$;6%R9VEN+71O<#HQ
M.'!X.VUA<F=I;BUB;W1T;VTZ,'!X/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M
M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^/&(^-2X@1F%I<B!686QU
M92!-96%S=7)E;65N=',@/"]B/CPO9F]N=#X\+W`^#0H@("`\<"!S='EL93TS
M1"=M87)G:6XM=&]P.C9P>#MM87)G:6XM8F]T=&]M.C!P>#L@=&5X="UI;F1E
M;G0Z-"4G/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R
M;VUA;B<@<VEZ93TS1#(^5&AE($-O;7!A;GD@9F]L;&]W<R!T:&4@<')O=FES
M:6]N<R!O9B!&05-"($%30R!4;W!I8R`X,C`L(#QI/B8C.#(R,#M&86ER(%9A
M;'5E($UE87-U<F5M96YT<R!A;F0@1&ES8VQO<W5R97,F(S@R,C$[/"]I/@T*
M("`@*"8C.#(R,#M!4T,@.#(P)B,X,C(Q.RD@9F]R('1H92!#;VUP86YY)B,X
M,C$W.W,@9FEN86YC:6%L(&%S<V5T<R!A;F0@;&EA8FEL:71I97,@=&AA="!A
M<F4@<F4M;65A<W5R960@86YD(')E<&]R=&5D(&%T(&9A:7(@=F%L=64@870@
M96%C:"!R97!O<G1I;F<@<&5R:6]D+"!A;F0@87)E(')E+6UE87-U<F5D(&%N
M9"!R97!O<G1E9"!A="!F86ER('9A;'5E(&%T(&QE87-T(&%N;G5A;&QY('5S
M:6YG(&$@9F%I<B!V86QU92!H:65R87)C:'D-"B`@('1H870@:7,@8G)O:V5N
M(&1O=VX@:6YT;R!T:')E92!L979E;',N($QE=F5L(&EN<'5T<R!A<F4@87,@
M9&5F:6YE9"!A<R!F;VQL;W=S.B`\+V9O;G0^/"]P/@T*("`@/'`@<W1Y;&4]
M,T1M87)G:6XM=&]P.C$R<'@[;6%R9VEN+6)O='1O;3HP<'@^/&9O;G0@<W1Y
M;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CY,
M979E;"`Q("8C.#(Q,CL@<75O=&5D('!R:6-E<R!I;B!A8W1I=F4@;6%R:V5T
M<R!F;W(@:61E;G1I8V%L#0H@("!A<W-E=',@;W(@;&EA8FEL:71I97,N(#PO
M9F]N=#X\+W`^#0H@("`\<"!S='EL93TS1&UA<F=I;BUT;W`Z,'!X.VUA<F=I
M;BUB;W1T;VTZ,'!X/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S
M(&YE=R!R;VUA;B<@<VEZ93TS1#(^3&5V96P@,B`F(S@R,3([(&]T:&5R('-I
M9VYI9FEC86YT(&]B<V5R=F%B;&4@:6YP=71S(&9O<B!T:&4@87-S971S(&]R
M(&QI86)I;&ET:65S('1H<F]U9V@@8V]R<F]B;W)A=&EO;B!W:71H#0H@("!M
M87)K970@9&%T82!A="!T:&4@;65A<W5R96UE;G0@9&%T92X@/"]F;VYT/CPO
M<#X-"B`@(#QP('-T>6QE/3-$;6%R9VEN+71O<#HQ,G!X.VUA<F=I;BUB;W1T
M;VTZ,'!X/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R
M;VUA;B<@<VEZ93TS1#(^3&5V96P@,R`F(S@R,3([('-I9VYI9FEC86YT('5N
M;V)S97)V86)L92!I;G!U=',@=&AA="!R969L96-T(&UA;F%G96UE;G0F(S@R
M,3<[<R!B97-T(&5S=&EM871E(&]F('=H870-"B`@(&UA<FME="!P87)T:6-I
M<&%N=',@=V]U;&0@=7-E('1O('!R:6-E('1H92!A<W-E=',@;W(@;&EA8FEL
M:71I97,@870@=&AE(&UE87-U<F5M96YT(&1A=&4N(#PO9F]N=#X\+W`^#0H@
M("`\<"!S='EL93TS1"=M87)G:6XM=&]P.C$R<'@[;6%R9VEN+6)O='1O;3HP
M<'@[('1E>'0M:6YD96YT.C0E)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL
M>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/E1H92!#;VUP86YY(&-A=&5G
M;W)I>F5D(&ET<R!C87-H#0H@("!E<75I=F%L96YT<R!A<R!A($QE=F5L(#$@
M:&EE<F%R8VAY+B!4:&4@=F%L=6%T:6]N(&9O<B!,979E;"`Q('=A<R!D971E
M<FUI;F5D(&)A<V5D(&]N(&$@)B,X,C(P.VUA<FME="!A<'!R;V%C:"8C.#(R
M,3L@=7-I;F<@<75O=&5D('!R:6-E<R!I;B!A8W1I=F4@;6%R:V5T<R!F;W(@
M:61E;G1I8V%L(&%S<V5T<RX@5F%L=6%T:6]N<R!O9B!T:&5S92!A<W-E=',@
M9&\@;F]T(')E<75I<F4@82!S:6=N:69I8V%N="!D96=R964@;V8-"B`@(&IU
M9&=M96YT+B!4:&4@0V]M<&%N>2!C871E9V]R:7IE9"!I=',@=V%R<F%N=',@
M<&]T96YT:6%L;'D@<V5T=&QE9"!I;B!C87-H(&%S(&$@3&5V96P@,B!H:65R
M87)C:'DN(%1H92!W87)R86YT<R!A<F4@;65A<W5R960@870@9F%I<B!M87)K
M970@=F%L=64@;VX@82!R96-U<G)I;F<@8F%S:7,@86YD(&%R92!B96EN9R!M
M87)K960@=&\@;6%R:V5T(&5A8V@@<75A<G1E<BUE;F0@=6YT:6P@=&AE>2!A
M<F4@<V5T=&QE9"X@5&AE#0H@("!C;VYT:6YG96YT('!U<F-H87-E('!R:6-E
M(&-O;G-I9&5R871I;VX@:7,@8V%T96=O<FEZ960@87,@82!,979E;"`S(&AI
M97)A<F-H>2!A;F0@:7,@;65A<W5R960@870@:71S(&5S=&EM871E9"!F86ER
M('9A;'5E(&]N(&$@<F5C=7)R:6YG(&)A<VES(&%N9"!I<R!A9&IU<W1E9"!A
M="!E86-H('%U87)T97(M96YD('5N=&EL(&ET(&ES(&-O;7!L971E;'D@<V5T
M=&QE9"X@5&AE(&-O;G1I;F=E;G0@<')I8V4@8V]N<VED97)A=&EO;B!I<PT*
M("`@=F%L=65D(&)A<V5D(&]N('1H92!E>'!E8W1E9"!T:6UI;F<@;V8@;6EL
M97-T;VYE<RP@=&AE(&5X<&5C=&5D('!R;V)A8FEL:71Y(&]F('-U8V-E<W,@
M9F]R(&5A8V@@;6EL97-T;VYE(&%N9"!T:&4@=7!D871E9"!D:7-C;W5N="!R
M871E<R!B87-E9"!O;B!A(&-O<G!O<F%T92!D96)T(&EN=&5R97-T(')A=&4@
M:6YD97@@<'5B;&EC;'D@:7-S=65D+B`\+V9O;G0^/"]P/@T*("`@/'`@<W1Y
M;&4],T1F;VYT+7-I>F4Z,3)P>#MM87)G:6XM=&]P.C!P>#MM87)G:6XM8F]T
M=&]M.C!P>#XF(S$V,#L\+W`^#0H@("`\=&%B;&4@8V5L;'-P86-I;F<],T0P
M(&-E;&QP861D:6YG/3-$,"!W:61T:#TS1#$P,"4@8F]R9&5R/3-$,"!S='EL
M93TS1"=B;W)D97(M8V]L;&%P<V4Z8V]L;&%P<V4[('1E>'0M86QI9VXZ(&QE
M9G0G(&%L:6=N/3-$8V5N=&5R/@T*("`@/"$M+2!"96=I;B!486)L92!(96%D
M("TM/@T*("`@/'1R/B`-"B`@(#QT9"!W:61T:#TS1#8V)3XF(S$V,#L\+W1D
M/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0T)3XF(S$V,#L\
M+W1D/B`-"B`@(#QT9#XF(S$V,#L\+W1D/B`-"B`@(#QT9#XF(S$V,#L\+W1D
M/B`-"B`@(#QT9#XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0T)3XF(S$V,#L\+W1D/B`-"B`@(#QT9#XF(S$V,#L\+W1D
M/B`-"B`@(#QT9#XF(S$V,#L\+W1D/B`-"B`@(#QT9#XF(S$V,#L\+W1D/B`-
M"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0T)3XF(S$V,#L\+W1D
M/B`-"B`@(#QT9#XF(S$V,#L\+W1D/B`-"B`@(#QT9#XF(S$V,#L\+W1D/B`-
M"B`@(#QT9#XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@
M=VED=&@],T0T)3XF(S$V,#L\+W1D/B`-"B`@(#QT9#XF(S$V,#L\+W1D/B`-
M"B`@(#QT9#XF(S$V,#L\+W1D/B`-"B`@(#QT9#XF(S$V,#L\+W1D/@T*("`@
M/"]T<CX@#0H@("`\='(^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R
M87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@
M;F5W(')O;6%N)R!S:7IE/3-$,3X\8CY$97-C<FEP=&EO;CPO8CX\+V9O;G0^
M/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q
M/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@
M8V]L<W!A;CTS1#(@86QI9VX],T1C96YT97(@<W1Y;&4],T0G8F]R9&5R+6)O
M='1O;3HQ<'@@<V]L:60@(S`P,#`P,"<^/&9O;G0@<W1Y;&4],T0G9F]N="UF
M86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,3X\8CY-87)C:"8C,38P
M.S,Q+#QB<B`O/C(P,3(\+V(^/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG
M;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@
M#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P
M.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@8V]L<W!A
M;CTS1#(@86QI9VX],T1C96YT97(@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3HQ
M<'@@<V]L:60@(S`P,#`P,"<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ
M=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,3X\8CY1=6]T960\8G(@+SY0<FEC
M97,F(S$V,#MI;CQB<B`O/D%C=&EV93QB<B`O/DUA<FME=',\8G(@+SXH3&5V
M96PF(S$V,#LQ*3PO8CX\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$
M8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@
M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F
M;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$
M,B!A;&EG;CTS1&-E;G1E<B!S='EL93TS1"=B;W)D97(M8F]T=&]M.C%P>"!S
M;VQI9"`C,#`P,#`P)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE
M<R!N97<@<F]M86XG('-I>F4],T0Q/CQB/E-I9VYI9FEC86YT/&)R("\^3W1H
M97(\8G(@+SY/8G-E<G9A8FQE/&)R("\^26YP=71S/&)R("\^*$QE=F5L(#(I
M/"]B/CPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O
M;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG
M;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@
M#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$
M8V5N=&5R('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ,7!X('-O;&ED(",P,#`P
M,#`G/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA
M;B<@<VEZ93TS1#$^/&(^56YO8G-E<G9A8FQE/&)R("\^26YP=71S/&)R("\^
M*$QE=F5L)B,Q-C`[,RD\+V(^/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG
M;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X-
M"B`@(#PO='(^#0H@("`\(2TM($5N9"!486)L92!(96%D("TM/@T*("`@/"$M
M+2!"96=I;B!486)L92!";V1Y("TM/@T*("`@/'1R(&)G8V]L;W(],T0C8V-E
M969F/B`-"B`@(#QT9"!V86QI9VX],T1T;W`^#0H@("`\<"!S='EL93TS1"=M
M87)G:6XM;&5F=#HQ+C`P96T[('1E>'0M:6YD96YT.BTQ+C`P96TG/CQF;VYT
M('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS
M1#(^07-S971S.CPO9F]N=#X\+W`^#0H@("`\+W1D/B`-"B`@(#QT9"!V86QI
M9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^
M(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3XF(S$V,#L\+W1D/B`-"B`@(#QT
M9"!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N
M/3-$8F]T=&]M/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O
M;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@
M=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS
M1&)O='1O;3XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^
M)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I
M>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B
M;W1T;VT^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C
M,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3XF(S$V,#L\+W1D
M/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q
M-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3XF(S$V
M,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X@
M#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^#0H@("`\+W1R
M/B`-"B`@(#QT<CX@#0H@("`\=&0@=F%L:6=N/3-$=&]P/@T*("`@/'`@<W1Y
M;&4],T0G;6%R9VEN+6QE9G0Z,2XP,&5M.R!T97AT+6EN9&5N=#HM,2XP,&5M
M)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG
M('-I>F4],T0R/D-A<V@@97%U:79A;&5N=',\+V9O;G0^/"]P/@T*("`@/"]T
M9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C
M,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O
M;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE
M/3-$,CXD/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;2!A
M;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S
M(&YE=R!R;VUA;B<@<VEZ93TS1#(^-RPT-3,\+V9O;G0^/"]T9#X@#0H@("`\
M=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL
M93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B8C
M,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O
M;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG
M;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N
M97<@<F]M86XG('-I>F4],T0R/B0\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L
M:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G9F]N
M="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXW+#0U,SPO9F]N
M=#X\+W1D/B`-"B`@(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T
M=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA
M;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG
M;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@
M#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M
M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)#PO9F]N=#X\+W1D
M/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N
M="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4]
M,T0R/B8C.#(Q,CLF(S$V,#LF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@
M;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS
M1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B8C,38P
M.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@
M<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS
M1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@
M<F]M86XG('-I>F4],T0R/B0\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N
M/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G9F]N="UF
M86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXF(S@R,3([)B,Q-C`[
M)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!V
M86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM
M97,@;F5W(')O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X-"B`@
M(#PO='(^(`T*("`@/'1R('-T>6QE/3-$9F]N="US:7IE.C%P>#X@#0H@("`\
M=&0@=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG
M;CTS1&)O='1O;3XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T
M;VT^#0H@("`\<"!S='EL93TS1"=B;W)D97(M=&]P.C%P>"!S;VQI9"`C,#`P
M,#`P)SXF(S$V,#L\+W`^#0H@("`\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B
M;W1T;VT^#0H@("`\<"!S='EL93TS1"=B;W)D97(M=&]P.C%P>"!S;VQI9"`C
M,#`P,#`P)SXF(S$V,#L\+W`^#0H@("`\+W1D/B`-"B`@(#QT9#XF(S$V,#L\
M+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X@#0H@
M("`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*("`@/'`@<W1Y;&4],T0G8F]R9&5R
M+71O<#HQ<'@@<V]L:60@(S`P,#`P,"<^)B,Q-C`[/"]P/@T*("`@/"]T9#X@
M#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*("`@/'`@<W1Y;&4],T0G8F]R
M9&5R+71O<#HQ<'@@<V]L:60@(S`P,#`P,"<^)B,Q-C`[/"]P/@T*("`@/"]T
M9#X@#0H@("`\=&0^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T
M=&]M/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`@
M(#QP('-T>6QE/3-$)V)O<F1E<BUT;W`Z,7!X('-O;&ED(",P,#`P,#`G/B8C
M,38P.SPO<#X-"B`@(#PO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X-
M"B`@(#QP('-T>6QE/3-$)V)O<F1E<BUT;W`Z,7!X('-O;&ED(",P,#`P,#`G
M/B8C,38P.SPO<#X-"B`@(#PO=&0^(`T*("`@/'1D/B8C,38P.SPO=&0^(`T*
M("`@/'1D('9A;&EG;CTS1&)O='1O;3XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V
M86QI9VX],T1B;W1T;VT^#0H@("`\<"!S='EL93TS1"=B;W)D97(M=&]P.C%P
M>"!S;VQI9"`C,#`P,#`P)SXF(S$V,#L\+W`^#0H@("`\+W1D/B`-"B`@(#QT
M9"!V86QI9VX],T1B;W1T;VT^#0H@("`\<"!S='EL93TS1"=B;W)D97(M=&]P
M.C%P>"!S;VQI9"`C,#`P,#`P)SXF(S$V,#L\+W`^#0H@("`\+W1D/B`-"B`@
M(#QT9#XF(S$V,#L\+W1D/@T*("`@/"]T<CX@#0H@("`\='(@8F=C;VQO<CTS
M1"-C8V5E9F8^(`T*("`@/'1D('9A;&EG;CTS1'1O<#X-"B`@(#QP('-T>6QE
M/3-$)VUA<F=I;BUL969T.C,N,#!E;3L@=&5X="UI;F1E;G0Z+3$N,#!E;2<^
M/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S
M:7IE/3-$,CY4;W1A;"!A<W-E=',\+V9O;G0^/"]P/@T*("`@/"]T9#X@#0H@
M("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO
M9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y
M;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXD
M/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS
M1')I9VAT/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R
M;VUA;B<@<VEZ93TS1#(^-RPT-3,\+V9O;G0^/"]T9#X@#0H@("`\=&0@;F]W
M<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F
M;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B8C,38P.SPO
M9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ
M93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O
M='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M
M86XG('-I>F4],T0R/B0\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$
M8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI
M;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXW+#0U,SPO9F]N=#X\+W1D
M/B`-"B`@(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M/CQF
M;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ
M93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O
M='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\
M=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY
M.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)#PO9F]N=#X\+W1D/B`-"B`@
M(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL
M93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B8C
M.#(Q,CLF(S$V,#LF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@;F]W<F%P
M/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT
M+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N
M=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS
M1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O
M;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG
M('-I>F4],T0R/B0\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T
M=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ
M=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXF(S@R,3([)B,Q-C`[)B,Q-C`[
M/"]F;VYT/CPO=&0^(`T*("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX]
M,T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W
M(')O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X-"B`@(#PO='(^
M(`T*("`@/'1R('-T>6QE/3-$9F]N="US:7IE.C%P>#X@#0H@("`\=&0@=F%L
M:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O
M='1O;3XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@
M("`\<"!S='EL93TS1"=B;W)D97(M=&]P.C-P>"!D;W5B;&4@(S`P,#`P,"<^
M)B,Q-C`[/"]P/@T*("`@/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M
M/@T*("`@/'`@<W1Y;&4],T0G8F]R9&5R+71O<#HS<'@@9&]U8FQE(",P,#`P
M,#`G/B8C,38P.SPO<#X-"B`@(#PO=&0^(`T*("`@/'1D/B8C,38P.SPO=&0^
M(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3XF(S$V,#L\+W1D/B`-"B`@(#QT
M9"!V86QI9VX],T1B;W1T;VT^#0H@("`\<"!S='EL93TS1"=B;W)D97(M=&]P
M.C-P>"!D;W5B;&4@(S`P,#`P,"<^)B,Q-C`[/"]P/@T*("`@/"]T9#X@#0H@
M("`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*("`@/'`@<W1Y;&4],T0G8F]R9&5R
M+71O<#HS<'@@9&]U8FQE(",P,#`P,#`G/B8C,38P.SPO<#X-"B`@(#PO=&0^
M(`T*("`@/'1D/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O
M;3XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@("`\
M<"!S='EL93TS1"=B;W)D97(M=&]P.C-P>"!D;W5B;&4@(S`P,#`P,"<^)B,Q
M-C`[/"]P/@T*("`@/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*
M("`@/'`@<W1Y;&4],T0G8F]R9&5R+71O<#HS<'@@9&]U8FQE(",P,#`P,#`G
M/B8C,38P.SPO<#X-"B`@(#PO=&0^(`T*("`@/'1D/B8C,38P.SPO=&0^(`T*
M("`@/'1D('9A;&EG;CTS1&)O='1O;3XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V
M86QI9VX],T1B;W1T;VT^#0H@("`\<"!S='EL93TS1"=B;W)D97(M=&]P.C-P
M>"!D;W5B;&4@(S`P,#`P,"<^)B,Q-C`[/"]P/@T*("`@/"]T9#X@#0H@("`\
M=&0@=F%L:6=N/3-$8F]T=&]M/@T*("`@/'`@<W1Y;&4],T0G8F]R9&5R+71O
M<#HS<'@@9&]U8FQE(",P,#`P,#`G/B8C,38P.SPO<#X-"B`@(#PO=&0^(`T*
M("`@/'1D/B8C,38P.SPO=&0^#0H@("`\+W1R/B`-"B`@(#QT<CX@#0H@("`\
M=&0@=F%L:6=N/3-$=&]P/@T*("`@/'`@<W1Y;&4],T0G;6%R9VEN+6QE9G0Z
M,2XP,&5M.R!T97AT+6EN9&5N=#HM,2XP,&5M)SX\9F]N="!S='EL93TS1"=F
M;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/DQI86)I;&ET
M:65S.CPO9F]N=#X\+W`^#0H@("`\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B
M;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@
M/'1D('9A;&EG;CTS1&)O='1O;3XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI
M9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T
M=&]M/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N
M="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N
M/3-$8F]T=&]M/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O
M;3XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^)B,Q-C`[
M/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q
M/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^
M)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO
M=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3XF(S$V,#L\+W1D/B`-"B`@
M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F
M;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3XF(S$V,#L\+W1D
M/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X@#0H@("`\
M=&0@=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^#0H@("`\+W1R/B`-"B`@
M(#QT<B!B9V-O;&]R/3-$(V-C965F9CX@#0H@("`\=&0@=F%L:6=N/3-$=&]P
M/@T*("`@/'`@<W1Y;&4],T0G;6%R9VEN+6QE9G0Z,2XP,&5M.R!T97AT+6EN
M9&5N=#HM,2XP,&5M)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE
M<R!N97<@<F]M86XG('-I>F4],T0R/E=A<G)A;G1S('!O=&5N=&EA;&QY('-E
M='1L96%B;&4@:6X@8V%S:#PO9F]N=#X\+W`^#0H@("`\+W1D/B`-"B`@(#QT
M9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT
M/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS
M1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B0\+V9O
M;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG
M:'0^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N
M)R!S:7IE/3-$,CXR,"PS-3<\+V9O;G0^/"]T9#X@#0H@("`\=&0@;F]W<F%P
M/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT
M+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N
M=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS
M1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O
M;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG
M('-I>F4],T0R/B0\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T
M=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ
M=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXF(S@R,3([)B,Q-C`[)B,Q-C`[
M/"]F;VYT/CPO=&0^(`T*("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX]
M,T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W
M(')O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@
M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\
M+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G
M9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXD/"]F;VYT
M/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT
M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@
M<VEZ93TS1#(^,C`L,S4W/"]F;VYT/CPO=&0^(`T*("`@/'1D(&YO=W)A<#TS
M1&YO=W)A<"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF
M86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^
M/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q
M/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^
M/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S
M:7IE/3-$,CXD/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O
M;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I
M;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)B,X,C$R.R8C,38P.R8C,38P.SPO
M9F]N=#X\+W1D/B`-"B`@(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$
M8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R
M;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^#0H@("`\+W1R/B`-
M"B`@(#QT<CX@#0H@("`\=&0@=F%L:6=N/3-$=&]P/@T*("`@/'`@<W1Y;&4]
M,T0G;6%R9VEN+6QE9G0Z,2XP,&5M.R!T97AT+6EN9&5N=#HM,2XP,&5M)SX\
M9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I
M>F4],T0R/D-O;G1I;F=E;G0@<'5R8VAA<V4@<')I8V4@8V]N<VED97)A=&EO
M;CPO9F]N=#X\+W`^#0H@("`\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T
M;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D
M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT
M:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-
M"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S
M='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R
M/C8L,3DU/"]F;VYT/CPO=&0^(`T*("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!V
M86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM
M97,@;F5W(')O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X@#0H@
M("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO
M9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y
M;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXF
M(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L
M:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@
M;F5W(')O;6%N)R!S:7IE/3-$,CXF(S@R,3([)B,Q-C`[)B,Q-C`[/"]F;VYT
M/CPO=&0^(`T*("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T
M;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N
M)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N
M/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-
M"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF
M86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^
M/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^
M/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S
M:7IE/3-$,CXF(S@R,3([)B,Q-C`[)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@
M/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y
M;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXF
M(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF
M;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI
M9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@
M;F5W(')O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\
M=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4]
M,T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXV+#$Y
M-3PO9F]N=#X\+W1D/B`-"B`@(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N
M/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE
M=R!R;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^#0H@("`\+W1R
M/B`-"B`@(#QT<B!S='EL93TS1&9O;G0M<VEZ93HQ<'@^(`T*("`@/'1D('9A
M;&EG;CTS1&)O='1O;3XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B
M;W1T;VT^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*
M("`@/'`@<W1Y;&4],T0G8F]R9&5R+71O<#HQ<'@@<V]L:60@(S`P,#`P,"<^
M)B,Q-C`[/"]P/@T*("`@/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M
M/@T*("`@/'`@<W1Y;&4],T0G8F]R9&5R+71O<#HQ<'@@<V]L:60@(S`P,#`P
M,"<^)B,Q-C`[/"]P/@T*("`@/"]T9#X@#0H@("`\=&0^)B,Q-C`[/"]T9#X@
M#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^(`T*("`@/'1D
M('9A;&EG;CTS1&)O='1O;3X-"B`@(#QP('-T>6QE/3-$)V)O<F1E<BUT;W`Z
M,7!X('-O;&ED(",P,#`P,#`G/B8C,38P.SPO<#X-"B`@(#PO=&0^(`T*("`@
M/'1D('9A;&EG;CTS1&)O='1O;3X-"B`@(#QP('-T>6QE/3-$)V)O<F1E<BUT
M;W`Z,7!X('-O;&ED(",P,#`P,#`G/B8C,38P.SPO<#X-"B`@(#PO=&0^(`T*
M("`@/'1D/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3XF
M(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@("`\<"!S
M='EL93TS1"=B;W)D97(M=&]P.C%P>"!S;VQI9"`C,#`P,#`P)SXF(S$V,#L\
M+W`^#0H@("`\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@("`\
M<"!S='EL93TS1"=B;W)D97(M=&]P.C%P>"!S;VQI9"`C,#`P,#`P)SXF(S$V
M,#L\+W`^#0H@("`\+W1D/B`-"B`@(#QT9#XF(S$V,#L\+W1D/B`-"B`@(#QT
M9"!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N
M/3-$8F]T=&]M/@T*("`@/'`@<W1Y;&4],T0G8F]R9&5R+71O<#HQ<'@@<V]L
M:60@(S`P,#`P,"<^)B,Q-C`[/"]P/@T*("`@/"]T9#X@#0H@("`\=&0@=F%L
M:6=N/3-$8F]T=&]M/@T*("`@/'`@<W1Y;&4],T0G8F]R9&5R+71O<#HQ<'@@
M<V]L:60@(S`P,#`P,"<^)B,Q-C`[/"]P/@T*("`@/"]T9#X@#0H@("`\=&0^
M)B,Q-C`[/"]T9#X-"B`@(#PO='(^(`T*("`@/'1R(&)G8V]L;W(],T0C8V-E
M969F/B`-"B`@(#QT9"!V86QI9VX],T1T;W`^#0H@("`\<"!S='EL93TS1"=M
M87)G:6XM;&5F=#HS+C`P96T[('1E>'0M:6YD96YT.BTQ+C`P96TG/CQF;VYT
M('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS
M1#(^5&]T86P@;&EA8FEL:71I97,\+V9O;G0^/"]P/@T*("`@/"]T9#X@#0H@
M("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO
M9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y
M;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXD
M/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS
M1')I9VAT/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R
M;VUA;B<@<VEZ93TS1#(^,C8L-34R/"]F;VYT/CPO=&0^(`T*("`@/'1D(&YO
M=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G
M9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXF(S$V,#L\
M+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I
M>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B
M;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O
M;6%N)R!S:7IE/3-$,CXD/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS
M1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M
M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)B,X,C$R.R8C,38P.R8C
M,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!N;W=R87`],T1N;W=R87`@=F%L
M:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S
M(&YE=R!R;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@
M/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O
M;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE
M/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)#PO
M9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R
M:6=H=#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M
M86XG('-I>F4],T0R/C(P+#,U-SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!N;W=R
M87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O
M;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F
M;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE
M/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T
M=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA
M;B<@<VEZ93TS1#(^)#PO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B
M;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL
M>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/C8L,3DU/"]F;VYT/CPO=&0^
M(`T*("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT^/&9O
M;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE
M/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X-"B`@(#PO='(^(`T*("`@/'1R('-T
M>6QE/3-$9F]N="US:7IE.C%P>#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M
M/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3XF(S$V,#L\
M+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@("`\<"!S='EL93TS
M1"=B;W)D97(M=&]P.C-P>"!D;W5B;&4@(S`P,#`P,"<^)B,Q-C`[/"]P/@T*
M("`@/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*("`@/'`@<W1Y
M;&4],T0G8F]R9&5R+71O<#HS<'@@9&]U8FQE(",P,#`P,#`G/B8C,38P.SPO
M<#X-"B`@(#PO=&0^(`T*("`@/'1D/B8C,38P.SPO=&0^(`T*("`@/'1D('9A
M;&EG;CTS1&)O='1O;3XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B
M;W1T;VT^#0H@("`\<"!S='EL93TS1"=B;W)D97(M=&]P.C-P>"!D;W5B;&4@
M(S`P,#`P,"<^)B,Q-C`[/"]P/@T*("`@/"]T9#X@#0H@("`\=&0@=F%L:6=N
M/3-$8F]T=&]M/@T*("`@/'`@<W1Y;&4],T0G8F]R9&5R+71O<#HS<'@@9&]U
M8FQE(",P,#`P,#`G/B8C,38P.SPO<#X-"B`@(#PO=&0^(`T*("`@/'1D/B8C
M,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3XF(S$V,#L\+W1D
M/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@("`\<"!S='EL93TS1"=B
M;W)D97(M=&]P.C-P>"!D;W5B;&4@(S`P,#`P,"<^)B,Q-C`[/"]P/@T*("`@
M/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*("`@/'`@<W1Y;&4]
M,T0G8F]R9&5R+71O<#HS<'@@9&]U8FQE(",P,#`P,#`G/B8C,38P.SPO<#X-
M"B`@(#PO=&0^(`T*("`@/'1D/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG
M;CTS1&)O='1O;3XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T
M;VT^#0H@("`\<"!S='EL93TS1"=B;W)D97(M=&]P.C-P>"!D;W5B;&4@(S`P
M,#`P,"<^)B,Q-C`[/"]P/@T*("`@/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$
M8F]T=&]M/@T*("`@/'`@<W1Y;&4],T0G8F]R9&5R+71O<#HS<'@@9&]U8FQE
M(",P,#`P,#`G/B8C,38P.SPO<#X-"B`@(#PO=&0^(`T*("`@/'1D/B8C,38P
M.SPO=&0^#0H@("`\+W1R/@T*("`@/"$M+2!%;F0@5&%B;&4@0F]D>2`M+3X-
M"B`@(#PO=&%B;&4^#0H@("`\<"!S='EL93TS1&9O;G0M<VEZ93HQ,G!X.VUA
M<F=I;BUT;W`Z,'!X.VUA<F=I;BUB;W1T;VTZ,'!X/B8C,38P.SPO<#X-"B`@
M(#QT86)L92!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P('=I9'1H
M/3-$,3`P)2!B;W)D97(],T0P('-T>6QE/3-$)V)O<F1E<BUC;VQL87!S93IC
M;VQL87!S93L@=&5X="UA;&EG;CH@;&5F="<@86QI9VX],T1C96YT97(^#0H@
M("`\(2TM($)E9VEN(%1A8FQE($AE860@+2T^#0H@("`\='(^(`T*("`@/'1D
M('=I9'1H/3-$-C8E/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O
M='1O;2!W:61T:#TS1#0E/B8C,38P.SPO=&0^(`T*("`@/'1D/B8C,38P.SPO
M=&0^(`T*("`@/'1D/B8C,38P.SPO=&0^(`T*("`@/'1D/B8C,38P.SPO=&0^
M(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#0E/B8C,38P.SPO
M=&0^(`T*("`@/'1D/B8C,38P.SPO=&0^(`T*("`@/'1D/B8C,38P.SPO=&0^
M(`T*("`@/'1D/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O
M;2!W:61T:#TS1#0E/B8C,38P.SPO=&0^(`T*("`@/'1D/B8C,38P.SPO=&0^
M(`T*("`@/'1D/B8C,38P.SPO=&0^(`T*("`@/'1D/B8C,38P.SPO=&0^(`T*
M("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#0E/B8C,38P.SPO=&0^
M(`T*("`@/'1D/B8C,38P.SPO=&0^(`T*("`@/'1D/B8C,38P.SPO=&0^(`T*
M("`@/'1D/B8C,38P.SPO=&0^#0H@("`\+W1R/B`-"B`@(#QT<CX@#0H@("`\
M=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL
M93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0Q/CQB
M/D1E<V-R:7!T:6]N/"]B/CPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX]
M,T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*
M("`@/'1D('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,B!A;&EG;CTS1&-E
M;G1E<B!S='EL93TS1"=B;W)D97(M8F]T=&]M.C%P>"!S;VQI9"`C,#`P,#`P
M)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG
M('-I>F4],T0Q/CQB/D1E8V5M8F5R)B,Q-C`[,S$L/&)R("\^,C`Q,3PO8CX\
M+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I
M>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B
M;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@
M/'1D('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,B!A;&EG;CTS1&-E;G1E
M<B!S='EL93TS1"=B;W)D97(M8F]T=&]M.C%P>"!S;VQI9"`C,#`P,#`P)SX\
M9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I
M>F4],T0Q/CQB/E%U;W1E9#QB<B`O/E!R:6-E<R!I;CQB<B`O/D%C=&EV93QB
M<B`O/DUA<FME=',\8G(@+SXH3&5V96PF(S$V,#LQ*3PO8CX\+V9O;G0^/"]T
M9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C
M,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O
M;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG
M;CTS1&)O='1O;2!C;VQS<&%N/3-$,B!A;&EG;CTS1&-E;G1E<B!S='EL93TS
M1"=B;W)D97(M8F]T=&]M.C%P>"!S;VQI9"`C,#`P,#`P)SX\9F]N="!S='EL
M93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0Q/CQB
M/E-I9VYI9FEC86YT/&)R("\^3W1H97(\8G(@+SY/8G-E<G9A8FQE/&)R("\^
M26YP=71S/&)R("\^*$QE=F5L(#(I/"]B/CPO9F]N=#X\+W1D/B`-"B`@(#QT
M9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT
M/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$
M,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M
M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R('-T>6QE/3-$)V)O<F1E<BUB
M;W1T;VTZ,7!X('-O;&ED(",P,#`P,#`G/CQF;VYT('-T>6QE/3-$)V9O;G0M
M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#$^/&(^56YO8G-E<G9A
M8FQE/&)R("\^26YP=71S/&)R("\^*$QE=F5L)B,Q-C`[,RD\+V(^/"]F;VYT
M/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$
M,3XF(S$V,#L\+V9O;G0^/"]T9#X-"B`@(#PO='(^#0H@("`\(2TM($5N9"!4
M86)L92!(96%D("TM/@T*("`@/"$M+2!"96=I;B!486)L92!";V1Y("TM/@T*
M("`@/'1R(&)G8V]L;W(],T0C8V-E969F/B`-"B`@(#QT9"!V86QI9VX],T1T
M;W`^#0H@("`\<"!S='EL93TS1"=M87)G:6XM;&5F=#HQ+C`P96T[('1E>'0M
M:6YD96YT.BTQ+C`P96TG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I
M;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^07-S971S.CPO9F]N=#X\+W`^#0H@
M("`\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS
M1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O
M;3XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^)B,Q-C`[
M/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^(`T*
M("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\
M+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO
M=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3XF(S$V,#L\+W1D/B`-"B`@
M(#QT9"!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L
M:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D
M/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X@#0H@("`\
M=&0@=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG
M;CTS1&)O='1O;3XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T
M;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D
M('9A;&EG;CTS1&)O='1O;3XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX]
M,T1B;W1T;VT^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M
M/B8C,38P.SPO=&0^#0H@("`\+W1R/B`-"B`@(#QT<CX@#0H@("`\=&0@=F%L
M:6=N/3-$=&]P/@T*("`@/'`@<W1Y;&4],T0G;6%R9VEN+6QE9G0Z,2XP,&5M
M.R!T97AT+6EN9&5N=#HM,2XP,&5M)SX\9F]N="!S='EL93TS1"=F;VYT+69A
M;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/D-A<V@@97%U:79A;&5N
M=',\+V9O;G0^/"]P/@T*("`@/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T
M=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT
M9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ
M=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXD/"]F;VYT/CPO=&0^(`T*("`@
M/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE
M/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^,3$L
M-#,S/"]F;VYT/CPO=&0^(`T*("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI
M9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@
M;F5W(')O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\
M=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N
M=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4]
M,T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXD/"]F
M;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I
M9VAT/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA
M;B<@<VEZ93TS1#(^,3$L-#,S/"]F;VYT/CPO=&0^(`T*("`@/'1D(&YO=W)A
M<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N
M="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O
M;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4]
M,T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T
M;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N
M)R!S:7IE/3-$,CXD/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O
M='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY
M.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)B,X,C$R.R8C,38P.R8C,38P
M.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N
M/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE
M=R!R;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D
M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^
M/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$
M)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)#PO9F]N
M=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H
M=#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG
M('-I>F4],T0R/B8C.#(Q,CLF(S$V,#LF(S$V,#L\+V9O;G0^/"]T9#X@#0H@
M("`\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;3X\9F]N="!S
M='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R
M/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@/"]T<CX@#0H@("`\='(@<W1Y;&4]
M,T1F;VYT+7-I>F4Z,7!X/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^)B,Q
M-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^
M(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`@(#QP('-T>6QE/3-$)V)O
M<F1E<BUT;W`Z,7!X('-O;&ED(",P,#`P,#`G/B8C,38P.SPO<#X-"B`@(#PO
M=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`@(#QP('-T>6QE/3-$
M)V)O<F1E<BUT;W`Z,7!X('-O;&ED(",P,#`P,#`G/B8C,38P.SPO<#X-"B`@
M(#PO=&0^(`T*("`@/'1D/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS
M1&)O='1O;3XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^
M#0H@("`\<"!S='EL93TS1"=B;W)D97(M=&]P.C%P>"!S;VQI9"`C,#`P,#`P
M)SXF(S$V,#L\+W`^#0H@("`\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T
M;VT^#0H@("`\<"!S='EL93TS1"=B;W)D97(M=&]P.C%P>"!S;VQI9"`C,#`P
M,#`P)SXF(S$V,#L\+W`^#0H@("`\+W1D/B`-"B`@(#QT9#XF(S$V,#L\+W1D
M/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X@#0H@("`\
M=&0@=F%L:6=N/3-$8F]T=&]M/@T*("`@/'`@<W1Y;&4],T0G8F]R9&5R+71O
M<#HQ<'@@<V]L:60@(S`P,#`P,"<^)B,Q-C`[/"]P/@T*("`@/"]T9#X@#0H@
M("`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*("`@/'`@<W1Y;&4],T0G8F]R9&5R
M+71O<#HQ<'@@<V]L:60@(S`P,#`P,"<^)B,Q-C`[/"]P/@T*("`@/"]T9#X@
M#0H@("`\=&0^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M
M/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`@(#QP
M('-T>6QE/3-$)V)O<F1E<BUT;W`Z,7!X('-O;&ED(",P,#`P,#`G/B8C,38P
M.SPO<#X-"B`@(#PO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`@
M(#QP('-T>6QE/3-$)V)O<F1E<BUT;W`Z,7!X('-O;&ED(",P,#`P,#`G/B8C
M,38P.SPO<#X-"B`@(#PO=&0^(`T*("`@/'1D/B8C,38P.SPO=&0^#0H@("`\
M+W1R/B`-"B`@(#QT<B!B9V-O;&]R/3-$(V-C965F9CX@#0H@("`\=&0@=F%L
M:6=N/3-$=&]P/@T*("`@/'`@<W1Y;&4],T0G;6%R9VEN+6QE9G0Z,RXP,&5M
M.R!T97AT+6EN9&5N=#HM,2XP,&5M)SX\9F]N="!S='EL93TS1"=F;VYT+69A
M;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/E1O=&%L(&%S<V5T<SPO
M9F]N=#X\+W`^#0H@("`\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^
M/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A
M;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE
M<R!N97<@<F]M86XG('-I>F4],T0R/B0\+V9O;G0^/"]T9#X@#0H@("`\=&0@
M=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G
M9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXQ,2PT,S,\
M+V9O;G0^/"]T9#X@#0H@("`\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS
M1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@
M<F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V
M86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO
M=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F
M;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B0\+V9O;G0^
M/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^
M/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S
M:7IE/3-$,CXQ,2PT,S,\+V9O;G0^/"]T9#X@#0H@("`\=&0@;F]W<F%P/3-$
M;F]W<F%P('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A
M;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\
M+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^
M)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\
M9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I
M>F4],T0R/B0\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M
M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM
M97,@;F5W(')O;6%N)R!S:7IE/3-$,CXF(S@R,3([)B,Q-C`[)B,Q-C`[/"]F
M;VYT/CPO=&0^(`T*("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B
M;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O
M;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L
M:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D
M/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N
M="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXD/"]F;VYT/CPO
M=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF
M;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ
M93TS1#(^)B,X,C$R.R8C,38P.R8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT
M9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE
M/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)B,Q
M-C`[/"]F;VYT/CPO=&0^#0H@("`\+W1R/B`-"B`@(#QT<B!S='EL93TS1&9O
M;G0M<VEZ93HQ<'@^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3XF(S$V,#L\
M+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X@#0H@
M("`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*("`@/'`@<W1Y;&4],T0G8F]R9&5R
M+71O<#HS<'@@9&]U8FQE(",P,#`P,#`G/B8C,38P.SPO<#X-"B`@(#PO=&0^
M(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`@(#QP('-T>6QE/3-$)V)O
M<F1E<BUT;W`Z,W!X(&1O=6)L92`C,#`P,#`P)SXF(S$V,#L\+W`^#0H@("`\
M+W1D/B`-"B`@(#QT9#XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B
M;W1T;VT^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*
M("`@/'`@<W1Y;&4],T0G8F]R9&5R+71O<#HS<'@@9&]U8FQE(",P,#`P,#`G
M/B8C,38P.SPO<#X-"B`@(#PO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O
M;3X-"B`@(#QP('-T>6QE/3-$)V)O<F1E<BUT;W`Z,W!X(&1O=6)L92`C,#`P
M,#`P)SXF(S$V,#L\+W`^#0H@("`\+W1D/B`-"B`@(#QT9#XF(S$V,#L\+W1D
M/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X@#0H@("`\
M=&0@=F%L:6=N/3-$8F]T=&]M/@T*("`@/'`@<W1Y;&4],T0G8F]R9&5R+71O
M<#HS<'@@9&]U8FQE(",P,#`P,#`G/B8C,38P.SPO<#X-"B`@(#PO=&0^(`T*
M("`@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`@(#QP('-T>6QE/3-$)V)O<F1E
M<BUT;W`Z,W!X(&1O=6)L92`C,#`P,#`P)SXF(S$V,#L\+W`^#0H@("`\+W1D
M/B`-"B`@(#QT9#XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T
M;VT^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*("`@
M/'`@<W1Y;&4],T0G8F]R9&5R+71O<#HS<'@@9&]U8FQE(",P,#`P,#`G/B8C
M,38P.SPO<#X-"B`@(#PO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X-
M"B`@(#QP('-T>6QE/3-$)V)O<F1E<BUT;W`Z,W!X(&1O=6)L92`C,#`P,#`P
M)SXF(S$V,#L\+W`^#0H@("`\+W1D/B`-"B`@(#QT9#XF(S$V,#L\+W1D/@T*
M("`@/"]T<CX@#0H@("`\='(^(`T*("`@/'1D('9A;&EG;CTS1'1O<#X-"B`@
M(#QP('-T>6QE/3-$)VUA<F=I;BUL969T.C$N,#!E;3L@=&5X="UI;F1E;G0Z
M+3$N,#!E;2<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W
M(')O;6%N)R!S:7IE/3-$,CY,:6%B:6QI=&EE<SH\+V9O;G0^/"]P/@T*("`@
M/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q
M/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^
M)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO
M=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3XF(S$V,#L\+W1D/B`-"B`@
M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F
M;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3XF(S$V,#L\+W1D
M/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X@#0H@("`\
M=&0@=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG
M;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@
M#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^(`T*("`@/'1D
M('9A;&EG;CTS1&)O='1O;3XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX]
M,T1B;W1T;VT^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M
M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V
M86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$
M8F]T=&]M/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3XF
M(S$V,#L\+W1D/@T*("`@/"]T<CX@#0H@("`\='(@8F=C;VQO<CTS1"-C8V5E
M9F8^(`T*("`@/'1D('9A;&EG;CTS1'1O<#X-"B`@(#QP('-T>6QE/3-$)VUA
M<F=I;BUL969T.C$N,#!E;3L@=&5X="UI;F1E;G0Z+3$N,#!E;2<^/&9O;G0@
M<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$
M,CY787)R86YT<R!P;W1E;G1I86QL>2!S971T;&5A8FQE(&EN(&-A<V@\+V9O
M;G0^/"]P/@T*("`@/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF
M;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI
M9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@
M;F5W(')O;6%N)R!S:7IE/3-$,CXD/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A
M;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)V9O
M;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^,RPW-#8\+V9O
M;G0^/"]T9#X@#0H@("`\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O
M='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M
M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI
M9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^
M(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT
M+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B0\+V9O;G0^/"]T
M9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O
M;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE
M/3-$,CXF(S@R,3([)B,Q-C`[)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D
M(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4]
M,T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXF(S$V
M,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT
M('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX]
M,T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W
M(')O;6%N)R!S:7IE/3-$,CXD/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG
M;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)V9O;G0M
M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^,RPW-#8\+V9O;G0^
M/"]T9#X@#0H@("`\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O
M;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG
M('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX]
M,T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*
M("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A
M;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B0\+V9O;G0^/"]T9#X@
M#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@
M<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$
M,CXF(S@R,3([)B,Q-C`[)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D(&YO
M=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G
M9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXF(S$V,#L\
M+V9O;G0^/"]T9#X-"B`@(#PO='(^(`T*("`@/'1R/B`-"B`@(#QT9"!V86QI
M9VX],T1T;W`^#0H@("`\<"!S='EL93TS1"=M87)G:6XM;&5F=#HQ+C`P96T[
M('1E>'0M:6YD96YT.BTQ+C`P96TG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M
M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^0V]N=&EN9V5N="!P=7)C
M:&%S92!P<FEC92!C;VYS:61E<F%T:6]N/"]F;VYT/CPO<#X-"B`@(#PO=&0^
M(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V
M,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT
M('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS
M1#(^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O
M;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I
M;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^-BPS-3$\+V9O;G0^/"]T9#X@#0H@
M("`\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;3X\9F]N="!S
M='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R
M/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^
M/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A
M;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE
M<R!N97<@<F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@
M(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL
M93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B8C
M.#(Q,CLF(S$V,#LF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@;F]W<F%P
M/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT
M+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N
M=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS
M1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O
M;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG
M('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX]
M,T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=F;VYT+69A
M;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B8C.#(Q,CLF(S$V,#LF
M(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@;F]W<F%P/3-$;F]W<F%P('9A
M;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE
M<R!N97<@<F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@
M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F
M;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL
M93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B8C
M,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@86QI
M9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N
M97<@<F]M86XG('-I>F4],T0R/C8L,S4Q/"]F;VYT/CPO=&0^(`T*("`@/'1D
M(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4]
M,T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXF(S$V
M,#L\+V9O;G0^/"]T9#X-"B`@(#PO='(^(`T*("`@/'1R('-T>6QE/3-$9F]N
M="US:7IE.C%P>#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO
M=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3XF(S$V,#L\+W1D/B`-"B`@
M(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@("`\<"!S='EL93TS1"=B;W)D97(M
M=&]P.C%P>"!S;VQI9"`C,#`P,#`P)SXF(S$V,#L\+W`^#0H@("`\+W1D/B`-
M"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@("`\<"!S='EL93TS1"=B;W)D
M97(M=&]P.C%P>"!S;VQI9"`C,#`P,#`P)SXF(S$V,#L\+W`^#0H@("`\+W1D
M/B`-"B`@(#QT9#XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T
M;VT^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*("`@
M/'`@<W1Y;&4],T0G8F]R9&5R+71O<#HQ<'@@<V]L:60@(S`P,#`P,"<^)B,Q
M-C`[/"]P/@T*("`@/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*
M("`@/'`@<W1Y;&4],T0G8F]R9&5R+71O<#HQ<'@@<V]L:60@(S`P,#`P,"<^
M)B,Q-C`[/"]P/@T*("`@/"]T9#X@#0H@("`\=&0^)B,Q-C`[/"]T9#X@#0H@
M("`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^(`T*("`@/'1D('9A
M;&EG;CTS1&)O='1O;3X-"B`@(#QP('-T>6QE/3-$)V)O<F1E<BUT;W`Z,7!X
M('-O;&ED(",P,#`P,#`G/B8C,38P.SPO<#X-"B`@(#PO=&0^(`T*("`@/'1D
M('9A;&EG;CTS1&)O='1O;3X-"B`@(#QP('-T>6QE/3-$)V)O<F1E<BUT;W`Z
M,7!X('-O;&ED(",P,#`P,#`G/B8C,38P.SPO<#X-"B`@(#PO=&0^(`T*("`@
M/'1D/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3XF(S$V
M,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@("`\<"!S='EL
M93TS1"=B;W)D97(M=&]P.C%P>"!S;VQI9"`C,#`P,#`P)SXF(S$V,#L\+W`^
M#0H@("`\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@("`\<"!S
M='EL93TS1"=B;W)D97(M=&]P.C%P>"!S;VQI9"`C,#`P,#`P)SXF(S$V,#L\
M+W`^#0H@("`\+W1D/B`-"B`@(#QT9#XF(S$V,#L\+W1D/@T*("`@/"]T<CX@
M#0H@("`\='(@8F=C;VQO<CTS1"-C8V5E9F8^(`T*("`@/'1D('9A;&EG;CTS
M1'1O<#X-"B`@(#QP('-T>6QE/3-$)VUA<F=I;BUL969T.C,N,#!E;3L@=&5X
M="UI;F1E;G0Z+3$N,#!E;2<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ
M=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CY4;W1A;"!L:6%B:6QI=&EE<SPO
M9F]N=#X\+W`^#0H@("`\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^
M/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A
M;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE
M<R!N97<@<F]M86XG('-I>F4],T0R/B0\+V9O;G0^/"]T9#X@#0H@("`\=&0@
M=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G
M9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXQ,"PP.3<\
M+V9O;G0^/"]T9#X@#0H@("`\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS
M1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@
M<F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V
M86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO
M=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F
M;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B0\+V9O;G0^
M/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^
M/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S
M:7IE/3-$,CXF(S@R,3([)B,Q-C`[)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@
M/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y
M;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXF
M(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF
M;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI
M9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@
M;F5W(')O;6%N)R!S:7IE/3-$,CXD/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A
M;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)V9O
M;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^,RPW-#8\+V9O
M;G0^/"]T9#X@#0H@("`\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O
M='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M
M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI
M9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^
M(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT
M+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B0\+V9O;G0^/"]T
M9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O
M;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE
M/3-$,CXV+#,U,3PO9F]N=#X\+W1D/B`-"B`@(#QT9"!N;W=R87`],T1N;W=R
M87`@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY
M.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^
M#0H@("`\+W1R/B`-"B`@(#QT<B!S='EL93TS1&9O;G0M<VEZ93HQ<'@^(`T*
M("`@/'1D('9A;&EG;CTS1&)O='1O;3XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V
M86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$
M8F]T=&]M/@T*("`@/'`@<W1Y;&4],T0G8F]R9&5R+71O<#HS<'@@9&]U8FQE
M(",P,#`P,#`G/B8C,38P.SPO<#X-"B`@(#PO=&0^(`T*("`@/'1D('9A;&EG
M;CTS1&)O='1O;3X-"B`@(#QP('-T>6QE/3-$)V)O<F1E<BUT;W`Z,W!X(&1O
M=6)L92`C,#`P,#`P)SXF(S$V,#L\+W`^#0H@("`\+W1D/B`-"B`@(#QT9#XF
M(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T
M9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*("`@/'`@<W1Y;&4],T0G
M8F]R9&5R+71O<#HS<'@@9&]U8FQE(",P,#`P,#`G/B8C,38P.SPO<#X-"B`@
M(#PO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`@(#QP('-T>6QE
M/3-$)V)O<F1E<BUT;W`Z,W!X(&1O=6)L92`C,#`P,#`P)SXF(S$V,#L\+W`^
M#0H@("`\+W1D/B`-"B`@(#QT9#XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI
M9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T
M=&]M/@T*("`@/'`@<W1Y;&4],T0G8F]R9&5R+71O<#HS<'@@9&]U8FQE(",P
M,#`P,#`G/B8C,38P.SPO<#X-"B`@(#PO=&0^(`T*("`@/'1D('9A;&EG;CTS
M1&)O='1O;3X-"B`@(#QP('-T>6QE/3-$)V)O<F1E<BUT;W`Z,W!X(&1O=6)L
M92`C,#`P,#`P)SXF(S$V,#L\+W`^#0H@("`\+W1D/B`-"B`@(#QT9#XF(S$V
M,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X@
M#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*("`@/'`@<W1Y;&4],T0G8F]R
M9&5R+71O<#HS<'@@9&]U8FQE(",P,#`P,#`G/B8C,38P.SPO<#X-"B`@(#PO
M=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`@(#QP('-T>6QE/3-$
M)V)O<F1E<BUT;W`Z,W!X(&1O=6)L92`C,#`P,#`P)SXF(S$V,#L\+W`^#0H@
M("`\+W1D/B`-"B`@(#QT9#XF(S$V,#L\+W1D/@T*("`@/"]T<CX-"B`@(#PA
M+2T@16YD(%1A8FQE($)O9'D@+2T^#0H@("`\+W1A8FQE/@T*("`@/'`@<W1Y
M;&4],T1M87)G:6XM=&]P.C$X<'@[;6%R9VEN+6)O='1O;3HP<'@^/&9O;G0@
M<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$
M,CX\:3Y&86ER(%9A;'5E(&]F($9I;F%N8VEA;"!);G-T<G5M96YT<R`\+VD^
M/"]F;VYT/CPO<#X-"B`@(#QP('-T>6QE/3-$)VUA<F=I;BUT;W`Z-G!X.VUA
M<F=I;BUB;W1T;VTZ,'!X.R!T97AT+6EN9&5N=#HT)2<^/&9O;G0@<W1Y;&4]
M,T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CX-"B`@
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M97)E<W0N(#PO9F]N=#X\+W`^#0H\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM
M+2TM+2T]7TYE>'1087)T7V)E9F4Y8S$Q7V,R9C-?-#AE8U]A,F%B7V9F,C@Y
M-C`W961C,`T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B]B969E.6,Q
M,5]C,F8S7S0X96-?83)A8E]F9C(X.38P-V5D8S`O5V]R:W-H965T<R]3:&5E
M=#$Q+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP
M<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U
M<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M
M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H
M87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S
M<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO
M/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,]
M,T1R97!O<G0@:60],T1)1#!%344^#0H@("`@("`\='(^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^
M4W1O8VL@0F%S960@0V]M<&5N<V%T:6]N/&)R/CPO<W1R;VYG/CPO=&@^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C,@36]N=&AS($5N
M9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1H/DUA<BX@,S$L(#(P,3(\8G(^/"]T:#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^4W1O8VL@0F%S960@0V]M<&5N
M<V%T:6]N(%M!8G-T<F%C=%T\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^4W1O8VL@0F%S960@0V]M<&5N<V%T:6]N/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\(2TM1$]#5%E012!H=&UL(%!5
M0DQ)0R`B+2\O5S-#+R]$5$0@6$A434P@,2XP(%1R86YS:71I;VYA;"\O14XB
M(")H='1P.B\O=W=W+G<S+F]R9R]44B]X:'1M;#$O1%1$+WAH=&UL,2UT<F%N
M<VET:6]N86PN9'1D(B`M+3X-"B`@(#PA+2T@0F5G:6X@0FQO8VL@5&%G9V5D
M($YO=&4@-B`M('5S+6=A87`Z1&ES8VQO<W5R94]F0V]M<&5N<V%T:6]N4F5L
M871E9$-O<W1S4VAA<F5"87-E9%!A>6UE;G1S5&5X=$)L;V-K+2T^#0H@("`\
M<"!S='EL93TS1&UA<F=I;BUT;W`Z,3AP>#MM87)G:6XM8F]T=&]M.C!P>#X\
M9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I
M>F4],T0R/CQB/C8N(%-T;V-K($)A<V5D($-O;7!E;G-A=&EO;B`\+V(^/"]F
M;VYT/CPO<#X-"B`@(#QP('-T>6QE/3-$)VUA<F=I;BUT;W`Z-G!X.VUA<F=I
M;BUB;W1T;VTZ,'!X.R!T97AT+6EN9&5N=#HT)2<^/&9O;G0@<W1Y;&4],T0G
M9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CY4:&4@0V]M
M<&%N>2!F;VQL;W=S('1H92!P<F]V:7-I;VYS(&]F('1H92!&05-"($%30R!4
M;W!I8R`W,3@L("8C.#(R,#L\:3Y#;VUP96YS871I;VX@)B,X,C$R.R!3=&]C
M:R!#;VUP96YS871I;VX\+VD^)B,X,C(Q.PT*("`@*"8C.#(R,#M!4T,@-S$X
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M:6]N(&5X<&5N<V4-"B`@(&)A<V5D(&]N('1H92!G<F%N="!D871E(&9A:7(@
M=F%L=64@97-T:6UA=&5D(&EN(&%C8V]R9&%N8V4@=VET:"!T:&4@<')O=FES
M:6]N<R!O9B!!4T,@-S$X(&ES(')E8V]G;FEZ960@87,@86X@97AP96YS92!O
M=F5R('1H92!R97%U:7-I=&4@<V5R=FEC92!P97)I;V0N(#PO9F]N=#X\+W`^
M#0H@("`\<"!S='EL93TS1"=M87)G:6XM=&]P.C$R<'@[;6%R9VEN+6)O='1O
M;3HP<'@[('1E>'0M:6YD96YT.C0E)SX\9F]N="!S='EL93TS1"=F;VYT+69A
M;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/@T*("`@1F]R('-T;V-K
M(&]P=&EO;G,@9W)A;G1E9"!A<R!C;VYS:61E<F%T:6]N(&9O<B!S97)V:6-E
M<R!R96YD97)E9"!B>2!N;VXM96UP;&]Y965S+"!T:&4@0V]M<&%N>2!R96-O
M9VYI>F5S(&-O;7!E;G-A=&EO;B!E>'!E;G-E(&EN(&%C8V]R9&%N8V4@=VET
M:"!T:&4@<F5Q=6ER96UE;G1S(&]F($9!4T(@05-#(%1O<&EC(#4P-2TU,"P@
M)B,X,C(P.SQI/D5Q=6ET>0T*("`@0F%S960@4&%Y;65N=',@=&\@3F]N+45M
M<&QO>65E<RXF(S@R,C$[/"]I/B`\+V9O;G0^/"]P/@T*("`@/'`@<W1Y;&4]
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M9R!M;V1E;"P@=VEL;"!B92!R92UM96%S=7)E9"!U<VEN9R!T:&4-"B`@(&9A
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M(&9U='5R92P@=&AE(&%M;W5N="!O9@T*("`@=&AE(&9U='5R92!C;VUP96YS
M871I;VX@97AP96YS92!W:6QL(&EN8VQU9&4@9F%I<B!V86QU92!R92UM96%S
M=7)E;65N=',@=6YT:6P@=&AE('-T;V-K(&]P=&EO;G,@87)E(&9U;&QY('9E
M<W1E9"X@/"]F;VYT/CPO<#X-"B`@(#QP('-T>6QE/3-$9F]N="US:7IE.C%P
M>#MM87)G:6XM=&]P.C$R<'@[;6%R9VEN+6)O='1O;3HP<'@^)B,Q-C`[/"]P
M/@T*("`@/'`@<W1Y;&4],T0G;6%R9VEN+71O<#HP<'@[;6%R9VEN+6)O='1O
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M,#LS,2P@,C`Q,B!A;F0@,C`Q,2P@=&AE(&9O;&QO=VEN9R!A<W-U;7!T:6]N
M<R!W97)E('5S960Z(#PO9F]N=#X\+W`^#0H@("`\<"!S='EL93TS1&9O;G0M
M<VEZ93HQ,G!X.VUA<F=I;BUT;W`Z,'!X.VUA<F=I;BUB;W1T;VTZ,'!X/B8C
M,38P.SPO<#X-"B`@(#QT86)L92!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I
M;F<],T0P('=I9'1H/3-$,3`P)2!B;W)D97(],T0P('-T>6QE/3-$)V)O<F1E
M<BUC;VQL87!S93IC;VQL87!S93L@=&5X="UA;&EG;CH@;&5F="<@86QI9VX]
M,T1C96YT97(^#0H@("`\(2TM($)E9VEN(%1A8FQE($AE860@+2T^#0H@("`\
M='(^(`T*("`@/'1D('=I9'1H/3-$.#DE/B8C,38P.SPO=&0^(`T*("`@/'1D
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#(E/B8C,38P.SPO=&0^(`T*("`@
M/'1D/B8C,38P.SPO=&0^(`T*("`@/'1D/B8C,38P.SPO=&0^(`T*("`@/'1D
M/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#(E/B8C,38P.SPO=&0^(`T*("`@/'1D/B8C,38P.SPO=&0^(`T*("`@/'1D
M/B8C,38P.SPO=&0^(`T*("`@/'1D/B8C,38P.SPO=&0^#0H@("`\+W1R/B`-
M"B`@(#QT<CX@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4]
M,T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T
M;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D
M('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$-B!A;&EG;CTS1&-E;G1E<B!S
M='EL93TS1"=B;W)D97(M8F]T=&]M.C%P>"!S;VQI9"`C,#`P,#`P)SX\9F]N
M="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4]
M,T0Q/CQB/D9O<B!4:&4@5&AR964\8G(@+SY-;VYT:',@16YD960\8G(@+SY-
M87)C:"`S,2P\+V(^/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O
M='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X-"B`@(#PO
M='(^(`T*("`@/'1R/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@
M<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS
M1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@
M("`\=&0@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N
M=&5R('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ,7!X('-O;&ED(",P,#`P,#`G
M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@
M<VEZ93TS1#$^/&(^,C`Q,CPO8CX\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L
M:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D
M/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q
M-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;2!C;VQS
M<&%N/3-$,B!A;&EG;CTS1&-E;G1E<B!S='EL93TS1"=B;W)D97(M8F]T=&]M
M.C%P>"!S;VQI9"`C,#`P,#`P)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL
M>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0Q/CQB/C(P,3$\+V(^/"]F;VYT
M/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$
M,3XF(S$V,#L\+V9O;G0^/"]T9#X-"B`@(#PO='(^#0H@("`\(2TM($5N9"!4
M86)L92!(96%D("TM/@T*("`@/"$M+2!"96=I;B!486)L92!";V1Y("TM/@T*
M("`@/'1R(&)G8V]L;W(],T0C8V-E969F/B`-"B`@(#QT9"!V86QI9VX],T1T
M;W`^#0H@("`\<"!S='EL93TS1"=M87)G:6XM;&5F=#HQ+C`P96T[('1E>'0M
M:6YD96YT.BTQ+C`P96TG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I
M;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^5V5I9VAT960@879E<F%G92!R:7-K
M+69R964@:6YT97)E<W0@<F%T93PO9F]N=#X\+W`^#0H@("`\+W1D/B`-"B`@
M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F
M;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL
M93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B8C
M,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@86QI
M9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N
M97<@<F]M86XG('-I>F4],T0R/C$N,#8\+V9O;G0^/"]T9#X@#0H@("`\=&0@
M;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS
M1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B4F(S$V
M,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT
M('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX]
M,T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W
M(')O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@
M=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G
M9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXR+C,S/"]F
M;VYT/CPO=&0^(`T*("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B
M;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O
M;6%N)R!S:7IE/3-$,CXE)B,Q-C`[/"]F;VYT/CPO=&0^#0H@("`\+W1R/B`-
M"B`@(#QT<CX@#0H@("`\=&0@=F%L:6=N/3-$=&]P/@T*("`@/'`@<W1Y;&4]
M,T0G;6%R9VEN+6QE9G0Z,2XP,&5M.R!T97AT+6EN9&5N=#HM,2XP,&5M)SX\
M9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I
M>F4],T0R/E=E:6=H=&5D(&%V97)A9V4@97AP96-T960@=F]L871I;&ET>3PO
M9F]N=#X\+W`^#0H@("`\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^
M/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A
M;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE
M<R!N97<@<F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@
M(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL
M93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/C<U
M+C8Y/"]F;VYT/CPO=&0^(`T*("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI
M9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@
M;F5W(')O;6%N)R!S:7IE/3-$,CXE)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@
M/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O
M;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE
M/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)B,Q
M-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG
M;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE
M=R!R;VUA;B<@<VEZ93TS1#(^,3$R+CDU/"]F;VYT/CPO=&0^(`T*("`@/'1D
M(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4]
M,T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXE)B,Q
M-C`[/"]F;VYT/CPO=&0^#0H@("`\+W1R/B`-"B`@(#QT<B!B9V-O;&]R/3-$
M(V-C965F9CX@#0H@("`\=&0@=F%L:6=N/3-$=&]P/@T*("`@/'`@<W1Y;&4]
M,T0G;6%R9VEN+6QE9G0Z,2XP,&5M.R!T97AT+6EN9&5N=#HM,2XP,&5M)SX\
M9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I
M>F4],T0R/E=E:6=H=&5D(&%V97)A9V4@97AP96-T960@;&EV97,@*'EE87)S
M*3PO9F]N=#X\+W`^#0H@("`\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T
M;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D
M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT
M:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-
M"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S
M='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R
M/C8N,3`\+V9O;G0^/"]T9#X@#0H@("`\=&0@;F]W<F%P/3-$;F]W<F%P('9A
M;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE
M<R!N97<@<F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@
M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F
M;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL
M93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B8C
M,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@86QI
M9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N
M97<@<F]M86XG('-I>F4],T0R/C4N-S8\+V9O;G0^/"]T9#X@#0H@("`\=&0@
M;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS
M1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B8C,38P
M.SPO9F]N=#X\+W1D/@T*("`@/"]T<CX@#0H@("`\='(^(`T*("`@/'1D('9A
M;&EG;CTS1'1O<#X-"B`@(#QP('-T>6QE/3-$)VUA<F=I;BUL969T.C$N,#!E
M;3L@=&5X="UI;F1E;G0Z+3$N,#!E;2<^/&9O;G0@<W1Y;&4],T0G9F]N="UF
M86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CY796EG:'1E9"!A=F5R
M86=E(&5X<&5C=&5D(&1I=FED96YD('EI96QD/"]F;VYT/CPO<#X-"B`@(#PO
M=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF
M(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF
M;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ
M93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O
M='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY
M.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^,"XP,#PO9F]N=#X\+W1D/B`-
M"B`@(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M/CQF;VYT
M('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS
M1#(^)28C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T
M;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D
M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT
M:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-
M"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S
M='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R
M/C`N,#`\+V9O;G0^/"]T9#X@#0H@("`\=&0@;F]W<F%P/3-$;F]W<F%P('9A
M;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE
M<R!N97<@<F]M86XG('-I>F4],T0R/B4F(S$V,#L\+V9O;G0^/"]T9#X-"B`@
M(#PO='(^#0H@("`\(2TM($5N9"!486)L92!";V1Y("TM/@T*("`@/"]T86)L
M93X-"B`@(#QP('-T>6QE/3-$)VUA<F=I;BUT;W`Z,3)P>#MM87)G:6XM8F]T
M=&]M.C!P>#L@=&5X="UI;F1E;G0Z-"4G/CQF;VYT('-T>6QE/3-$)V9O;G0M
M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^5&AE('=E:6=H=&5D
M(&%V97)A9V4@9F%I<B!V86QU92!O9B!O<'1I;VYS(&=R86YT960@9'5R:6YG
M('1H92!T:')E92!M;VYT:"!P97)I;V0@96YD960@36%R8V@F(S$V,#LS,2P-
M"B`@(#(P,3(@86YD(#(P,3$@=V%S("0P+C0X(&%N9"`D,2XR,"!P97(@<VAA
M<F4L(')E<W!E8W1I=F5L>2X@/"]F;VYT/CPO<#X-"B`@(#QP('-T>6QE/3-$
M)VUA<F=I;BUT;W`Z,3)P>#MM87)G:6XM8F]T=&]M.C!P>#L@=&5X="UI;F1E
M;G0Z-"4G/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R
M;VUA;B<@<VEZ93TS1#(^5&AE($-O;7!A;GDF(S@R,3<[<R!E>'!E8W1E9"!C
M;VUM;VX@<W1O8VL@<')I8V4@=F]L871I;&ET>0T*("`@87-S=6UP=&EO;B!I
M<R!B87-E9"!U<&]N('1H92!V;VQA=&EL:71Y(&]F(&$@8F%S:V5T(&]F(&-O
M;7!A<F%B;&4@8V]M<&%N:65S+B!4:&4@97AP96-T960@;&EF92!A<W-U;7!T
M:6]N<R!F;W(@96UP;&]Y964@9W)A;G1S('=E<F4@8F%S960@=7!O;B!T:&4@
M<VEM<&QI9FEE9"!M971H;V0@<')O=FED960@9F]R('5N9&5R($%30R`W,3@M
M,3`N(%1H92!E>'!E8W1E9"!L:69E(&%S<W5M<'1I;VYS(&9O<B!N;VXM96UP
M;&]Y965S('=E<F4-"B`@(&)A<V5D('5P;VX@=&AE(&-O;G1R86-T=6%L('1E
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M=&5D(&%N(&%N;G5A;&EZ960@9F]R9F5I='5R92!R871E(&]F(#$U+C`E(&9O
M<B!O<'1I;VYS(&=R86YT960@=&\@:71S(&5M<&QO>65E<RP@."XP)2!F;W(@
M;W!T:6]N<R!G<F%N=&5D('1O('-E;FEO<B!M86YA9V5M96YT(&%N9"!N;R!F
M;W)F96ET=7)E(')A=&4@9F]R('1H90T*("`@9&ER96-T;W)S+B!26&D@=VEL
M;"!R96-O<F0@861D:71I;VYA;"!E>'!E;G-E(&EF('1H92!A8W1U86P@9F]R
M9F5I='5R97,@87)E(&QO=V5R('1H86X@97-T:6UA=&5D(&%N9"!W:6QL(')E
M8V]R9"!A(')E8V]V97)Y(&]F('!R:6]R(&5X<&5N<V4@:68@=&AE(&%C='5A
M;"!F;W)F96ET=7)E(')A=&5S(&%R92!H:6=H97(@=&AA;B!E<W1I;6%T960N
M(#PO9F]N=#X\+W`^#0H@("`\<"!S='EL93TS1"=M87)G:6XM=&]P.C$R<'@[
M;6%R9VEN+6)O='1O;3HP<'@[('1E>'0M:6YD96YT.C0E)SX\9F]N="!S='EL
M93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/E1H
M92!F;VQL;W=I;F<@=&%B;&4@<W5M;6%R:7IE<R!S=&]C:R!O<'1I;VX@86-T
M:79I='D@9G)O;2!*86YU87)Y)B,Q-C`[,2P@,C`Q,B!T:')O=6=H($UA<F-H
M)B,Q-C`[,S$L(#(P,3(Z(#PO9F]N=#X\+W`^#0H@("`\<"!S='EL93TS1&9O
M;G0M<VEZ93HQ,G!X.VUA<F=I;BUT;W`Z,'!X.VUA<F=I;BUB;W1T;VTZ,'!X
M/B8C,38P.SPO<#X-"B`@(#QT86)L92!C96QL<W!A8VEN9STS1#`@8V5L;'!A
M9&1I;F<],T0P('=I9'1H/3-$,3`P)2!B;W)D97(],T0P('-T>6QE/3-$)V)O
M<F1E<BUC;VQL87!S93IC;VQL87!S93L@=&5X="UA;&EG;CH@;&5F="<@86QI
M9VX],T1C96YT97(^#0H@("`\(2TM($)E9VEN(%1A8FQE($AE860@+2T^#0H@
M("`\='(^(`T*("`@/'1D('=I9'1H/3-$-S<E/B8C,38P.SPO=&0^(`T*("`@
M/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#(E/B8C,38P.SPO=&0^(`T*
M("`@/'1D/B8C,38P.SPO=&0^(`T*("`@/'1D/B8C,38P.SPO=&0^(`T*("`@
M/'1D/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#(E/B8C,38P.SPO=&0^(`T*("`@/'1D/B8C,38P.SPO=&0^(`T*("`@
M/'1D/B8C,38P.SPO=&0^(`T*("`@/'1D/B8C,38P.SPO=&0^(`T*("`@/'1D
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#(E/B8C,38P.SPO=&0^(`T*("`@
M/'1D/B8C,38P.SPO=&0^(`T*("`@/'1D/B8C,38P.SPO=&0^(`T*("`@/'1D
M/B8C,38P.SPO=&0^#0H@("`\+W1R/B`-"B`@(#QT<CX@#0H@("`\=&0@=F%L
M:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D
M/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q
M-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;2!C;VQS
M<&%N/3-$,B!A;&EG;CTS1&-E;G1E<B!S='EL93TS1"=B;W)D97(M8F]T=&]M
M.C%P>"!S;VQI9"`C,#`P,#`P)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL
M>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0Q/CQB/E1O=&%L/&)R("\^3G5M
M8F5R(&]F/&)R("\^4VAA<F5S/"]B/CPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V
M86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO
M=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF
M(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M(&-O
M;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R('-T>6QE/3-$)V)O<F1E<BUB;W1T
M;VTZ,7!X('-O;&ED(",P,#`P,#`G/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M
M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#$^/&(^5V5I9VAT960\8G(@
M+SY!=F5R86=E/&)R("\^17AE<F-I<V4\8G(@+SY0<FEC93PO8CX\+V9O;G0^
M/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q
M/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^
M/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A
M;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,B!A;&EG;CTS1&-E;G1E<B!S='EL
M93TS1"=B;W)D97(M8F]T=&]M.C%P>"!S;VQI9"`C,#`P,#`P)SX\9F]N="!S
M='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0Q
M/CQB/D%G9W)E9V%T93QB<B`O/DEN=')I;G-I8SQB<B`O/E9A;'5E/"]B/CPO
M9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ
M93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^#0H@("`\+W1R/@T*("`@/"$M+2!%
M;F0@5&%B;&4@2&5A9"`M+3X-"B`@(#PA+2T@0F5G:6X@5&%B;&4@0F]D>2`M
M+3X-"B`@(#QT<B!B9V-O;&]R/3-$(V-C965F9CX@#0H@("`\=&0@=F%L:6=N
M/3-$=&]P/@T*("`@/'`@<W1Y;&4],T0G;6%R9VEN+6QE9G0Z,2XP,&5M.R!T
M97AT+6EN9&5N=#HM,2XP,&5M)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL
M>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/D]U='-T86YD:6YG(&%T($IA
M;G5A<GDF(S$V,#LQ+"`R,#$R/"]F;VYT/CPO<#X-"B`@(#PO=&0^(`T*("`@
M/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O
M;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE
M/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)B,Q
M-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG
M;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE
M=R!R;VUA;B<@<VEZ93TS1#(^-BPQ-C,L,3,W/"]F;VYT/CPO=&0^(`T*("`@
M/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y
M;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXF
M(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF
M;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI
M9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@
M;F5W(')O;6%N)R!S:7IE/3-$,CXD/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A
M;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)V9O
M;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^,RXP,SPO9F]N
M=#X\+W1D/B`-"B`@(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T
M=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA
M;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG
M;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@
M#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M
M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)#PO9F]N=#X\+W1D
M/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N
M="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4]
M,T0R/B8C.#(Q,CLF(S$V,#LF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@
M;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS
M1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B8C,38P
M.SPO9F]N=#X\+W1D/@T*("`@/"]T<CX@#0H@("`\='(^(`T*("`@/'1D('9A
M;&EG;CTS1'1O<#X-"B`@(#QP('-T>6QE/3-$)VUA<F=I;BUL969T.C,N,#!E
M;3L@=&5X="UI;F1E;G0Z+3$N,#!E;2<^/&9O;G0@<W1Y;&4],T0G9F]N="UF
M86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CY'<F%N=&5D/"]F;VYT
M/CPO<#X-"B`@(#PO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N
M="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N
M/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE
M=R!R;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D
M('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$
M)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^,2PR-S4L
M,#`P/"]F;VYT/CPO=&0^(`T*("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI
M9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@
M;F5W(')O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\
M=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N
M=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4]
M,T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXF(S$V
M,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N
M/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W
M(')O;6%N)R!S:7IE/3-$,CXP+C<R/"]F;VYT/CPO=&0^(`T*("`@/'1D(&YO
M=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G
M9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXF(S$V,#L\
M+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I
M>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B
M;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O
M;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L
M:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G9F]N
M="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXQ+#DQ,BPU,#`\
M+V9O;G0^/"]T9#X@#0H@("`\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS
M1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@
M<F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@/"]T<CX@
M#0H@("`\='(@8F=C;VQO<CTS1"-C8V5E9F8^(`T*("`@/'1D('9A;&EG;CTS
M1'1O<#X-"B`@(#QP('-T>6QE/3-$)VUA<F=I;BUL969T.C,N,#!E;3L@=&5X
M="UI;F1E;G0Z+3$N,#!E;2<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ
M=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CY%>&5R8VES960\+V9O;G0^/"]P
M/@T*("`@/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I
M>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B
M;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O
M;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L
M:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G9F]N
M="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXF(S@R,3([)B,Q
M-C`[)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D(&YO=W)A<#TS1&YO=W)A
M<"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ
M=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X@
M#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P
M.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@
M<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$
M,CXF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M
M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM
M97,@;F5W(')O;6%N)R!S:7IE/3-$,CXF(S@R,3([)B,Q-C`[)B,Q-C`[/"]F
M;VYT/CPO=&0^(`T*("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B
M;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O
M;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L
M:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D
M/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N
M="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O
M;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG
M:'0^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N
M)R!S:7IE/3-$,CXF(S@R,3([)B,Q-C`[)B,Q-C`[/"]F;VYT/CPO=&0^(`T*
M("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT^/&9O;G0@
M<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$
M,CXF(S$V,#L\+V9O;G0^/"]T9#X-"B`@(#PO='(^(`T*("`@/'1R/B`-"B`@
M(#QT9"!V86QI9VX],T1T;W`^#0H@("`\<"!S='EL93TS1"=M87)G:6XM;&5F
M=#HS+C`P96T[('1E>'0M:6YD96YT.BTQ+C`P96TG/CQF;VYT('-T>6QE/3-$
M)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^0V%N8V5L
M;&5D/"]F;VYT/CPO<#X-"B`@(#PO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O
M='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\
M=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY
M.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^
M(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT
M('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS
M1#(^)B,X,C$R.R8C,38P.R8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!N
M;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$
M)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)B,Q-C`[
M/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S
M:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$
M8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R
M;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A
M;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)V9O
M;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)B,X,C$R.R8C
M,38P.R8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!N;W=R87`],T1N;W=R
M87`@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY
M.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^
M(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V
M,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT
M('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS
M1#(^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O
M;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I
M;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)B,X,C$R.R8C,38P.R8C,38P.SPO
M9F]N=#X\+W1D/B`-"B`@(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$
M8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R
M;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^#0H@("`\+W1R/B`-
M"B`@(#QT<B!S='EL93TS1&9O;G0M<VEZ93HQ<'@^(`T*("`@/'1D('9A;&EG
M;CTS1&)O='1O;3XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T
M;VT^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*("`@
M/'`@<W1Y;&4],T0G8F]R9&5R+71O<#HQ<'@@<V]L:60@(S`P,#`P,"<^)B,Q
M-C`[/"]P/@T*("`@/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*
M("`@/'`@<W1Y;&4],T0G8F]R9&5R+71O<#HQ<'@@<V]L:60@(S`P,#`P,"<^
M)B,Q-C`[/"]P/@T*("`@/"]T9#X@#0H@("`\=&0^)B,Q-C`[/"]T9#X@#0H@
M("`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^(`T*("`@/'1D('9A
M;&EG;CTS1&)O='1O;3XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B
M;W1T;VT^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C
M,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3XF(S$V,#L\+W1D
M/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X@#0H@("`\
M=&0@=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG
M;CTS1&)O='1O;3XF(S$V,#L\+W1D/@T*("`@/"]T<CX@#0H@("`\='(@8F=C
M;VQO<CTS1"-C8V5E9F8^(`T*("`@/'1D('9A;&EG;CTS1'1O<#X-"B`@(#QP
M('-T>6QE/3-$)VUA<F=I;BUL969T.C$N,#!E;3L@=&5X="UI;F1E;G0Z+3$N
M,#!E;2<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O
M;6%N)R!S:7IE/3-$,CY/=71S=&%N9&EN9R!A="!-87)C:"8C,38P.S,Q+"`R
M,#$R/"]F;VYT/CPO<#X-"B`@(#PO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O
M='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\
M=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY
M.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^
M(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT
M('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS
M1#(^-RPT,S@L,3,W/"]F;VYT/CPO=&0^(`T*("`@/'1D(&YO=W)A<#TS1&YO
M=W)A<"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI
M;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T
M9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C
M,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O
M;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE
M/3-$,CXD/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;2!A
M;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S
M(&YE=R!R;VUA;B<@<VEZ93TS1#(^,BXV,SPO9F]N=#X\+W1D/B`-"B`@(#QT
M9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE
M/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)B,Q
M-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N
M="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N
M/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE
M=R!R;VUA;B<@<VEZ93TS1#(^)#PO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI
M9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=F;VYT
M+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/C4L,S`X+#DU,#PO
M9F]N=#X\+W1D/B`-"B`@(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$
M8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R
M;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^#0H@("`\+W1R/B`-
M"B`@(#QT<B!S='EL93TS1&9O;G0M<VEZ93HQ<'@^(`T*("`@/'1D('9A;&EG
M;CTS1&)O='1O;3XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T
M;VT^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*("`@
M/'`@<W1Y;&4],T0G8F]R9&5R+71O<#HS<'@@9&]U8FQE(",P,#`P,#`G/B8C
M,38P.SPO<#X-"B`@(#PO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X-
M"B`@(#QP('-T>6QE/3-$)V)O<F1E<BUT;W`Z,W!X(&1O=6)L92`C,#`P,#`P
M)SXF(S$V,#L\+W`^#0H@("`\+W1D/B`-"B`@(#QT9#XF(S$V,#L\+W1D/B`-
M"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X@#0H@("`\=&0@
M=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS
M1&)O='1O;3XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^
M)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO
M=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3XF(S$V,#L\+W1D/B`-"B`@
M(#QT9"!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L
M:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^#0H@("`\+W1R/B`-"B`@(#QT<CX@
M#0H@("`\=&0@=F%L:6=N/3-$=&]P/@T*("`@/'`@<W1Y;&4],T0G;6%R9VEN
M+6QE9G0Z,2XP,&5M.R!T97AT+6EN9&5N=#HM,2XP,&5M)SX\9F]N="!S='EL
M93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/D]P
M=&EO;G,@97AE<F-I<V%B;&4@870@36%R8V@F(S$V,#LS,2P@,C`Q,CPO9F]N
M=#X\+W`^#0H@("`\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O
M;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG
M;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N
M97<@<F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT
M9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS
M1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/C0L.3@U
M+#4T.#PO9F]N=#X\+W1D/B`-"B`@(#QT9"!N;W=R87`],T1N;W=R87`@=F%L
M:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S
M(&YE=R!R;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@
M/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O
M;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE
M/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)#PO
M9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R
M:6=H=#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M
M86XG('-I>F4],T0R/C,N,S$\+V9O;G0^/"]T9#X@#0H@("`\=&0@;F]W<F%P
M/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT
M+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N
M=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS
M1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O
M;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG
M('-I>F4],T0R/B0\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T
M=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ
M=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXR+#,V-2PU.3,\+V9O;G0^/"]T
M9#X@#0H@("`\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;3X\
M9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I
M>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@/"]T<CX@#0H@("`\='(@
M<W1Y;&4],T1F;VYT+7-I>F4Z,7!X/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T
M;VT^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C,38P
M.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`@(#QP('-T>6QE
M/3-$)V)O<F1E<BUT;W`Z,W!X(&1O=6)L92`C,#`P,#`P)SXF(S$V,#L\+W`^
M#0H@("`\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@("`\<"!S
M='EL93TS1"=B;W)D97(M=&]P.C-P>"!D;W5B;&4@(S`P,#`P,"<^)B,Q-C`[
M/"]P/@T*("`@/"]T9#X@#0H@("`\=&0^)B,Q-C`[/"]T9#X@#0H@("`\=&0@
M=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS
M1&)O='1O;3XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^
M)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO
M=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3XF(S$V,#L\+W1D/B`-"B`@
M(#QT9"!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L
M:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O
M='1O;3XF(S$V,#L\+W1D/@T*("`@/"]T<CX-"B`@(#PA+2T@16YD(%1A8FQE
M($)O9'D@+2T^#0H@("`\+W1A8FQE/@T*("`@/'`@<W1Y;&4],T0G;6%R9VEN
M+71O<#HQ,G!X.VUA<F=I;BUB;W1T;VTZ,'!X.R!T97AT+6EN9&5N=#HT)2<^
M/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S
M:7IE/3-$,CY4:&4@86=G<F5G871E(&EN=')I;G-I8R!V86QU97,@;V8@;W5T
M<W1A;F1I;F<@86YD(&5X97)C:7-A8FQE(&]P=&EO;G,@870@36%R8V@F(S$V
M,#LS,2P@,C`Q,B!W97)E#0H@("!C86QC=6QA=&5D(&)A<V5D(&]N('1H92!C
M;&]S:6YG('!R:6-E(&]F('1H92!#;VUP86YY)B,X,C$W.W,@8V]M;6]N('-T
M;V-K(&]N($UA<F-H)B,Q-C`[,S$L(#(P,3(@;V8@)#(N,C(@<&5R('-H87)E
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M(#PO9F]N=#X\+W`^#0H\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]
M7TYE>'1087)T7V)E9F4Y8S$Q7V,R9C-?-#AE8U]A,F%B7V9F,C@Y-C`W961C
M,`T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B]B969E.6,Q,5]C,F8S
M7S0X96-?83)A8E]F9C(X.38P-V5D8S`O5V]R:W-H965T<R]3:&5E=#$R+FAT
M;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B
M;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I
M:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78]
M,T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]
M=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13
M:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I
M<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O
M<G0@:60],T1)1#!%344^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^3F5T($QO
M<W,@4&5R(%-H87)E/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1H(&-O;'-P86X],T0Q/C,@36]N=&AS($5N9&5D/"]T:#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H
M/DUA<BX@,S$L(#(P,3(\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/CQS=')O;F<^3F5T($QO<W,@4&5R(%-H87)E(%M!8G-T<F%C=%T\
M+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3F5T
M($QO<W,@4&5R(%-H87)E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\(2TM1$]#5%E012!H=&UL(%!50DQ)0R`B+2\O5S-#+R]$5$0@6$A434P@
M,2XP(%1R86YS:71I;VYA;"\O14XB(")H='1P.B\O=W=W+G<S+F]R9R]44B]X
M:'1M;#$O1%1$+WAH=&UL,2UT<F%N<VET:6]N86PN9'1D(B`M+3X-"B`@(#PA
M+2T@0F5G:6X@0FQO8VL@5&%G9V5D($YO=&4@-R`M('5S+6=A87`Z16%R;FEN
M9W-097)3:&%R951E>'1";&]C:RTM/@T*("`@/'`@<W1Y;&4],T1M87)G:6XM
M=&]P.C$X<'@[;6%R9VEN+6)O='1O;3HP<'@^/&9O;G0@<W1Y;&4],T0G9F]N
M="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CX\8CXW+B!.970@
M3&]S<R!097(@4VAA<F4@/"]B/CPO9F]N=#X\+W`^#0H@("`\<"!S='EL93TS
M1"=M87)G:6XM=&]P.C9P>#MM87)G:6XM8F]T=&]M.C!P>#L@=&5X="UI;F1E
M;G0Z-"4G/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R
M;VUA;B<@<VEZ93TS1#(^5&AE($-O;7!A;GD@86-C;W5N=',@9F]R(&%N9"!D
M:7-C;&]S97,@;F5T(&QO<W,@<&5R(&-O;6UO;B!S:&%R92!I;B!A8V-O<F1A
M;F-E('=I=&@@1D%30B!!4T,@5&]P:6,@,C8P("8C.#(R,#L-"B`@(#QI/D5A
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M:7,@8V]M<'5T960@8GD-"B`@(&1I=FED:6YG(&YE="!L;W-S(&%T=')I8G5T
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M<VAA<F4@:7,@=&AE('-A;64@87,-"B`@(&)A<VEC(&YE="!L;W-S('!E<B!C
M;VUM;VX@<VAA<F4N(#PO9F]N=#X\+W`^#0H@("`\<"!S='EL93TS1"=M87)G
M:6XM=&]P.C$R<'@[;6%R9VEN+6)O='1O;3HP<'@[('1E>'0M:6YD96YT.C0E
M)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG
M('-I>F4],T0R/E1H92!F;VQL;W=I;F<@=&%B;&4@<V5T<R!F;W)T:"!T:&4@
M<&]T96YT:6%L(&-O;6UO;B!S:&%R97,@97AC;'5D960@9G)O;2!T:&4@8V%L
M8W5L871I;VX@;V8-"B`@(&YE="!L;W-S('!E<B!C;VUM;VX@<VAA<F4@8F5C
M875S92!T:&5I<B!I;F-L=7-I;VX@=V]U;&0@8F4@86YT:2UD:6QU=&EV93H@
M/"]F;VYT/CPO<#X-"B`@(#QP('-T>6QE/3-$9F]N="US:7IE.C$R<'@[;6%R
M9VEN+71O<#HP<'@[;6%R9VEN+6)O='1O;3HP<'@^)B,Q-C`[/"]P/@T*("`@
M/'1A8FQE(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`@=VED=&@]
M,T0Q,#`E(&)O<F1E<CTS1#`@<W1Y;&4],T0G8F]R9&5R+6-O;&QA<'-E.F-O
M;&QA<'-E.R!T97AT+6%L:6=N.B!L969T)R!A;&EG;CTS1&-E;G1E<CX-"B`@
M(#PA+2T@0F5G:6X@5&%B;&4@2&5A9"`M+3X-"B`@(#QT<CX@#0H@("`\=&0@
M=VED=&@],T0X,B4^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$,24^)B,Q-C`[/"]T9#X@#0H@("`\=&0^)B,Q-C`[/"]T
M9#X@#0H@("`\=&0^)B,Q-C`[/"]T9#X@#0H@("`\=&0^)B,Q-C`[/"]T9#X@
M#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^)B,Q-C`[/"]T
M9#X@#0H@("`\=&0^)B,Q-C`[/"]T9#X@#0H@("`\=&0^)B,Q-C`[/"]T9#X@
M#0H@("`\=&0^)B,Q-C`[/"]T9#X-"B`@(#PO='(^(`T*("`@/'1R/B`-"B`@
M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F
M;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE
M/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T
M=&]M(&-O;'-P86X],T0V(&%L:6=N/3-$8V5N=&5R('-T>6QE/3-$)V)O<F1E
M<BUB;W1T;VTZ,7!X('-O;&ED(",P,#`P,#`G/CQF;VYT('-T>6QE/3-$)V9O
M;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#$^/&(^36%R8V@F
M(S$V,#LS,2P\+V(^/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O
M='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X-"B`@(#PO
M='(^(`T*("`@/'1R/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@
M<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS
M1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@
M("`\=&0@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N
M=&5R('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ,7!X('-O;&ED(",P,#`P,#`G
M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@
M<VEZ93TS1#$^/&(^,C`Q,CPO8CX\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L
M:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D
M/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q
M-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;2!C;VQS
M<&%N/3-$,B!A;&EG;CTS1&-E;G1E<B!S='EL93TS1"=B;W)D97(M8F]T=&]M
M.C%P>"!S;VQI9"`C,#`P,#`P)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL
M>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0Q/CQB/C(P,3$\+V(^/"]F;VYT
M/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$
M,3XF(S$V,#L\+V9O;G0^/"]T9#X-"B`@(#PO='(^#0H@("`\(2TM($5N9"!4
M86)L92!(96%D("TM/@T*("`@/"$M+2!"96=I;B!486)L92!";V1Y("TM/@T*
M("`@/'1R(&)G8V]L;W(],T0C8V-E969F/B`-"B`@(#QT9"!V86QI9VX],T1T
M;W`^#0H@("`\<"!S='EL93TS1"=M87)G:6XM;&5F=#HQ+C`P96T[('1E>'0M
M:6YD96YT.BTQ+C`P96TG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I
M;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^3W!T:6]N<R!T;R!P=7)C:&%S92!C
M;VUM;VX@<W1O8VL\+V9O;G0^/"]P/@T*("`@/"]T9#X@#0H@("`\=&0@=F%L
M:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D
M/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N
M="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O
M;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG
M:'0^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N
M)R!S:7IE/3-$,CXW+#0S."PQ,S<\+V9O;G0^/"]T9#X@#0H@("`\=&0@;F]W
M<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F
M;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B8C,38P.SPO
M9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ
M93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O
M='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M
M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI
M9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=F;VYT
M+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/C8L,#8U+#(V-#PO
M9F]N=#X\+W1D/B`-"B`@(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$
M8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R
M;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^#0H@("`\+W1R/B`-
M"B`@(#QT<CX@#0H@("`\=&0@=F%L:6=N/3-$=&]P/@T*("`@/'`@<W1Y;&4]
M,T0G;6%R9VEN+6QE9G0Z,2XP,&5M.R!T97AT+6EN9&5N=#HM,2XP,&5M)SX\
M9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I
M>F4],T0R/E=A<G)A;G1S('1O('!U<F-H87-E(&-O;6UO;B!S=&]C:SPO9F]N
M=#X\+W`^#0H@("`\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O
M;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG
M;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N
M97<@<F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT
M9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS
M1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/C$S+#$Q
M-BPV.3@\+V9O;G0^/"]T9#X@#0H@("`\=&0@;F]W<F%P/3-$;F]W<F%P('9A
M;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE
M<R!N97<@<F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@
M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F
M;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL
M93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B8C
M,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@86QI
M9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N
M97<@<F]M86XG('-I>F4],T0R/C@L,C4P+#8T,CPO9F]N=#X\+W1D/B`-"B`@
M(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T
M>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^
M)B,Q-C`[/"]F;VYT/CPO=&0^#0H@("`\+W1R/B`-"B`@(#QT<B!S='EL93TS
M1&9O;G0M<VEZ93HQ<'@^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3XF(S$V
M,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X@
M#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*("`@/'`@<W1Y;&4],T0G8F]R
M9&5R+71O<#HQ<'@@<V]L:60@(S`P,#`P,"<^)B,Q-C`[/"]P/@T*("`@/"]T
M9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*("`@/'`@<W1Y;&4],T0G
M8F]R9&5R+71O<#HQ<'@@<V]L:60@(S`P,#`P,"<^)B,Q-C`[/"]P/@T*("`@
M/"]T9#X@#0H@("`\=&0^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$
M8F]T=&]M/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X-
M"B`@(#QP('-T>6QE/3-$)V)O<F1E<BUT;W`Z,7!X('-O;&ED(",P,#`P,#`G
M/B8C,38P.SPO<#X-"B`@(#PO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O
M;3X-"B`@(#QP('-T>6QE/3-$)V)O<F1E<BUT;W`Z,7!X('-O;&ED(",P,#`P
M,#`G/B8C,38P.SPO<#X-"B`@(#PO=&0^(`T*("`@/'1D/B8C,38P.SPO=&0^
M#0H@("`\+W1R/B`-"B`@(#QT<B!B9V-O;&]R/3-$(V-C965F9CX@#0H@("`\
M=&0@=F%L:6=N/3-$=&]P/@T*("`@/'`@<W1Y;&4],T0G;6%R9VEN+6QE9G0Z
M,2XP,&5M.R!T97AT+6EN9&5N=#HM,2XP,&5M)SX\9F]N="!S='EL93TS1"=F
M;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/E1O=&%L/"]F
M;VYT/CPO<#X-"B`@(#PO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\
M9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L
M:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S
M(&YE=R!R;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@
M/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE
M/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^,C`L
M-34T+#@S-3PO9F]N=#X\+W1D/B`-"B`@(#QT9"!N;W=R87`],T1N;W=R87`@
M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I
M;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*
M("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\
M+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T
M>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^
M)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;2!A
M;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S
M(&YE=R!R;VUA;B<@<VEZ93TS1#(^,30L,S$U+#DP-CPO9F]N=#X\+W1D/B`-
M"B`@(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M/CQF;VYT
M('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS
M1#(^)B,Q-C`[/"]F;VYT/CPO=&0^#0H@("`\+W1R/B`-"B`@(#QT<B!S='EL
M93TS1&9O;G0M<VEZ93HQ<'@^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3XF
M(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T
M9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*("`@/'`@<W1Y;&4],T0G
M8F]R9&5R+71O<#HS<'@@9&]U8FQE(",P,#`P,#`G/B8C,38P.SPO<#X-"B`@
M(#PO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`@(#QP('-T>6QE
M/3-$)V)O<F1E<BUT;W`Z,W!X(&1O=6)L92`C,#`P,#`P)SXF(S$V,#L\+W`^
M#0H@("`\+W1D/B`-"B`@(#QT9#XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI
M9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T
M=&]M/@T*("`@/'`@<W1Y;&4],T0G8F]R9&5R+71O<#HS<'@@9&]U8FQE(",P
M,#`P,#`G/B8C,38P.SPO<#X-"B`@(#PO=&0^(`T*("`@/'1D('9A;&EG;CTS
M1&)O='1O;3X-"B`@(#QP('-T>6QE/3-$)V)O<F1E<BUT;W`Z,W!X(&1O=6)L
M92`C,#`P,#`P)SXF(S$V,#L\+W`^#0H@("`\+W1D/B`-"B`@(#QT9#XF(S$V
M,#L\+W1D/@T*("`@/"]T<CX-"B`@(#PA+2T@16YD(%1A8FQE($)O9'D@+2T^
M#0H@("`\+W1A8FQE/B`-"CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM
M+3U?3F5X=%!A<G1?8F5F93EC,3%?8S)F,U\T.&5C7V$R86)?9F8R.#DV,#=E
M9&,P#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+V)E9F4Y8S$Q7V,R
M9C-?-#AE8U]A,F%B7V9F,C@Y-C`W961C,"]7;W)K<VAE971S+U-H965T,3,N
M:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT
M86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S
M8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I
M=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E
M=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS
M1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C
M<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E
M<&]R="!I9#TS1$E$,$5-13X-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY,:6-E
M;G-E($%G<F5E;65N=',\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^,R!-;VYT:',@16YD960\+W1H/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&@^36%R+B`S,2P@,C`Q,CQB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^/'-T<F]N9SY,:6-E;G-E($%G<F5E;65N=',@6T%B<W1R86-T
M73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y,
M:6-E;G-E($%G<F5E;65N=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CPA+2U$3T-465!%(&AT;6P@4%5"3$E#("(M+R]7,T,O+T141"!82%1-
M3"`Q+C`@5')A;G-I=&EO;F%L+R]%3B(@(FAT='`Z+R]W=W<N=S,N;W)G+U12
M+WAH=&UL,2]$5$0O>&AT;6PQ+71R86YS:71I;VYA;"YD=&0B("TM/@T*("`@
M/"$M+2!"96=I;B!";&]C:R!486=G960@3F]T92`X("T@=7,M9V%A<#I);G1A
M;F=I8FQE07-S971S1&ES8VQO<W5R951E>'1";&]C:RTM/@T*("`@/'`@<W1Y
M;&4],T1M87)G:6XM=&]P.C$X<'@[;6%R9VEN+6)O='1O;3HP<'@^/&9O;G0@
M<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$
M,CX\8CXX+B!,:6-E;G-E($%G<F5E;65N=',@/"]B/CPO9F]N=#X\+W`^#0H@
M("`\<"!S='EL93TS1&9O;G0M<VEZ93HV<'@[;6%R9VEN+71O<#HP<'@[;6%R
M9VEN+6)O='1O;3HP<'@^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO
M<#X-"B`@(#QP('-T>6QE/3-$9F]N="US:7IE.C%P>#MM87)G:6XM=&]P.C$R
M<'@[;6%R9VEN+6)O='1O;3HP<'@^)B,Q-C`[/"]P/@T*("`@/'`@<W1Y;&4]
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M;VX@82!P97)C96YT86=E(&]F('!R;V1U8W0@<V%L97,N(#PO9F]N=#X\+W`^
M#0H@("`\<"!S='EL93TS1"=M87)G:6XM=&]P.C$R<'@[;6%R9VEN+6)O='1O
M;3HP<'@[('1E>'0M:6YD96YT.C0E)SX\9F]N="!S='EL93TS1"=F;VYT+69A
M;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/@T*("`@06X@:6YD:79I
M9'5A;"!M:6QE<W1O;F4@<&%Y;65N="!R97%U:7)E9"!U;F1E<B!T:&4@;&EC
M96YS:6YG(&%R<F%N9V5M96YT<R!M87D@8F4@;6%T97)I86PL(&%N9"!I;B!T
M:&4@979E;G0@=&AA="!M=6QT:7!L92!M:6QE<W1O;F5S(&%R92!R96%C:&5D
M(&EN('1H92!S86UE('!E<FEO9"P@=&AE(&%G9W)E9V%T92!P87EM96YT<R!A
M<W-O8VEA=&5D('=I=&@-"B`@('1H92!M:6QE<W1O;F5S(&-O=6QD(&%D=F5R
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M("`@<')O9'5C="P@=VAI8V@@=V]U;&0@86QL;W<@=&AE($-O;7!A;GD@=&\@
M879O:60@;6%K:6YG('1H92!C;VYT:6YG96YT('!A>6UE;G1S.R!H;W=E=F5R
M+"!T:&4@0V]M<&%N>2!I<R!U;FQI:V5L>2!T;R!C96%S92!D979E;&]P;65N
M="!I9B!T:&4@8V]M<&]U;F0@<W5C8V5S<V9U;&QY(&%C:&EE=F5S(&-L:6YI
M8V%L('1E<W1I;F<@;V)J96-T:79E<RX@5&AE($-O;7!A;GDF(S@R,3<[<R!C
M;VYT<F%C='5A;"!O8FQI9V%T:6]N<PT*("`@<F5L871I;F<@=&\@;6EN:6UU
M;2!A;FYU86P@;6%I;G1E;F%N8V4@9F5E<R!A;F0@;6EL97-T;VYE('!A>6UE
M;G1S(&AA=F4@;F]T(&-H86YG960@<VEG;FEF:6-A;G1L>2!F<F]M($1E8V5M
M8F5R)B,Q-C`[,S$L(#(P,3$N(#PO9F]N=#X\+W`^#0H\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*
M/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7V)E9F4Y8S$Q7V,R9C-?-#AE
M8U]A,F%B7V9F,C@Y-C`W961C,`T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO
M+R]#.B]B969E.6,Q,5]C,F8S7S0X96-?83)A8E]F9C(X.38P-V5D8S`O5V]R
M:W-H965T<R]3:&5E=#$T+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I
M;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL
M.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@
M(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T
M97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O
M:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI
M<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\
M=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%344^#0H@("`@("`\='(^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X]
M,T0R/CQS=')O;F<^4W1O8VMH;VQD97)S)R!%<75I='D\8G(^/"]S=')O;F<^
M/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^,R!-
M;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&@^36%R+B`S,2P@,C`Q,CQB<CX\+W1H/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY3=&]C:VAO;&1E
M<G,G($5Q=6ET>2!;06)S=')A8W1=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/E-T;V-K:&]L9&5R<R<@17%U:71Y/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\(2TM1$]#5%E012!H=&UL(%!5
M0DQ)0R`B+2\O5S-#+R]$5$0@6$A434P@,2XP(%1R86YS:71I;VYA;"\O14XB
M(")H='1P.B\O=W=W+G<S+F]R9R]44B]X:'1M;#$O1%1$+WAH=&UL,2UT<F%N
M<VET:6]N86PN9'1D(B`M+3X-"B`@(#PA+2T@0F5G:6X@0FQO8VL@5&%G9V5D
M($YO=&4@.2`M('5S+6=A87`Z4W1O8VMH;VQD97)S17%U:71Y3F]T941I<V-L
M;W-U<F5497AT0FQO8VLM+3X-"B`@(#QP('-T>6QE/3-$;6%R9VEN+71O<#HQ
M.'!X.VUA<F=I;BUB;W1T;VTZ,'!X/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M
M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^/&(^.2X@4W1O8VMH;VQD
M97)S)B,X,C$W.R!%<75I='D@/"]B/CPO9F]N=#X\+W`^#0H@("`\<"!S='EL
M93TS1"=M87)G:6XM=&]P.C9P>#MM87)G:6XM8F]T=&]M.C!P>#L@=&5X="UI
M;F1E;G0Z-"4G/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE
M=R!R;VUA;B<@<VEZ93TS1#(^/&D^4')E9F5R<F5D(%-T;V-K/"]I/B`F(S@R
M,3([(%1H92!#;VUP86YY(&AA<R!A=71H;W)I>F5D('5P('1O(#4L,#`P+#`P
M,"8C,38P.W-H87)E<R!O9B!P<F5F97)R960@<W1O8VLL#0H@("`D,"XP,#`Q
M)B,Q-C`[<&%R('9A;'5E('!E<B!S:&%R92P@9F]R(&ES<W5A;F-E+B!4:&4@
M<')E9F5R<F5D('-T;V-K('=I;&P@:&%V92!S=6-H(')I9VAT<RP@<')E9F5R
M96YC97,L('!R:79I;&5G97,@86YD(')E<W1R:6-T:6]N<RP@:6YC;'5D:6YG
M('9O=&EN9R!R:6=H=',L(&1I=FED96YD(')I9VAT<RP@8V]N=F5R<VEO;B!R
M:6=H=',L(')E9&5M<'1I;VX@<')I=FEL96=E<R!A;F0@;&EQ=6ED871I;VX@
M<')E9F5R96YC97,L(&%S#0H@("!S:&%L;"!B92!D971E<FUI;F5D(&)Y('1H
M92!#;VUP86YY)B,X,C$W.W,@8F]A<F0@;V8@9&ER96-T;W)S('5P;VX@:71S
M(&ES<W5A;F-E+B!4;R!D871E+"!T:&4@0V]M<&%N>2!H87,@;F]T(&ES<W5E
M9"!A;GD@<')E9F5R<F5D('-H87)E<RX@/"]F;VYT/CPO<#X-"B`@(#QP('-T
M>6QE/3-$)VUA<F=I;BUT;W`Z,3)P>#MM87)G:6XM8F]T=&]M.C!P>#L@=&5X
M="UI;F1E;G0Z-"4G/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S
M(&YE=R!R;VUA;B<@<VEZ93TS1#(^#0H@("`\:3Y#;VUM;VX@4W1O8VL\+VD^
M("8C.#(Q,CL@5&AE($-O;7!A;GD@:&%S(&%U=&AO<FEZ960@=7`@=&\@,3(U
M+#`P,"PP,#`F(S$V,#MS:&%R97,@;V8@8V]M;6]N('-T;V-K+"`D,"XP,#`Q
M)B,Q-C`[<&%R('9A;'5E('!E<B!S:&%R92P@9F]R(&ES<W5A;F-E+B!3:&%R
M97,@;V8@8V]M;6]N('-T;V-K(&%R92!R97-E<G9E9"!A<R!F;VQL;W=S.@T*
M("`@/"]F;VYT/CPO<#X-"B`@(#QP('-T>6QE/3-$9F]N="US:7IE.C$R<'@[
M;6%R9VEN+71O<#HP<'@[;6%R9VEN+6)O='1O;3HP<'@^)B,Q-C`[/"]P/@T*
M("`@/'1A8FQE(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`@=VED
M=&@],T0Y,B4@8F]R9&5R/3-$,"!S='EL93TS1"=B;W)D97(M8V]L;&%P<V4Z
M8V]L;&%P<V4[('1E>'0M86QI9VXZ(&QE9G0G(&%L:6=N/3-$8V5N=&5R/@T*
M("`@/"$M+2!"96=I;B!486)L92!(96%D("TM/@T*("`@/'1R/B`-"B`@(#QT
M9"!W:61T:#TS1#@Y)3XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0R)3XF(S$V,#L\+W1D/B`-"B`@(#QT9#XF(S$V,#L\
M+W1D/B`-"B`@(#QT9#XF(S$V,#L\+W1D/B`-"B`@(#QT9#XF(S$V,#L\+W1D
M/@T*("`@/"]T<CX@#0H@("`\='(^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O
M;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@
M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\
M+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(@86QI
M9VX],T1C96YT97(@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3HQ<'@@<V]L:60@
M(S`P,#`P,"<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W
M(')O;6%N)R!S:7IE/3-$,3X\8CY!<R!O9CQB<B`O/DUA<F-H)B,Q-C`[,S$L
M/&)R("\^,C`Q,CPO8CX\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$
M8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@
M/"]T<CX-"B`@(#PA+2T@16YD(%1A8FQE($AE860@+2T^#0H@("`\(2TM($)E
M9VEN(%1A8FQE($)O9'D@+2T^#0H@("`\='(@8F=C;VQO<CTS1"-C8V5E9F8^
M(`T*("`@/'1D('9A;&EG;CTS1'1O<#X-"B`@(#QP('-T>6QE/3-$)VUA<F=I
M;BUL969T.C$N,#!E;3L@=&5X="UI;F1E;G0Z+3$N,#!E;2<^/&9O;G0@<W1Y
M;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CY7
M87)R86YT<R!O=71S=&%N9&EN9SPO9F]N=#X\+W`^#0H@("`\+W1D/B`-"B`@
M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F
M;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL
M93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B8C
M,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@86QI
M9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N
M97<@<F]M86XG('-I>F4],T0R/C$S+#$Q-BPV.3@\+V9O;G0^/"]T9#X@#0H@
M("`\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;3X\9F]N="!S
M='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R
M/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@/"]T<CX@#0H@("`\='(^(`T*("`@
M/'1D('9A;&EG;CTS1'1O<#X-"B`@(#QP('-T>6QE/3-$)VUA<F=I;BUL969T
M.C$N,#!E;3L@=&5X="UI;F1E;G0Z+3$N,#!E;2<^/&9O;G0@<W1Y;&4],T0G
M9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CY3=&]C:R!O
M<'1I;VYS(&]U='-T86YD:6YG/"]F;VYT/CPO<#X-"B`@(#PO=&0^(`T*("`@
M/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O
M;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE
M/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)B,Q
M-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG
M;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE
M=R!R;VUA;B<@<VEZ93TS1#(^-RPT,S@L,3,W/"]F;VYT/CPO=&0^(`T*("`@
M/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y
M;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXF
M(S$V,#L\+V9O;G0^/"]T9#X-"B`@(#PO='(^(`T*("`@/'1R(&)G8V]L;W(]
M,T0C8V-E969F/B`-"B`@(#QT9"!V86QI9VX],T1T;W`^#0H@("`\<"!S='EL
M93TS1"=M87)G:6XM;&5F=#HQ+C`P96T[('1E>'0M:6YD96YT.BTQ+C`P96TG
M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@
M<VEZ93TS1#(^3W!T:6]N<R!R97-E<G9E9"!F;W(@9G5T=7)E(&ES<W5A;F-E
M('5N9&5R('1H92!#;VUP86YY)B,X,C$W.W,@,C`P-R!);F-E;G1I=F4@4&QA
M;CPO9F]N=#X\+W`^#0H@("`\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T
M;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D
M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT
M:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-
M"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S
M='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R
M/C(T+#<Q-SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!N;W=R87`],T1N;W=R87`@
M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I
M;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^#0H@
M("`\+W1R/B`-"B`@(#QT<B!S='EL93TS1&9O;G0M<VEZ93HQ<'@^(`T*("`@
M/'1D('9A;&EG;CTS1&)O='1O;3XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI
M9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T
M=&]M/@T*("`@/'`@<W1Y;&4],T0G8F]R9&5R+71O<#HQ<'@@<V]L:60@(S`P
M,#`P,"<^)B,Q-C`[/"]P/@T*("`@/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$
M8F]T=&]M/@T*("`@/'`@<W1Y;&4],T0G8F]R9&5R+71O<#HQ<'@@<V]L:60@
M(S`P,#`P,"<^)B,Q-C`[/"]P/@T*("`@/"]T9#X@#0H@("`\=&0^)B,Q-C`[
M/"]T9#X-"B`@(#PO='(^(`T*("`@/'1R/B`-"B`@(#QT9"!V86QI9VX],T1T
M;W`^#0H@("`\<"!S='EL93TS1"=M87)G:6XM;&5F=#HQ+C`P96T[('1E>'0M
M:6YD96YT.BTQ+C`P96TG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I
M;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^5&]T86P@<F5S97)V960@9F]R(&9U
M='5R92!I<W-U86YC93PO9F]N=#X\+W`^#0H@("`\+W1D/B`-"B`@(#QT9"!V
M86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO
M=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F
M;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B8C,38P.SPO
M9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R
M:6=H=#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M
M86XG('-I>F4],T0R/C(P+#4W.2PU-3(\+V9O;G0^/"]T9#X@#0H@("`\=&0@
M;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS
M1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B8C,38P
M.SPO9F]N=#X\+W1D/@T*("`@/"]T<CX@#0H@("`\='(@<W1Y;&4],T1F;VYT
M+7-I>F4Z,7!X/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T
M9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^(`T*("`@
M/'1D('9A;&EG;CTS1&)O='1O;3X-"B`@(#QP('-T>6QE/3-$)V)O<F1E<BUT
M;W`Z,W!X(&1O=6)L92`C,#`P,#`P)SXF(S$V,#L\+W`^#0H@("`\+W1D/B`-
M"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@("`\<"!S='EL93TS1"=B;W)D
M97(M=&]P.C-P>"!D;W5B;&4@(S`P,#`P,"<^)B,Q-C`[/"]P/@T*("`@/"]T
M9#X@#0H@("`\=&0^)B,Q-C`[/"]T9#X-"B`@(#PO='(^#0H@("`\(2TM($5N
M9"!486)L92!";V1Y("TM/@T*("`@/"]T86)L93X-"B`@(#QP('-T>6QE/3-$
M)VUA<F=I;BUT;W`Z,3)P>#MM87)G:6XM8F]T=&]M.C!P>#L@=&5X="UI;F1E
M;G0Z-"4G/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R
M;VUA;B<@<VEZ93TS1#(^/&D^0V]M;6]N(%-T;V-K(%=A<G)A;G1S/"]I/B`F
M(S@R,3([($]N($%U9W5S="8C,38P.S<L(#(P,#@L('1H92!#;VUP86YY(&ES
M<W5E9"`Q.3`L,#`P('=A<G)A;G1S('1O(&%N#0H@("!I;G9E<W1M96YT(&)A
M;FL@87,@8V]N<VED97)A=&EO;B!F;W(@:6YV97-T;65N="!A;F0@8G5S:6YE
M<W,@861V:7-O<GD@<V5R=FEC97,N(%1H92!W87)R86YT<R!H879E(&%N(&5X
M97)C:7-E('!R:6-E(&]F("0W+C`S-B!P97(@<VAA<F4@86YD(&5X<&ER92`U
M)B,Q-C`[>65A<G,@9G)O;2!T:&4@9&%T92!O9B!I<W-U86YC92P@;VX@075G
M=7-T)B,Q-C`[-RP@,C`Q,RX@5&AE('=A<G)A;G1S('9E<W1E9"!A<R!T;PT*
M("`@.30L,#`P)B,Q-C`[<VAA<F5S('5P;VX@:7-S=6%N8V4L(&%N9"!V97-T
M960@870@82!R871E(&]F(#,R+#`P,"8C,38P.W-H87)E<R8C,38P.W!E<B!M
M;VYT:"!S=&%R=&EN9R!O;B!T:&4@.3`F(S$V,#MD87D@86YN:79E<G-A<GD@
M;V8@:7-S=6%N8V4L(&%N9"!A<F4@97AE<F-I<V%B;&4@9F]R(&$@<&5R:6]D
M(&]F(&9I=F4@>65A<G,N($%L;"!S:&%R97,@=V5R92!V97-T960@86YD(&-O
M;7!E;G-A=&EO;B!C;W-T('=A<R!F=6QL>0T*("`@<F5C;W)D960@870@1&5C
M96UB97(F(S$V,#LS,2P@,C`P.2X@5&AE($-O;7!A;GD@86QS;R!A9W)E960@
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M;F<@;V8@:71S(&-O;6UO;B!S=&]C:RX@/"]F;VYT/CPO<#X-"B`@(#QP('-T
M>6QE/3-$)VUA<F=I;BUT;W`Z,3)P>#MM87)G:6XM8F]T=&]M.C!P>#L@=&5X
M="UI;F1E;G0Z-"4G/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S
M(&YE=R!R;VUA;B<@<VEZ93TS1#(^3VX@2F%N=6%R>28C,38P.S(Y+`T*("`@
M,C`P.2P@=&AE($-O;7!A;GD@:7-S=65D(#$T,BPU,#`@=V%R<F%N=',@=&\@
M86X@:6YV97-T;65N="!B86YK(&%S(&-O;G-I9&5R871I;VX@9F]R(&EN=F5S
M=&UE;G0@86YD(&)U<VEN97-S(&%D=FES;W)Y('-E<G9I8V5S+B!4:&4@=V%R
M<F%N=',@:&%V92!A;B!E>&5R8VES92!P<FEC92!O9B`D-"XR-S,@<&5R('-H
M87)E(&%N9"!E>'!I<F4@9FEV92!Y96%R<R!F<F]M('1H92!D871E(&]F(&ES
M<W5A;F-E(&]N#0H@("!*86YU87)Y)B,Q-C`[,CDL(#(P,30N(%1H92!W87)R
M86YT<R!V97-T960@87,@=&\@-S$L,C4P)B,Q-C`[<VAA<F5S('5P;VX@:7-S
M=6%N8V4L(&%N9"!V97-T960@870@82!R871E(&]F(#(S+#<U,"8C,38P.W-H
M87)E<R8C,38P.W!E<B!M;VYT:"!S=&%R=&EN9R!O;B!T:&4@.3`F(S$V,#MD
M87D@86YN:79E<G-A<GD@;V8@:7-S=6%N8V4L(&%N9"!A<F4@97AE<F-I<V%B
M;&4@9F]R(&$@<&5R:6]D(&]F(&9I=F4@>65A<G,N($%L;`T*("`@<VAA<F5S
M('=E<F4@=F5S=&5D(&%N9"!C;VUP96YS871I;VX@97AP96YS92!W87,@9G5L
M;'D@<F5C;W)D960@870@1&5C96UB97(F(S$V,#LS,2P@,C`P.2X@5&AE($-O
M;7!A;GD@:&%S(&%L<V\@86=R965D('1O(&=I=F4@=&AE(&AO;&1E<B!O9B!T
M:&4@=V%R<F%N=',@=6YL:6UI=&5D("8C.#(R,#MP:6=G>2!B86-K)B,X,C(Q
M.R!R96=I<W1R871I;VX@<FEG:'1S('=I=&@@<F5S<&5C="!T;R!T:&4@<VAA
M<F5S(&]F($-O;6UO;B!3=&]C:PT*("`@=6YD97)L>6EN9R!T:&4@=V%R<F%N
M=',@:6X@86YY(')E9VES=')A=&EO;B!S=&%T96UE;G0@=&AE($-O;7!A;GD@
M9FEL97,@:6X@8V]N;F5C=&EO;B!W:71H(&%N('5N9&5R=W)I='1E;B!O9F9E
M<FEN9R!O9B!T:&4@8V]M;6]N('-T;V-K+B`\+V9O;G0^/"]P/@T*("`@/'`@
M<W1Y;&4],T0G;6%R9VEN+71O<#HQ,G!X.VUA<F=I;BUB;W1T;VTZ,'!X.R!T
M97AT+6EN9&5N=#HT)2<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM
M97,@;F5W(')O;6%N)R!S:7IE/3-$,CX-"B`@($EN(&-O;FYE8W1I;VX@=VET
M:"!T:&4@,C`P.2!/9F9E<FEN9RP@=&AE($-O;7!A;GD@:7-S=65D('=A<G)A
M;G1S('1O('!U<F-H87-E(#DW."PQ-#(F(S$V,#MS:&%R97,@;V8@=&AE($-O
M;7!A;GDF(S@R,3<[<R!C;VUM;VX@<W1O8VLN($1E=&%I;',@;V8@=&AE('1R
M86YS86-T:6]N(&-A;B!B92!F;W5N9"!U;F1E<B!T:&4@:&5A9&EN9R`F(S@R
M,C`[,C`P.0T*("`@4F5G:7-T97)E9"!$:7)E8W0@3V9F97)I;F<F(S@R,C$[
M(&)E;&]W+B`\+V9O;G0^/"]P/@T*("`@/'`@<W1Y;&4],T0G;6%R9VEN+71O
M<#HQ,G!X.VUA<F=I;BUB;W1T;VTZ,'!X.R!T97AT+6EN9&5N=#HT)2<^/&9O
M;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE
M/3-$,CY);B!C;VYN96-T:6]N('=I=&@@=&AE(#(P,3`@3V9F97)I;F<L('1H
M92!#;VUP86YY(&ES<W5E9"!W87)R86YT<R!T;R!P=7)C:&%S90T*("`@-30P
M+#`P,"8C,38P.W-H87)E<R!O9B!T:&4@0V]M<&%N>28C.#(Q-SMS(&-O;6UO
M;B!S=&]C:RX@1&5T86EL<R!O9B!T:&4@=')A;G-A8W1I;VX@8V%N(&)E(&9O
M=6YD('5N9&5R('1H92!H96%D:6YG("8C.#(R,#LR,#$P(%)E9VES=&5R960@
M1&ER96-T($]F9F5R:6YG)B,X,C(Q.R!B96QO=RX@/"]F;VYT/CPO<#X-"B`@
M(#QP('-T>6QE/3-$)VUA<F=I;BUT;W`Z,3)P>#MM87)G:6XM8F]T=&]M.C!P
M>#L@=&5X="UI;F1E;G0Z-"4G/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY
M.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^#0H@("!);B!C;VYN96-T:6]N
M('=I=&@@=&AE($UA<F-H(#(P,3$@3V9F97)I;F<L('1H92!#;VUP86YY(&ES
M<W5E9"!W87)R86YT<R!T;R!P=7)C:&%S92`V+#`P,"PP,#`F(S$V,#MS:&%R
M97,@;V8@=&AE($-O;7!A;GDF(S@R,3<[<R!C;VUM;VX@<W1O8VLN($1E=&%I
M;',@;V8@=&AE('1R86YS86-T:6]N(&-A;B!B92!F;W5N9"!U;F1E<B!T:&4@
M:&5A9&EN9PT*("`@)B,X,C(P.TUA<F-H(#(P,3$@4F5G:7-T97)E9"!$:7)E
M8W0@3V9F97)I;F<F(S@R,C$[(&)E;&]W+B`\+V9O;G0^/"]P/@T*("`@/'`@
M<W1Y;&4],T0G;6%R9VEN+71O<#HQ,G!X.VUA<F=I;BUB;W1T;VTZ,'!X.R!T
M97AT+6EN9&5N=#HT)2<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM
M97,@;F5W(')O;6%N)R!S:7IE/3-$,CY);B!C;VYN96-T:6]N('=I=&@@=&AE
M($%P<FEL(#(P,3$@3V9F97)I;F<L('1H92!#;VUP86YY(&ES<W5E9`T*("`@
M=V%R<F%N=',@=&\@<'5R8VAA<V4@,3$L.34P+#`P,"8C,38P.W-H87)E<R!O
M9B!T:&4@0V]M<&%N>28C.#(Q-SMS(&-O;6UO;B!S=&]C:RX@1&5T86EL<R!O
M9B!T:&4@=')A;G-A8W1I;VX@8V%N(&)E(&9O=6YD('5N9&5R('1H92!H96%D
M:6YG("8C.#(R,#M!<')I;"`R,#$Q(%)E9VES=&5R960@1&ER96-T($]F9F5R
M:6YG)B,X,C(Q.R!B96QO=RX@/"]F;VYT/CPO<#X-"B`@(#QP('-T>6QE/3-$
M)VUA<F=I;BUT;W`Z,3)P>#MM87)G:6XM8F]T=&]M.C!P>#L@=&5X="UI;F1E
M;G0Z-"4G/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R
M;VUA;B<@<VEZ93TS1#(^1'5R:6YG(#(P,3$L('1H92!#;VUP86YY(&ES<W5E
M9"`Q-3`L,#`P('=A<G)A;G1S(&EN(&5X8VAA;F=E(&9O<B!B=7-I;F5S<R!A
M9'9I<V]R>2!S97)V:6-E<RX@5&AE($-O;7!A;GD@<F5C;V=N:7IE<R!T:&4@
M=&]T86P@9F%I<B!V86QU90T*("`@;V8@=&AE<V4@=V%R<F%N=',@87,@<W1O
M8VL@8V]M<&5N<V%T:6]N(&5X<&5N<V4L(&]V97(@=&AE(')E<75I<VET92!S
M97)V:6-E('!E<FEO9"X@5&AE($-O;7!A;GD@=7-E9"!T:&4@0FQA8VLM4V-H
M;VQE<R!O<'1I;VX@<')I8VEN9R!M;V1E;"!T;R!C;VUP=71E('1H92!E<W1I
M;6%T960@9F%I<B!V86QU92!O9B!T:&5S92!W87)R86YT(&=R86YT<R!O;B!T
M:&4@9&%T92!O9B!T:&4@87=A<F0N(%1O=&%L(&5X<&5N<V4@<F5L871E9`T*
M("`@=&\@=&AE<V4@=V%R<F%N=',@=V%S("0Q,#@L,#`P(&EN(#(P,3$@86YD
M(&-O;7!E;G-A=&EO;B!E>'!E;G-E('=A<R!F=6QL>2!R96-O<F1E9"!A<R!O
M9B!$96-E;6)E<B`S,2P@,C`Q,2X@/"]F;VYT/CPO<#X-"B`@(#QP('-T>6QE
M/3-$)VUA<F=I;BUT;W`Z,3)P>#MM87)G:6XM8F]T=&]M.C!P>#L@=&5X="UI
M;F1E;G0Z-"4G/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE
M=R!R;VUA;B<@<VEZ93TS1#(^1'5R:6YG('1H90T*("`@<75A<G1E<B!E;F1E
M9"!-87)C:"8C,38P.S,Q+"`R,#$R+"!T:&4@0V]M<&%N>2!I<W-U960@-#`P
M+#`P,"!W87)R86YT<R!I;B!E>&-H86YG92!F;W(@8G5S:6YE<W,@861V:7-O
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M;R!T:&5S92!W87)R86YT<R!W87,@)#$T."PP,#`@9F]R('1H90T*("`@<75A
M<G1E<B!E;F1E9"!-87)C:"8C,38P.S,Q+"`R,#$R+B`\+V9O;G0^/"]P/@T*
M("`@/'`@<W1Y;&4],T1F;VYT+7-I>F4Z,3AP>#MM87)G:6XM=&]P.C!P>#MM
M87)G:6XM8F]T=&]M.C!P>#X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^
M/"]P/@T*("`@/'`@<W1Y;&4],T1F;VYT+7-I>F4Z,7!X.VUA<F=I;BUT;W`Z
M,3)P>#MM87)G:6XM8F]T=&]M.C!P>#XF(S$V,#L\+W`^#0H@("`\<"!S='EL
M93TS1"=M87)G:6XM=&]P.C!P>#MM87)G:6XM8F]T=&]M.C!P>#L@=&5X="UI
M;F1E;G0Z-"4G/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE
M=R!R;VUA;B<@<VEZ93TS1#(^/&D^4')I=F%T92!);G9E<W1M96YT#0H@("!I
M;B!0=6)L:6,@17%U:71Y/"]I/B`F(S@R,3([($]N($IU;F4@,C0L(#(P,#@L
M('1H92!#;VUP86YY(&5N=&5R960@:6YT;R!A(%-E8W5R:71I97,@4'5R8VAA
M<V4@06=R965M96YT('!U<G-U86YT('1O('=H:6-H('1H92!#;VUP86YY(&ES
M<W5E9"!A;F0@<V]L9"!T;R!C97)T86EN(&EN=F5S=&]R<R!A;B!A9V=R96=A
M=&4@;V8@,2PP-S,L,CDY)B,Q-C`[<VAA<F5S(&]F(&-O;6UO;B!S=&]C:R!I
M;B!A('!R:79A=&4@<&QA8V5M96YT(&%T#0H@("!A('!R:6-E(&]F("0X+C$R
M('!E<B!S:&%R92X@3F5T('!R;V-E961S('1O('1H92!#;VUP86YY('=E<F4@
M87!P<F]X:6UA=&5L>2`D-RXY)B,Q-C`[;6EL;&EO;BX@/"]F;VYT/CPO<#X-
M"B`@(#QP('-T>6QE/3-$)VUA<F=I;BUT;W`Z,3)P>#MM87)G:6XM8F]T=&]M
M.C!P>#L@=&5X="UI;F1E;G0Z-"4G/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M
M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^/&D^,C`P.2!296=I<W1E
M<F5D($1I<F5C=`T*("`@3V9F97)I;F<\+VD^("8C.#(Q,CL@3VX@36%R8V@F
M(S$V,#LQ-RP@,C`P.2P@=&AE($-O;7!A;GD@96YT97)E9"!I;G1O(&$@<&QA
M8V5M96YT(&%G96YC>2!A9W)E96UE;G0L('=H:6-H('=A<R!S=6)S97%U96YT
M;'D@86UE;F1E9"!O;B!-87DF(S$V,#LR-BP@,C`P.2!A;F0@2G5L>28C,38P
M.S(R+"`R,#`Y+"!W:71H(%)O9&UA;B8C,38P.R8C,#,X.R!296YS:&%W+"!,
M3$,@*"8C.#(R,#M2;V1M86XF(S@R,C$[*2!A<R!T:&4@97AC;'5S:79E#0H@
M("!P;&%C96UE;G0@86=E;G0L(')E;&%T:6YG('1O(&$@<')O<&]S960@;V9F
M97)I;F<@8GD@=&AE($-O;7!A;GD@;V8@;F5W('-E8W5R:71I97,@=&\@<&]T
M96YT:6%L(&EN=F5S=&]R<RX@3VX@2G5L>28C,38P.S,P+"`R,#`Y+"!T:&4@
M0V]M<&%N>2!E;G1E<F5D(&EN=&\@9&5F:6YI=&EV92!A9W)E96UE;G1S(&9O
M<B!T:&4@<V%L92!A;F0@:7-S=6%N8V4@8GD@=&AE($-O;7!A;GD@=&\@8V5R
M=&%I;B!I;G9E<W1O<G,@;V8-"B`@(#(L,S@U+#<Q-28C,38P.W5N:71S+"!W
M:71H(&5A8V@@=6YI="!C;VYS:7-T:6YG(&]F(&]N92!S:&%R92!O9B!T:&4@
M0V]M<&%N>28C.#(Q-SMS(&-O;6UO;B!S=&]C:R!A;F0@82!W87)R86YT('1O
M('!U<F-H87-E(#`N-#`@;V8@82!S:&%R92!O9B!C;VUM;VX@<W1O8VLL(&%T
M(&$@<'5R8VAA<V4@<')I8V4@;V8@)#,N-3`@<&5R('5N:70@*'1H92`F(S@R
M,C`[,C`P.2!/9F9E<FEN9R8C.#(R,3LI+B!4:&4@,C`P.2!/9F9E<FEN9PT*
M("`@8VQO<V5D(&]N($%U9W5S="8C,38P.S0L(#(P,#DN(%1H92!W87)R86YT
M<R!H879E(&%N(&5X97)C:7-E('!R:6-E(&]F("0T+C4P('!E<B!S:&%R92!A
M;F0@87)E(&5X97)C:7-A8FQE(&9O<B!A('!E<FEO9"!B96=I;FYI;F<@;VX@
M1F5B<G5A<GDF(S$V,#LS+"`R,#$P('5N=&EL('1H96ER(&5X<&ER871I;VX@
M;VX@075G=7-T)B,Q-C`[,RP@,C`Q-"X@5&AE($-O;7!A;GD@<F%I<V5D(&=R
M;W-S('!R;V-E961S(&]F#0H@("!A<'!R;WAI;6%T96QY("0X+#,U,"PP,#`@
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M#0H@("!T<F%N<V%C=&EO;B!W97)E(#DU-"PR.#4N(#PO9F]N=#X\+W`^#0H@
M("`\<"!S='EL93TS1"=M87)G:6XM=&]P.C$R<'@[;6%R9VEN+6)O='1O;3HP
M<'@[('1E>'0M:6YD96YT.C0E)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL
M>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/D%S('!A<G0@;V8@=&AE('!L
M86-E;65N="!A9V5N8WD@86=R965M96YT+"!T:&4@0V]M<&%N>2!I<W-U960@
M82!W87)R86YT('1O('!U<F-H87-E#0H@("`R,RPX-3<F(S$V,#MS:&%R97,@
M;V8@=&AE($-O;7!A;GDF(S@R,3<[<R!C;VUM;VX@<W1O8VL@=&\@4F]D;6%N
M+B!4:&4@=V%R<F%N="!H87,@86X@97AE<F-I<V4@<')I8V4@;V8@)#0N,S@@
M<&5R('-H87)E+B!4:&4@=V%R<F%N="!I<R!I;6UE9&EA=&5L>2!V97-T960@
M86YD(&ES(&5X97)C:7-A8FQE('5N=&EL(&ET<R!E>'!I<F%T:6]N(&]N($%U
M9W5S="8C,38P.S,L(#(P,30N(#PO9F]N=#X\+W`^#0H@("`\<"!S='EL93TS
M1"=M87)G:6XM=&]P.C$R<'@[;6%R9VEN+6)O='1O;3HP<'@[('1E>'0M:6YD
M96YT.C0E)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@
M<F]M86XG('-I>F4],T0R/D-E<G1A:6X@=V%R<F%N=',@:7-S=65D(&EN(&-O
M;FYE8W1I;VX@=VET:"!T:&4@<W1O8VL@;V9F97)I;F<@;VX@075G=7-T)B,Q
M-C`[-"P@,C`P.2!W97)E(&1E=&5R;6EN960@;F]T('1O(&)E(&EN9&5X960@
M=&\@=&AE#0H@("!#;VUP86YY)B,X,C$W.W,@8V]M;6]N('-T;V-K(&%S('1H
M97D@87)E('!O=&5N=&EA;&QY('-E='1L96%B;&4@:6X@8V%S:"X@5&AE(&9A
M:7(@=F%L=64@;V8@=&AE('=A<G)A;G1S(&%T('1H92!D871E<R!O9B!I<W-U
M86YC92!T;W1A;&EN9R`D,BPX-C,L,#`P('=A<R!R96-O<F1E9"!A<R!A(&QI
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M(&%R92!P=6)L:6-L>0T*("`@=')A9&5D+B!4:&4@0V]M<&%N>2!U<V5D(&$@
M=V5I9VAT960@879E<F%G92!E>'!E8W1E9"!S=&]C:R!V;VQA=&EL:71Y(&]F
M(#$R,BXV.24N(%1H92!E>'!E8W1E9"!L:69E(&%S<W5M<'1I;VX@:7,@8F%S
M960@;VX@=&AE(&-O;G1R86-T('1E<FT@;V8@9FEV92!Y96%R<RX@5&AE(&1I
M=FED96YD('EI96QD(&]F('IE<F\@:7,@8F%S960@;VX@=&AE(&9A8W0@=&AA
M="!T:&4@0V]M<&%N>2!H87,@;F\@<')E<V5N="!I;G1E;G1I;VX@=&\-"B`@
M('!A>2!C87-H(&1I=FED96YD<R!I;B!T:&4@9G5T=7)E+B!4:&4@<FES:R!F
M<F5E(')A=&4@;V8@,2XW,B4@=7-E9"!F;W(@=&AE('=A<G)A;G0@:7,@97%U
M86P@=&\@=&AE('IE<F\@8V]U<&]N(')A=&4@:6X@969F96-T(&%T('1H92!T
M:6UE(&]F('1H92!G<F%N="X@5&AE(&EN8W)E87-E(&EN('1H92!F86ER('9A
M;'5E(&]F('=A<G)A;G1S(&9R;VT@1&5C96UB97(F(S$V,#LS,2P@,C`Q,2!T
M;R!-87)C:"8C,38P.S,Q+"`R,#$R(&]F#0H@("`D,S@T+#`P,"!H87,@8F5E
M;B!I;F-L=61E9"!I;B!O=&AE<B!E>'!E;G-E(&EN('1H92!A8V-O;7!A;GEI
M;F<@8V]N9&5N<V5D('-T871E;65N=',@;V8@97AP96YS97,@9F]R('1H92!T
M:')E92!M;VYT:',@96YD960@36%R8V@F(S$V,#LS,2P@,C`Q,BX@5&AE(&9A
M:7(@=F%L=64@;V8@=&AE('=A<G)A;G1S(&%T($UA<F-H)B,Q-C`[,S$L(#(P
M,3(@;V8@)#0T."PP,#`@:7,@:6YC;'5D960@87,@82!C=7)R96YT(&QI86)I
M;&ET>2!I;@T*("`@=&AE(&%C8V]M<&%N>6EN9R!C;VYD96YS960@8F%L86YC
M92!S:&5E=',@86YD('=A<R!D971E<FUI;F5D('5S:6YG('1H92!";&%C:RU3
M8VAO;&5S(&]P=&EO;B!P<FEC:6YG(&UO9&5L+B!$=64@=&\@=&AE(&9A8W0@
M=&AA="!T:&4@0V]M<&%N>2!H87,@;&EM:71E9"!T<F%D:6YG(&AI<W1O<GDL
M('1H92!#;VUP86YY)B,X,C$W.W,@97AP96-T960@<W1O8VL@=F]L871I;&ET
M>2!A<W-U;7!T:6]N(&ES(&)A<V5D(&]N(&$-"B`@(&-O;6)I;F%T:6]N(&]F
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M=')A8W0@=&5R;0T*("`@;V8@,BXS('EE87)S+B!4:&4@9&EV:61E;F0@>6EE
M;&0@;V8@>F5R;R!I<R!B87-E9"!O;B!T:&4@9F%C="!T:&%T('=E(&AA=F4@
M;F\@<')E<V5N="!I;G1E;G1I;VX@=&\@<&%Y(&-A<V@@9&EV:61E;F1S+B!4
M:&4@<FES:R!F<F5E(')A=&4@;V8@,"XS.24@=7-E9"!F;W(@=&AE('=A<G)A
M;G1S(&ES(&5Q=6%L('1O('1H92!Z97)O(&-O=7!O;B!R871E(&EN(&5F9F5C
M="!O;B!T:&4@9&%T92!O9B!T:&4@<F4M;65A<W5R96UE;G0N#0H@("`\+V9O
M;G0^/"]P/@T*("`@/'`@<W1Y;&4],T0G;6%R9VEN+71O<#HQ,G!X.VUA<F=I
M;BUB;W1T;VTZ,'!X.R!T97AT+6EN9&5N=#HT)2<^/&9O;G0@<W1Y;&4],T0G
M9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CX\:3XR,#$P
M(%)E9VES=&5R960@1&ER96-T($]F9F5R:6YG/"]I/B`F(S@R,3([($]N($UA
M<F-H)B,Q-C`[,C(L(#(P,3`L('1H92!#;VUP86YY(&5N=&5R960@:6YT;R!A
M('!L86-E;65N="!A9V5N8WD@86=R965M96YT#0H@("!R96QA=&EN9R!T;R!A
M('!R;W!O<V5D(&]F9F5R:6YG(&)Y('1H92!#;VUP86YY(&]F(&YE=R!S96-U
M<FET:65S('1O('!O=&5N=&EA;"!I;G9E<W1O<G,N($]N($UA<F-H)B,Q-C`[
M,C,L(#(P,3`L('1H92!#;VUP86YY(&5N=&5R960@:6YT;R!D969I;FET:79E
M(&%G<F5E;65N=',@9F]R('1H92!S86QE(&%N9"!I<W-U86YC92!B>2!T:&4@
M0V]M<&%N>2!T;R!C97)T86EN(&EN=F5S=&]R<R!O9B`R+#<P,"PP,#`F(S$V
M,#MU;FET<RP-"B`@('=I=&@@96%C:"!U;FET(&-O;G-I<W1I;F<@;V8@;VYE
M('-H87)E(&]F('1H92!#;VUP86YY)B,X,C$W.W,@8V]M;6]N('-T;V-K(&%N
M9"!A('=A<G)A;G0@=&\@<'5R8VAA<V4@,"XR,"!O9B!A('-H87)E(&]F('1H
M92!#;VUP86YY)B,X,C$W.W,@8V]M;6]N('-T;V-K+"!A="!A('!U<F-H87-E
M('!R:6-E(&]F("0V+C`P('!E<B!U;FET("AT:&4@)B,X,C(P.S(P,3`@3V9F
M97)I;F<F(S@R,C$[*2X@5&AE(#(P,3`@3V9F97)I;F<@8VQO<V5D#0H@("!O
M;B!-87)C:"8C,38P.S(V+"`R,#$P+B!4:&4@0V]M<&%N>2!I<W-U960@=V%R
M<F%N=',@=&\@<'5R8VAA<V4@-30P+#`P,"8C,38P.W-H87)E<R!O9B!T:&4@
M0V]M<&%N>28C.#(Q-SMS(&-O;6UO;B!S=&]C:R!A="!A;B!E>&5R8VES92!P
M<FEC92!O9B`D-BXP,"!P97(@<VAA<F4@86YD('1H870@87)E(&5X97)C:7-A
M8FQE(&)E9VEN;FEN9R!O;B!397!T96UB97(F(S$V,#LR-BP@,C`Q,"!U;G1I
M;"!T:&5I<B!E>'!I<F%T:6]N(&]N#0H@("!-87)C:"8C,38P.S(V+"`R,#$V
M+B!4:&4@0V]M<&%N>2!R86ES960@9W)O<W,@<')O8V5E9',@;V8@87!P<F]X
M:6UA=&5L>2`D,38N,B8C,38P.VUI;&QI;VX@:6X@=&AE(#(P,3`@3V9F97)I
M;F<@86YD(&YE="!C87-H('!R;V-E961S+"!A9G1E<B!D961U8W1I;F<@=&AE
M('!L86-E;65N="!A9V5N="!F965S(&%N9"!O=&AE<B!O9F9E<FEN9R!E>'!E
M;G-E<R!P87EA8FQE(&)Y('1H92!#;VUP86YY+"!O9B!A<'!R;WAI;6%T96QY
M#0H@("`D,34N,B8C,38P.VUI;&QI;VXN(#PO9F]N=#X\+W`^#0H@("`\<"!S
M='EL93TS1"=M87)G:6XM=&]P.C$R<'@[;6%R9VEN+6)O='1O;3HP<'@[('1E
M>'0M:6YD96YT.C0E)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE
M<R!N97<@<F]M86XG('-I>F4],T0R/D%S('!A<G0@;V8@=&AE(#(P,3`@3V9F
M97)I;F<L('1H92!#;VUP86YY(&5N=&5R960@:6X@82!S=&]C:R!R961E;7!T
M:6]N(&%G<F5E;65N="!W:&5R96)Y('1H92!#;VUP86YY('=A<PT*("`@<F5Q
M=6ER960@=&\@=7-E(#(U)2!O9B!T:&4@;F5T('!R;V-E961S(&9R;VT@=&AE
M(#(P,3`@3V9F97)I;F<@=&\@<F5P=7)C:&%S92!F<F]M($-Y=%)X($-O<G!O
M<F%T:6]N("@F(S@R,C`[0WET4G@F(S@R,C$[*2`V-S4L,#`P('-H87)E<R!O
M9B!T:&4@0V]M<&%N>28C.#(Q-SMS(&-O;6UO;B!S=&]C:R!H96QD(&)Y($-Y
M=%)X("@F(S@R,C`[0WET4G@@<VAA<F5S)B,X,C(Q.RDN(%1H92!#;VUP86YY
M(')E<'5R8VAA<V5D('-U8V@@<VAA<F5S#0H@("!O;B!-87)C:"8C,38P.S(Y
M+"`R,#$P+B!4:&4@=F%L=65S(&]F('1H92!S:&%R97,@870@=&AE(&1A=&4@
M;V8@<F5P=7)C:&%S92!T;W1A;&EN9R`D,RPX-#DL,#`P('=E<F4@<F5C;W)D
M960@870@8V]S="!A;F0@:&%V92!B965N(&EN8VQU9&5D(&EN('1R96%S=7)Y
M('-T;V-K(&EN('1H92!A8V-O;7!A;GEI;F<@8V]N9&5N<V5D(&-O;G-O;&ED
M871E9"!B86QA;F-E('-H965T(&%T($UA<F-H(#,Q+"`R,#$R(&%N9"`R,#$Q
M+@T*("`@/"]F;VYT/CPO<#X-"B`@(#QP('-T>6QE/3-$;6%R9VEN+71O<#HQ
M,G!X.VUA<F=I;BUB;W1T;VTZ,'!X/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M
M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)B,Q-C`[)B,Q-C`[)B,Q
M-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[0V5R=&%I;B!W87)R
M86YT<R!I<W-U960@:6X@8V]N;F5C=&EO;B!W:71H('1H92`R,#$P($]F9F5R
M:6YG('=E<F4@9&5T97)M:6YE9"!N;W0@=&\@8F4-"B`@(&EN9&5X960@=&\@
M=&AE($-O;7!A;GDF(S@R,3<[<R!C;VUM;VX@<W1O8VL@87,@=&AE>2!A<F4@
M<&]T96YT:6%L;'D@<V5T=&QE86)L92!I;B!C87-H+B!4:&4@9F%I<B!V86QU
M92!O9B!T:&4@=V%R<F%N=',@870@=&AE(&1A=&5S(&]F(&ES<W5A;F-E('1O
M=&%L:6YG("0R+#0V-BPP,#`@=V%S(')E8V]R9&5D(&%S(&$@;&EA8FEL:71Y
M(&%N9"!A(&-O<W0@;V8@97%U:71Y(&%N9"!W87,@9&5T97)M:6YE9"!U<VEN
M9R!T:&4-"B`@($)L86-K+5-C:&]L97,@;W!T:6]N('!R:6-I;F<@;6]D96PN
M($1U92!T;R!T:&4@9F%C="!T:&%T('1H92!#;VUP86YY(&AA<R!L:6UI=&5D
M('1R861I;F<@:&ES=&]R>2P@=&AE($-O;7!A;GDF(S@R,3<[<R!E>'!E8W1E
M9"!S=&]C:R!V;VQA=&EL:71Y(&%S<W5M<'1I;VX@:7,@8F%S960@;VX@82!C
M;VUB:6YA=&EO;B!O9B!I;7!L:65D('9O;&%T:6QI=&EE<R!O9B!S:6UI;&%R
M(&5N=&ET:65S('=H;W-E('-H87)E(&]R(&]P=&EO;@T*("`@<')I8V5S(&%R
M92!P=6)L:6-A;&QY('1R861E9"X@5&AE($-O;7!A;GD@=7-E9"!A('=E:6=H
M=&5D(&%V97)A9V4@97AP96-T960@<W1O8VL@=F]L871I;&ET>2!O9B`Q,3DN
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M,3(L(#$X,"PP,#`@;V8@=&AE(&9I=F4M>65A<B!W87)R86YT<PT*("`@=V5R
M92!E>&5R8VES960@870@)#(N-3`@<&5R(&-O;6UO;B!S:&%R92X@5&AE<V4@
M=V%R<F%N=',@=V5R92!M87)K960@=&\@;6%R:V5T('1H<F]U9V@@36%R8V@@
M,S$L(#(P,3(L(')E<W5L=&EN9R!I;B!A9&1I=&EO;F%L(&5X<&5N<V4@;V8@
M)#(Q-2PP,#`N(%5P;VX@97AE<F-I<V4L(&$@;&EA8FEL:71Y(&EN('1H92!A
M;6]U;G0@;V8@)#(U-"PP,#`@=V%S(')E;&EE=F5D(&%S(&$@8W)E9&ET('1O
M(&%D9&ET:6]N86P@<&%I9"UI;@T*("`@8V%P:71A;"X@5&AE(&EN8W)E87-E
M(&EN('1H92!F86ER('9A;'5E(&]F('=A<G)A;G1S(&9R;VT@1&5C96UB97(F
M(S$V,#LS,2P@,C`Q,2!T;R!-87)C:"8C,38P.S,Q+"`R,#$R(&]F("0T,#(L
M,#`P(&AA<R!B965N(&EN8VQU9&5D(&EN(&]T:&5R(&5X<&5N<V4@:6X@=&AE
M(&%C8V]M<&%N>6EN9R!C;VYD96YS960@<W1A=&5M96YT<R!O9B!E>'!E;G-E
M<R!F;W(@=&AE('1H<F5E(&UO;G1H<R!E;F1E9"!-87)C:"8C,38P.S,Q+`T*
M("`@,C`Q,BX@5&AE(&9A:7(@=F%L=64@;V8@=&AE('=A<G)A;G1S(&%T($UA
M<F-H)B,Q-C`[,S$L(#(P,3(@;V8@)#0W.2PP,#`@:7,@:6YC;'5D960@87,@
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M97)A9V4-"B`@(&5X<&5C=&5D('-T;V-K('9O;&%T:6QI='D@;V8@.#$N.#8E
M+B!4:&4@97AP96-T960@;&EF92!A<W-U;7!T:6]N(&ES(&)A<V5D(&]N('1H
M92!R96UA:6YI;F<@8V]N=')A8W0@=&5R;2!O9B`T+C4@>65A<G,N(%1H92!D
M:79I9&5N9"!Y:65L9"!O9B!Z97)O(&ES(&)A<V5D(&]N('1H92!F86-T('1H
M870@=V4@:&%V92!N;R!P<F5S96YT(&EN=&5N=&EO;B!T;R!P87D@8V%S:"!D
M:79I9&5N9',N(%1H92!R:7-K(&9R964@<F%T92!O9@T*("`@,"XY,24@=7-E
M9"!F;W(@=&AE('=A<G)A;G1S(&ES(&5Q=6%L('1O('1H92!Z97)O(&-O=7!O
M;B!R871E(&EN(&5F9F5C="!O;B!T:&4@9&%T92!O9B!T:&4@<F4M;65A<W5R
M96UE;G0N(#PO9F]N=#X\+W`^#0H@("`\<"!S='EL93TS1&9O;G0M<VEZ93HQ
M<'@[;6%R9VEN+71O<#HQ,G!X.VUA<F=I;BUB;W1T;VTZ,'!X/B8C,38P.SPO
M<#X-"B`@(#QP('-T>6QE/3-$)VUA<F=I;BUT;W`Z,'!X.VUA<F=I;BUB;W1T
M;VTZ,'!X.R!T97AT+6EN9&5N=#HT)2<^/&9O;G0@<W1Y;&4],T0G9F]N="UF
M86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CX\:3Y-87)C:"`R,#$Q
M#0H@("!296=I<W1E<F5D($1I<F5C="!/9F9E<FEN9SPO:3X@)B,X,C$R.R!/
M;B!-87)C:"8C,38P.S0L(#(P,3$L('1H92!#;VUP86YY(&-L;W-E9"!A;B!U
M;F1E<G=R:71T96X@<'5B;&EC(&]F9F5R:6YG(&]F(#8L,#`P+#`P,"!U;FET
M<R!A="!A('!R:6-E('1O('1H92!P=6)L:6,@;V8@)#$N,S4@<&5R('5N:70@
M9F]R(&=R;W-S('!R;V-E961S(&]F("0X+C$F(S$V,#MM:6QL:6]N("AT:&4@
M)B,X,C(P.TUA<F-H)B,Q-C`[,C`Q,0T*("`@3V9F97)I;F<F(S@R,C$[*2X@
M5&AE(&]F9F5R:6YG('!R;W9I9&5D(&%P<')O>&EM871E;'D@)#<N,R8C,38P
M.VUI;&QI;VX@=&\@=&AE($-O;7!A;GD@869T97(@9&5D=6-T:6YG('1H92!U
M;F1E<G=R:71I;F<@9&ES8V]U;G1S(&%N9"!C;VUM:7-S:6]N<R!A;F0@;V9F
M97)I;F<@97AP96YS97,N($5A8V@@=6YI="!C;VYS:7-T<R!O9B`H:2DF(S$V
M,#MO;F4@<VAA<F4@;V8@8V]M;6]N('-T;V-K+"`H:6DI)B,Q-C`[80T*("`@
M=&AI<G1E96XM;6]N=&@@=V%R<F%N="!T;R!P=7)C:&%S92`P+C4P(&]F(&$@
M<VAA<F4@;V8@8V]M;6]N('-T;V-K(&%T(&%N(&5X97)C:7-E('!R:6-E(&]F
M("0Q+C<P('!E<B!S:&%R92`H<W5B:F5C="!T;R!A;G1I+61I;'5T:6]N(&%D
M:G5S=&UE;G0I(&%N9"`H:6EI*28C,38P.V$@9FEV92UY96%R('=A<G)A;G0@
M=&\@<'5R8VAA<V4@,"XU,"!O9B!A('-H87)E(&]F(&-O;6UO;B!S=&]C:R!A
M="!A;B!E>&5R8VES92!P<FEC92!O9@T*("`@)#$N.#<@<&5R('-H87)E("AS
M=6)J96-T('1O(&%N=&DM9&EL=71I;VX@861J=7-T;65N="DN($]N($%P<FEL
M)B,Q-C`[,34L(#(P,3$L('1H92!H;VQD97)S(&]F(&]U='-T86YD:6YG('=A
M<G)A;G1S(&ES<W5E9"!I;B!T:&4@36%R8V@F(S$V,#LR,#$Q($]F9F5R:6YG
M('1O('!U<F-H87-E(&%N(&%G9W)E9V%T92!O9B`S+#0U,"PP,#`@<VAA<F5S
M(&]F(&-O;6UO;B!S=&]C:R!A9W)E960@=&\@97AC:&%N9V4@<W5C:"!W87)R
M86YT<PT*("`@9F]R('=A<G)A;G1S(&5X97)C:7-A8FQE(&9O<B!T:&4@<V%M
M92!N=6UB97(@;V8@<VAA<F5S(&%S('1H;W-E(&)E:6YG(&5X8VAA;F=E9"P@
M8G5T(&]T:&5R=VES92!O;B!T:&4@<V%M92!T97)M<R!O9B!T:&4@=V%R<F%N
M=',@<V]L9"!I;B!T:&4@0V]M<&%N>28C.#(Q-SMS($%P<FEL)B,Q-C`[,C`Q
M,2!F:6YA;F-I;F<N(%!R:6]R('1O('1H92!E>&-H86YG92P@=&AE($-O;7!A
M;GD@<F5C;W)D960@82!D96-R96%S92!I;B!F86ER#0H@("!V86QU92!O9B`D
M,2PP,#`L,#`P(')E;&%T960@=&\@=&AE(&5X8VAA;F=E9"!W87)R86YT<RX@
M57!O;B!T:&4@97AC:&%N9V4L('1H92!#;VUP86YY(')E8V]R9&5D(&$@;&]S
M<R!O9B`D.3`P+#`P,"P@=VAI8V@@<F5P<F5S96YT960@=&AE(&1I9F9E<F5N
M8V4@8F5T=V5E;B!T:&4@861J=7-T960@9F%I<B!V86QU92!O9B!T:&4@36%R
M8V@F(S$V,#LR,#$Q('=A<G)A;G1S(&%S(&-O;7!A<F5D('1O('1H92!F86ER
M('9A;'5E(&]F('1H90T*("`@07!R:6PF(S$V,#LR,#$Q('=A<G)A;G1S(')E
M8V5I=F5D(&EN('1H92!E>&-H86YG92X@07,@82!R97-U;'0@;V8@82!S=6)S
M97%U96YT(&]F9F5R:6YG('1H870@=V%S(&-O;7!L971E9"!O;B!!<')I;"8C
M,38P.S$U+"`R,#$Q+"!T:&4@97AE<F-I<V4@<')I8V4@;V8@=&AE(')E;6%I
M;FEN9R`R+#4U,"PP,#`@;W5T<W1A;F1I;F<@=V%R<F%N=',@<V]L9"!I;B!T
M:&4@36%R8V@F(S$V,#LR,#$Q($]F9F5R:6YG('=A<R!R961U8V5D('1O#0H@
M("`D,2XP,"!P97(@<VAA<F4@87,@82!R97-U;'0@;V8@=&AE(&%N=&DM9&EL
M=71I;VX@861J=7-T;65N="X@07,@82!R97-U;'0@;V8@=&AE('-U8G-E<75E
M;G0@;V9F97)I;F<@;VX@4V5P=&5M8F5R)B,Q-C`[,C8L(#(P,3$L('1H92!E
M>&5R8VES92!P<FEC92!O9B!A;&P@=V%R<F%N=',@<V]L9"!I;B!T:&4@36%R
M8V@F(S$V,#LT+"`R,#$Q($]F9F5R:6YG('=E<F4@<F5D=6-E9"!T;R`D,"XV
M-2!P97(@<VAA<F4@87,@82!R97-U;'0@;V8-"B`@('1H92!A;G1I+61I;'5T
M:6]N(&%D:G5S=&UE;G0N($%T($UA<F-H)B,Q-C`[,S$L(#(P,3(L(&]F('1H
M92`R+#4U,"PP,#`@=6YE>&-H86YG960@=V%R<F%N=',@9G)O;2!T:&4@36%R
M8V@F(S$V,#LR,#$Q($]F9F5R:6YG+"`Q+#,W,RPY-#0@=V%R<F%N=',@:&%D
M(&)E96X@97AE<F-I<V5D('=I=&@@82!R96UA:6YI;F<@;W5T<W1A;F1I;F<@
M8F%L86YC92!O9B`Q+#$W-BPP-38N(#PO9F]N=#X\+W`^#0H@("`\<"!S='EL
M93TS1"=M87)G:6XM=&]P.C$R<'@[;6%R9VEN+6)O='1O;3HP<'@[('1E>'0M
M:6YD96YT.C0E)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N
M97<@<F]M86XG('-I>F4],T0R/E1H92!T:&ER=&5E;BUM;VYT:"!A;F0@9FEV
M92UY96%R('=A<G)A;G1S(&ES<W5E9"!I;B!C;VYN96-T:6]N('=I=&@@=&AE
M($UA<F-H(#(P,3$@3V9F97)I;F<@=V5R92!D971E<FUI;F5D(&YO="!T;R!B
M92!I;F1E>&5D('1O('1H90T*("`@0V]M<&%N>28C.#(Q-SMS(&-O;6UO;B!S
M=&]C:R!A<R!T:&5Y(&%R92!P;W1E;G1I86QL>2!S971T;&5A8FQE(&EN(&-A
M<V@N(%1H92!F86ER('9A;'5E(&]F('1H92`R+#4U,"PP,#`@=V%R<F%N=',@
M870@=&AE(&1A=&4@;V8@:7-S=6%N8V4@=&]T86QI;F<@)#$L-SDP+#`P,"!W
M87,@<F5C;W)D960@87,@82!L:6%B:6QI='D@86YD(&$@8V]S="!O9B!E<75I
M='D@86YD('=A<R!D971E<FUI;F5D('5S:6YG('1H92!";&%C:RU38VAO;&5S
M#0H@("!O<'1I;VX@<')I8VEN9R!M;V1E;"X@1'5E('1O('1H92!F86-T('1H
M870@=&AE($-O;7!A;GD@:&%S(&QI;6ET960@=')A9&EN9R!H:7-T;W)Y+"!T
M:&4@0V]M<&%N>2!E>'!E8W1E9"!S=&]C:R!V;VQA=&EL:71Y(&%S<W5M<'1I
M;VX@:7,@8F%S960@;VX@82!C;VUB:6YA=&EO;B!O9B!I;7!L:65D('9O;&%T
M:6QI=&EE<R!O9B!S:6UI;&%R(&5N=&ET:65S('=H;W-E('-H87)E<R!O<B!O
M<'1I;VYS(&%R92!P=6)L:6-L>2!T<F%D960N#0H@("!4:&4@0V]M<&%N>2!U
M<V5D(&$@=V5I9VAT960@879E<F%G92!E>'!E8W1E9"!S=&]C:R!V;VQA=&EL
M:71Y(&]F(#$Q,RXR-24N(%1H92!E>'!E8W1E9"!L:69E(&%S<W5M<'1I;VX@
M:7,@8F%S960@;VX@=&AE(&-O;G1R86-T('1E<FT@;V8@,2XP."!Y96%R<R!U
M<V5D(&9O<B!T:&4@=&AI<G1E96XM;6]N=&@@=V%R<F%N=',@86YD(#4@>65A
M<G,@=7-E9"!F;W(@=&AE(&9I=F4M>65A<B!W87)R86YT<RX@5&AE(&1I=FED
M96YD('EI96QD#0H@("!O9B!Z97)O(&ES(&)A<V5D(&]N('1H92!F86-T('1H
M870@=V4@:&%V92!N;R!P<F5S96YT(&EN=&5N=&EO;B!T;R!P87D@8V%S:"!D
M:79I9&5N9',N(%1H92!R:7-K(&9R964@<F%T92!O9B`P+C(V)2!U<V5D(&9O
M<B!T:&4@=&AI<G1E96XM;6]N=&@@=V%R<F%N=',@86YD(#(N,3<E('5S960@
M9F]R('1H92!F:79E+7EE87(@=V%R<F%N=',@:7,@97%U86P@=&\@=&AE('IE
M<F\@8V]U<&]N(')A=&4@:6X@969F96-T(&%T('1H92!T:6UE#0H@("!O9B!T
M:&4@9W)A;G0N($EN($IU;'D@,C`Q,2P@-S4L,#`P(&]F('1H92!T:&ER=&5E
M;BUM;VYT:"!W87)R86YT<R!W97)E(&5X97)C:7-E9"!A="`D,2XP,"!P97(@
M8V]M;6]N('-H87)E+"!W:&EC:"!R97-U;'1E9"!I;B!A("0S-"PP,#`@<F5D
M=6-T:6]N(&]F('1H92!W87)R86YT(&QI86)I;&ET>2X@26X@2G5L>2`R,#$Q
M+"`W-2PP,#`@;V8@=&AE(&9I=F4M>65A<B!W87)R86YT<R!W97)E(&5X97)C
M:7-E9"!A="`D,2XP,"!P97(-"B`@(&-O;6UO;B!S:&%R92P@=VAI8V@@<F5S
M=6QT960@:6X@82`D-C@L,#`P(')E9'5C=&EO;B!O9B!T:&4@=V%R<F%N="!L
M:6%B:6QI='DN($1U<FEN9R!T:&4@=&AR964@;6]N=&AS(&5N9&5D($UA<F-H
M(#,Q+"`R,#$R+"`X-C(L-3`P(&]F('1H92!T:&ER=&5E;BUM;VYT:"!W87)R
M86YT<R!A;F0@,S8Q+#0T-"!O9B!T:&4@9FEV92UY96%R('=A<G)A;G1S('=E
M<F4@97AE<F-I<V5D(&%T("0P+C8U('!E<B!C;VUM;VX@<VAA<F4N(%1H97-E
M#0H@("!W87)R86YT<R!W97)E(&UA<FME9"!T;R!M87)K970@=&AR;W5G:"!-
M87)C:"`S,2P@,C`Q,BP@<F5S=6QT:6YG(&EN(&%D9&ET:6]N86P@97AP96YS
M92!O9B`D,2PR-38L,#`P+B!5<&]N(&5X97)C:7-E+"!A(&QI86)I;&ET>2!I
M;B!T:&4@86UO=6YT(&]F("0Q+#0P-2PP,#`@=V%S(')E;&EE=F5D(&%S(&$@
M8W)E9&ET('1O(&%D9&ET:6]N86P@<&%I9"UI;B!C87!I=&%L+B!4:&4@:6YC
M<F5A<V4@:6X@=&AE(&9A:7(@=F%L=64@;V8-"B`@('=A<G)A;G1S(&9R;VT@
M1&5C96UB97(F(S$V,#LS,2P@,C`Q,2!T;R!-87)C:"8C,38P.S,Q+"`R,#$R
M(&]F("0Q+#<V-2PP,#`@:&%S(&)E96X@:6YC;'5D960@:6X@;W1H97(@97AP
M96YS92!I;B!T:&4@86-C;VUP86YY:6YG(&-O;F1E;G-E9"!S=&%T96UE;G1S
M(&]F(&5X<&5N<V5S(&9O<B!T:&4@=&AR964@;6]N=&AS(&5N9&5D($UA<F-H
M)B,Q-C`[,S$L(#(P,3(N(%1H92!F86ER('9A;'5E(&]F('1H92!W87)R86YT
M<R!A=`T*("`@36%R8V@F(S$V,#LS,2P@,C`Q,B!O9B`D,BPP,C@L,#`P(&ES
M(&EN8VQU9&5D(&%S(&$@8W5R<F5N="!L:6%B:6QI='D@:6X@=&AE(&%C8V]M
M<&%N>6EN9R!C;VYD96YS960@8F%L86YC92!S:&5E=',@86YD('=A<R!D971E
M<FUI;F5D('5S:6YG('1H92!";&%C:RU38VAO;&5S(&]P=&EO;B!P<FEC:6YG
M(&UO9&5L+B!$=64@=&\@=&AE(&9A8W0@=&AA="!T:&4@0V]M<&%N>2!H87,@
M;&EM:71E9"!T<F%D:6YG(&AI<W1O<GDL('1H90T*("`@0V]M<&%N>28C.#(Q
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M;V8@-#<N,CDE(&9O<@T*("`@=&AE('1H:7)T965N+6UO;G1H('=A<G)A;G1S
M(&%N9"`X,2XY.24@9F]R('1H92!F:79E+7EE87(@=V%R<F%N=',N(%1H92!E
M>'!E8W1E9"!L:69E(&%S<W5M<'1I;VX@:7,@8F%S960@;VX@=&AE(')E;6%I
M;FEN9R!C;VYT<F%C="!T97)M(&]F(#`N,#$@>65A<G,@=7-E9"!F;W(@=&AE
M('1H:7)T965N+6UO;G1H('=A<G)A;G1S(&%N9"`S+CDS('EE87)S('5S960@
M9F]R('1H92!F:79E+7EE87(@=V%R<F%N=',N(%1H92!D:79I9&5N9`T*("`@
M>6EE;&0@;V8@>F5R;R!I<R!B87-E9"!O;B!T:&4@9F%C="!T:&%T('=E(&AA
M=F4@;F\@<')E<V5N="!I;G1E;G1I;VX@=&\@<&%Y(&-A<V@@9&EV:61E;F1S
M+B!4:&4@<FES:R!F<F5E(')A=&4@;V8@,"XP,24@=7-E9"!F;W(@=&AE('1H
M:7)T965N+6UO;G1H('=A<G)A;G1S(&%N9"`P+C<X)2!U<V5D(&9O<B!T:&4@
M9FEV92UY96%R('=A<G)A;G1S(&ES(&5Q=6%L('1O('1H92!Z97)O(&-O=7!O
M;B!R871E(&EN(&5F9F5C="!A="!T:&4-"B`@('1I;64@;V8@=&AE(')E+6UE
M87-U<F5M96YT+B`\+V9O;G0^/"]P/@T*("`@/'`@<W1Y;&4],T0G;6%R9VEN
M+71O<#HQ,G!X.VUA<F=I;BUB;W1T;VTZ,'!X.R!T97AT+6EN9&5N=#HT)2<^
M/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S
M:7IE/3-$,CX\:3Y!<')I;"`R,#$Q(%)E9VES=&5R960@1&ER96-T($]F9F5R
M:6YG/"]I/B`F(S@R,3([($]N($%P<FEL)B,Q-C`[,C`L(#(P,3$L('1H92!#
M;VUP86YY(&-O;7!L971E9`T*("`@86X@=6YD97)W<FET=&5N('!U8FQI8R!O
M9F9E<FEN9R!O9B`Q,2PY-3`L,#`P('5N:71S(&%T(&$@<')I8V4@=&\@=&AE
M('!U8FQI8R!O9B`D,2XP,"!P97(@=6YI="!F;W(@9W)O<W,@<')O8V5E9',@
M;V8@87!P<F]X:6UA=&5L>2`D,3(F(S$V,#MM:6QL:6]N("AT:&4@)B,X,C(P
M.T%P<FEL)B,Q-C`[,C`Q,2!/9F9E<FEN9R8C.#(R,3LI+B!%86-H('5N:70@
M8V]N<VES=&5D(&]F(&]N92!S:&%R92!O9B!C;VUM;VX@<W1O8VL@86YD(&$-
M"B`@('=A<G)A;G0@=&\@<'5R8VAA<V4@;VYE('-H87)E(&]F(&-O;6UO;B!S
M=&]C:R!A="!A;B!E>&5R8VES92!P<FEC92!O9B`D,2XP,"!P97(@<VAA<F4@
M*'-U8FIE8W0@=&\@86YT:2UD:6QU=&EO;B!A9&IU<W1M96YT*2X@5&AE('-H
M87)E<R!O9B!C;VUM;VX@<W1O8VL@86YD('=A<G)A;G1S('=E<F4@:6UM961I
M871E;'D@<V5P87)A8FQE(&%N9"!N;R!S97!A<F%T92!U;FET<R!W97)E(&ES
M<W5E9"X@5&AE('=A<G)A;G1S(&%R90T*("`@97AE<F-I<V%B;&4@8F5G:6YN
M:6YG(&]N92!Y96%R(&%N9"!O;F4@9&%Y(&9R;VT@=&AE(&1A=&4@;V8@:7-S
M=6%N8V4L(&%N9"!E>'!I<F4@;VX@=&AE('-I>'1H(&%N;FEV97)S87)Y(&]F
M('1H92!D871E(&]F(&ES<W5A;F-E+B!.970@<')O8V5E9',L(&%F=&5R('5N
M9&5R=W)I=&EN9R!D:7-C;W5N=',@86YD(&-O;6UI<W-I;VYS(&%N9"!O=&AE
M<B!O9F9E<FEN9R!E>'!E;G-E<RP@=V5R92!A<'!R;WAI;6%T96QY#0H@("`D
M,3`N.28C,38P.VUI;&QI;VXN($%S(&$@<F5S=6QT(&]F('1H92!S=6)S97%U
M96YT(&]F9F5R:6YG('1H870@=V%S(&-O;7!L971E9"!O;B!397!T96UB97(F
M(S$V,#LR-BP@,C`Q,2P@=&AE(&5X97)C:7-E('!R:6-E(&]F('1H92`Q,2PY
M-3`L,#`P(&]U='-T86YD:6YG('=A<G)A;G1S('-O;&0@:6X@=&AE($%P<FEL
M)B,Q-C`[,C`Q,2!/9F9E<FEN9R!W87,@<F5D=6-E9"!T;R`D,"XV-2!P97(@
M<VAA<F4@87,@82!R97-U;'0@;V8-"B`@('1H92!A;G1I+61I;'5T:6]N(&%D
M:G5S=&UE;G0N)B,Q-C`[3VX@1&5C96UB97(F(S$V,#LV+"`R,#$Q+"!T:&4@
M0V]M<&%N>2!E9F9E8W1E9"!A('=A<G)A;G0@97AC:&%N9V4@=VET:"!A(')A
M=&EO(&]F(#$N-#(X-3<@=V%R<F%N=',@:6X@97AC:&%N9V4@9F]R(&]N92!S
M:&%R92!O9B!C;VUM;VX@<W1O8VL@=VET:"!S979E<F%L(&]F('1H92!!<')I
M;"`R,#$Q('=A<G)A;G0@:&]L9&5R<RX@26X@=&]T86PL(#4L.3,P+#`P,`T*
M("`@=V%R<F%N=',@=V5R92!E>&-H86YG960@9F]R(#0L,34Q+#`P,"!S:&%R
M97,@;V8@8V]M;6]N('-T;V-K(&EN('1H:7,@=')A;G-A8W1I;VXN($%T($UA
M<F-H(#,Q+"`R,#$R+"`V+#`R,"PP,#`@=V%R<F%N=',@<V]L9"!I;B!T:&4@
M07!R:6PF(S$V,#LR,"P@,C`Q,2!/9F9E<FEN9R!R96UA:6YE9"!O=71S=&%N
M9&EN9RX@/"]F;VYT/CPO<#X-"B`@(#QP('-T>6QE/3-$;6%R9VEN+71O<#HQ
M,G!X.VUA<F=I;BUB;W1T;VTZ,'!X/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M
M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^#0H@("`F(S$V,#LF(S$V
M,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#M4:&4@=V%R
M<F%N=',@:7-S=65D(&EN(&-O;FYE8W1I;VX@=VET:"!T:&4@07!R:6P@,C`Q
M,2!/9F9E<FEN9RP@:6YC;'5D:6YG('1H92!W87)R86YT<R!I<W-U960@:6X@
M97AC:&%N9V4@9F]R('1H92`S+#0U,"PP,#`F(S$V,#M-87)C:"`R,#$Q('=A
M<G)A;G1S+"!W97)E#0H@("!D971E<FUI;F5D(&YO="!T;R!B92!I;F1E>&5D
M('1O('1H92!#;VUP86YY)B,X,C$W.W,@8V]M;6]N('-T;V-K(&%S('1H97D@
M87)E('!O=&5N=&EA;&QY('-E='1L96%B;&4@:6X@8V%S:"X@5&AE(&9A:7(@
M=F%L=64@;V8@=&AE('=A<G)A;G1S(&%T('1H92!D871E<R!O9B!I<W-U86YC
M92!T;W1A;&EN9R`D,3$L-#0R+#`P,"!W87,@<F5C;W)D960@87,@82!L:6%B
M:6QI='D@86YD(&$@8V]S="!O9B!E<75I='D@86YD('=A<PT*("`@9&5T97)M
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M;6EL87(@96YT:71I97,-"B`@('=H;W-E('-H87)E<R!O<B!O<'1I;VYS(&%R
M92!P=6)L:6-L>2!T<F%D960N(%1H92!#;VUP86YY('5S960@82!W96EG:'1E
M9"!A=F5R86=E(&5X<&5C=&5D('-T;V-K('9O;&%T:6QI='D@;V8@.3DN,#0E
M+B!4:&4@97AP96-T960@;&EF92!A<W-U;7!T:6]N(&ES(&)A<V5D(&]N('1H
M92!C;VYT<F%C="!T97)M(&]F(#8N,"!Y96%R<RX@5&AE(&1I=FED96YD('EI
M96QD(&]F('IE<F\@:7,@8F%S960@;VX@=&AE(&9A8W0@=&AA="!W90T*("`@
M:&%V92!N;R!P<F5S96YT(&EN=&5N=&EO;B!T;R!P87D@8V%S:"!D:79I9&5N
M9',N(%1H92!R:7-K(&9R964@<F%T92!O9B`R+C@Q)2!U<V5D(&9O<B!T:&4@
M=V%R<F%N=',@:7,@97%U86P@=&\@=&AE('IE<F\@8V]U<&]N(')A=&4@:6X@
M969F96-T(&%T('1H92!T:6UE(&]F('1H92!G<F%N="X@26X@1&5C96UB97(@
M,C`Q,2P@=&AE($-O;7!A;GD@97AC:&%N9V5D(#0L,34Q+#`P,"!S:&%R97,@
M;V8@8V]M;6]N('-T;V-K(&EN#0H@("!E>&-H86YG92!F;W(@-2PY,S`L,#`P
M(&]F('1H97-E($%P<FEL('=A<G)A;G1S(&%T(&$@<F%T:6\@;V8@,"XW(&-O
M;6UO;B!S:&%R97,@9F]R(&5A8V@@=V%R<F%N="!W:&EC:"!R97-U;'1E9"!I
M;B!A(')E9'5C=&EO;B!T;R!W87)R86YT(&QI86)I;&ET>2!O9B`D,RPQ,C`L
M,#`P+B!4:&4@:6YC<F5A<V4@:6X@=&AE(&9A:7(@;6%R:V5T('9A;'5E(&]F
M('1H92!W87)R86YT<RP@:6YC;'5D:6YG('1H92!W87)R86YT<R!E>&-H86YG
M960-"B`@(&9O<B!T:&4@,RPT-3`L,#`P($UA<F-H(#(P,3$@=V%R<F%N=',L
M(&9R;VT@1&5C96UB97(F(S$V,#LS,2P@,C`Q,2!T;R!-87)C:"8C,38P.S,Q
M+"`R,#$R(&]F("0Q-"PR-#@L,#`P(&AA<R!B965N(&EN8VQU9&5D(&EN(&]T
M:&5R(&5X<&5N<V4@:6X@=&AE(&%C8V]M<&%N>6EN9R!C;VYD96YS960@<W1A
M=&5M96YT<R!O9B!E>'!E;G-E<R!F;W(@=&AE('1H<F5E(&UO;G1H<R!E;F1E
M9"!-87)C:"8C,38P.S,Q+"`R,#$R+B!4:&4@9F%I<@T*("`@=F%L=64@;V8@
M=&AE('=A<G)A;G1S(&%T($UA<F-H)B,Q-C`[,S$L(#(P,3(@;V8@)#$W+#0P
M,BPP,#`@:7,@:6YC;'5D960@87,@82!C=7)R96YT(&QI86)I;&ET>2!I;B!T
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M;2!O9B`U+C$@>65A<G,N(%1H92!D:79I9&5N9"!Y:65L9"!O9B!Z97)O(&ES
M(&)A<V5D(&]N('1H92!F86-T('1H870@=V4@:&%V92!N;R!P<F5S96YT(&EN
M=&5N=&EO;B!T;R!P87D@8V%S:"!D:79I9&5N9',N(%1H90T*("`@<FES:R!F
M<F5E(')A=&4@;V8@,2XP-"4@=7-E9"!F;W(@=&AE('=A<G)A;G1S(&ES(&5Q
M=6%L('1O('1H92!Z97)O(&-O=7!O;B!R871E(&EN(&5F9F5C="!O;B!T:&4@
M9&%T92!O9B!T:&4@<F4M;65A<W5R96UE;G0N(#PO9F]N=#X\+W`^#0H@("`\
M<"!S='EL93TS1"=M87)G:6XM=&]P.C$R<'@[;6%R9VEN+6)O='1O;3HP<'@[
M('1E>'0M:6YD96YT.C0E)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT
M:6UE<R!N97<@<F]M86XG('-I>F4],T0R/CQI/E-E<'1E;6)E<B`R,#$Q(%)E
M9VES=&5R960@1&ER96-T($]F9F5R:6YG/"]I/B`F(S@R,3([($]N(%-E<'1E
M;6)E<B8C,38P.S(V+"`R,#$Q+"!T:&4@0V]M<&%N>2!C;VUP;&5T960@82!D
M:7)E8W0@;V9F97)I;F<@;V8@-S`P+#`P,`T*("`@<VAA<F5S(&]F(&-O;6UO
M;B!S=&]C:R!F;W(@9W)O<W,@<')O8V5E9',@;V8@)#0U-2PP,#`N(#PO9F]N
M=#X\+W`^#0H\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'10
M87)T7V)E9F4Y8S$Q7V,R9C-?-#AE8U]A,F%B7V9F,C@Y-C`W961C,`T*0V]N
M=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B]B969E.6,Q,5]C,F8S7S0X96-?
M83)A8E]F9C(X.38P-V5D8S`O5V]R:W-H965T<R]3:&5E=#$U+FAT;6P-"D-O
M;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O
M;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*
M/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT
M96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G
M/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS
M/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H
M96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60]
M,T1)1#!%344^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L
M(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^3&ET:6=A=&EO;CQB
M<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS
M<&%N/3-$,3XS($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y-87(N(#,Q+"`R,#$R
M/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG
M/DQI=&EG871I;VX@6T%B<W1R86-T73PO<W1R;VYG/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y,:71I9V%T:6]N/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\(2TM1$]#5%E012!H=&UL(%!50DQ)0R`B+2\O
M5S-#+R]$5$0@6$A434P@,2XP(%1R86YS:71I;VYA;"\O14XB(")H='1P.B\O
M=W=W+G<S+F]R9R]44B]X:'1M;#$O1%1$+WAH=&UL,2UT<F%N<VET:6]N86PN
M9'1D(B`M+3X-"B`@(#PA+2T@0F5G:6X@0FQO8VL@5&%G9V5D($YO=&4@,3`@
M+2!U<RUG86%P.D-O;6UI=&UE;G1S06YD0V]N=&EN9V5N8VEE<T1I<V-L;W-U
M<F5497AT0FQO8VLM+3X-"B`@(#QP('-T>6QE/3-$;6%R9VEN+71O<#HQ.'!X
M.VUA<F=I;BUB;W1T;VTZ,'!X/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY
M.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^/&(^,3`N($QI=&EG871I;VX@
M/"]B/CPO9F]N=#X\+W`^#0H@("`\<"!S='EL93TS1"=M87)G:6XM=&]P.C9P
M>#MM87)G:6XM8F]T=&]M.C!P>#L@=&5X="UI;F1E;G0Z-"4G/CQF;VYT('-T
M>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^
M5&AE($-O;7!A;GD@:7,@:6X@;&ET:6=A=&EO;B!W:71H('-E=F5R86P@;V8@
M:71S($%P<FEL(#(P,3$@=V%R<F%N=',@:&]L9&5R<R`H)B,X,C(P.U!L86EN
M=&EF9G,F(S@R,C$[*2!W:&\@:&%V92!A<W-E<G1E9`T*("`@=&AA="!T:&4@
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M=&\@<F5P=7)C:&%S90T*("`@-BPX-3`L,#`P('=A<G)A;G1S+"!W:&EC:"!R
M97!R97-E;G1E9"!A;B!A<'!R;WAI;6%T92!T;W1A;"!D96UA;F0@;V8@)#4N
M,B!M:6QL:6]N+B`\+V9O;G0^/"]P/@T*("`@/'`@<W1Y;&4],T0G;6%R9VEN
M+71O<#HQ,G!X.VUA<F=I;BUB;W1T;VTZ,'!X.R!T97AT+6EN9&5N=#HT)2<^
M/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S
M:7IE/3-$,CY/;B!-87)C:"8C,38P.S(Q+"`R,#$R+"!W92!R96-E:79E9`T*
M("`@;&5T=&5R<R!F<F]M(&5A8V@@;V8@=&AE('!L86EN=&EF9BUW87)R86YT
M(&AO;&1E<G,@=VET:&1R87=I;F<@=&AE:7(@<F5P=7)C:&%S92!D96UA;F1S
M('=I=&@@<F5S<&5C="!T;R!T:&5I<B!W87)R86YT<R!C;W9E<FEN9R!A;B!A
M9V=R96=A=&4@;V8@-BPS-3`L,#`P('-H87)E<R!O=70@;V8@82!T;W1A;"!O
M9B`V+#@U,"PP,#`@<VAA<F5S(&]F(&-O;6UO;B!S=&]C:R!P=7)C:&%S86)L
M92!U;F1E<B!T:&5I<B!W87)R86YT<R`H=&AE#0H@("`F(S@R,C`[5VET:&1R
M87=A;"!.;W1I8V4\8CYS/"]B/B8C.#(R,3LI+B!!9G1E<B!G:79I;F<@969F
M96-T('1O('1H92!7:71H9')A=V%L($YO=&EC97,L('1H92!P;&%I;G1I9F8M
M=V%R<F%N="!H;VQD97)S(&-O;G1I;G5E9"!T;R!D96UA;F0@=&AA="!W92!R
M97!U<F-H87-E('1H96ER('=A<G)A;G1S(&-O=F5R:6YG('1H92!B86QA;F-E
M(&]F(#4P,"PP,#`@<VAA<F5S(&]F(&-O;6UO;B!S=&]C:R!I;B!T:&4@86=G
M<F5G871E+B!"87-E9`T*("`@;VX@=&AE('!L86EN=&EF9BUW87)R86YT(&AO
M;&1E<G,F(S@R,3<[(&-L86EM<R!I;B!T:&5I<B!#;VUP;&%I;G1S+"!W92!B
M96QI979E('1H870@=&AE(')E<'5R8VAA<V4@<')I8V4@9F]R('1H97-E('=A
M<G)A;G1S(&ES("0P+C<Q('!E<B!U;F1E<FQY:6YG('-H87)E+"!O<B!A;B!A
M9V=R96=A=&4@;V8@)#,U-2PP,#`N($]N($UA<F-H(#(W+"`R,#$R+"!W92!T
M96YD97)E9"!T;R!T:&4@<&QA:6YT:69F+7=A<G)A;G0@:&]L9&5R<R!A;@T*
M("`@86=G<F5G871E(&]F("0S-34L,#`P(&%S('!A>6UE;G0@:6X@9G5L;"!O
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M97)S('5N9&5R('1H92!#;VUP;&%I;G1S+B`\+V9O;G0^/"]P/@T*("`@/'`@
M<W1Y;&4],T0G;6%R9VEN+71O<#HQ,G!X.VUA<F=I;BUB;W1T;VTZ,'!X.R!T
M97AT+6EN9&5N=#HT)2<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM
M97,@;F5W(')O;6%N)R!S:7IE/3-$,CX-"B`@($]N($UA>28C,38P.S<L(#(P
M,3(L('1H92!#;VUP86YY(&5N=&5R960@:6YT;R!A(&-O;F9I9&5N=&EA;"!S
M971T;&5M96YT(&%G<F5E;65N="!W:71H(&]N92!O9B!T:&4@4&QA:6YT:69F
M<RP@/'4^/"]U/FEN('=H:6-H('1H92!0;&%I;G1I9F8@=VET:&1R97<@86QL
M(&-L86EM<R!I;B!T:&4@869O<F5M96YT:6]N960@;6%T=&5R+B`\+V9O;G0^
M/"]P/@T*/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO
M=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R
M=%]B969E.6,Q,5]C,F8S7S0X96-?83)A8E]F9C(X.38P-V5D8S`-"D-O;G1E
M;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO8F5F93EC,3%?8S)F,U\T.&5C7V$R
M86)?9F8R.#DV,#=E9&,P+U=O<FMS:&5E=',O4VAE970Q-BYH=&UL#0I#;VYT
M96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT
M96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH
M=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N
M="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\
M<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO
M*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A
M9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$
M240P14U%/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C
M;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/E-U8G-E<75E;G0@179E
M;G1S/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H
M(&-O;'-P86X],T0Q/C,@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DUA<BX@,S$L
M(#(P,3(\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS
M=')O;F<^4W5B<V5Q=65N="!%=F5N=',@6T%B<W1R86-T73PO<W1R;VYG/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3=6)S97%U96YT($5V
M96YT<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/"$M+41/0U19
M4$4@:'1M;"!054),24,@(BTO+U<S0R\O1%1$(%A(5$U,(#$N,"!4<F%N<VET
M:6]N86PO+T5.(B`B:'1T<#HO+W=W=RYW,RYO<F<O5%(O>&AT;6PQ+T141"]X
M:'1M;#$M=')A;G-I=&EO;F%L+F1T9"(@+2T^#0H@("`\(2TM($)E9VEN($)L
M;V-K(%1A9V=E9"!.;W1E(#$Q("T@=7,M9V%A<#I3=6)S97%U96YT179E;G1S
M5&5X=$)L;V-K+2T^#0H@("`\<"!S='EL93TS1&UA<F=I;BUT;W`Z,3AP>#MM
M87)G:6XM8F]T=&]M.C!P>#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT
M:6UE<R!N97<@<F]M86XG('-I>F4],T0R/CQB/C$Q+B!3=6)S97%U96YT($5V
M96YT<R`\+V(^/"]F;VYT/CPO<#X-"B`@(#QP('-T>6QE/3-$)VUA<F=I;BUT
M;W`Z-G!X.VUA<F=I;BUB;W1T;VTZ,'!X.R!T97AT+6EN9&5N=#HT)2<^/&9O
M;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE
M/3-$,CY4:&4@0V]M<&%N>2!E=F%L=6%T960@86QL(&5V96YT<R!O<B!T<F%N
M<V%C=&EO;G,@=&AA="!O8V-U<G)E9"!A9G1E<B!-87)C:"8C,38P.S,Q+"`R
M,#$R('5P('1H<F]U9V@@=&AE(&1A=&4@=&AE<V4-"B`@(&9I;F%N8VEA;"!S
M=&%T96UE;G1S('=E<F4@:7-S=65D+B!/=&AE<B!T:&%N('=H870@:7,@9&ES
M8VQO<V5D(&)E;&]W+"!T:&4@0V]M<&%N>2!D:60@;F]T(&AA=F4@86YY(&UA
M=&5R:6%L(')E8V]G;FEZ86)L92!O<B!U;G)E8V]G;FEZ86)L92!S=6)S97%U
M96YT(&5V96YT<RX@/"]F;VYT/CPO<#X-"B`@(#QP('-T>6QE/3-$)VUA<F=I
M;BUT;W`Z,3)P>#MM87)G:6XM8F]T=&]M.C!P>#L@=&5X="UI;F1E;G0Z-"4G
M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@
M<VEZ93TS1#(^#0H@("!3:6YC92!-87)C:"`S,2P@,C`Q,BP@=&AE($-O;7!A
M;GD@:&%S(&ES<W5E9"`V+#,V,RPQ.3$@<VAA<F5S(&]F('1H92!#;VUP86YY
M)B,X,C$W.W,@8V]M;6]N('-T;V-K('!U<G-U86YT('1O('1H92!E>&5R8VES
M92!O9B!O=71S=&%N9&EN9R!W87)R86YT<R!F<F]M('9A<FEO=7,@=V%R<F%N
M="!H;VQD97)S+B!4:&4@0V]M<&%N>2!R96-E:79E9`T*("`@)#0L,3,V+#`W
M-"!I;B!T;W1A;"!P87EM96YT<R!A="!A;B!E>&5R8VES92!P<FEC92!O9B`D
M,"XV-2!P97(@<VAA<F4N(#PO9F]N=#X\+W`^#0H@("`\<"!S='EL93TS1"=M
M87)G:6XM=&]P.C$R<'@[;6%R9VEN+6)O='1O;3HP<'@[('1E>'0M:6YD96YT
M.C0E)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M
M86XG('-I>F4],T0R/D]N($%P<FEL)B,Q-C`[-2P@,C`Q,BP@=&AE($-O;7!A
M;GD@:7-S=65D(#$R,"PP-C4-"B`@('-H87)E<R!O9B!C;VUM;VX@<W1O8VL@
M:6X@8V]N;F5C=&EO;B!W:71H(&$@8V%S:&QE<W,@97AE<F-I<V4@;V8@,3@R
M+#4P,"!T:&ER=&5E;BUM;VYT:"!W87)R86YT<R!F<F]M('1H92!-87)C:"`R
M,#$Q($]F9F5R:6YG('=H:6-H(&AA9"!E>'!I<F5D+"!I;B!T:&4@;6]N97DL
M(&]N($%P<FEL)B,Q-C`[-"P@,C`Q,BX@/"]F;VYT/CPO<#X-"B`@(#QP('-T
M>6QE/3-$)VUA<F=I;BUT;W`Z,3)P>#MM87)G:6XM8F]T=&]M.C!P>#L@=&5X
M="UI;F1E;G0Z-"4G/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S
M(&YE=R!R;VUA;B<@<VEZ93TS1#(^3VX@07!R:6PF(S$V,#LQ,2P@,C`Q,BP@
M=&AE($-O;7!A;GD@:7-S=65D(#@L-3`P+#`P,"!S:&%R97,@;V8@:71S(&-O
M;6UO;B!S=&]C:R!I;B!A;B!U;F1E<G=R:71T96X@<'5B;&EC(&]F9F5R:6YG
M(&%T("0Q+C4P('!E<B!S:&%R92X-"B`@(%1H92!#;VUP86YY(&%L<V\@9W)A
M;G1E9"!T;R!T:&4@=6YD97)W<FET97)S(&$@,S`M9&%Y(&]P=&EO;B!T;R!P
M=7)C:&%S92!U<"!T;R!A;B!A9&1I=&EO;F%L(#$L,C<U+#`P,"!S:&%R97,@
M=&\@8V]V97(@;W9E<F%L;&]T;65N=',@:6X@8V]N;F5C=&EO;B!W:71H('1H
M92!O9F9E<FEN9RX@3VX@07!R:6PF(S$V,#LQ,RP@,C`Q,BP@=&AE('5N9&5R
M=W)I=&5R<R!E>&5R8VES960@=&AE:7(@;W!T:6]N('1O('!U<F-H87-E(&%N
M#0H@("!A9&1I=&EO;F%L(#$L,C4Q+#`P,"!S:&%R97,@;V8@8V]M;6]N('-T
M;V-K+B!!9G1E<B!T:&4@=6YD97)W<FET:6YG(&1I<V-O=6YT(&%N9"!E<W1I
M;6%T960@;V9F97)I;F<@97AP96YS97,@<&%Y86)L92!B>2!T:&4@0V]M<&%N
M>2P@=&AE($-O;7!A;GD@<F5C96EV960@;F5T('!R;V-E961S(&]F(&%P<')O
M>&EM871E;'D@)#$S+C,@;6EL;&EO;BX@/"]F;VYT/CPO<#X-"B`@(#QP('-T
M>6QE/3-$)VUA<F=I;BUT;W`Z,3)P>#MM87)G:6XM8F]T=&]M.C!P>#L@=&5X
M="UI;F1E;G0Z-"4G/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S
M(&YE=R!R;VUA;B<@<VEZ93TS1#(^3VX@07!R:6PF(S$V,#LR-BP@,C`Q,BP@
M=&AE($-O;7!A;GD@8V]M<&QE=&5D('1H92!S<&EN+6]F9B!O9B!26&DL(&ET
M<R!W:&]L;'DM;W=N960@<W5B<VED:6%R>2!P<FEO<B!T;R!T:&4@<W!I;BUO
M9F8L('!U<G-U86YT('1O('1H90T*("`@4V5C=7)I=&EE<R!0=7)C:&%S92!!
M9W)E96UE;G0@9&5S8W)I8F5D(&EN($YO=&4@-"P@86YD(&]N($%P<FEL)B,Q
M-C`[,C<L(#(P,3(L('1H92!#;VUP86YY(&-L;W-E9"!T:&4@=')A;G-A8W1I
M;VYS('5N9&5R('1H92!396-U<FET:65S(%!U<F-H87-E($%G<F5E;65N="X@
M/"]F;VYT/CPO<#X-"B`@(#QP('-T>6QE/3-$)VUA<F=I;BUT;W`Z,3)P>#MM
M87)G:6XM8F]T=&]M.C!P>#L@=&5X="UI;F1E;G0Z-"4G/CQF;VYT('-T>6QE
M/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^#0H@
M("!/;B!-87DF(S$V,#LW+"`R,#$R+"!A<R!M;W)E(&9U;&QY(&1E<V-R:6)E
M9"!I;B!.;W1E(#$P+"!T:&4@0V]M<&%N>2!E;G1E<F5D(&EN=&\@82!C;VYF
M:61E;G1I86P@<V5T=&QE;65N="!A9W)E96UE;G0@=VET:"!O;F4@;V8@=&AE
M(%!L86EN=&EF9G,@:6X@=&AE(&%C=&EO;G,@9&5S8W)I8F5D(&EN($YO=&4@
M,3`N(#PO9F]N=#X\+W`^#0H\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM
M+2T]7TYE>'1087)T7V)E9F4Y8S$Q7V,R9C-?-#AE8U]A,F%B7V9F,C@Y-C`W
M961C,`T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B]B969E.6,Q,5]C
M,F8S7S0X96-?83)A8E]F9C(X.38P-V5D8S`O5V]R:W-H965T<R]F:6QE;&ES
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M:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#`R+FAT;6PB+SX-"B`\
M;SI&:6QE($A2968],T0B4VAE970P,RYH=&UL(B\^#0H@/&\Z1FEL92!(4F5F
M/3-$(E-H965T,#0N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#`U
M+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970P-BYH=&UL(B\^#0H@
M/&\Z1FEL92!(4F5F/3-$(E-H965T,#<N:'1M;"(O/@T*(#QO.D9I;&4@2%)E
M9CTS1")3:&5E=#`X+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970P
M.2YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,3`N:'1M;"(O/@T*
M(#QO.D9I;&4@2%)E9CTS1")3:&5E=#$Q+FAT;6PB+SX-"B`\;SI&:6QE($A2
M968],T0B4VAE970Q,BYH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T
M,3,N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#$T+FAT;6PB+SX-
M"B`\;SI&:6QE($A2968],T0B4VAE970Q-2YH=&UL(B\^#0H@/&\Z1FEL92!(
M4F5F/3-$(E-H965T,38N:'1M;"(O/@T*/"]X;6P^#0HM+2TM+2T]7TYE>'10
L87)T7V)E9F4Y8S$Q7V,R9C-?-#AE8U]A,F%B7V9F,C@Y-C`W961C,"TM#0H`
`
end

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Apthera Acquisition<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Apthera Acquisition [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationDisclosureTextBlock', window );">Apthera Acquisition</a></td>
        <td class="text"><!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
   <!-- Begin Block Tagged Note 3 - us-gaap:BusinessCombinationDisclosureTextBlock-->
   <p style="margin-top:18px;margin-bottom:0px"><font style="font-family:times new roman" size="2"><b>3.&#160;Apthera Acquisition </b></font></p>
   <p style="margin-top:6px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">On April&#160;13, 2011, the Company completed its acquisition of Apthera, Inc., a Delaware corporation
   (&#8220;Apthera&#8221;), under an Agreement and Plan of Merger (&#8220;Merger Agreement&#8221;) entered into on March&#160;31, 2011. Subject to the terms and conditions of the Merger Agreement, the Company&#8217;s wholly owned subsidiary formed for this
   purpose was merged with and into Apthera, with Apthera surviving as a wholly-owned subsidiary of the Company. Under the Merger Agreement, the Company issued to Apthera&#8217;s stockholders approximately 5.0&#160;million shares of common stock of the
   Company (the &#8220;Aggregate Stock Consideration&#8221;) and agreed to make future contingent payments of up to $32&#160;million based on the achievement of certain development and commercial milestones relating to the Company&#8217;s NeuVax&#8482;
   product candidate. The contingent consideration is payable, at the election of the Company, in either cash or additional shares of common stock, provided that the Company may not issue any shares in satisfaction of any contingent consideration
   unless it has first obtained approval of its stockholders in accordance with Rule 5635(a) of the NASDAQ Marketplace Rules. </font></p>
   <p style="margin-top:12px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">In
   connection with the Merger Agreement, the Company deposited with a third-party escrow agent certificates representing 10% of the Aggregate Stock Consideration, which shares will be available to compensate the Company and related parties for certain
   indemnifiable losses as described in the Merger Agreement. On October&#160;13, 2011, the escrow agent released from the escrow 5% of the Aggregate Stock Consideration, or 248,705 shares. The remaining Aggregate Stock Consideration held with the
   escrow agent was released in April 2012 (see Note 11). </font></p>
   <p style="margin-top:12px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">The Company&#8217;s acquisition of Apthera was in concert with the
   decision by the Company&#8217;s Board of Directors to diversify its development programs and to become a late stage clinical development company. The Company does not expect any of its goodwill to be deductible for tax purposes. </font></p>
   <p style="margin-top:12px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">The purchase price consideration and allocation of purchase price of Apthera were as follows: </font></p>
   <p style="font-size:12px;margin-top:0px;margin-bottom:0px">&#160;</p>
   <table cellspacing="0" cellpadding="0" width="92%" border="0" style="border-collapse:collapse; text-align: left" align="center">
   <!-- Begin Table Head -->
   <tr>
   <td width="91%">&#160;</td>
   <td valign="bottom" width="5%">&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   </tr>
   <tr>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>(in 000&#8217;s)</b></font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   </tr>
   <!-- End Table Head -->
   <!-- Begin Table Body -->
   <tr bgcolor="#cceeff">
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2"><b>Calculation of allocable purchase price:</b></font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   </tr>
   <tr>
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Fair value of shares issued at closing including escrowed shares expected to be released</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">&#160;6,367</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">(i)</font></td>
   </tr>
   <tr bgcolor="#cceeff">
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Estimated value of earn-out</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">6,460</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   </tr>
   <tr style="font-size:1px">
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   </tr>
   <tr>
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Total allocable purchase price</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">12,827</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   </tr>
   <tr style="font-size:1px">
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   </tr>
   <tr bgcolor="#cceeff">
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2"><b>Allocation of purchase price:</b></font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   </tr>
   <tr>
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Cash</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">168</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   </tr>
   <tr bgcolor="#cceeff">
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Prepaid expenses and other current assets</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">14</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   </tr>
   <tr>
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Equipment and furnishings</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">11</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   </tr>
   <tr bgcolor="#cceeff">
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Goodwill</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">5,898</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   </tr>
   <tr>
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">In-process research and development</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">12,864</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   </tr>
   <tr bgcolor="#cceeff">
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Accounts payable</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">(931</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">)</font></td>
   </tr>
   <tr>
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Accrued expenses and other current liabilities</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">(143</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">)</font></td>
   </tr>
   <tr bgcolor="#cceeff">
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Notes payable</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">(1</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">)</font></td>
   </tr>
   <tr>
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Deferred tax liability, non-current</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">(5,053</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">)</font></td>
   </tr>
   <tr style="font-size:1px">
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   </tr>
   <tr bgcolor="#cceeff">
   <td valign="top">&#160;</td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">12,827</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   </tr>
   <tr style="font-size:1px">
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   </tr>
   <!-- End Table Body -->
   </table>
   <p style="line-height:8px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:10%">&#160;</p>
   <table style="border-collapse:collapse; text-align: left" border="0" cellpadding="0" cellspacing="0" width="100%">
   <tr>
   <td width="4%" valign="top" align="left"><font style="font-family:times new roman" size="2">(i)</font></td>
   <td align="left" valign="top"><font style="font-family:times new roman" size="2">The value of the Company&#8217;s common stock was based upon a per share value of $1.28, the closing price of the Company&#8217;s common stock as of the close of business
   on April&#160;13, 2011. </font></td>
   </tr>
   </table>
   <p style="font-size:1px;margin-top:12px;margin-bottom:0px">&#160;</p>
   <p style="margin-top:0px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">The estimated value of
   the earn-out consideration of $6.5 million originally recorded was based on the expected probability of achievement in the future of certain development and commercial milestones relating to the Company&#8217;s NeuVax product candidate and then
   applying a discount rate, based on a corporate debt interest rate index publicly issued, to the expected future payments. The expected timing of the milestones, the probability of success for each milestone and the discount rates applied are updated
   quarterly using the most current information to measure the contingent liability as of the reporting date. On January&#160;19, 2012, the first milestone of $1,000,000 of this contingent liability was triggered with the first patient enrolled in our
   Phase 3 PRESENT clinical trial of NeuVax for breast cancer. The Company issued 1,315,789 restricted shares of common stock in payment of the first milestone. The certificates evidencing the milestone shares have been deposited with a third party
   escrow agent. The milestone shares will be released to the Apthera shareholders from escrow if the issuance of the milestone shares is approved by the stockholders of the Company at our 2012 annual stockholders meeting. Since the release of the
   shares is subject to stockholder approval, the $1,000,000 has been recorded in accrued expenses and other current liabilities at March&#160;31, 2012 in the accompanying condensed consolidated balance sheet. </font></p>
   <p style="margin-top:12px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">If stockholder approval is obtained, the number of milestone shares will be subject to increase to the extent that $0.76 (<i>i.e</i>.,
   the closing price of the Company&#8217;s common stock as reported on The NASDAQ Capital Market on January&#160;18, 2012, the day prior to achievement of its first milestone, used for purposes of determining the number of milestone shares) is greater
   than the closing price of common stock as of the most recent trading day prior to the receipt of stockholder approval. Whether or not stockholder approval is obtained, in addition to the release from escrow of the milestone shares or the payment in
   cash of the initial milestone, as the case may be, the Company will pay concurrently to the former Apthera shareholders in cash an interest factor of ten percent (10%)&#160;per annum on the amount of the final milestone from February&#160;10, 2012
   through the day immediately prior to the release of the milestone shares from escrow or the cash payment, as the case may be, less certain legal fees of the stockholder representative to be paid or reimbursed by the Company. As of March&#160;31,
   2012, $13,699 of interest had been accrued on this note and is included in accrued expenses and other current liabilities in the accompanying condensed consolidated balance sheet. </font></p>
   <p style="margin-top:12px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">The increase in the fair value of the contingent liability during the three months ended March&#160;31, 2012 is $844,000, which was
   included in other income (expense) in the accompanying consolidated statements of expenses. The fair value of the contingent liability at March&#160;31, 2012 was $6,195,000. Of this amount, $898,000 was recorded as a current contingent liability.
   </font></p>
   <p style="margin-top:12px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">The following presents the pro forma net loss and pro forma net loss per common share for the three months ended
   March&#160;31, 2011: </font></p>
   <p style="font-size:12px;margin-top:0px;margin-bottom:0px">&#160;</p>
   <table cellspacing="0" cellpadding="0" width="92%" border="0" style="border-collapse:collapse; text-align: left" align="center">
   <!-- Begin Table Head -->
   <tr>
   <td width="87%">&#160;</td>
   <td valign="bottom" width="8%">&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   </tr>
   <tr>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>For the Three<br />Months&#160;Ended<br />March&#160;31,&#160;2011</b></font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   </tr>
   <!-- End Table Head -->
   <!-- Begin Table Body -->
   <tr bgcolor="#cceeff">
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Net loss</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">(4,397</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">)&#160;</font></td>
   </tr>
   <tr style="font-size:1px">
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   </tr>
   <tr>
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Net loss per common share</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">(0.17</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">)&#160;</font></td>
   </tr>
   <tr style="font-size:1px">
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   </tr>
   <tr bgcolor="#cceeff">
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Weighted average shares outstanding</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">25,290,260</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   </tr>
   <tr style="font-size:1px">
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   </tr>
   <!-- End Table Body -->
   </table>
<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 141<br><br> -Paragraph 51, 52<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 805<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6909870&amp;loc=d3e1500-128463<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 805<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6911361&amp;loc=d3e7000-128479<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 805<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6911361&amp;loc=d3e6927-128479<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 805<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6911361&amp;loc=d3e7008-128479<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 805<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6909870&amp;loc=d3e1490-128463<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 805<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6911361&amp;loc=d3e6996-128479<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 805<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6910749&amp;loc=d3e4922-128472<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 805<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6910749&amp;loc=d3e4934-128472<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 141R<br><br> -Appendix F<br><br> -Paragraph F4<br><br> -Subparagraph e<br><br><br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 805<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6910749&amp;loc=d3e4926-128472<br><br><br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 805<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6909870&amp;loc=d3e1383-128463<br><br><br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 805<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6909870&amp;loc=d3e1392-128463<br><br><br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 805<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6909870&amp;loc=d3e1497-128463<br><br><br><br>Reference 15: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 141R<br><br> -Paragraph 67-73<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 16: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 805<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 7<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6909870&amp;loc=d3e1524-128463<br><br><br><br>Reference 17: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Emerging Issues Task Force (EITF)<br><br> -Number 88-16<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 18: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 805<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6909870&amp;loc=d3e1486-128463<br><br><br><br>Reference 19: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 805<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6910749&amp;loc=d3e4845-128472<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_BusinessCombinationDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_BusinessCombinationsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EQKAG">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Unaudited) (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th">
          <div>Mar. 31, 2012</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
        <td class="nump">$ 8,701<span></span></td>
        <td class="nump">$ 11,433<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue', window );">Restricted cash</a></td>
        <td class="nump">101<span></span></td>
        <td class="nump">101<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses</a></td>
        <td class="nump">290<span></span></td>
        <td class="nump">276<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
        <td class="nump">9,092<span></span></td>
        <td class="nump">11,810<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Equipment and furnishings, net</a></td>
        <td class="nump">351<span></span></td>
        <td class="nump">393<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rxii_InProcessResearchDevelopment', window );">In-process research and development</a></td>
        <td class="nump">12,864<span></span></td>
        <td class="nump">12,864<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
        <td class="nump">5,898<span></span></td>
        <td class="nump">5,898<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepositsAssetsNoncurrent', window );">Deposits</a></td>
        <td class="nump">3<span></span></td>
        <td class="nump">3<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
        <td class="nump">28,208<span></span></td>
        <td class="nump">30,968<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
        <td class="nump">2,581<span></span></td>
        <td class="nump">2,155<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses and other current liabilities</a></td>
        <td class="nump">3,532<span></span></td>
        <td class="nump">2,984<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeaseObligationsCurrent', window );">Current maturities of capital lease obligations</a></td>
        <td class="nump">24<span></span></td>
        <td class="nump">35<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleNotesPayableCurrent', window );">Convertible notes payable, current</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">500<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rxii_FairValueOfWarrantsPotentiallySettleableInCash', window );">Fair value of warrants potentially settleable in cash</a></td>
        <td class="nump">20,357<span></span></td>
        <td class="nump">3,746<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rxii_CurrentContingentPurchasePriceConsideration', window );">Current contingent purchase price consideration</a></td>
        <td class="nump">898<span></span></td>
        <td class="nump">1,782<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
        <td class="nump">27,392<span></span></td>
        <td class="nump">11,202<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeaseObligationsNoncurrent', window );">Capital lease obligations, net of current maturities</a></td>
        <td class="nump">36<span></span></td>
        <td class="nump">32<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleLongTermNotesPayable', window );">Convertible notes payable, non-current</a></td>
        <td class="nump">1,000<span></span></td>
        <td class="nump">0<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent', window );">Deferred tax liability, non-current</a></td>
        <td class="nump">5,053<span></span></td>
        <td class="nump">5,053<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rxii_ContingentPurchasePriceConsiderationNetOfCurrentPortion', window );">Contingent purchase price consideration, net of current portion</a></td>
        <td class="nump">5,297<span></span></td>
        <td class="nump">4,569<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
        <td class="nump">38,778<span></span></td>
        <td class="nump">20,856<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' (deficit) equity:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.0001 par value; 5,000,000 shares authorized; no shares issued and outstanding</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.0001 par value; 125,000,000 shares authorized; 50,082,148 shares issued and 49,407,148 shares outstanding and 47,811,453 shares issued and 47,136,453 outstanding at March 31, 2012 and December 31, 2011, respectively</a></td>
        <td class="nump">5<span></span></td>
        <td class="nump">5<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
        <td class="nump">85,263<span></span></td>
        <td class="nump">81,184<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rxii_DeficitAccumulatedDuringDevelopmentalStage', window );">Deficit accumulated during the developmental stage</a></td>
        <td class="num">(91,989)<span></span></td>
        <td class="num">(67,228)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValue', window );">Less treasury shares at cost, 675,000 shares</a></td>
        <td class="num">(3,849)<span></span></td>
        <td class="num">(3,849)<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' (deficit) equity</a></td>
        <td class="num">(10,570)<span></span></td>
        <td class="nump">10,112<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
        <td class="nump">$ 28,208<span></span></td>
        <td class="nump">$ 30,968<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rxii_ContingentPurchasePriceConsiderationNetOfCurrentPortion">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Contingent purchase price consideration, net of current portion</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>rxii_ContingentPurchasePriceConsiderationNetOfCurrentPortion</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>rxii_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rxii_CurrentContingentPurchasePriceConsideration">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Current contingent purchase price consideration</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>rxii_CurrentContingentPurchasePriceConsideration</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>rxii_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rxii_DeficitAccumulatedDuringDevelopmentalStage">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Deficit accumulated during the developmental stage</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>rxii_DeficitAccumulatedDuringDevelopmentalStage</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>rxii_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rxii_FairValueOfWarrantsPotentiallySettleableInCash">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Fair value of warrants potentially settleable in cash</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>rxii_FairValueOfWarrantsPotentiallySettleableInCash</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>rxii_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rxii_InProcessResearchDevelopment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>In-process research and development</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>rxii_InProcessResearchDevelopment</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>rxii_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 19<br><br><br><br> -Subparagraph a<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.19(a))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccountsPayableCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 20<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.20)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccruedLiabilitiesCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 31<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.30(a)(1))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AdditionalPaidInCapitalCommonStock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Article 7<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 12<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br> -Section S99<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Publisher FASB<br><br><br><br> -Paragraph 1<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Concepts (CON)<br><br><br><br> -Number 6<br><br><br><br> -Paragraph 25<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 18<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.18)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_Assets</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6801-107765<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Section 45<br><br><br><br> -SubTopic 10<br><br><br><br> -Topic 210<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6676-107765<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Paragraph 1<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 9<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.9)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6676-107765<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AssetsCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AssetsCurrentAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeaseObligationsCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount equal to the present value (the principal) at the beginning of the lease term of minimum lease payments during the lease term (excluding that portion of the payments representing executory costs such as insurance, maintenance, and taxes to be paid by the lessor, together with any profit thereon) net of payments or other amounts applied to the principal, through the balance sheet date and due to be paid within one year (or one operating cycle, if longer) of the balance sheet date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 840<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6455398&amp;loc=d3e45280-112737<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 840<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6455314&amp;loc=d3e45023-112735<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 13<br><br><br><br> -Paragraph 7, 10, 13<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 19<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.20)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CapitalLeaseObligationsCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeaseObligationsNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount equal to the present value (the principal) at the beginning of the lease term of minimum lease payments during the lease term (excluding that portion of the payments representing executory costs such as insurance, maintenance, and taxes to be paid by the lessor, together with any profit thereon) net of payments or other amounts applied to the principal, through the balance sheet date and due to be paid more than one year (or one operating cycle, if longer) after the balance sheet date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 840<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6455314&amp;loc=d3e45023-112735<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.22)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 13<br><br><br><br> -Paragraph 7, 10, 13<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 22<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 840<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6455398&amp;loc=d3e45280-112737<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CapitalLeaseObligationsNoncurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the Entity may deposit additional funds at any time and also effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Compensating balance arrangements that do not legally restrict the withdrawal or usage of cash amounts may be reported as Cash and Cash Equivalents, while legally restricted deposits held as compensating balances against borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits are not generally reported as cash and cash equivalents. Includes cash and cash equivalents associated with the entity's continuing operations. Excludes cash and cash equivalents associated with the disposal group (and discontinued operation).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 1<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 95<br><br><br><br> -Paragraph 7<br><br><br><br> -Footnote 1<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 4<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3044-108585<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 95<br><br><br><br> -Paragraph 8, 9<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6676-107765<br><br><br><br><br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Cash<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br><br><br><br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 95<br><br><br><br> -Paragraph 7, 26<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Cash Equivalents<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CashAndCashEquivalentsAtCarryingValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 30<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleLongTermNotesPayable">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value as of the balance sheet date of long-term debt (with maturities initially due after one year or beyond the operating cycle if longer) identified as Convertible Notes Payable, excluding current portion. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 22<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.22)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ConvertibleLongTermNotesPayable</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleNotesPayableCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value as of the balance sheet date of the portion of long-term debt due within one year or the operating cycle if longer identified as Convertible Notes Payable. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 20<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.20)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ConvertibleNotesPayableCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>For entities that net deferred tax assets and tax liabilities, represents the net amount of deferred tax assets (after reduction for valuation allowance) and liabilities as of the balance sheet date, which result from applying the applicable enacted tax rate to net temporary differences and carryforwards pertaining to assets or liabilities that are classified as noncurrent in the financial statements, or that are expected to reverse after the next twelve months (or beyond the normal operating cycle, if longer). A temporary difference is a difference between the tax basis of an asset or liability and its carrying amount in the financial statements prepared in accordance with generally accepted accounting principles that will reverse in ensuing periods. In a classified statement of financial position, an enterprise separates deferred tax liabilities and assets into a current amount and a noncurrent amount. Deferred tax liabilities and assets are classified as current or noncurrent based on the classification of the related asset or liability for financial reporting. A deferred tax liability or asset that is not related to an asset or liability for financial reporting, including deferred tax assets related to carryforwards, are classified according to the expected reversal date of the temporary difference.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 740<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32537-109319<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 109<br><br><br><br> -Paragraph 41, 42, 43<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 740<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 4<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907571&amp;loc=d3e31917-109318<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 740<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 6<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907571&amp;loc=d3e31931-109318<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepositsAssetsNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment after one year or beyond the operating cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 17<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.17)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DepositsAssetsNoncurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying amount as of the balance sheet date, which is the cumulative amount paid and (if applicable) the fair value of any noncontrolling interest in the acquiree, adjusted for any amortization recognized prior to the adoption of any changes in generally accepted accounting principles (as applicable) and for any impairment charges, in excess of the fair value of net assets acquired in one or more business combination transactions.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 142<br><br><br><br> -Paragraph 45<br><br><br><br> -Subparagraph e<br><br><br><br> -Clause 1<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 142<br><br><br><br> -Paragraph 43<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 141R<br><br><br><br> -Paragraph 68<br><br><br><br> -Subparagraph l<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 142<br><br><br><br> -Paragraph 45<br><br><br><br> -Subparagraph e<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 141R<br><br><br><br> -Paragraph 34<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 350<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6905597&amp;loc=d3e13816-109267<br><br><br><br><br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 350<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6388280&amp;loc=d3e13770-109266<br><br><br><br><br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 141R<br><br><br><br> -Paragraph 72<br><br><br><br> -Subparagraph d<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_Goodwill</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.19-26)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_Liabilities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total of all Liabilities and Stockholders' Equity items (or Partners' Capital, as applicable), including the portion of equity attributable to noncontrolling interests, if any.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 32<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.32)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Article 7<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 25<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LiabilitiesAndStockholdersEquity</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 21<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.21)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LiabilitiesCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LiabilitiesCurrentAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 129<br><br><br><br> -Paragraph 2, 3, 4, 5, 6, 7, 8<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.3-04)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6959260&amp;loc=d3e187085-122770<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher AICPA<br><br><br><br> -Name Accounting Principles Board Opinion (APB)<br><br><br><br> -Number 12<br><br><br><br> -Paragraph 10<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.28)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 04<br><br><br><br> -Article 3<br><br><br><br><br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Article 5<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 29<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PreferredStockValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The total of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer, and the aggregate carrying amount of current assets, as of the balance sheet date, not separately presented elsewhere in the balance sheet. Current assets are expected to be realized or consumed within one year (or the normal operating cycle, if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 8<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher AICPA<br><br><br><br> -Name Accounting Research Bulletin (ARB)<br><br><br><br> -Number 43<br><br><br><br> -Section A<br><br><br><br> -Paragraph 4<br><br><br><br> -Chapter 3<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Section 45<br><br><br><br> -SubTopic 10<br><br><br><br> -Topic 210<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6676-107765<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Paragraph 1<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PrepaidExpenseAndOtherAssetsCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tangible assets that are held by an entity for use in the production or supply of goods and services, for rental to others, or for administrative purposes and that are expected to provide economic benefit for more than one year; net of accumulated depreciation. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.13)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Article 7<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 8<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 13<br><br><br><br> -Subparagraph a<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 12<br><br><br><br> -Paragraph 5<br><br><br><br> -Subparagraph b, c<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 360<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PropertyPlantAndEquipmentNet</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The carrying amounts of cash and cash equivalent items which are restricted as to withdrawal or usage. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or entity statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits. Excludes compensating balance arrangements that are not agreements which legally restrict the use of cash amounts shown on the balance sheet. For a classified balance sheet represents the current portion only (the noncurrent portion has a separate concept); there is a separate and distinct element for unclassified presentations.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 1<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher AICPA<br><br><br><br> -Name Audit and Accounting Guide (AAG)<br><br><br><br> -Number AAG-BRD<br><br><br><br> -Chapter 4<br><br><br><br> -Paragraph 80<br><br><br><br> -Subparagraph Exhibit 4-8, 3<br><br><br><br> -IssueDate 2006-05-01<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29-31)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher AICPA<br><br><br><br> -Name Accounting Research Bulletin (ARB)<br><br><br><br> -Number 51<br><br><br><br> -Paragraph A3<br><br><br><br> -Appendix A<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 29, 30, 31<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Staff Accounting Bulletin (SAB)<br><br><br><br> -Number Topic 4<br><br><br><br> -Section E<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 310<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SAB TOPIC 4.E)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6228006&amp;loc=d3e74512-122707<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockholdersEquity</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockholdersEquityAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name FASB Technical Bulletin (FTB)<br><br><br><br> -Number 85-6<br><br><br><br> -Paragraph 3<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 4<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23315-112656<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_TreasuryStockValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Description of Business and Basis of Presentation<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Description of Business and Basis of Presentation [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock', window );">Description of Business and Basis of Presentation</a></td>
        <td class="text"><!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
   <!-- Begin Block Tagged Note 1 - us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock-->
   <!-- xbrl,ns -->
   <!-- xbrl,nx -->
   <font style="font-family:times new roman" size="2"><b></b></font>
   <font style="font-family:times new roman" size="2"><b></b></font>
   <font style="font-family:times new roman" size="2">
   <b></b></font>
   <font style="font-family:times new roman" size="2"><b>
   </b></font>
   <p style="margin-top:12px;margin-bottom:0px"><font style="font-family:times new roman" size="2"><b>1. Description of Business and Basis of Presentation </b></font></p>
   <p style="margin-top:6px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">Galena Biopharma, Inc. (&#8220;we,&#8221; &#8220;us,&#8221; &#8220;our,&#8221; &#8220;Galena&#8221; or the &#8220;Company&#8221;)
   is a biopharmaceutical company focused on developing innovative, next-generation cancer immunotherapies which address major unmet medical needs to advance care. Galena is developing innovative, peptide antigen-based &#8220;off the shelf&#8221; cancer
   immunotherapies for potential application to treatment of large populations of Cancer Survivors. Peptide vaccines have several potential clinical advantages over existing cancer treatments including excellent safety profiles, long-lasting protection
   through immune system activation, as well as an acceptable mode of administration (intradermal injection). A key differentiator in Galena&#8217;s approach is the focus on &#8220;minimal residual disease&#8221; that may remain in Cancer Survivors. The
   strategy is to prevent recurrence in early stage patient groups who may harbor &#8220;occult&#8221; residual cancer cells that are not detectable by current imaging and biomarkers, and despite adjuvant therapy and radiation therapy will relapse in
   significant numbers over time. </font></p>
   <p style="margin-top:12px;margin-bottom:0px; text-indent:4%;padding-bottom:0px;"><font style="font-family:times new roman" size="2">Our lead product candidate, NeuVax<font style="font-family:times new roman" size="1">
   <sup>&#8482;</sup></font> (E75), targets the HER2 tumor associated antigen peptide and is being developed to prevent or delay breast cancer
   recurrence in a Phase 3 clinical trial under an FDA approved SPA (Special Protocol Assessment) and in combination with
   Herceptin<b><font style="font-family:times new roman" size="1"><sup>&reg;</sup></font></b> (trastuzumab: Genentech/Roche) in a Phase 2 clinical trial. Our second product candidate,
   Folate Binding Protein (FBP), a targeted vaccine which consists of the E39 peptide over-expressed (20-80 fold) in more than 90% of ovarian and endometrial cancers, is currently in a Phase 1 clinical trial. </font></p>
   <p style="margin-top:12px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">The Company was incorporated as Argonaut Pharmaceuticals, Inc., in Delaware, on April&#160;3, 2006. The Company changed its name to RXi
   Pharmaceuticals Corporation on November&#160;28, 2006. </font></p>
   <p style="margin-top:12px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">We acquired Apthera Inc., or &#8220;Apthera,&#8221; and our NeuVax
   product candidate in April 2011. Prior to that time, we were engaged primarily in conducting discovery research and preclinical development activities based on RNAi. Our acquisition of Apthera followed from the determination by our board of
   directors to broaden our strategic direction by giving us access to a late-stage clinical candidate, NeuVax. In connection with our acquisition of Apthera, we reduced the scope of our RNAi activities. </font></p>
   <p style="margin-top:12px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">On September&#160;26, 2011, the Company changed its name from RXi Pharmaceuticals Corporation to Galena Biopharma, Inc. in connection
   with the Company&#8217;s separation into two companies: (i)&#160;Galena, which will operate as a late-stage oncology drug development company; and (ii)&#160;RXi Pharmaceuticals Corporation, or RXi, which will continue to develop novel RNAi-based
   therapies utilizing our historical RNAi assets. RXi was initially incorporated as RNCS, Inc. and assumed the name RXi Pharmaceuticals Corporation in conjunction with the change in the Company&#8217;s name to Galena. On April 27, 2012, the planned
   spin-out of RXi was completed (See Note 4). </font></p>
   <p style="margin-top:12px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">The Company has not generated any revenue from inception through March&#160;31,
   2012 and is considered a development-stage company for accounting purposes. The Company may not generate product revenue in the foreseeable future, if ever. The Company expects to incur significant operating losses as it advances its product
   candidates through the drug development and regulatory process. The Company expects to continue to devote a substantial portion of its resources to research and development programs. As a result of the costs expected to be incurred in connection
   with our recently commenced clinical trials of NeuVax and FBP, the Company expects that our research and development expense will increase significantly from historic levels for the foreseeable future. The Company will need to generate significant
   revenue to achieve profitability and might never do so. In the absence of product revenue, our potential sources of operational funding are expected to be the proceeds from equity financings, funded research and development payments and payments
   received under partnership and collaborative agreements. There is no guarantee that additional funding will be available to the Company on acceptable terms, or at all. If the Company fails to obtain additional funding when needed, it would be forced
   to scale back or terminate operations or to seek to merge with or to be acquired by another company. </font></p>
   <p style="margin-top:18px;margin-bottom:0px"><font style="font-family:times new roman" size="2"><i>Use of Estimates </i></font></p>
   <p style="margin-top:6px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">The preparation of consolidated financial statements in accordance with accounting principles generally accepted in the United States of
   America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses
   during the reporting period. Actual results could differ from these estimates. </font></p>
   <p style="margin-top:18px;margin-bottom:0px"><font style="font-family:times new roman" size="2"><i>Derivative Financial Instruments </i></font></p>
   <p style="margin-top:6px;margin-bottom:0px"><font style="font-family:times new roman" size="2">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;During the normal course of business, from time to time, the Company issues warrants and options to
   vendors as consideration to perform services. It may also issue warrants as part of financing transactions. The Company does not enter into any derivative contracts for speculative purposes. The Company recognizes all derivatives, including
   warrants, as assets or liabilities measured at fair value with changes in fair value of derivatives reflected as current period income or loss unless the derivatives qualify for hedge accounting and are accounted for as such. In accordance with
   Financial Accounting Standards Board (&#8220;FASB&#8221;) Accounting Standards Codification (&#8220;ASC&#8221;) Topic 815-40, &#8220;<i>Derivatives and Hedging &#8212; Contracts in Entity&#8217;s Own Stock</i>&#8221;, the value of some of our warrants is
   required to be recorded as a liability, as the holders have an option to put the warrants back to the Company in specified events (see Note 9). </font></p>
   <p style="margin-top:18px;margin-bottom:0px"><font style="font-family:times new roman" size="2"><i>Principles of Consolidation </i></font></p>
   <p style="margin-top:6px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">
   The consolidated financial statements include the accounts of Galena and its consolidated subsidiaries. All material intercompany accounts have been eliminated in consolidation. </font></p>
   <p style="margin-top:18px;margin-bottom:0px"><font style="font-family:times new roman" size="2"><i>Comprehensive Loss </i></font></p>
   <p style="margin-top:6px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">The
   Company&#8217;s comprehensive loss is equal to its net loss for all periods presented. </font></p>
   <p style="font-size:1px;margin-top:18px;margin-bottom:0px">&#160;</p>
<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccountingPoliciesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for the general note to the financial statements for the reporting entity which may include, descriptions of the basis of presentation, business description, significant accounting policies, consolidations, reclassifications, new pronouncements not yet adopted and changes in accounting principles.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/**
 * Rivet Software Inc.
 *
 * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved.
 * Version 2.1.0.1
 *
 */

var moreDialog = null;
var Show = {
    Default:'raw',

    more:function( obj ){
        var bClosed = false;
        if( moreDialog != null )
        {
			try
			{
				bClosed = moreDialog.closed;
			}
			catch(e)
			{
				//Per article at http://support.microsoft.com/kb/244375 there is a problem with the WebBrowser control
				// that somtimes causes it to throw when checking the closed property on a child window that has been
				//closed.  So if the exception occurs we assume the window is closed and move on from there.
				bClosed = true;
			}

			if( !bClosed ){
				moreDialog.close();
			}
        }

        obj = obj.parentNode.getElementsByTagName( 'pre' )[0];
		var hasHtmlTag = false;
		var objHtml = '';
		var raw = '';

		//Check for raw HTML
		var nodes = obj.getElementsByTagName( '*' );
		if( nodes.length ){
			objHtml = obj.innerHTML;
		}else{
			if( obj.innerText ){
				raw = obj.innerText;
			}else{
				raw = obj.textContent;
			}

			var matches = raw.match( /<\/?[a-zA-Z]{1}\w*[^>]*>/g );
			if( matches && matches.length ){
				objHtml = raw;

				//If there is an html node it will be 1st or 2nd,
				//   but we can check a little further.
				var n = Math.min( 5, matches.length );
				for( var i = 0; i < n; i++ ){
					var el = matches[ i ].toString().toLowerCase();
					if( el.indexOf( '<html' ) >= 0 ){
						hasHtmlTag = true;
						break;
					}
				}
			}
		}

        if( objHtml.length ){
			var html = '';

			if( hasHtmlTag ){
				html = objHtml;
			}else{
				html = '<html>'+
					"\n"+'<head>'+
					"\n"+'    <title>Report Preview Details</title>'+
					"\n"+'    <style type="text/css">'+
					"\n"+'    body {'+
					"\n"+'    }'+
					"\n"+'    table {'+
					"\n"+'    }'+
					"\n"+'    </style>'+
					"\n"+'</head>'+
					"\n"+'<body>'+
						objHtml +
					"\n"+'</body>'+
					"\n"+'</html>';
			}

			moreDialog = window.open("","More","width=700,height=650,status=0,resizable=yes,menubar=no,toolbar=no,scrollbars=yes");
			moreDialog.document.write( html );
			moreDialog.document.close();

			if( !hasHtmlTag ){
				moreDialog.document.body.style.margin = '0.5em';
			}
        }
        else
        {
			//default view logic
			var lines = raw.split( "\n" );
			var longest = 0;

			if( lines.length > 0 ){
				for( var p = 0; p < lines.length; p++ ){
					longest = Math.max( longest, lines[p].length );
				}
			}

			//Decide on the default view
			this.Default = longest < 120 ? 'raw' : 'formatted';

			//Build formatted view
			var text = raw.split( "\n\n" ) >= raw.split( "\r\n\r\n" ) ? raw.split( "\n\n" ) : raw.split( "\r\n\r\n" ) ;
			var formatted = '';

			if( text.length > 0 ){
				if( text.length == 1 ){
					text = raw.split( "\n" ) >= raw.split( "\r\n" ) ? raw.split( "\n" ) : raw.split( "\r\n" ) ;
					formatted = "<p>"+ text.join( "<br /><br />\n" ) +"</p>";
				}else{
					for( var p = 0; p < text.length; p++ ){
						formatted += "<p>" + text[p] + "</p>\n";
					}
				}
			}else{
				formatted = '<p>' + raw + '</p>';
			}

			html = '<html>'+
				"\n"+'<head>'+
				"\n"+'    <title>Report Preview Details</title>'+
				"\n"+'    <style type="text/css">'+
				"\n"+'    body {'+
				"\n"+'       background-color: #f0f9ee;'+
				"\n"+'       font-family: Arial, san-serif; font-size: 0.8em;'+
				"\n"+'    }'+
				"\n"+'    table {'+
				"\n"+'       font-size: 1em;'+
				"\n"+'    }'+
				"\n"+'    </style>'+
				"\n"+'</head>'+
				"\n"+'<body>'+
				"\n"+'    <table border="0" width="100%">'+
				"\n"+'    <tr>'+
				"\n"+'        <td>'+
				"\n"+'            formatted: <a href="javascript:void(0);" onclick="opener.Show.toggle( window, this );">'+ ( this.Default == 'raw' ? 'as Filed' : 'with Text Wrapped' ) +'</a>'+
				"\n"+'        </td>'+
				"\n"+'    </tr>'+
				"\n"+'    <tr>'+
				"\n"+'        <td>'+
				"\n"+'            <div id="formatted" style="display: none;">'+formatted+'</div>'+
				"\n"+'        </td>'+
				"\n"+'    </tr>'+
				"\n"+'    <tr>'+
				"\n"+'        <td>'+
				"\n"+'            <pre id="raw" style="display: none; font-size: 1.2em;">'+raw+'</pre>'+
				"\n"+'        </td>'+
				"\n"+'    </tr>'+
				"\n"+'    </table>'+
				"\n"+'</body>'+
				"\n"+'</html>';

			moreDialog = window.open("","More","width=700,height=650,status=0,resizable=yes,menubar=no,toolbar=no,scrollbars=yes");
			moreDialog.document.write(html);
			moreDialog.document.close();

			this.toggle( moreDialog );
        }

		moreDialog.document.title = 'Report Preview Details';
    },

    toggle:function( win, domLink ){
        var domId = this.Default;

        var doc = win.document;
        var domEl = doc.getElementById( domId );
        domEl.style.display = 'block';

        this.Default = domId == 'raw' ? 'formatted' : 'raw';

        if( domLink ){
            domLink.innerHTML = this.Default == 'raw' ? 'with Text Wrapped' : 'as Filed';
        }

        var domElOpposite = doc.getElementById( this.Default );
        domElOpposite.style.display = 'none';
    },

	LastAR : null,
	showAR : function ( link, id, win ){
		if( Show.LastAR ){
			Show.hideAR();
		}

		var ref = link;
		do {
			ref = ref.nextSibling;
		} while (ref && ref.nodeName != 'TABLE');

		if (!ref || ref.nodeName != 'TABLE') {
			var tmp = win ?
				win.document.getElementById(id) :
				document.getElementById(id);

			if( tmp ){
				ref = tmp.cloneNode(true);
				ref.id = '';
				link.parentNode.appendChild(ref);
			}
		}

		if( ref ){
			ref.style.display = 'block';
			Show.LastAR = ref;
		}
	},

	toggleNext : function( link ){
		var ref = link;

		do{
			ref = ref.nextSibling;
		}while( ref.nodeName != 'DIV' );

		if( ref.style &&
			ref.style.display &&
			ref.style.display == 'none' ){
			ref.style.display = 'block';

			if( link.textContent ){
				link.textContent = link.textContent.replace( '+', '-' );
			}else{
				link.innerText = link.innerText.replace( '+', '-' );
			}
		}else{
			ref.style.display = 'none';

			if( link.textContent ){
				link.textContent = link.textContent.replace( '-', '+' );
			}else{
				link.innerText = link.innerText.replace( '-', '+' );
			}
		}
	},

	hideAR : function(){
		Show.LastAR.style.display = 'none';
	}
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Recent Accounting Pronouncements<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingChangesAndErrorCorrectionsAbstract', window );"><strong>Recent Accounting Pronouncements [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingChangesAndErrorCorrectionsTextBlock', window );">Recent Accounting Pronouncements</a></td>
        <td class="text"><!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
   <!-- Begin Block Tagged Note 2 - us-gaap:AccountingChangesAndErrorCorrectionsTextBlock-->
   <p style="margin-top:0px;margin-bottom:0px"><font style="font-family:times new roman" size="2"><b>2. Recent Accounting Pronouncements </b></font></p>
   <p style="margin-top:6px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2"><i></i>In May&#160;2011, the FASB issued Accounting Standards Updated (&#8220;ASU&#8221;) 2011-04<i>, Fair Value
   Measurement</i> (Topic 820): <i>Amendments to Achieve Common Fair Value Measurement and Disclosure Requirements in U.S. GAAP and IFRSs</i>, a new accounting standard that clarifies the application of certain existing fair value measurement guidance
   and expands the disclosures for fair value measurements that are estimated using significant unobservable (Level 3) inputs. This new standard is effective on a prospective basis for annual and interim reporting periods beginning on or after
   December&#160;15, 2011. The Company&#8217;s adoption of this new standard did not have a material impact on the Company&#8217;s consolidated financial statements. </font></p>
   <p style="margin-top:12px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">
   <i></i>In June&#160;2011, the FASB issued ASU 2011-05, <i>Comprehensive Income</i> (Topic 220): <i>Presentation of Comprehensive Income</i>, a new accounting standard that eliminates the option to present
   the components of other comprehensive income as part of the statement of changes in stockholders&#8217; equity, requires the consecutive presentation of the statement of net income and other comprehensive income and requires an entity to present
   reclassification adjustments on the face of the financial statements from other comprehensive income to net income. The amendments in this new standard do not change the items that must be reported in other comprehensive income or when an item of
   other comprehensive income must be reclassified to net income nor do the amendments affect how earnings per share is calculated or presented. This new standard is required to be applied retrospectively and is effective for fiscal years and interim
   periods within those years beginning after December&#160;15, 2011. As this new standard only requires enhanced disclosure, the adoption of this standard did not impact the Company&#8217;s consolidated financial statements. </font></p>
<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingChangesAndErrorCorrectionsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccountingChangesAndErrorCorrectionsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingChangesAndErrorCorrectionsTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for reporting accounting changes and error corrections. It includes the conveyance of information necessary for a user of the Company's financial information to understand all aspects and required disclosure information concerning all changes and error corrections reported in the Company's financial statements for the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 250<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SAB TOPIC 1.N.Q3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6369664&amp;loc=d3e30840-122693<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 250<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 23<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6368906&amp;loc=d3e21914-107793<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 154<br><br> -Paragraph 17, 22, 25, 26<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 250<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6801783&amp;loc=d3e22499-107794<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 1<br><br> -Section N<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 250<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6801783&amp;loc=d3e22595-107794<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 250<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 7<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6801783&amp;loc=d3e22644-107794<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccountingChangesAndErrorCorrectionsTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EAAAE">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) (USD $)<br></strong></div>
        </th>
        <th class="th">
          <div>Mar. 31, 2012</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Condensed Consolidated Balance Sheets [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
        <td class="nump">$ 0.0001<span></span></td>
        <td class="nump">$ 0.0001<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
        <td class="nump">5,000,000<span></span></td>
        <td class="nump">5,000,000<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
        <td class="nump">$ 0.0001<span></span></td>
        <td class="nump">$ 0.0001<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
        <td class="nump">125,000,000<span></span></td>
        <td class="nump">125,000,000<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
        <td class="nump">50,082,148<span></span></td>
        <td class="nump">47,811,453<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
        <td class="nump">49,407,148<span></span></td>
        <td class="nump">47,136,453<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockShares', window );">Treasury stock, shares</a></td>
        <td class="nump">675,000<span></span></td>
        <td class="nump">675,000<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Face amount or stated value of common stock per share; generally not indicative of the fair market value per share.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 129<br><br> -Paragraph 4<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockParOrStatedValuePerShare</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockSharesAuthorized</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockSharesIssued</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total number of shares of common stock held by shareholders. May be all or portion of the number of common shares authorized. These shares represent the ownership interest of the common shareholders. Shares outstanding equals shares issued minus shares held in treasury and other adjustments, if any.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6959260&amp;loc=d3e187085-122770<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 12<br><br> -Paragraph 10<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockSharesOutstanding</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Face amount or stated value per share of nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer); generally not indicative of the fair market value per share.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 12<br><br> -Paragraph 10<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Article 5<br><br> -Section 02<br><br> -Paragraph 29<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 129<br><br> -Paragraph 2, 3, 4, 5, 6, 7, 8<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PreferredStockParOrStatedValuePerShare</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Article 5<br><br> -Section 02<br><br> -Paragraph 29<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 129<br><br> -Paragraph 2, 3, 4, 5, 6, 7, 8<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PreferredStockSharesAuthorized</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Article 5<br><br> -Section 02<br><br> -Paragraph 29<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PreferredStockSharesIssued</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Article 5<br><br> -Section 02<br><br> -Paragraph 29<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PreferredStockSharesOutstanding</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StatementOfFinancialPositionAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockShares">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28,29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_TreasuryStockShares</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EQAAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Document and Entity Information<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
        <th class="th" colspan="1"></th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2012</div>
        </th>
        <th class="th">
          <div>May 11, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rxii_DocumentAndEntityInformationAbstract', window );"><strong>Document and Entity Information [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
        <td class="text">Galena Biopharma, Inc.<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
        <td class="text">0001390478<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
        <td class="text">10-Q<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
        <td class="text">Mar. 31,
         2012<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
        <td class="text">false<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
        <td class="text">2012<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
        <td class="text">Q1<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
        <td class="text">--12-31<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
        <td class="text">Smaller Reporting Company<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">65,643,905<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>If the value is true, then the document as an amendment to previously-filed/accepted document.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_AmendmentFlag</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:booleanItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>End date of current fiscal year in the format --MM-DD.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_CurrentFiscalYearEndDate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:gMonthDayItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_DocumentFiscalPeriodFocus</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:fiscalPeriodItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_DocumentFiscalYearFocus</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:gYearItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_DocumentPeriodEndDate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:dateItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The type of document being provided (such as 10-K, 10-Q, N-1A, etc). The document type is limited to the same value as the supporting SEC submission type, minus any "/A" suffix. The acceptable values are as follows: S-1, S-3, S-4, S-11, F-1, F-3, F-4, F-9, F-10, 6-K, 8-K, 10, 10-K, 10-Q, 20-F, 40-F, N-1A, 485BPOS, 497, NCSR, N-CSR, N-CSRS, N-Q, 10-KT, 10-QT, 20-FT, POS AM and Other.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_DocumentType</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:submissionTypeItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation 12B<br><br> -Number 240<br><br> -Section 12b<br><br> -Subsection 1<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityCentralIndexKey</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:centralIndexKeyItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Indicate number of shares outstanding of each of registrant's classes of common stock, as of latest practicable date. Where multiple classes exist define each class by adding class of stock items such as Common Class A [Member], Common Class B [Member] onto the Instrument [Domain] of the Entity Listings, Instrument</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityCommonStockSharesOutstanding</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, or (4) Smaller Reporting Company. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityFilerCategory</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:filerCategoryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation 12B<br><br> -Number 240<br><br> -Section 12b<br><br> -Subsection 1<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityRegistrantName</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:normalizedStringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rxii_DocumentAndEntityInformationAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>rxii_DocumentAndEntityInformationAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>rxii_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EK5AE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Condensed Consolidated Statements of Expenses (Unaudited) (USD $)<br>In Thousands, except Share data, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="2">3 Months Ended</th>
        <th class="th" colspan="1">111 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2012</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2011</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Expenses:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development expense</a></td>
        <td class="nump">$ 3,392<span></span></td>
        <td class="nump">$ 1,941<span></span></td>
        <td class="nump">$ 40,817<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rxii_ResearchAndDevelopmentEmployeeStockBasedCompensationExpense', window );">Research and development employee stock-based compensation expense</a></td>
        <td class="nump">72<span></span></td>
        <td class="nump">246<span></span></td>
        <td class="nump">3,345<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rxii_ResearchAndDevelopmentNonEmployeeStockBasedCompensationExpense', window );">Research and development non-employee stock-based compensation expense (income)</a></td>
        <td class="nump">157<span></span></td>
        <td class="num">(31)<span></span></td>
        <td class="nump">6,150<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rxii_FairValueOfCommonStockInExchangeForResearchAndDevelopmentExpenses', window );">Fair value of common stock issued in exchange for research and development expense</a></td>
        <td class="nump">50<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">4,004<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Total research and development expense</a></td>
        <td class="nump">3,671<span></span></td>
        <td class="nump">2,156<span></span></td>
        <td class="nump">54,316<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rxii_GeneralAndAdministrativeExpenses', window );">General and administrative expense</a></td>
        <td class="nump">1,458<span></span></td>
        <td class="nump">1,921<span></span></td>
        <td class="nump">29,431<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rxii_GeneralAndAdministrativeEmployeeStockBasedCompensation', window );">General and administrative employee stock-based compensation expense</a></td>
        <td class="nump">198<span></span></td>
        <td class="nump">1,099<span></span></td>
        <td class="nump">9,788<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rxii_FairValueOfCommonStockWarrantsIssuedForGeneralAndAdministrativeExpenses', window );">Fair value of common stock warrants issued for general and administrative expense</a></td>
        <td class="nump">148<span></span></td>
        <td class="nump">76<span></span></td>
        <td class="nump">2,550<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rxii_FairValueOfCommonStockIssuedInExchangeForGeneralAndAdministrativeExpenses', window );">Fair value of common stock issued in exchange for general and administrative expense</a></td>
        <td class="nump">135<span></span></td>
        <td class="nump">23<span></span></td>
        <td class="nump">489<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">Total general and administrative expense</a></td>
        <td class="nump">1,939<span></span></td>
        <td class="nump">3,119<span></span></td>
        <td class="nump">42,258<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Operating loss</a></td>
        <td class="num">(5,610)<span></span></td>
        <td class="num">(5,275)<span></span></td>
        <td class="num">(96,574)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rxii_InterestIncome', window );">Interest (expense) income</a></td>
        <td class="num">(37)<span></span></td>
        <td class="num">(1)<span></span></td>
        <td class="nump">621<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other (expense) income</a></td>
        <td class="num">(19,114)<span></span></td>
        <td class="nump">1,435<span></span></td>
        <td class="num">(6,077)<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
        <td class="num">$ (24,761)<span></span></td>
        <td class="num">$ (3,841)<span></span></td>
        <td class="num">$ (102,030)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net loss per common share:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Basic and diluted loss per share</a></td>
        <td class="num">$ (0.52)<span></span></td>
        <td class="num">$ (0.19)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Weighted average common shares outstanding:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rxii_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Basic and diluted</a></td>
        <td class="nump">47,967,499<span></span></td>
        <td class="nump">20,316,170<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rxii_FairValueOfCommonStockInExchangeForResearchAndDevelopmentExpenses">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Fair value of common stock issued in exchange for research and development expense</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>rxii_FairValueOfCommonStockInExchangeForResearchAndDevelopmentExpenses</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>rxii_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rxii_FairValueOfCommonStockIssuedInExchangeForGeneralAndAdministrativeExpenses">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Fair value of common stock issued in exchange for general and administrative expense</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>rxii_FairValueOfCommonStockIssuedInExchangeForGeneralAndAdministrativeExpenses</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>rxii_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rxii_FairValueOfCommonStockWarrantsIssuedForGeneralAndAdministrativeExpenses">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Fair value of common stock warrants issued for general and administrative expense</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>rxii_FairValueOfCommonStockWarrantsIssuedForGeneralAndAdministrativeExpenses</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>rxii_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rxii_GeneralAndAdministrativeEmployeeStockBasedCompensation">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>General and administrative employee stock-based compensation expense</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>rxii_GeneralAndAdministrativeEmployeeStockBasedCompensation</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>rxii_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rxii_GeneralAndAdministrativeExpenses">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>General and administrative expense</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>rxii_GeneralAndAdministrativeExpenses</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>rxii_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rxii_InterestIncome">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Interest (expense) income</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>rxii_InterestIncome</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>rxii_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rxii_ResearchAndDevelopmentEmployeeStockBasedCompensationExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Research and development employee stock-based compensation expense</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>rxii_ResearchAndDevelopmentEmployeeStockBasedCompensationExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>rxii_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rxii_ResearchAndDevelopmentNonEmployeeStockBasedCompensationExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Research and development non-employee stock-based compensation expense (income)</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>rxii_ResearchAndDevelopmentNonEmployeeStockBasedCompensationExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>rxii_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rxii_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Basic and diluted</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>rxii_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>rxii_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EarningsPerShareAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EarningsPerShareBasicAndDiluted</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.4)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_GeneralAndAdministrativeExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.22)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.18)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph 38<br><br> -Subparagraph a<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 220<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6920043&amp;loc=d3e565-108580<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph A7<br><br> -Appendix A<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 130<br><br> -Paragraph 10, 15<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Other Comprehensive Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6519514<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph 38<br><br> -Subparagraph d<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Emerging Issues Task Force (EITF)<br><br> -Number 87-21<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Net Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6518256<br><br><br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.19)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Article 5<br><br> -Section 03<br><br> -Paragraph 19<br><br><br><br>Reference 15: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28, 29, 30<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 16: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 20<br><br> -Article 9<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetIncomeLoss</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OperatingExpenses</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OperatingExpensesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The net amount of other income and expense amounts, the components of which are not separately disclosed on the income statement, resulting from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business) also known as other nonoperating income (expense) recognized for the period. Such amounts may include: (a) dividends, (b) interest on securities, (c) net gains or losses on securities, (d) unusual costs, (e) gains or losses on foreign exchange transactions, and (f) miscellaneous other income and expense items.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Article 5<br><br> -Section 03<br><br> -Paragraph 9<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.9)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OtherNonoperatingIncomeExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 985<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 730<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 141<br><br> -Paragraph 51<br><br> -Subparagraph g<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 2<br><br> -Paragraph 12, 13<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 86<br><br> -Paragraph 11, 12<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ResearchAndDevelopmentExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 730<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Research and Development<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6523717<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 86<br><br> -Paragraph 11<br><br> -Subparagraph b<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 86<br><br> -Paragraph 3<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 2<br><br> -Paragraph 8, 12, 13<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Net Loss Per Share<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net Loss Per Share [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss Per Share</a></td>
        <td class="text"><!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
   <!-- Begin Block Tagged Note 7 - us-gaap:EarningsPerShareTextBlock-->
   <p style="margin-top:18px;margin-bottom:0px"><font style="font-family:times new roman" size="2"><b>7. Net Loss Per Share </b></font></p>
   <p style="margin-top:6px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">The Company accounts for and discloses net loss per common share in accordance with FASB ASC Topic 260 &#8220;
   <i>Earnings per Share.&#8221;</i> Basic net loss per common share is computed by dividing net loss attributable to common stockholders by the weighted average number of common shares outstanding. Diluted net loss per common share is computed by
   dividing net loss attributable to common stockholders by the weighted average number of common shares that would have been outstanding during the period assuming the issuance of common shares for all potential dilutive common shares outstanding.
   Potential common shares consist of shares issuable upon the exercise of stock options and warrants. Because the inclusion of potential common shares would be anti-dilutive for all periods presented diluted net loss per common share is the same as
   basic net loss per common share. </font></p>
   <p style="margin-top:12px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">The following table sets forth the potential common shares excluded from the calculation of
   net loss per common share because their inclusion would be anti-dilutive: </font></p>
   <p style="font-size:12px;margin-top:0px;margin-bottom:0px">&#160;</p>
   <table cellspacing="0" cellpadding="0" width="100%" border="0" style="border-collapse:collapse; text-align: left" align="center">
   <!-- Begin Table Head -->
   <tr>
   <td width="82%">&#160;</td>
   <td valign="bottom" width="1%">&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   <td valign="bottom" width="1%">&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   </tr>
   <tr>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom" colspan="6" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>March&#160;31,</b></font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   </tr>
   <tr>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>2012</b></font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>2011</b></font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   </tr>
   <!-- End Table Head -->
   <!-- Begin Table Body -->
   <tr bgcolor="#cceeff">
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Options to purchase common stock</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">7,438,137</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">6,065,264</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   </tr>
   <tr>
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Warrants to purchase common stock</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">13,116,698</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">8,250,642</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   </tr>
   <tr style="font-size:1px">
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   </tr>
   <tr bgcolor="#cceeff">
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Total</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">20,554,835</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">14,315,906</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   </tr>
   <tr style="font-size:1px">
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   </tr>
   <!-- End Table Body -->
   </table>
<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EarningsPerShareAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for earnings per share.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6920599&amp;loc=d3e1252-109256<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 55<br><br> -Paragraph 52<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6945512&amp;loc=d3e4984-109258<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 128<br><br> -Paragraph 40<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6920599&amp;loc=d3e1278-109256<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.21)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EarningsPerShareTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Stock Based Compensation<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Stock Based Compensation [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock Based Compensation</a></td>
        <td class="text"><!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
   <!-- Begin Block Tagged Note 6 - us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-->
   <p style="margin-top:18px;margin-bottom:0px"><font style="font-family:times new roman" size="2"><b>6. Stock Based Compensation </b></font></p>
   <p style="margin-top:6px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">The Company follows the provisions of the FASB ASC Topic 718, &#8220;<i>Compensation &#8212; Stock Compensation</i>&#8221;
   (&#8220;ASC 718&#8221;), which requires the measurement and recognition of compensation expense for all share-based payment awards made to employees, non-employee directors, and consultants, including employee stock options. Stock compensation expense
   based on the grant date fair value estimated in accordance with the provisions of ASC 718 is recognized as an expense over the requisite service period. </font></p>
   <p style="margin-top:12px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">
   For stock options granted as consideration for services rendered by non-employees, the Company recognizes compensation expense in accordance with the requirements of FASB ASC Topic 505-50, &#8220;<i>Equity
   Based Payments to Non-Employees.&#8221;</i> </font></p>
   <p style="margin-top:12px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">Non-employee option grants that do not vest immediately upon grant are recorded as
   an expense over the vesting period of the underlying stock options. At the end of each financial reporting period prior to vesting, the value of these options, as calculated using the Black-Scholes option-pricing model, will be re-measured using the
   fair value of the Company&#8217;s common stock and the non-cash compensation recognized during the period will be adjusted accordingly. Since the fair market value of options granted to non-employees is subject to change in the future, the amount of
   the future compensation expense will include fair value re-measurements until the stock options are fully vested. </font></p>
   <p style="font-size:1px;margin-top:12px;margin-bottom:0px">&#160;</p>
   <p style="margin-top:0px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">The Company is
   currently using the Black-Scholes option-pricing model to determine the fair value of all its option grants. For option grants issued in the three month period ended March&#160;31, 2012 and 2011, the following assumptions were used: </font></p>
   <p style="font-size:12px;margin-top:0px;margin-bottom:0px">&#160;</p>
   <table cellspacing="0" cellpadding="0" width="100%" border="0" style="border-collapse:collapse; text-align: left" align="center">
   <!-- Begin Table Head -->
   <tr>
   <td width="89%">&#160;</td>
   <td valign="bottom" width="2%">&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   <td valign="bottom" width="2%">&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   </tr>
   <tr>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom" colspan="6" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>For The Three<br />Months Ended<br />March 31,</b></font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   </tr>
   <tr>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>2012</b></font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>2011</b></font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   </tr>
   <!-- End Table Head -->
   <!-- Begin Table Body -->
   <tr bgcolor="#cceeff">
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Weighted average risk-free interest rate</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">1.06</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">%&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">2.33</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">%&#160;</font></td>
   </tr>
   <tr>
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Weighted average expected volatility</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">75.69</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">%&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">112.95</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">%&#160;</font></td>
   </tr>
   <tr bgcolor="#cceeff">
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Weighted average expected lives (years)</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">6.10</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">5.76</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   </tr>
   <tr>
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Weighted average expected dividend yield</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">0.00</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">%&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">0.00</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">%&#160;</font></td>
   </tr>
   <!-- End Table Body -->
   </table>
   <p style="margin-top:12px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">The weighted average fair value of options granted during the three month period ended March&#160;31,
   2012 and 2011 was $0.48 and $1.20 per share, respectively. </font></p>
   <p style="margin-top:12px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">The Company&#8217;s expected common stock price volatility
   assumption is based upon the volatility of a basket of comparable companies. The expected life assumptions for employee grants were based upon the simplified method provided for under ASC 718-10. The expected life assumptions for non-employees were
   based upon the contractual term of the option. The dividend yield assumption of zero is based upon the fact that the Company has never paid cash dividends and presently has no intention of paying cash dividends. The risk-free interest rate used for
   each grant was also based upon prevailing short-term interest rates. The Company has estimated an annualized forfeiture rate of 15.0% for options granted to its employees, 8.0% for options granted to senior management and no forfeiture rate for the
   directors. RXi will record additional expense if the actual forfeitures are lower than estimated and will record a recovery of prior expense if the actual forfeiture rates are higher than estimated. </font></p>
   <p style="margin-top:12px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">The following table summarizes stock option activity from January&#160;1, 2012 through March&#160;31, 2012: </font></p>
   <p style="font-size:12px;margin-top:0px;margin-bottom:0px">&#160;</p>
   <table cellspacing="0" cellpadding="0" width="100%" border="0" style="border-collapse:collapse; text-align: left" align="center">
   <!-- Begin Table Head -->
   <tr>
   <td width="77%">&#160;</td>
   <td valign="bottom" width="2%">&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   <td valign="bottom" width="2%">&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   <td valign="bottom" width="2%">&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   </tr>
   <tr>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>Total<br />Number of<br />Shares</b></font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>Weighted<br />Average<br />Exercise<br />Price</b></font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>Aggregate<br />Intrinsic<br />Value</b></font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   </tr>
   <!-- End Table Head -->
   <!-- Begin Table Body -->
   <tr bgcolor="#cceeff">
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Outstanding at January&#160;1, 2012</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">6,163,137</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">3.03</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">&#8212;&#160;&#160;</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   </tr>
   <tr>
   <td valign="top">
   <p style="margin-left:3.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Granted</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">1,275,000</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">0.72</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">1,912,500</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   </tr>
   <tr bgcolor="#cceeff">
   <td valign="top">
   <p style="margin-left:3.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Exercised</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">&#8212;&#160;&#160;</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">&#8212;&#160;&#160;</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">&#8212;&#160;&#160;</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   </tr>
   <tr>
   <td valign="top">
   <p style="margin-left:3.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Cancelled</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">&#8212;&#160;&#160;</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">&#8212;&#160;&#160;</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">&#8212;&#160;&#160;</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   </tr>
   <tr style="font-size:1px">
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   </tr>
   <tr bgcolor="#cceeff">
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Outstanding at March&#160;31, 2012</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">7,438,137</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">2.63</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">5,308,950</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   </tr>
   <tr style="font-size:1px">
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   </tr>
   <tr>
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Options exercisable at March&#160;31, 2012</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">4,985,548</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">3.31</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">2,365,593</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   </tr>
   <tr style="font-size:1px">
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   </tr>
   <!-- End Table Body -->
   </table>
   <p style="margin-top:12px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">The aggregate intrinsic values of outstanding and exercisable options at March&#160;31, 2012 were
   calculated based on the closing price of the Company&#8217;s common stock on March&#160;31, 2012 of $2.22 per share less the exercise price of those shares. The aggregate intrinsic values of options exercised was calculated based on the difference
   between the exercise price of the underlying awards and the quoted price of the Company&#8217;s common stock on the date of exercise. </font></p>
<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5444-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Statement of Position (SOP)<br><br> -Number 93-6<br><br> -Paragraph 53<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 14<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 123R<br><br> -Paragraph 64, 65, A240<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 40<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6418621&amp;loc=d3e17540-113929<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 50<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6406099&amp;loc=d3e25284-112666<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Litigation<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Litigation [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Litigation</a></td>
        <td class="text"><!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
   <!-- Begin Block Tagged Note 10 - us-gaap:CommitmentsAndContingenciesDisclosureTextBlock-->
   <p style="margin-top:18px;margin-bottom:0px"><font style="font-family:times new roman" size="2"><b>10. Litigation </b></font></p>
   <p style="margin-top:6px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">The Company is in litigation with several of its April 2011 warrants holders (&#8220;Plaintiffs&#8221;) who have asserted
   that the Company&#8217;s spin-off of RXi and related actions give the Plaintiffs the right to require us to repurchase our outstanding warrants held by them. Originally, the Plaintiffs made aggregate repurchase demands to the Company to repurchase
   6,850,000 warrants, which represented an approximate total demand of $5.2 million. </font></p>
   <p style="margin-top:12px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">On March&#160;21, 2012, we received
   letters from each of the plaintiff-warrant holders withdrawing their repurchase demands with respect to their warrants covering an aggregate of 6,350,000 shares out of a total of 6,850,000 shares of common stock purchasable under their warrants (the
   &#8220;Withdrawal Notice<b>s</b>&#8221;). After giving effect to the Withdrawal Notices, the plaintiff-warrant holders continued to demand that we repurchase their warrants covering the balance of 500,000 shares of common stock in the aggregate. Based
   on the plaintiff-warrant holders&#8217; claims in their Complaints, we believe that the repurchase price for these warrants is $0.71 per underlying share, or an aggregate of $355,000. On March 27, 2012, we tendered to the plaintiff-warrant holders an
   aggregate of $355,000 as payment in full of the repurchase price for those warrants. We believe that the Withdrawal Notices and our tender of payment as described above render moot the majority of the claims of the plaintiff-warrant holders in their
   Complaints, although the Withdrawal Notices purport to reserve all rights of the plaintiff-warrant holders under the Complaints. </font></p>
   <p style="margin-top:12px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">
   On May&#160;7, 2012, the Company entered into a confidential settlement agreement with one of the Plaintiffs, <u></u>in which the Plaintiff withdrew all claims in the aforementioned matter. </font></p>
<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommitmentsAndContingenciesDisclosureAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for commitments and contingencies.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 450<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6952336&amp;loc=d3e14435-108349<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 460<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6398077&amp;loc=d3e12565-110249<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name FASB Interpretation (FIN)<br><br> -Number 14<br><br> -Paragraph 3<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 440<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6394976&amp;loc=d3e25287-109308<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 5<br><br> -Paragraph 9, 10, 11, 12<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.25)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6449706&amp;loc=d3e16207-108621<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>License Agreements<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>License Agreements [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsDisclosureTextBlock', window );">License Agreements</a></td>
        <td class="text"><!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
   <!-- Begin Block Tagged Note 8 - us-gaap:IntangibleAssetsDisclosureTextBlock-->
   <p style="margin-top:18px;margin-bottom:0px"><font style="font-family:times new roman" size="2"><b>8. License Agreements </b></font></p>
   <p style="font-size:6px;margin-top:0px;margin-bottom:0px"><font size="1">&#160;</font></p>
   <p style="font-size:1px;margin-top:12px;margin-bottom:0px">&#160;</p>
   <p style="margin-top:0px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">As part of its
   business, the Company enters into licensing agreements, which often require milestone and royalty payments based on the progress of the asset through development stages. Milestone payments may be required, for example, upon approval of the product
   for marketing by a regulatory agency. In certain agreements, the Company is required to make royalty payments based upon a percentage of product sales. </font></p>
   <p style="margin-top:12px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">
   An individual milestone payment required under the licensing arrangements may be material, and in the event that multiple milestones are reached in the same period, the aggregate payments associated with
   the milestones could adversely affect the results of operations or affect the comparability of our period-to-period results. In addition, these licensing arrangements often give the Company the discretion to unilaterally terminate development of the
   product, which would allow the Company to avoid making the contingent payments; however, the Company is unlikely to cease development if the compound successfully achieves clinical testing objectives. The Company&#8217;s contractual obligations
   relating to minimum annual maintenance fees and milestone payments have not changed significantly from December&#160;31, 2011. </font></p>
<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for all or part of the information related to intangible assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 350<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6905858&amp;loc=d3e16373-109275<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 142<br><br> -Paragraph 44, 45, 46<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 350<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6905858&amp;loc=d3e16323-109275<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 350<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6905858&amp;loc=d3e16265-109275<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IntangibleAssetsDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Stockholders' Equity [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity</a></td>
        <td class="text"><!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
   <!-- Begin Block Tagged Note 9 - us-gaap:StockholdersEquityNoteDisclosureTextBlock-->
   <p style="margin-top:18px;margin-bottom:0px"><font style="font-family:times new roman" size="2"><b>9. Stockholders&#8217; Equity </b></font></p>
   <p style="margin-top:6px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2"><i>Preferred Stock</i> &#8212; The Company has authorized up to 5,000,000&#160;shares of preferred stock,
   $0.0001&#160;par value per share, for issuance. The preferred stock will have such rights, preferences, privileges and restrictions, including voting rights, dividend rights, conversion rights, redemption privileges and liquidation preferences, as
   shall be determined by the Company&#8217;s board of directors upon its issuance. To date, the Company has not issued any preferred shares. </font></p>
   <p style="margin-top:12px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">
   <i>Common Stock</i> &#8212; The Company has authorized up to 125,000,000&#160;shares of common stock, $0.0001&#160;par value per share, for issuance. Shares of common stock are reserved as follows:
   </font></p>
   <p style="font-size:12px;margin-top:0px;margin-bottom:0px">&#160;</p>
   <table cellspacing="0" cellpadding="0" width="92%" border="0" style="border-collapse:collapse; text-align: left" align="center">
   <!-- Begin Table Head -->
   <tr>
   <td width="89%">&#160;</td>
   <td valign="bottom" width="2%">&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   </tr>
   <tr>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>As of<br />March&#160;31,<br />2012</b></font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   </tr>
   <!-- End Table Head -->
   <!-- Begin Table Body -->
   <tr bgcolor="#cceeff">
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Warrants outstanding</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">13,116,698</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   </tr>
   <tr>
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Stock options outstanding</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">7,438,137</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   </tr>
   <tr bgcolor="#cceeff">
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Options reserved for future issuance under the Company&#8217;s 2007 Incentive Plan</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">24,717</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   </tr>
   <tr style="font-size:1px">
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   </tr>
   <tr>
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Total reserved for future issuance</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">20,579,552</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   </tr>
   <tr style="font-size:1px">
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   </tr>
   <!-- End Table Body -->
   </table>
   <p style="margin-top:12px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2"><i>Common Stock Warrants</i> &#8212; On August&#160;7, 2008, the Company issued 190,000 warrants to an
   investment bank as consideration for investment and business advisory services. The warrants have an exercise price of $7.036 per share and expire 5&#160;years from the date of issuance, on August&#160;7, 2013. The warrants vested as to
   94,000&#160;shares upon issuance, and vested at a rate of 32,000&#160;shares&#160;per month starting on the 90&#160;day anniversary of issuance, and are exercisable for a period of five years. All shares were vested and compensation cost was fully
   recorded at December&#160;31, 2009. The Company also agreed to give the holder of the warrants unlimited &#8220;piggy back&#8221; registration rights with respect to the shares of the Company&#8217;s common stock underlying the warrants in any
   registration statement the Company files in connection with an underwritten offering of its common stock. </font></p>
   <p style="margin-top:12px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">On January&#160;29,
   2009, the Company issued 142,500 warrants to an investment bank as consideration for investment and business advisory services. The warrants have an exercise price of $4.273 per share and expire five years from the date of issuance on
   January&#160;29, 2014. The warrants vested as to 71,250&#160;shares upon issuance, and vested at a rate of 23,750&#160;shares&#160;per month starting on the 90&#160;day anniversary of issuance, and are exercisable for a period of five years. All
   shares were vested and compensation expense was fully recorded at December&#160;31, 2009. The Company has also agreed to give the holder of the warrants unlimited &#8220;piggy back&#8221; registration rights with respect to the shares of Common Stock
   underlying the warrants in any registration statement the Company files in connection with an underwritten offering of the common stock. </font></p>
   <p style="margin-top:12px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">
   In connection with the 2009 Offering, the Company issued warrants to purchase 978,142&#160;shares of the Company&#8217;s common stock. Details of the transaction can be found under the heading &#8220;2009
   Registered Direct Offering&#8221; below. </font></p>
   <p style="margin-top:12px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">In connection with the 2010 Offering, the Company issued warrants to purchase
   540,000&#160;shares of the Company&#8217;s common stock. Details of the transaction can be found under the heading &#8220;2010 Registered Direct Offering&#8221; below. </font></p>
   <p style="margin-top:12px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">
   In connection with the March 2011 Offering, the Company issued warrants to purchase 6,000,000&#160;shares of the Company&#8217;s common stock. Details of the transaction can be found under the heading
   &#8220;March 2011 Registered Direct Offering&#8221; below. </font></p>
   <p style="margin-top:12px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">In connection with the April 2011 Offering, the Company issued
   warrants to purchase 11,950,000&#160;shares of the Company&#8217;s common stock. Details of the transaction can be found under the heading &#8220;April 2011 Registered Direct Offering&#8221; below. </font></p>
   <p style="margin-top:12px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">During 2011, the Company issued 150,000 warrants in exchange for business advisory services. The Company recognizes the total fair value
   of these warrants as stock compensation expense, over the requisite service period. The Company used the Black-Scholes option pricing model to compute the estimated fair value of these warrant grants on the date of the award. Total expense related
   to these warrants was $108,000 in 2011 and compensation expense was fully recorded as of December 31, 2011. </font></p>
   <p style="margin-top:12px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">During the
   quarter ended March&#160;31, 2012, the Company issued 400,000 warrants in exchange for business advisory services. The Company recognizes the total fair value of these warrants as stock compensation expense, over the requisite service period. The
   Company used the Black-Scholes option pricing model to compute the estimated fair value of these warrant grants which are marked to market over the vesting period of the related warrants. Total expense related to these warrants was $148,000 for the
   quarter ended March&#160;31, 2012. </font></p>
   <p style="font-size:18px;margin-top:0px;margin-bottom:0px"><font size="1">&#160;</font></p>
   <p style="font-size:1px;margin-top:12px;margin-bottom:0px">&#160;</p>
   <p style="margin-top:0px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2"><i>Private Investment
   in Public Equity</i> &#8212; On June 24, 2008, the Company entered into a Securities Purchase Agreement pursuant to which the Company issued and sold to certain investors an aggregate of 1,073,299&#160;shares of common stock in a private placement at
   a price of $8.12 per share. Net proceeds to the Company were approximately $7.9&#160;million. </font></p>
   <p style="margin-top:12px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2"><i>2009 Registered Direct
   Offering</i> &#8212; On March&#160;17, 2009, the Company entered into a placement agency agreement, which was subsequently amended on May&#160;26, 2009 and July&#160;22, 2009, with Rodman&#160;&#038; Renshaw, LLC (&#8220;Rodman&#8221;) as the exclusive
   placement agent, relating to a proposed offering by the Company of new securities to potential investors. On July&#160;30, 2009, the Company entered into definitive agreements for the sale and issuance by the Company to certain investors of
   2,385,715&#160;units, with each unit consisting of one share of the Company&#8217;s common stock and a warrant to purchase 0.40 of a share of common stock, at a purchase price of $3.50 per unit (the &#8220;2009 Offering&#8221;). The 2009 Offering
   closed on August&#160;4, 2009. The warrants have an exercise price of $4.50 per share and are exercisable for a period beginning on February&#160;3, 2010 until their expiration on August&#160;3, 2014. The Company raised gross proceeds of
   approximately $8,350,000 in the 2009 Offering and net cash proceeds, after deducting the placement agents&#8217; fees and other offering expenses payable by the Company, of approximately $7.7&#160;million. Total warrants issued in connection with the
   transaction were 954,285. </font></p>
   <p style="margin-top:12px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">As part of the placement agency agreement, the Company issued a warrant to purchase
   23,857&#160;shares of the Company&#8217;s common stock to Rodman. The warrant has an exercise price of $4.38 per share. The warrant is immediately vested and is exercisable until its expiration on August&#160;3, 2014. </font></p>
   <p style="margin-top:12px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">Certain warrants issued in connection with the stock offering on August&#160;4, 2009 were determined not to be indexed to the
   Company&#8217;s common stock as they are potentially settleable in cash. The fair value of the warrants at the dates of issuance totaling $2,863,000 was recorded as a liability and a cost of equity and was determined using the Black-Scholes option
   pricing model. Due to the fact that the Company has limited trading history, the Company&#8217;s expected stock volatility assumption is based on a combination of implied volatilities of similar entities whose share or option prices are publicly
   traded. The Company used a weighted average expected stock volatility of 122.69%. The expected life assumption is based on the contract term of five years. The dividend yield of zero is based on the fact that the Company has no present intention to
   pay cash dividends in the future. The risk free rate of 1.72% used for the warrant is equal to the zero coupon rate in effect at the time of the grant. The increase in the fair value of warrants from December&#160;31, 2011 to March&#160;31, 2012 of
   $384,000 has been included in other expense in the accompanying condensed statements of expenses for the three months ended March&#160;31, 2012. The fair value of the warrants at March&#160;31, 2012 of $448,000 is included as a current liability in
   the accompanying condensed balance sheets and was determined using the Black-Scholes option pricing model. Due to the fact that the Company has limited trading history, the Company&#8217;s expected stock volatility assumption is based on a
   combination of implied volatilities of similar entities whose share or option prices are publically traded. The Company used a weighted average expected stock volatility of 68.29%. The expected life assumption is based on the remaining contract term
   of 2.3 years. The dividend yield of zero is based on the fact that we have no present intention to pay cash dividends. The risk free rate of 0.39% used for the warrants is equal to the zero coupon rate in effect on the date of the re-measurement.
   </font></p>
   <p style="margin-top:12px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2"><i>2010 Registered Direct Offering</i> &#8212; On March&#160;22, 2010, the Company entered into a placement agency agreement
   relating to a proposed offering by the Company of new securities to potential investors. On March&#160;23, 2010, the Company entered into definitive agreements for the sale and issuance by the Company to certain investors of 2,700,000&#160;units,
   with each unit consisting of one share of the Company&#8217;s common stock and a warrant to purchase 0.20 of a share of the Company&#8217;s common stock, at a purchase price of $6.00 per unit (the &#8220;2010 Offering&#8221;). The 2010 Offering closed
   on March&#160;26, 2010. The Company issued warrants to purchase 540,000&#160;shares of the Company&#8217;s common stock at an exercise price of $6.00 per share and that are exercisable beginning on September&#160;26, 2010 until their expiration on
   March&#160;26, 2016. The Company raised gross proceeds of approximately $16.2&#160;million in the 2010 Offering and net cash proceeds, after deducting the placement agent fees and other offering expenses payable by the Company, of approximately
   $15.2&#160;million. </font></p>
   <p style="margin-top:12px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">As part of the 2010 Offering, the Company entered in a stock redemption agreement whereby the Company was
   required to use 25% of the net proceeds from the 2010 Offering to repurchase from CytRx Corporation (&#8220;CytRx&#8221;) 675,000 shares of the Company&#8217;s common stock held by CytRx (&#8220;CytRx shares&#8221;). The Company repurchased such shares
   on March&#160;29, 2010. The values of the shares at the date of repurchase totaling $3,849,000 were recorded at cost and have been included in treasury stock in the accompanying condensed consolidated balance sheet at March 31, 2012 and 2011.
   </font></p>
   <p style="margin-top:12px;margin-bottom:0px"><font style="font-family:times new roman" size="2">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Certain warrants issued in connection with the 2010 Offering were determined not to be
   indexed to the Company&#8217;s common stock as they are potentially settleable in cash. The fair value of the warrants at the dates of issuance totaling $2,466,000 was recorded as a liability and a cost of equity and was determined using the
   Black-Scholes option pricing model. Due to the fact that the Company has limited trading history, the Company&#8217;s expected stock volatility assumption is based on a combination of implied volatilities of similar entities whose share or option
   prices are publically traded. The Company used a weighted average expected stock volatility of 119.49%. The expected life assumption is based on the contract term of 6.5&#160;years. The dividend yield of zero is based on the fact that the Company
   has no present intention to pay cash dividends. The risk free rate of 3.22% used for the warrant is equal to the zero coupon rate in effect at the time of the grant. During the three months ended March 31, 2012, 180,000 of the five-year warrants
   were exercised at $2.50 per common share. These warrants were marked to market through March 31, 2012, resulting in additional expense of $215,000. Upon exercise, a liability in the amount of $254,000 was relieved as a credit to additional paid-in
   capital. The increase in the fair value of warrants from December&#160;31, 2011 to March&#160;31, 2012 of $402,000 has been included in other expense in the accompanying condensed statements of expenses for the three months ended March&#160;31,
   2012. The fair value of the warrants at March&#160;31, 2012 of $479,000 is included as a current liability in the accompanying condensed balance sheets and was determined using the Black-Scholes option pricing model. Due to the fact that the Company
   has limited trading history, the Company&#8217;s expected stock volatility assumption is based on a combination of implied volatilities of similar entities whose share or option prices are publically traded. The Company used a weighted average
   expected stock volatility of 81.86%. The expected life assumption is based on the remaining contract term of 4.5 years. The dividend yield of zero is based on the fact that we have no present intention to pay cash dividends. The risk free rate of
   0.91% used for the warrants is equal to the zero coupon rate in effect on the date of the re-measurement. </font></p>
   <p style="font-size:1px;margin-top:12px;margin-bottom:0px">&#160;</p>
   <p style="margin-top:0px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2"><i>March 2011
   Registered Direct Offering</i> &#8212; On March&#160;4, 2011, the Company closed an underwritten public offering of 6,000,000 units at a price to the public of $1.35 per unit for gross proceeds of $8.1&#160;million (the &#8220;March&#160;2011
   Offering&#8221;). The offering provided approximately $7.3&#160;million to the Company after deducting the underwriting discounts and commissions and offering expenses. Each unit consists of (i)&#160;one share of common stock, (ii)&#160;a
   thirteen-month warrant to purchase 0.50 of a share of common stock at an exercise price of $1.70 per share (subject to anti-dilution adjustment) and (iii)&#160;a five-year warrant to purchase 0.50 of a share of common stock at an exercise price of
   $1.87 per share (subject to anti-dilution adjustment). On April&#160;15, 2011, the holders of outstanding warrants issued in the March&#160;2011 Offering to purchase an aggregate of 3,450,000 shares of common stock agreed to exchange such warrants
   for warrants exercisable for the same number of shares as those being exchanged, but otherwise on the same terms of the warrants sold in the Company&#8217;s April&#160;2011 financing. Prior to the exchange, the Company recorded a decrease in fair
   value of $1,000,000 related to the exchanged warrants. Upon the exchange, the Company recorded a loss of $900,000, which represented the difference between the adjusted fair value of the March&#160;2011 warrants as compared to the fair value of the
   April&#160;2011 warrants received in the exchange. As a result of a subsequent offering that was completed on April&#160;15, 2011, the exercise price of the remaining 2,550,000 outstanding warrants sold in the March&#160;2011 Offering was reduced to
   $1.00 per share as a result of the anti-dilution adjustment. As a result of the subsequent offering on September&#160;26, 2011, the exercise price of all warrants sold in the March&#160;4, 2011 Offering were reduced to $0.65 per share as a result of
   the anti-dilution adjustment. At March&#160;31, 2012, of the 2,550,000 unexchanged warrants from the March&#160;2011 Offering, 1,373,944 warrants had been exercised with a remaining outstanding balance of 1,176,056. </font></p>
   <p style="margin-top:12px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">The thirteen-month and five-year warrants issued in connection with the March 2011 Offering were determined not to be indexed to the
   Company&#8217;s common stock as they are potentially settleable in cash. The fair value of the 2,550,000 warrants at the date of issuance totaling $1,790,000 was recorded as a liability and a cost of equity and was determined using the Black-Scholes
   option pricing model. Due to the fact that the Company has limited trading history, the Company expected stock volatility assumption is based on a combination of implied volatilities of similar entities whose shares or options are publicly traded.
   The Company used a weighted average expected stock volatility of 113.25%. The expected life assumption is based on the contract term of 1.08 years used for the thirteen-month warrants and 5 years used for the five-year warrants. The dividend yield
   of zero is based on the fact that we have no present intention to pay cash dividends. The risk free rate of 0.26% used for the thirteen-month warrants and 2.17% used for the five-year warrants is equal to the zero coupon rate in effect at the time
   of the grant. In July 2011, 75,000 of the thirteen-month warrants were exercised at $1.00 per common share, which resulted in a $34,000 reduction of the warrant liability. In July 2011, 75,000 of the five-year warrants were exercised at $1.00 per
   common share, which resulted in a $68,000 reduction of the warrant liability. During the three months ended March 31, 2012, 862,500 of the thirteen-month warrants and 361,444 of the five-year warrants were exercised at $0.65 per common share. These
   warrants were marked to market through March 31, 2012, resulting in additional expense of $1,256,000. Upon exercise, a liability in the amount of $1,405,000 was relieved as a credit to additional paid-in capital. The increase in the fair value of
   warrants from December&#160;31, 2011 to March&#160;31, 2012 of $1,765,000 has been included in other expense in the accompanying condensed statements of expenses for the three months ended March&#160;31, 2012. The fair value of the warrants at
   March&#160;31, 2012 of $2,028,000 is included as a current liability in the accompanying condensed balance sheets and was determined using the Black-Scholes option pricing model. Due to the fact that the Company has limited trading history, the
   Company&#8217;s expected stock volatility assumption is based on a combination of implied volatilities of similar entities whose share or option prices are publically traded. The Company used a weighted average expected stock volatility of 47.29% for
   the thirteen-month warrants and 81.99% for the five-year warrants. The expected life assumption is based on the remaining contract term of 0.01 years used for the thirteen-month warrants and 3.93 years used for the five-year warrants. The dividend
   yield of zero is based on the fact that we have no present intention to pay cash dividends. The risk free rate of 0.01% used for the thirteen-month warrants and 0.78% used for the five-year warrants is equal to the zero coupon rate in effect at the
   time of the re-measurement. </font></p>
   <p style="margin-top:12px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2"><i>April 2011 Registered Direct Offering</i> &#8212; On April&#160;20, 2011, the Company completed
   an underwritten public offering of 11,950,000 units at a price to the public of $1.00 per unit for gross proceeds of approximately $12&#160;million (the &#8220;April&#160;2011 Offering&#8221;). Each unit consisted of one share of common stock and a
   warrant to purchase one share of common stock at an exercise price of $1.00 per share (subject to anti-dilution adjustment). The shares of common stock and warrants were immediately separable and no separate units were issued. The warrants are
   exercisable beginning one year and one day from the date of issuance, and expire on the sixth anniversary of the date of issuance. Net proceeds, after underwriting discounts and commissions and other offering expenses, were approximately
   $10.9&#160;million. As a result of the subsequent offering that was completed on September&#160;26, 2011, the exercise price of the 11,950,000 outstanding warrants sold in the April&#160;2011 Offering was reduced to $0.65 per share as a result of
   the anti-dilution adjustment.&#160;On December&#160;6, 2011, the Company effected a warrant exchange with a ratio of 1.42857 warrants in exchange for one share of common stock with several of the April 2011 warrant holders. In total, 5,930,000
   warrants were exchanged for 4,151,000 shares of common stock in this transaction. At March 31, 2012, 6,020,000 warrants sold in the April&#160;20, 2011 Offering remained outstanding. </font></p>
   <p style="margin-top:12px;margin-bottom:0px"><font style="font-family:times new roman" size="2">
   &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The warrants issued in connection with the April 2011 Offering, including the warrants issued in exchange for the 3,450,000&#160;March 2011 warrants, were
   determined not to be indexed to the Company&#8217;s common stock as they are potentially settleable in cash. The fair value of the warrants at the dates of issuance totaling $11,442,000 was recorded as a liability and a cost of equity and was
   determined using the Black-Scholes option pricing model. Due to the fact that the Company has limited trading history, the Company&#8217;s expected stock volatility assumption is based on a combination of implied volatilities of similar entities
   whose shares or options are publicly traded. The Company used a weighted average expected stock volatility of 99.04%. The expected life assumption is based on the contract term of 6.0 years. The dividend yield of zero is based on the fact that we
   have no present intention to pay cash dividends. The risk free rate of 2.81% used for the warrants is equal to the zero coupon rate in effect at the time of the grant. In December 2011, the Company exchanged 4,151,000 shares of common stock in
   exchange for 5,930,000 of these April warrants at a ratio of 0.7 common shares for each warrant which resulted in a reduction to warrant liability of $3,120,000. The increase in the fair market value of the warrants, including the warrants exchanged
   for the 3,450,000 March 2011 warrants, from December&#160;31, 2011 to March&#160;31, 2012 of $14,248,000 has been included in other expense in the accompanying condensed statements of expenses for the three months ended March&#160;31, 2012. The fair
   value of the warrants at March&#160;31, 2012 of $17,402,000 is included as a current liability in the accompanying condensed balance sheets and was determined using the Black-Scholes option pricing model. Due to the fact that the Company has limited
   trading history, the Company&#8217;s expected stock volatility assumption is based on a combination of implied volatilities of similar entities whose share or option prices are publically traded. The Company used a
   weighted average expected stock volatility of 79.77%. The expected life assumption is based on the remaining contract term of 5.1 years. The dividend yield of zero is based on the fact that we have no present intention to pay cash dividends. The
   risk free rate of 1.04% used for the warrants is equal to the zero coupon rate in effect on the date of the re-measurement. </font></p>
   <p style="margin-top:12px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2"><i>September 2011 Registered Direct Offering</i> &#8212; On September&#160;26, 2011, the Company completed a direct offering of 700,000
   shares of common stock for gross proceeds of $455,000. </font></p>
<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EquityAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for shareholders' equity, comprised of portions attributable to the parent entity and noncontrolling interest, if any, including other comprehensive income (as applicable).  Including, but not limited to: (1) balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings; (2) accumulated balance for each classification of other comprehensive income and total amount of comprehensive income; (3) amount and nature of changes in separate accounts, including the number of shares authorized and outstanding, number of shares issued upon exercise and conversion, and for other comprehensive income, the adjustments for reclassifications to net income; (4) rights and privileges of each class of stock authorized; (5) basis of treasury stock, if other than cost, and amounts paid and accounting treatment for treasury stock purchased significantly in excess of market; (6) dividends paid or payable per share and in the aggregate for each class of stock for each period presented; (7) dividend restrictions and accumulated preferred dividends in arrears (in aggregate and per share amount); (8) retained earnings appropriations or restrictions, such as dividend restrictions; (9) impact of change in accounting principle, initial adoption of new accounting principle and correction of an error in previously issued financial statements; (10) shares held in trust for Employee Stock Ownership Plan (ESOP); (11) deferred compensation related to issuance of capital stock; (12) note received for issuance of stock; (13) unamortized discount on shares; (14) description, terms, and number of warrants or rights outstanding; (15) shares under subscription and subscription receivables, effective date of new retained earnings after quasi-reorganization and deficit eliminated by quasi-reorganization and, for a period of at least ten years after the effective date, the point in time from which the new retained dates; and (16) retroactive effective of subsequent change in capital structure.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30, 31<br><br> -Article 5<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 310<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SAB TOPIC 4.E)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6228006&amp;loc=d3e74512-122707<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21484-112644<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 4<br><br> -Subparagraph (SAB TOPIC 4.C)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6959260&amp;loc=d3e187143-122770<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 129<br><br> -Paragraph 2, 3, 4, 5, 6, 7, 8<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Preferred Stock<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6521494<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 5<br><br> -Paragraph 15<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Article 4<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6959260&amp;loc=d3e187085-122770<br><br><br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 4<br><br> -Section C<br><br><br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21488-112644<br><br><br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29-31)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Article 4<br><br> -Section 08<br><br> -Paragraph d<br><br><br><br>Reference 15: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 4<br><br> -Section E<br><br><br><br>Reference 16: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23285-112656<br><br><br><br>Reference 17: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br><br><br><br>Reference 18: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(d),(e))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6881521&amp;loc=d3e23780-122690<br><br><br><br>Reference 19: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 43<br><br> -Chapter 1<br><br> -Section B<br><br> -Paragraph 7, 11A<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 20: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 21: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 12<br><br> -Paragraph 10<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 22: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21506-112644<br><br><br><br>Reference 23: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 11<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21564-112644<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockholdersEquityNoteDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Subsequent Events<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
        <td class="text"><!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
   <!-- Begin Block Tagged Note 11 - us-gaap:SubsequentEventsTextBlock-->
   <p style="margin-top:18px;margin-bottom:0px"><font style="font-family:times new roman" size="2"><b>11. Subsequent Events </b></font></p>
   <p style="margin-top:6px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">The Company evaluated all events or transactions that occurred after March&#160;31, 2012 up through the date these
   financial statements were issued. Other than what is disclosed below, the Company did not have any material recognizable or unrecognizable subsequent events. </font></p>
   <p style="margin-top:12px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">
   Since March 31, 2012, the Company has issued 6,363,191 shares of the Company&#8217;s common stock pursuant to the exercise of outstanding warrants from various warrant holders. The Company received
   $4,136,074 in total payments at an exercise price of $0.65 per share. </font></p>
   <p style="margin-top:12px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">On April&#160;5, 2012, the Company issued 120,065
   shares of common stock in connection with a cashless exercise of 182,500 thirteen-month warrants from the March 2011 Offering which had expired, in the money, on April&#160;4, 2012. </font></p>
   <p style="margin-top:12px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">On April&#160;11, 2012, the Company issued 8,500,000 shares of its common stock in an underwritten public offering at $1.50 per share.
   The Company also granted to the underwriters a 30-day option to purchase up to an additional 1,275,000 shares to cover overallotments in connection with the offering. On April&#160;13, 2012, the underwriters exercised their option to purchase an
   additional 1,251,000 shares of common stock. After the underwriting discount and estimated offering expenses payable by the Company, the Company received net proceeds of approximately $13.3 million. </font></p>
   <p style="margin-top:12px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">On April&#160;26, 2012, the Company completed the spin-off of RXi, its wholly-owned subsidiary prior to the spin-off, pursuant to the
   Securities Purchase Agreement described in Note 4, and on April&#160;27, 2012, the Company closed the transactions under the Securities Purchase Agreement. </font></p>
   <p style="margin-top:12px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">
   On May&#160;7, 2012, as more fully described in Note 10, the Company entered into a confidential settlement agreement with one of the Plaintiffs in the actions described in Note 10. </font></p>
<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SubsequentEventsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SubsequentEventsTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EW3AI">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows (Unaudited) (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="2">3 Months Ended</th>
        <th class="th" colspan="1">111 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2012</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2011</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rxii_NetIncomeLossIncludingOther', window );">Net loss</a></td>
        <td class="num">$ (24,761)<span></span></td>
        <td class="num">$ (3,841)<span></span></td>
        <td class="num">$ (102,030)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization expense</a></td>
        <td class="nump">42<span></span></td>
        <td class="nump">37<span></span></td>
        <td class="nump">706<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnDispositionOfAssets', window );">Loss on disposal of equipment</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">19<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rxii_NonCashRentExpense', window );">Non-cash rent expense</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">29<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments', window );">Accretion and receipt of bond discount</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">35<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Non-cash share-based compensation</a></td>
        <td class="nump">427<span></span></td>
        <td class="nump">1,314<span></span></td>
        <td class="nump">19,285<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rxii_LossOnExchangeOfEquityInstruments', window );">Loss on exchange of equity instruments</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">900<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rxii_FairValueOfSharesMandatorilyRedeemableForCashUponExerciseOfWarrants', window );">Fair value of shares mandatorily redeemable for cash upon exercise of warrants</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(785)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rxii_FairValueOfParentCompanyCommonStockIssuedInExchangeForServices', window );">Fair value of common stock warrants issued in exchange for services</a></td>
        <td class="nump">148<span></span></td>
        <td class="nump">76<span></span></td>
        <td class="nump">2,550<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims', window );">Fair value of common stock issued in exchange for services</a></td>
        <td class="nump">185<span></span></td>
        <td class="nump">23<span></span></td>
        <td class="nump">539<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rxii_ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings', window );">Change in fair value of common stock warrants issued in connection with various equity financings</a></td>
        <td class="nump">18,270<span></span></td>
        <td class="num">(1,435)<span></span></td>
        <td class="nump">6,198<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rxii_FairValueOfCommonStockIssuedInExchangeForLicensingRights', window );">Fair value of common stock issued in exchange for licensing rights</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">3,954<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rxii_ChangeInFairValueOfContingentPurchaseConsideration', window );">Change in fair value of contingent purchase consideration</a></td>
        <td class="nump">844<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">735<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in assets and liabilities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
        <td class="num">(14)<span></span></td>
        <td class="num">(133)<span></span></td>
        <td class="num">(263)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
        <td class="nump">426<span></span></td>
        <td class="nump">2<span></span></td>
        <td class="nump">1,650<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDueToOtherRelatedPartiesCurrent', window );">Due to former parent</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(207)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses and other current liabilities</a></td>
        <td class="num">(452)<span></span></td>
        <td class="nump">930<span></span></td>
        <td class="nump">3,022<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
        <td class="num">(4,885)<span></span></td>
        <td class="num">(3,027)<span></span></td>
        <td class="num">(63,663)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInRestrictedCash', window );">Change in restricted cash</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(101)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rxii_CashReceivedInAcquisition', window );">Cash received in acquisition</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">168<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireShortTermInvestments', window );">Purchase of short-term investments</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(37,532)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments', window );">Maturities of short-term investments</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">37,497<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Cash paid for purchase of equipment and furnishings</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(40)<span></span></td>
        <td class="num">(739)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment', window );">Disposal of equipment and furnishings</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(1)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rxii_CashRefundedPaidForLeaseDeposit', window );">Cash refunded (paid) for lease deposit</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(45)<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(40)<span></span></td>
        <td class="num">(753)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Net proceeds from issuance of common stock</a></td>
        <td class="nump">385<span></span></td>
        <td class="nump">7,314<span></span></td>
        <td class="nump">65,367<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Cash paid for repurchase of common stock</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(3,849)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Net proceeds from exercise of common stock options</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">610<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rxii_NetProceedsFromExerciseOfCommonStockWarrants', window );">Net proceeds from exercise of common stock warrants</a></td>
        <td class="nump">1,236<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1,386<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rxii_CommonStockIssuedInConnectionWithEspp', window );">Common stock issued in connection with ESPP</a></td>
        <td class="nump">39<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">54<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rxii_NetProceedsFromIssuanceOfConvertibleNotesPayable', window );">Net proceeds from issuance of convertible notes payable</a></td>
        <td class="nump">500<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1,000<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations', window );">Repayments of capital lease obligations</a></td>
        <td class="num">(7)<span></span></td>
        <td class="num">(23)<span></span></td>
        <td class="num">(217)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromRelatedPartyDebt', window );">Cash advances from former parent company, net</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">8,766<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
        <td class="nump">2,153<span></span></td>
        <td class="nump">7,291<span></span></td>
        <td class="nump">73,117<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease', window );">Net (decrease) increase in cash and cash equivalents</a></td>
        <td class="num">(2,732)<span></span></td>
        <td class="nump">4,224<span></span></td>
        <td class="nump">8,701<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents at the beginning of period</a></td>
        <td class="nump">11,433<span></span></td>
        <td class="nump">6,891<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents at end of period</a></td>
        <td class="nump">8,701<span></span></td>
        <td class="nump">11,115<span></span></td>
        <td class="nump">8,701<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure of cash flow information:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromInterestReceived', window );">Cash received during the period for interest</a></td>
        <td class="nump">1<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">727<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaid', window );">Cash paid during the period for interest</a></td>
        <td class="nump">1<span></span></td>
        <td class="nump">1<span></span></td>
        <td class="nump">12<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental disclosure of non-cash investing and financing activities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssued1', window );">Settlement of corporate formation expenses in exchange for common stock</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">978<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rxii_FairValueOfWarrantsIssuedInConnectionWithCommonStockRecordedAsCostOfEquity', window );">Fair value of warrants issued in connection with common stock recorded as a cost of equity</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">4,212<span></span></td>
        <td class="nump">18,038<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rxii_IssuanceOfCommonStockInExchangeOfOutstandingWarrants', window );">Issuance of common stock in exchange for outstanding warrants</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">3,120<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rxii_FairValueOfSharesMandatorilyRedeemableForCashUponExerciseOfWarrant', window );">Fair value of shares mandatorily redeemable for cash upon the exercise of warrants</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">785<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rxii_ReclassificationOfWarrantLiabilityUponExercise', window );">Reclassification of warrant liability upon exercise</a></td>
        <td class="nump">1,659<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1,659<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rxii_AllocationOfManagementExpenses', window );">Allocation of management expenses</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">551<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rxii_EquipmentAndFurnishingsExchangedForCommonStock', window );">Equipment and furnishings exchanged for common stock</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">48<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOfAssetsAcquired', window );">Equipment and furnishings acquired through capital lease</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">44<span></span></td>
        <td class="nump">277<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rxii_ValueOfRestrictedStockUnitsAndCommonStockIssuedInLieuOfCashBonuses', window );">Value of restricted stock units and common stock issued in lieu of bonuses included in accrued expenses</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">427<span></span></td>
        <td class="nump">634<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeaseObligationsIncurred', window );">Non-cash lease deposit</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 50<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rxii_AllocationOfManagementExpenses">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Allocation of management expenses</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>rxii_AllocationOfManagementExpenses</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>rxii_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rxii_CashReceivedInAcquisition">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Cash received in acquisition</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>rxii_CashReceivedInAcquisition</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>rxii_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rxii_CashRefundedPaidForLeaseDeposit">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Cash refunded (paid) for lease deposit</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>rxii_CashRefundedPaidForLeaseDeposit</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>rxii_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rxii_ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Change in fair value of common stock warrants issued in connection with various equity financings</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>rxii_ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>rxii_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rxii_ChangeInFairValueOfContingentPurchaseConsideration">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Change in fair value of contingent purchase consideration</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>rxii_ChangeInFairValueOfContingentPurchaseConsideration</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>rxii_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rxii_CommonStockIssuedInConnectionWithEspp">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Common stock issued in connection with ESPP</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>rxii_CommonStockIssuedInConnectionWithEspp</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>rxii_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rxii_EquipmentAndFurnishingsExchangedForCommonStock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Equipment and furnishings exchanged for common stock</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>rxii_EquipmentAndFurnishingsExchangedForCommonStock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>rxii_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rxii_FairValueOfCommonStockIssuedInExchangeForLicensingRights">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Fair value of common stock issued in exchange for licensing rights</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>rxii_FairValueOfCommonStockIssuedInExchangeForLicensingRights</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>rxii_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rxii_FairValueOfParentCompanyCommonStockIssuedInExchangeForServices">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Fair value of common stock warrants issued in exchange for services</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>rxii_FairValueOfParentCompanyCommonStockIssuedInExchangeForServices</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>rxii_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rxii_FairValueOfSharesMandatorilyRedeemableForCashUponExerciseOfWarrant">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Fair value of shares mandatorily redeemable for cash upon the exercise of warrants</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>rxii_FairValueOfSharesMandatorilyRedeemableForCashUponExerciseOfWarrant</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>rxii_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rxii_FairValueOfSharesMandatorilyRedeemableForCashUponExerciseOfWarrants">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Fair value of shares mandatorily redeemable for cash upon exercise of warrants</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>rxii_FairValueOfSharesMandatorilyRedeemableForCashUponExerciseOfWarrants</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>rxii_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rxii_FairValueOfWarrantsIssuedInConnectionWithCommonStockRecordedAsCostOfEquity">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Fair value of warrants issued in connection with common stock recorded as a cost of equity</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>rxii_FairValueOfWarrantsIssuedInConnectionWithCommonStockRecordedAsCostOfEquity</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>rxii_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rxii_IssuanceOfCommonStockInExchangeOfOutstandingWarrants">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Issuance of common stock in exchange for outstanding warrants</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>rxii_IssuanceOfCommonStockInExchangeOfOutstandingWarrants</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>rxii_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rxii_LossOnExchangeOfEquityInstruments">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Loss on exchange of equity instruments</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>rxii_LossOnExchangeOfEquityInstruments</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>rxii_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rxii_NetIncomeLossIncludingOther">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Net loss</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>rxii_NetIncomeLossIncludingOther</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>rxii_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rxii_NetProceedsFromExerciseOfCommonStockWarrants">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Net proceeds from exercise of common stock warrants</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>rxii_NetProceedsFromExerciseOfCommonStockWarrants</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>rxii_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rxii_NetProceedsFromIssuanceOfConvertibleNotesPayable">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Net proceeds from issuance of convertible notes payable</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>rxii_NetProceedsFromIssuanceOfConvertibleNotesPayable</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>rxii_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rxii_NonCashRentExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Non-cash rent expense</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>rxii_NonCashRentExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>rxii_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rxii_ReclassificationOfWarrantLiabilityUponExercise">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Reclassification of warrant liability upon exercise</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>rxii_ReclassificationOfWarrantLiabilityUponExercise</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>rxii_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rxii_ValueOfRestrictedStockUnitsAndCommonStockIssuedInLieuOfCashBonuses">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Value of restricted stock units and common stock issued in lieu of bonuses included in accrued expenses</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>rxii_ValueOfRestrictedStockUnitsAndCommonStockIssuedInLieuOfCashBonuses</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>rxii_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeaseObligationsIncurred">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase during the period in capital lease obligations due to entering into new capital leases.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 32<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4313-108586<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4304-108586<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CapitalLeaseObligationsIncurred</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the Entity may deposit additional funds at any time and also effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Compensating balance arrangements that do not legally restrict the withdrawal or usage of cash amounts may be reported as Cash and Cash Equivalents, while legally restricted deposits held as compensating balances against borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits are not generally reported as cash and cash equivalents. Includes cash and cash equivalents associated with the entity's continuing operations. Excludes cash and cash equivalents associated with the disposal group (and discontinued operation).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 1<br><br> -Article 5<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 7<br><br> -Footnote 1<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3044-108585<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 8, 9<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 1<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6676-107765<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Cash<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 7, 26<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Cash Equivalents<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CashAndCashEquivalentsAtCarryingValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in cash and cash equivalents. While for technical reasons this element has no balance attribute, the default assumption is a debit balance consistent with its label.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 26<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3521-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DepreciationDepletionAndAmortization</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfAssetsAcquired">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The fair value of assets acquired in noncash investing or financing activities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4332-108586<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 32<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4313-108586<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4304-108586<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FairValueOfAssetsAcquired</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDispositionOfAssets">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The gains (losses) included in earnings resulting from the sale or disposal of tangible assets. This item does not include any gain (loss) recognized on the sale of oil and gas property or timber property.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 144<br><br> -Paragraph 47<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391110&amp;loc=d3e2941-110230<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 205<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6360339&amp;loc=d3e1361-107760<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_GainLossOnDispositionOfAssets</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInAccountsPayable</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInAccruedLiabilities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDueToOtherRelatedPartiesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in current obligations (due within one year or one operating cycle) to be paid to other entities that could exert significant influence over the reporting entity, not otherwise defined in the taxonomy.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInDueToOtherRelatedPartiesCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in the value of prepaid expenses and other assets not separately disclosed in the statement of cash flows, for example, deferred expenses, intangible assets,or  income taxes.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInRestrictedCash">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The net cash inflow or outflow for the increase (decrease) associated with funds that are not available for withdrawal or use (such as funds held in escrow) and are associated with underlying transactions that are classified as investing activities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 13<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3213-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 15, 16, 17<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 12<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3179-108585<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Investing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInRestrictedCash</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaid">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of cash paid for interest during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 29<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 25<br><br> -Subparagraph (e)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3536-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4297-108586<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InterestPaid</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The fair value of restricted stock or stock options granted to nonemployees as payment for services rendered or acknowledged claims.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The net cash inflow or outflow from financing activity for the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 26<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3521-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 26<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3574-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInFinancingActivities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The net cash inflow or outflow from investing activity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 26<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3521-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 26<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3574-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInInvestingActivities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The net cash from (used in) all of the entity's operating activities, including those of discontinued operations, of the reporting entity. Operating activities generally involve producing and delivering goods and providing services. Operating activity cash flows include transactions, adjustments, and changes in value that are not defined as investing or financing activities. While for technical reasons this element has no balance attribute, the default assumption is a debit balance consistent with its label.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3521-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 25<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3536-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 26<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInOperatingActivities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash outflow to reacquire common stock during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 15<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3291-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 18<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 20<br><br> -Subparagraph a<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PaymentsForRepurchaseOfCommonStock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 13<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3213-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 15<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 17<br><br> -Subparagraph c<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Investing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireShortTermInvestments">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 13<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3213-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 15, 17<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 159<br><br> -Section Appendix C<br><br> -Paragraph 5<br><br> -Subparagraph c<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Investing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PaymentsToAcquireShortTermInvestments</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromInterestReceived">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Interest received on loans and other debt instruments during the current period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 27<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 25<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3536-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromInterestReceived</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow from the additional capital contribution to the entity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 14<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3255-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 18<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 19<br><br> -Subparagraph a<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromIssuanceOfCommonStock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromRelatedPartyDebt">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow from a long-term borrowing made from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Proceeds from Advances from Affiliates.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 14<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3255-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 18<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 19<br><br> -Subparagraph b<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromRelatedPartyDebt</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow associated with the sale, maturity and collection of all investments such as debt, security and so forth during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 31<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 12<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3179-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 15<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Investing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 16<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 115<br><br> -Paragraph 18<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 12<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3179-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 15<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 16<br><br> -Subparagraph c<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Investing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow associated with the amount received from holders exercising their stock options. This item inherently excludes any excess tax benefit, which the entity may have realized and reported separately.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (j)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 123R<br><br> -Paragraph A240<br><br> -Subparagraph i<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 14<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3255-108585<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 18<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 19<br><br> -Subparagraph a<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromStockOptionsExercised</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash outflow for the obligation for a lease meeting the criteria for capitalization (with maturities exceeding one year or beyond the operating cycle of the entity, if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 26, 31<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 15<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3291-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RepaymentsOfLongTermCapitalLeaseObligations</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensation</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssued1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The fair value of stock issued in noncash financing activities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4332-108586<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 32<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4313-108586<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4304-108586<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssued1</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SupplementalCashFlowInformationAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>33
<FILENAME>0001193125-12-231316-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-12-231316-xbrl.zip
M4$L#!!0````(`&2!KD#?+$3":&```/A5`P`1`!P`<GAI:2TR,#$R,#,S,2YX
M;6Q55`D``]MFL4_;9K%/=7@+``$$)0X```0Y`0``U%WI<^.XL?^>JOP/>'Z5
MK9DJ2^*AT^.9E"S;NW[Q6([MR6P^;<$D)&&75WC8UO[UKQLD)9(Z2(F0QDEM
M96020/_Z0*/1.'C^]S?;(B_,#[CK?#Y1F\H)88[AFMR9?CZ)@@8-#,Y/_O[E
MKW\Y_Y]&@_QZ\7!+?F8.\VG(3/+*PYEX]I7Z?Y"1Z\U]/IV%Y,/H(WF>DX<'
M<NDZ#K,L-B>-1MK(!0V@KNO$K6E--7GW]NQ;!/`XP>>361AZ9ZW6Z^MK$Q\W
M77_:TA1%;W$G"*ECL).XY)G%G3^V%,?7ST`O+?ZV4OY5%Z75P6#0$F_3HOX;
MYXN2\(<WH[Y-FX9K0].JINBZFA;E@=O6U-XVV'&)M`)(=DJIMZ@PH<&S*)R\
M0`IJ0U$;2QK8'M]!,/C67%;(%NZVXI=I49,5R@7,:$[=EQ:\6(<DX.LD"`VK
MK5^_WCX:,V;3Q@(/J):0<Y3L62!>/;`)$9(^"^<>^WP2<-NS$+=X-O/9Y/,)
M"K^1BKGY%I@GI)7:S\AU0O86DD=FA&"VB?48R5-N?CZYH!:2'@;CR6^J^I7.
ML24$<LZ<D(=S_,5-_#WAS"<"%LOQE$I@=/./DR\*<*8/E':O?]Y:5L-&6LOV
M/.9SUQ0M"\[#+TBTH70:JGK>2I]AG67)5@)Z&WX=\/L_$+\.FJ^'_Y(9:$0_
M`K_:`!9VQ_\$1LB^PH-9<.68S/P!2@"X?G@)7C91`_;!\];RJ8!A9@K$>DJ?
MU>3S>,K*\:F6\:GNQ^>UZS_-V+TH]YOZ?]1!CPG,N]%T]F-5"^P<1K7KNJ#R
M([J@LE\77.<"?Y`+J>P"87#ZYO#%P"3&)7(>X2-DZ=OCY=7]8SP>DG.3OP"0
M^`\2E[J+;`RL7#]]"L]M1H/(9U^2`.(,&CEOI0])6KNUMKIH])(YKLV=#<V*
MJ.(L@-"&!9O:76GAO+4$'Q?),_HHFDL9W4Y*!`>+-O+22EHH$4*NA21$N++`
M&IQBB`!O+ETC$F]NG(D+X=Q"3^<0ZYQ="5-X8%,>A#[H^H[:C"0*?L"P9-O`
M\#.UF$/)!7?C2/$4:!C-\]:FAO-$1P#*I]8-M/KV#PB7JU+-&O;&UE)2H\CW
MX<TU#PQJ_9M1_RKV*96I-=+.O*VU/&/7W&+^"!Y/7;\Z6X\VA5F#3QZ8Y_HA
MS$8@ZK,]ZLRS7.::3JFF&GZ"V+(R.?!2_XQ;SE9/FQS"`Q,?7EMT6KG-";4"
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MA_S>9Q[EYM6;QYR`0=5Q.&/^,`A8&"0#1ETY:P,EA[8"27D(*\E3ZW7K()0J
MK8$RT')@:I.MV'W[JE*-[KWO0CP=SN^!2`C"04/ST&/>L=K<ZQVUH(G-M"1@
MJB0:?:#OA`ES86<W#A0S6!!`WX2!T)A=LA=FN:)<;<>E];MM`:F45%T\U6QG
M-SRI'']V7?.56U9=<73Z@WY.06G#.Q*KQ&LE8I<0!0<<_*[H0G>N8\CQ#7D[
MW$2E)I)J?6)G)/&[VF-)7U/Z:]S43I0J<CCHEE(R##>"\?6>SNFSQ62-EYU^
MW@FN)U,+2+5A4>UT=@?B1\R\Y?296SSD3-:PJ'=TK8AE/:6Z<*J)9M!O[PYG
M1#T>4NN6T8"-GRT^%?D,:7%6NQ!^;R,F!5:UCM39%Y;KO,`XR\'2[MR02>YE
M64A;"4F!5&UL4?(16#DN,=Y>4^Z+N'X\^0YA/L4."L5AXDLM:_[(PM!B6._&
MP6E!;2M3]$YO.=CO1EP^YFHFV&MW:T-.Q(ZKF3"1PLQ-!+$-6/$]3+T8/`ZX
MB?E<S%_6G?(G,<:N="5CK1;\]?K:WF!32Y<_7F@]O3"/VNZ:Y0\1JJHINR#8
MX!@E1H_=*HYX??16!URU+JK5`+?TD[>N,WUBOIWUE_7S1)O]\CIZ<J!5DMI^
MH"[9A($0S2?Z%L>T&<.$.:P\BVMTE$YQIE"1M&R\E<19$V_L`2NX/J@YGB0N
MX![72^H/&1UMD!F5]P1Q0"8JR;_=Z0ZD,+'&X];VGOU>K[_)G>].L]HL0^EW
MNE5HWON)G8HECCVSXV\!/W.X]?DDA)E,LG]K/P(;F*M.X)[Z8_\QQ$V+@M8]
M\\6ZS:Y,X?I]8<'HB]+$-=A<LK<"9:E8U\KG&%CCQ:]A%,Y<G__)S)WDF2RP
M%3%VBL/C=I)2P*T*\#C@;H(@VE-JU8V_(JG-,MB55)4%6)FL5:.W'W^9E5XI
MBX2%Y$6A]3TI5\X&[$SYF(ZS`EEY*/=VF?NC/(2S5+45C[2%8GU@E1VE1&`U
MG.2J]^YK:KN_!5-,K!Z>RD)J]_JJVN[H]?#4=;=%4(.VTMLNI,)NEYK(=A"7
MJG>WBVL#LJ%I<HSEJ75/N8F).)$.R%2OG6+K:-W\5*^<IC2$E?P_F%IQC:$2
M0C%W@GDK-W@X-(S(CBST>)>1#T+.+,52"USAM/8`V1BH@WYFUE:=LERPU2;X
MW9ZF]?<%F^KAR1=;6>?RH@R]WQ[D5+U*8F\`U=)O-0#$/5F&*^OV.IM!Q'7V
M1U'9;>V(0CR>N9;)_`"W@H3SVEU*5<022P;#*I&](53=8:9J.R#(Y"6&CBE?
M)*OK_F44):';<Z]`%72;-YT^/GV]>_KMYFXT_GI5V'*:[JF!5C-.*MFI=O5F
M6!&.I4,#J,"D:[$59^0&^>SHEAV]VUDM+JO4`'14OLH,?M!>V5/YGOBJ=B1J
M>W95Z:L]F3R*(71#&[9GN7/&A.6+`\1X'@":%5G;A((4@^QE5A]K8#D>/V4Y
MW^Q2]7MB2((%ZGJ[<PSF[J#@T0Q0S6Z'J(?GJ&R5A<JZ^I[9DF"-7;6C2&<Q
ML[DD,R^[@7+&C#I3!KBW>MW*YV[*=Q*M;G?9#]&!>),RHBEMR8Q6&AKE1%+=
MW@X1AV1LY3L_NX?&)D'_G;:N[HA36$I\(XH%A8:FS1UQR#/D+TQJ'U3;G4RF
MH8RD9&RET:ZF'AJ;!/UJ@[8N%>=65RY'ZX,J2M^*XRALE,[_!X/WQ(<$8QKT
M^O)4LWZL2;>3QHL`@/E(CJ9?-@CN#.S',%IBE+WUFWC?+9\R/&"G/)23S73<
M3BYN.HX=ZYW28&YW:#^*V;((2__OXU5&Q)Y=*I+*]^(\WO:RD@9Y/;]:4D)4
M.KZR?+2J'@6?#(/0M$Y_7ZQC3VP#=:9R)\_=PDGH%3(2,)1M_M$*BU`U,,B(
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M=&MA_IER!ZUD[%SR0%SD`@7&DS77J$@QU,+,=!OQ94]RQ5G\A\,M)6F9O,0J
MM>*=(K%(,_(<3P!^?#D*2/K>9S:/;.AW+Q"PQSY5MASUE:M9]D"5VT28#-P'
M6!1I:_E>M9Z4+#!E4P6],)&1@D:"2M6!UN]41";L-.XW:9YL/(FW%N)P[D<'
M,;J!DAEA2JFORT;&T<Q7B$?P>F)NS1^8R9B-)]0!'_:Z;QYNJF"^P8/,!1W2
M?69_?:YY7WSK>+VG\548XA[<[0G.1^:_<./`ZT%[X#DJ6_NM_KP3K@ZYUK,G
MBZD7P6(8WX-U8RT8"5*KS508^R.+<EN2!1;\V$X(#@R]VKK,#T0N8U],87EB
M9R[B^Q>$4=TX558=;YP1?CE(W-[^G8>S?U&`'R6;W:^Y`]0Q/R`I%]G7>IF>
M<@"</UX&5?.=__42D))3S>VZ.:0T*B]9WD*7<@*H^X"I&>DLZX-.^<['4E3;
ME5R\?66T\=JPO7MRO]TNT=M6$++PR[#!7FF'+&5EX:X=`X^<L4L6_XL'+\2%
MU.EM1&LOII84.^8'CKV0'(N7THF>_OZ8D1$G=@_/5^&F5TE9@&X)[@+5`T`L
MO7#I2`!EI`NZ'44FW,N(/;G"0!Z8.`H-TXY-UR'*<)B:TBN!7X*H5/J%"WGE
M#%GM3@4C*5`^#-(26Q[H%<Q#)E`988VBU9/N'0LQ27/ON_C!*_-B_BW`$&BQ
M6V4(D=Z+3&OH%Z:ZU0$<$G;I6I92R,@>%;:4D%_O%H;!_5A8-;#\QU2D>^W"
MIUO*Z"]#7+$B83#^@ER),[GQ8HG\%9IN=C*UB6SNDB\Z%QG?)S<Y*_PX<_T0
MKR`]X`J(WBM>"5\)1OYR,M=@S`RN?==^I!;[2L/(AXD??D''M:QX6AB,)P?E
MHCW(=\4]0&W5Q<;/E4AQ)6UENPHV4I>`6<8Z0"%3MB?^@LK&DZ,QT%CY7DY5
M)`7/,HE0[7BQ$.8)8I<DUF.E(\Z>`2^A76&PB;O!`<;(@F57)R\!M)2$1*?2
M^%C"0-:@EFGD3==<[7T6MA!%E5(]`,2RY:?BLO$!,<K8.MS1NYO'E7*\B1\4
M9Z:])&%U4,`K-U"50]CH@O'EV!/C9+I4:TH7<.&00"F`[+:P;.'E8O*:++6<
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M4./.GQ+/1##)8=4T=2QG'K-Y/EL@MQ<L&3Y-VS+GWH(Q?8<IL`.(*MM\/;*E
MUP;5(BMCLEA</UP/(3/'40]PT5!^%W^&UKJ-9-MWI&7F9&`YK@_:&(H;6-,=
M]Y(&!C5SCZH\<(?F5X;%]!5]_89Y6;ROS;;=9(Y.9,YH'BJ)H@O]+NX2V`.1
MQ.,<[_PT1^:^4L.B0<`GW$C.4R4ETMT'\VQ].8Z[V\DDD'8#(`.WG(U)]5D8
M6I:;5@`%TBD[Y$6BG4[F:.]VT@N$BX4T")*N(]_AP0RW"J=]")>R#I@NSY[Q
MV0U)=AC,])5X5V!ZU[><024_U]A(;'=$,A(JA6LXMJ(38D[>+O=G"'%^`QJ!
M6)M?R9W><A:!AP4W<^$ZD:RK@=+#E)(P'8H]&4LL>ELVI\O)S=I4V4W\.5?I
MQE;8J5E"/;V8X8)-N4,N+'0?3W0*/9E@$KCP18BQ/Z5.<N`7MY2[%C?%'WC=
M0X`;`%B`W[$1CZ*`.RP(+EE@^-Q+#X;'VT3!9]Q#98.SX`EXC^E6'-.^_&2%
MGP#SY7CT]._[*S(+;8O<?[NXO1F1DT:K]5T?M5J73Y?DUU^>OMX2M:F0)Q@$
M@N1[1JW6U=T).9F%H7?6:KV^OC9?]:;K3UM/#ZTW;$O%RLG/1IBIV31#\P0D
M\M,T_/37OQ!"$B`;A:>2!CF*Z-9@>GOVK5,G6`<W?O56?#4!:9,@G%OL\PG^
M;DRH#7',6<AMZ&\.>R4PLZ3."0GXGPQO9L':6/$Y_=%:_L(&WGOKB]I'8&#1
MS#827MJ^37VPJ$;H>F>JYKU]2OY^=L/0M<\4[VW1>#U4:I-D;(RX$Y*:'H%`
ME@C3Q*=9X]S$A?C#*^6GNXZ=3P0[?H-#3W?"L_;?ZK'W,Z:/*+G@K@=!N4U/
M"7B[)OGP$[6]3__;US3ETRL[7?RE?B*9-U&PZ8T;^9M>Q12S+UV?A#.6+9.<
MJ<T4^B@$!1*FY#G%:K`HA.C5`F<HBI.):T2XI0`$;\:WC.,7\[CCN"_BJL)3
MD`*(;BIN,HSW:.)LRR?<MB/'Q1WM,`*`L%YGW)@1:IH^JM>FOP/$R+%92&QF
M"I(.IH](Z$*A%W%)CP%3FB9)Q`DX-P#P&)B/R<!D0@XX&L]XBT!.<I.)D$8P
M8]8D*Z48:BR&`ER\%\@#)PIM`C3J>582U"/`T&=4;$=$X[3`FAB4]?"K:F(]
M#!Z.8B$\1OX+?W']H$GN$Y0OU##0Q,F,O@`DAO<861E2AL4=(0XA!?P>&S0(
MA0A[XV+S4BK@!8@`I)%<>@.%#&9A]I($=,+".?%\=\(M%IP2RW6F#9B?B#;@
M<1C/[P7W83S$QU(`5/,@9#:AN`@A>#HE%#0(+>._U($W!K`C5HMM%Y@"CFGF
M!DN0T@?NP$^3@4U9@._WF-C')AF2/]B<F'PR8;Y@&::K4(#D;5CM?0I0ZKY+
MP6I`]Z@_88MHB1G=(E$D`5;%S0A^F#"U`@/(JCF<4;`R.H="-@52\-^J?B#N
M$:(0'+#I7!!U05"@(1"GST3`@F8)U1GUK3D4Q>_T><`PEIB""#VT<U?0@N[T
M#)QES=`P(BO,`EN`3E2*N@MBN/B)6+!'L'G4DY#T\YP8R0$58'F*:D0O"7T7
M'-H?S`<=X]\F"R#D@NY@_AZA!9'8J.?B):B$)V:</'WE%DK/HEZ`K,4RX%-'
MS&*AMB-NV$IL$/U>D^SC=]>/(T7'^\D#!P&,98O4<\;CR"<6HR9:O!D9(8K:
MQ-`'',<=B_Y%W_9H6LV/WT$D^$\TV^YKL5#2QUEID0]7O<['4Q*BTPACL_[E
MZD$C862#M=`@</$Z(_!?B3?+>#<33?*9H=X33PC%,B8*]4W0XYP\X_)/F/5N
M>>NEY!XWF!%]Z6Q@H@'_CWM3?>S?UY?#N/?APL'C_9!\>/3PGB4(=,%QN(9K
M$9PY!@'ZGX\Q-MR=;S]S)S:O5Q[.!.E?F(^^@CNY2&<O@1=E[;/I9DDOPP3R
M`;IT$$9_1C9]/B-XZ2X$^L:L]>`:,_8Q*Q&M()$F0?L)&$P-UEF08/#:Q>5]
M&.[CC\FB@$!'Y,/UQ3THFB:J!CDFGC\9"0T\$AN$8K1`*[C2!PM=8U]KL#</
MATJH^$%3&GT%W)]E"K1@*0R]A$,&RM^P/@R%@-81>F".Z<*H*O096P#X!3"<
MQ'6`V\KPJZ[P>[B^7:\?@WLF20A#7JD8\ES?<_VXKP1DZ$]ACA2%R%@FC@GB
MX.L4F;Z$SO$*?O44AY"AYW,K[K%J5_FDGQ*8ZG;%,+"@D^24",R[B4-MAIWM
MX5<N9%$@`W5B-"*.=6#^]<+0;RXI:/V4Q'L5\7=P,FD&:NB)\2$17GX<2][E
M@E&T/`A0$Y<J6%GI+J@#(7:"F1^(B'R.8:H;#W@([11B#/@/K)LY4XJBA^+`
M-8^M%GLAM"@<(%[V!;T$Q_3X,S@"`MX&EQJTN?PH3AS)Q%L[XN@05/1P-^1Q
M_Z:9$T;0FU+>H;]9[BL4GH"P1!_%P=BW4Q<'XS&R_.Q2'QJ<"*9-D)X!$8V(
M'9XA>@'-B%))6,&-I$C2P!1@`3L0UF!(%<3A+T&'THBCBP4[*^-6$Y2#(DG6
M:83'%:36LR-D"ZJ-#!PU,!HV8``1W@/JH#`R4GJ_1CIVR"-XR6+GZIX*HSH5
MG&WLOT*1T(.W]E[0P(89',_*6TA"R#Q#,A>^!LRC29L0#(.9O[K)M`HD?`81
M\L<E`S'%TV1L$#%9?$DR$Q%WUB)<\'R6"P&JZ4?3G)4G<[:X-W[@V?9+F!9=
M',KD`&`^C#N1<'L)&0A)X5]A+?$T*YD]I+,F:-KB?Z)%HU'-8'QS?6&]L7V)
M9'-3:"#VX1RG/*)SY[WYP]WH,1$Z\@(5(SLQ6Z'(,AW&FOH]<C)=X__;^_+F
MMI$DWZ^"YW5'V!$0S5ND>V<BY&O&\]QMKZ6>GOWK!4@4)72#``>'9,VG?WG4
M"0(4)>L@:43L;%L2@*K*S,K*XU>9^#)+!/ZYB6E*SS-#0#]HG75,(M9G$5O%
M`0@"+Q_,[>0H+<D95$M#5L1TZK\X%8+#<<.7N[NM[&,/+`-R/:1/3[8HZEDP
M,DNYAX!?8B7="/8<?T$=;)VG/3:.D&+*=)W+(B#X05MNE:;3$0=482K6Z*U*
M8&LN<O=H1@_+GJ,^;=0T)8OA8W`^"/*?%F51XND?+3STNMT/@K4%^YKT;X2Q
M:<<'TO7*P8E&LQ=%-"I4G"(G!2,G0*O6NCK7]*'CH[IAR2,3YQ@X2#/RU?$,
M:)Q894.B3`5>7LXP?4VQ@Q76PV2MCU."I<,VQ`G""\XY:4\"1CW/@B4,>X*:
M!IX#+U59I?,4352>`WL;,\$$0C8V*$3<^W#&L;4);%VBXQ%63$TR?/DDHRF!
MN>QJ;[UPM`[XDPTK$+).*FFM2*+@;`;"-$ALE4("CQ#>YB!/O92X/*`/8W@*
M":!%SAI`.EDL>GB$SR\B^(FC+X5,_M*\EUB-"+Z%WG28>GE*QSA.(ICEY*`!
M62K"[-/R38A(<17/[I4,N\&O\6HA!070?G(Y1BI+`K28%((!)@M=]\GW^&KB
M!D&1*&RVM.0/RKUDC!D[D'#L%4"C_"):T;-P7L7!+.7>)EYPG@DNODU$ALE&
MJ&^\\S+`7+D0,@`2AE%E8<0&6$UP&40Q,8N,1\.GU(E,H:V6T\F&GXO!N?FX
M<!Y?P&=H;Z2S`N-"=4->@/V&G!>ACUO^*BWC$.<`(C-7QQ^P$<1:@&DY_Y,B
MK])(%(8]N<>F+DC9G_C?I<"@(>^63#))&]\S%)54ULZFJ=[QX)@\3.P^PG_\
MEI.HOL_A<=)T-*EHA^/R9[0)C%$&LY_K3!B:^;P7<(,5\`L56J7#*`LI(DT,
MLP^G#-1-!"=]+M4"&C,L@JP>4=PP<8MAE(+()!V%$Y``4!VP=8CI&!%7\`N2
MC^!/V,2:MMH(XHMV<H<L%K#':0A8%:A^/%B75`6'`K)<D0E?C:TR)K2KP7N"
MDPSTG"2"+-?5^`Z/0DZ</!AJB87O-4U'*FE6&&&9(?G,LT1,2CO#,30O2H[H
MPD&$9@-N.0X8:U<LMZBS@YOC'2R%TQ/>!TTHNUKQ`VR6[YRZ-MWNYU_O#(>3
ME)(`P,>,=<9,)OE\R<Z(36Z.`-@*.D)\0PX&M00*4I1!;8&42'2)\:Z,++*Y
M4_0.`Z,B`S6]!*7+93_A`.`\`%@?*7_<^G9.YQ;.3Q^*'J7?`RY#X9H$82K8
M2L988L8.'OW><![W51;,99.)'`YDRA"A65!KT\(IFH)%\1_<<'%L?0D#>"K#
MPU:6G#2E9>2>A2'L+;L$&Z@D4[O`<R[S+@DZ3PJ,O2#2;=:?8.'6D#";1<PF
M1*"#AW*+DKL&/,,AL4=-F<04NJ`(B?G"OV$71PLVZ"]$>"YLS4D:+=._0O5+
M\6^P9^<79!-5U"['6O5F,F@$5*Q)&&1@V;RA4(R=:/UP<OK&3GG6O_<V#35H
MSWG]Y/2M\_99N@+K<=(;'0V[OAT3J]GY+*Y_AX7C8-K)[/_LO=6"`1QX#Y,I
M7!_T\U7B$;['TA)F%KQ%-,]RX@1'<;0P1\HNDQ8%&QB9Q.[*D((")9(4X3<O
MTCC$5`]E)H-$;C7:226?`'H`,G4JUA<L!H4<*`E#4$HB]U[DRON=WM7[?4@]
M_<6<WYBTM7$QNV_/T/AGY*3=;,6@^F`_0.XX6K$,=)&#SD!L\R%T+*,P"C**
M!YZ`1L+3EO(*$>H\Y:_K[Y'8S`08S"*.V`!6+J(AZPX*`<IO)BZP6BPL@+IN
M[3SO5;:Z+H0U=]9#&AH\+('JF,(;&`T5!?^!E"ZPEA4[1C$(:2/"6_"))HV3
M>]TS"[^):\9DL+YL=8I[2+B:`AV^1XQ1`^1P>U"B&8A+X2)&\WV6(1`YDY'^
M0P89]BV0X:U(41FC;B-U'Q![UN]X7RE&99L$7[(T@7_/A66E[S+43.LPH[#`
M<OHEN+92(SHM@K806[UAO1GTVXHUOVL!_>980/BYH^Y0#^Q[B";W"+),U/B%
M#4\DH)F4]T):3OWNR]>>?AF<X"1D4H-B.I%!,P8X6]^UOTEGU3OCOWYE$T<[
MZ[]U3CO>WTY.OM"#'S]\/<W--#`=CY2T[-!<KIY=ZGD,Q]TB$FP/V:@O])-%
M1F$B#<2RC.>E-</S,B*SE<A!*?EOH*-#:2#KJ;/RK?^&!0)2;F[HH9H[=^+2
M99+.T+FA<->+3QBK\P8($0![C9R+B"5'+Q+/`8H:X,F`T3*,"J+11K^8$=Z2
MCH0DP=."<1UXZ"_7_'2$HH!H)Y3L22C*MB@DW.0=;"PW0=<;^3+K:WD\+M@K
M3#4*M%B;>!B%Y&VQ:6I9(O"A>>&ES0F=&XVCW4W*Z`FL;_%_E(FX<8^?_B:W
M*Q"_P=KAQGGK&[7O;E0'@$N6\J:/W+C-M'W(>\+R,W@<E54D4R9-A+1634C4
MC"U=4<M[I]RVXB[M6^/NYNA523?'DA(9#?=--*Z09C7X[.RQ5PBP-@A:5&HN
M&*78,%5*^LAQP,L2Y`!65Y]5[I(1G$\5YI3BO@CFF^-Q%%[9,!48T\R;MV9@
M5#*%+]<V8DK[4"92<>0(1I/Z:@DS9$=3QO_@$QN&!YU!\74@`GY$A48WO&$&
M4-1AY]:B?I)28J5PUR)CI1?I%6(WJ8$KZC$OQVN3E)P,8@K/(#8DL\W@6B5:
M<:SIH*#426'4:7RM$I]&Y9+&CS!;X%W#/');PS)H1NI6C'@0_=-<R$>-NB5%
MNU')GN0UK$N3^-I(GD@N`DK+F1.)5<B:(EY3PE+I/H3&=;K\;6]+WJ]%KQR*
MMP;/:"R.`S;E!Y8IOQT-MK#A'\IU)[-\T#'2KV!;=KWHG3?@/Z\A$7N#6BB3
MQI.@^]Z$\&*T7J"1CM[<8&)HI8YESV_9UKUO$,`G*DM+*@HKZN)(OV#:,G,^
M(W^EGW>\!0J.TSF`6=:D!B4B%=9I.?N#DEFLN2EU*W/'"2=E-5"V.J#?J(BN
MX*0'E9=>)78XBP+22QEP1@7'BI=#\@3>H>1L*)-]B9R]@='AKY6PY72!@)0R
MQE1YQ*.U$5,G\=SQ?B,RW[@:9<F9X5V`F67-,%S[&[D*L.91IVO(#&(8HZC0
M89=SRH]<+/J`G)P=3O)>5"X/G9S#_,XQ_<<WO)U^/@['*:Z/BPEU&I,1%7::
M42,)8.ARA0\^'_37YZNAFARV).]0&W72&:O":0ANDM&!L\1[+T6:4#(C9OR.
M&[)VJ"EO`Q@0?SV*M:-"KFHQ;MHI0D.4"A?Z*FTJ9"'SBA00)EE$;.Q@^7UT
MH0P"H9Y9/DZ(2H9)U&P-)HH36_@;^0TT?&%V^2+0\V"=4K\&6K?,Z40%P<$6
M40:&%\,D,']`5P-@DA)HY`AB3<;\:PG^Z6@\&+T(7BHJ_'IR^N[D?U`C_"F*
M58RF+#ZVP^[81Z9,%7)[\RX.N<*W5BFH=;+P"!V6:P^#EF"5!LP'+(!))C\)
MK31#47![C/3'SV[<C`K!*5E?"YF9JPZ[PIDF.R9L`Z^X_0SI2+G5^)H<D'*)
M\0?ZED'#A11[G1G00Y4BA*3\/"]2UV)U#CN'%#`30?M?HZ_EGT?;$@*FWA].
M_./N2%*#MRY?`D.:;GS?NQ!QJ#E,BW?FAP>%GJ.-;.];2:]>;S\PGVXDIAX.
MSXA=%'\4")<R6`(@EY#V)OWZ1N+DO7<V1CX$MRC+,4V,BJ0.E\BH$O2SV'TF
M++170<?7P*";\O6$C",%*+77>9J&M$_8F0L%73(@+"!:",$W*U^_R[Q4A<,1
ME307E7.)SF5=[85`AN[C-J<1E(=:GRY`Y*_OE`KJN[F@#:'\VE20_#(C^>A>
M)/B<L&G_\JS[C'Z6-P7IYZLH+"[^\FS:_^F9-\,4=T:_EI/BWQP1"G&5B]?J
M'Y(#01R=)Z^]6"R*9Q[]\)=G<S)<GS5X3F<TJ;_CK<**`U1D%$0S/X=Z;KV?
MZE9;A&LO7,HY,)GTXD9;OO\(#YEB`FOK75]_93FNE-N7^]R1'&F[F4H/]%F$
MKH+@);C-*K)1D2XIU+W5-X^"']Y_<=7KNV[KGNOHO@"Q@Z_9"O7E)N?V02E6
MY;^S13`$T[Q!JIOH31I>KV\B;W:.=UQ@%__7?"[$8O&L<36@6]QM6M7`N*]?
M]SK=KEBZ*O>(?WE/D8BW,GZH[&M2M;A"5\V^WCXB\712?R<]=;\OW4G%/+$L
M?'"P=,KW8@^><HMISJ4K=+$&LB<Q4L#/5D#[RKK<<4&Y*[F>WTDARQ\SO$9Q
M7XC7L3\8'V\UFR2]RH+57Y[Q?Y_=*SWP/N"6"M?;2UWY7F>R]2;!7`Q>G3M0
M$?].X^/^9'WL#\?=)Y?PVUL6CJ#7P<V:A?U)SK+UG27-0_(#ZVW#3>[/[@Q[
M4"?U65H@NJ7!1CM09?34YVVO[T_Z3W_,_N!*:`#:($Q+E/I'U4+W-.Z=U-#^
MF$C:G3S9$*IK?<C#]2&QAN^.,W5OSY_Q9-\/G[W18U_PFG44ZDN_-B927B7D
M:XL'*NL[X_CUAGLN\[LJX:;+.8KVPK0B:"7Z@26ZM^<2O3]:_&\R,=Z*],.*
M],B?3/?=-ME5&?Z8',FR6HV%C5KQ?OC`SWC?[9#]T=HGZCZ^Q*&VXOVPXOUB
M.GAZD^1.J<,=EN`,D^8;O$>KU$TKWP\LW[WA8#_E>W]T-H*%6X7]:`*]G^*\
MJ\+[3BP$E8-%J+1552I)DR.IKUN1?F"1'OG=T;YJZ7U/J?YXN(X['*QWX]6.
M[?<G3V&U$(H=V.\_"H1"_^S"^NL@^Z_HGD[]"N(H$4<7`J7_]>2F2T%X:\B]
M4='MC%:%J^A^IBLQKWO=VBLQ=1>([G`3R+I'5+UN5+V.)&_H]+IR0AN--OGP
M\*=GCHY46H(&_SY;H!E'[$S$'G!=7=]U]#.[-FESA1#K^CG>*^2;WN6*2U+I
MNBSZ0\]['>R?1%5Y)(Q>WUK;:I!`EP_`]YTJQ$23]8Y0ZFIJW9V_&_:+V0W>
M^G9PU-[/-UX3O%G"MRZ<=_\W#L4:HIMF19=U);*[<@T1>3GNC#QUQ3^%4S%*
MJ&RZKDYK!$)>_=?W(E99.E/-%/"2C5420/7[X%H##U@@H*:OE2Q[SC>DL1;0
M-16$X"95)=YEIK9->DV!KLN!MTUG!5<`@JG0@W3'&N^<SN)H'JL:$+Z:F2:&
M7*JJI<#77<T5$JRP=:Z$WJS45[T@;$+F)3>?PONN`AMNZN=U27=G+;FN>(2[
MM.2R@;3Z?Y=!!FN!:7.U.AH\Q6:$JG-E@M4W=(EN6?-.U=M2]0BT%VEM7%.`
MCLLP?$Z\?P0)C&<5.^Q-[28]7+7`K(44B0\'"/Y/ES>J'19EL`#9/*?R)?J>
M/W]1=?P4208'B"QS57+I.]59\<O7]Z?O?SVK=E@T/4^0UDZC1O>^LKPWU/,'
MO9%_/)EB]DIV@V^JXP&SD,)@BH(Y!)"E*^P:`P)K2<A:Y[:<J#%,3=_Z(@94
M*.":5F[?CN>1UKZFJA'H>_-2IG4U%7Q,U9'@-B7\T8C7@T0)$J/VUP:(<M.V
M4EY%=VI3N,>%)QO+R"9%5/+0>7PI!(I&QSO%AD=2"FGJ=M$4,W9NJMA8W]'E
M,E@J+1'$TAI$7*W[N'C&+:+?N(;ZJCI]I1.Q&@>MEYH'IZC^D?9.F:Y9$!-A
M\PM8\NY><_^XJ"4LTEX5)V$B<]=:Y%*C$%K,TCV#M(XMJ`\'5EAYWNT<C[T7
M.&4J;AAUK$J''5\?>'>V2W2Q//CEF2F,\C9817A+@0NDX!_7M=W$UG9A@!VD
M9$O%2K4<+'-040:^1WV]J<^U+&_`+0"X>XUNWM!(R)=(]7-L0BVK?E)'TEI2
M-)AB=#!PHRCLM!"R;K=6P1MN+J(5K:*.]1WO]PM!FP->P?H.-\N'U>G'#,*[
MVM8Y33I&]HQ2JE861N$*/E)-<5\[F]:RPOX<!\$Z/;-*IPL22O@DE=?0G5KE
M[*A>55:O);$B!PX=),:*P#H_*?&LH`;"&5'X!?A+5D?`E>`RKTM=8(EZM=CU
M)*T5,&4^B%E6$<$NBZ`4`*O7&:PE6F)K=RY(5>&IK4372>RP(5.4NU`TKR<G
MU2M25E\LSK&+DQ!:V&RYT)5UN!T'7[<EP&J*?XR6,VQ5$E:JF5!912R"UMSJ
MS@?M/O#'TREM.L6/BR!D-:]4>ZHJ:Z:%;NPL2_3?Y0@X/#U_1KM(*F5EVCO7
MJQL-1JNU4(%%&4'+8%5&[(L,ZV\\*G/O^60XI)-9]<`,V#6T&<,\D)5&7TCV
MO&QB@-5+P=1DM5HAL96TY;HVG/-HK#X?^[WI".</EK&T;'E'@TQ.IA.R-[AF
MD=T$1(E3W9`=X]#NJ(AP@1H^:F@_Y\J[(9T9F#X'W!QX[=<K+C2[5,7Q=$?`
M==&A!3?4+VPKY.@XX=TKY$R.O[-"SJ2MD//XG]V9"CD?Y,ZE2KSTV\Q[A7_@
MJKQFE52?UWE@;5.;'W!W$R5FFB:/1_<M`_(_0IV=7Z7&ODG/MHG%N^4,AOY@
M^O2)Q9>WWQ-M9G%WQKW?XW!'-,Z:C=BJH(=10=U.K]5`K0;:"S33$^FDWPE%
M@;[[I<BP_JT*298%->D`;^]`M=/.("W[([\_[?K]MIQ6JZIV&(;EV:UTMNOE
M<C\]=+)O4?3Z2Y`5B<ADW/R`.^8,O2-OTXJ?NC_.T.J/\_5?D7>Z@E$^EP5+
M2T-,X\Z-<>PSL'\/G2WU_&3CNJ3(HEE)>3O3GH:F;!KDW?>:[KV?W^?$.Q6K
MHM*ZJS^LZ_KCM,\)O`8*V-UXZA_1#V"'%N[(`<*P*C.$4U`&7*8\L.P[-IA$
M$X.;[_#7&*J!+V%3&S`U,+^)#<[BN*9]C)/N_OKK272DVDH48GZ1@*UU'LFD
M%E>!,3U5U&BRJ3V!QQ!QDT7`FRB^5IW.DQ1[7>*WN4=@B?TU\8-Q-.>4F8WH
MPC?H67M\RB)>"5B!S";JG"0^_GN:S44.Y/>]7V`RP?RBA!G!E.)@ALBM%/L(
M!7-YU641?9,9`CEQD[`3NE`(5?3B6L"<SYK+S`X^"T.*Y2I..:E,;=;/9<:(
M&*82F_D<H4>(W_$M%!F1,L2T?5YDG-0$MS7'3B4Q-B52.![*6_$X,C4*/'6!
M1T&<IPXKGO<Z(R.H&KBWX)0L9W1E"IP1"^JK=]F%CY$Y^F+)/>^VNCWCD[@#
M.TOL%:7(OY:9E>+R]5\?CWK=J8TVI'7*)A:J_0)M'Y`(@F7,P.X(N+55J?M!
MV917LNPWBH81LT#-&S833ARA1?5]F$RV7;=A@B=*NQG3<)WAOMJ+"E5XA0V]
MQ!%2VN[G1*M^WJN1&)SK\\%Z6RKLNFEZ)OJ(]2+*,X(E5\`LS-GE02RL3N9I
MIO`GC#UY/NIV/6>XGAEM5C^:[H5T29I6@CM5/TN"%BBFVD!`FTUKFF6W$Z<?
MDXU2[W:4"F&I)4C+$KN8V;`)E%HD\17)(\$0Y`F!+76R4.7@+4+5Z\=E4``#
M41M+I*EJ/<2M?K4(FVD@KY(`Q6UM*`+FLOYQ#B&%]0:MF.CG<S2&TL7"48-J
M=%*#E2FHYD?7#))5&P_T0E[H7DA91-@G@K`$A/"<*V!0Q#@I(X!5BOHV.?D`
M5DL%JF%R&L0OVL2_6VC=9B#Z!HOTGH#H#VLIGHIYF1$TAB&YJGKF7AJ-M[$7
M26@K1J,A1@TA:'&V_;CQZ7HSDO;M%>X..!R*4K:O^YA<XBF3Y6N]!/5?[,_Y
M-=8HOF<^8[:AKH8:P$_2X'@^]4<&UWTJ,BP,H:EUXGW)U"7E4]7S$.=N+QU_
MUH\18>A19]'2=%,`1P4M<Q6)KSI6Q:!LU)':T_.3:A+^LR@3[N<)9TLF=>I,
M%%<(%:,V[WB+`+6`'*Y*R3=9%)X+[U,:.#T869%9,4$TGY-YM)(=W94-8_""
MJL.:]4%")#*P37R;@P!*&T490O,HFY=+'`',9*O]VPQ.RBL?3TU0QW"F%DH2
M'?)*+FQ%3CYF$!^IM25>$L*[`*:GHL5_EHF(!(>/-!8G:MNL;JJ#;H>UHT''
MMK\K![1LV;DX.>]8Q"72ZM,%94L_I@^PZORIG9:%-K9.,KEPT^34M]J#,%+R
M7)KTL%9C)5K;](1/O-YT,""/AII>PQ*KPN*^XNX]2<00AU)'RNQ:VH0:YJZ6
MI9KI[:J!(UFT)FT*^"T%DSJ\P2H#3Z&%N2L<6;0DLN:>!7[.;</)FX)AK^N@
M<?Q9?O4J+>,0>]!ZRY0NNL#>FG:FTZEN8]@\C+.);30M=P`_Y\ZSW%Z<+AV4
M(.>\/.S&U_%^!R6-E[#84.*9\I47^0CX&,NHD`T3W<G@3U42,E*6.B/.KC7T
MW2AINL$G>Q5;NQ/7M<4^J>'/#7QP>V2Z+7`G@VTH3.QB'LT<I>FS[V<9EXID
M$O&]*'7PHTHGW\13Z`^$R%]3-$%^9'2D/:DUA>.@Q%&4W)7V^GJEC=]L!F/7
MGEXGX664)8'O??KT%CM*LRO*H')Z"*="9)@)W:78::XYVF).JXHGKIU8V639
MFH3;9)1.F3MJH%KK]OY-4K9$*=X*M*T8G+MG9CHA(#:UI*.QT22DT`$>2P5&
M&*B?ISQ#A`J\N1>P\/8C;<<C\&:.&'0["W+9A;NR@[<0(26/N=M`W#DWZXXW
MOO6H^^3>=+3:"'SKL.9M[GP8,=:F6WNJ&\,>^[7-8<\JG;<O"*(M^RP/;R8`
M;U<3[?&W8IM/5V50M6+\$[8U+&&5YAOO+6U0HHB:#B@<="V"#$./41I:Z.SU
M$\%2.K1\\K]_JV-"W>3U51%]=*!VT)(GL>UA1)<;B0GDA>M7_A:`:1ZP[H],
MCS:*PYH#U[YZBIAYNG>J$>)5:9)LYEOC_3W0336;^4QDLM_N6RWDNZ^Z:/R/
M6TG]6GSIUA$N_`+K`1TIHOUWRUB5?-G:8!XW9\_UA;*:-N-UGE$EBN:Z#XLH
MEHY5@&$G$'M7,^I[*?+7(N.;ZQ7ORMGLI"KYBGO%,*HWAFX;5Z/5WR&V=D]Q
MM8T2U/&^2`T5&*$BH[?&CZ7,,G/57S\(?!DLU9?-*DDT;28;ZSJJ7M1[/I`^
M+P>[^8=JA)L4EID*K#TOZ@H>-(>#-UL`:I[6&'`"!G0QGBZY7[L$NZOG^)BZ
MT0Z$[(?^JR:UME"$1K#PEFR$00-KW3DR3H;:4$[<R@DY?IXO%VI?#;ZRA*,4
M,Z,)U;-L"++9[]"#Z\$K%8-9>Y3#4BHDM>X3^%LXD#51J,!68_K:,B_9U*/1
M<ZN9UUI0C;Y*R5GXTO%/=1=O7\#NZ$UJ_\1;7:95V2X#4127\CYW*!9!&1<O
M:?.![B=>K->P,;K&5D]</L.ZR^JIFX2^3!V&%6[7+]FRE>AS=B2:;QK&F,$+
M=:4-D_$T.I./M%**I%1MJBZ"3)?8%Q;C-#D_PBOJ:S5"W*7`C!Q?XGF_IU9C
MW<O=S?(+=T\?/I*.=-,MTDW?S_0*C7^2DWUBEXBBH]$Z-4G5@%L6&\>X`8Z#
M\G*#]L7]Y*9IDDVQ#]]*B*@-1CHLY\`2T]`H6?6N'48*O+FR*Q9H%0:ZDLM)
M$L`VSJ/`^[\7ERG62_"]+Q>==QU_+8TJ"Q&<B@3C1_]$-0G*%,L[R76_O8C$
MPCO5&!7O,PQ&M6VD?6Z934IL7*0"A:\I*2*^2;3!*BBTG:&R[-<2J,04=])9
M.C$%7Q,8WDP((0-^KJ[%XY8WRM+K(`8U8L,AU.1,7$#%U?5@/SL(#@Y\::P%
M,I1Q"\HL\_#O!5J=0+6%D)@=@Z%8@V6P@3?222,]):4Z[6HX`:--F%)$`82U
M8NHHB)8YPQN4Q:XA7H::H"UE10R$=?E..#9#!)-,FF"%BL#K_:1I9LV+@@`@
M7QPJQ,$R/*]*6<)#EN3!+\OY2WB+"7'(::D/VM,#\8$S_P*1+SP[%7-,>0-7
M:5.[A:UB)AN"&1I>LDT$<]>Q3C2!LS7K''&XRQ5C\J1]OMG(IQR6"6M%VINI
M"6DUTN*_7VW"RMX/_EAAGC]PNB&(/X(#F96TL6M`SX<'21YY1]XMB?#4*.51
MQ_N`13#^244P?N&2<*R*=]Y^L./F'/#4-2@NHYQV&^B(#R>G;[R3T[?>6;J"
M4W'2!R]=VT_6R=U$!CPK#.-LA\F86FM8#AP/1G(`#"IZ61?@72AIL4%:MJU+
M\5(,H6;B2!;NXZBI+F$5%'8Y$_B)(C2F<A]'ACEF?;L/Q50IC\]475TPL!\"
MTR-#2USE)3FV.\O2/[%Z'6;-R-3BRAXQ0OKRCO<)_PM_6)6XWDRPG;>@Z'N0
M*X[>HK['E@4][RIN/-^>MO9Z_9^]?Y<I%\>,YEP,*.`@V)(JAW%51S+1T/:Q
M07CP>XN]=SO$-E0M^;XU]ITUL@-&H!@L74CPV5QDEP'[^,0^)=NUJ_-4<2KP
M]+*4(-PJM$KK8V*A;QPH6,K2[$#I,^^6%`P<"MFT*9-UZM"&`*\AQBP9?#$X
M=S!=#)-$KU@5=46]=04OV>2A*"XBB0B73EGSDLOF<="DF?R/0-.'4^R(VS]/
M,_@KNR:(?&=H%)C&EYA,0NV!X0FU/[4RXI@1:B@6.!12]=`5.Y54;X^"`+H^
MK*7%)>4I,QJH.`/[=*P$;[7]]86+?ZH9J217KCD7II0=E'8_YFLMT0H%VH0J
M;?='&9XO=;W/)G+)X#LXV2GZ)WQU!&]32&>:"]@9\O6KY-,?0`UM#@QY1D@*
MR1):":4Z,%2#Q*'4LCYN9@)_1\]+6#R]28>4K%Q[1)@]F&2,1+FFU^143;+6
MJI;EMF:O5#M&J(U%"VN)`[-$50#.7A?YO[JXLETAK&EY^)_PCS*7AV?#DB(Z
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M7&\Q$&C%5'=<A=UUF4]=:O/8'^Y`L^"=-,):OK9\W3F^6FD^BPJWHT?+\9;C
M;>G1[5]:MX`.ON-[2\>6CBT=#X^.&U7Q?4>U!@_E&YY161^&J+1^8>L_M'QM
M^?J#\W7_O826XS\:QP_:+SS4EA0M)5M*MI0\5$KN8Z;PD[E:T@(=VN1WN^H?
M=]6/&MYZN-9^S7>DY"T^NB:UX[IN7_VJ?M<?C)Z^^VCK,+<.<\OQ=BNWC#W(
MK;R/CA86.=OBJO.!VB7?-_0]"O_8[TU'>R#B+8-_6.W6LKYE?<OZPU3K!YVU
M.TS45TO'EHXM'0^/CH\:[GY@-*=5(.Y`'<BG#IKTQ_YHU-\#"Z-E;.LTM!QO
M`]L_(&-;)W`'C,5#!7>UE&PIV5+R4"E95<GZ9[?J55U%JU=4A;9^!986;RO>
M2M:W%6_;Z1[R=#=9=S<NIZUXZRJ<QRW8^$[,!3:V,LM9+WK;VTD2'CIGFHK>
M>FVMVWUE:5OK]I"XV=:Z;6O='OH%F7;5[:H/>]5W\EV>&EC=UKI]C.1*K^</
M!VWQFY:Q+6/WA+$MLJ'E^+YQ_*!3XX>)HVSIV-*QI>/AT7&C*MXS?'1;[;9U
M(%K&MHQM&7L@?D++\1^-XP?M&1XJK+*E9$O)EI*'2LE]S!:V]6[;!'B[ZG;5
M-UF4>P/<:NO=/J5?-?"/A^,]\)Y:OOYH_G++\78GMWP]A)V\CVY66^WV.^YT
MW)_PC_W!J+<'(MXR^(?5;BWK6]:WK#],M7[0.;O#1'VU=&SIV-+Q\.CXJ,'N
MMMKMG@=->EV_.VU+9!X>8UNGX4?C>!O7/DR^MC[@#MB*AXKL:BG94K*EY*%2
MLJJ2]<_?5^S6JF[;FS27M[WS40,O1OB/#T&4>?\,XE)XZ<+[$"5!,H_`+?R8
MY$56+K$&#,\UTD?1!@^Q;OKCNMF[[JPJ.'K7U=#X9Q?"FP=9=ATEYUZP3$N<
M>B96:5:($)%;!3PP"V)8H/#R"R$*;Y%FA.>R*][X7C"?\\NKX!H9Y,,SJXA\
M91'D,(L`N#I/DTN1%1'R-DD+H9_V@M4J2[]%RZ`0."20=X$TOD0:YUX(A"Y2
M^8?\`B9W5(ALZ25!468"/TV+65*E12\+\,O`F`BKT(F\Z'B-+/CO5V5^=!X$
MJ]>:BQ83WT7Y/$YS&.,,"/\F3N=__A7>44)*OP!1/3\'6OT*ZP%957_GRFQ-
M3ZA!S0"?%V_3Y4HD.66EOXH8%A&^3?,B/[T(,O$&:!A^":YI6GHR2%`4B:]B
M\9=G9Q>9$+_`+RYRF)P(_]^@]TN0];N]_K._RJWU[O/;L__]\MZ[*):Q]^6W
M-Y\^OO6>';UZ]?O@[:M7[\[>>?_Z^]DOG[Q>I^N=94&21SB7('[UZOVOS[QG
M%T6Q>OWJU=755>=JT$FS\U=G7U]]PV_U\&7YSZ/">K,3%N&SYL)UZ^09>T?>
M/1&G,NIC*HD9F<<=[[3`]='T/'L%+(^S'58.J!=PQD%R#1L^CM.KG%0![-++
M*(<ET`;#WWPX.7WCG9R^]<[2533WCGL3WU,^?K]K=*:[?A,$D$2R_VRI3O6A
M'E/DA?5E'!-&LQYYZ7M7%]'\`A08J";8^33!)>@?D"$4#E)"F9BGYPD)**YA
M;L]+?,-_"])Q01R#K@'Q.IH1`U<L8%YP%61A#LHF)*4DEJLXO18"=&"2)D?J
M1R^$"<R+-$/=R*HO+^,B(&49)?.XQ%KI^FU@$%(AI1+)N9*<NKD1'7A&*:OG
M<T3?>B&J3J,T/=![I$Y)BZ-VSD)2XE=1<5'#2DE-+\H5@?X#KP:HMS554E#>
M]"K1%_8X3%MDEXBI68DL2L,-BG;3+NP_TF'W(<U<.C/I>)T.*H@$0*X-"0*3
MR."QV;7#8^!D8>T33;>\7J@:^""%E:T&-"?<#37JCHY&W?H]]1[>+*YI;:QD
ME!)$P?P59OI>S;1C;1.SO7:67;_:.XF9Q;S"+1V`L*=H/WB7(.1>M%R*,`))
MCZ^]<J4>]&#C$D?`ID7^TI+J9!F_@3N1)5AIM1(Y'I-55-F9)P4]`"*!SXH`
MU,U"&X!L.5F?6\'_SY`;<AB6F$ME.L(/N5H@*@J0G"">EW2^P3F('\+GW\0!
MG&>G\XLT1LN&'C]",!L^L$Q#$8/FBT!?S7#-1U+C65^@U5O*0:Y22J[6QL<_
MD^@N@8B\:M1<^"!*/=E\CF!;BB(L,S59N7(UGR#\H\QICY'LPU/Q->BW"/<`
M/DZSDI:;GEQU?Q:IN_%03>7E[`_0L/BW^460G`MEKBY*M`J9TFS2PB>)`N:O
M]3N4YLS*V=&EAJ:\N^"344Q?<]4)RMRBQ.L/R&YQ&WWH!*!^OG&[W>R.U6W=
MVI8?#V<X1+SKYF4&&K3`[7D+B4:^A@+-_"BQ)$6+"![/49&[VJ%#.MY5&%&>
ME\:7*=!*AA'`3%:2BMH]],!6GE\8B@YZOH>V,VT!++K/\L2V$#E+\-FEY/L5
MG`ZP.!&^OA/#V\8L,DPA)S>9?F=CEO[N].+8L^ENBI5O%0*+'SA'\@!UZ\=/
M6[<>-19J3?+?Z;>J<03Y\AXY\\[O45-YLB](DQ?YH'3]$:7DB;L;X%GT9/S^
MP0G_=`UWMHR3_PCM(7X7F+%&/P(\MP"L_2S*_SQ:H#6GXKP4^;W)`-N5G;*O
MR&_@Y=.#.7[:29UU&`SN=W:@XMX6#+Z3$;)K2@PC#W/\Q64:!P5"2J];!?:P
M\GT\ZHRG^R#@+8?O7#6TW]F!-NS?J</VV#336BV.+N&U%]<BR/*7K6)[8#QF
MI]=]<J%OU=J#\7?4.7YZR_M'L\O"Z#(*,=EW'8DX;%78PXIX%WCYY"+>FF8M
M@Q\!H/H(,`I,*UQ559N;1JUFVJU$_BU2I;12)UWJ706Y][S;&4[H5\][G7X7
MO\*0*M_+1(X:%NQ#A`/<I%>?DH!U(`E]/#AH"2XO9#QYQISH/#&"%ABX13`5
M`H+H9RFEC7]&'(2$I049IW1I`I'(.Y0GLHSKA7#2T`A:TJ@9F?VFU'1EU#R"
MAZ)%!+];BN*"8"HI'G,A?8*P+PH0=M3K;C.LB\[`02V<FAX8X:I9,"_*(/8(
MP"MQ*"R$/(Y[X-KD@X?_([*TAHR+`'$@"`RR\5@7`?(5<3ZK(`H9LZR^SGCD
M%4@A(Q/HV90BR8D:;!40_L=]CR?9$'LF#`#2@Q9/V"`&(^%F".(\M2<.@U\&
MP'N$&!E(L_,].9J](`/K"Q+XOP1(20`<&'0A(H*VT$Q@_KU1I_L3<:<&3H/0
M"0O'-MGP*)`(04RP.4!]:!@E4*LZ)KZOP$8:_MCQOOXK8F0-P[$\1",P/-A`
MXU@.I&B8[S*D)DZO"*R%\"UK^:'[5?H'<)NV$N.N;OJ\A(KC&!>@)=<&V6W%
M9+`H#/V`C0*C$O[0AB7ALD%Z0<4LX$/>/P*0F>S:J&\%=`%UGY;G%TU`F!;:
M<A_0EN/C%MK23K=%XNQDJI]J>]!/$FGS:[F<P:&0+NQ?TI43+OO18C$>ET$J
M3&.SXX3=&OM7[[^);![ESN^^H&W>,NT)F'9R?IZ)<XG,4.SX"(Y`E.31W/XE
MW:A\,AZU6!MM77XNB[P``YMPSD6CR7B30;@K>VI?@V5COS<>^+U!6P;I_IG\
MU,53!IWNTZ-L6K:VU:T>,7WW8$7Y_L;!JO8\>F!<C=\_'OG='<C@')[BVADF
M=SO'-89=R]]#X6_/G_;Z_F@O-O&CPN,>['12X8CV?&J-KU:KM:QO6=^R?N]=
MKK=8Q":.VT.M%>]6L[6L;UG?LOX6OMN^5]T^S`XMNT/\]J5-+SUJ6.2QDLP-
ML,/6O'S@V]#^<#!I<\P'F8SL=\9MCOGPV#KR!]V)/QWM?01_WZW`0^W.L#OD
M;U^ZJQVXLU:?O%\D."G&S1]:Z^^)CI*A/YV,_-%PL@='R;XQ^:G-A$%GL`_=
MV5JVWM*H]P=CV++3?;#L6^NOM?[:EQ[)^M,_[UV)BD#=$,+;[WPMB`M44#^4
MU(X3PK)LRU$W7FBT($TM`JNSAM,^!WM,4<<.JMZP;6<,^$?3B/")Y_U.OV_*
M77BQR+D9D9R\L$=+<\&/R>O^-Y##-:!A'5=NVQ!G<6&T6``!DKFLQR"**R&2
MQJDXC4]DHR/5`^3?98J?OS69:!JR)($:<ZN.;-_9_^M^.[6]#[($B))_$1F-
M><`]V(ZM'FR-RW[J[FK''>]747B?4MA8,#F/9L=2-=,BM<%SW(&^:KIE(G4;
M2[#6&`D\O5UX,2X-58C:4+3"FB92E891_7'7;A:E5\P=HR0_Z<-$LX;.4+"G
MX%L;YL%-KLJ"VV)1?114&OJ-H`#=-2NY=`/VZ+'4PD4:@Y;)\<6BKD11HNY=
M.V/F]E'0\=Y%,8V^[1R)$(\S3RI%<Y66<>A=P+.@=D'GVN?8>KLDJG.C?H<M
M:XB_:U]6C>E6*16J"6)8$9`ANA0;2$4K_Z+?<!^DOF<YU1R2OZ'1D1JZOHX^
M*O`AM^,15F$),ME\YXV8!V7.W7JHC5*N2NDT#,XTPBY1\-<CO12]2J)-KNKT
M4#F^+9A.-8Z"I5!MOV:;97G/JKP(UABJBU\#9<4WZF(5<M$7LG.DB<`LH;4U
M4W%F.!EE%B_K&=;6AJF>JG=J>[1M]9&FZB6]W:E>LF?3O5,D?<_+0CQQVZ-U
M[VF3\?:@]/H1N?_T777:=D9M.Z/ZD-4/46)%&M#@<:Q*T(1!+AS7XR:#:E=V
MR+YF/EO<VP_`Y+'?'8_\_GBX!TS>1S#'[]+S;[784UWF'_B]WM@?3UL`QP%S
M>>+W1UU_/-R'NAP'G?)OK_WLTH)VC8X;17]O'!-=!+<]MQ\0Q-7U1Z.A/QD\
M?9>Z]MQ^..MLZ`]Z(W^Z`PUS?_"#N\7J[=B*=HZ2]X*F\VSX4B-TYGZ!21^3
M(DC.(YC!28ZY88.:.F"(TL2"*&U!@*<&*TTZWJ=H3JUH3LZ!_`14NPM8R2C@
M\=;)\]N>SC<G[MVAZX$0-^_..B[4+N-^,14GN;<*,L*[1(7$AY1YE(@\]YWV
M492=R1&#F7HQ<8]`D9I_OG=U$<TOX$.%2+Q,_+N,,N'!!$1>I(D@:$R67@=Q
M<8VMI)CG#CASE:7PM3Q7:,H`Y5?WX0G%I8C3%35<RHO@'.&AO^BOZR\N@VO$
M8\CQ0Y^[@'T#RL?"9PA/L,+^7D&LQH&?PG)>T-H7U-DI^U,4N+K9-?51.D><
M2)K!#^<BF5]WO(^)-Q=9$2#ZS"*`3:XHUW/`<.`R^%,T+9\GA:`33($AD(HZ
M-M&DO#R(<:5;R^4C0W)H`B<)B`5!R;"?U++*%$,(;J6&9+(D"&.FY\+A'G:;
MRJ(@]DEJ(HFZNL1O$99L6<9%!`PU8W'7J@Q[C`G]!H&>&#3%S#%08LT"$+)T
M'A%2&-&#M!Y\U/KRG$`^07@)\B]BD(+%0LRYMQJ(*TQ%`I%%%G`2"^%:YAG5
MND[WM4O+3,X*V'0D`6_R2R1;JB,833IO)!;OM'-$B-F2QSCG?)X)PC:!\)5)
MA!#A+(AA]MA6+4J0!O:.XJU`JY>2I_8S0YP"1%VYPZ1><)E&(8JV`NKAP0K_
MQ@\J`O_L7:17V'5N;7N421S]B?1$E*'`4+D](=FC#(F7@MAX>3F?@VY8E+@&
MX'(DL)7V/(Z2:$[M\W+:L>GL#VZCZ/:*JR"R3=N]=`9V%[.-%I\AF)J6`WL6
MOKTLE[*M'*R3VN$1$'&!;?U0-M>$/6>(8Y(6WOP">053!\LN6L`TJ;4>`=#>
MB;E`K.0:7+ZW%11\BS/^?JVJ4PO^^1XV<W&-#_T0MM74LJVV)L-36UC3CF?/
MU1)_C^>]^]!P?)&PUU\RL1`9'A^G.H?&H&R]K/[/:XTA@[*X2+'['YZON)NI
M4CM5:]=[3F&#\;158U">CANX/L?NO-V>>1[4.-\\L3NWHL6@`,JL<RH?X[:,
MI!5`B5UX%$D!:X$?P[LH]`,<G[$XEVH%6UYFT9STDL]X4P)*7Z:DG-0G='-0
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M4E-LZOEQISL86S6RN+;7"D$4([.H:Q%DN2EBH0I)*1WN(Y:BEA"]064JN``.
M\Q8I+7PZK`TX<PQ??Q^GI5XM$!TA9S#HU[UM1:5A84M,!2)X(^-<+6?II]9;
M87"-Z=8(DQA!=NTN#8=&RM@5SZ@TBBH:`T\OT+XF(G6\DSC6A54$O*>F#9^9
M6_6SX(>\H*IAE%R6:6"L*<1K;,K5=J=.BAE.BCQE.`@A/G1>GG-P"FRBZ8_I
M[V6$$U)RW`<J1>?GUR!W\S_U+WL_(P(ER@LI?IS7X5)'L+05P0Q2QCOHL/Y6
MQ<BLVF;.S!#5DB@Z6",#XPJ"'C@[:H$9<'P'=DDB*&7%DP,QIQ&NLJA`H$**
MI=>([P0U<N:RN]D=4"S_")(2A-'POS_E!"'*0+UZ&5)+V8IZ>3+5,NSTCP?U
MJL7LEV:E`AN5EEM'!]0LPPV:Q3ONX6VMNVJ5_L`_7G_[J;6*RH[>J%F`R(1R
MU,KE3HJ%<H0[I%SL<YE(L5F1/)@2D?B@/5`B-(&/ZZO#%2"_O<]R6;7:Y*KN
M6O'T>.*#FJG+#V^C_#L@?440Q?H%PL@$/+<Y4'V&NP"!5R:R=2$"`B%8(H63
MI\5])1X+S->_H_2_7I(M:S,1IU>[RZ9&#O6ZM^<0K68T;,SB/RJ78`$'P:%-
M&XFRH82AN\-V&F\"7#PPJYBJAEW60@Z":0W\.@$#);Z97S3]6I[U>MCU9P?V
ME[62@V#8.R['B0NJ-V]'%>\Y0E.'X:YD.]UDM*KOH35TGL#(7*2RH!CE(H@D
M@(D(P9S)+;,"S"%V8.IL+?"`+R6G"':>@Q6D1I<6G3N'$B'X^/B;&"RCH],Y
MF%0H01HRAX@C,#)#$<MZJ%A!E1'I.9"1H.-FSFOS]<YE]M\M_4QP=*PHC9`X
M7+:R%3,NY\Q`]+2Z=K0DG_>Z$Z(_D)V$[E9V)\FZ,CV]+6#'NR&,"IW^;W!!
M8']Y`@'%337':Z5VV'T<J7THB:7E/[;4\AT`](_H5HR\RX+W8\RL+R7VWOA+
MO!:NOV[*X=;*>:.,#UG&D3&WXOTM)-D*8$_:^V/?#=..+E&W?=3Q"QE.];Z4
MLSB:2^!Y<_SV'V4"MO:P+FI+:#NZUX.!%.]4S$$I%!',ZHLR!O1%0K0/T+<G
MQY7%MT89H,K,P7?FRR=\E8LC+XA;#A+KJA#(<\_O'@_\_G1Z$QR77%["6=,E
M(]B;/*>`B1%809E)IV>U1.#R[:LLG8.'GRN?6TV:@@QT;>T;;5U0Z,^/.]9L
M@$\Q;/S=U>):3,C=7;.2:'[:4FH4D<J6[W&(?[I16"PFT.T]<V-/WW!"]5S.
M<E"^@J[H!$O6,-34PHYWC7D\DIY_E+']I[Z:"MFW7],02&#M5_I7=S#Y&=:>
M`,>O?._3I[?>"\N*M-\A,_$EA="HWCC5F[Z4][.<!16^<V<))2Q=I72K4H5*
M7,P^"A\R*3>;"(UJ73=;[X(.;TI[E8/NC00/Q2)*(H*YF*N12HO3;4:^TZ=B
MBY7)U6Y'69Z[[P\F(_^X9Z5#2A@JES3'NW]XU:U0-=QEF`@O9W'<<]O`.(4$
M]4EHNQS=SK"+GPG,%UTT/D4O]>-FMP\ZHR[M=IK@"YQ&)8Q2YRB\9,/#^3.1
M@OHBA'7)GJ$=0=PN."QG9F+#&\.A,X3F)C+2^D',,C<F//`Y7E*"-,6R7CK%
MFF6E]?49#^P@LK:Q`NKE<IY1.7:E%J4@5#3AQ!](AT3>^W3H12O"RN[S(+_0
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MB"Q=^TXSJY)4M7WQZ!JZO-O/K`^N^713H^3J)&2('T\AB_(_O04H6)U=[76.
M^S\QF92!9FDQD,8@5C)$LYVGE+;-N!>;)[C&@9PLJ@BU42AXP*-&R3RCR_UJ
M1LZNTCOJAEOQ.(WF_G)$A.>#"0%8B%K488BOS;(BXD-;Q1[D7+!S%%$891]8
M&.(?0Y.BS+E'FSS?%8D*O-7.6>?\IE#$S7ID4]>\H8R!X)&BUD(*!"SW#"7!
M*)*(E<"&5<V"F%14?B&P9<ZME<RN*ABVAQ]6R7#AC/M2,>-)IW]K#9,)K#\A
M66ITC0J1]SN#[U(W5T+5K:A5,S4JIDFI=#N#:;U2R6^C56K"Y9DX6H(J`86&
MF[-CL(L[:!-9\8[-N==M8QT<8.AU[QCKD&BNAPL45*<[N'&Z#Q,I\/K^<363
MRU$"3B0^7J2@7XT4;//%Y@C"N-/=&$&P,`IU$03KSS)ZP*ICG7-CYIRKZ#;E
MSK\3Y$`KKG6S]))-:(*4534^X80D3L6JJ%@1:DG-00FB13TAQML%)JH^/KS7
M7W/R38#"9L?=`Q3W%Y1@$ZHWJIGT[CJ>E7#"!IR.43RX(4GJK+HH6OV`/0"/
M513-5:!*0YER;M@+L#_Z28V<V+%[C:-TN0QO94+O&7KH[77Q]1N,DZU2*8EV
M/)C^ZH2#Q\=4%^2V.-\+-`%@43S<VA">#:JTE8;)=ZIIAUS!AE]HTA]36W^8
M1LV%P1!:[C/^Q2*+\9\'_F0X9?]94%D2@YLD=QF%WC03M4W](B,CX=ID9#98
MQ7@`X$4QV2K:,I&U<>YIFQS'I&3Y/9L>]W:9YU[^=<MPCBOEC2$;F0RTPS:[
M%[(9CL?W'[*AE>^31W6_WI0.3CV@1]7K33O#[P_:C#O5FS;?'[RAY6\(X-S"
MLQIT^@\:KC%(F\88AV<0-KT)YUSD-S#@=80TTUN.[6UA;#76WL_[*N$T=YH.
MGU5`(*(.<Z**P58GP]4S<?:1*9]I@4W0FNSWZ/3L>+^M4F-N^L[F5H?%$CN1
M\UNCH:428BP[J8(P8`M$I-VL`5=!%![)8,P\6$6@6QXO#N8]'W;[NQ,#DW=D
M[B$.=CS=/@ZV2S$PO?GW3FM_O\:FM6_4VI->9S*^IS@8?F_8&>U&#(R6WNU,
M>X\2![L3WNTP,&<&*7_3)91MPVQ#OP;V+-$6U;M(O"^<*TGZ&@%%:7(9S*&`
MAF2U?@F\[<Y@9"(Z*"3K406$B:V'$:K1GZH+I@C2'!#2D\92Z!$IU"I&8;`^
M;@665A>AT!3"7V`9:CQ)<P517H+93<5T*&91C59TO/?5R!P1X47TTLS%"=*Y
MH;,7D?U@(#,B45;`27C$UP3K0W6C3:">YOA4KW-LQZ=>Y"55G^;;GD5T%$9Q
MR0&&\(^2,9$O:>4P46>FZ];3?4Q0QG0ZD^/;3I(BNG2KP0+;C>RM(0L+4]34
M%/^J\QGQZ1KY=`(C>J55X.7`'TIH3P/>TER)U%!N"E$X1BAN+3VS*K")@\U@
M#"<E(>+QB)1A"O0^\6R<"9926=#;]V9EP=;4%=([M:K-XUF4K]DWA#25M*@[
M[2ND)OHL(BPU#@-WO"]9A!--%1B0IN&J*..MPGXTEB;:7$0";7<][VD5Y2*P
MS?HLR#:9REN-&J?<N.'YE+^NP)69D&>IQ*N'T4(6&@:R%E=HHY+!1L)7ATFO
M%1X;64^67F;6L?8%(D`=B?578!TBNC3RJE;;\4YRZ@"!WH7<@1HH:O076P]R
M*K$H)#)OT_Y9UR:N<=/W1U+P:[>7+5`;-Q>[+:"@B3Y*([AA=7>)Q(T&Q;!&
M#Y+[&HILC,,WD@#+36^S1'E(5Z).9IE8$WD\:ERBR90W+[/1(?%UM%ESJ$S6
MMXZ)`F]B#WC1_N!XX$^'0QNK&;+O9MQFO@IMB8<M%,JI(9QZ[QA,D-%X=V/V
M9^0].F<RGHCKX8,;PHXUMSUW#B]F1*0N#-D0A>SYQ[HXS8,!QSAV_[!1R"?R
M87/CQ+HX,>6\TMKO(>0XZ/1'WQUR!%T\D?4W'%>QWFQENWE4]\+Z!JKS@A5<
MY!'1(/WQ3]LOK=_I'?]TT\+N&.VT;I.JB.='ON`@#R6975-7@1NF61/1U`>J
M'=$T!A`>.RKW^'PPE+87.4TLYG8D5V_QS;.KH<J&B2F,U$V3&T^VGMSM@L63
M,1?$N8&V*`*#<<\?PGEXJX7J\[XFINQ>(+__N#(6N!G?(;(,R^R.[A!;OD5<
MV5WZ=\:6X6`:CW8GNKQM9+D.VN&LJ^]W^[?`6>Y2?/G&L[C1TMG_^/+FXWEX
MC!A+E"AM[6]2.I->9\J/;SQ,[R-*W>UT>[<]\0>=Z>`NASZM_2D@H-UJZ'O3
MZKJ=X\D#'/K,>"O->>>X^5-A1[>K*])<$+,:\JB-;:N0!=^LNSG$;:JN;!?C
MME&+]3'N*G*N!C=7#7C717/J@]UK$64"O'J-463VK.R#TPE0;GBO.4K<O764
MF'=64\PS"2OVC'WA+!?4;5*B9V$S\R\*(=G%+Y!O7;DD"H/)I%T]M)(OM'#H
M/D$?]GI3(5*KR*`*D$;?R-MW"O'5O>Q>AE=(R-MD%HI:-*1?<Y%>AL2ZM;?I
MMXQVU<?_[A``P]]:^^O&T-^F;5`)_7UW3,P,`ZIEW8H<URD7UL?"QDCK,+V*
M::%!P9[PL#\9'3>79VG>>O2I')N,FJ:^EN[4]SDY9T&.%<5;?&_D3P=$ZQHG
MP03U</2AWQOU-F4BB"5P2%FW<DT<T7(IP%7H5X)"&UE:C76R:8$B9J3C/L^R
M^VB&=\^(1$=+;0X+UA85,_T3B_HO.7*&S^B\DYF$%7!47V!]0DO>(NJX:W#'
M'OK9_>^*-%:7OI\WR.[JV;#.N$7D\?O=FNFTTQW>`\ZQ^YU`&0ELNA=OH=^9
MW`=0IAG7^-&<5W5GE%;S6ZAX:1]9VD*?('+07.D@>RM:QQPX.TZ0BJ,>="-)
MG5-UH3D3DL.J1M5P'-F9`[_'!\N&P)`,=]7JC$8]J2FDD^F.BO1J->/W!IN&
M?E_>?MW%:).;4Z]JWHT+._852'.OPTWZUOV.*>5["C=)\/)M=//QM'-\?(]P
MQE&G]Q1P1K[K5%,K``Z>W8(S/E581CMV=P_-W.@;KH5G$-C#7[>#,?*JJUV0
MOGIH->`*AR.)AF\D]W^_NG7;^[_"6_]']IJA7WAGP3D>K?B\=W2D_L[M79N>
M4,.^1:^>G,_\)`G?PA1AU2*9PRZO&9LV$/SP52S^\NP,=?HOI-+?HT;_?X,>
M*&54PL_^*AOBO/O\]NQ_O[SW+HIE['WY[<VGCV^]9T>O7OT^>/OJU;NS=]Z_
M_G[VRR>4>^\,73J9A7GUZOVOS[QG%T6Q>OWJU=755>=JT$FS\U=G7U]]PV_U
M\&7YSZ/">K,3%N&SYF:WZ]3H=;TC[V[$J(Q2NV4F#W`5+9:MBO'ZWR=8]SGK
M;Q*KAC;$-V_N\>.@4LQ59]17L9E]-;R`4;3U\$*N,9'V#<LO,:CW(EHLG/N5
M>$C)FFQY+C)]G%;.6^<(S5>P?MC[.(.O_XKHM%<(/@XWY*8MA!F652R>8WP#
ME>ZP@E15[J.F958?;E*71^$SRX[W&;X$AS*<G7YUG"4<I19XT_IV"&=<LE[4
MTID`K7_L3RIXF3H4(6)$301/EM_E,4BSC3I];^>O+M=43-`1HBNA`8DT3]#_
MA5`-6LA32'7]-*;^427$12(;9L&5M/[`\J_A1TV7C\A*N,RQP"_?3W=!N6-=
M;T\=.:4$1S(OZ)')9MRNG(PLA"9KJ]NCOU`9'&LS_2Y7!6.`@HRX92&IE=S2
M,$[X_X1"Q[`O*`[,-HB4P[6OY?X-5)V3UBTYHB,E3IE:]B7F!CKBQRVPWJB[
MD4+*]%>4[WAO`JMJP\:96HK#F\-#2U40"N:%VX_>H_`5EJ)'W('1/=9"."XM
MS;W<-?B>@R/;DYD=W?U%8DNP7&1%9IX/E+VA)-_K'UL"7Z#C98%XFYD@V[35
M?AW=*#!KEVSK4NES8V76+BNUEM7Q?J^AQ[J8<(H!%"9/&D=0@Y+WE<^S:(:*
M:@:<AX'IH66:\O>6P1]I)ET&BLXP?V[<THJ!.J6OF!C$L`P$KS3,%M:]2C.I
M_JG])P%M9:N?&\=U.QOSH+NK5_G:2Z5NKQ8T)^[CELZ!O;U`+XA*VW#`5=;9
MT+4A4%UB$D*2S)Q]/BVYU*2@?^$->EU]6C\K-3-,'GG@[$TO`)&DH>#D@HG!
MZ08SW,I`OYUQ>+]6^JE.B+V_Q`D<LD'>LPSRQG4_N>W=ZWAF<A[/;K],<(&A
M-;9L89<(7@'J:Y-;RUE#IW,*FH4R1]P4>2M7&N*GPP^%!@?*JS:X\4VHT,F3
M?Z9P(XR(FSJ@^_8A;RP,PV$W%U>YA!'G@63=Y6O<S&`$4`=F;AY!ED^*IZ?S
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M]=S@$VMC\QCCO8$PDM$W]"7B;6T1M6Z%M`DHL6A;*\:-VCB!W>7B9L\*#OEE
MBOV$J=O8.A5O*%SZ/=Z729(RI>L&WR[-T631;^DP?0`7/\'?G+(&HS_@`-]F
M60S__/]02P,$%`````@`9(&N0`6L?Q/S#```+90``!4`'`!R>&EI+3(P,3(P
M,S,Q7V-A;"YX;6Q55`D``]MFL4_;9K%/=7@+``$$)0X```0Y`0``W5U1<]LV
M$GZ_F?L///7AV@=9EMVF3::YCBS''<TXED=.VKQU:!*R,*4`%B!MJ[_^`)"0
M*!(@0(J*P#Y9%K'+W?T6"V"Q@'[^Y74=><^`4(C1^\'X['S@`13@$**G]X.4
M#GT:0#CXY7___M?/_QD.O2]7BUOO5X``\1,0>B\P68GO/OKD3V^*XPV!3ZO$
M^W;ZG?>X\18+[QHC!*((;+SA4#*Y\BFCQ2CC=G$VSI]%$/WYR)YY3"9$WP]6
M21*_&XU>7E[.7A])=(;)T^CB_/QR)!L.LI;O7BG<:_UR*=N.1U\^WCX$*[#V
MAQ#1Q$?!CHJS4=&-W[Y].Q)/65,*WU%!?XL#/Q%6,LKE:5OP_X:RV9!_-1Q?
M#"_'9Z\T''`;$!R!!5AZXO7ODDT,W@\H7,<1%UM\MR)@^7Y`7B%D]..+\\N,
M^IMK'*1K@)()"C^@!":;&5IBLA8R#SS.]_-BMA6>T<<KGST^"_!ZQ)^.ZAF,
MN'2!'P5I)+ZY9;+L20E>$X!"$$HY.<_VK\LYPX0S.3_WAIYL7_SHH]#+B+VJ
ML-*4%JI?^1'WC(<5``DU&5K9>!^I@]Y_[Q.FVPHDD)F[D3!*RJIDS61[2%A7
MY]:F\^6,A8:UT1/U%(=9J<AWZM/5381?C&C5$BGD4;NXR9G5/I%[+XMOWE8,
M]GF*63]!/`:R3Q1',!3!-.?A94R\;S\C/PTA>_+=0-W11,S$P=[#B$<I3/:M
MDLLM0M'2IX\B'K'@_N3[,8M+X_$(1`F5WW#[C8?GXSPL?9-__<>$4B;7-"7<
MR>0+(O\11.*UY>>CKRP>!Y?%$O[GPU\I?/8C#OHDF?J$;-AP]IL?I4`AMB5=
MV3DF9%\SGP22.?NXYR_582!O,:+I.@M90X;S6M(O"5XK39J_#S<2'),0$#:T
M#[R4,IEPS-_'P\,+X&.U>/*UL5H`FA`8,-]NBUIC#N[AUUB%',D+EY"\)R#V
M8?CA->81C2DQ9^,/,84**RKW$+,2.T?ITB64,A&U,?NDMBX;66W.[UTRYSW!
M,2#)YIX-V&+^RCIMS`?W.Z#V]KKF#IF^7M`<B1^Z0:(Z4^/?_#%#3(@`4,JB
M(V#:K*[!,XBPD*)D6HOVCMC60M+<N&]<<O-?,0Y?8!0I7'KWR!$3[PN56_-'
MEZQY#6),(1O6A>QW&`7:X5'?U"%KZX7,K?^32]:_A?XCC&`"0<VT1-7HJP_5
M08!3Q-?R&_\Q`C7++4W#D[B(WKS;85TC;NXL;UUR%B8K24%HY3,U;=U%0B>Q
M7"N>NX3&U(]AXD>WP*=@_AC!)Z%^#20F`D=Q,8DMP7%J)3_%Z)E-&2'KTG<X
M`>:P92)P%1R#V!*<CA;GFMGQC0^)2`;,E[_[A/@\GC)I4`+]*-H\@"2)`!=K
MAG@N035?;LK!03A:Z2'QZ6A9KL$GEY8Y2P+1$_MTG[*)/NO/]P0&@&=[8<BW
MS@I;'$5P&I&[BDPC)20L3BWO"TK63Q)/#T(Y3-4-ZATMW(\ZJ-<NBRQH7,/#
M0F0)CU-+_\)P=XO1TR=`UL5AKWY<5U,X!XU)8`F,8UF$)6".$W[R7[.%=T'#
M.Y`8T@K6M*Z!U4!T"9L^_3#L9*BW&-^89/-E'H?O,=$.^VU9N83289I(T)Q*
M`Q0TG:#P(<'!GRL<,4$I3XPGF_K)@8;DU)C5:J*81NRV'9U*"EBAH;7_U]T@
MS4*7$$:WG:UL=1)7,3N'4E;I)(XE)]9KC&H-7VWBJ-6K@DJ3.U4/,`E#F(EQ
M[\.0K[[%!+@@O2J':D'D*"PVHDN@CIM[8%,D&,!D$@3IFML(A-<I88-Q89O1
MCQX2_ZG<#1I3.PA%8QTD)DXE'CX1MDY,R:8V8JD:.8B(3E1I>'TV8CL]=WV6
MI&HAU3.OYD>E2M/VQ:<U];9Y!>J%707JCI&'EUY>YN1@):JLH&`H%?IV+J^B
MRQC:GZ#Z42_.A]<@2OGQBTG`7(K-LK9U(U-,5:OZ@[B=I)]9P5>HDFROGNR-
M':5P-".O1L1U'.$-`")*B",O;%+`I1:F43OKX>S<!O1P_22B'167-$+TCLG1
M+:CV''N+J[V*$MJ.<D#F+=3")'W&Q`A6/GH"-YC4JEW>$NJ*:0\`[D!+61SM
M5"YI'HO4)'K20,PMI6AS$L2TLEJ-ESL`G,K39`=*(R;R)%Q#!&G"=7P&^AF=
MD>+@.&%X@S(,F&E.XC.6YMWV<[,:THN.6^VBE:-V/&D$C(%3O^$R*"=!/&Y:
M2CUHR)J=&:4I"-G`T::[=<:Z%S!WIJW$O:/45[-YEA!S;\K0'?*MF/<8^U;Z
M2O3-U4#.36V,5I.Z.55*<P>2+"EWBZEJ9EEZ?A+3*V649E?@(@VMSZMT4F,Q
M0PD@@";[2<W]XU_[+=RRGE)$:3NGCL>(@ZQLJ8XEUIFT^@FXB<`M(&PDEKB8
MTP_'R=Q7+Z?(D_>7;9+WG)LGV+F7OF<P<?'N"7Z&[/57F\^4#V/;.#,)6%37
ME=\V(3XX`.TY%/N4)9N%)ZFB46WS4_6(AJ;>QJU:9>2I;*?R.-<@)B"`PA[L
M<P2$F=EL8<W+S/Y6K0ZSVD(;LA[!9Z^4A-&M;)`/$?>Y.;J&5)PQ93+-E]H[
M#`SM>P:<01N)F#[STLG,BXV37/Z%=EM5VZI'YM;J((WLUAT>04"R7ESHPO,E
M\Y+L8"WKW/<$K&&Z9M'ZF4TXQ5Q`56W5DE&/D#U$30F^/CW2K(=U5._*9H[`
ME.L412F:ACU#3Z>&1.>XMY!D`5CF5>;+K+IGAFA"4E6WLB7J$0BV*DE`.LJY
MF+.)PC/H1Q^%G!I&FP4(`5CS,SLWF'!-/\=\5QF0`-+"\5!#'K$]V[Z!VHG2
M$O8C9X`*LF:76_)HX*--?1;T`9!G&!A3QZTX]ACM5OI*H)U*5W&)^5V9S(.Y
M`FPHEYY9D'U.II$/UZHI4$/Z'F'>0CN)\''K;J;"M6;(9AMKAJ;\VNB`R_$[
M3%:_^03B-*^QO8&(*<<,H.S>1WE-C_`_GA'D]6_ZE$_7$;\^1-TR+T:4R;;@
M;S]LF[#"JV^(M]=4PMI1"JA)[R^?%37?C]&"2]^0;*.CQ+"KI%!'@S0*^/D/
M<`VRO[PV6]R?*@]S*^]158W6+1GU"/I#U)3HZ[-5;J!?N@'."N@*3>\QK6@D
MX7/J)%I5[NL4?,+"[Q9`G*UCJXGZF_%:\.@]ND8-)=I.7<:C]-+2'8&VW;5"
MUGM,54I)&)VJ-%)?(W\/V(0^+*NE@+,9^4E@;:.A!+:)2TAXG;KZ1Z-`MGG1
MLFQ"27SZ\+/_TPA6H:=,XE+8J8%('W;*"DF?//:]1F(S-`#PF4LNSE5F>]#*
M!9F^<8_L;U)%6EZ?(#O%!)M-(,46S"><'WY]6&&2\&O,ZK=_+>EZA%\#K>0U
M^UTEL3K[/8D`@)#>,$,\L#'MHY^D!"8;/M3A*,J2<^)P?RVP;;CT#>8V.DK0
MG:IRJCBL]L<W;/IP#7'?$&Z@F@36K;Q7V4?GRT;0-J'N&[9-=)/@'OG&9C'L
M+U->!\UO<.(I\FP>)FKO]).>&I(>H6*GD(3"G*+Z!RP(E1:3%G`J;:-18+MI
MUV9!J"0^903=;6;7WR%G0>-2OZP!214M-1I)MW0J#25'<'$=1)SO6!GALR#J
M&WX6*DD`NRJC.L(,A@LZ%V)160@6FN8M:IJ^X6?62,)WW-N(F`I%67;E>(JB
M#M6$I1E]CU!JH9U$[,C%3M4:C/TJFP\TCI5S2SO"OF%DJ9;\V;XCEQB5/*8X
MMBI_Y,>B3UGPZ!MFS364\.GS+*<8S-C8FP_$\Z7\H0?-SW(HAK5&U#V"N+%N
M$EQW<RV%'??--7@T)5>JS7L&7[TR$B]S^N0?L&976DM:P)RU4!SH9]]R919@
MN6<0"M?Q;D#0C3+7@`8$QMF!LZN40@0H/V]VY5-(>=(+4'X7=;:[Q%_S>3&K
MNR:@$;\RIERA/1VVQ_[S;TV7%#1Z>_ZB_.J"-^?G8V_H\3-W$:8I`?R?'3M^
M48%DZ/DH]`1+_JU"I?9P\&T]E.2%5\Q)F/<@]C$`^?Z`!0(F%IT;W?3"BITO
MRG;..'@[%IY2Z/9FG<2\SLG?VRJU,*6*K'/SJ5Y2,=EEV60YE5>5[0#G>X4/
M,43S-+%SM$+S[IVJP+QBC>\K#O0%>KSY<"=,>S-LRYD_BBOA&W0]#67GQM&\
MIV*G'\IVXH2>H/04(K8WF>[>/@N;V=YG>+#1ZJ]@+%CM3=EJ@M(3I)Y"R/9F
M8U,$?FR5S2?$Z48K>U5H.C=4Y0T5"_U8MA`C\3B-QXB\HESM;9.=_@"3)P(:
M]$`%5>?V4;RC8J&?RA;*B;R*9`=VNM)O.MAV.,,O?773V=2_2+$STEME1\NI
M_NOM"7>((R7YTM#2@W;-C^`Z.^9E<XS/JSY3$N4`7TD?*?@KY3>'/%MWIBI1
M]WY2>47%+)59^8[&VY-KQ"D?691F__P?4$L#!!0````(`&2!KD!NT^>Y"B8`
M`&DH`@`5`!P`<GAI:2TR,#$R,#,S,5]L86(N>&UL550)``/;9K%/VV:Q3W5X
M"P`!!"4.```$.0$``.U=ZW/<N)'_?E7W/^"<JXI=-5I;N]DDN]G-U5B2<ZIH
M+9VDS:-25UL4!Y)XX9`3DF-[\M<?'GR`0SSY0,-[]R%964(W^@>B&XU&H_'=
M?WS:IN@#+LHDS[Y_<?K%FQ<(9W&^2;*G[U_LRY.HC)/DQ7_\_E__Y;M_.SE!
M?WE[>X7^@#-<1!7>H(])]<Q^]T-4_!V=Y;M#D3P]5^CEV2OT<$"WM^@\SS*<
MIOB`3DX:)F^CDM#F&>?VY1>G]=_2)/O[`_D;(C)EY?<OGJMJ]^WKUQ\_?OSB
MTT.1?I$73Z^_?//FJ]=-PQ>\Y;>?RJ37^N-73=O3UW_YX>HN?L;;Z"3)RBK*
MXHZ*LI'1G7[SS3>OV5])TS+YMF3T5WD<56R4C'(A90OZKY.FV0G]U<GIER=?
MG7[QJ=R\(&.`T'=%GN);_(B8`-]6AQW^_D69;'<I%9S][KG`CW(ITJ)X3>E?
M9_B)?B#:PS>TA]-?TQY^4?_Z*GK`Z0M$6_YX>ZD$]$V/5TWTVIN4]WD5I:-$
M%2EK>5/ZKRLB5T]B_*G"V09O&IDI$\WW97VP><&84K9YW&.8TDF2%PT_UNOW
M+XI/2?+3>1[OMSBKUMGF(JN2ZG"9/>;%ELVI]4-9%5%<]<>.DI&Q.?WRS5=\
MAOS"@='K5D0JP[KHRQD5<=,7^=$`NV[Q.LZ)]NRJDY2/+"=_+/+M"(15[D#T
M4_J0'B/JP2EPF>^+&(\==]X!,0N$DAH^G)W\>.<T*=B0_+[I"T79!O'>D-`=
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MT.ADO=;!:>)-@7=1LKGXM,-9B0G8Z^H9%[UE6S%,5I0P&N<`2M0R"S(HS;(6
M;3`/:TJ$.:G_U6RZZ#4I4R%&C(Y<Q4"V/C8^<!!;'>,6)XBMC6)6L$@ABGL;
M&]A]C=U^9H68Y(N(6@G1TT4'UN?"E.]P41UNB(PL$$B6S1T-U+W'ZA5)1P*U
M%)EA]-<@=7NXQ<<DTV`NM4V8T7[<%UE2/A./B:A#A@?VVL,:Y(R@(5DA1L3#
MPPW9"KT?HK#1#<7YP&5&NHMQ61*O$9/9]7R./^`T9WW)`N3Z]@#G"#8`VO,#
M7>-%YKAL:EA*,I@7EQFJ:5!#A`2J1::V1D?'PSC9U3"*!@:=XIN%H6SJXQ9V
MN`*'Q=\Z]H<\WWQ,4I5EZOX,LSX=BR>N1<W?H-:=?O^#S][\V?MJ,E(N?W/N
M'._R,JE*[O6])[-`NT%1-X>9DR;QQ3FJ:@LU9_7R#.9*T]S['!XI9[OS[BB@
M-]_:'0_L=EN]SX;=8&LW@*`[:L-6&GP'/6+D_.G#51(])&E2);@D>YR[*H__
M_IRG&UR4=.-2'0Q'\_;D,#KE"D_4.EM:*+UTDV\P_ZXNUV\OKR[O+R_NT/K]
M.;J[OS[[XW]>7YU?W-[]$KT\OWAW>79Y_PI=_->/E_=_]:[;4]%UY.TVO#H$
MD1\@B&:7_Z(C`%<KBTP8=>L`5,<M)R;M"/TGQCA++1"$E2*SCN-\GU7E372(
M'E)L.`M1-`;RTK2B][PV:4LP+TXCS=!WJANC'6_MW[,;)6W=.H0SOC@N]G@S
MU%@U7E5[L&FN!W`TT^6-`2>[3B#9#*+MVP-OYC+D[-@X'EI^"&T8!4=F_R'S
M(G<)W3#AJ,37#VGRQ.*Y!L4P$4%E0MI`Z:=`ZBC@<A_-4BE]H6U4[0ON8>>/
M*.:L4$IYH;QC!I`*.094+3ZC0@)9"(J39^1;5@E9VM[G%;;SFDQ$0(IC!:6G
M.%H*,,6QD&HXQSHBE%&JQKU:-:N,?UV9BH-1S>)X*8ZYWT5)P7(FKQ__'!5%
M1)U"TF=6)5&:'NYP51&+0_J^S&BFI.QTT)4#P%'X.)#MX;@;N=_C\C&R#68<
M9<+SS^E2T_!!`B/4<4))QK)F08[5YX/[H8'[L8&[$^"6/;B+Y3P;C][#P3O!
MQM16B]BU*LF>R$\W9)R>B2-P4R0Q)K\NDPV]"J\8`R=R`.LR`EYK6AQH_=H5
M9\&4?FS'`C4\$&.">EQ`S,E\*.,.Y:Y!N6,HX\51&JT(.$S(Z+]UM#><:+]=
ME#^<Z+Y5]C)DA,=:9%E(!_2,>_[!!H](&9.?+.B"BDOITZ&,1(%%IXR)1V>J
M4!1+)&?!JD$(*Y0HE34X2:`JA/PJ(39PE6=/][C8BH$%<QA"3@4>K=*!482K
M9"0!Q*O48KD$K+(\.PD@:#42S%'4*@3%.<>/F(BPN8\^\;0Q86%]CRN+A%QK
M>J@,74>`_91=2V*X'%XG`27)LIP>5=&GUCDZP.K9;)@(@SH)&+T4>+QB5Z)T
MZC<-HK2P72A?;TJXRF*;3*2^?JP=\IN\4&Z\Q[*""&--@]V%M,;Q\1S>FB*D
M;.VS"7%1=:3N<1-,J9G"1+Z6&@!=6&BP0=@M.`+FJ%C(0P`2,3/'(`*(D1F"
M8P%$Q;01FD#"8#;QKS#"7F-'TY\&.5_K".\BA]O5C?`N:SA?8!`)?HE>;O!C
M$B?5*U9DKCKX3SZ?"*"^?[&NJB)YV%?L(+?*R18\F)STFZ)VXIG@NAIRTI9@
M5:M40A]5J3IN!EB52BZ*K)13O:LJ:=,5^O<W7[QY\^84[:(Z6^!WZ.L5^0W]
M'RJ?R50J4;2OGO,B^2?>_([LOIK?)F5)\V%95N^^HO7A:>5[B+)6SMCO.';6
M>(4N&9!0E(1H[W5Q5]'=-9/O!A=W=,"MX*N)0U`E$S2U=JDHPU`XO71F'6QU
M#UAY1N.H]8G0H[Q`G$.=6D9X(,8D%/UBPI3KUJ19C<R0*`1]4D%1Z]$Q11CZ
M(Y?*K#>#Y0E8?YQQU'K#Z=!:B0-65_CZZ#`"#4$X.M*'8-(/WCHDW1`ELM:+
M1.K7@.B$I?Q]?0C++^-"77>>K@/\'E4X6B$!8U(-@20D_1B(9:TDX6Q=W)'T
MU>5:C<1GJLIVFV?&W?ZP&50RBES<?O9)OPU<NHE,#LF1!&VFV=Z??JG=X']-
M_O+;+U>GO_JM9*/_JV]6OWKS&_&/@O[P%K]9_?;T=/6KK[^2D1/2KW[-_MBC
MJ]`/K%C@5Z<K1(]F6>-S'./M`]D^U+\E_T_8[7!<)1]P>@#(D'$9_[!"#(+L
MCO$%*TIPY76)+%B0!:#BCGOQOM;#!10F(P@[E"#`LXPC:"G`]<8F@J!I'H">
M6.ZY^_H!'S@8C2"\D,$`BC9>H&P=B"ZH(P6*IL'H@':/+9W_0`&"49+WYGU0
M#I5M8$!/$LCT-X0$=.V#403S%EJJ#9"1@/$8CO0BB"#`>K-):'I;E-Y$R8;>
M4F?7:P20BF&P(00JW64-J5?#RT@%5LS+4K)A&:R6$-$WH4Y8X0!&Z[^"UPP8
M*"6O;<%H5TA4JQG3R\]YJM$ZCO?;?4HW->?[@BBI\*A"E)+=SI/\'6X':HC'
MRYW!=4^86Y/Z315WE4MV>X$R0`('Q%F@'@_$F(!D@\^&,1(P;CC&ZAF+SWX0
MG.5B.(TYWP$`];?XWA<X*O?%P1B#ES6$65S5(HN+Z;`5U.*IDF286$V?PJGJ
MUFW4@1;4**L5^O5OOA:"\-Z73VL43<->3!OJ5IF7L0?25N[$VP!O6@:@KWVA
ME0K+FP6AL:(HZLG>VQS"*J>=P+V=8$CW(A0090U#N0<AF\[#5N'<>]!>ERFU
MMQX"N/0P_;(#Z+6E13]'.*_6*-";R<`O#VKAN+Q.$\`U0XU<YMMR+*^B/_^`
MC,!(1/(7:$*YM.CGV_BS"-<[=G\Y>ZH??B\--QPU[6%L@!&`J/S*QE!:;Q!H
M^-9SW<S_/4972=OVJ"$(XK;B;?UH+=%C(314BWCQ*4[W]%QE'1.U+/"F?2#W
MC.PH%0,SB2.,SLPP"*)636`'I7>311[,]UO%:\C-VRC>%79AB`+/1L/1RY8M
M:OC2@Y?F#6_*^M6,!RX*A-M=FA\P9LOTVZC$F[-\2^5CL>-:5%D(>1([@".9
M&>"W9S03>/D]M)DLJ,.LKIGRJ`MB;)'(MYGW("<["P]$SX(U`\%<UY,'-A"Q
M.!!+VCCCT<_G,!*S6[GW!,.\ALZ>8S"VSG40#.;.EET(%L]-5GNC]YZ:M<_0
M\,TY'J+&TTJ$UEJ/7B89^3T>.#F0AC#LD9GGA2,A'^B2X(F?"0+\+B^T/O#Q
M*=Q<3&'?09HV%+*GD<9Q!'LM:8JXA@>4Q,0QNK%IN*/'O$"FW=$R!XP.[RK-
M/S#MTT.QD&S;7`9,J/(+XU-`;)!=WF'ZS,8GD)C9F.A#D'$OY\A6D+$K[5$$
MB`J.CE&-C$*!GA3Y^S83'*<_X`P744ID7&^V29;0H#R]<*WSB\PT`&Z/+9#6
MJS$1^'5:[*09S)>:C$V4/B&LJS$#G*@/!]0S\`9G"4W6;OB<T!HXA:3U5J#-
MMD#+)A`+82&CD]TP17S",BA3T1_K9=CQ[>"'8?883O,B+K\!3+9@8SR6V5@'
M$\\9/2R&J(XSWQ!B.R.%=HGPM.]E\S[8+CU4Y\O#(,FC&>VKTTDW2$^!NG2?
M^2#-'RMGTO2"7?-9VE',@[&U$X;&%$-WYQR"O1TMMHO%O6Q#H[W0^N=E=&<>
M*:<@\N=E>3^OD?(7<#<,@B+V:*2"";I;@A'#[@82J,"[E5B*\"Z08NJ"[^/@
MF&TQ:`#>[S<"O*>AP"]I%\B]#)FB#QH%<P_#>*LAS4O_5X;=Q5S&/^K?Y;\W
M*>4\HSMA^W.959@`K"Y9$I+,03EN`;`1D0O9[B;Z?_:[)9#U/?AZ32/$6X%X
MY&Z"OJS-^BN4+">RT3>>5V:/2U+UC(OW>98W6LL!Z)U4$Q'08F4%I;=R:2G`
MEC$+J896EQ+YT07MVC9>=I&JMC[T+A+'`Z<@[W&MTU=D-5.@/FH#,_VE@HJS
MO=<`:G)+A!C,!_H0-XAG9BM<,SMILU>*2A<P.Z<IP^M/IRZB(B-:7C:5Y@W7
MU=7-833-)+ZH=*JVWEP_.T&DDX3.H:Z8O^;FMR_C,0(#G>B(+"MM.)'2#2[>
MPTW]MU&9Q#31,$GWE;(8NY$J#$50@-'IPQ$)U+)D)=9@@K%6/->3M^NF6RE[
M_\*[DMO!:*@Z75^A#EI-"Z<R?\;)TS.18$V^8_2$W^_I8T/7CX/ZVX95Q)T-
MC%*-A2MJF2L/*+4;)^=@`C=L4,3Y](Q]KV"\_Y(K<T.L^2#.B!Z4#9^56S5*
M.[%:BR(0IX,D2*%?VB9Q`@CL30/=!@#'L?$;*)PBH_/$%>>M>=7Q$G^<%?_`
M1X")3_K%Y#4\<Q:5SS=%_B'9X,W;PX\E349H#R'6]!5"7O1-[QZ,8006Z!D)
M^2@:Y,@%,&0T2M+A2RR$"WI,\X\EHB.*NG!CU++P[R#,!H]N=QG$AA5Z.*"7
ME!M*LE>H.Y?K."[C'_2"4.0G7DV*17EEIDG;'&"EMQ"_7<XU;?VNV49!=(%,
M%NAIB1"C`EEYQZ%8+%9L7%7GD]?GHT__LR\K"JN\SV\QU88DQ3TD]_D\:^HR
M74$]++7<L/6?HIJ_'[C'JY;"(GDJJNV*GL$436<H:X+`Y+?TYYBND'N^*`;B
M`<`-4]L9&AYKD3_[]2;F,6_G>$<^?L),-ODYQ?0'FDFXS8LJ^:?,E+N1PI@?
M%UBB.;&A@S(/]K))'GKJ2'FJIT`#EHP[$Z`5:HEYAJY`#IC/'B49M0S7V7E2
M[O*2O<QW_;@N2URI$B,,-$"Y[#9`>IGL.@*P/':S4,.J_'0=))-JPRBBE`;A
M:.UZ5J/$?^KZ"`24IEF@"!"!D&+AI%`O7BW^1:9LR?.,+N:WRI)/RE80&W"E
ML-V^>]#$\W9;T?]POY=GW(VZ%:H;P>RM'40^85YR`5[8;5Z9/>ZQX[C@B[^P
M=%\_$KL0YWOB>Q.?X*;`VV2_+2^S#[CVR%7;@Y',@/;)DZ#W=L*C.('M=2=(
M.]RF-<R8_T<<0YSL*KHV/.3LT(7S]+]170;C2Y'=*PJSY<CP-SQ72.`*M<H'
M\)T]OA%8)Q%I2T^9&@.]%:@5O?=>H+0EV)N!&FG4RQ[+=)%4^_'_:*"+^'>"
MU+I"51,<7^Z0-W?3KQ_Y6U^765D5>]FB:TL$X!9;0VF]9".%7Z?94ASE)JDM
M)T$,9/W*I$`,XE1/A80%2/P5.90L#,GH=/O%-$\]')X#]P-912EUDAYN\0;C
M+;V2\2XOZ![BQQTMDH^+."E)^Z9<D`S_+&QA:^!,'0Y9]9NQ/,'JWDP3V%#Q
MIDZZ%+BCCCVK3<)V_;0'U'1!Z9I.H$O=+#$X;>F6.N]V*PQ.T1\<?@JW8]:B
M&YR/2PZ.2WF;_T.C8][Y?-:#,\_RPJ_T41<UR@[ZVD=WN/B0Q,8::Z,XPBXJ
M$P9!MIZ,8`>VE(R6U;"*<+ZH9FQ51JWA#[V`S#PD=B47C^M_E4L.ALN"$?1H
M^(L74;@1,2ADD:`2K[--8_P%X-?%61HE6U6XVY$'3'1I%%`QZ.3$`"H6-4+(
M&8KZ+:K4NMC5''`;'FR/P%#2R&Y;A%BTX(AN$ABO&9V6,S:.EYE-E=S+["S/
M,AQ3^_;GI'K^4U0D^;[D^_UW249PT&NA,M.W2#<`[LV"P]7Z/`OTX=<16@S`
M\(8&MP+$(CA4]":MNS[11](IJGMMHH1=OR!>$\3X/3JY$?'1^'VHQZ\.WSTN
M.WY&1^O_!W#:YOUG/'X^RJE?D=4Z*TGOM_0.Y;3JZ0->(1=+5P!WKXU^Q"C0
M4NA2*6>H?-[R19PQ]-9]ME%P<NO3=A2*Y49AOAKF4,,PM^^?T4L:9$1NR%`^
M1R4FORF3#;N\X;#8&KB$XKE;@=4[YEH6`?C=%O(YN-4--]2P0SU^X;C+TV`?
M.R,M[%T#.UX<]C@O]S/&/<4Y!87M,5Z:Q04F\IQC_E_A2M]9M$NJ*#7<L'5A
M`!0I=8;8"Y-:4X/%2!TE5$S;DL[;B%T581'#-(D>DA3H0NID3`T#]+)A02L2
M"Y=&:S9!W!@=HKTI\"Y*-N?X$1<%WM17#];9AMWLU]YX&\LL%.5T@:Y75!M.
MX2BMO;2#R5Z3-K=.N/[FK*9UO"_8`6^TP,6T47H\`:9"IQOT-2L&GA?TAKV-
M%\8GAK1BZYC?2+B)#C1YQGJ<!G2AV"8%(+T9.B(*Q^)(!9/=$.$787:\60`V
MQ$YPA;EH\=S(\4`JS/D>W^?,&-SBE-J7FZB@#M@95W'K`3+R"46A+`'K%<S`
M)!R%LQ)T6)AASXKZ/^;%EEC[W7*U_=V4<!P8A5+6&/FR7?-#-<,5JEF&I*GT
MWMR>K/_=)LG%>@U(0]%'-2SC&G=$%X[6J623WH6D`7.-CR5LB@-006MDZJ60
M`;Y2HPJQCJIB?%P8A%XW5:9U]M3AUTG5U"8TED<+N#[J?'51P1[O`?B`X#:&
M7Y.?H5:SEE%0-L<"LH7MT7`)S`89)376:DX:#B'6:G:'9[!)+</0JBL.O:!;
M(FB1Q&3'0/%8.T_'9*&XX'(X>O>[3Q..ZRV32W-J6K3-V2(2@(=M!4#A77>T
M3-'""4//^U6FI`NQREHQ3CY0&[:._[%/>,TZZ2F]NC%$\H])]"['1]72<RJ/
M7@SY\M<0\,UB2P*3E#,&0"$`B!8&8$ZO"1:!;:+,@@#\>1`WT:&N=,T0%/CN
M.2^J>UQLS97P+&EA?`DG8*)#844(Y54X"#<\-6VRK=B]?D)V4A&ZVI5?KL"-
MSL>8!*>FI:'RFAK==;`"J$WG]V-YM!E%'F.\*=\1A;N+4OQ#5.V+I#JLL\U9
MGJ;\XDAY_6AA0<9P`K(GXT'WK(L[&S!;,U;4P62N*>FN.2#;,QN\AA,/C5!>
M*]1P8\<F'3^*7V.9`-=]`F*'B^IP0Z!59`PNFK+7ML9-PR`0#\`(4>L&**F#
M\04,$LH]4I9(16_"[(05IZUYSJ;OX[[(DO)YL0NG3AZ"*TB9F]#P6"'&9<50
MMHR"<1<`OB><$W']Z&R!7#B$X318@-0Y"QKR4)P$HXC#C![96POP=F<RKJ%7
MP$I,.9F>R>'$QWVVH<E(R8;>H>213_86ACJBH2$!"RT:81P%&)7M(<*,!F%4
MP49.AFX:>\XH44T*&'0<!:=HX+RDZ],K?O66`=HL",@R".D'48@'^Y//5<,_
MR)]V@!_^P;UM[HGLQ#[@`_OY#NJ#2AY:^`."VYBV(LW4Y"$MHZ!LC@5D"]NC
MX1*8#3)*:DP>:LL'A9@\Y`[/8)-:AJ$E#XE;G*[6HE"&Q6)KI*"#WVUK`:GV
MV%*B$';6&L&DTW'7VWLF0A%,L28.Z*;:!5)_*RW6]!3K/<$'T\GVX18W<3<K
M5;(@A`V>FR')@N9J*NA@N4DR0U"UP&)8%5:9QB)J(^(4T&T/D$Z=?(?!O7TI
MH)@W%>5ZQPX9F\<9-C;!2#D=_(JK!:2,:LN(0EAQ-8)9K+CB4QB]*G0YYP@;
MSG:`=A3$9AAJTO8=G<V<#R/C2A2U>[5$4B!5%M!SHX=X3'D$P.Z990=BSP\P
M.TLFU:+^=!,?:I*6G(9YN'D>J)8&`_8-IC"P3CD%&Q85[==3OBAW.^G)@!TA
MQ(F8"Z3N7,R&RO/IF+U(0U]/7N?WN/`\Y0!S5#8=VW'9VN.:W!=W-S=`IV:?
M(SC;K'X8;/.Y3&)<)2/3M$H>4OP^K["B\-1('O"NDS50E?MD9`#J0EE*9^%&
M]>-E+2_$F*D*/T&X4E,@ZR*>'>2,05ZR=I>K2_598[:TJ6%!]A?NN<6[.I9U
M_7B59T_TYD==:95EF5P_I,D3FRBJ1`PG#C`AH!$@Q6"0`SE46,A9Q,',[3BP
MF5H7V^790GE'[3TJ-#<RRH-?[&@*"O.DM>NE,-I'E<$^(DQT6:A"=SC'#S8I
MU$,2^)BR"H8JG'S</H1(LEPF^>E%M/E`U[,F3T(L<DA#)?0UTQ7*L/^*AR,`
M]9U0L8SA`5&RSR%W:7+J2/BY2M-RE,+/33*EU^V$I!U98E+`>4GSY2,%E2/I
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M07CI\UF%:67`IAZ8Q2YZ2`(?;E'!4.;+'[4/(=PBE\E0C6VS+^B*1=<O;M)9
M"FE2LX+-D[?#<W3D5Q.U-0LA2]1R4>CU6@7<?A.HTK-#,?ME9KN_PY64/99!
MDP,=V)2VD+V=M+0-[(Z=+CCOR:0A/W8W-K.-)#)QWJZ_!F=K.ENXG?T<PW&\
MVY_"$S(",%UN%X<NR[,3YM0)MW]I990@;E`N-!RMR[="-6?A7C=%+[U1V;$/
MPCL4,LA.55YRKPG0'DLB9F\C)?P=;+<TD&&H0;BJN`;Q5)!BEQ=1A5&W8VB?
M,4KHSS&OYTU71-`[7#;0A!37&;,&A>>]FP1N>;ZCD!!)G,F\V.#-NCS+R^KZ
MD894JH,LXV=.[@"9AO,/3IN#.!]KO]F)<\L]F.>T`_2GYI'XI@]-;G<O!;SI
M"JU+1#NC/'AW((F-?D;K0S-:S<4)3=)Q[Z)%T8Q65**(_(F/%UYNO(Q9D3^C
M`9M@E*5WXB^SBWJ]NGZ\WE=E15P@XOOH;L&-XP-@:*<`;DWJ&"9^C>=X"8>;
M9$7Q`SJ%&W[T;P)'V.MR"V'OJ>>Q3Y<+X&$OT(6*?A[/\>XY(J/V`^F+4B?I
MX19O,-[2K.MW>4'W<3_N\JR[-5@C-"P`H[G">HH3!T/F(8YD">893I+7X!%R
MWDA@CCKN;-ZSN`'MH'=QN.X#V@U<8&A:;Z;D0[,5AJ;H#PTO)$>'AL:#Q0NX
ML.;Q,QZ@"1:4.*YI5);)8Q*SD6G!-$\/'T2HLG%SY0!@&<>!;*V@&[E?BS=&
M-LEU@CX3P5:U3U`?^N8,Q(8M!K96K/85\0/7/[PD6*-!"@7M!.NR3EEK)CPQ
MI]$3BXM>U/%/&6@3!8#UL`/16@M]<[_6P4:6P93IB.ADZ<A00P>B^S-`V790
M\))0C)KM!\L$O6T?`:#'9]W+!\U6D=8F5Q<4',4!0*_'@6SUW(W<K]Z/D6TP
MX2YZ#V`(;-K@#L_C6*Y0GZ5I6`"M\-Q'&]#8^#FC,UJ/8.#Z.\$6]F;KLL15
M6;]*I,KBTK2'.=LV`A`/NI6-H4Z]#0(Y3*ZH)B1;VR+?/SWW[RY[/_-V!=8/
M`W&2YB6O.4_$:YFZ]\"9*O^8)41"^B3@H"[058+WUX\T,O$VS_8*WWH.K@#K
M]'R#T:[=TUGZ7<_GDG<PH=NYW+&NSW`8\_K%2&E],]H%._FAX:JZ%Y#E?_G!
M*;K!X<<<^W9P^J<?[>"D]>`\\`[H/:QTOVG>VHX+V@QV#_)S&S6?2;G24AV7
M6;POU"Z)D0HJI=8*3#]C5DL"EQ!K(=;POF23U+K\"V`Z1V2<\,K*-J@AA-.2
MZ^(IRI)_,GG.B$AYFFS8/]Y&95+2)PQQV=BGM_LRR7!9GN,R+A)6TIG8H'4<
MY_N,9MK>$.(XP>4]_E2]3=5/&"S<)XR&>AE(4;\7[1#*.G@`-7Q-M*.GJUK#
MEJV`K%O^"&?7L7>S`S$J8I\KU.MU)1^653=TXI#28>RZ1TW_Z&]4`L1$`$RZ
M'PZ,X5*.C@#&\I@AB&9#W1I*YTT235=8S?6.Q747%!V$'IVQL"3=G5P4!8UQ
M$@>')<D:_0)''M#:Y@!4KH`6#.!UTEI(V9DVC2V*MK_(,_)SS`[$_%>IF0.4
M@*9FPI_CIFR0P">XY4T-V7K!LV$1KE+:+8IF^I!5TK"TF#0RC'42`IX_C6S6
M\[-\^Y!D;`'O[J&:5DA;8A@M=(,FZI\=)93FN4@W7#!VU3,N(G[\5"8@^\=)
M`%H'5*#N79T.8J&30#0M;'J28%1(NW#IV@>D+B;++5$2R+5H<003SIQI->0,
MT]016MI9M6#HFP*<#AO$;H]\%>W\GN-JA9`\CLI:H[JYUB!Z.6EU$__V+PFZ
MVR79R?5^F0,5XQGG?/+Z?*BCJVA^7T19&5EMILQD4$]RV,'IO\.AIX%[?,-&
M+NV\@EQ\EA7?8S(@+[D3I9<9D859@-)^IV--#90HZ`:NES9H1PJ61.@BGB[S
M[@<<40J84-]$%`TU$LC#V_/P$E=,N'6:7E,'5/R5?B6R)8:JK>@"K5]UT882
MKAZCO72VR@6Y6'G&XT^W.F5G=1AH,AOS7^O5F9:/*=G]X[=121=K_LR3:56;
MS!5&&V<:#%%-)[*$TM]9Q%84;&,D2.3J79V7@7?>JT\I\FW?>&*<5[QBP\D#
M&XB&>R"+K?70/(A#8UB$IS(-W!QHAV*4-9!R#-X8:*2VM@60JWPH0/UI^T54
MT`=)Z*,N#)AI8=>TA]%1(P!1_92-H33+()#T.9VKO"SI4T%\$?&N(ZXB-^T[
MD0-9Z"ZSBLA)'T7F%^?L8S96E&"U^FU!'97P-Y$!5O:W$VTP\ZZ2F%[-0>NG
M`@.%9\8+WU$V]SJ#"\O\(<\W'Y,T76<;-4Z#8^C(`T:I1@$5U<N)`92BC1#2
M0N4@W3GOB#S7T'_.TPTN2E[<]WU>8?LES($>L/J^"\!!:7X;8M"Z_?8"RO<4
M-?TOEZSFK5.O)4`@RB*\I8X+9UC+CAL!;8BDHO9V0;T68%L?B11V4P1P15E"
M:(\WQ?/M-JE/+.B=>I8[C+.X]P*-:>5P90)TCWP4U-ZU<B<.8+?,1T@I\7&J
M^J:V_XOF<\@O,*DKA`ALPEM,K#";GDQSXQ&P$FH?0W-A$+0*&G<9C09"KF[>
MD/A\!?JAQ/_8TW*6'VP.KC7MH5YZ-@#HO^VL:`SWFK-6(,ES?TU[Q`D`WF>>
M*'$@B\PQ#N-[YZKF84Q[_8OF\K:A3'KC$Y>#&02W!"PHNW[NUW)L</+3FJQ`
M&[H*O4NC)[5NE#C^XBG_\)J0<+4@/QQK@X2=W_FLQ$,G\."/SC-6-6KRS^4\
M1W[?,D64Z^@O>D:+/Q')B!,1I7_%47&1;<ZC"D__N&K._K^S"67SR57MIGQ]
M/<_I$Z'FCW@'B/:`2!>(]C%Z6IS7%V9NV"/<L\T)!5O_$T*+KYD-TD93IH*&
MX?1YT#!'G/M\<^">M)OOTW-N<%]<1'/\H>G?YOB^'9\9/RME.OI;7I`-8W4X
M(WP*>B%A@S_]$1^F?U0%6_]?5XNO^<S21E.^MX;A]`_/F:.:.V+L$>$_=0YT
M]5KYXU7"6WZS30AM'V"SPP+YT5314,PP;XS<YYM$0F'F5?,HG=#=Q#GU+DEQ
M<4;6FJ>\F,VJ'#&%FC52;/UITFLR?5Y(V,TV$1AOU#"?^-EO\5-"=Y19]3[:
MSN`BR+E"?7@YNOZ7[[>9_NEE_&;[]AUS1+E/]@OYAH-[F^_([\KI,T##&LYC
M5.(\=A\'#>?P)15,9W0LZXUCO6U@?<PT-^A>=)&9(3"&GA<#C/)9T3:;;TX<
ML9Q_1K!0PHCY,&\V'5FKJ%#7C^V5Z)N<5[<Q!<ZM2*%RZ.QA]=/GS'3>"M6X
M"R7)#R#;FHS?OVG*.V-:9#9ECX;?/6,<2%KG91;G6]Q"-5YM5[2&NGN@%;Y_
MWT#:U/NDTLIA.X]:<E:QN'DV,8CY)"@-?2GE79I_-)X$:DG`#9D2AL*`#=I#
M&BZ%,.,F&GOHB'%33+7ZYRLB$_DW^1?Y@5Y<)/_X7U!+`P04````"`!D@:Y`
MLFAQC`X5``!?,@$`%0`<`')X:6DM,C`Q,C`S,S%?<')E+GAM;%54"0`#VV:Q
M3]MFL4]U>`L``00E#@``!#D!``#M74MSXSB2OD_$_`>NY[#=!S]D=U=7=4SM
MA/SJ<*S+4MBNZ=Y3!T5"$K8I0`V2+FM^_0(@(5(B`((/B2!G3^62D%!F?IEX
M)!*)O__C?14X;X"$$*//)Z.SBQ,'(`_[$"T^G\3AJ1MZ$)[\X[_^^I>__\?I
MJ?/;]?.C\PM`@+@1\)UO,%KRS[ZXY`_G!J\W!"Z6D?/=S??.;.,\/SNW&"$0
M!&#CG)Z*3J[=D-)BE/1V>39*OPL@^F-&OW,H3RC\^3V$GT^64;3^^?S\V[=O
M9]^NSC!9G%]>7(S.?_OR^.(MP<H]A2B,7.2!$X>V_SGD'SYBSXVX0#GR]QD)
M1`=7Y]O?4K9@_SL5S4[91Z>CR].KT=E[Z)\D+!KT?R*$81_(Q!E]^O3IG'][
MPG1`<`">P=QA_WY]?MA2D'>X7KIDY9YY>'7.OCV_Q5Z\`B@:(_\.13#:/*`Y
MIBV8Y/1G69<_1YLU^'P2PM4Z`.*S)0'SSR>T0TBE&EU>7"4R_4W?WWF>NQJ=
M@]`C<,WZFLROXQ`B$(;TEZ@MP'`RGQ(0TI].?\M$^"K]->3]&7A,+9Z'8ZH7
MM)@2C.B?'F#:"HW8+>NB(8?C=;2D+CGV_HQA"(V5*"-KJJMW^+*&:!)'9GK)
M-6_XR_<N)/]T@QA\`6X8DPK@*"@;\O,28>\//M3=X-4:H-#<N%6D#3EZ`M$C
M#L,I("_T!X$1*P6:ACP\0NH((1@O"*B`D(2J#726./#IU'='S3_:F".S1]98
M(Q%<F-M&OGE3'<2S$/P94WW>O1E#423B7*QS`^XC_='TIQE)XSD,1JR3BPOG
MU!'M\W^ZR'<28D<Y`X+W""`?^'R.#;"W\V7`E@N8E*F+??*[CN'Q+(R(ZT6B
MH\"=@2#IR9#NW)B]5*5\T1$"[VR!W\Y]`.GB8S1B?S#61Z<7HW3!\C?ZT9:'
M5]KM'H_%KPNHCLDN6R[Q1"?TSQV@B\NAM,7YFHXA*#KUEC#P!?6<X%4E+:5<
M8!G;F%#7_'SRX]G%U8D3AY0GS!<);G!H[8XI$SYCY#YP%Q+U[GW?&_WN\9TI
M^,<C*U@P3^<BB"G__BW=@VCL>*]=;Q2NX#]3_`]'5GS"^3-80,8PBI[<E4SO
M\F:]4;N<_4SKHTZT?D.E(&[P0">O]_\&&Z7:"^UZIO<"_YGB+X^L^)N8,"'O
M8>BYP?\`EZB'&G73WJA?+4*&P,=.3/\>!H#<4%86F*@-?Z]5;_0NY7ZK\M&Q
MC3[U0KQ:8<0W.7R[%]*-.0NOL7"@>NC1$O4,$+TP&3['GH.%1(F?)DN#>_I9
MJ%D`2=KV!@V-#-FX]%.G(+#!T@R"7,N>`I"3(%/_![GZS_=C`<VB%-=NP.+[
M+TL`#$,4>Q0-HR0[O4VYHI<@@AZ3MRHS>^2-8UATXN#AL,G\`=%?-`OIR<A:
MY.3&#9?W`?YF&$Z24^IB2GL1'<-(TYY1[(:61LZIL^6$_GV#:=>(G5+1OT(<
M0)\?=Z5].$DGSG=?D1O[D'[SO7E<*3_NS-UPQITY#D\7KKM.!A\01*'X9'\4
M2C_^?<OL9'X/$64*TD$2)S%\11B*<F-(5F\0K2_,.`RI.C5L[S<X]B!JKKIL
M#)7QG0Z=H[/"P$F%F0.Z$/<?$ZF5S').WP"9X1#PMHP68D('==HQ4XWC=(%>
MNHTH!;'0K@LLY0:WBUJ!T12\R[-B(*#'Z+$QERX+V#_L/./-#=A8/(YN7$(V
M=,W+S\4D:!K2=8>NPB`%R(;\IZ!?L;R(`N@YX)I8P+&'VV=`50(].FW5!;]R
M#]::065)4H/X84@&,25@[4+_[GW-#UF1/V%I`3OZDQB!$96UP!MQGVUUA@-V
M&:Q]`5`.U8=VH8IPY`:=>25>`Q)MIG3/P7?N=%1:LP7H$Y"[HZZY?:LL/;\I
MG#_9X7F*7(`'1(7P0!C26010G2QOP1L(,)="E@.@;V\71`8,IQA]M`.C=ISN
M%XS];S`()`Z6?6474KN\I:!\&A(HMV#--MIAHH,GC#SE[*5N:A]H:EY%G.!B
M2"@F8BI7'#8B)#@3>(R&L[IXA.X,!C""@&5-%],:-8$<<]*^Q.G,)1*6,+`H
M4$X!Y8$\7>,N$*]JRA+45<&^T=59\2"^QSBG%Q#"J;MQ9P'0[`(5#3O&MVQ/
MJ.!:H#FHJ`T5EL24TX)VY'"JVEJ/J(IQ`>J@HC,W[AJR10%P0S"9!6FFOP;9
M,@*[X2WC7F#<<EBG8XPQH@Q$D(Y03S@"Y8-Q&8'E&)=P+S"V.]:SO2,VF?_J
M$I8?'$ZI-"BBR\M@\P*B*`!,K`?$3A!DT9^J/=B+:BUQ!,R6A(L4,*=24YME
MMS3I7].8>$LZ.DT)]`!+!H$^N_N<NV"4Q[@2N>4`5Y)%H#NHN)/1TJI_:RK-
M8NJRY8A3EQ$.Q=I"&SXTH.G3#M=`'`%\RZ$M:U98CQ@M7@%9Y9<>^B66G*)7
ML)<)(T"_'!+HMRFKK^Y[$K?-J>\)1"7'!L:T?3*$"F()DV@KT^E38A((+%CF
M;&O+,X/%"!5L,D\GMBDFRJ5:W:[Z8@#-I!3V,*B064Z-^I5<?U`N,"Z`:SDL
MUN5*KM+IE&WG475!-3B%NOPPK%.HJ6"=RZY*/I6VZN:DT11+*<L"1$OB7FVM
MO+?7)Y69XX4F=H-7Y%<@9TDHJZ7C)-^'B1!3%_HL:L?WCCGI9>=*!D1VHVLB
M@<#;DN"6JC(1F$,/LAIS\2H.V*K[-B9T[9?+V7.#E\A=[#ME96I[$:TLBKC?
M,:A,JU?"Z]AMM,.PK)&]P*HX%OBU%;YJN&T]U'K7:)UK.WXRC@5^+4>B;,ZL
MJY%1UZ^=2[DT`O66K]454)=6(CC<K?*]V_UIO^**>>,[YLYW.S_P_8GS_Y?.
MV]IL4LU."&?4YS-+5N^T9/^I)NQ+\JNI/-E^519TZ.E2:5?XI.+/.(Z65)I_
M9:.`$OTB03]1+\J1H2U+@!T0V@]A&!LC+1KW&64A0X9PL5+JH!!6US!3J:C3
M`F9M8BTK7D8!+Q8OZRW@N4!-A3G<B*HOP!L)D\4L!S1[%XKU::=N;>L>@JV>
MM#\.:=(N2*R<L94M>PON_ES]<4AS=85BHU+E]'*6-JHO2G$>T!2]$[=-A"Z+
M1XM6?4%5RGP6FS[TE'OX.)>L9N1N?.O2++R5=>3@N9.6W^FTE&(BSI8O32!+
MV?+8'C59\]0MM!#ZTS"M:=N%=Y5H6SB4ANMM$<5!Y;Z("BMCY.?.*5/I[]Z]
M(&8S!'^IB\JW+<QR@T,9Z(UZZ\(L2BTZ5["MOF3;$HY6'/8JSO$5$J[6`=X`
M('\:+)5?=K#?J#MK3:&Y:'95=JQD"T]4C';-P;S'/EJ$N71V57<LOXJ:VTT\
M4"F\I8L6X!X3[2BYO_INJU.[3:,%`8=8#E(K<]65A<4V8,"[324D%:Z?O+P<
M4`'&_@HB_E)5!-^`SK/+::P%S9#_7A2+5(JAG9DJ`5K24T]A+I'*KBJ4E:9L
M43<AB?+2":B.>[?6M=WFT9J8=A7(K+;$XU+N+%G:LYA:G??19FH).LB*G"5B
M2U9_I136&H01]P.L\UE0CDF(N%^AX7Q5SD/<`GAM<P7_@")`U1KM'J+DA^?]
M%I9"(>4U*YLYH&&2OPSQA!$6AI=(JQXERP@L1=2$]4%6TGP"J0$_XE`V/NY]
M;S%\>YP>J$1FE_/9G4L0-<M09+9I3C[532U&4,UT5@MS4`>?^P+3+3[T6(0.
M!G$D3?,JI>@"WC*[5.%;8-ZR<ICM@/PK@(LE%6],V7`7X"E>S0"9S`L94!IO
MKMZ%Q5Y>79BL?*8EWJ]8W^HDRPFF]_)&/74!>UW[WBZDZPI[O+J;Q\TQRST%
MG':9IIE=U4DS8[TYO#M+WNS=BF=V;5+2O(,U,N-B2O`;I)A>;[Z&+(BVW8R/
MO0B^)7=^U2+5Z:3C%%`E4KDE=V69;$MA4XSE.[L)^E>26\6WB+(!6]N\"QCK
MV^QV7-;*9%<Z65ME@/XW#B,^<K[B9^!AY,$`[*CA%3<?"0[S,_TSLL/I8IO?
M9LD8TU:15\J\!SFX].\`<)21/UZQPI7_DIV9![P0J@E9)P^0'=#?<@_-&4AO
M5^Y;2R=<+D1,A1-T"\-U>HEC,E<^15?2?J@&4B)VRWEOARD-_(3Y0Q//RNPU
M9:LAHJH4]C!);MV_A)6,:;D!;3*GMIP\!T:'NBD!*QBOZ!+N#:1ZEZU*:G8T
M1`MJHH^6$_+L*,J61FNU^7E\\ZAH.%0C4<G;B\2\9-83J4"3>5*A[`%146/9
M*&%*-$2P367O6X9=$J7]XB*?4<-@\PQ\`%;LJ8Q[3)C"OJ[9'1%`/!CFGKLJ
MR:VKW^U@C:<5[;2=BG>8Y6A.U*1J'QL<7;31)R*^`/(&O=*TS5H]_CM852W%
M'"CKK]LU,9.8U9&DGL840%=JPH-RLD_(3>#"E6PI7)%^B,950PUM)R(>Z)%#
M[@,/R"2G_@'=8(2`QZ3X%4;+?[I4C#BMY)K6QT`+Z8!UD)\9HJ$=3EMMYV,>
M?*[4C]F/U-M02$5[9J?ES2XW%/H:K&755XEEV9Y5AK/]9Z_*GVZMT<M@3::.
M,MI.-K4BZD.5RDH[@5N0_)M38_I2B+Y>D#'Q$$VIJ@X&FN%:5,&4@+4+??$\
M8QJ<IXM+GEB@/)VJVU%'B9`5'4=M,692MITX:^GX,_:2V+OZ+5L#FKY;1$$@
MRUZ7/Q3XMS%XQ=SJGP%_V6CJ$OWSY#7ZZ+MQE`HXR,?JI4Y"Z!)?_^BI&5G?
M34(FTX&>O._\*IOA@JU1>FY?4^VJ2"CL8T"7P17B)V?W#9.XM9WT-(E;*Y.P
MC\NA[U:>J0X(].A$RG1D-(?LDU@T6A@8NWH>V9=+V(#=\=4D"<P#\(TI@-=&
M35+\I'$P=>/^H5@F4=NOW%NQ9Z2;HC2FDY;!?5EB$KT"LM)GOQG2]<\**@@G
M#&)004Q>`QGXX3W5YXL;@"]N%#-!QLB_P4&0G"/QPNY:\ZC32T^-I8ZHPG0&
ME5I;<!NJ&KI8CC;3P$41U0<[<^1E-$T&%`UQ3PVE@H39\UL#'EHF\TH&4H6Z
MIQ921<3L^1<KAA#M<G(>L[O=4Q>RLHN/R3*97QU1+RHU)/T#UTPN@>B@0HWF
MBFL4/NBC55254-S2;#D(:6&0:9N6U"3(I.VDIT$FK4SZ-Z1Z&V3*SXI9BF4N
M.ZEDL:"@L6B\,#!WV1)!(9@P`TOR2MO=6_"7%]9I4E&I%1@0]=0,#"03=F!)
MO/$`>P@FYX3+%(K+'_+'N4MI>FH%Y8()([`[*Y.J(B]+=I-'DM4LVS)4H^\?
MV#6$%,!;\@"-:GM8S#'>S5:_"]=KZ2;1C+"G4!M*)S!N*XIXH&(+NW:;7[70
M70Z)X"P`3S@"BBRUFGWT%/GJ@@HC&%2HD"YJTA7.9/Z(T8*=O:2)/#QF,ID%
M<,%AE84-*E'WSU`JBRA,I*U0H14FDG>37.[>YA;,RL+'Q>;]-`*]3`+U?X=P
MHD1IC0)%?;6(*A**&EX#"B<RV=FY*_V'G92\N0$;(:>`2N/O)^A([*,:N>TA
MQ&K2"&L84`:C7`%CZB&$;*@S\,MJQF90H.LG_@4Q!/`MAPO7W,XHOR0:(OR_
MCP9B`$P080(MO\23F,`=ZJP*5[Q>!UQ9;B"4]8#FF*P2M#3EM$TI;3<!8T&$
M"?PPX+.C]/TID=Y9=FQ4:-X)V-5L6'I,5!!$@&U);+"M7/1$3)9:(<T[SW_=
M(RAW&1?0#2IQ4&CC"2./_IDE/R!?LG-A%24#',;:]YR:=VG[T-Y<0F%+/PUK
MS,^%S4>RN7WGZRY0;LO<MY/\CD0"5;OS`G/%0O3EBG)'(:SJ!!7.'X<W.(Q$
M.4G9<4&;O??=0EI7B#`P2^**JK=39<DQ#[EBI+F7DG1'R_7Z&831U!-=%("W
MY*KTP4JZEHP[M7L=A.FTH0AA2):4VE08$ATE`S<,X1QZ:<7S5`!1/V"3%T]F
M-%5[&(2!5!5:&(,E28T*8Q@'O#67AUJ\N^"+><5KZD84@P"[3$@!KB4O@2O`
MW=Z]87J("8+ADA7.%-,AN\^A3D>MU<,@P*\JM#`&2S(6V]F3YN;#I`19>@50
M%JG2M.V[092()Z"W)"ZI&`=2YK/R#MQPOR+(WSB1I.X]0A`G`9UKC&+%1-!&
MKWTWC]84(0QI8%%2:7K7`_)8K3+92%)*T7>#,1)2&,/A'TD__+/'MR#T"%PG
M2ZGK.(0(A,PMV%O/(;LNG/W65D_I8\@?+BY&SJF3*93])^N./7TL.G3H9LWA
M7;)/=SH]_FM=K'8C-8DI#J!7\DZHIO&QG75"%BY*'\'*'INF_Y$@)=2>0X,]
MN%B0YI5:RW4@O^ITX-_KI.)P*?9B"#BP\-L7F/L_?K`S8+H2SZ0E&-$_/;!3
MR"4W9%SN#QE)#T[6A;/71V<C1%*'G(V&=X2P306%(BF^8C1FF)!W\%AA*7>Z
M4:$B?;=>;HY?[LG!*N(-R(_':U:RUI649\OY[M6^[Z943I[LR!8MAE^ZCI_1
MU5Z9>^J;']L=)=QD^M7YH2EA%PYH@HAP.%,Y!N1IS^_P90W1)(XD'O9#87;\
M#3JL^2EK?_0[4]D-D%?BHM`MG?W*21I'2UC?")#TF365D^B;=N$6IMK<QBV4
MW`_(&;:QNR]TMTTM7K5J_''?+QBAPRF='=*CYPAN:_"-@X"7?<]_I'N=Q8SP
MZ''E)&+B!KE'5<VF)&/*;LJY5\%I&UDV%6E`'LDCH<J7IG,N^6'?)3FEPTF=
M'=HCFW#&%,\SV?*1#L`L]RCD.00SQJHH?*+QU:8='MN'C?F]SO.K\^W&/7;A
M\^W8@1@+&JM@0&/$$XC8\UQ30+C$DL'AI_W!@9(XC,:A1$Y"=62ON',)8N?$
M@FN-PZN;'MN5]SG1.:FF;1?N5Z9OX5@:M@?D,LGKEF"\($"YR/VX[S0ID9.C
M.K+]_8*Q_PT&P1CY#U05:,'*A22G[$:W)BK2=W#%1\&3SM&,J+IPN5IHY:X%
ME4LU((_DR]4E#JA`X6[B?\XE/TD7N2G5?SHIW;$G!?ZKNOEKK\'1[\D65,LJ
M#)DY5P7:3F8UJ>YW+LZ8,3\@3WJ$49HD4?2@T45Q4MNV/G:^"UZM8+KC9XD_
MZ9/"GO$5P&KT1T_G,6%/YWI5.^@DV:<.AMO,GHH"#LA'7^)9"/Z,69;TFWSY
M.2HD\V0T3DIT]'H+NTQK"RRHFAZ_2,0N)]K)3MVVFPOE>GUG12"4;'?K,N>,
M31;.H?_YZU_^#U!+`P04````"`!D@:Y`2CU_W\@(``!M1@``$0`<`')X:6DM
M,C`Q,C`S,S$N>'-D550)``/;9K%/VV:Q3W5X"P`!!"4.```$.0$``.U<6V_C
MMA)^+W#^`X]?N@6.HSAIMTV0M$B<I##@C0UGM[MO!2V-;6)E4DM22?SO.Z.+
M3=FR?$F":G'\$DCDS,>YD*,AA\[%'\_3D#V"-D+)RT;KZ+C!0/HJ$')\V8A-
MDQM?B,8?O__GAXO_-IOLR_6@R_X$"9I;"-B3L).D[0/77UE;13,MQA/+WK5_
M8L,9&PS8C9(2PA!FK-G,0:ZY05XE4[23HU;69_P)3#E#B:2Y;$RLC<X][^GI
MZ>CI]$CIL7=R?-SROGSH/B1TC93P_'FH0U$@IY:<X=03TE@N?<CI0R&_5I!3
M]Q`%G,.OT&?2M,[.SKRDM\$LUV.P]WP*)N(^S,GULX@F7$_YD:^FB-\Z.3X]
M;>70V"LVDD((4Y#V3NGI#8QX'-K+QK>8AV(D(&@P;JT6P]A"@2"6#LG"3(&=
M#^<J_8N7=N:DZ'8[B\`4B0WX1V/UZ.6])&.K>=QJ+A22Z.QX6F[<P&J/^#PD
M:B(5:.'/^38S90PX31B[X%(JRRU.V>2=6J)(R)'*7K&!_'*N50@?D9W1PZ=!
M9XVQJ=>[47Y,AKZ2P:VTPLXZB(<4-$J#B>"R44DQ'SD?.X"1D"*1\?B8-5G.
M[3YR&;`4BCE8%]XRP#)VC.NG)W]/GB,-!K$2SBXV9-P9217G8H#=^'P>^G&X
M8<"L-??`"QQSS4-:O@\3`&M23Q2;*DV/L84]H'4@LWU;R0`DQ1]\,BH401+(
M,D260K)WGR2/`X$]/QV\L=X;?:Y1V0E8@5*4N*;87^VG%SN*O2L,=W!<T7%S
MVYK>J(-?^"FD#BMIKW34R79^6L`R-6*WSQ'1'!;6=OYI<S.Y"]636771HJO2
M2Z?[>(FP60)^\-/Z/`&,KT5$P_5&U[$1$HS!E`"36H'^Z3OZ9VG##@R5/GU_
MG'S-;H3Q0V5B#?2R`"</YO!)9I$,0*WN$`=O%KPY`)\R.M]7,>9A<MS72N*C
MGRZ*U($;:#;Y[&399RD>6P"R(N+!1047747X2=?\RO\6"R,6ZZJD?9,K3I==
MD6$P!^1@_>(">18/N+7JQ39;#(OW3=;^>67B?Q&,F)O(?3!SP<QW7.B_>!C#
M!^!D+2?\E'=M,OXOR\8G&);@,!?HX(>E+$SY7Y/SJ;::4L[J?,C7]&WRQ/ME
M3R0XV2&8BW1P1<$5]V"[RI@^Z`?LR78KRXV;C/_KLO$1@!$"0PB68!S,7C![
M5_BT4;@::W"CT&KS)M/_MFSZ#((M,`ZF7PT^$Q4&H,TM)B1VY@2>8OLFXY^5
M!IT,XT>6HAS,OS3SK1@[\=YYWV#NUO'J7,]Y#T8NSO%X:.!;C#K>/BZBRTKK
M)H.O;(07""R%^#^P._VA4M4`1BPI1)U3K>2R8<0T"JF`E;1--(PN&U1K:N95
MI;]Q\*/G:9B3$'Y%22QQW)*\V;@Y`M?^"LA*G<R+M(I`6P'&RV7/`:RPQ-Y>
MC,)H&/,_QD.4TWLUU='3NZJ^/#G>2'?WF.:-E`_Y<%?ED07"-]2Z2_BEZEYX
M;E4/WXI5OPO45FG+Y$K5M:H&G-:8N\I/@"I8Z*V9\S6IJ=DZ:9ZVCIY-D,NX
MBP@+]7<3(>=[F0@KA=2MI%CF(AG.2(;6^Q?)X%:`=Y-#R?L]11EQ,TS`2NO7
M:Z1()'`YQYQ'":,'H35SK.8":W=IYI@O%X9:=I:E4-T/0&PMRS(//:P;G>Y]
M9%<93'K=`QNSAD2FZOKZU=!8S?WL$(J"VM_;D:>1,;DC<HYM0HX[%J;T,47=
M,&=`QI@X_M0JCG)"@208II)G#%]"!1\3F"#667[(LP$N&U;'""5%B(&2XEGZ
M[I4IV)%]K7PP9H"!'N/GY`8>(501D3B*59.Y"DV5!,OU;&N5EL5<53&->#;O
M&J;E5E0=AL*NT6M^0M4;?>9:([OI*XO]`N/Y[`$L!GH:M2.IPN1HNBOCOZ2[
MKR%8JWP[UE1U;JOD*!^?^C&Z#`-V'Z,44+5-!*"=;46B^4Y<M51["\GOP?9&
MF:9]C#U+)M@7H8[FN,%=@"^H2!1/*7^%X":F8.,L71X^6#X&-X+MP%1'I?/X
MA!'8$?D6DU`U`R@_+LUN`CA6>!'*&YME$?!W"(?E"MVCU*]BF>V!ZF@<)^2C
MS"A5HD,'A<80@-'@3NDU$R*[0E+^^=@7JXXF2J_7ABCR53`54E"F8<4CE%A@
M,^EWI6#EM-Y&[0T`=31&^23.TZ&.,3$$.)%WF!2OAOC]F"M5JK#R7VRPO3#K
M:+*.M*#!6/?67[;1*';\6\)7)AF?@7Y1`,'5(YI^#+C]'X+NC9+272^VE+;0
MCQ7HLI-/45Z$L:5;[W,M]P4H[!R)V+R)+4J5QKPW=0J5*O$IC$G$'EU6<32K
MI*JE,S%WH9W<8/$-=M4IZ:SC>B)K]^9AH3=*BVD=S*!U[%1,$YVVH*VCBDY$
M3-:)^8"+A%NE13@;0``PI4$Q(I+#/D64<X+VA7$V\N7Q=7^T6LYG1[/T\CGE
M&US.JC\C#Z`?<:>[QD1[`=5Q$K43,3MRFWRD(]OT0S&?!ODL[.0OCH/'6;7[
M3D@<#4.;:[$W0:_[)*N>#ND%"]1D0%^\O3*<%8CO9F(M'R:M/7G;@[F6TR+]
M5OJ`^2?Z<.5Z;*KL>IH:ZS2*90!!GPO:IG0!_7$#D3+"KFA605G'B8L)6W*T
M#X&YTVJZ^,R51*YBGK<#6QT5+PDZQ8A\:Z*H<#:\%7TMY_"2MTA^XDK"S"/5
MPG',>V7!]/F,QE_OZ"U8:VF!DK).N1<=-V.44AK7\I5I*V/S1+FZ5K0W:!V7
MB.OLDK/,WLC9JY;$B/W8ZSY]]MPNO.K>HZ96PKD=<F/$2*2E^;F\7<&'(L1Y
M[FI3J"KLQEA+[:_"4.7BHT?Y&-;4"#81UC$44)B*LJL-=[&6PDQH>Y*O9<IU
MG$7N*+LK8QV5SQ;K`.BVAF\A2&3])(6E'TV6)`9=`7'ZN]AK)>.B]U\#K);S
MO\^UE:"S4X*/\&ROP^)<6$N1ZI/^JXYSF[>_V=GFA9=>(<+'?P!02P$"'@,4
M````"`!D@:Y`WRQ$PFA@``#X50,`$0`8```````!````I($`````<GAI:2TR
M,#$R,#,S,2YX;6Q55`4``]MFL4]U>`L``00E#@``!#D!``!02P$"'@,4````
M"`!D@:Y`!:Q_$_,,```ME```%0`8```````!````I(&S8```<GAI:2TR,#$R
M,#,S,5]C86PN>&UL550%``/;9K%/=7@+``$$)0X```0Y`0``4$L!`AX#%```
M``@`9(&N0&[3Y[D*)@``:2@"`!4`&````````0```*2!]6T``')X:6DM,C`Q
M,C`S,S%?;&%B+GAM;%54!0`#VV:Q3W5X"P`!!"4.```$.0$``%!+`0(>`Q0`
M```(`&2!KD"R:'&,#A4``%\R`0`5`!@```````$```"D@4Z4``!R>&EI+3(P
M,3(P,S,Q7W!R92YX;6Q55`4``]MFL4]U>`L``00E#@``!#D!``!02P$"'@,4
M````"`!D@:Y`2CU_W\@(``!M1@``$0`8```````!````I(&KJ0``<GAI:2TR
M,#$R,#,S,2YX<V155`4``]MFL4]U>`L``00E#@``!#D!``!02P4&``````4`
,!0"_`0``OK(`````
`
end

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsAllOtherInvestmentsAbstract', window );"><strong>Fair Value Measurements [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsDisclosureTextBlock', window );">Fair Value Measurements</a></td>
        <td class="text"><!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
   <!-- Begin Block Tagged Note 5 - us-gaap:FinancialInstrumentsDisclosureTextBlock-->
   <p style="margin-top:18px;margin-bottom:0px"><font style="font-family:times new roman" size="2"><b>5. Fair Value Measurements </b></font></p>
   <p style="margin-top:6px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">The Company follows the provisions of FASB ASC Topic 820, <i>&#8220;Fair Value Measurements and Disclosures&#8221;</i>
   (&#8220;ASC 820&#8221;) for the Company&#8217;s financial assets and liabilities that are re-measured and reported at fair value at each reporting period, and are re-measured and reported at fair value at least annually using a fair value hierarchy
   that is broken down into three levels. Level inputs are as defined as follows: </font></p>
   <p style="margin-top:12px;margin-bottom:0px"><font style="font-family:times new roman" size="2">Level 1 &#8212; quoted prices in active markets for identical
   assets or liabilities. </font></p>
   <p style="margin-top:0px;margin-bottom:0px"><font style="font-family:times new roman" size="2">Level 2 &#8212; other significant observable inputs for the assets or liabilities through corroboration with
   market data at the measurement date. </font></p>
   <p style="margin-top:12px;margin-bottom:0px"><font style="font-family:times new roman" size="2">Level 3 &#8212; significant unobservable inputs that reflect management&#8217;s best estimate of what
   market participants would use to price the assets or liabilities at the measurement date. </font></p>
   <p style="margin-top:12px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">The Company categorized its cash
   equivalents as a Level 1 hierarchy. The valuation for Level 1 was determined based on a &#8220;market approach&#8221; using quoted prices in active markets for identical assets. Valuations of these assets do not require a significant degree of
   judgment. The Company categorized its warrants potentially settled in cash as a Level 2 hierarchy. The warrants are measured at fair market value on a recurring basis and are being marked to market each quarter-end until they are settled. The
   contingent purchase price consideration is categorized as a Level 3 hierarchy and is measured at its estimated fair value on a recurring basis and is adjusted at each quarter-end until it is completely settled. The contingent price consideration is
   valued based on the expected timing of milestones, the expected probability of success for each milestone and the updated discount rates based on a corporate debt interest rate index publicly issued. </font></p>
   <p style="font-size:12px;margin-top:0px;margin-bottom:0px">&#160;</p>
   <table cellspacing="0" cellpadding="0" width="100%" border="0" style="border-collapse:collapse; text-align: left" align="center">
   <!-- Begin Table Head -->
   <tr>
   <td width="66%">&#160;</td>
   <td valign="bottom" width="4%">&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   <td valign="bottom" width="4%">&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   <td valign="bottom" width="4%">&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   <td valign="bottom" width="4%">&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   </tr>
   <tr>
   <td valign="bottom" nowrap="nowrap"><font style="font-family:times new roman" size="1"><b>Description</b></font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>March&#160;31,<br />2012</b></font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>Quoted<br />Prices&#160;in<br />Active<br />Markets<br />(Level&#160;1)</b></font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>Significant<br />Other<br />Observable<br />Inputs<br />(Level 2)</b></font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>Unobservable<br />Inputs<br />(Level&#160;3)</b></font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   </tr>
   <!-- End Table Head -->
   <!-- Begin Table Body -->
   <tr bgcolor="#cceeff">
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Assets:</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   </tr>
   <tr>
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Cash equivalents</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">7,453</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">7,453</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">&#8212;&#160;&#160;</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">&#8212;&#160;&#160;</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   </tr>
   <tr style="font-size:1px">
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   </tr>
   <tr bgcolor="#cceeff">
   <td valign="top">
   <p style="margin-left:3.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Total assets</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">7,453</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">7,453</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">&#8212;&#160;&#160;</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">&#8212;&#160;&#160;</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   </tr>
   <tr style="font-size:1px">
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   </tr>
   <tr>
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Liabilities:</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   </tr>
   <tr bgcolor="#cceeff">
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Warrants potentially settleable in cash</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">20,357</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">&#8212;&#160;&#160;</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">20,357</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">&#8212;&#160;&#160;</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   </tr>
   <tr>
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Contingent purchase price consideration</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">6,195</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">&#8212;&#160;&#160;</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">&#8212;&#160;&#160;</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">6,195</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   </tr>
   <tr style="font-size:1px">
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   </tr>
   <tr bgcolor="#cceeff">
   <td valign="top">
   <p style="margin-left:3.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Total liabilities</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">26,552</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">&#8212;&#160;&#160;</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">20,357</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">6,195</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   </tr>
   <tr style="font-size:1px">
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   </tr>
   <!-- End Table Body -->
   </table>
   <p style="font-size:12px;margin-top:0px;margin-bottom:0px">&#160;</p>
   <table cellspacing="0" cellpadding="0" width="100%" border="0" style="border-collapse:collapse; text-align: left" align="center">
   <!-- Begin Table Head -->
   <tr>
   <td width="66%">&#160;</td>
   <td valign="bottom" width="4%">&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   <td valign="bottom" width="4%">&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   <td valign="bottom" width="4%">&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   <td valign="bottom" width="4%">&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   </tr>
   <tr>
   <td valign="bottom" nowrap="nowrap"><font style="font-family:times new roman" size="1"><b>Description</b></font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>December&#160;31,<br />2011</b></font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>Quoted<br />Prices in<br />Active<br />Markets<br />(Level&#160;1)</b></font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>Significant<br />Other<br />Observable<br />Inputs<br />(Level 2)</b></font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>Unobservable<br />Inputs<br />(Level&#160;3)</b></font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   </tr>
   <!-- End Table Head -->
   <!-- Begin Table Body -->
   <tr bgcolor="#cceeff">
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Assets:</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   </tr>
   <tr>
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Cash equivalents</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">11,433</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">11,433</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">&#8212;&#160;&#160;</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">&#8212;&#160;&#160;</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   </tr>
   <tr style="font-size:1px">
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   </tr>
   <tr bgcolor="#cceeff">
   <td valign="top">
   <p style="margin-left:3.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Total assets</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">11,433</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">11,433</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">&#8212;&#160;&#160;</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">&#8212;&#160;&#160;</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   </tr>
   <tr style="font-size:1px">
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   </tr>
   <tr>
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Liabilities:</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   </tr>
   <tr bgcolor="#cceeff">
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Warrants potentially settleable in cash</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">3,746</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">&#8212;&#160;&#160;</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">3,746</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">&#8212;&#160;&#160;</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   </tr>
   <tr>
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Contingent purchase price consideration</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">6,351</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">&#8212;&#160;&#160;</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">&#8212;&#160;&#160;</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">6,351</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   </tr>
   <tr style="font-size:1px">
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   </tr>
   <tr bgcolor="#cceeff">
   <td valign="top">
   <p style="margin-left:3.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Total liabilities</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">10,097</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">&#8212;&#160;&#160;</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">3,746</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">6,351</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   </tr>
   <tr style="font-size:1px">
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   </tr>
   <!-- End Table Body -->
   </table>
   <p style="margin-top:18px;margin-bottom:0px"><font style="font-family:times new roman" size="2"><i>Fair Value of Financial Instruments </i></font></p>
   <p style="margin-top:6px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">
   The carrying amounts reported in the balance sheet for cash equivalents, accounts payable, capital leases and convertible notes payable approximate their fair values due to their short-term nature and
   market rates of interest. </font></p>
<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentsDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for financial instruments. This disclosure includes, but is not limited to, fair value measurements of short and long term marketable securities, international currencies forward contracts, and auction rate securities. Financial instruments may include hedging and non-hedging currency exchange instruments, derivatives, securitizations and securities available for sale at fair value. Also included are investment results, realized and unrealized gains and losses as well as impairments and risk management disclosures.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FinancialInstrumentsDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsAllOtherInvestmentsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InvestmentsAllOtherInvestmentsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<FilingSummary xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xsd="http://www.w3.org/2001/XMLSchema">
  <Version>2.4.0.6</Version>
  <ProcessingTime />
  <ReportFormat>Html</ReportFormat>
  <ContextCount>8</ContextCount>
  <ElementCount>122</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>3</UnitCount>
  <MyReports>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://rxipharma.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
    </Report>
    <Report>
      <IsDefault>true</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>01 - Statement - Condensed Consolidated Balance Sheets (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://rxipharma.com/role/BalanceSheets</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Unaudited)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>011 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://rxipharma.com/role/BalanceSheetsParenthetical</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>02 - Statement - Condensed Consolidated Statements of Expenses (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://rxipharma.com/role/StatementsOfIncome</Role>
      <ShortName>Condensed Consolidated Statements of Expenses (Unaudited)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>03 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://rxipharma.com/role/StatementsOfCashFlows</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows (Unaudited)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>06001 - Disclosure - Description of Business and Basis of Presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://rxipharma.com/role/DescriptionOfBusinessAndBasisOfPresentation</Role>
      <ShortName>Description of Business and Basis of Presentation</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>06002 - Disclosure - Recent Accounting Pronouncements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://rxipharma.com/role/RecentAccountingPronouncements</Role>
      <ShortName>Recent Accounting Pronouncements</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>06003 - Disclosure - Apthera Acquisition</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://rxipharma.com/role/AptheraAcquisition</Role>
      <ShortName>Apthera Acquisition</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>06004 - Disclosure - RXi Spin-Out</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://rxipharma.com/role/RxiSpinOut</Role>
      <ShortName>RXi Spin-Out</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>06005 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://rxipharma.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>06006 - Disclosure - Stock Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://rxipharma.com/role/StockBasedCompensation</Role>
      <ShortName>Stock Based Compensation</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>06007 - Disclosure - Net Loss Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://rxipharma.com/role/NetLossPerShare</Role>
      <ShortName>Net Loss Per Share</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>06008 - Disclosure - License Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://rxipharma.com/role/LicenseAgreements</Role>
      <ShortName>License Agreements</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>06009 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://rxipharma.com/role/StockholdersEquity</Role>
      <ShortName>Stockholders' Equity</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>06010 - Disclosure - Litigation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://rxipharma.com/role/Litigation</Role>
      <ShortName>Litigation</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>06011 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://rxipharma.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Info">Process Flow-Through: 01 - Statement - Condensed Consolidated Balance Sheets (Unaudited)</Log>
    <Log type="Info">	Process Flow-Through: Removing column 'Mar. 31, 2011'</Log>
    <Log type="Info">	Process Flow-Through: Removing column 'Dec. 31, 2010'</Log>
    <Log type="Info">Process Flow-Through: 011 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)</Log>
    <Log type="Info">Process Flow-Through: 02 - Statement - Condensed Consolidated Statements of Expenses (Unaudited)</Log>
    <Log type="Info">Process Flow-Through: 03 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)</Log>
  </Logs>
  <InputFiles>
    <File>rxii-20120331.xml</File>
    <File>rxii-20120331.xsd</File>
    <File>rxii-20120331_cal.xml</File>
    <File>rxii-20120331_lab.xml</File>
    <File>rxii-20120331_pre.xml</File>
  </InputFiles>
  <SupplementalFiles />
  <BaseTaxonomies />
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XBRL>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
